

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:44:45 ; Search time 4 Seconds  
(without alignments)  
2.954 Million cell updates/sec

Title: us-10-828-394-1  
Perfect score: 1643  
Sequence: 1 gaattccgcgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 198 seqs, 3596 residues

Total number of hits satisfying chosen parameters: 396

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 198 summaries

Database : rni:db:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	26	1.6	26	1	US-08-859-998-747
2	26	1.6	26	1	US-09-225-928-747
3	26	1.6	26	1	US-09-225-201B-747
C 4	25	1.5	25	1	US-08-859-998-748
C 5	25	1.5	25	1	US-09-225-928-748
C 6	25	1.5	25	1	US-09-225-201B-748
C 7	23	1.4	23	1	US-09-659-791A-5
8	21.8	1.3	25	1	US-09-396-196G-31760
9	21	1.3	21	1	US-08-410-540-21
10	21	1.3	21	1	US-09-659-791A-6
11	21	1.3	21	1	US-09-459-749D-14
12	20.6	1.3	21	1	US-09-657-472-2421
13	20.6	1.3	21	1	US-09-657-472-2422
14	20.6	1.3	21	1	US-09-657-472-2423
15	20.6	1.3	21	1	US-09-657-472-2424
16	20.2	1.2	25	1	US-09-396-196G-31758
C 17	20	1.2	20	1	US-09-659-791A-14
C 18	20	1.2	20	1	US-09-659-791A-15
C 19	20	1.2	20	1	US-09-659-791A-16
C 20	20	1.2	20	1	US-09-659-791A-17
C 21	20	1.2	20	1	US-09-659-791A-18
C 22	20	1.2	20	1	US-09-659-791A-19
C 23	20	1.2	20	1	US-09-659-791A-20
C 24	20	1.2	20	1	US-09-659-791A-21
C 25	20	1.2	20	1	US-09-659-791A-22
C 26	20	1.2	20	1	US-09-659-791A-23
C 27	20	1.2	20	1	US-09-659-791A-24
C 28	20	1.2	20	1	US-09-659-791A-25
C 29	20	1.2	20	1	US-09-659-791A-26
C 30	20	1.2	20	1	US-09-659-791A-27
C 31	20	1.2	20	1	US-09-659-791A-28
C 32	20	1.2	20	1	US-09-659-791A-29
C 33	20	1.2	20	1	US-09-659-791A-30

Sequence 31, Appl	1	US-09-659-791A-31	20	1.2	C 34
Sequence 32, Appl	1	US-09-659-791A-32	20	1.2	C 35
Sequence 33, Appl	1	US-09-659-791A-33	20	1.2	C 36
Sequence 34, Appl	1	US-09-659-791A-34	20	1.2	C 37
Sequence 35, Appl	1	US-09-659-791A-35	20	1.2	C 38
Sequence 36, Appl	1	US-09-659-791A-36	20	1.2	C 39
Sequence 37, Appl	1	US-09-659-791A-37	20	1.2	C 40
Sequence 38, Appl	1	US-09-659-791A-38	20	1.2	C 41
Sequence 39, Appl	1	US-09-659-791A-39	20	1.2	C 42
Sequence 40, Appl	1	US-09-659-791A-40	20	1.2	C 43
Sequence 41, Appl	1	US-09-659-791A-41	20	1.2	C 44
Sequence 42, Appl	1	US-09-659-791A-42	20	1.2	C 45
Sequence 43, Appl	1	US-09-659-791A-43	20	1.2	C 46
Sequence 44, Appl	1	US-09-659-791A-44	20	1.2	C 47
Sequence 45, Appl	1	US-09-659-791A-45	20	1.2	C 48
Sequence 46, Appl	1	US-09-659-791A-46	20	1.2	C 49
Sequence 47, Appl	1	US-09-659-791A-47	20	1.2	C 50
Sequence 48, Appl	1	US-09-659-791A-48	20	1.2	C 51
Sequence 49, Appl	1	US-09-659-791A-49	20	1.2	C 52
Sequence 50, Appl	1	US-09-659-791A-50	20	1.2	C 53
Sequence 51, Appl	1	US-09-659-791A-51	20	1.2	C 54
Sequence 52, Appl	1	US-09-659-791A-52	20	1.2	C 55
Sequence 53, Appl	1	US-09-659-791A-53	20	1.2	C 56
Sequence 54, Appl	1	US-09-659-791A-54	20	1.2	C 57
Sequence 55, Appl	1	US-09-659-791A-55	20	1.2	C 58
Sequence 56, Appl	1	US-09-659-791A-56	20	1.2	C 59
Sequence 57, Appl	1	US-09-659-791A-57	20	1.2	C 60
Sequence 58, Appl	1	US-09-659-791A-58	20	1.2	C 61
Sequence 59, Appl	1	US-09-659-791A-59	20	1.2	C 62
Sequence 60, Appl	1	US-09-659-791A-60	20	1.2	C 63
Sequence 61, Appl	1	US-09-659-791A-61	20	1.2	C 64
Sequence 62, Appl	1	US-09-659-791A-62	20	1.2	C 65
Sequence 63, Appl	1	US-09-659-791A-63	20	1.2	C 66
Sequence 64, Appl	1	US-09-659-791A-64	20	1.2	C 67
Sequence 65, Appl	1	US-09-659-791A-65	20	1.2	C 68
Sequence 66, Appl	1	US-09-659-791A-66	20	1.2	C 69
Sequence 67, Appl	1	US-09-659-791A-67	20	1.2	C 70
Sequence 68, Appl	1	US-09-659-791A-68	20	1.2	C 71
Sequence 69, Appl	1	US-09-659-791A-69	20	1.2	C 72
Sequence 70, Appl	1	US-09-659-791A-70	20	1.2	C 73
Sequence 71, Appl	1	US-09-659-791A-71	20	1.2	C 74
Sequence 72, Appl	1	US-09-659-791A-72	20	1.2	C 75
Sequence 73, Appl	1	US-09-659-791A-73	20	1.2	C 76
Sequence 74, Appl	1	US-09-659-791A-74	20	1.2	C 77
Sequence 75, Appl	1	US-09-659-791A-75	20	1.2	C 78
Sequence 76, Appl	1	US-09-659-791A-76	20	1.2	C 79
Sequence 77, Appl	1	US-09-659-791A-77	20	1.2	C 80
Sequence 78, Appl	1	US-09-659-791A-78	20	1.2	C 81
Sequence 79, Appl	1	US-09-659-791A-79	20	1.2	C 82
Sequence 80, Appl	1	US-09-659-791A-80	20	1.2	C 83
Sequence 81, Appl	1	US-09-659-791A-81	20	1.2	C 84
Sequence 82, Appl	1	US-09-659-791A-82	20	1.2	C 85
Sequence 83, Appl	1	US-09-659-791A-83	20	1.2	C 86
Sequence 84, Appl	1	US-09-659-791A-84	20	1.2	C 87
Sequence 85, Appl	1	US-09-659-791A-85	20	1.2	C 88
Sequence 86, Appl	1	US-09-659-791A-86	20	1.2	C 89
Sequence 87, Appl	1	US-09-659-791A-87	20	1.2	C 90
Sequence 88, Appl	1	US-09-659-791A-88	20	1.2	C 91
Sequence 89, Appl	1	US-09-659-791A-89	20	1.2	C 92
Sequence 90, Appl	1	US-09-659-791A-90	20	1.2	C 93
Sequence 91, Appl	1	US-09-659-791A-91	20	1.2	C 94
Sequence 92, Appl	1	US-09-659-791A-92	20	1.2	C 95
Sequence 93, Appl	1	US-09-659-791A-93	20	1.2	C 96
Sequence 94, Appl	1	US-09-659-791A-94	20	1.2	C 97
Sequence 95, Appl	1	US-09-659-791A-95	20	1.2	C 98
Sequence 96, Appl	1	US-09-659-791A-96	20	1.2	C 99
Sequence 97, Appl	1	US-09-659-791A-97	20	1.2	C 100
Sequence 98, Appl	1	US-09-659-791A-98	20	1.2	C 101
Sequence 99, Appl	1	US-09-659-791A-99	20	1.2	C 102
Sequence 100, Appl	1	US-09-659-791A-100	20	1.2	C 103
Sequence 101, Appl	1	US-09-659-791A-101	20	1.2	C 104
Sequence 102, Appl	1	US-09-659-791A-102	20	1.2	C 105
Sequence 103, Appl	1	US-09-659-791A-103	20	1.2	C 106





```
;
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 747:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 747:
US-09-225-201B-747

Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 934 TCGCGATGAAGGACCAGTGTGACAAG 959
Db 1 TCGCGATGAAGGACCAGTGTGACAAG 26

RESULT 4
US-08-859-998-748/c
; Sequence 748, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 747:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 747:
US-09-225-201B-747

Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 934 TCGCGATGAAGGACCAGTGTGACAAG 959
Db 1 TCGCGATGAAGGACCAGTGTGACAAG 26

RESULT 3
US-09-225-201B-747
; Sequence 747, Application US/09225201B
; Patent No. 6489455
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
```

Query Match	1.5%	Score 25;	DB 1;	Length 25;	
Best Local Similarity	100.0%;	Pred. No. 3;			
Matches	25;	Conservative	0;	Mismatches	0;
			0;	Indels	0;
				Gaps	0;

Qy 1190 GTACTATCTCGGGTCAACCGGTG 1214  
Db 25 GTACTATCTCGGGTCAACCGGTG 1

RESULT 7  
US-09-659-791A-5/c  
; Sequence 5, Application US/09659791A  
; Patent No. 6383808  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/09/659,791A  
; CURRENT FILING DATE: 2000-09-11  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 5  
; LENGTH: 23  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: PCR Primer  
US-09-659-791A-5

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 5.4;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 789 CTTGAGATGATACACGAGGCTCA 811  
Db 23 CTTGAGATGATACACGAGGCTCA 1

RESULT 8  
US-09-396-196G-31760  
; Sequence 31760, Application US/09396196G  
; Patent No. 6821724  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; CURRENT FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 31760  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-09-396-196G-31760

Query Match 1.3%; Score 21.8; DB 1; Length 25;  
Best Local Similarity 92.0%; Pred. No. 10;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1270 AGCTCTTTGACTCTGATCCCATCAC 1294  
Db 1 AGCTTTTGACTCTGACCCCATCAC 25

RESULT 9  
US-08-410-540-21  
; Sequence 21, Application US/08410540  
; Patent No. 5807878  
; GENERAL INFORMATION:  
; APPLICANT: Miller, Walter L.  
; APPLICANT: Lin, Dong

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 9.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1354 AGAAGCGCTGCAGGAATACC 1374  
Db 1 AGAAGCGCTGCAGGAATACC 21

RESULT 10  
US-09-659-791A-6  
; Sequence 6, Application US/09659791A  
; Patent No. 6383808  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/09/659,791A  
; CURRENT FILING DATE: 2000-09-11  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 6  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: PCR Probe  
US-09-659-791A-6

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 9.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCACGCCATGTTCACGCCT 786

APPLICANT: Strauss III, Jerome F.  
TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS  
TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA  
NUMBER OF SEQUENCES: 30  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooley Godward Castro Huddleson & Tatum  
STREET: 5 Palo Alto Square  
CITY: Palo Alto  
STATE: CA  
COUNTRY: US  
ZIP: 94306-2155  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/410,540  
FILING DATE: 23-MAR-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Neeley, Richard L.  
REGISTRATION NUMBER: 30,092  
REFERENCE/DOCKET NUMBER: UCAL-238/000S  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415 853 5070  
TELEFAX: 415 857 0663  
TELEX: 380816COOLEYPA  
INFORMATION FOR SEQ ID NO: 21:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 21 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (synthetic)  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-08-410-540-21

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 9.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Db 1 TCCACGCCATGTTCCAGCCCT 21
|||||
RESULT 11
US-09-459-749D-14
; Sequence 14, Application US/09459749D
; Patent No. 6464975
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer_bind
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-09-459-749D-14
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 274 AGCCAGAGAGAGAGAGAGG 294
|||||
Db 1 AGCCAGAGAGAGAGAGAGG 21
|||||

RESULT 12
US-09-657-472-2421
; Sequence 2421, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2421
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2421
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1050 GAGAGGTTGACGAGGAATAC 1070
|||||
Db 1 GAGAGGTTGAYCAGGAAATAC 21
|||||

RESULT 13
US-09-657-472-2422
; Sequence 2422, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2422
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2422
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 999 CCTCTCCAGGCTAAGCTGCGG 1019
|||||
Db 1 CCTCTCCAGGYTAAGCTGCGG 21
|||||

RESULT 14
US-09-657-472-2423
; Sequence 2423, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2423
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2423
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1170 CTCACGCAAGCGGAGACGAG 1190
```

```
Db 1 CTCACGCAAGSCGAAGACCAG 21
|||||
RESULT 15
US-09-657-472-2424
; Sequence 2424, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Landier, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2424
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2424
Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1105 TCACACCTCTCTCTGCTGG 1125
|||||
Db 1 TCACACCTCTCTCTGCTGG 21
|||||
RESULT 16
US-09-396-196G-31758
; Sequence 31758, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31758
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31758
Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 18;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1171 TCACGCAAGGCGAAGACCAAGTACTA 1195
|||||
Db 1 TCACACGGGCGAAGACCAAGTACTA 25
|||||

RESULT 17
US-09-659-791A-14/c
; Sequence 14, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-14
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 TGACCGAGCGCTGCAAAAGAC 32
|||||
Db 20 TGACCGAGCGCTGCAAAAGAC 1
|||||

RESULT 18
US-09-659-791A-15/c
; Sequence 15, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-15
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 21 GCGTGCAAGACTCCAGAAT 40
|||||
Db 20 GCGTGCAAGACTCCAGAAT 1
|||||

RESULT 19
US-09-659-791A-16/c
; Sequence 16, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 16
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-16

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 ATTGGAGGCATCATGAAGAC 58
Db 20 ATTGGAGGCATCATGAAGAC 1

RESULT 20
US-09-659-791A-17/c
; Sequence 17, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-17

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCTGCTGCTGACCTGGGAGA 96
Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 21
US-09-659-791A-18/c
; Sequence 18, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-18

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 GCAGGTCCTGGGGACCAGA 120
Db 20 GCAGGTCCTGGGGACCAGA 1

RESULT 22
US-09-659-791A-19/c
; Sequence 19, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-19

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 122 GGTCTCAGACAATGAGCTCC 141
Db 20 GGTCTCAGACAATGAGCTCC 1

RESULT 23
US-09-659-791A-20/c
; Sequence 20, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-20

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 149 GTCCAATCAGGGAAGTAAGT 168
Db 20 GTCCAATCAGGGAAGTAAGT 1

RESULT 24
US-09-659-791A-21/c
; Sequence 21, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-21

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 166 AGTACGTCATTAAGGAATT 185
Db 20 AGTACGTCATTAAGGAATT 1

RESULT 25
US-09-659-791A-22/c
; Sequence 22, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-22

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 GGGGTGAACAGATAAGAC 220
Db 20 GGGGTGAACAGATAAGAC 1

RESULT 26
US-09-659-791A-23/c
; Sequence 23, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-23

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 281 GAAGAAGAAAGAGATGCC 300
Db 20 GAAGAAGAAAGAGATGCC 1

RESULT 27
US-09-659-791A-24/c
; Sequence 24, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-24

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 286 AGAAGAGGATGCCCTAAAT 305
Db 20 AGAAGAGGATGCCCTAAAT 1

RESULT 28
US-09-659-791A-25/c
; Sequence 25, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-25

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 298 CCTAAATGAGACGAGGAA 317
Db 20 CCTAAATGAGACGAGGAA 1

RESULT 29
US-09-659-791A-26/c
; Sequence 26, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```



```
; ;
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-26

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    307 AGACGAGGAATCAGAGACA 326
      |||||
Db     20 AGACGAGGAATCAGAGACA 1

RESULT 30
US-09-659-791A-27/c
; Sequence 27, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-29

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    364 TGATGGCCCTCTGGGAAGAG 383
      |||||
Db     20 TGATGGCCCTCTGGGAAGAG 1

RESULT 33
US-09-659-791A-30/c
; Sequence 30, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-30

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    380 AGAGTGTAAAGCCCTGCCTGA 399
      |||||
Db     20 AGAGTGTAAAGCCCTGCCTGA 1

RESULT 34
US-09-659-791A-31/c
; Sequence 31, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-28

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    324 ACAAGAGCTGAAGGAGTGCCC 343
      |||||
Db     20 ACAAGAGCTGAAGGAGTGCCC 1

RESULT 31
US-09-659-791A-28/c
; Sequence 28, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-28

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    359 GACCATGATGCCCTCTGGG 378
      |||||
Db     20 GACCATGATGCCCTCTGGG 1

RESULT 32
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-31

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTGCATGAAGTTCACGCAC 426
      |||||
Db 20 CTGCATGAAGTTCACGCAC 1

RESULT 35
US-09-659-791A-32/c
; Sequence 32, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-34

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TGGCGCCGACGTTGAGGAGT 474
      |||||
Db 20 TGGCGCCGACGTTGAGGAGT 1

RESULT 38
US-09-659-791A-35/c
; Sequence 35, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-35

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 501
      |||||
Db 20 CCAGAGCTCGCCCTTCTACT 1

RESULT 39
US-09-659-791A-36/c
; Sequence 36, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-31

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTGCATGAAGTTCACGCAC 426
      |||||
Db 20 CTGCATGAAGTTCACGCAC 1

RESULT 35
US-09-659-791A-32/c
; Sequence 32, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-32

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 CTCAGGCTGTTGGCGGCC 462
      |||||
Db 20 CTCAGGCTGTTGGCGGCC 1

RESULT 36
US-09-659-791A-33/c
; Sequence 33, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-33

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 444 TCAGGCTGTTGGCGGCCA 463
      |||||
Db 20 TCAGGCTGTTGGCGGCCA 1

RESULT 37
US-09-659-791A-34/c
; Sequence 34, Application US/09659791A
```

```
US-09-659-791A-36
Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCCTTCTACTTCTGGATGA 511
Db 20 CCCTTCTACTTCTGGATGAA 1

RESULT 40
US-09-659-791A-37/c
; Sequence 37, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-37

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 ACCGCATCGACTCCCTGCTG 536
Db 20 ACCGCATCGACTCCCTGCTG 1

RESULT 41
US-09-659-791A-38/c
; Sequence 38, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-38

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 533 GCTGGAGAACGACCGGCAGC 552
Db 20 GCTGGAGAACGACCGGCAGC 1

RESULT 42
US-09-659-791A-39/c
; Sequence 39, Application US/09659791A
; Patent No. 6383808
```

```
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-39

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 GCAGACGCACATGCTGGATG 570
Db 20 GCAGACGCACATGCTGGATG 1

RESULT 43
US-09-659-791A-40/c
; Sequence 40, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-40

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGACGCACATGCTGGATGTC 572
Db 20 AGACGCACATGCTGGATGTC 1

RESULT 44
US-09-659-791A-41/c
; Sequence 41, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-41
```

```
Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 565 TGGATGTCATGCAGGACCAC 584
    |||||
Db 20 TGGATGTCATGCAGGACCAC 1

RESULT 45
US-09-659-791A-42/c
; Sequence 42, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-42

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 567 GATGTCATGCAGGACCACTT 586
    |||||
Db 20 GATGTCATGCAGGACCACTT 1

RESULT 46
US-09-659-791A-43/c
; Sequence 43, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-43

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 604 TCATAGACGAGCTCTTCCAG 623
    |||||
Db 20 TCATAGACGAGCTCTTCCAG 1

RESULT 47
US-09-659-791A-44/c
; Sequence 44, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
```

```
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-44

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 608 AGACGAGCTCTTCCAGGACA 627
    |||||
Db 20 AGACGAGCTCTTCCAGGACA 1

RESULT 48
US-09-659-791A-45/c
; Sequence 45, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-45

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 613 AGCTCTTCCAGGACAGGTTT 632
    |||||
Db 20 AGCTCTTCCAGGACAGGTTT 1

RESULT 49
US-09-659-791A-46/c
; Sequence 46, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-46
```

```
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 AGGCTTCACCTTCTTCTTCC 709
Db 20 AGGCTTCACCTTCTTCTTCC 1

RESULT 50
US-09-659-791A-47/c
; Sequence 47, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-47

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 TCGTCCGCGAGCTTGATGCC 740
Db 20 TCGTCCGCGAGCTTGATGCC 1

RESULT 51
US-09-659-791A-48/c
; Sequence 48, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-48

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 775 TGTTCAGCCCTTCCTTGAG 794
Db 20 TGTTCAGCCCTTCCTTGAG 1

RESULT 52
US-09-659-791A-49/c
; Sequence 49, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-49

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GTTCCAGCCCTTCCTTGAGA 795
Db 20 GTTCCAGCCCTTCCTTGAGA 1

RESULT 53
US-09-659-791A-50/c
; Sequence 50, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-50

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 783 CCCTTCCTTGAGATGATACA 802
Db 20 CCCTTCCTTGAGATGATACA 1

RESULT 54
US-09-659-791A-51/c
; Sequence 51, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-51

Query Match      1.2%; Score 20; DB 1; Length 20;
```

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-54

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      893 GACTGTGTGCGGGAGATCC 912
Db      20 GACTGTGTGCGGGAGATCC 1

RESULT 58
US-09-659-791A-55/c
; Sequence 55, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-55

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      894 ACTGTGTGCGGGAGATCCG 913
Db      20 ACTGTGTGCGGGAGATCCG 1

RESULT 59
US-09-659-791A-56/c
; Sequence 56, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-56

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      853 ACCCGCCCAACAGATTTCATA 872
Db      20 ACCCGCCCAACAGATTTCATA 1

RESULT 57
US-09-659-791A-54/c
; Sequence 54, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-53

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      848 CCAGCACCGCCCAACAGAAAT 867
Db      20 CCAGCACCGCCCAACAGAAAT 1

RESULT 56
US-09-659-791A-53/c
; Sequence 53, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-52/c
; Sequence 52, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-52

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      820 TGGACATCCACTTCCACAGC 839
Db      20 TGGACATCCACTTCCACAGC 1
```





**Page 17**

**Page 17**

```
QY 1182 GAAGACCACTACTATCTGGC 1201
Db 20 GAAGACCACTACTATCTGGC 1

RESULT 70
US-09-659-791A-67/c
; Sequence 67, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-67
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1194 TATCTGGGGTCAACACGGT 1213
Db 20 TATCTGGGGTCAACACGGT 1

RESULT 71
US-09-659-791A-68/c
; Sequence 68, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-68
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1216 CTTCCACACTTCTGACTCG 1235
Db 20 CTTCCACACTTCTGACTCG 1

RESULT 72
US-09-659-791A-69/c
; Sequence 69, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A

QY 1275 TTTGACTCTGATCCCATCAC 1294
Db 20 TTTGACTCTGATCCCATCAC 1

RESULT 73
US-09-659-791A-70/c
; Sequence 70, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-70
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAAGTCTCC 1319
Db 20 CGGTCCCTGTAGAAGTCTCC 1

RESULT 74
US-09-659-791A-71/c
; Sequence 71, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-71
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1332 AAATTATGGAGACCGTGGC 1351
```

```
Db      20 AAATTTATGAGACCGTGGC 1
|||||
RESULT 75
US-09-659-791A-72/c
; Sequence 72, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-72
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1398 GATGTGGATGTTGCTTTTGC 1417
|||||
Db      20 GATGTGGATGTTGCTTTTGC 1
|||||
RESULT 76
US-09-659-791A-73/c
; Sequence 73, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-73
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1545 GCTCTGGATCCTGCACCTTA 1564
|||||
Db      20 GCTCTGGATCCTGCACCTTA 1
|||||
RESULT 77
US-09-659-791A-74/c
; Sequence 74, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-74
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1600 TGCTCTGTCATGCAACTAAT 1619
|||||
Db      20 TGCTCTGTCATGCAACTAAT 1
|||||
RESULT 78
US-09-659-791A-75/c
; Sequence 75, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-75
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1615 CTAATTCATATAAACTGTCT 1634
|||||
Db      20 CTAATTCATATAAACTGTCT 1
|||||
RESULT 79
US-09-659-791A-78/c
; Sequence 78, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-78
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      979 TGGACTCTTCACCAACAAC 998
|||||
```

Db 20 TGGACTGTTCCACCAACAAC 1

RESULT 80

US-09-659-791A-80/c

; Sequence 80, Application US/09659791A

; Patent No. 6383808

; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION

; FILE REFERENCE: RTS-0156

; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11

; NUMBER OF SEQ ID NOS: 90

; SEQ ID NO 80

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-659-791A-80

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1383 CACCGGAGGAGTGAGATGT 1402

Db 20 CACCGGAGGAGTGAGATGT 1

RESULT 81

US-09-459-749D-13

; Sequence 13, Application US/09459749D

; Patent No. 6464875

; GENERAL INFORMATION:

; APPLICANT: Millis, Albert J. T.

; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration

; FILE REFERENCE: 0794.016A

; CURRENT APPLICATION NUMBER: US/09/459,749D

; CURRENT FILING DATE: 1999-12-10

; PRIOR APPLICATION NUMBER: 60/111,856

; PRIOR FILING DATE: 1998-12-11

; NUMBER OF SEQ ID NOS: 17

; SOFTWARE: Patentin Ver. 2.1

; SEQ ID NO 13

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence:primer\_bind

; OTHER INFORMATION: synthetic antisense primer based on murine clusterin

US-09-459-749D-13

Query Match 1.2%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 17;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 271 AGAAGCCCAAGAGAGAAAG 291

Db 1 AGAAGCCCAAGAGAGAAAG 21

RESULT 82

US-08-855-449-10

; Sequence 10, Application US/08855449

; Patent No. 5910412

; GENERAL INFORMATION:

; APPLICANT: AKAMATSU, TOYOKAZU

; APPLICANT: SUZUKI, TAKAO

; TITLE OF INVENTION: METHOD FOR IDENTIFYING THE SEX OF

; TITLE OF INVENTION: SPINACH BY DNA MARKERS

NUMBER OF SEQUENCES: 24

CORRESPONDENCE ADDRESS:

ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,

ADDRESSEE: P. C.

STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400

CITY: ARLINGTON

STATE: VA

COUNTRY: USA

ZIP: 22202

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/855,449

FILING DATE: 13-MAY-1997

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 119124/1996

FILING DATE: 14-MAY-1996

ATTORNEY/AGENT INFORMATION:

NAME: OBLON, NORMAN F.

REGISTRATION NUMBER: 24,618

REFERENCE/DOCKET NUMBER: 7828-0003-0

TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-413-3000

TELEFAX: 703-413-2220

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 22 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

DESCRIPTION: /desc = "SYNTHETIC DNA"

US-08-855-449-10

Query Match 1.1%; Score 18.8; DB 1; Length 22;

Best Local Similarity 90.9%; Pred. No. 23;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 865 AATTCATACGAGAGCGACGA 886

Db 1 AATTCATACGAGAGCGTACGA 22

RESULT 83

US-08-410-540-22/c

; Sequence 22, Application US/08410540

; Patent No. 5807678

; GENERAL INFORMATION:

; APPLICANT: Miller, Walter L.

; APPLICANT: Lin, Dong

; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS

; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Cooley Godward Castro Huddleson & Tatum

STREET: 5 Palo Alto Square

CITY: Palo Alto

STATE: CA

COUNTRY: US

ZIP: 94306-2155

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/410,540

FILING DATE: 23-MAR-1995

```
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neeley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-239/0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816COOLEYPA
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-410-540-22

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 GAGAGCTCTGCACGCTCAC 1492
Db 18 GAGAGCTCTGCACGCTCAC 1

RESULT 84
US-09-659-791A-4
; Sequence 4, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
; US-09-659-791A-4

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTCGAA 763
Db 1 TCCGTACGAGCCCTCGAA 18

RESULT 85
US-08-397-220B-43/c
; Sequence 43, Application US/08397220B
; Patent No. 6284458
; GENERAL INFORMATION:
; APPLICANT: Anderson et al.
; TITLE OF INVENTION: Compositions And Methods For Treatment Of Hepatitis C Virus-Associated Diseases
; NUMBER OF SEQUENCE ADDRESSES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jane Massey Licata, Esq.
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
```

```
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM 486
; OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,220B
; FILING DATE: 09-Mar-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/01293
; FILING DATE: 10-Sep-93
; APPLICATION NUMBER: JP 5-87195
; FILING DATE: 14-Apr-93
; APPLICATION NUMBER: 07/945,289
; FILING DATE: 10-Sep-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-08-397-220B-43

Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GCCTCCAGGCCCCCACTCC 1529
Db 20 GCCTCCAGGCCCCCTCC 1

RESULT 86
US-08-650-093C-43/c
; Sequence 43, Application US/08650093C
; Patent No. 6391542
; GENERAL INFORMATION:
; APPLICANT: Kevin P. Anderson et al.
; TITLE OF INVENTION: Compositions And Methods For Treatment Of Hepatitis C Virus-Associated Diseases
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LICATA & TYRRELL P.C.
; STREET: 66 E. Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.1 for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/650,093C
; FILING DATE: 17-May-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/452,841
; FILING DATE: May 30, 1995
; APPLICATION NUMBER: 08/397,220
; FILING DATE: March 9, 1995
```

```

; APPLICATION NUMBER: 07/945,289
; FILING DATE: September 10, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-08-650-093C-43

Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GCCTCCAGGCCCACTCC 1529
DB 20 GCCTCCAGGCCCACTCC 1

RESULT 87
US-10-023-649A-37/c
; Sequence 37, Application US/10023649A
; Patent No. 6800289
; GENERAL INFORMATION:
; APPLICANT: Nagata, Leslie P.
; APPLICANT: Wong, Jonathan P.
; TITLE OF INVENTION: A STRAIN OF THE WESTERN EQUINE ENCEPHALITIS VIRUS (AS AMENDED)
; FILE REFERENCE: NEL-001
; CURRENT APPLICATION NUMBER: US/10/023,649A
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/256,948
; PRIOR FILING DATE: 2000-12-21
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: DNA Primer
US-10-023-649A-37

Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 524 CGACTCCCTGCTGGAGACG 543
DB 20 CGACACGCTGCTGGAGACG 1

RESULT 88
US-08-256-568B-97/c
; Sequence 97, Application US/08256568B
; Patent No. 5846704
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,369B
```

```

; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/256,568B
; FILING DATE: 18-JUL-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-08-256-568B-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
DB 16 CAGCCTCCAGGCCCCC 1

RESULT 89
US-09-038-369B-97/c
; Sequence 97, Application US/09038369B
; Patent No. 6171784
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,369B
```

```
;
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-378-900A-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 91
US-09-899-044-97/c
; Sequence 97, Application US/09899044
; Patent No. 6548244
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWEYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,044
; FILING DATE: 06-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
;

;
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-378-900A-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 90
US-09-378-900A-97/c
; Sequence 97, Application US/09378900A
; Patent No. 6495670
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWEYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,900A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
```



INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: YES  
SEQUENCE DESCRIPTION: SEQ ID NO: 97:  
US-09-899-044-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 32;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523  
DB 16 CAGCCTCCAGGCCCC 1

RESULT 92  
US-08-173-489C-37  
; Sequence 37, Application US/08173489C  
; Patent No. 5861244  
; GENERAL INFORMATION:  
; APPLICANT: WANG, C. -G.  
; APPLICANT: HEPBURN, A. G.  
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA  
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.  
; NUMBER OF SEQUENCES: 365  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,  
; STREET: 510 EAST 73RD STREET,  
; CITY: NEW YORK  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 10021.

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44Mb storage  
COMPUTER: IBM PC/XT/AT  
OPERATING SYSTEM: MS-DOS version 6.2  
SOFTWARE: Wordperfect Version 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/173,489C  
FILING DATE: 22 DEC 1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/968,436  
FILING DATE: 29 OCT 1992

ATTORNEY/AGENT INFORMATION:  
NAME: Handelman, Joseph H.  
REGISTRATION NUMBER: 26,179  
REFERENCE/DOCKET NUMBER: U9518-6  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (attorney) (212) 708-1880  
TELEFAX: (attorney) (212) 246-8959  
INFORMATION FOR SEQ ID NO: 37:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: Nucleic Acid  
STRANDEDNESS: double stranded  
TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA  
DESCRIPTION: dystrophin gene (Accession # M18533, 5983  
DESCRIPTION: M17154, M18026) nucleotides 5967 to 5983  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
POSITION IN GENOME: X-chromosome  
CHROMOSOME/SEGMENT: Xp21.3-p21.1  
MAP POSITION: Xp21.3-p21.1

PUBLICATION INFORMATION:  
AUTHORS: Koenig, M, Hoffman, E P, Bertelson, C J,  
AUTHORS: Monaco, A P, Feener, C, Kunkel, L M.  
TITLE: Complete cloning of the  
TITLE: Duchenne muscular dystrophy (DMD) cDNA and  
TITLE: preliminary genomic organization of the DMD  
TITLE: gene in normal and affected individuals  
JOURNAL: Cell  
VOLUME: 50  
PAGES: 509-517  
DATE: 1987  
AUTHORS: Hoffman, E P, Monaco, A P, Feener, C C,  
AUTHORS: Kunkel, L M.  
TITLE: Conservation of the Duchenne  
TITLE: muscular dystrophy gene in mice and humans  
JOURNAL: Science  
VOLUME: 238  
PAGES: 347-350  
DATE: 1987  
AUTHORS: Koenig, M, Monaco, A P, Kunkel, L M.  
TITLE: The complete sequence of  
TITLE: dystrophin predicts a rod-shaped cytoskeletal  
TITLE: protein  
JOURNAL: Cell  
VOLUME: 53  
PAGES: 219-228  
DATE: 1988  
RELEVANT RESIDUES IN SEQ ID NO: 37 :FROM 1 TO 17  
US-08-173-489C-37

Query Match 1.0%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAGAAAGAGGA 295  
DB 1 AGAAGAAGAAAGAGGA 16

RESULT 93  
US-08-390-850-535/c  
; Sequence 535, Application US/08390850  
; Patent No. 5612215  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 535:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-535

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 46;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1589 AAGACAGAGATTCTCC 1605  
Db 17 AAGACAGAGATTCTCC 1

RESULT 94  
US-08-435-634-535/c  
Sequence 535, Application US/08435634  
Patent No. 5731295  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 535:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-634-535

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 46;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1589 AAGACAGAGATTCTCC 1605  
Db 17 AAGACAGAGATTCTCC 1

RESULT 95  
US-09-866-108A-8666  
Sequence 8666, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8666  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8666

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 46;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCAAAGAGAGAA 289  
Db 1 GAAGCCAAAGAGAGAA 17

RESULT 96  
US-08-105-483-280/c  
; Sequence 280, Application US/08105483  
; Patent No. 5494807  
; GENERAL INFORMATION:  
; APPLICANT: Paoletti, Enzo  
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE  
; TITLE OF INVENTION: STRAIN  
; NUMBER OF SEQUENCES: 462  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Curtis, Morris & Safford  
; ADDRESSEE: c/o William S. Frommer  
; STREET: 530 Fifth Avenue  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/105,483  
; FILING DATE: 12-AUG-1993  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/847,951  
; FILING DATE: 06-MAR-1992  
; NAME: Frommer, William S.  
; REGISTRATION NUMBER: 25,506  
; REFERENCE/DOCKET NUMBER: 454310-2400  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 840-3333  
; TELEFAX: (212) 840-0712  
; INFORMATION FOR SEQ ID NO: 280:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-105-483-280  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 63;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAAACAAAC 239  
DB 18 CTAATAGAAAAAACCAAC 1  
RESULT 97  
US-08-709-209-280/c  
; Sequence 280, Application US/08709209  
; Patent No. 5762938  
; GENERAL INFORMATION:  
; APPLICANT: Paoletti, Enzo  
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE  
; TITLE OF INVENTION: STRAIN  
; NUMBER OF SEQUENCES: 462  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Curtis, Morris & Safford  
; ADDRESSEE: c/o William S. Frommer  
; STREET: 530 Fifth Avenue  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036  
; COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/709,209  
FILING DATE: 21-AUG-1996  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/105,483  
FILING DATE: 12-AUG-1993  
APPLICATION NUMBER: US 07/847,951  
FILING DATE: 06-MAR-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Frommer, William S.  
REGISTRATION NUMBER: 25,506  
REFERENCE/DOCKET NUMBER: 454310-2400  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 840-3333  
TELEFAX: (212) 840-0712  
INFORMATION FOR SEQ ID NO: 280:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-709-209-280  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 63;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAAACAAAC 239  
DB 18 CTAATAGAAAAAACCAAC 1  
RESULT 98  
US-08-458-101-280/c  
; Sequence 280, Application US/08458101  
; Patent No. 5766599  
; GENERAL INFORMATION:  
; APPLICANT: Paoletti, Enzo  
; APPLICANT: Perkus, Marion E.  
; APPLICANT: Taylor, Jill  
; APPLICANT: Tartaglia, James  
; APPLICANT: No. 5766599ton, Elizabeth K.  
; APPLICANT: Riviere, Michel  
; APPLICANT: de Taisne, Charles  
; APPLICANT: Limbach, Keith J.  
; APPLICANT: Johnson, Gerard P.  
; APPLICANT: Pincus, Steven E.  
; APPLICANT: Cox, William I.  
; APPLICANT: Audonnet, Jean-Christophe Francis  
; APPLICANT: Gettig, Russell Robert  
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE  
; TITLE OF INVENTION: STRAIN  
; NUMBER OF SEQUENCES: 467  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Curtis, Morris & Safford  
; ADDRESSEE: c/o William S. Frommer  
; STREET: 530 Fifth Avenue  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/458,101

```
; FILING DATE: 01-JUN-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Frommer, William S.
; REGISTRATION NUMBER: 25,506
; REFERENCE/DOCKET NUMBER: 454310-2740
; TELEPHONE: (212) 840-3333
; TELEFAX: (212) 840-0712
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-458-101-280

Query Match          0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 63;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAAACAAAC 239
       |||||
Db      18 CTATAGAAAAAACCAC 1

RESULT 99
US-08-758-306-953/c
; Sequence 953, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; FILING DATE: December 3, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 953:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-458-101-280

Query Match          0.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 63;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAAACAAAC 239
       |||||
Db      18 CTATAGAAAAAACCAC 1

RESULT 100
US-08-390-850-536/c
; Sequence 536, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 536:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-536

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1589 AAGAACAAGATTGCTC 1604
       |||||
Db      16 AAGAACAAGATTTC 1
```

```

; TITLE OF INVENTION: TRANSCRIPTION FACTOR CONTROLLING PHENYLPROPANOID
; FILE REFERENCE: 4859-0027-0
; CURRENT APPLICATION NUMBER: US/09/282,146A
; CURRENT FILING DATE: 1999-03-31
; EARLIER APPLICATION NUMBER: JP 10-125171
; EARLIER FILING DATE: 1998-03-31
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 7
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-282-146-7

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCAACACCTCTCCT 1119
DB 2 CTCAACAACTCCTCCT 17

RESULT 103
US-09-866-108A-8352/c
; Sequence 8352, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;
; APPLICANT: KAWAOKA, Akiyoshi
; APPLICANT: EBINUMA, Hiroyasu

; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 536:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-536

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGACAGAAATTCCTC 1604
DB 16 AAGACAGAAATTCCTC 1

RESULT 102
US-09-282-146-7
; Sequence 7, Application US/09282146A
; Patent No. 6303847
; GENERAL INFORMATION:
; APPLICANT: KAWAOKA, Akiyoshi
; APPLICANT: EBINUMA, Hiroyasu
```

```
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACCTCTCTCTGCTG 1124
Db 17 CAGCTCTCTCTGCTG 2

RESULT 104
US-09-866-108A-8353/C
; Sequence 8353, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8665

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCCAAGAAGA 288
Db 2 GAAGCCCAAGAAGA 17

RESULT 106
US-09-866-108A-8667
; Sequence 8667, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8353

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACCTCTCTCTGCTG 1124
Db 16 CAGCTCTCTCTGCTG 1

RESULT 105
US-09-866-108A-8665
; Sequence 8665, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; Patent No. 6686188
 ; SEQ ID NO 8667
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-09-866-108A-8667

 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 65;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 Qy 274 AAGCCAGAGAGAGAA 289
 Db 1 AAGCCAGAGAGAGAA 16

 RESULT 107
 US-09-866-108A-10037/c
 ; Sequence 10037, Application US/09866108A
 ; Patent No. 6686188
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharon G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AECOMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108A
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; Patent No. 6686188
 ; SEQ ID NO 10037
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-09-866-108A-10037

Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 65;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 Qy 715 CCGCATCGTCCGACG 730
 Db 17 CCGCATCGTCCACAG 2

 RESULT 108
 US-09-866-108A-10038/c
 ; Sequence 10038, Application US/09866108A
 ; Patent No. 6686188
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharon G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AECOMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108A
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; Patent No. 6686188
 ; SEQ ID NO 10038
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-09-866-108A-10038

 Query Match 0.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 65;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 Qy 715 CCGCATCGTCCGACG 730
 Db 16 CCGCATCGTCCACAG 1

 RESULT 109
 US-08-117-952-797/c
 ; Sequence 797, Application US/08117952
 ; Patent No. 5851760
 ; GENERAL INFORMATION:
 ; APPLICANT: Evans, Glen A.
 ; APPLICANT: Smith, Michael W.
 ; TITLE OF INVENTION: METHOD FOR GENERATION OF SEQUENCE
 ; TITLE OF INVENTION: SAMPLED MAPS OF COMPLEX GENOMES



Mon Nov 7 09:26:59 2005

```
;
; NUMBER OF SEQUENCES: 797
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,952
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/078,471
; FILING DATE: 15-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: F41 9423
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-546-4737
; TELEFAX: 619-546-9392
; INFORMATION FOR SEQ ID NO: 797:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Oligonucleotide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-117-952-797

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 73;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1520 CCCCAACTCCGCCAG 1535
Db 18 CCCTAACTCCGCCAG 3

RESULT 110
US-08-758-306-467
; Sequence 467, Application US/08/58306
; Patent No. 580743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

;
; NUMBER OF SEQUENCES: 797
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,952
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/078,471
; FILING DATE: 15-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: F41 9423
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-546-4737
; TELEFAX: 619-546-9392
; INFORMATION FOR SEQ ID NO: 797:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Oligonucleotide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-117-952-797

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 73;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1520 CCCCAACTCCGCCAG 1535
Db 18 CCCTAACTCCGCCAG 3

RESULT 110
US-08-758-306-467
; Sequence 467, Application US/08/58306
; Patent No. 580743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

;
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 467:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-758-306-467

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 80;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 693 CCTCACTTCTTCTTCC 709
Db 1 CCUCCUCCUCCUCCUCC 17

RESULT 111
US-08-599-455B-25
; Sequence 25, Application US/08/599455B
; Patent No. 5972621
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT
; TITLE OF INVENTION: MODULATE BODY WEIGHT USING THE OB RECEPTOR
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/599,455B
; FILING DATE: 22-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Weiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
```

```

; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-599-455B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGGCCCTTCAG 17

RESULT 112
US-08-599-455B-27
; Sequence 27, Application US/08599455B
; Patent No. 5972621
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT
; TITLE OF INVENTION: MODULATE BODY WEIGHT USING THE OB RECEPTOR
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/599,455B
; FILING DATE: 22-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-474-700B-21

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAAACAAA 238
Db 17 CTCAGAGAAAAACAAA 1

RESULT 114
US-08-757-024-874/c
; Sequence 874, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
```

Mon Nov 7 09:26:59 2005

```

; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 874:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-757-024-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCAGCCTCTCCCGC 1546
Db 17 GCCAGCCTGTGCCGC 1

RESULT 116
US-09-069-781B-25
; Sequence 25, Application US/09069781B
; Patent No. 6287782
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Cupepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/069,781B
; FILING DATE: 29-APRIL-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: US 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: US 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: US 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: US 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: US 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: US 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: US 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: US 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/082001
; TELECOMMUNICATION INFORMATION:

; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:

Qy 1530 GCCAGCCTCTCCCGC 1546
Db 17 GCCAGCCTGTGCCGC 1

RESULT 115
US-08-757-024-944/c
; Sequence 944, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCAGCCTCTCCCGC 1546
Db 17 GCCAGCCTGTGCCGC 1
```

TELEPHONE: (617) 542-5070  
TELEFAX: (617) 542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-09-069-781B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
||||| |||||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 117  
US-09-069-781B-27  
Sequence 27, Application US/09069781B  
Patent No. 6287782  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: Fast-SEQ for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/069,781B  
FILING DATE: 29-APRIL-1998  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/864,564  
FILING DATE: 28-MAY-1997  
APPLICATION NUMBER: US 08/708,123  
FILING DATE: 03-SEP-1996  
APPLICATION NUMBER: US 08/638,524  
FILING DATE: 26-APR-1996  
APPLICATION NUMBER: US 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: US 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: US 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: US 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: US 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: US 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/082001  
TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542-5070  
TELEFAX: (617) 542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-09-069-781B-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
||||| |||||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 118  
US-08-584-040-7759  
Sequence 7759, Application US/08584040  
Patent No. 6346398  
GENERAL INFORMATION:  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: TREATMENT OF DISEASES OR  
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
TITLE OF INVENTION: GROWTH FACTOR  
NUMBER OF SEQUENCES: 8502  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: Storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 7759:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-7759

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 80;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1112 CTCCTCTGCTGAGC 1128  
Db 1 CUCGCCUUGCUGAAGC 17

RESULT 119

US-08-679-645-687/c  
; Sequence 687, Application US/08679645  
; Patent No. 6350934  
; GENERAL INFORMATION:  
; APPLICANT: Zwick, Michael G.  
; APPLICANT: Edington, Brent E.  
; APPLICANT: McSwiggan, James A.  
; APPLICANT: Merlo, Patricia Ann Owens  
; APPLICANT: Guo, Lining  
; APPLICANT: Skokut, Thomas A.  
; APPLICANT: Young, Scott A.  
; APPLICANT: Folkerts, Otto  
; APPLICANT: Merlo, Donald J.  
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR  
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION  
; TITLE OF INVENTION: IN PLANTS  
; NUMBER OF SEQUENCES: 1263  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/679,645  
; FILING DATE: July 12, 1996  
; CLASSIFICATION: 800  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/001,135  
; FILING DATE: July 13, 1995  
; APPLICATION NUMBER: 08/300,726  
; FILING DATE: September 2, 1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 219/247  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 687:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-679-645-687

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1213 TGGCTTCCCACTTCT 1229  
Db 17 TGGCTGCAACACTTCT 1

RESULT 120

US-09-137-132-25  
; Sequence 25, Application US/09137132  
; Patent No. 6380363  
; GENERAL INFORMATION:  
; APPLICANT: Tartaglia, Louis A.  
; APPLICANT: Tepper, Robert I.  
; APPLICANT: Culpepper, Janice A.  
; APPLICANT: White, David W.  
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/137,132  
; FILING DATE: 18-AUG-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/864,564  
; FILING DATE: 28-MAY-1997  
; APPLICATION NUMBER: 08/708,123  
; FILING DATE: 03-SEP-1996  
; APPLICATION NUMBER: 08/638,524  
; FILING DATE: 26-APR-1996  
; APPLICATION NUMBER: 08/599,455  
; FILING DATE: 22-JAN-1996  
; APPLICATION NUMBER: 08/583,153  
; FILING DATE: 28-DEC-1995  
; APPLICATION NUMBER: 08/570,142  
; FILING DATE: 11-DEC-1995  
; APPLICATION NUMBER: 08/569,485  
; FILING DATE: 08-DEC-1995  
; APPLICATION NUMBER: 08/566,622  
; FILING DATE: 04-DEC-1995  
; APPLICATION NUMBER: 08/562,663  
; FILING DATE: 27-NOV-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meiklejohn, Ph.D., Anita L.  
; REGISTRATION NUMBER: 35,283  
; REFERENCE/DOCKET NUMBER: 07334/019004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-09-137-132-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACTGCGCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17

RESULT 122  
US-08-864-564A-25  
; Sequence 25, Application US/08864564A  
; Patent No. 6395498  
; GENERAL INFORMATION:  
; APPLICANT: Tartaglia, Louis A.  
; APPLICANT: Tepper, Robert I.  
; APPLICANT: Culpepper, Janice A.  
; APPLICANT: White, David W.  
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/864,564A  
; FILING DATE: 28-MAY-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/708,123  
; FILING DATE: 03-SEP-1996  
; APPLICATION NUMBER: 08/638,524  
; FILING DATE: 26-APR-1996  
; APPLICATION NUMBER: 08/599,455  
; FILING DATE: 22-JAN-1996  
; APPLICATION NUMBER: 08/583,153  
; FILING DATE: 28-DEC-1995  
; APPLICATION NUMBER: 08/570,142  
; FILING DATE: 11-DEC-1995  
; APPLICATION NUMBER: 08/569,485  
; FILING DATE: 08-DEC-1995  
; APPLICATION NUMBER: 08/566,622  
; FILING DATE: 04-DEC-1995  
; APPLICATION NUMBER: 08/562,663  
; FILING DATE: 27-NOV-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meiklejohn, Ph.D., Anita L.  
; REGISTRATION NUMBER: 35,283  
; REFERENCE/DOCKET NUMBER: 07334/019002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
; US-08-864-564A-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17

RESULT 121  
US-09-137-132-27  
; Sequence 27, Application US/09137132  
; Patent No. 6380363  
; GENERAL INFORMATION:  
; APPLICANT: Tartaglia, Louis A.  
; APPLICANT: Tepper, Robert I.  
; APPLICANT: Culpepper, Janice A.  
; APPLICANT: White, David W.  
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/137,132  
; FILING DATE: 18-AUG-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/864,564  
; FILING DATE: 28-MAY-1997  
; APPLICATION NUMBER: 08/708,123  
; FILING DATE: 03-SEP-1996  
; APPLICATION NUMBER: 08/638,524  
; FILING DATE: 26-APR-1996  
; APPLICATION NUMBER: 08/599,455  
; FILING DATE: 22-JAN-1996  
; APPLICATION NUMBER: 08/583,153  
; FILING DATE: 28-DEC-1995  
; APPLICATION NUMBER: 08/570,142  
; FILING DATE: 11-DEC-1995  
; APPLICATION NUMBER: 08/569,485  
; FILING DATE: 08-DEC-1995  
; APPLICATION NUMBER: 08/566,622  
; FILING DATE: 04-DEC-1995  
; APPLICATION NUMBER: 08/562,663  
; FILING DATE: 27-NOV-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meiklejohn, Ph.D., Anita L.  
; REGISTRATION NUMBER: 35,283  
; REFERENCE/DOCKET NUMBER: 07334/019004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 27:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
; US-09-137-132-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17

```

; Sequence 25, Application US/09094410
; Patent No. 6403552
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,410
; FILING DATE: 09-JUN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-09-094-410-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17

RESULT 125
US-09-094-410-27

```

```

; Sequence 27, Application US/08864564A
; Patent No. 6395498
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/864,564A
; FILING DATE: 28-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-864-564A-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17

RESULT 124
US-09-094-410-25

```

```
; Sequence 27, Application US/09094410
; Patent No. 6403552
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,410
; FILING DATE: 09-JUN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-09-094-410-27
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTTCCTTCAG 17

RESULT 126
US-08-708-123D-25
; Sequence 27, Application US/08708123D
; Patent No. 6482927
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/708,123D
; FILING DATE: 03-SEP-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-708-123D-25
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTTCCTTCAG 17

RESULT 127
US-08-708-123D-27
; Sequence 27, Application US/08708123D
; Patent No. 6482927
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
```



APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/708,123D  
FILING DATE: 03-SEP-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/538,524  
FILING DATE: 26-APR-1996  
APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/019001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-708-123D-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACTGCGCCTTCAG 676  
||||| |||||||  
Db 1 CACTATTGCGCCTTCAG 17

RESULT 128  
US-08-583-153A-25  
Sequence 25, Application US/08583153A  
Patent No. 6506877  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING

TITLE OF INVENTION: OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 41  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/583,153A  
FILING DATE: 28-DEC-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/016001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-583-153A-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACTGCGCCTTCAG 676  
||||| |||||||  
Db 1 CACTATTGCGCCTTCAG 17

RESULT 129  
US-08-583-153A-27  
Sequence 27, Application US/08583153A  
Patent No. 6506877  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING

COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/583,153A  
FILING DATE: 28-DEC-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/016001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-583-153A-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17

RESULT 130  
US-08-524B-25  
Sequence 25, Application US/08639524B  
Patent No. 6548269  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING OB  
TITLE OF INVENTION: CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/638,524B  
FILING DATE: 26-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153

FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/018001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-638-524B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCGCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17

RESULT 131  
US-08-524B-27  
Sequence 27, Application US/08638524B  
Patent No. 6548269  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING OB  
TITLE OF INVENTION: CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/638,524B  
FILING DATE: 26-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622



Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 80;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGTCCT 109  
 ||||| ||||| ||||| |||||  
 DB 17 GAGAGAGCCAGGTCCT 1

RESULT 135  
 US-09-866-108A-2643/c  
 ; Sequence 2643, Application US/09866108A  
 ; Patent No. 6686188  
 ; GENERAL INFORMATION:  
 ; APPLICANT: GU, Yizhong  
 ; APPLICANT: JI, Yonggang  
 ; APPLICANT: PENN, Sharron G.  
 ; APPLICANT: HANZEL, David K.  
 ; APPLICANT: RANK, David R.  
 ; APPLICANT: CHEN, Wensheng  
 ; APPLICANT: SHANNON, Mark  
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
 ; FILE REFERENCE: AEOMICA-7  
 ; CURRENT APPLICATION NUMBER: US/09/866,108A  
 ; CURRENT FILING DATE: 2001-05-25  
 ; PRIOR APPLICATION NUMBER: US 60/207,456  
 ; PRIOR FILING DATE: 2000-05-26  
 ; PRIOR APPLICATION NUMBER: GB 24263.6  
 ; PRIOR FILING DATE: 2000-10-04  
 ; PRIOR APPLICATION NUMBER: US 60/236,359  
 ; PRIOR FILING DATE: 2000-09-27  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663  
 ; PRIOR FILING DATE: 2001-01-30  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 15755  
 ; SOFTWARE: Aecomica Sequence Listing Engine  
 ; Patent No. 6686188  
 ; SEQ ID NO 7355  
 ; LENGTH: 17  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-866-108A-7355

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 80;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 CTTCAGCACCCTCCAA 861  
 ||||| ||||| ||||| |||||  
 DB 17 CTGCCAGGACCCGCCAA 1

RESULT 136  
 US-09-866-108A-7355  
 ; Sequence 7355, Application US/09866108A  
 ; Patent No. 6686188  
 ; GENERAL INFORMATION:  
 ; APPLICANT: GU, Yizhong  
 ; APPLICANT: JI, Yonggang

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7485

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GTCCAGCCTCTCTCGC 1

RESULT 138
US-09-866-108A-8568
; Sequence 8568, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-8568

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 292 AGGATGCCCTAAATGAG 308
Db 1 AGGATGACCTGAATGAG 17

RESULT 139
US-09-866-108A-8660
; Sequence 8660, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8660

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 267 CTGAGAGAGCCCAAGAA 283
Db 1 CTGAGAGAGCCCAAGAA 17

RESULT 140
US-09-866-108A-8661
; Sequence 8661, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US 60/236,359  
CURRENT FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8661  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8661

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 268 TAGAAGAAGCCCAAGAAG 284  
DB 1 TGGAGGAAGCCCAAGAAG 17

RESULT 141  
US-09-866-108A-8663  
Sequence 8663, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8661  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8661

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 268 TAGAAGAAGCCCAAGAAG 284  
DB 1 TGGAGGAAGCCCAAGAAG 17

RESULT 142  
US-09-866-108A-8664  
Sequence 8664, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8664  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8663

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 270 GAAGAAGCCCAAGAGAA 286  
DB 1 GAGGAAGCCCAAGAGGA 17

```
; ORGANISM: Homo sapiens
US-09-866-108A-9687

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCAGAGGAG 287
Db 1 AGGAGCCAGAGGAG 17

RESULT 143
US-09-866-108A-9687/c
; Sequence 9687, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9687

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGTCCT 109
Db 17 GAGAGTGGCAGGTCCT 1

RESULT 144
US-09-866-108A-9688/c
; Sequence 9688, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9688

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 92 GGAGAGTGGCAGGTCC 108
Db 17 GGAGAGTGGCAGGTCC 1

RESULT 145
US-09-866-108A-9689/c
; Sequence 9689, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 686188
; SEQ ID NO 9689
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9689

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GCGAGAGTGGCGAGTC 107
Db 17 GCGAGAGTGGCGAGTC 1

RESULT 146
US-09-685-664B-3543
; Sequence 3543, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685.664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3543
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3543

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 80;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1112 CTCCTCCTTGCTGGAGC 1128
Db 1 CUCCCCUUGCUGAAGC 17

RESULT 147
US-09-093-972C-874/c
; Sequence 874, Application US/09093972C
; Patent No. 6825174
```

```

; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/093.972C
; FILING DATE: 09-Jun-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 08/757,024
; FILING DATE: 26-11-1996
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 09/016,464
; FILING DATE: 30-January-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 874:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 874:
US-09-093-972C-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCGC 1

RESULT 148
US-09-093-972C-944/c
; Sequence 944, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
```



```

1  COUNTRY: USA
2  ZIP: 08512
3  COMPUTER READABLE FORM:
4  MEDIUM TYPE: Floppy disk
5  COMPUTER: IBM PC compatible
6  OPERATING SYSTEM: PC-DOS/MS-DOS
7  SOFTWARE: Patentin Release #1.0, Version #1.30
8  CURRENT APPLICATION DATA:
9  APPLICATION NUMBER: US/09/093,972C
10 FILING DATE: 09-Jun-1998
11 CLASSIFICATION: <Unknown>
12 PRIOR APPLICATION DATA:
13 APPLICATION NUMBER: US 08/472,527
14 FILING DATE: 7-June-1995
15 APPLICATION NUMBER: US 08/757,024
16 FILING DATE: 26-11-1996
17 APPLICATION NUMBER: US 08/472,527
18 FILING DATE: 7-June-1995
19 APPLICATION NUMBER: US 09/016,464
20 FILING DATE: 30-January-1998
21 ATTORNEY/AGENT INFORMATION:
22 NAME: Anzel, Viviana
23 REGISTRATION NUMBER: 30,930
24 REFERENCE/DOCKET NUMBER: EPI-00672
25 TELECOMMUNICATION INFORMATION:
26 TELEPHONE: 609-409-3035
27 TELEFAX: 413-254-9245
28 TELEX: <Unknown>
29 INFORMATION FOR SEQ ID NO: 944:
30 SEQUENCE CHARACTERISTICS:
31 LENGTH: 17 base pairs
32 TYPE: nucleic acid
33 STRANDEDNESS: single
34 TOPOLOGY: linear
35 MOLECULE TYPE: DNA (genomic)
36 SEQUENCE DESCRIPTION: SEQ ID NO: 944:
37 US-09-093-972C-944
38
39 Query Match 0.8% Score 13.8; DB 1; Length 17;
40 Best Local Similarity 88.2%; Pred. No. 80;
41 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
42
43 QY 1530 GCCCAGCCTCTCCCGC 1546
44 ||||||| |||||
45 Db 17 GCCCAGCCTGTGCCGC 1
46
47 RESULT 149
48 PCT-US95-05812-21/c
49 Sequence 21, Application PC/TUS9505812
50 GENERAL INFORMATION:
51 APPLICANT: Wakita, Takaji
52 APPLICANT: Wands, Jack
53 TITLE OF INVENTION: ANTISENSE INHIBITION OF
54 TITLE OF INVENTION: HEPATITIS C VIRUS
55 NUMBER OF SEQUENCES: 38
56 CORRESPONDENCE ADDRESS:
57 ADDRESSEE: Fish & Richardson
58 STREET: 225 Franklin Street
59 CITY: Boston
60 STATE: Massachusetts
61 COUNTRY: U.S.A.
62 ZIP: 02110-2804
63 COMPUTER READABLE FORM:
64 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
65 COMPUTER: IBM PS/2 Model 50z or 55SX
66 OPERATING SYSTEM: MS-DOS (Version 5.0)
67 SOFTWARE: WordPerfect (Version 5.1)
68 CURRENT APPLICATION DATA:
69 APPLICATION NUMBER: PCT/US95/05812
70 FILING DATE:
71 CLASSIFICATION:
72 PRIOR APPLICATION DATA:

```

```
; INFORMATION FOR SEQ ID NO: 160:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-291-932A-160

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 71;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCCTCCAGGCC 1521
Db 1 CCAGGCCUCCAGGCUC 15

RESULT 151
US-09-180-437-151/c
; Sequence 151, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshifumi
; APPLICANT: KUSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209P
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; NUMBER OF SEQ ID NOS: 289
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 151
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:other nucleic
; OTHER INFORMATION: acid
US-09-180-437-151

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 432 TGCAGAGTGGCTCA 446
Db 15 TGCAGCAGTGGCTCA 1

RESULT 152
US-09-081-646-174/c
; Sequence 174, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 174
; LENGTH: 15
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-174

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1

RESULT 153
US-09-081-646-783/c
; Sequence 783, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 783
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-783

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1

RESULT 154
US-09-736-116-75/c
; Sequence 75, Application US/09736116
; Patent No. 6727085
; GENERAL INFORMATION:
; APPLICANT: Sejersgard, Tina
; APPLICANT: Mikkelsen, Frank
; TITLE OF INVENTION: Subtilase variants having an improved wash performance on egg stain
; FILE REFERENCE: 6108.410
; CURRENT APPLICATION NUMBER: US/09/736,116
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 75
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-736-116-75

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1076 GCTGCTAAAGTCTTA 1090
Db 1076 GCTGCTAAAGTCTTA 1090
```

Db 15 GCTGTTAAAGTCCTA 1

RESULT 155

US-08-173-489C-32/c

Sequence 32, Application US/08173489C

Patent No. 5861244

GENERAL INFORMATION:

APPLICANT: WANG, C. -G.

APPLICANT: HEPBURN, A. G.

TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA

TITLE OF INVENTION: TRIPLE-STRAND FORMATION.

NUMBER OF SEQUENCES: 365

CORRESPONDENCE ADDRESS:

ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,

STREET: 510 EAST 73RD STREET,

CITY: NEW YORK

STATE: NEW YORK

COUNTRY: USA

ZIP: 10021.

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44Mb storage

COMPUTER: IBM PC/XT/AT

OPERATING SYSTEM: MS-DOS version 6.2

SOFTWARE: Wordperfect Version 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08173.489C

FILING DATE: 22 DEC 1993

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/968,436

FILING DATE: 29 OCT 1992

ATTORNEY/AGENT INFORMATION:

NAME: Handelsman, Joseph H.

REGISTRATION NUMBER: 26,179

REFERENCE/DOCKET NUMBER: U9518-6

TELECOMMUNICATION INFORMATION:

TELEPHONE: (attorney) (212) 708-1880

TELEFAX: (attorney) (212) 246-8959

INFORMATION FOR SEQ ID NO: 32:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 bases

TYPE: Nucleic Acid

STRANDEDNESS: single stranded

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

DESCRIPTION: third strand derived from dystrophin

DESCRIPTION: sequence region in Seq ID No. 586124431

HYPOTHETICAL: Yes

ANTI-SENSE: NO

PUBLICATION INFORMATION:

RELEVANT RESIDUES IN SEQ ID NO: 32 :FROM 1 TO 16

US-08-173-489C-32

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 81;

Mismatches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 15 AAGAAGCAAGAAGA 285

15 AAGAAGCAAGAAGA 1

RESULT 156

US-09-034-205-67

Sequence 67, Application US/09034205

Patent No. 6194149

GENERAL INFORMATION:

APPLICANT: Lyamichev, Victor I.

APPLICANT: Brow, Mary Ann D.

APPLICANT: Fors, Lance

APPLICANT: Neri, Bruce P.

TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING

TITLE OF INVENTION: STRUCTURE-BRIDGING OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 68

CORRESPONDENCE ADDRESS:

ADDRESSEE: MEDLEN & CARROLL, LLP

STREET: 220 Montgomery Street, Suite 2200

CITY: San Francisco

STATE: CA

COUNTRY: USA

ZIP: 94104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/034,205

FILING DATE:

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: MacKnight, Kamrin T.

REGISTRATION NUMBER: 38,230

REFERENCE/DOCKET NUMBER: FORS-03268

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 705-8410

TELEFAX: (415) 397-8338

INFORMATION FOR SEQ ID NO: 67:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

DESCRIPTION: /desc = "DNA"

US-09-034-205-67

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 81;

Mismatches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 1508 CAGCCTCCAGGCCCC 1522

2 CAGCCTCCAGGCCCC 16

RESULT 157

US-09-034-205-68

Sequence 68, Application US/09034205

Patent No. 6194149

GENERAL INFORMATION:

APPLICANT: Lyamichev, Victor I.

APPLICANT: Brow, Mary Ann D.

APPLICANT: Fors, Lance

APPLICANT: Neri, Bruce P.

TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING

TITLE OF INVENTION: STRUCTURE-BRIDGING OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 68

CORRESPONDENCE ADDRESS:

ADDRESSEE: MEDLEN & CARROLL, LLP

STREET: 220 Montgomery Street, Suite 2200

CITY: San Francisco

STATE: CA

COUNTRY: USA

ZIP: 94104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/034,205

FILING DATE:

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

```

; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-034-205-68
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 158
US-09-677-218B-67
; Sequence 67, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; Fors, Lance P.
; Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
; STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-677-218B-67
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 158
US-09-677-218B-67
; Sequence 67, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; Fors, Lance P.
; Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
; STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-677-218B-67
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 160
US-09-677-192-67
; Sequence 67, Application US/09677192
; Patent No. 6358691
; GENERAL INFORMATION:
```

```

; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-034-205-68
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 159
US-09-677-218B-68
; Sequence 68, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; Brow, Mary Ann D.
; Fors, Lance P.
; Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
; STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-677-218B-68
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 160
US-09-677-192-67
; Sequence 67, Application US/09677192
; Patent No. 6358691
; GENERAL INFORMATION:
```

RESULT 162  
US-09-402-618B-67  
; Sequence 67, Application US/09402618B  
; Patent No. 6709815  
; GENERAL INFORMATION:  
; APPLICANT: Dong, Fang  
; APPLICANT: Lyvamichev, Victor  
; APPLICANT: Prudent, James

RESULT 164  
US-08-796-031-1/c  
; Sequence 1, Application US/08796031  
; Patent No. 5849903  
; GENERAL INFORMATION:

APPLICANT: Zbigniew Pietrzkowski, Gordana Olbina and Dariusz Cieslak  
TITLE OF INVENTION: Inhibition of Tumor Growth by Antisense  
TITLE OF INVENTION: Oligonucleotides for 11-8 and 11-8 Receptor  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Crockett & Fish  
STREET: 3000 S. Augusta Court  
CITY: La Habra  
STATE: California  
COUNTRY: United States of America  
ZIP: 90631  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WordPerfect 6.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/796,031  
FILING DATE: 1 January 1997  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/561,302  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Fish, Robert D.  
REGISTRATION NUMBER: 33,880  
REFERENCE/DOCKET NUMBER: 213/015-CIP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-525-3433  
TELEFAX: 714-525-3303  
TELEX:  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 14 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: DNA (genomic)  
US-08-796-031-1  
Query Match 0.8%; Score 13; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 71;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1239 GTTCCTCCGGTG 1251  
Db 13 GTTCCTCCGGTG 1  
RESULT 165  
US-09-055-913-1/C  
Sequence 1, Application US/09055913  
Patent No. 6017898  
GENERAL INFORMATION:  
APPLICANT: Zbigniew Pietrzkowski, Gordana Olbina and Dariusz Cieslak  
TITLE OF INVENTION: Inhibition of Tumor Growth by Antisense  
TITLE OF INVENTION: Oligonucleotides for 11-8 and 11-8 Receptor  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Crockett & Fish  
STREET: 3000 S. Augusta Court  
CITY: La Habra  
STATE: California  
COUNTRY: United States of America  
ZIP: 90631  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WordPerfect 6.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/055,913  
FILING DATE:

CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/561,302  
FILING DATE: 1 January 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Fish, Robert D.  
REGISTRATION NUMBER: 33,880  
REFERENCE/DOCKET NUMBER: 213/015-CIP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-525-3433  
TELEFAX: 714-525-3303  
TELEX:  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 14 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: DNA (genomic)  
US-09-055-913-1  
Query Match 0.8%; Score 13; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 71;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1239 GTTCCTCCGGTG 1251  
Db 13 GTTCCTCCGGTG 1  
RESULT 166  
US-08-985-090-23/c  
Sequence 23, Application US/08985090  
Patent No. 5885893  
GENERAL INFORMATION:  
APPLICANT: Andrew D. J. Goodearl  
TITLE OF INVENTION: MUSCARINIC RECEPTORS AND USES THEREFOR  
NUMBER OF SEQUENCES: 28  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/985,090  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Jean M. Silveri  
REGISTRATION NUMBER: 39,030  
REFERENCE/DOCKET NUMBER: MNI-032  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 23:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-985-090-23  
Query Match 0.8%; Score 12.8; DB 1; Length 16;

Mon Nov 7 09:26:59 2005

```
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 72 GTGGGGCTGTGCTGA 87
Db 16 GTGGGGCAGTGCTCA 1

RESULT 167
US-08-757-024-875/c
; Sequence 875, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 882:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-757-024-882

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCAGCCTCTCCCGC 1545
Db 16 GCCAGCCTGTGCCCG 1

RESULT 169
US-08-757-024-945/c
; Sequence 945, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1531 CCCAGCCTCTCCCGC 1546
Db 16 CCCAGCCTGTGCCCG 1

RESULT 168
US-08-757-024-882/c
; Sequence 882, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
```

```

; MOLECULE TYPE: DNA (genomic)
US-08-757-024-945
Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCAGCCTCTCCCG 1545
Db 16 GCCAGCCTGTGCCG 1

RESULT 170
US-09-165-543-25/c
; Sequence 25, Application US/09165543
; Patent No. 6093545
; GENERAL INFORMATION:
; APPLICANT: Andrew D.J. Goodearl and Sandra Glucksman
; TITLE OF INVENTION: Muscarinic Receptors and Uses Therefor
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/165,543
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/042,780
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Elizabeth A. Hanley
; REGISTRATION NUMBER: 33,505
; REFERENCE/DOCKET NUMBER: MN1-032CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-09-165-543-25
Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 72 GTGGGGCTGCTGCTCA 87
Db 16 GTGGGGCAGCTGCTCA 1

RESULT 171
US-08-679-645-523
; Sequence 523, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
```

```

; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 523:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-523
Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 99;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 666 CTGCCCTTCAGCCTGC 681
Db 1 CUGCGGUCAGCCUGC 16

RESULT 172
US-09-093-972C-875/c
; Sequence 875, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
```



ZIP: 08512  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-Jun-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930  
REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-409-3035  
TELEFAX: 413-254-9245  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 875:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 875:  
US-09-093-972C-875  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 99;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1531 CCCAGCCTCTCCCGC 1546  
Db 16 CCCAGCCTGTGCCGC 1  
RESULT 173  
US-09-093-972C-882/c  
Sequence 882, Application US/09093972C  
Patent No. 6825174  
GENERAL INFORMATION:  
APPLICANT: Nyce, Jonathan W.  
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION  
NUMBER OF SEQUENCES: 996  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
STREET: 7 Clarke Drive  
CITY: Cranbury  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 08512  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-Jun-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930  
REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-409-3035  
TELEFAX: 413-254-9245  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 882:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 882:  
US-09-093-972C-882  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 99;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1530 GCCAGCCTCTCCCGC 1545  
Db 16 GCCAGCCTGTGCCGC 1  
RESULT 174  
US-09-093-972C-945/c  
Sequence 945, Application US/09093972C  
Patent No. 6825174  
GENERAL INFORMATION:  
APPLICANT: Nyce, Jonathan W.  
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION  
NUMBER OF SEQUENCES: 996  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
STREET: 7 Clarke Drive  
CITY: Cranbury  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 08512  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-Jun-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930

```

; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 945:
US-09-093-972C-945

Query Match      0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCACGCTCTCCCG 1545
Db 16 GCCACGCTGTGCCG 1

RESULT 175
US-08-650-093C-97
; Sequence 97, Application US/08650093C
; Patent No. 6391542
; GENERAL INFORMATION:
; APPLICANT: Kevin P. Anderson et al.
; TITLE OF INVENTION: Compositions And Methods For Treatment Of
; HEPATITIS C VIRUS-ASSOCIATED DISEASES
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LICATA & TYRRELL P.C.
; STREET: 66 E. Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.1 for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/650,093C
; FILING DATE: 17-May-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/452,841
; FILING DATE: May 30, 1995
; APPLICATION NUMBER: 08/397,220
; FILING DATE: March 9, 1995
; APPLICATION NUMBER: 07/945,289
; FILING DATE: September 10, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: No
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-08-650-093C-97

; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 945:
US-09-093-972C-945

Query Match      0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 88;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1510 GCCTCCAGGCCCCC 1523
Db 1 GCCUCCAGGACCCC 14

RESULT 176
US-09-720-435A-172
; Sequence 172, Application US/09720435A
; Patent No. 6803187
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease
; FILE REFERENCE: 11362.0030.PCUS00 INNS:030
; CURRENT APPLICATION NUMBER: US/09/720,435A
; PRIOR FILING DATE: 2001-06-25
; PRIOR APPLICATION NUMBER: PCT/EP99/04317
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 98870143.9
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 172
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Aids-associated retrovirus
US-09-720-435A-172

Query Match      0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 37 GAATTGGAGGCATG 50
Db 1 GAATTGGAGGCCTG 14

RESULT 177
US-08-050-073-65
; Sequence 65, Application US/08050073
; Patent No. 5567809
; GENERAL INFORMATION:
; APPLICANT: Apple, Raymond J.
; APPLICANT: Begovich, Ann B.
; APPLICANT: Bugawan, Teodorica L.
; APPLICANT: Erlich, Henry A.
; APPLICANT: Griffith, Robert L.
; APPLICANT: Scharf, Stephen J.
; TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 315
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/050,073
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry, Douglas A.
```

QY 1508 CAGCCTCCAGGCC 1521  
Db 2 CAGCCTCCAGGCC 15

RESULT 179  
US-08-182-968A-422/c  
; Sequence 422, Application US/08182968A  
; Patent No. 5610054  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: INHIBITING HEPATITIS C  
; TITLE OF INVENTION: VIRUS REPLICATION  
; NUMBER OF SEQUENCES: 497  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/182,968A  
; FILING DATE: 13-JANUARY-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/882,888  
; FILING DATE: 14-MAY-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 205/277  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 422:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-182-968A-422

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1e+02; Mismatches 0; Gaps 0;  
Matches 13; Conservative 0; Indels 1; Indels 0; Gaps 0;

QY 870 ATACGAGAGCGCA 883  
Db 15 ATACGAGAGCGCA 2

RESULT 180  
US-08-182-968A-423/c  
; Sequence 423, Application US/08182968A  
; Patent No. 5610054  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: INHIBITING HEPATITIS C  
; TITLE OF INVENTION: VIRUS REPLICATION  
; NUMBER OF SEQUENCES: 497  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: Suite 4700

; REGISTRATION NUMBER: 35,321  
; REFERENCE/DOCKET NUMBER: 8769  
; TELEPHONE: (510) 814-2974  
; TELEFAX: (510) 814-2977  
; INFORMATION FOR SEQ ID NO: 65:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: genomic DNA  
; US-08-050-073-65

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1e+02; Mismatches 0; Gaps 0;  
Matches 13; Conservative 0; Indels 1; Indels 0; Gaps 0;

QY 1074 GAGCTGCTAAAGTC 1087  
Db 1 GAGCTGCTAAAGTC 14

RESULT 178  
US-08-182-968A-2  
; Sequence 2, Application US/08182968A  
; Patent No. 5610054  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: INHIBITING HEPATITIS C  
; TITLE OF INVENTION: VIRUS REPLICATION  
; NUMBER OF SEQUENCES: 497  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/182,968A  
; FILING DATE: 13-JANUARY-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/882,888  
; FILING DATE: 14-MAY-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 205/277  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-182-968A-2

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 85.7%; Pred. No. 1e+02; Mismatches 1; Indels 0; Gaps 0;  
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 423:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-182-968A-423

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1;

QY 870 ATACGAGAGCGCA 883
DB 14 ATACGATAGCGCA 1

RESULT 181
US-08-363-240A-237
; Sequence 237, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
;

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
;

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-237

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 3; Mismatches 1;

QY 1309 TAGAGTCTCCAGG 1322
DB 1 UAGAAGUCCUCCAG 14

RESULT 182
US-08-363-240A-528
; Sequence 528, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
;

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-237
```

TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-363-240A-528

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 78.6%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 841 CGGCCTTCCAGCAC 854  
||||:|||||  
Db 2 CGCCUCCAGCGC 15

RESULT 183  
US-08-363-240A-529  
; Sequence 529, Application US/08363240A  
; Patent No. 5705388  
; GENERAL INFORMATION:  
; APPLICANT: Couture, Larry  
; APPLICANT: McSwiggen, James  
; APPLICANT: Bisgaier, Charles  
; APPLICANT: Pape, Michael  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: PREVENTION, INHIBITION OF  
; TITLE OF INVENTION: PROGRESSION AND REGRESSION  
; TITLE OF INVENTION: OF VASCULAR DISEASES  
; NUMBER OF SEQUENCES: 1243  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/363,240A  
; FILING DATE: December 23, 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 210/096  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 529:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-363-240A-529

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 78.6%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 841 CGGCCTTCCAGCAC 854  
||||:|||||  
Db 1 CGGCCUCCAGCGC 14

RESULT 184  
US-08-363-240A-724/c  
; Sequence 724, Application US/08363240A  
; Patent No. 5705388  
; GENERAL INFORMATION:  
; APPLICANT: Couture, Larry  
; APPLICANT: McSwiggen, James  
; APPLICANT: Bisgaier, Charles  
; APPLICANT: Pape, Michael  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: PREVENTION, INHIBITION OF  
; TITLE OF INVENTION: PROGRESSION AND REGRESSION  
; TITLE OF INVENTION: OF VASCULAR DISEASES  
; NUMBER OF SEQUENCES: 1243  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/363,240A  
; FILING DATE: December 23, 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 210/096  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 724:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-363-240A-724

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1471 CAGAGAGAGCTCTG 1484  
||||:|||||  
Db 14 CGGAGAGAGCTCTG 1

RESULT 185  
US-08-311-486C-533/c  
; Sequence 533, Application US/08311486C  
; Patent No. 581300  
; GENERAL INFORMATION:  
; APPLICANT: Sean Sullivan  
; APPLICANT: Kenneth Draper  
; APPLICANT: Kevin Kisch  
; APPLICANT: Dan T. Stinchcomb  
; APPLICANT: James McSwiggen  
; TITLE OF INVENTION: RIBOZYME TREATMENT OF  
; TITLE OF INVENTION: DISEASES OR CONDITIONS  
; TITLE OF INVENTION: RELATED TO LEVELS OF  
; TITLE OF INVENTION: TNF-  
US-08-363-240A-529

ZIP	90071-2066	90071-2066
NUMBER OF SEQUENCES:	1157	two
CORRESPONDENCE ADDRESS:		
ADDRESSEE:	Lyon & Lyon	
STREET:	633 West Fifth Street	
SUITE:	Suite 4700	
CITY:	Los Angeles	
STATE:	California	
COUNTRY:	U.S.A.	
ZIP:	90071-2066	
COMPUTER READABLE FORM:		
MEDIUM TYPE:	3.5" Diskette, 1.44 Mb	
COMPUTER:	IBM Compatible	
OPERATING SYSTEM:	IBM P.C. DOS 5.0	
SOFTWARE:	Word Perfect 5.1	
CURRENT APPLICATION DATA:		
APPLICATION NUMBER:	US/08/311,486C	
FILING DATE:	September 23, 1994	
CLASSIFICATION:	435	
PRIOR APPLICATION DATA:	including application	
PRIOR APPLICATION DATA:	described below:	
APPLICATION NUMBER:	08/008,895	
FILING DATE:	January 19, 1993	
APPLICATION NUMBER:	07/989,849	
FILING DATE:	December 7, 1992	
ATTORNEY/AGENT INFORMATION:		
NAME:	Warburg, Richard J.	
REGISTRATION NUMBER:	32,327	
REFERENCE/DOCKET NUMBER:	209/166	
TELECOMMUNICATION INFORMATION:		
TELEPHONE:	(213) 489-1600	
TELEFAX:	(213) 955-0440	
TELEX:	67-3510	
INFORMATION FOR SEQ ID NO:	533:	
SEQUENCE CHARACTERISTICS:		
LENGTH:	15 base pairs	
TYPE:	nucleic acid	
STRANDEDNESS:	single	
TOPOLOGY:	linear	
US-08-311-486C-533		
Query Match	0.8%; Score 12.4; DB 1; Length 15;	
Best Local Similarity	92.9%; Pred. No. 1e+02; 1; Indels	
Matches	13; Conservative 0; Mismatches 0; Gaps 0;	
QY	1391 GGAGTGAGATGTGG 1404	
DB	15 GGAGGGAGATGTGG 2	
RESULT 186		
US-08-311-486C-687/c		
Sequence 687, Application US/08311486C		
Patent No. 5811300		
GENERAL INFORMATION:		
APPLICANT:	Sean Sullivan	
APPLICANT:	Kenneth Draper	
APPLICANT:	Kevin Kisich	
APPLICANT:	Dan T. Stinchcomb	
APPLICANT:	James McSwiggen	
TITLE OF INVENTION:	RIBOZYME TREATMENT OF	
TITLE OF INVENTION:	DISEASES OR CONDITIONS	
TITLE OF INVENTION:	RELATED TO LEVELS OF	
TITLE OF INVENTION:	TNF-	
NUMBER OF SEQUENCES:	1157	
CORRESPONDENCE ADDRESS:		
ADDRESSEE:	Lyon & Lyon	
STREET:	633 West Fifth Street	
SUITE:	Suite 4700	
CITY:	Los Angeles	
STATE:	California	
COUNTRY:	U.S.A.	

ZIP	90071-2066	90071-2066
NUMBER OF SEQUENCES:	1157	two
CORRESPONDENCE ADDRESS:		
ADDRESSEE:	Lyon & Lyon	
STREET:	633 West Fifth Street	
SUITE:	Suite 4700	
CITY:	Los Angeles	
STATE:	California	
COUNTRY:	U.S.A.	
ZIP:	90071-2066	
COMPUTER READABLE FORM:		
MEDIUM TYPE:	3.5" Diskette, 1.44 Mb	
COMPUTER:	IBM Compatible	
OPERATING SYSTEM:	IBM P.C. DOS 5.0	
SOFTWARE:	Word Perfect 5.1	
CURRENT APPLICATION DATA:		
APPLICATION NUMBER:	US/08/311,486C	
FILING DATE:	September 23, 1994	
CLASSIFICATION:	435	
PRIOR APPLICATION DATA:	including application	
PRIOR APPLICATION DATA:	described below:	
APPLICATION NUMBER:	08/008,895	
FILING DATE:	January 19, 1993	
APPLICATION NUMBER:	07/989,849	
FILING DATE:	December 7, 1992	
ATTORNEY/AGENT INFORMATION:		
NAME:	Warburg, Richard J.	
REGISTRATION NUMBER:	32,327	
REFERENCE/DOCKET NUMBER:	209/166	
TELECOMMUNICATION INFORMATION:		
TELEPHONE:	(213) 489-1600	
TELEFAX:	(213) 955-0440	
TELEX:	67-3510	
INFORMATION FOR SEQ ID NO:	533:	
SEQUENCE CHARACTERISTICS:		
LENGTH:	15 base pairs	
TYPE:	nucleic acid	
STRANDEDNESS:	single	
TOPOLOGY:	linear	
US-08-311-486C-533		
Query Match	0.8%; Score 12.4; DB 1; Length 15;	
Best Local Similarity	92.9%; Pred. No. 1e+02; 1; Indels	
Matches	13; Conservative 0; Mismatches 0; Gaps 0;	
QY	1391 GGAGTGAGATGTGG 1404	
DB	15 GGAGGGAGATGTGG 2	
RESULT 186		
US-08-311-486C-687/c		
Sequence 687, Application US/08311486C		
Patent No. 5811300		
GENERAL INFORMATION:		
APPLICANT:	Sean Sullivan	
APPLICANT:	Kenneth Draper	
APPLICANT:	Kevin Kisich	
APPLICANT:	Dan T. Stinchcomb	
APPLICANT:	James McSwiggen	
TITLE OF INVENTION:	RIBOZYME TREATMENT OF	
TITLE OF INVENTION:	DISEASES OR CONDITIONS	
TITLE OF INVENTION:	RELATED TO LEVELS OF	
TITLE OF INVENTION:	TNF-	
NUMBER OF SEQUENCES:	1157	
CORRESPONDENCE ADDRESS:		
ADDRESSEE:	Lyon & Lyon	
STREET:	633 West Fifth Street	
SUITE:	Suite 4700	
CITY:	Los Angeles	
STATE:	California	
COUNTRY:	U.S.A.	

Query Match	0.8%	Score 12.4	DB 1	Length 15
Best Local Similarity	85.7%	Pred. No. 1e+02		
Matches	12	Conservative	1	Mismatches 1; Indels 0; Gaps 0
QY	1508	CAGCCTCCAGGCC	1521	
DB	2	CAGCCUCCAGGACC	15	
RESULT 189				
US-08-774-306A-422/c				
Sequence 422, Application US/08774306A				
Patent No. 5869253				
GENERAL INFORMATION:				
APPLICANT: Draper, Kenneth G.				
TITLE OF INVENTION: METHOD AND REAGENT FOR				
TITLE OF INVENTION: INHIBITING HEPATITIS C				
TITLE OF INVENTION: VIRUS REPLICATION				
NUMBER OF SEQUENCES: 497				
CORRESPONDENCE ADDRESS:				
ADDRESSEE: Lyon & Lyon				
STREET: 633 West Fifth Street				
CITY: Los Angeles				
STATE: California				
COUNTRY: U.S.A.				
ZIP: 90071-2066				
COMPUTER READABLE FORM:				
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb				
COMPUTER: IBM Compatible				
OPERATING SYSTEM: IBM P.C. DOS 5.0				
SOFTWARE: Word Perfect 5.1				
CURRENT APPLICATION DATA:				
APPLICATION NUMBER: US/08/774,306A				
FILING DATE: December 26, 1996				
PRIOR APPLICATION DATA:				
APPLICATION NUMBER: 08/182,968				
FILING DATE: January 13, 1994				
APPLICATION NUMBER: 07/882,888				
FILING DATE: May 14, 1992				
ATTORNEY/AGENT INFORMATION:				
NAME: Warburg, Richard J.				
REGISTRATION NUMBER: 32,327				
REFERENCE/DOCKET NUMBER: 223/227				
TELEPHONE: (213) 489-1600				
TELEFAX: (213) 955-0440				
TELEX: 67-3510				
INFORMATION FOR SEQ ID NO: 422:				
SEQUENCE CHARACTERISTICS:				
LENGTH: 15				
TYPE: nucleic acid				
STRANDEDNESS: single				
TOPOLOGY: linear				
US-08-774-306A-422				
Query Match	0.8%	Score 12.4	DB 1	Length 15
Best Local Similarity	92.9%	Pred. No. 1e+02		
Matches	13	Conservative	0	Mismatches 0; Indels 1; Gaps 0
QY	870	ATACGAGAGCGCA	883	
DB	15	ATACGATAGCGCA	2	
RESULT 190				
US-08-774-306A-423/c				
Sequence 423, Application US/08774306A				
Patent No. 5869253				
GENERAL INFORMATION:				
APPLICANT: Draper, Kenneth G.				
TITLE OF INVENTION: METHOD AND REAGENT FOR				
TITLE OF INVENTION: INHIBITING HEPATITIS C				
TITLE OF INVENTION: VIRUS REPLICATION				
NUMBER OF SEQUENCES: 497				
CORRESPONDENCE ADDRESS:				
ADDRESSEE: Lyon & Lyon				
STREET: 633 West Fifth Street				
CITY: Los Angeles				
STATE: California				
COUNTRY: U.S.A.				
ZIP: 90071-2066				
COMPUTER READABLE FORM:				
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb				
COMPUTER: IBM Compatible				
OPERATING SYSTEM: IBM P.C. DOS 5.0				
SOFTWARE: Word Perfect 5.1				
CURRENT APPLICATION DATA:				
APPLICATION NUMBER: US/08/774,306A				
FILING DATE: December 26, 1996				
PRIOR APPLICATION DATA:				
APPLICATION NUMBER: 08/182,968				
FILING DATE: January 13, 1994				
APPLICATION NUMBER: 07/882,888				
FILING DATE: May 14, 1992				
ATTORNEY/AGENT INFORMATION:				
NAME: Warburg, Richard J.				
REGISTRATION NUMBER: 32,327				
REFERENCE/DOCKET NUMBER: 223/227				
TELEPHONE: (213) 489-1600				
TELEFAX: (213) 955-0440				
TELEX: 67-3510				
INFORMATION FOR SEQ ID NO: 2:				
SEQUENCE CHARACTERISTICS:				

APPLICANT: Draper, Kenneth G.  
TITLE OF INVENTION: METHOD AND REAGENT FOR  
INHIBITING HEPATITIS C  
TITLE OF INVENTION: VIRUS REPLICATION  
NUMBER OF SEQUENCES: 497  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
STATE: Los Angeles  
COUNTRY: California  
ZIP: 90071-2066  
COMPUTER: IBM Compatible  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
FILING DATE: December 26, 1996  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/774,306A  
FILING DATE: January 13, 1994  
APPLICATION NUMBER: 07/882,888  
FILING DATE: May 14, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 223/227  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 423:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-774-306A-423

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGAGCGGA 883  
DB 14 ATACGATAAGCGGA 1  
RESULT 191  
US-09-064-156A-2  
Sequence 2, Application US/09064156A  
Patent No. 6132966  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
TITLE OF INVENTION: METHOD AND REAGENT FOR  
INHIBITING HEPATITIS C  
TITLE OF INVENTION: VIRUS REPLICATION  
NUMBER OF SEQUENCES: 498  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
STATE: Los Angeles  
COUNTRY: California  
ZIP: 90071-2066  
COMPUTER: IBM Compatible  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/064,156A  
FILING DATE: April 21, 1998  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/774,306  
FILING DATE: December 26, 1996  
APPLICATION NUMBER: 08/182,968  
FILING DATE: January 13, 1994  
APPLICATION NUMBER: 07/882,888  
FILING DATE: May 14, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 234/083  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-064-156A-2

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 85.7%; Pred. No. 1e+02;  
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1521  
DB 2 CAGCCUCCAGGACC 15  
RESULT 192  
US-09-064-156A-422/c  
Sequence 422, Application US/09064156A  
Patent No. 6132966  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
TITLE OF INVENTION: METHOD AND REAGENT FOR  
INHIBITING HEPATITIS C  
TITLE OF INVENTION: VIRUS REPLICATION  
NUMBER OF SEQUENCES: 498  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
STATE: Los Angeles  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER: IBM Compatible  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/064,156A  
FILING DATE: April 21, 1998  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/774,306  
FILING DATE: December 26, 1996  
APPLICATION NUMBER: 08/182,968  
FILING DATE: January 13, 1994  
APPLICATION NUMBER: 07/882,888  
FILING DATE: May 14, 1992  
ATTORNEY/AGENT INFORMATION:



```
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 422:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-064-156A-422

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

Qy      870 ATACGAGAAGCGCA 883
Db      15 ATACGATAAGCGCA 2

RESULT 193
US-09-064-156A-423/c
; Sequence 423, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 423:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-064-156A-423

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

Qy      870 ATACGAGAAGCGCA 883
Db      15 ATACGATAAGCGCA 2

RESULT 194
US-09-081-646-126
; Sequence 126, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 126
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-126

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

Qy      1101 ATGCTCAACACCTC 1114
Db      2 ATGCTCAACATCTC 15

RESULT 195
US-09-081-646-326
; Sequence 326, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 326
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-326

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

Qy      923 CACGGGCTGCCTGC 936
Db      15 ATACGATAAGCGCA 2
```

```
Db      1  CATGGGCTGCCTGC 14

RESULT 196
US-09-081-646-808
; Sequence 808, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: PastSeq for Windows Version 3.0
; SEQ ID NO 808
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-808

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1101 ATGCTCAACACCTC 1114
Db      2  ATGCTCAACATCTC 15

RESULT 197
US-08-453-623-30/c
; Sequence 30, Application US/08453623
; Patent No. 6649340
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: Walk-Through Mutagenesis
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: 2 Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/453,623
; FILING DATE: 30-May-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/930,600
; FILING DATE: 05-APR-1991
; APPLICATION NUMBER: PCT/US91/02362
; FILING DATE: 05-APR-1991
; APPLICATION NUMBER: US 07/505,314
; FILING DATE: 05-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Brook, David E.
; REGISTRATION NUMBER: 22,592
; REFERENCE/DOCKET NUMBER: RC90-01AY
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240

TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
; SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-08-453-623-30

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1303 TCCCTGTAGAGTC 1316
Db      14  TCCATGTAGAGTC 1

RESULT 198
US-09-720-435A-171
; Sequence 171, Application US/09720435A
; Patent No. 6803187
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease
; FILE REFERENCE: 11362.0030.PCUS00 INNS:030
; CURRENT APPLICATION NUMBER: US/09/720,435A
; CURRENT FILING DATE: 2001-06-25
; PRIOR APPLICATION NUMBER: PCT/EP99/04317
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 98870143.9
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 171
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Aids-associated retrovirus
US-09-720-435A-171

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      37  GAATTGGAGGCGCATG 50
Db      2  GAATTGGAGGCTTG 15

Search completed: September 13, 2005, 10:44:50
Job time : 5 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:39:51 ; Search time 5 Seconds  
(without alignments)  
3.649 Million cell updates/sec

Title: us-10-828-394-1  
Perfect score: 1643  
Sequence: 1 gaattccgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 298 seqs, 5552 residues  
Total number of hits satisfying chosen parameters: 596

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 298 summaries

Database : rgedb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	27.2	1.7	32	1 A21575	ACCESSION: A21575
2	26	1.6	26	1 AR090627	ACCESSION: AR090627
3	26	1.6	26	1 AR197662	ACCESSION: AR197662
4	26	1.6	26	1 AR259816	ACCESSION: AR259816
5	25	1.5	25	1 AR090628	ACCESSION: AR090628
6	25	1.5	25	1 AR197663	ACCESSION: AR197663
7	25	1.5	25	1 AR259817	ACCESSION: AR259817
8	23	1.4	23	1 CQ786169	ACCESSION: CQ786169
9	23	1.4	23	1 CQ786172	ACCESSION: CQ786172
10	23	1.4	23	1 CQ786175	ACCESSION: CQ786175
11	23	1.4	23	1 CQ786178	ACCESSION: CQ786178
12	23	1.4	23	1 AR208706	ACCESSION: AR208706
13	21	1.3	21	1 AR038687	ACCESSION: AR038687
14	21	1.3	21	1 CQ786113	ACCESSION: CQ786113
15	21	1.3	21	1 CQ786114	ACCESSION: CQ786114
16	21	1.3	21	1 CQ786115	ACCESSION: CQ786115
17	21	1.3	21	1 CQ786116	ACCESSION: CQ786116
18	21	1.3	21	1 CQ786117	ACCESSION: CQ786117
19	21	1.3	21	1 CQ786118	ACCESSION: CQ786118
20	21	1.3	21	1 CQ786170	ACCESSION: CQ786170
21	21	1.3	21	1 CQ786171	ACCESSION: CQ786171
22	21	1.3	21	1 CQ786173	ACCESSION: CQ786173
23	21	1.3	21	1 CQ786174	ACCESSION: CQ786174
24	21	1.3	21	1 CQ786176	ACCESSION: CQ786176
25	21	1.3	21	1 CQ786177	ACCESSION: CQ786177
26	21	1.3	21	1 CQ786614	ACCESSION: CQ786614
27	21	1.3	21	1 CQ786615	ACCESSION: CQ786615
28	21	1.3	21	1 CQ786616	ACCESSION: CQ786616
29	21	1.3	21	1 CQ786617	ACCESSION: CQ786617
30	21	1.3	21	1 CQ786618	ACCESSION: CQ786618
31	21	1.3	21	1 CQ786619	ACCESSION: CQ786619
32	21	1.3	21	1 CQ786620	ACCESSION: CQ786620
33	21	1.3	21	1 CQ786621	ACCESSION: CQ786621

ACCESSION: CQ786622	1	1.3	21	1 CQ786622
ACCESSION: CQ786623	1	1.3	21	1 CQ786623
ACCESSION: CQ786631	1	1.3	21	1 CQ786631
ACCESSION: CQ786632	1	1.3	21	1 CQ786632
ACCESSION: CQ786633	1	1.3	21	1 CQ786633
ACCESSION: CQ786634	1	1.3	21	1 CQ786634
ACCESSION: CQ786636	1	1.3	21	1 CQ786636
ACCESSION: CQ786647	1	1.3	21	1 CQ786647
ACCESSION: CQ786648	1	1.3	21	1 CQ786648
ACCESSION: CQ786649	1	1.3	21	1 CQ786649
ACCESSION: CQ786650	1	1.3	21	1 CQ786650
ACCESSION: CQ786651	1	1.3	21	1 CQ786651
ACCESSION: AR208707	1	1.3	21	1 CQ786652
ACCESSION: AR236282	1	1.3	21	1 AR208707
ACCESSION: BD230318	1	1.3	24	1 AR236282
ACCESSION: AR531218	1	1.3	21	1 BD230318
ACCESSION: AR531219	1	1.3	21	1 AR531218
ACCESSION: AR531220	1	1.3	21	1 AR531219
ACCESSION: AR531221	1	1.3	21	1 AR531220
ACCESSION: AX097243	1	1.3	21	1 AR531221
ACCESSION: AX097244	1	1.3	21	1 AX097243
ACCESSION: AX097245	1	1.3	21	1 AX097244
ACCESSION: AX097246	1	1.3	21	1 AX097245
ACCESSION: CQ803453	1	1.2	20	1 AX097246
ACCESSION: CQ803454	1	1.2	20	1 CQ803453
ACCESSION: AR208715	1	1.2	20	1 CQ803454
ACCESSION: AR208716	1	1.2	20	1 AR208715
ACCESSION: AR208717	1	1.2	20	1 AR208716
ACCESSION: AR208718	1	1.2	20	1 AR208717
ACCESSION: AR208719	1	1.2	20	1 AR208718
ACCESSION: AR208720	1	1.2	20	1 AR208719
ACCESSION: AR208721	1	1.2	20	1 AR208720
ACCESSION: AR208722	1	1.2	20	1 AR208721
ACCESSION: AR208723	1	1.2	20	1 AR208722
ACCESSION: AR208724	1	1.2	20	1 AR208723
ACCESSION: AR208725	1	1.2	20	1 AR208724
ACCESSION: AR208726	1	1.2	20	1 AR208725
ACCESSION: AR208727	1	1.2	20	1 AR208726
ACCESSION: AR208728	1	1.2	20	1 AR208727
ACCESSION: AR208729	1	1.2	20	1 AR208728
ACCESSION: AR208730	1	1.2	20	1 AR208729
ACCESSION: AR208731	1	1.2	20	1 AR208730
ACCESSION: AR208732	1	1.2	20	1 AR208731
ACCESSION: AR208733	1	1.2	20	1 AR208732
ACCESSION: AR208734	1	1.2	20	1 AR208733
ACCESSION: AR208735	1	1.2	20	1 AR208734
ACCESSION: AR208736	1	1.2	20	1 AR208735
ACCESSION: AR208737	1	1.2	20	1 AR208736
ACCESSION: AR208738	1	1.2	20	1 AR208737
ACCESSION: AR208739	1	1.2	20	1 AR208738
ACCESSION: AR208740	1	1.2	20	1 AR208739
ACCESSION: AR208741	1	1.2	20	1 AR208740
ACCESSION: AR208742	1	1.2	20	1 AR208741
ACCESSION: AR208743	1	1.2	20	1 AR208742
ACCESSION: AR208744	1	1.2	20	1 AR208743
ACCESSION: AR208745	1	1.2	20	1 AR208744
ACCESSION: AR208746	1	1.2	20	1 AR208745
ACCESSION: AR208747	1	1.2	20	1 AR208746
ACCESSION: AR208748	1	1.2	20	1 AR208747
ACCESSION: AR208749	1	1.2	20	1 AR208748
ACCESSION: AR208750	1	1.2	20	1 AR208749
ACCESSION: AR208751	1	1.2	20	1 AR208750
ACCESSION: AR208752	1	1.2	20	1 AR208751
ACCESSION: AR208753	1	1.2	20	1 AR208752
ACCESSION: AR208754	1	1.2	20	1 AR208753
ACCESSION: AR208755	1	1.2	20	1 AR208754
ACCESSION: AR208756	1	1.2	20	1 AR208755
ACCESSION: AR208757	1	1.2	20	1 AR208756
ACCESSION: AR208758	1	1.2	20	1 AR208757
ACCESSION: AR208759	1	1.2	20	1 AR208758
ACCESSION: AR208760	1	1.2	20	1 AR208759
ACCESSION: AR208761	1	1.2	20	1 AR208760

C 107	20	1.2	20	1	AR208762	ACCESSION:AR208762	C 180	14.4	0.9	17	1	AR466360	ACCESSION:AR466360
C 108	20	1.2	20	1	AR208763	ACCESSION:AR208763	C 181	14.4	0.9	17	1	AR466361	ACCESSION:AR466361
C 109	20	1.2	20	1	AR208764	ACCESSION:AR208764	C 182	14.4	0.9	17	1	AX214729	ACCESSION:AX214729
C 110	20	1.2	20	1	AR208765	ACCESSION:AR208765	C 183	14.4	0.9	17	1	AX688718	ACCESSION:AX688718
C 111	20	1.2	20	1	AR208766	ACCESSION:AR208766	C 184	14.4	0.9	17	1	AX688720	ACCESSION:AX688720
C 112	20	1.2	20	1	AR208767	ACCESSION:AR208767	C 185	14.4	0.9	17	1	AX732888	ACCESSION:AX732888
C 113	20	1.2	20	1	AR208768	ACCESSION:AR208768	C 186	14.4	0.9	17	1	AX760623	ACCESSION:AX760623
C 114	20	1.2	20	1	AR208769	ACCESSION:AR208769	C 187	14.4	0.9	17	1	AR067404	ACCESSION:AR067404
C 115	20	1.2	20	1	AR208770	ACCESSION:AR208770	C 188	14.4	0.9	17	1	AX837978	ACCESSION:AX837978
C 116	20	1.2	20	1	AR208771	ACCESSION:AR208771	C 189	14	0.9	18	1	AX324817	ACCESSION:AX324817
C 117	20	1.2	20	1	AR208772	ACCESSION:AR208772	C 190	14	0.9	17	1	AX324818	ACCESSION:AX324818
C 118	20	1.2	20	1	AR208773	ACCESSION:AR208773	C 191	13.8	0.8	17	1	AR039619	ACCESSION:AR039619
C 119	20	1.2	20	1	AR208774	ACCESSION:AR208774	C 192	13.8	0.8	17	1	AR081753	ACCESSION:AR081753
C 120	20	1.2	20	1	AR208775	ACCESSION:AR208775	C 193	13.8	0.8	17	1	AR081755	ACCESSION:AR081755
C 121	20	1.2	20	1	AR208776	ACCESSION:AR208776	C 194	13.8	0.8	17	1	AR094983	ACCESSION:AR094983
C 122	20	1.2	20	1	AR208777	ACCESSION:AR208777	C 195	13.8	0.8	17	1	AR167985	ACCESSION:AR167985
C 123	20	1.2	20	1	AR208781	ACCESSION:AR208781	C 196	13.8	0.8	17	1	AR167987	ACCESSION:AR167987
C 124	20	1.2	21	1	CQ786121	ACCESSION:CQ786121	C 197	13.8	0.8	17	1	BD254845	ACCESSION:BD254845
C 125	20	1.2	21	1	CQ786639	ACCESSION:CQ786639	C 198	13.8	0.8	17	1	CO617155	ACCESSION:CO617155
C 126	19.4	1.2	21	1	AR216281	ACCESSION:AR216281	C 199	13.8	0.8	17	1	CO617155	ACCESSION:CO617155
C 127	19	1.2	19	1	CQ786179	ACCESSION:CQ786179	C 200	13.8	0.8	17	1	CO622615	ACCESSION:CO622615
C 128	19	1.2	19	1	CQ786653	ACCESSION:CQ786653	C 201	13.8	0.8	17	1	CO622745	ACCESSION:CO622745
C 129	19	1.2	19	1	CQ786654	ACCESSION:CQ786654	C 202	13.8	0.8	17	1	CO623828	ACCESSION:CO623828
C 130	19	1.2	19	1	CQ786654	ACCESSION:CQ786654	C 203	13.8	0.8	17	1	CO623920	ACCESSION:CO623920
C 131	19	1.2	21	1	CQ786122	ACCESSION:CQ786122	C 204	13.8	0.8	17	1	CO623923	ACCESSION:CO623923
C 132	19	1.2	21	1	CQ786640	ACCESSION:CQ786640	C 205	13.8	0.8	17	1	CO623924	ACCESSION:CO623924
C 133	18.8	1.1	22	1	AR071119	ACCESSION:AR071119	C 206	13.8	0.8	17	1	CO624947	ACCESSION:CO624947
C 134	18.8	1.1	22	1	E15141	ACCESSION:E15141	C 207	13.8	0.8	17	1	CO624948	ACCESSION:CO624948
C 135	18	1.1	18	1	AR038688	ACCESSION:AR038688	C 208	13.8	0.8	17	1	CO624949	ACCESSION:CO624949
C 136	18	1.1	18	1	AR208705	ACCESSION:AR208705	C 209	13.8	0.8	17	1	E65210	ACCESSION:E65210
C 137	17	1.0	17	1	AX728619	ACCESSION:AX728619	C 210	13.8	0.8	17	1	AR192271	ACCESSION:AR192271
C 138	17	1.0	17	1	AX767010	ACCESSION:AX767010	C 211	13.8	0.8	17	1	AR196222	ACCESSION:AR196222
C 139	16.8	1.0	20	1	AR167026	ACCESSION:AR167026	C 212	13.8	0.8	17	1	AR213316	ACCESSION:AR213316
C 140	16.8	1.0	20	1	AR210681	ACCESSION:AR210681	C 213	13.8	0.8	17	1	AR213318	ACCESSION:AR213318
C 141	16	1.0	16	1	A39125	ACCESSION:A39125	C 214	13.8	0.8	17	1	AR256153	ACCESSION:AR256153
C 142	16	1.0	16	1	AR063448	ACCESSION:AR063448	C 215	13.8	0.8	17	1	AR256155	ACCESSION:AR256155
C 143	16	1.0	16	1	AR123639	ACCESSION:AR123639	C 216	13.8	0.8	17	1	AR275110	ACCESSION:AR275110
C 144	16	1.0	16	1	AR273380	ACCESSION:AR273380	C 217	13.8	0.8	17	1	AR306243	ACCESSION:AR306243
C 145	16	1.0	16	1	AR305790	ACCESSION:AR305790	C 218	13.8	0.8	17	1	AR306245	ACCESSION:AR306245
C 146	16	1.0	16	1	AX417393	ACCESSION:AX417393	C 219	13.8	0.8	17	1	AR326141	ACCESSION:AR326141
C 147	16	1.0	16	1	AR029848	ACCESSION:AR029848	C 220	13.8	0.8	17	1	AR326780	ACCESSION:AR326780
C 148	16	1.0	19	1	CQ891900	ACCESSION:CQ891900	C 221	13.8	0.8	17	1	AR371631	ACCESSION:AR371631
C 149	16	1.0	19	1	CQ786119	ACCESSION:CQ786119	C 222	13.8	0.8	17	1	AR371633	ACCESSION:AR371633
C 150	15.8	1.0	19	1	CQ786120	ACCESSION:CQ786120	C 223	13.8	0.8	17	1	AR458218	ACCESSION:AR458218
C 151	15.8	1.0	19	1	CQ786635	ACCESSION:CQ786635	C 224	13.8	0.8	17	1	AR458966	ACCESSION:AR458966
C 152	15.8	1.0	19	1	CQ786637	ACCESSION:CQ786637	C 225	13.8	0.8	17	1	AR458966	ACCESSION:AR458966
C 153	15.8	1.0	19	1	CQ786638	ACCESSION:CQ786638	C 226	13.8	0.8	17	1	AR463678	ACCESSION:AR463678
C 154	15.8	1.0	19	1	CQ786638	ACCESSION:CQ786638	C 227	13.8	0.8	17	1	AR463808	ACCESSION:AR463808
C 155	15.4	0.9	17	1	CO623926	ACCESSION:CO623926	C 228	13.8	0.8	17	1	AR464891	ACCESSION:AR464891
C 156	15.4	0.9	17	1	I37522	ACCESSION:I37522	C 229	13.8	0.8	17	1	AR464983	ACCESSION:AR464983
C 157	15.4	0.9	17	1	I94372	ACCESSION:I94372	C 230	13.8	0.8	17	1	AR464984	ACCESSION:AR464984
C 158	15.4	0.9	17	1	AR464989	ACCESSION:AR464989	C 231	13.8	0.8	17	1	AR464986	ACCESSION:AR464986
C 159	15.4	0.9	17	1	AX214728	ACCESSION:AX214728	C 232	13.8	0.8	17	1	AR464987	ACCESSION:AR464987
C 160	15.4	0.9	17	1	AX688719	ACCESSION:AX688719	C 233	13.8	0.8	17	1	AR466010	ACCESSION:AR466010
C 161	15.4	0.9	17	1	AX762505	ACCESSION:AX762505	C 234	13.8	0.8	17	1	AR466011	ACCESSION:AR466011
C 162	14.8	0.9	18	1	AR011407	ACCESSION:AR011407	C 235	13.8	0.8	17	1	AR466012	ACCESSION:AR466012
C 163	14.8	0.9	18	1	AR040105	ACCESSION:AR040105	C 236	13.8	0.8	17	1	AX215611	ACCESSION:AX215611
C 164	14.8	0.9	18	1	I18045	ACCESSION:I18045	C 237	13.8	0.8	17	1	AX215611	ACCESSION:AX215611
C 165	14.8	0.9	18	1	AX115178	ACCESSION:AX115178	C 238	13.8	0.8	17	1	AX216443	ACCESSION:AX216443
C 166	14.8	0.9	18	1	AX776586	ACCESSION:AX776586	C 239	13.8	0.8	17	1	AX272871	ACCESSION:AX272871
C 167	14.4	0.9	17	1	AR173373	ACCESSION:AR173373	C 240	13.8	0.8	17	1	AX422540	ACCESSION:AX422540
C 168	14.4	0.9	17	1	CO623612	ACCESSION:CO623612	C 241	13.8	0.8	17	1	AX423446	ACCESSION:AX423446
C 169	14.4	0.9	17	1	CO623613	ACCESSION:CO623613	C 242	13.8	0.8	17	1	AX475287	ACCESSION:AX475287
C 170	14.4	0.9	17	1	CO623925	ACCESSION:CO623925	C 243	13.8	0.8	17	1	AX475288	ACCESSION:AX475288
C 171	14.4	0.9	17	1	CO623927	ACCESSION:CO623927	C 244	13.8	0.8	17	1	AX475289	ACCESSION:AX475289
C 172	14.4	0.9	17	1	CO625297	ACCESSION:CO625297	C 245	13.8	0.8	17	1	AX475290	ACCESSION:AX475290
C 173	14.4	0.9	17	1	CO625298	ACCESSION:CO625298	C 246	13.8	0.8	17	1	AX475291	ACCESSION:AX475291
C 174	14.4	0.9	17	1	I37523	ACCESSION:I37523	C 247	13.8	0.8	17	1	AX475293	ACCESSION:AX475293
C 175	14.4	0.9	17	1	I94373	ACCESSION:I94373	C 248	13.8	0.8	17	1	AX475720	ACCESSION:AX475720
C 176	14.4	0.9	17	1	AR464675	ACCESSION:AR464675	C 249	13.8	0.8	17	1	AX499441	ACCESSION:AX499441
C 177	14.4	0.9	17	1	AR464676	ACCESSION:AR464676	C 250	13.8	0.8	17	1	AX499442	ACCESSION:AX499442
C 178	14.4	0.9	17	1	AR464988	ACCESSION:AR464988	C 251	13.8	0.8	17	1	AX499931	ACCESSION:AX499931
C 179	14.4	0.9	17	1	AR464990	ACCESSION:AR464990	C 252	13.8	0.8	17	1	AX687958	ACCESSION:AX687958

c 253 13.8 0.8 17 1 AX688721  
ACCESSION:AX688721  
c 254 13.8 0.8 17 1 AX690667  
ACCESSION:AX690667  
c 255 13.8 0.8 17 1 AX727197  
ACCESSION:AX727197  
c 256 13.8 0.8 17 1 AX728423  
ACCESSION:AX728423  
c 257 13.8 0.8 17 1 AX731740  
ACCESSION:AX731740  
c 258 13.8 0.8 17 1 AX734894  
ACCESSION:AX734894  
c 259 13.8 0.8 17 1 AX756729  
ACCESSION:AX756729  
c 260 13.4 0.8 15 1 I61606  
ACCESSION:I61606  
c 261 13.4 0.8 15 1 AR180106  
ACCESSION:AR180106  
c 262 13.4 0.8 15 1 AR180715  
ACCESSION:AR180715  
c 263 13.4 0.8 15 1 AR532147  
ACCESSION:AR532147  
c 264 13.4 0.8 15 1 AX167089  
ACCESSION:AX167089  
c 265 13.4 0.8 15 1 AX635964  
ACCESSION:AX635964  
c 266 13.4 0.8 16 1 AR029843  
ACCESSION:AR029843  
c 267 13.4 0.8 16 1 AR131574  
ACCESSION:AR131574  
c 268 13.4 0.8 16 1 AR131575  
ACCESSION:AR131575  
c 269 13.4 0.8 16 1 CO796994  
ACCESSION:CO796994  
c 270 13.4 0.8 16 1 CO858546  
ACCESSION:CO858546  
c 271 13.4 0.8 16 1 AR199508  
ACCESSION:AR199508  
c 272 13.4 0.8 16 1 AR199509  
ACCESSION:AR199509  
c 273 13.4 0.8 16 1 AR200979  
ACCESSION:AR200979  
c 274 13.4 0.8 16 1 AR200980  
ACCESSION:AR200980  
c 275 13.4 0.8 16 1 AR488738  
ACCESSION:AR488738  
c 276 13.4 0.8 16 1 AR488739  
ACCESSION:AR488739  
c 277 13.4 0.8 16 1 AX419730  
ACCESSION:AX419730  
c 278 13.4 0.8 16 1 AX419731  
ACCESSION:AX419731  
c 279 13.4 0.8 16 1 BD084992  
ACCESSION:BD084992  
c 280 13.4 0.8 16 1 BD084993  
ACCESSION:BD084993  
c 281 13.4 0.8 16 1 S81287  
ACCESSION:S81287  
c 282 13 0.8 14 1 AR066302  
ACCESSION:AR066302  
c 283 13 0.8 15 1 AX377347  
ACCESSION:AX377347  
c 284 13 0.8 15 1 ATH551605  
ACCESSION:AJ551605  
c 285 13 0.8 16 1 CO806753  
ACCESSION:CO806753  
c 286 12.8 0.8 16 1 A88141  
ACCESSION:A88141  
c 287 12.8 0.8 16 1 A89435  
ACCESSION:A89435  
c 288 12.8 0.8 16 1 A90108  
ACCESSION:A90108  
c 289 12.8 0.8 16 1 AR104209  
ACCESSION:AR104209  
c 290 12.8 0.8 16 1 CO786338  
ACCESSION:CO786338  
c 291 12.8 0.8 16 1 AR196058  
ACCESSION:AR196058  
c 292 12.8 0.8 16 1 AX003952  
ACCESSION:AX003952  
c 293 12.8 0.8 16 1 AX255603  
ACCESSION:AX255603  
c 294 12.8 0.8 16 1 AX255637  
ACCESSION:AX255637  
c 295 12.8 0.8 16 1 AX713247  
ACCESSION:AX713247  
c 296 12.8 0.8 16 1 BD065654  
ACCESSION:BD065654  
c 297 12.8 0.8 16 1 BD066948  
ACCESSION:BD066948  
c 298 12.8 0.8 16 1 BD086293  
ACCESSION:BD086293

ALIGNMENTS

RESULT 1  
A21575 A21575 32 bp DNA linear PAT 26-JUL-1994  
LOCUS oligonucleotide.  
DEFINITION A21575  
ACCESSION A21575  
VERSION A21575.1 GI:583580  
KEYWORDS Synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 32)  
1. .32.  
CYTOLYSIS INHIBITOR PROTEINS (CLI) AND DNA SEQUENCES CODING FOR  
SAID PROTEINS  
JOURNAL Patent: WO 9105043-A 1 18-APR-1991;  
FEATURES Location/Qualifiers  
source  
1. .32.  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

Query Match 1.7%; Score 27.2; DB 1; Length 32;

Best Local Similarity 90.6%; Pred. No. 8.1;  
Matches 29; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 129 GACATGAGCTCCAGGAATGTCATCAGG 160  
|||||  
Db 1 GACATGAGCTCCAGGAGATGTCACACAGG 32  
|||||  
RESULT 2  
AR090627 26 bp DNA linear PAT 07-SEP-2000  
LOCUS AR090627  
DEFINITION Sequence 747 from patent US 5994076.  
ACCESSION AR090627  
VERSION AR090627.1 GI:10017382  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 26)  
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.  
TITLE Methods of assaying differential expression  
JOURNAL Patent: US 5994076-A 747 30-NOV-1999;  
FEATURES Location/Qualifiers  
source  
1. .26  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.6%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 6.5;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 934 TCGGATGAAGCACCAGTGTGACAAG 959  
|||||  
Db 1 TCGGATGAAGCACCAGTGTGACAAG 26  
|||||  
RESULT 3  
AR197662 26 bp DNA linear PAT 20-APR-2002  
LOCUS AR197662  
DEFINITION Sequence 747 from patent US 6352829.  
ACCESSION AR197662  
VERSION AR197662.1 GI:20247511  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 26)  
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.  
TITLE Methods of assaying differential expression  
JOURNAL Patent: US 6352829-A 747 05-MAR-2002;  
FEATURES Location/Qualifiers  
source  
1. .26  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.6%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 6.5;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 934 TCGGATGAAGCACCAGTGTGACAAG 959  
|||||  
Db 1 TCGGATGAAGCACCAGTGTGACAAG 26  
|||||  
RESULT 4  
AR259816 26 bp DNA linear PAT 20-DEC-2002  
LOCUS AR259816  
DEFINITION Sequence 747 from patent US 6489455.  
ACCESSION AR259816  
VERSION AR259816.1 GI:27310327  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

```
Unclassified.
1 (bases 1 to 26)
Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE
Methods of assaying differential expression
JOURNAL
Patent: US 6489455-A 747 03-DEC-2002;
Location/Qualifiers
FEATURES
source
1..26
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.6%; Score 26; DB 1; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 TCGGATGAAGACCAAGTGTGACAAG 959
Db 1 TCGGATGAAGACCAAGTGTGACAAG 26

RESULT 5
AR090628/c
LOCUS
Sequence 748 from patent US 5994076.
ACCESSION
AR090628
VERSION
AR090628.1 GI:10017383
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 25)
AUTHORS
Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE
Methods of assaying differential expression
JOURNAL
Patent: US 5994076-A 748 30-NOV-1999;
Location/Qualifiers
FEATURES
source
1..25
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1190 GTACTATCTCGGGTCCACCGGTG 1214
Db 25 GTACTATCTCGGGTCCACCGGTG 1

RESULT 6
AR197663/c
LOCUS
Sequence 748 from patent US 6352829.
ACCESSION
AR197663
VERSION
AR197663.1 GI:20247512
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 25)
AUTHORS
Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE
Methods of assaying differential expression
JOURNAL
Patent: US 6352829-A 748 05-MAR-2002;
Location/Qualifiers
FEATURES
source
1..25
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1190 GTACTATCTCGGGTCCACCGGTG 1214
Db 25 GTACTATCTCGGGTCCACCGGTG 1

RESULT 7
AR259817/c
LOCUS
Sequence 748 from patent US 6489455.
ACCESSION
AR259817
VERSION
AR259817.1 GI:27310328
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 25)
AUTHORS
Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE
Methods of assaying differential expression
JOURNAL
Patent: US 6489455-A 748 03-DEC-2002;
Location/Qualifiers
FEATURES
source
1..25
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1190 GTACTATCTCGGGTCCACCGGTG 1214
Db 25 GTACTATCTCGGGTCCACCGGTG 1

RESULT 8
CQ786169
LOCUS
Sequence 57 from Patent WO2004018676.
ACCESSION
CQ786169
VERSION
CQ786169.1 GI:45721272
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
REFERENCE
1
AUTHORS
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE
Rnai probes targeting cancer-related proteins
JOURNAL
Patent: WO 2004018676-A 57 04-MAR-2004;
The University of British Columbia (CA)
Location/Qualifiers
FEATURES
source
1..23
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.4%; Score 23; DB 1; Length 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTACTT 502
Db 1 AACGAGCTCGCCCTTCTACTT 23

RESULT 9
CQ786172
LOCUS
Sequence 60 from Patent WO2004018676.
ACCESSION
CQ786172
VERSION
CQ786172.1 GI:45721275
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
REFERENCE
1
AUTHORS
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE
Rnai probes targeting cancer-related proteins
JOURNAL
Patent: WO 2004018676-A 57 04-MAR-2004;
The University of British Columbia (CA)
Location/Qualifiers
FEATURES
source
1..23
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.4%; Score 23; DB 1; Length 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTACTT 502
Db 1 AACGAGCTCGCCCTTCTACTT 23

RESULT 10
CQ786172
LOCUS
Sequence 60 from Patent WO2004018676.
ACCESSION
CQ786172
VERSION
CQ786172.1 GI:45721275
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
REFERENCE
1
AUTHORS
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE
Rnai probes targeting cancer-related proteins
JOURNAL
Patent: WO 2004018676-A 57 04-MAR-2004;
The University of British Columbia (CA)
Location/Qualifiers
FEATURES
source
1..23
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.4%; Score 23; DB 1; Length 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTACTT 502
Db 1 AACGAGCTCGCCCTTCTACTT 23
```

REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 60 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source  
1. .23  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AAGTCCCGCATCTCCGCGACTT 733  
|||||  
Db 1 AAGTCCCGCATCTCCGCGACTT 23

RESULT 10  
LOCUS CQ786175 23 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 63 from Patent WO2004018676.  
ACCESSION CQ786175  
VERSION CQ786175.1 GI:45721278  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 63 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source  
1. .23  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGCTT 1635  
|||||  
Db 1 AACTAATTCATAAACTGCTT 23

RESULT 11  
LOCUS CQ786178 23 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 66 from Patent WO2004018676.  
ACCESSION CQ786178  
VERSION CQ786178.1 GI:45721281  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 66 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source  
1. .23  
/organism="Homo sapiens"

/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 GCATGATGAAGACTCTGCTGCTG 68  
|||||  
Db 1 GCATGATGAAGACTCTGCTGCTG 23

RESULT 12  
LOCUS AR208706/c 23 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 5 from patent US 6383808.  
ACCESSION AR208706  
VERSION AR208706.1 GI:21509931  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 23)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 5 07-MAY-2002;  
FEATURES  
source  
1. .23  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 789 CTTGAGATGATACAGAGGCTCA 811  
|||||  
Db 23 CTTGAGATGATACAGAGGCTCA 1

RESULT 13  
LOCUS AR038687 21 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 21 from patent US 5807678.  
ACCESSION AR038687  
VERSION AR038687.1 GI:5958050  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Miller,W.L., Lin,D. and Strauss,J.F. III.  
TITLE Identification of gene mutations associated with congenital lipoid adrenal hyperplasia  
JOURNAL Patent: US 5807678-A 21 15-SEP-1999;  
FEATURES  
source  
1. .21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AGAAGCGCTGCAGGAATACC 1374  
|||||  
Db 1 AGAAGCGCTGCAGGAATACC 21

RESULT 14  
LOCUS CQ786113 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 1 from Patent WO2004018676.

```
ACCESSION      CQ786113
VERSION        CQ786113.1  GI:45721216
KEYWORDS      synthetic construct
SOURCE        synthetic constructs; artificial sequences.
ORGANISM      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
REFERENCE     1
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018676-A 1 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES     source
              1..21
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Rnai for human clusterin"
Query Match  1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          482 CCAGAGCTCGCCCTTCTACTT 502
Db          1 CCAGAGCTCGCCCTTCTACTT 21
RESULT 15
CQ786114/c
LOCUS       CQ786114                21 bp    DNA                linear    PAT 24-MAR-2004
DEFINITION Sequence 2 from Patent WO2004018676.
ACCESSION  CQ786114
VERSION    CQ786114.1  GI:45721217
KEYWORDS   synthetic construct
SOURCE     synthetic construct
           other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
           Gonos,E.
TITLE      Rnai probes targeting cancer-related proteins
JOURNAL    Patent: WO 2004018676-A 2 04-MAR-2004;
           The University of British Columbia (CA)
FEATURES   source
           1..21
           /organism="synthetic construct"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32630"
           /note="Rnai for human clusterin"
Query Match  1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          480 AACGAGAGCTCGCCCTTCTAC 500
Db          21 AACGAGAGCTCGCCCTTCTAC 1
RESULT 16
CQ786115
LOCUS       CQ786115                21 bp    DNA                linear    PAT 24-MAR-2004
DEFINITION Sequence 3 from Patent WO2004018676.
ACCESSION  CQ786115
VERSION    CQ786115.1  GI:45721218
KEYWORDS   synthetic construct
SOURCE     synthetic construct
           other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
           Gonos,E.
ACCESSION      CQ786113
VERSION        CQ786113.1  GI:45721216
KEYWORDS      synthetic construct
SOURCE        synthetic constructs; artificial sequences.
ORGANISM      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
REFERENCE     1
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018676-A 3 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES     source
              1..21
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Rnai for human clusterin"
Query Match  1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          1100 GATGCTCAACACCTCTCTCTT 1120
Db          1 GATGCTCAACACCTCTCTCTT 21
RESULT 17
CQ786116/c
LOCUS       CQ786116                21 bp    DNA                linear    PAT 24-MAR-2004
DEFINITION Sequence 4 from Patent WO2004018676.
ACCESSION  CQ786116
VERSION    CQ786116.1  GI:45721219
KEYWORDS   synthetic construct
SOURCE     synthetic construct
           other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
           Gonos,E.
TITLE      Rnai probes targeting cancer-related proteins
JOURNAL    Patent: WO 2004018676-A 4 04-MAR-2004;
           The University of British Columbia (CA)
FEATURES   source
           1..21
           /organism="synthetic construct"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32630"
           /note="Rnai for human clusterin"
Query Match  1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          1098 AAGATGCTCAACACCTCTCTCC 1118
Db          21 AAGATGCTCAACACCTCTCTCC 1
RESULT 18
CQ786117
LOCUS       CQ786117                21 bp    DNA                linear    PAT 24-MAR-2004
DEFINITION Sequence 5 from Patent WO2004018676.
ACCESSION  CQ786117
VERSION    CQ786117.1  GI:45721220
KEYWORDS   synthetic construct
SOURCE     synthetic construct
           other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
           Gonos,E.
TITLE      Rnai probes targeting cancer-related proteins
JOURNAL    Patent: WO 2004018676-A 5 04-MAR-2004;
           The University of British Columbia (CA)
FEATURES   source
           1..21
           /organism="synthetic construct"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32630"
           /note="Rnai for human clusterin"
```



```
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCAATAAACTGCTTT 1635
|||||
Db 1 CTAATTCAATAAACTGCTTT 21

RESULT 19
CQ786118/c
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 6 from Patent WO2004018676.
ACCESSION CQ786118
VERSION CQ786118.1 GI:45721221
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 6 04-MAR-2004; The University of British Columbia (CA)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTAC 500
|||||
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 20
CQ786170
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 58 from Patent WO2004018676.
ACCESSION CQ786170
VERSION CQ786170.1 GI:45721273
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 58 04-MAR-2004; The University of British Columbia (CA)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633
|||||
Db 21 AACTAATTCATAAACTGTC 1

RESULT 21
CQ786170
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 58 from Patent WO2004018676.
ACCESSION CQ786170
VERSION CQ786170.1 GI:45721273
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 58 04-MAR-2004; The University of British Columbia (CA)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
|||||
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 22
CQ786173
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 61 from Patent WO2004018676.
ACCESSION CQ786173
VERSION CQ786173.1 GI:45721276
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 61 04-MAR-2004; The University of British Columbia (CA)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTAC 500
|||||
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 23
CQ786174/c
LOCUS 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 62 from Patent WO2004018676.
ACCESSION CQ786174
VERSION CQ786174.1 GI:45721277
KEYWORDS
SOURCE synthetic construct
```

```
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018676-A 62 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCGCAGC 731
Db 21 AAGTCCCGCATCGTCGCAGC 1

RESULT 24
LOCUS      CQ786176          21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION Sequence 64 from Patent WO2004018676.
ACCESSION  CQ786176
VERSION     CQ786176.1 GI:45721279
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Jansen,B.
TITLE     Treatment of melanoma by reduction in clusterin levels
JOURNAL   Patent: WO 2004018675-A 3 04-MAR-2004;
            The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CCGAGCGGTGCAAGACTCCA 36
Db 21 CCGAGCGGTGCAAGACTCCA 1

RESULT 27
LOCUS      CQ786615/c      21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION Sequence 4 from Patent WO2004018675.
ACCESSION  CQ786615
VERSION     CQ786615.1 GI:45721635
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Jansen,B.
TITLE     Treatment of melanoma by reduction in clusterin levels
JOURNAL   Patent: WO 2004018675-A 4 04-MAR-2004;
            The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGTGCTG 68
Db 48 ATGATGAAGACTCTGTGCTG 68
```

```
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018676-A 64 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCGCAGC 731
Db 21 AAGTCCCGCATCGTCGCAGC 1

RESULT 24
LOCUS      CQ786176          21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION Sequence 64 from Patent WO2004018676.
ACCESSION  CQ786176
VERSION     CQ786176.1 GI:45721279
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE     Rnai probes targeting cancer-related proteins
JOURNAL   Patent: WO 2004018676-A 64 04-MAR-2004;
            The University of British Columbia (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1615 CTAATTCATATAAACTGCTTT 1635
Db 1 CTAATTCATATAAACTGCTTT 21

RESULT 25
LOCUS      CQ786177/c      21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION Sequence 65 from Patent WO2004018676.
ACCESSION  CQ786177
VERSION     CQ786177.1 GI:45721280
KEYWORDS   .
SOURCE     synthetic construct
            synthetic construct
            other sequences; artificial sequences.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE     Rnai probes targeting cancer-related proteins
JOURNAL   Patent: WO 2004018676-A 65 04-MAR-2004;
            The University of British Columbia (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"
```



```

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.3%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGGCTGCTGC 936
Db 21 ACAACTCCACGGGCTGCTGC 1

RESULT 33
CQ786621/c
LOCUS CQ786621 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 10 from Patent WO2004018675.
ACCESSION CQ786621
VERSION CQ786621.1 GI:45721641
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 10 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.3%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCGCCCGCAGC 1536
Db 21 AGGCCCCCAACTCGCCCGCAGC 1

RESULT 36
CQ786631/c
LOCUS CQ786631 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 20 from Patent WO2004018675.
ACCESSION CQ786631
VERSION CQ786631.1 GI:45721651
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 20 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match
Best Local Similarity 1.3%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 37
CQ786632/c
LOCUS CQ786632 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 21 from Patent WO2004018675.
ACCESSION CQ786632
VERSION CQ786632.1 GI:45721652
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
```

```
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 21 04-MAR-2004; Gleave, Martin E. (CA)
FEATURES
source
    Location/Qualifiers
        1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTAC 500
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 38
LOCUS CQ786633 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 22 from Patent WO2004018675.
ACCESSION CQ786633
VERSION CQ786633.1 GI:45721653
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 22 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
    Location/Qualifiers
        1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GATGCTCAACACCTCTCTT 1120
Db 1 GATGCTCAACACCTCTCTT 21

RESULT 39
LOCUS CQ786634/c 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 23 from Patent WO2004018675.
ACCESSION CQ786634
VERSION CQ786634.1 GI:45721654
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 23 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
    Location/Qualifiers
        1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 21 04-MAR-2004; Gleave, Martin E. (CA)
FEATURES
source
    Location/Qualifiers
        1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633
Db 21 AACTAATTCATAAACTGTC 1

RESULT 41
LOCUS CQ786647 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 36 from Patent WO2004018675.
ACCESSION CQ786647
VERSION CQ786647.1 GI:45721667
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Jansen,B.
TITLE Treatment of melanoma by reduction in clusterin levels
JOURNAL Patent: WO 2004018675-A 36 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
    Location/Qualifiers
        1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCTCGCCCTTCTACTT 21
```

RESULT 42  
CQ786648/c  
LOCUS CQ786648 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 37 from Patent WO2004018675.  
ACCESSION CQ786648  
VERSION CQ786648.1 GI:45721668  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 37 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 480 AACGAGCTCGCCCTTCTAC 500  
|||||  
Db 21 AACGAGCTCGCCCTTCTAC 1  
RESULT 43  
CQ786649  
LOCUS CQ786649 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 38 from Patent WO2004018675.  
ACCESSION CQ786649  
VERSION CQ786649.1 GI:45721669  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 38 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 713 GTCCCGCATCGTCGCGAGCTT 733  
|||||  
Db 1 GTCCCGCATCGTCGCGAGCTT 21  
RESULT 44  
CQ786650/c  
LOCUS CQ786650 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 39 from Patent WO2004018675.  
ACCESSION CQ786650  
VERSION CQ786650.1 GI:45721670  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1

Jansen,B.  
Treatment of melanoma by reduction in clusterin levels  
Patent: WO 2004018675-A 39 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 711 AAGTCCCGCATCGTCGCGAGC 731  
|||||  
Db 21 AAGTCCCGCATCGTCGCGAGC 1  
RESULT 45  
CQ786651  
LOCUS CQ786651 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 40 from Patent WO2004018675.  
ACCESSION CQ786651  
VERSION CQ786651.1 GI:45721671  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 40 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1615 CTAATTCAATAAAACTGTCTT 1635  
|||||  
Db 1 CTAATTCAATAAAACTGTCTT 21  
RESULT 46  
CQ786652/c  
LOCUS CQ786652 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 41 from Patent WO2004018675.  
ACCESSION CQ786652  
VERSION CQ786652.1 GI:45721672  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 41 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATATAAACTGTC 1633  
|||||  
Db 21 AACTAATTCATATAAACTGTC 1

RESULT 47  
AR208707  
LOCUS AR208707 21 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 6 from patent US 6383808.  
ACCESSION AR208707  
VERSION AR208707.1 GI:21509932  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Monis,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 6 07-MAY-2002;  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCCAGCCCT 786  
|||||  
Db 1 TCCACGCCATGTTCCAGCCCT 21

RESULT 48  
AR236282  
LOCUS AR236282 21 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 14 from patent US 6464975.  
ACCESSION AR236282  
VERSION AR236282.1 GI:27280110  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Millis,A.J.T.  
TITLE Compositions and methods for altering cell migration  
JOURNAL Patent: US 6464975-A 14 15-OCT-2002;  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AACCCAAGAGAGAAAGAGG 294  
|||||  
Db 1 AACCCAAGAGAGAAAGAGG 21

RESULT 49  
BD230318  
LOCUS BD230318 24 bp DNA linear PAT 17-JUL-2003  
DEFINITION Total genome radiation hybrid map of canine genome and its use for identification of interesting genes.  
ACCESSION BD230318  
VERSION BD230318.1 GI:33040088  
KEYWORDS JP 2002530091-A/187.

SOURCE Canis familiaris (dog)  
ORGANISM Canis familiaris  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
REFERENCE 1 (bases 1 to 24)  
AUTHORS Galibert,F. and Andre,C.  
TITLE Total genome radiation hybrid map of canine genome and its use for identification of interesting genes  
JOURNAL PATENT: JP 2002530091-A 187 17-SEP-2002;  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  
COMMENT OS Canis familiaris (dog)  
PN JP 2002530091-A/187  
PD 17-SEP-2002  
PF 15-NOV-1999 JP 2000582596  
PR 13-NOV-1998 US 60/108193  
PI FRANCIS GALIBERT,CATHERINE ANDRE  
PC C12N15/09,C12Q1/68,C12N15/00  
CC A0133  
FH Key Location/Qualifiers  
FT source 1..24  
FT /organism='Canis familiaris (dog)'.  
FEATURES  
source Location/Qualifiers  
1..24  
/organism="Canis familiaris"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9615"

Query Match 1.3%; Score 20.8; DB 1; Length 24;  
Best Local Similarity 91.7%; Pred. No. 32;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CCCCCAGAGAGAGCTCTGCAGTC 1490  
|||||  
Db 1 CCCCTAGAGAGAGCTCTGCATGTC 24

RESULT 50  
AR531218  
LOCUS AR531218 21 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 2421 from patent US 6727063.  
ACCESSION AR531218  
VERSION AR531218.1 GI:53919655  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and  
McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: US 6727063-A 2421 27-APR-2004;  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.3%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 23;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GAGAGGTTACCAGGAATAC 1070  
|||||  
Db 1 GAGAGGTTGAYCAGGAATAC 21

RESULT 51  
AR531219  
LOCUS AR531219 21 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 2422 from patent US 6727063.  
ACCESSION AR531219  
VERSION AR531219.1 GI:53919656  
KEYWORDS  
SOURCE Unknown.

ORGANISM	Unknown:	Unclassified:	1 (bases 1 to 21)	Score 20.6;	DB 1;	Length 21;
REFERENCE	Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and					
AUTHORS	McCarthy,J.J.					
TITLE	Single nucleotide polymorphisms in genes					
JOURNAL	Patent: US 6727063-A 2422 27-APR-2004;					
FEATURES	Location/Qualifiers					
source	1..21					
	/organism="unknown"					
	/mol_type="genomic DNA"					
Query Match	1.3%;	Score 20.6;	DB 1;	Length 21;		
Best Local Similarity	95.2%;	Pred. No. 23;				
Matches	20;	Conservative 1;	Mismatches 0;	Indels 0;	Gaps 0;	
Qy	999	CCCTCCGAGGCTAAGTCGCG 1019				
Db	1	CCCTCCGAGGCTAAGTCGCG 21				
RESULT 52						
AR531220						
LOCUS	AR531220	21 bp	DNA	linear	PAT 08-OCT-2004	
DEFINITION	Sequence 2423 from patent US 6727063.					
ACCESSION	AR531220					
VERSION	AR531220.1	GI:53919657				
KEYWORDS						
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 21)					
AUTHORS	Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and					
	McCarthy,J.J.					
TITLE	Single nucleotide polymorphisms in genes					
JOURNAL	Patent: US 6727063-A 2423 27-APR-2004;					
FEATURES	Location/Qualifiers					
source	1..21					
	/organism="unknown"					
	/mol_type="genomic DNA"					
Query Match	1.3%;	Score 20.6;	DB 1;	Length 21;		
Best Local Similarity	95.2%;	Pred. No. 23;				
Matches	20;	Conservative 1;	Mismatches 0;	Indels 0;	Gaps 0;	
Qy	1170	CTCAGCGCAGGCGAAGACCAG 1190				
Db	1	CTCAGCGCAGGCGAAGACCAG 21				
RESULT 53						
AR531221						
LOCUS	AR531221	21 bp	DNA	linear	PAT 08-OCT-2004	
DEFINITION	Sequence 2424 from patent US 6727063.					
ACCESSION	AR531221					
VERSION	AR531221.1	GI:53919658				
KEYWORDS						
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 21)					
AUTHORS	Lander,E.S., Cargill,M., Ireland,J.S., Bolck,S., Daley,G.Q. and					
	McCarthy,J.J.					
TITLE	Single nucleotide polymorphisms in genes					
JOURNAL	Patent: US 6727063-A 2424 27-APR-2004;					
FEATURES	Location/Qualifiers					
source	1..21					
	/organism="unknown"					
	/mol_type="genomic DNA"					
Query Match	1.3%;	Score 20.6;	DB 1;	Length 21;		
Best Local Similarity	95.2%;	Pred. No. 23;				
Matches	20;	Conservative 1;	Mismatches 0;	Indels 0;	Gaps 0;	

QY	1105	TCAACACCTCTCTCTGCTGG	1125
Db	1	TCAACACCTCTCTCTGCTGG	21
RESULT 54			
AX097243			
LOCUS	AX097243	Sequence 2421 from Patent WO0118250.	21 bp DNA linear PAT 30-MAR-2001
DEFINITION	AX097243		
ACCESSION	AX097243		
VERSION	AX097243.1	GI:13513638	
KEYWORDS			
SOURCE		Homo sapiens (human)	
ORGANISM		Homo sapiens	
REFERENCE		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS		Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.	
TITLE		Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and	
JOURNAL		McCarthy, J.J.	
		Single nucleotide polymorphisms in genes	
		Patent: WO 0118250-A 2421 15-MAR-2001;	
		WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium	
		Pharmaceuticals, Inc. (US)	
FEATURES		Location/Qualifiers	
source		1..21	
		/organism="Homo sapiens"	
		/mol_type="unassigned DNA"	
		/db_xref="taxon:9606"	
Query Match		1.3%; Score 20.6; DB 1; Length 21;	
Best Local Similarity		95.2%; Pred. No. 23;	
Matches	20; Conservative	1; Mismatches	0; Indels 0; Gaps 0
QY	1050	GAGAGGTTCAGCAGGAATAC	1070
Db	1	GAGAGGTTCAGCAGGAATAC	21
RESULT 55			
AX097244			
LOCUS	AX097244	Sequence 2422 from Patent WO0118250.	21 bp DNA linear PAT 30-MAR-2001
DEFINITION	AX097244		
ACCESSION	AX097244		
VERSION	AX097244.1	GI:13513640	
KEYWORDS			
SOURCE		Homo sapiens (human)	
ORGANISM		Homo sapiens	
REFERENCE		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS		Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.	
TITLE		Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and	
JOURNAL		McCarthy, J.J.	
		Single nucleotide polymorphisms in genes	
		Patent: WO 0118250-A 2422 15-MAR-2001;	
		WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium	
		Pharmaceuticals, Inc. (US)	
FEATURES		Location/Qualifiers	
source		1..21	
		/organism="Homo sapiens"	
		/mol_type="unassigned DNA"	
		/db_xref="taxon:9606"	
Query Match		1.3%; Score 20.6; DB 1; Length 21;	
Best Local Similarity		95.2%; Pred. No. 23;	
Matches	20; Conservative	1; Mismatches	0; Indels 0; Gaps 0
QY	999	CCCTCCAGGCTAAGCTCGG	1019
Db	1	CCCTCCAGGCTAAGCTCGG	21
RESULT 56			



AX097245  
LOCUS AX097245 21 bp DNA linear PAT 30-MAR-2001  
DEFINITION Sequence 2423 from Patent WO0118250.  
ACCESSION AX097245  
VERSION AX097245.1 GI:13513642  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolck, S., Daley, G.Q. and  
McCarthy, J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 2423 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 1..3%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 23;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1170 CTCACGCAAGCGGAGACACG 1190  
Db 1 CTCACGCAAGCGGAGACACG 21  
RESULT 57  
AX097246  
LOCUS AX097246 21 bp DNA linear PAT 30-MAR-2001  
DEFINITION Sequence 2424 from Patent WO0118250.  
ACCESSION AX097246  
VERSION AX097246.1 GI:13513644  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolck, S., Daley, G.Q. and  
McCarthy, J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 2424 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 1..3%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 23;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1105 TCAACACCTCTCTCTGCTGG 1125  
Db 1 TCAACACCTCTCTCTGCTGG 21  
RESULT 58  
CQ803453  
LOCUS CQ803453 20 bp DNA linear PAT 10-MAY-2004  
DEFINITION Sequence 5 from Patent WO2004035827.  
ACCESSION CQ803453  
VERSION CQ803453.1 GI:47110310  
KEYWORDS  
SOURCE unidentified

ORGANISM unidentified  
REFERENCE 1 unclassified.  
AUTHORS Breban, M., Gidrol, X., Marion, S. and Chiochia, G.  
TITLE Microarrays allowing molecular profiling of rheumatoid arthritis  
comparatively to osteoarthritis and their use  
JOURNAL Patent: WO 2004035827-A 5 29-APR-2004;  
INSERM, The French Institute of Health and Medical Research (FR);  
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR); COMMISSARIAT A  
L'ENERGIE ATOMIQUE (FR)  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
misc\_feature 1..20  
/note="CLU forward primer for PCR"  
Query Match 1..2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1180 GCGAAGACCACTACTATCTG 1199  
Db 1 GCGAAGACCACTACTATCTG 20  
RESULT 59  
CQ803454/c  
LOCUS CQ803454 20 bp DNA linear PAT 10-MAY-2004  
DEFINITION Sequence 6 from Patent WO2004035827.  
ACCESSION CQ803454  
VERSION CQ803454.1 GI:47110311  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 unclassified.  
AUTHORS Breban, M., Gidrol, X., Marion, S. and Chiochia, G.  
TITLE Microarrays allowing molecular profiling of rheumatoid arthritis  
comparatively to osteoarthritis and their use  
JOURNAL Patent: WO 2004035827-A 6 29-APR-2004;  
INSERM, The French Institute of Health and Medical Research (FR);  
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR); COMMISSARIAT A  
L'ENERGIE ATOMIQUE (FR)  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
misc\_feature 1..20  
/note="CLU reverse primer for PCR"  
Query Match 1..2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1361 GCTGCAGGAATACCGCAAAA 1380  
Db 20 GCTGCAGGAATACCGCAAAA 1  
RESULT 60  
AR208715/c  
LOCUS AR208715 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 14 from patent US 6383808.  
ACCESSION AR208715  
VERSION AR208715.1 GI:21509942  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20) unclassified.

```

AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 14 07-MAY-2002;
FEATURES     Location/Qualifiers
             source
             1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGCGGTGCAAGAC 32
      |||||||
Db 20 TGACCGAGCGGTGCAAGAC 1

RESULT 61
LOCUS      AR208716/c
DEFINITION Sequence 15 from patent US 6383808.
ACCESSION AR208716
VERSION AR208716.1 GI:21509944
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 15 07-MAY-2002;
FEATURES   Location/Qualifiers
             source
             1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 GCGTGCAAGACTCCAGAT 40
      |||||||
Db 20 GCGTGCAAGACTCCAGAT 1

RESULT 62
LOCUS      AR208717/c
DEFINITION Sequence 16 from patent US 6383808.
ACCESSION AR208717
VERSION AR208717.1 GI:21509945
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 16 07-MAY-2002;
FEATURES   Location/Qualifiers
             source
             1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 ATTGGAGGCATGATGAAGAC 58
      |||||||
Db 20 ATTGGAGGCATGATGAAGAC 1

AUTHORS      Monia,B.P. and Freier,S.M.
TITLE        Antisense inhibition of clusterin expression
JOURNAL      Patent: US 6383808-A 14 07-MAY-2002;
FEATURES     Location/Qualifiers
             source
             1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGCGGTGCAAGAC 32
      |||||||
Db 20 TGACCGAGCGGTGCAAGAC 1

RESULT 63
LOCUS      AR208718/c
DEFINITION Sequence 17 from patent US 6383808.
ACCESSION AR208718
VERSION AR208718.1 GI:21509946
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 17 07-MAY-2002;
FEATURES   Location/Qualifiers
             source
             1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCTGCTGCTGACCTGGGAGA 96
      |||||||
Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 64
LOCUS      AR208719/c
DEFINITION Sequence 18 from patent US 6383808.
ACCESSION AR208719
VERSION AR208719.1 GI:21509947
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 18 07-MAY-2002;
FEATURES   Location/Qualifiers
             source
             1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 GCAGGTCCTGGGGACCAGA 120
      |||||||
Db 20 GCAGGTCCTGGGGACCAGA 1

RESULT 65
LOCUS      AR208720/c
DEFINITION Sequence 19 from patent US 6383808.
ACCESSION AR208720
VERSION AR208720.1 GI:21509949
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Monia,B.P. and Freier,S.M.
TITLE      Antisense inhibition of clusterin expression
JOURNAL    Patent: US 6383808-A 19 07-MAY-2002;
FEATURES   Location/Qualifiers
             source
             1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 GCAGGTCCTGGGGACCAGA 120
      |||||||
Db 20 GCAGGTCCTGGGGACCAGA 1
```

/mol_type="unassigned DNA"		/mol_type="unassigned DNA"	
Query Match	1.2%; Score 20; DB 1; Length 20;	Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 24;	Best Local Similarity	100.0%; Pred. No. 24;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
122 GGTCTCAGACAATGAGCTCC 141		201 GGGGTCAACAGATAAAGAC 220	
Db	20 GGTCTCAGACAATGAGCTCC 1	Db	20 GGGGTCAACAGATAAAGAC 1
RESULT 66		RESULT 69	
AR208721/c	AR208721	AR208724/c	AR208724
LOCUS	Sequence 20 from patent US 6383808.	LOCUS	Sequence 23 from patent US 6383808.
DEFINITION	20 bp DNA linear PAT 20-JUN-2002	DEFINITION	20 bp DNA linear PAT 20-JUN-2002
ACCESSION	AR208721	ACCESSION	AR208724
VERSION	AR208721.1 GI:21509950	VERSION	AR208724.1 GI:21509954
KEYWORDS		KEYWORDS	
SOURCE	Unknown.	SOURCE	Unknown.
ORGANISM	Unknown.	ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 20)	REFERENCE	1 (bases 1 to 20)
AUTHORS	Monia,B.P. and Freier,S.M.	AUTHORS	Monia,B.P. and Freier,S.M.
TITLE	Antisense inhibition of Clusterin expression	TITLE	Antisense inhibition of clusterin expression
JOURNAL	Patent: US 6383808-A 20 07-MAY-2002;	JOURNAL	Patent: US 6383808-A 23 07-MAY-2002;
FEATURES	Location/Qualifiers	FEATURES	Location/Qualifiers
source	1. .20	source	1. .20
/organism="unknown"		/organism="unknown"	
/mol_type="unassigned DNA"		/mol_type="unassigned DNA"	
Query Match	1.2%; Score 20; DB 1; Length 20;	Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 24;	Best Local Similarity	100.0%; Pred. No. 24;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
149 GTCCATCAGGAAGTAAGT 168		281 GAAGAGAAAGAGGATGCC 300	
Qy	20 GTCCATCAGGAAGTAAGT 1	Qy	20 GAAGAGAAAGAGGATGCC 1
Db		Db	
RESULT 67		RESULT 70	
AR208722/c	AR208722	AR208725/c	AR208725
LOCUS	Sequence 21 from patent US 6383808.	LOCUS	Sequence 24 from patent US 6383808.
DEFINITION	20 bp DNA linear PAT 20-JUN-2002	DEFINITION	20 bp DNA linear PAT 20-JUN-2002
ACCESSION	AR208722	ACCESSION	AR208725
VERSION	AR208722.1 GI:21509951	VERSION	AR208725.1 GI:21509955
KEYWORDS		KEYWORDS	
SOURCE	Unknown.	SOURCE	Unknown.
ORGANISM	Unknown.	ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 20)	REFERENCE	1 (bases 1 to 20)
AUTHORS	Monia,B.P. and Freier,S.M.	AUTHORS	Monia,B.P. and Freier,S.M.
TITLE	Antisense inhibition of Clusterin expression	TITLE	Antisense inhibition of clusterin expression
JOURNAL	Patent: US 6383808-A 21 07-MAY-2002;	JOURNAL	Patent: US 6383808-A 24 07-MAY-2002;
FEATURES	Location/Qualifiers	FEATURES	Location/Qualifiers
source	1. .20	source	1. .20
/organism="unknown"		/organism="unknown"	
/mol_type="unassigned DNA"		/mol_type="unassigned DNA"	
Query Match	1.2%; Score 20; DB 1; Length 20;	Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 24;	Best Local Similarity	100.0%; Pred. No. 24;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
166 AGTACGTCATAGGAATT 185		20 AGTACGTCATAGGAATT 1	
Qy	20 AGTACGTCATAGGAATT 1	Qy	
Db		Db	
RESULT 68		RESULT 68	
AR208723/c	AR208723	AR208723/c	AR208723
LOCUS	Sequence 22 from patent US 6383808.	LOCUS	Sequence 22 from patent US 6383808.
DEFINITION	20 bp DNA linear PAT 20-JUN-2002	DEFINITION	20 bp DNA linear PAT 20-JUN-2002
ACCESSION	AR208723	ACCESSION	AR208723
VERSION	AR208723.1 GI:21509952	VERSION	AR208723.1 GI:21509952
KEYWORDS		KEYWORDS	
SOURCE	Unknown.	SOURCE	Unknown.
ORGANISM	Unknown.	ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 20)	REFERENCE	1 (bases 1 to 20)
AUTHORS	Monia,B.P. and Freier,S.M.	AUTHORS	Monia,B.P. and Freier,S.M.
TITLE	Antisense inhibition of Clusterin expression	TITLE	Antisense inhibition of clusterin expression
JOURNAL	Patent: US 6383808-A 21 07-MAY-2002;	JOURNAL	Patent: US 6383808-A 24 07-MAY-2002;
FEATURES	Location/Qualifiers	FEATURES	Location/Qualifiers
source	1. .20	source	1. .20
/organism="unknown"		/organism="unknown"	
/mol_type="unassigned DNA"		/mol_type="unassigned DNA"	
Query Match	1.2%; Score 20; DB 1; Length 20;	Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 24;	Best Local Similarity	100.0%; Pred. No. 24;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 286 AGAAGAGGATGCCCTAAAT 305
Db 20 AGAAGAGGATGCCCTAAAT 1

RESULT 71
AR208726/c
LOCUS AR208726 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 25 from patent US 6383808.
ACCESSION AR208726
VERSION AR208726.1 GI:21509956
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 25 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 298 CCTAATGAGACCGAGAA 317
Db 20 CCTAATGAGACCGAGAA 1

RESULT 72
AR208727/c
LOCUS AR208727 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 26 from patent US 6383808.
ACCESSION AR208727
VERSION AR208727.1 GI:21509957
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 26 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 307 AGACCAGGAATCAGAGACA 326
Db 20 AGACCAGGAATCAGAGACA 1

RESULT 73
AR208728/c
LOCUS AR208728 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 27 from patent US 6383808.
ACCESSION AR208728
VERSION AR208728.1 GI:21509959
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.

TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 27 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 324 ACAAGCTGAAGGAGCTCCC 343
Db 20 ACAAGCTGAAGGAGCTCCC 1

RESULT 74
AR208729/c
LOCUS AR208729 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 28 from patent US 6383808.
ACCESSION AR208729
VERSION AR208729.1 GI:21509960
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 28 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 359 GACCATGATGGCCCTCTGGG 378
Db 20 GACCATGATGGCCCTCTGGG 1

RESULT 75
AR208730/c
LOCUS AR208730 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 29 from patent US 6383808.
ACCESSION AR208730
VERSION AR208730.1 GI:21509961
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 29 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 364 TGATGGCCCTCTGGGAAGAG 383
Db 20 TGATGGCCCTCTGGGAAGAG 1

RESULT 76
```

AR208731/c  
 LOCUS AR208731 20 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 30 from patent US 6383808.  
 ACCESSION AR208731  
 VERSION AR208731.1 GI:21509962  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 30 07-MAY-2002;  
 FEATURES  
 source  
 1. .20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 380 AGAGTGTAGCCCTGCTGA 399  
 Db 20 AGAGTGTAGCCCTGCTGA 1  
 RESULT 77  
 LOCUS AR208732/c PAT 20-JUN-2002  
 DEFINITION Sequence 31 from patent US 6383808.  
 ACCESSION AR208732  
 VERSION AR208732.1 GI:21509964  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 31 07-MAY-2002;  
 FEATURES  
 source  
 1. .20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 407 CTGCATGAAGTTCTACGCAC 426  
 Db 20 CTGCATGAAGTTCTACGCAC 1  
 RESULT 78  
 LOCUS AR208733/c PAT 20-JUN-2002  
 DEFINITION Sequence 32 from patent US 6383808.  
 ACCESSION AR208733  
 VERSION AR208733.1 GI:21509965  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 32 07-MAY-2002;  
 FEATURES  
 source  
 1. .20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 443 CTCAGGCTGTGGCCGCC 462  
 Db 20 CTCAGGCTGTGTGGCCGCC 1  
 RESULT 79  
 LOCUS AR208734/c PAT 20-JUN-2002  
 DEFINITION Sequence 33 from patent US 6383808.  
 ACCESSION AR208734  
 VERSION AR208734.1 GI:21509966  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 33 07-MAY-2002;  
 FEATURES  
 source  
 1. .20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 444 TCAGGCTGTGTGGCCGCCA 463  
 Db 20 TCAGGCTGTGTGGCCGCCA 1  
 RESULT 80  
 LOCUS AR208735/c PAT 20-JUN-2002  
 DEFINITION Sequence 34 from patent US 6383808.  
 ACCESSION AR208735  
 VERSION AR208735.1 GI:21509967  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 34 07-MAY-2002;  
 FEATURES  
 source  
 1. .20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 455 TGGCCGCCAGCTTGAGGAGT 474  
 Db 20 TGGCCGCCAGCTTGAGGAGT 1  
 RESULT 81  
 LOCUS AR208736/c PAT 20-JUN-2002  
 DEFINITION Sequence 35 from patent US 6383808.  
 ACCESSION AR208736  
 VERSION AR208736.1 GI:21509969  
 KEYWORDS

SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Monia,B.P. and Freier,S.M.
TITLE	Antisense inhibition of clusterin expression
JOURNAL	Patent: US 6383808-A 35 07-MAY-2002;
FEATURES	Location/Qualifiers source 1..20 /organism="unknown" /mol_type="unassigned DNA"
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred.No. 24;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	482 CCAGAGCTCGCCCTTCTACT 501
DB	20 CCAGAGCTCGCCCTTCTACT 1
RESULT 82	
LOCUS	AR208737 20 bp DNA linear PAT 20-JUN-2002
DEFINITION	Sequence 36 from patent US 6383808.
ACCESSION	AR208737
VERSION	AR208737.1 GI:21509970
KEYWORDS	.
SOURCE	Unknown. Unclassified.
ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Monia,B.P. and Freier,S.M.
TITLE	Antisense inhibition of clusterin expression
JOURNAL	Patent: US 6383808-A 36 07-MAY-2002;
FEATURES	Location/Qualifiers source 1..20 /organism="unknown" /mol_type="unassigned DNA"
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred.No. 24;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	492 CCTTCTACTCTGGATGAA 511
DB	20 CCTTCTACTCTGGATGAA 1
RESULT 83	
LOCUS	AR208738 20 bp DNA linear PAT 20-JUN-2002
DEFINITION	Sequence 37 from patent US 6383808.
ACCESSION	AR208738
VERSION	AR208738.1 GI:21509971
KEYWORDS	.
SOURCE	Unknown. Unclassified.
ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Monia,B.P. and Freier,S.M.
TITLE	Antisense inhibition of clusterin expression
JOURNAL	Patent: US 6383808-A 37 07-MAY-2002;
FEATURES	Location/Qualifiers source 1..20 /organism="unknown" /mol_type="unassigned DNA"
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred.No. 24;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	517 ACCGCATCGATCCCTGTCTG 536

```
JOURNAL Patent: US 6383808-A 40 07-MAY-2002;
FEATURES
  source
    LOCATION/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
  1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGACGCACATGCTGGATGTC 572
    |||||
Db 20 AGACGCACATGCTGGATGTC 1

RESULT 87
AR208742/c
LOCUS AR208742 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 41 from patent US 6383808.
ACCESSION AR208742
VERSION AR208742.1 GI:21509976
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 41 07-MAY-2002;
FEATURES
  source
    LOCATION/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
  1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCAGGACCAC 584
    |||||
Db 20 TGGATGTCATGCAGGACCAC 1

RESULT 88
AR208743/c
LOCUS AR208743 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 42 from patent US 6383808.
ACCESSION AR208743
VERSION AR208743.1 GI:21509977
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 42 07-MAY-2002;
FEATURES
  source
    LOCATION/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
  1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 567 GATGTCATGCAGGACCACCTT 586
    |||||
Db 20 GATGTCATGCAGGACCACCTT 1

RESULT 89
AR208744/c
LOCUS AR208744 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 43 from patent US 6383808.
ACCESSION AR208744
VERSION AR208744.1 GI:21509979
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 43 07-MAY-2002;
FEATURES
  source
    LOCATION/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
  1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 TCATAGCAGGCTCTTCCAG 623
    |||||
Db 20 TCATAGCAGGCTCTTCCAG 1

RESULT 90
AR208745/c
LOCUS AR208745 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 44 from patent US 6383808.
ACCESSION AR208745
VERSION AR208745.1 GI:21509980
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 44 07-MAY-2002;
FEATURES
  source
    LOCATION/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
  1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 608 AGACGAGCTCTTCCAGGACA 627
    |||||
Db 20 AGACGAGCTCTTCCAGGACA 1

RESULT 91
AR208746/c
LOCUS AR208746 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 45 from patent US 6383808.
ACCESSION AR208746
VERSION AR208746.1 GI:21509981
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 45 07-MAY-2002;
FEATURES
  source
    LOCATION/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"
```

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 613 AGCTCTCCAGGACAGGTTCC 632  
|||||  
Db 20 AGCTCTCCAGGACAGGTTCC 1

RESULT 92  
AR208747/c  
LOCUS AR208747 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 46 from patent US 6383808.  
ACCESSION AR208747  
VERSION AR208747.1 GI:21509982  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 46 07-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 AGGCCTCAGCTTCTTTCTTCC 709  
|||||  
Db 20 AGGCCTCAGCTTCTTTCTTCC 1

RESULT 93  
AR208748/c  
LOCUS AR208748 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 47 from patent US 6383808.  
ACCESSION AR208748  
VERSION AR208748.1 GI:21509984  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 47 07-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 TCGTCGCGAGCTTGATGCC 740  
|||||  
Db 20 TCGTCGCGAGCTTGATGCC 1

RESULT 94  
AR208749/c  
LOCUS AR208749 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 48 from patent US 6383808.  
ACCESSION AR208749  
VERSION AR208749.1 GI:21509985  
KEYWORDS  
SOURCE Unknown.

ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 48 07-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 775 TGTTCAGCCCTTCCTTGAG 794  
|||||  
Db 20 TGTTCAGCCCTTCCTTGAG 1

RESULT 95  
AR208750/c  
LOCUS AR208750 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 49 from patent US 6383808.  
ACCESSION AR208750  
VERSION AR208750.1 GI:21509986  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 49 07-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GTTCCAGCCCTTCCTTGAGA 795  
|||||  
Db 20 GTTCCAGCCCTTCCTTGAGA 1

RESULT 96  
AR208751/c  
LOCUS AR208751 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 50 from patent US 6383808.  
ACCESSION AR208751  
VERSION AR208751.1 GI:21509987  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 50 07-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 783 CCCTTCCTTGAGATGATACA 802  
|||||





DEFINITION Sequence 56 from patent US 6383808.  
ACCESSION AR208757  
VERSION AR208757.1 GI:21509995  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 56 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 906 GAGATCCGCCACAACTCCAC 925  
Db 20 GAGATCCGCCACAACTCCAC 1

RESULT 103  
LOCUS AR208758/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 57 from patent US 6383808.  
ACCESSION AR208758  
VERSION AR208758.1 GI:21509996  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of Clusterin expression  
JOURNAL Patent: US 6383808-A 57 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 GCTGCTCGCGATGAAGGAC 947  
Db 20 GCTGCTCGCGATGAAGGAC 1

RESULT 104  
LOCUS AR208759/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 58 from patent US 6383808.  
ACCESSION AR208759  
VERSION AR208759.1 GI:21509997  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 58 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 967 AGATCTTGCTGTGGACTGT 986  
Db 20 AGATCTTGCTGTGGACTGT 1

RESULT 105  
LOCUS AR208760/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 59 from patent US 6383808.  
ACCESSION AR208760  
VERSION AR208760.1 GI:21509999  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 59 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTCGCGGGAGCTC 1028  
Db 20 CTAAGCTCGCGGGAGCTC 1

RESULT 106  
LOCUS AR208761/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 60 from patent US 6383808.  
ACCESSION AR208761  
VERSION AR208761.1 GI:21510000  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 60 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1022 GGAGCTCGACGAATCCCTCC 1041  
Db 20 GGAGCTCGACGAATCCCTCC 1

RESULT 107  
LOCUS AR208762/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 61 from patent US 6383808.  
ACCESSION AR208762  
VERSION AR208762.1 GI:21510001  
KEYWORDS  
SOURCE  
ORGANISM

```
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 61 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 AAGTCTTACCAGTGGAGAT 1102
|||||
Db 20 AAGTCTTACCAGTGGAGAT 1

RESULT 108
AR208763/c
LOCUS AR208763 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 62 from patent US 6383808.
ACCESSION AR208763
VERSION AR208763.1 GI:21510002
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 62 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 CCAGTGGAGATGCTCAACA 1110
|||||
Db 20 CCAGTGGAGATGCTCAACA 1

RESULT 109
AR208764/c
LOCUS AR208764 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 63 from patent US 6383808.
ACCESSION AR208764
VERSION AR208764.1 GI:21510003
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 63 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1113 TCCTCCTTGTGGAGAGCT 1132
|||||
Db 20 TCCTCCTTGTGGAGAGCT 1

Unclassified.
REFERENCE 110
LOCUS AR208765/c 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 64 from patent US 6383808.
ACCESSION AR208765
VERSION AR208765.1 GI:21510005
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 64 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 GCTGGAGCAGCTGAACGAGC 1140
|||||
Db 20 GCTGGAGCAGCTGAACGAGC 1

RESULT 111
AR208766/c
LOCUS AR208766 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 65 from patent US 6383808.
ACCESSION AR208766
VERSION AR208766.1 GI:21510006
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 65 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 CTGGGTGTCCTGGCGCTGGCAA 1167
|||||
Db 20 CTGGGTGTCCTGGCGCTGGCAA 1

RESULT 112
AR208767/c
LOCUS AR208767 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 66 from patent US 6383808.
ACCESSION AR208767
VERSION AR208767.1 GI:21510007
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 66 07-MAY-2002;
FEATURES Location/Qualifiers
```

[illegible]

Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	1332 AAATTTATGGAGACCGTGGC 1351 				
Db	20 AAATTTATGGAGACCGTGGC 1				
RESULT 118					
AR208773/c	AR208773	20 bp	DNA	linear	PAT 20-JUN-2002
LOCUS	Sequence 72 from patent US 6383808.				
DEFINITION	AR208773				
ACCESSION	AR208773				
VERSION	AR208773.1	GI:21510015			
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 20)				
AUTHORS	Monia,B.P. and Freier,S.M.				
TITLE	Antisense inhibition of clusterin expression				
JOURNAL	Patent: US 6383808-A 72 07-MAY-2002;				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	1.2%; Score 20; DB 1; Length 20;				
Best Local Similarity	100.0%; Pred. No. 24;				
Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	1398 GATGTGGATGTCCTTTTGC 1417 				
Db	20 GATGTGGATGTCCTTTTGC 1				
RESULT 119					
AR208774/c	AR208774	20 bp	DNA	linear	PAT 20-JUN-2002
LOCUS	Sequence 73 from patent US 6383808.				
DEFINITION	AR208774				
ACCESSION	AR208774				
VERSION	AR208774.1	GI:21510016			
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 20)				
AUTHORS	Monia,B.P. and Freier,S.M.				
TITLE	Antisense inhibition of clusterin expression				
JOURNAL	Patent: US 6383808-A 73 07-MAY-2002;				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	1.2%; Score 20; DB 1; Length 20;				
Best Local Similarity	100.0%; Pred. No. 24;				
Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	1545 GCTCTGGATCCTGCACCTCTA 1564 				
Db	20 GCTCTGGATCCTGCACCTCTA 1				
RESULT 120					
AR208775/c	AR208775	20 bp	DNA	linear	PAT 20-JUN-2002
LOCUS	Sequence 74 from patent US 6383808.				
DEFINITION	AR208775				
ACCESSION	AR208775				
VERSION	AR208775.1	GI:21510017			
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 20)				
AUTHORS	Monia,B.P. and Freier,S.M.				
TITLE	Antisense inhibition of clusterin expression				
JOURNAL	Patent: US 6383808-A 74 07-MAY-2002;				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	1.2%; Score 20; DB 1; Length 20;				
Best Local Similarity	100.0%; Pred. No. 24;				
Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	1615 CTAAATTCATAAACTGTCT 1634 				
Db	20 CTAAATTCATAAACTGTCT 1				
RESULT 121					
AR208776/c	AR208776	20 bp	DNA	linear	PAT 20-JUN-2002
LOCUS	Sequence 75 from patent US 6383808.				
DEFINITION	AR208776				
ACCESSION	AR208776				
VERSION	AR208776.1	GI:21510018			
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 20)				
AUTHORS	Monia,B.P. and Freier,S.M.				
TITLE	Antisense inhibition of clusterin expression				
JOURNAL	Patent: US 6383808-A 75 07-MAY-2002;				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	1.2%; Score 20; DB 1; Length 20;				
Best Local Similarity	100.0%; Pred. No. 24;				
Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	1615 CTAAATTCATAAACTGTCT 1634 				
Db	20 CTAAATTCATAAACTGTCT 1				
RESULT 122					
AR208779/c	AR208779	20 bp	DNA	linear	PAT 20-JUN-2002
LOCUS	Sequence 78 from patent US 6383808.				
DEFINITION	AR208779				
ACCESSION	AR208779				
VERSION	AR208779.1	GI:21510022			
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 20)				
AUTHORS	Monia,B.P. and Freier,S.M.				
TITLE	Antisense inhibition of clusterin expression				
JOURNAL	Patent: US 6383808-A 78 07-MAY-2002;				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	1.2%; Score 20; DB 1; Length 20;				
Best Local Similarity	100.0%; Pred. No. 24;				
Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	979 TGGACTGTTCCACCAAC 998 				
Db	20 TGGACTGTTCCACCAAC 1				

```
RESULT 123
AR208781/c
LOCUS AR208781 linear PAT 20-JUN-2002
DEFINITION Sequence 80 from patent US 6383808.
ACCESSION AR208781
VERSION AR208781.1 GI:21510025
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 80 07-MAY-2002;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1383 CACCGGAGGAGTGTGATGT 1402
Db 20 CACCGGAGGAGTGTGATGT 1
RESULT 124
CQ786121
LOCUS CQ786121 linear PAT 24-MAR-2004
DEFINITION Sequence 9 from Patent WO2004018676.
ACCESSION CQ786121
VERSION CQ786121.1 GI:45721224
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 9 04-MAR-2004;
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"
Query Match 1.2%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGCT 67
Db 1 ATGATGAAGACTCTGCTGCT 20
RESULT 125
CQ786639
LOCUS CQ786639 linear PAT 24-MAR-2004
DEFINITION Sequence 28 from Patent WO2004018675.
ACCESSION CQ786639
VERSION CQ786639.1 GI:45721659
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Jansen,B.
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
TITLE Treatment of melanoma by reduction in clusterin levels
PATENT: WO 2004018675-A 28 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"
Query Match 1.2%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGCT 67
Db 1 ATGATGAAGACTCTGCTGCT 20
RESULT 126
AR236281
LOCUS AR236281 linear PAT 20-DEC-2002
DEFINITION Sequence 13 from patent US 6464975.
ACCESSION AR236281
VERSION AR236281.1 GI:27280109
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Millis,A.J.T.
TITLE Compositions and methods for altering cell migration
JOURNAL Patent: US 6464975-A 13 15-OCT-2002;
FEATURES
source
1..21
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 35;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 271 AAGAAGCCCAAGAGAGAAAG 291
Db 1 ACGAAGCCCAAGAGAGAAAG 21
RESULT 127
CQ786179
LOCUS CQ786179 linear PAT 24-MAR-2004
DEFINITION Sequence 67 from Patent WO2004018676.
ACCESSION CQ786179
VERSION CQ786179.1 GI:45721282
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 67 04-MAR-2004;
The University of British Columbia (CA)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 48 ATGATGAAGACTCTGCTGC 66  
|||||  
Db 1 ATGATGAAGACTCTGCTGC 19

RESULT 128  
CQ786180/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

CQ786180 19 bp RNA linear PAT 24-MAR-2004  
Sequence 68 from Patent WO2004018676.  
CQ786180  
CQ786180.1 GI:45721283  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and  
Gonos,E.  
Rnai probes targeting cancer-related proteins  
Patent: WO 2004018676-A 68 04-MAR-2004;  
The University of British Columbia (CA)  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66  
|||||  
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 129  
CQ786653  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

CQ786653 19 bp RNA linear PAT 24-MAR-2004  
Sequence 42 from Patent WO2004018675.  
CQ786653  
CQ786653.1 GI:45721673  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
Jansen,B.  
Treatment of melanoma by reduction in clusterin levels  
Patent: WO 2004018675-A 42 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66  
|||||  
Db 1 ATGATGAAGACTCTGCTGC 19

RESULT 130  
CQ786654/c  
LOCUS  
DEFINITION

CQ786654 19 bp RNA linear PAT 24-MAR-2004  
Sequence 43 from Patent WO2004018675.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

CQ786654  
CQ786654.1 GI:45721674  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
Jansen,B.  
Treatment of melanoma by reduction in clusterin levels  
Patent: WO 2004018675-A 43 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
Location/Qualifiers  
1. .19  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66  
|||||  
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 131  
CQ786122/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

CQ786122 21 bp DNA linear PAT 24-MAR-2004  
Sequence 10 from Patent WO2004018676.  
CQ786122  
CQ786122.1 GI:45721225  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and  
Gonos,E.  
Rnai probes targeting cancer-related proteins  
Patent: WO 2004018676-A 10 04-MAR-2004;  
The University of British Columbia (CA)  
Location/Qualifiers  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 40;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGC 66  
|||||  
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 132  
CQ786640/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL

CQ786640 21 bp DNA linear PAT 24-MAR-2004  
Sequence 29 from Patent WO2004018675.  
CQ786640  
CQ786640.1 GI:45721660  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
Jansen,B.  
Treatment of melanoma by reduction in clusterin levels  
Patent: WO 2004018675-A 29 04-MAR-2004;

The University of British Columbia (CA); Gleave, Martin E. (CA)

FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match  
Best Local Similarity 1.2%; Score 19; DB 1; Length 21;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGC 66  
|||||  
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 133  
AR071119 22 bp DNA linear PAT 18-FEB-2000  
LOCUS  
DEFINITION Sequence 10 from patent US 5910412.  
ACCESSION AR071119  
VERSION AR071119.1 GI:7222007  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 22)  
AUTHORS Akamatsu,T. and Suzuki,T.  
TITLE Method for identifying the sex of spinach by DNA markers  
JOURNAL Patent: US 5910412-A 10 08-JUN-1999;  
FEATURES  
source  
1. .22  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 1.1%; Score 18.8; DB 1; Length 22;  
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 865 AATTCATACGAGGCGACGA 886  
|||||  
Db 1 AATTCATACGAGGCGACGA 22

RESULT 134  
E15141 22 bp DNA linear PAT 28-JUL-1999  
LOCUS  
DEFINITION PCR primer for detecting male spinach DNA.  
ACCESSION E15141  
VERSION E15141.1 GI:5709824  
KEYWORDS JP 1998052284-A/10.  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 22)  
AUTHORS Akamatsu,T., Suzuki,T. and Uchimiya,H.  
TITLE DETERMINATION OF MALE OR FEMALE OF SPINACH BY USING DNA MARKER  
JOURNAL Patent: JP 1998052284-A 10 24-FEB-1998;  
COMMENT SAKATA NO TANE:KK  
OS None  
OC Artificial sequences.  
PN JP 1998052284-A/10  
PD 24-FEB-1998  
PF 14-MAY-1997 JP 1997124012  
PI 14-MAY-1996 JP 96P 119124  
PR AKAMATSU TOYOKAZU, SUZUKI TAKAO, UCHIMIYA HIROBUMI PC  
C12N15/09,C07H21/04,C12Q1/68;  
CC strandedness: Single;  
CC topology: linear;  
CC hypothetical: No;  
CC anti-sense: No; Location/Qualifiers  
FH Key

1. .22  
/organism="Artificial sequences".

FEATURES  
source  
1. .22  
Location/Qualifiers  
1. .22  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match  
Best Local Similarity 1.1%; Score 18.8; DB 1; Length 22;  
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 865 AATTCATACGAGGCGACGA 886  
|||||  
Db 1 AATTCATACGAGGCGACGA 22

RESULT 135  
AR038688 18 bp DNA linear PAT 29-SEP-1999  
LOCUS  
DEFINITION Sequence 22 from patent US 5807678.  
ACCESSION AR038688  
VERSION AR038688.1 GI:5958051  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Miller,W.L., Lin,D. and Strauss,J.F. III.  
TITLE Identification of gene mutations associated with congenital lipoid  
adrenal hyperplasia  
JOURNAL Patent: US 5807678-A 22 15-SEP-1998;  
FEATURES  
source  
1. .18  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 1.1%; Score 18; DB 1; Length 18;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 GAGAGCTCTGCAGTCAC 1492  
|||||  
Db 18 GAGAGCTCTGCAGTCAC 1

RESULT 136  
AR208705 18 bp DNA linear PAT 20-JUN-2002  
LOCUS  
DEFINITION Sequence 4 from patent US 6383808.  
ACCESSION AR208705  
VERSION AR208705.1 GI:21509929  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 4 07-MAY-2002;  
FEATURES  
source  
1. .18  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 1.1%; Score 18; DB 1; Length 18;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTGAA 763  
|||||  
Db 1 TCCGTACGAGCCCTGAA 18



```
RESULT 137
AX728619
LOCUS AX728619 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 253 from Patent WO03025175.
ACCESSION AX728619
VERSION AX728619.1 GI:30507962
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 253 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1551 GATCCTGCACTCTAACA 1567
|||||
Db 1 GATCCTGCACTCTAACA 17

RESULT 138
AX762710
LOCUS AX762710 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 6031 from Patent WO03040369.
ACCESSION AX762710
VERSION AX762710.1 GI:32257326
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 6031 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1551 GATCCTGCACTCTAACA 1567
|||||
Db 1 GATCCTGCACTCTAACA 17

RESULT 139
AR167026/c
LOCUS AR167026 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 43 from patent US 6284458.
ACCESSION AR167026
```

```
VERSION AR167026.1 GI:16243448
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Anderson,K.P., Hanecak,R.C., Hoshiko,K., Nozaki,C., Nishihara,T.,
Nakatake,H., Hamada,F., Eto,T. and Furukawa,S.
TITLE Compositions and methods for treatment of hepatitis C
virus-associated diseases
JOURNAL Patent: US 6284458-A 43 04-SEP-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1510 GCCTCCAGGCCGCCCAACTCC 1529
|||||
Db 20 GCCTCCAGGCCGCCCCCTCC 1

RESULT 140
AR210681/c
LOCUS AR210681 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 43 from patent US 6391542.
ACCESSION AR210681
VERSION AR210681.1 GI:21513473
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Anderson,K.P., Hanecak,R.C., Hoshiko,K., Nozaki,C., Nishihara,T.,
Nakatake,H., Hamada,F., Eto,T., Furukawa,S., Furusako,S.,
Bruce,T.W. and Lima,W.F.
TITLE Compositions and methods for treatment of Hepatitis C
virus-associated diseases
JOURNAL Patent: US 6391542-A 43 21-MAY-2002;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1510 GCCTCCAGGCCGCCCAACTCC 1529
|||||
Db 20 GCCTCCAGGCCGCCCCCTCC 1

RESULT 141
A39125/c
LOCUS A39125 16 bp DNA linear PAT 05-MAR-1997
DEFINITION Sequence 97 from Patent WO9412670.
ACCESSION A39125
VERSION A39125.1 GI:2295500
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van,H.H.
TITLE PROCESS FOR TYPING OF HCV ISOLATES
JOURNAL Patent: WO 9412670-A 97 09-JUN-1994;
INNOGENETICS NV (BE)
COMMENT Other publication AU 5628294 940622
Other publication CA 2128528 940609
```

```

FEATURES
  source
    Other publication JP 7503143T 950406.
    Location/Qualifiers
      1..16
      /organism="unidentified"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32644"

Query Match
  Best Local Similarity 1.0%; Score 16; DB 1; Length 16;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 142
AR063448/c
LOCUS
  DEFINITION Sequence 97 from patent US 5846704.
  ACCESSION AR063448
  VERSION AR063448.1 GI:5992756
  KEYWORDS
  SOURCE Unknown.
  ORGANISM Unknown.
  UNCLASSIFIED.
  REFERENCE 1 (bases 1 to 16)
  AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
  TITLE Process for typing of HCV isolates
  JOURNAL Patent: US 5846704-A 97 08-DEC-1998;
  FEATURES
    Location/Qualifiers
      1..16
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 1.0%; Score 16; DB 1; Length 16;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 143
AR123639/c
LOCUS
  DEFINITION Sequence 97 from patent US 6171784.
  ACCESSION AR123639
  VERSION AR123639.1 GI:14109000
  KEYWORDS
  SOURCE Unknown.
  ORGANISM Unknown.
  UNCLASSIFIED.
  REFERENCE 1 (bases 1 to 16)
  AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
  TITLE Process for typing of HCV isolates
  JOURNAL Patent: US 6171784-A 97 09-JAN-2001;
  FEATURES
    Location/Qualifiers
      1..16
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 1.0%; Score 16; DB 1; Length 16;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 144
AR063448/c
LOCUS
  DEFINITION Sequence 97 from patent US 5846704.
  ACCESSION AR063448
  VERSION AR063448.1 GI:5992756
  KEYWORDS
  SOURCE Unknown.
  ORGANISM Unknown.
  UNCLASSIFIED.
  REFERENCE 1 (bases 1 to 16)
  AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
  TITLE Process for typing of HCV isolates
  JOURNAL Patent: US 5846704-A 97 08-DEC-1998;
  FEATURES
    Location/Qualifiers
      1..16
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 1.0%; Score 16; DB 1; Length 16;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 145
AR305790/c
LOCUS
  DEFINITION Sequence 97 from patent US 6548244.
  ACCESSION AR305790
  VERSION AR305790.1 GI:31695399
  KEYWORDS
  SOURCE Unknown.
  ORGANISM Unknown.
  UNCLASSIFIED.
  REFERENCE 1 (bases 1 to 16)
  AUTHORS Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.
  TITLE Process for typing HCV isolates
  JOURNAL Patent: US 6548244-A 97 15-APR-2003;
  FEATURES
    Location/Qualifiers
      1..16
      /organism="unknown"
      /mol_type="mrna"

Query Match
  Best Local Similarity 1.0%; Score 16; DB 1; Length 16;
  Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523
Db 16 CAGCCTCCAGGCCCCC 1

RESULT 146
AX023187/c
LOCUS
  DEFINITION Sequence 97 from Patent EP0905258.
  ACCESSION AX023187
  VERSION AX023187.1 GI:10046644
  KEYWORDS
  SOURCE unidentified
  ORGANISM unidentified
  UNCLASSIFIED.
  REFERENCE 1
  AUTHORS
  TITLE Method for detecting nucleic acid sequences based on the use of
  JOURNAL solid phase immobilised nucleotide probes (line probe assay)
  INNOGENETICS NV (BE)
  FEATURES
    Location/Qualifiers
      1..16
      /organism="unknown"
      /mol_type="mrna"

```

```
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match      1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
Db 16 CAGCCTCCAGGCCCC 1

RESULT 147
AX417393/c
LOCUS      AX417393      16 bp      DNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 97 from Patent EP1197568.
ACCESSION  AX417393
VERSION     AX417393.1 GI:21522686
KEYWORDS    .
SOURCE      Hepatitis C virus
ORGANISM    Hepatitis C virus
            Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
            Hepacivirus.
REFERENCE   1
AUTHORS    Maertens,G., Rossau,R., Stuyver,L. and van Heuverswyn,H.
TITLE      Detection and typing of hcv using 5'utr and ns5 nucleic acid
            sequences
JOURNAL    Patent: EP 1197568-A 97 17-APR-2002;
            Innogenetics N.V. (BE)
FEATURES    Location/Qualifiers
            source
              1..16
              /organism="Hepatitis C virus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:11103"

Query Match      1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
Db 16 CAGCCTCCAGGCCCC 1

RESULT 148
AR029848
LOCUS      AR029848      17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 37 from patent US 5861244.
ACCESSION  AR029848
VERSION     AR029848.1 GI:5943062
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS    Wang,C.-G. and Hepburn,A.G.
TITLE      Genetic sequence assay using DNA triple strand formation
JOURNAL    Patent: US 5861244-A 37 19-JAN-1999;
FEATURES    Location/Qualifiers
            source
              1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAGAAAGAGGA 295
Db 1 AGAAGAGAAAGAGGA 16
```

```
RESULT 149
CQ881900/c
LOCUS      CQ881900      19 bp      RNA      linear      PAT 11-OCT-2004
DEFINITION Sequence 15 from Patent WO2004083446.
ACCESSION  CQ881900
VERSION     CQ881900.1 GI:54034672
KEYWORDS    .
SOURCE      synthetic construct
            other sequences; artificial sequences.
ORGANISM    1
REFERENCE   1
AUTHORS    van Ommeren,J.J., van Deutekom,J.C., den Dunnen,J.T. and
            Aartema-Rus,A.
TITLE      Modulation of exon recognition in pre-mrna by interfering with the
            secondary rna structure
JOURNAL    Patent: WO 2004083446-A 15 30-SEP-2004;
            Academisch Ziekenhuis Leiden (NL)
FEATURES    Location/Qualifiers
            source
              1..19
              /organism="synthetic construct"
              /mol_type="unassigned RNA"
              /db_xref="taxon:32630"
              /notes="Description of Artificial Sequence: h41AON1"

Query Match      1.0%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAGAAAGAGGA 295
Db 17 AGAAGAGAAAGAGGA 2

RESULT 150
CQ786119
LOCUS      CQ786119      19 bp      DNA      linear      PAT 24-MAR-2004
DEFINITION Sequence 7 from Patent WO2004018676.
ACCESSION  CQ786119
VERSION     CQ786119.1 GI:45721222
KEYWORDS    .
SOURCE      synthetic construct
            other sequences; artificial sequences.
ORGANISM    1
REFERENCE   1
AUTHORS    Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
            Gonos,E.
TITLE      Rnai probes targeting cancer-related proteins
JOURNAL    Patent: WO 2004018676-A 7 04-MAR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
              1..19
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /notes="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATAAAACTGTCT 1634
Db 1 TAATTCACAAACTGTTT 19

RESULT 151
CQ786120/c
LOCUS      CQ786120      19 bp      DNA      linear      PAT 24-MAR-2004
DEFINITION Sequence 8 from Patent WO2004018676.
ACCESSION  CQ786120
VERSION     CQ786120.1 GI:45721223
KEYWORDS    .
SOURCE      synthetic construct
```

```
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018675-A 8 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 TAATTCAATAAAACTGCT 1634
Db      1 TAATTCAACAAACTGTT 19
|||||
|

RESULT 153
LOCUS      CQ786637
DEFINITION Sequence 26 from Patent WO2004018675.
ACCESSION  CQ786637
VERSION     CQ786637.1 GI:45721657
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 26 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 ACTAATTCATAAACTGCT 1632
Db      19 AATAATTCACAAACTGTT 1
|||||
|

RESULT 152
LOCUS      CQ786635
DEFINITION Sequence 24 from Patent WO2004018675.
ACCESSION  CQ786635
VERSION     CQ786635.1 GI:45721655
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 24 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 TAATTCAATAAACTGCT 1634
Db      1 TAATTCAACAAACTGTT 19
|||||
|

RESULT 153
LOCUS      CQ786637
DEFINITION Sequence 26 from Patent WO2004018675.
ACCESSION  CQ786637
VERSION     CQ786637.1 GI:45721657
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 26 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"

ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018675-A 8 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 TAATTCAATAAACTGCT 1634
Db      1 TAATTCAACAAACTGTT 19
|||||
|

RESULT 154
LOCUS      CQ786638
DEFINITION Sequence 27 from Patent WO2004018675.
ACCESSION  CQ786638
VERSION     CQ786638.1 GI:45721658
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 27 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 TAATTCAATAAACTGCT 1634
Db      1 TAATTCAACAAACTGTT 19
|||||
|

RESULT 155
LOCUS      CQ623926
DEFINITION Sequence 8666 from Patent WO0192524.
ACCESSION  CQ623926
VERSION     CQ623926.1 GI:41674144
KEYWORDS   .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
              Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8666 06-DEC-2001;
              Asomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      273 GAACCCAGAGAGAGAA 289
|||||
|
```

Db 1 GAAGCCAAGAAGGAGAA 17

RESULT 156  
LOCUS 137522/c  
DEFINITION Sequence 535 from patent US 5612215.  
ACCESSION 137522  
VERSION 137522.1 GI:2085482  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 535 18-MAR-1997;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAAGATTGCTCC 1605  
|||||  
17 AAGAACAAGATTGCTCC 1

Db 17 AAGAACAAGATTGCTCC 1

RESULT 157  
LOCUS 194372/c  
DEFINITION Sequence 535 from patent US 5731295.  
ACCESSION 194372  
VERSION 194372.1 GI:3938842  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 535 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAAGATTGCTCC 1605  
|||||  
17 AAGAACAAGATTGCTCC 1

Db 17 AAGAACAAGATTGCTCC 1

RESULT 158  
LOCUS AR464989  
DEFINITION Sequence 8666 from patent US 6686188.  
ACCESSION AR464989  
VERSION AR464989.1 GI:42700046  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 8666 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCAAGAAGAGAA 289  
|||||  
1 GAAGCCAAGAAGAGAA 17

Db 1 GAAGCCAAGAAGAGAA 17

RESULT 159  
LOCUS AX214728/c  
DEFINITION Sequence 170 from Patent WO0159103.  
ACCESSION AX214728  
VERSION AX214728.1 GI:15524771  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 170 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES Location/Qualifiers  
source 1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/notes="Nucleic Acid"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAAACTGCTTT 1635  
|||||  
17 TTCAATAAAACTGCTTT 1

Db 17 TTCAATAAAACTGCTTT 1

RESULT 160  
LOCUS AX688719/c  
DEFINITION Sequence 1451 from Patent EP1281758.  
ACCESSION AX688719  
VERSION AX688719.1 GI:29411423  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1451 05-FEB-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAAACTGCTTT 1635  
|||||  
17 TTCAATAAAACTGCTTT 1

Db 17 TTCAATAAAACTGCTTT 1

RESULT 160  
LOCUS AX688719/c  
DEFINITION Sequence 1451 from Patent EP1281758.  
ACCESSION AX688719  
VERSION AX688719.1 GI:29411423  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1451 05-FEB-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 928 GCTGCTCGGATGAAG 944  
DB 17 GCTGCTCGGCTGAAG 1

RESULT 161  
LOCUS AX762505 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 5826 from Patent WO03040369.  
ACCESSION AX762505  
VERSION AX762505.1 GI:32257121  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 5826 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1.17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1551 GATCCTGCACTTAACA 1567  
DB 1 GATCCTGCACTTACCA 17

RESULT 162  
LOCUS AR011407/c 18 bp DNA linear PAT 04-DEC-1998  
DEFINITION Sequence 280 from patent US 5762938.  
ACCESSION AR011407  
VERSION AR011407.1 GI:3969397  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18) Paoletti,E., Perkus,M.E., Taylor,J., Tartaglia,J., Norton,E.K., Riviere,M., de Taisne,C., Limbach,K.J., Johnson,G.P., Pincus,S.E., Cox,W.I., Audonnet,J.-C.Francis. and Gettig,R.Robert.  
TITLE Modified recombinant vaccinia virus and expression vectors thereof  
JOURNAL Patent: US 5762938-A 280 09-JUN-1998;  
FEATURES Location/Qualifiers  
source 1.18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAAACAAAC 239  
DB 18 CTAATAGAAAAACCAAC 1

RESULT 163  
LOCUS AR040105/c 18 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 953 from patent US 5807743.  
ACCESSION AR040105  
VERSION AR040105.1 GI:5959468  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18) Stinchcomb,D.T. and McSwiggen,J.A.  
AUTHORS Interleukin-2 receptor gamma-chain ribozymes  
TITLE Patent: US 5807743-A 953 15-SEP-1998;  
JOURNAL Location/Qualifiers  
FEATURES 1.18  
source /organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 GCTGAGCAGCTGAACGA 1138  
DB 18 GCAGGAGCAGCTGAAGGA 1

RESULT 164  
LOCUS I18045/c 18 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 280 from patent US 5494807.  
ACCESSION I18045  
VERSION I18045.1 GI:1598400  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18) Paoletti,E., Perkus,M.E., Taylor,J., Tartaglia,J., Norton,E.K., Riviere,M., de Taisne,C., Limbach,K.J., Johnson,G.P., Pincus,S.E., Cox,W.I., Audonnet,J.-C.F. and Gettig,R.R.  
TITLE NYVAC vaccinia virus recombinants comprising heterologous inserts  
JOURNAL Patent: US 5494807-A 280 27-FEB-1996;  
FEATURES Location/Qualifiers  
source 1.18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAAACAAAC 239  
DB 18 CTAATAGAAAAACCAAC 1

RESULT 165  
LOCUS AX115178 18 bp DNA linear PAT 11-MAY-2001  
DEFINITION Sequence 301 from Patent WO0129262.  
ACCESSION AX115178  
VERSION AX115178.1 GI:14032120  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1 Picoult-Newburg,L. and Pohl,M.  
AUTHORS Genotyping reagents, kits and methods of use thereof  
TITLE Patent: WO 0129262-A 301 26-APR-2001;  
JOURNAL Orchid Biosciences, Inc. (US)

```
FEATURES
  source
    Location/Qualifiers
      1..18
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Primer"

Query Match
  Best Local Similarity 0.9%; Score 14.8; DB 1; Length 18;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1492 CCAAGTAACGAGCCCA 1509
Db 1 CCAGGTGACGAGCCCA 18

RESULT 166
AX776586
LOCUS AX776586 18 bp DNA linear PAT 14-JUL-2003
DEFINITION Sequence 11 from Patent WO03047611.
ACCESSION AX776586
VERSION AX776586.1 GI:32694120
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Weise,M., Eulenberg,K., Fritsch,R., Haeder,T., Broenner,G. and
Steuernagel,A.
TITLE Ppl0d, tec protein tyrosine kinase and edtp homologous proteins
JOURNAL Involved in the regulation of energy homeostasis
  Patent: WO 03047611-A 11 12-JUN-2003;
  DeveloGen Aktiengesellschaft fuer entwicklungsbiologische Forschung
  (DE)
FEATURES
  source
    Location/Qualifiers
      1..18
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="mouse PTRB reverse primer"

Query Match
  Best Local Similarity 0.9%; Score 14.8; DB 1; Length 18;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 764 CTCCAGCCATGTTCCA 781
Db 1 CTCCAGCCATGTTCCA 18

RESULT 167
AR173373
LOCUS AR173373 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 7 from patent US 6303847.
ACCESSION AR173373
VERSION AR173373.1 GI:17912864
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1
AUTHORS (bases 1 to 17)
  Kawaoka,A. and Ebinuma,H.
TITLE DNA encoding a transcription factor controlling phenylpropanoid
  biosynthesis pathway
JOURNAL Patent: US 6303847-A 7 16-OCT-2001;
  Location/Qualifiers
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.9%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCAACACCTCTCTCT 1119
Db 2 CTCAACACCTCTCTCT 17

RESULT 168
CQ623612/c
LOCUS CQ623612 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8352 from Patent WO0192524.
ACCESSION CQ623612
VERSION CQ623612.1 GI:41673830
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8352 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.9%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTCTGCTG 1124
Db 17 CAGCTCTCTCTGCTG 2

RESULT 169
CQ623613/c
LOCUS CQ623613 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8353 from Patent WO0192524.
ACCESSION CQ623613
VERSION CQ623613.1 GI:41673831
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8353 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.9%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTCTGCTG 1124
Db 16 CAGCTCTCTCTGCTG 1

RESULT 170
CQ623925
LOCUS CQ623925 17 bp DNA linear PAT 02-FEB-2004
```

DEFINITION Sequence 8665 from Patent WO0192524.  
ACCESSION CQ623925  
VERSION CQ623925.1 GI:41674143  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8665 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 273 GAAGCCCAAGAGGAGA 288  
Db 2 GAAGCCCAAGAGGAGA 17  
RESULT 171  
LOCUS CQ623927 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 8667 from Patent WO0192524.  
ACCESSION CQ623927  
VERSION CQ623927.1 GI:41674145  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8667 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 274 AAGCCCAAGAGGAGAA 289  
Db 1 AAGCCCAAGAGGAGAA 16  
RESULT 172  
LOCUS CQ625297 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10037 from Patent WO0192524.  
ACCESSION CQ625297  
VERSION CQ625297.1 GI:41675515  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10037 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 715 CCGCATCGTCGCCAG 730  
Db 16 CCGCATCGTCGCCAG 1  
RESULT 174  
LOCUS I37523 17 bp DNA linear PAT 13-MAY-1997  
DEFINITION Sequence 536 from patent US 5612215.  
ACCESSION I37523  
VERSION I37523.1 GI:2085483  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and Stinchcomb, D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 536 18-MAR-1997;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;



Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGACAGAAATTTGCTC 1604  
|||||  
Db 16 AAGACAGAAATTTGCTC 1

RESULT 175  
I94373/c  
LOCUS I94373 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 536 from patent US 5731295.  
ACCESSION I94373  
VERSION I94373.1 GI:3938843  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 536 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGACAGAAATTTGCTC 1604  
|||||  
Db 16 AAGACAGAAATTTGCTC 1

RESULT 176  
AR464675/c  
LOCUS AR464675 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8352 from patent US 6686188.  
ACCESSION AR464675  
VERSION AR464675.1 GI:42699732  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8352 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCCTCTTGCTG 1124  
|||||  
Db 17 CAGCTCCTCTTGCTG 2

RESULT 177  
AR464676/c  
LOCUS AR464676 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8353 from patent US 6686188.  
ACCESSION AR464676  
VERSION AR464676.1 GI:42699733

KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8353 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCCTCTTGCTG 1124  
|||||  
Db 16 CAGCTCCTCTTGCTG 1

RESULT 178  
AR464988  
LOCUS AR464988 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8665 from patent US 6686188.  
ACCESSION AR464988  
VERSION AR464988.1 GI:42700045  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8665 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCCAAGAAGA 288  
|||||  
Db 2 GAAGCCCAAGAAGA 17

RESULT 179  
AR464990  
LOCUS AR464990 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8667 from patent US 6686188.  
ACCESSION AR464990  
VERSION AR464990.1 GI:42700047  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8667 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"

Query Match		0.9%; Score 14.4; DB 1; Length 17;	
Best Local Similarity		93.8%; Pred. No. 1e+02;	
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	274 AAGCCCAAGAAGAA 289		
Db	1 AAGCCCAAGAAGAA 16		
/mol_type="genomic DNA"			
RESULT 180			
LOCUS	AR466360/c	17 bp	DNA
DEFINITION	Sequence 10037 from patent US 6686188.		
ACCESSION	AR466360		
VERSION	AR466360.1	GI:42701417	
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.		
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle		
JOURNAL	Patent: US 6686188-A 10037 03-FEB-2004;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="genomic DNA"		
Query Match	0.9%; Score 14.4; DB 1; Length 17;		
Best Local Similarity	93.8%; Pred. No. 1e+02;		
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	715 CCGCATCGTCCGAC 730		
Db	17 CCGCATCGTCCAC 2		
RESULT 181			
LOCUS	AR466361/c	17 bp	DNA
DEFINITION	Sequence 10038 from patent US 6686188.		
ACCESSION	AR466361		
VERSION	AR466361.1	GI:42701418	
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.		
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle		
JOURNAL	Patent: US 6686188-A 10038 03-FEB-2004;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="genomic DNA"		
Query Match	0.9%; Score 14.4; DB 1; Length 17;		
Best Local Similarity	93.8%; Pred. No. 1e+02;		
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	715 CCGCATCGTCCGAC 730		
Db	16 CCGCATCGTCCAC 1		
RESULT 182			
LOCUS	AX214729/c	17 bp	DNA
DEFINITION	Sequence 1452 from Patent EP1281758.		
ACCESSION	AX688720		
VERSION	AX688720.1	GI:29411424	
KEYWORDS	Homo sapiens (human)		
SOURCE	Homo sapiens		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		

Query Match		0.9%; Score 14.4; DB 1; Length 17;	
Best Local Similarity		93.8%; Pred. No. 1e+02;	
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	929 CTCCTCGCGATGAAG 944		
Db	17 CTCCTCGCGCTGAAG 2		
RESULT 183			
LOCUS	AX688718/c	17 bp	DNA
DEFINITION	Sequence 1450 from Patent EP1281758.		
ACCESSION	AX688718		
VERSION	AX688718.1	GI:29411422	
KEYWORDS	Homo sapiens (human)		
SOURCE	Homo sapiens		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
REFERENCE	1		
AUTHORS	Shannon, M., Gu, Y. and Nguyen, C.T.		
TITLE	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12		
JOURNAL	Patent: EP 1281758-A 1450 05-FEB-2003;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="Homo sapiens"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:9606"		
Query Match	0.9%; Score 14.4; DB 1; Length 17;		
Best Local Similarity	93.8%; Pred. No. 1e+02;		
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	929 CTCCTCGCGATGAAG 944		
Db	17 CTCCTCGCGCTGAAG 2		
RESULT 184			
LOCUS	AX688720/c	17 bp	DNA
DEFINITION	Sequence 1452 from Patent EP1281758.		
ACCESSION	AX688720		
VERSION	AX688720.1	GI:29411424	
KEYWORDS	Homo sapiens (human)		
SOURCE	Homo sapiens		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		

Query Match		0.9%; Score 14.4; DB 1; Length 17;	
Best Local Similarity		93.8%; Pred. No. 1e+02;	
Matches		15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	715 CCGCATCGTCCGAC 730		
Db	16 CCGCATCGTCCAC 1		
RESULT 182			
LOCUS	AX214729/c	17 bp	DNA
DEFINITION	Sequence 1452 from Patent EP1281758.		
ACCESSION	AX688720		
VERSION	AX688720.1	GI:29411424	
KEYWORDS	Homo sapiens (human)		
SOURCE	Homo sapiens		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		

REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1452 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 928 GCTGCTCGCGATGAA 943  
Db 16 GCTGCTCGCGATGAA 1  
RESULT 185  
AX732888/c  
LOCUS AX732888 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 4522 from Patent WO03025175.  
ACCESSION AX732888  
VERSION AX732888.1 GI:30512231  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025175-A 4522 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 326 AAAGCTGAGGAGTC 341  
Db 16 AAAGCTGAGGAGTC 1  
RESULT 186  
AX760623  
LOCUS AX760623 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 3944 from Patent WO03040369.  
ACCESSION AX760623  
VERSION AX760623.1 GI:32255239  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 3944 15-MAY-2003;  
Molecular Engines Laboratories (FR)

FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 154 ATCAGGGAAGTAAGTA 169  
Db 2 ATCAGGGAAGTAAGTA 17  
RESULT 187  
AR067404/c  
LOCUS AR067404 18 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 797 from patent US 5851760.  
ACCESSION AR067404  
VERSION AR067404.1 GI:5998626  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Evans,G.A. and Smith,M.W.  
TITLE Method for generation of sequence sampled maps of complex genomes  
JOURNAL Patent: US 5851760-A 797 22-DEC-1998;  
FEATURES  
source Location/Qualifiers  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1520 CCCCAACTCGCCCGAG 1535  
Db 18 CCTTAACCTCGCCCGAG 3  
RESULT 188  
AX837978  
LOCUS AX837978 18 bp DNA linear PAT 15-DEC-2003  
DEFINITION Sequence 5102 from Patent EP1347046.  
ACCESSION AX837978  
VERSION AX837978.1 GI:39921670  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Isegai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S., Yamamoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R., Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and Masuko,Y.  
TITLE Full-length cDNA sequences  
JOURNAL Patent: EP 1347046-A 5102 24-SEP-2003;  
Research Association for Biotechnology (JP)  
FEATURES  
source Location/Qualifiers  
1. .18  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="Description of Artificial Sequence: an artificially synthesized primer se q"  
Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1094 GTGGAAGATGCTCAAC 1109  
Db 1 GTGGAAGATGCTCGAC 16

RESULT 189  
AX324817/c  
LOCUS AX324817 17 bp DNA linear PAT 02-SEP-2002  
DEFINITION Sequence 955 from Patent WO0192512.  
ACCESSION AX324817  
VERSION AX324817.1 GI:18095570  
KEYWORDS Eucalyptus camaldulensis (Murray red gum)  
SOURCE Eucalyptus camaldulensis  
ORGANISM Eucalyptus camaldulensis  
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
AUTHORS Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
TITLE Rosids; Myrtales; Myrtaceae; Eucalyptus.  
JOURNAL Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.  
FEATURES Targeted chromosomal genomic alterations in plants using modified  
source single stranded oligonucleotides  
/organism="Eucalyptus camaldulensis"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:34316"

Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1202 GGTCAACACGGTGG 1215  
Db 14 GGTCAACACGGTGG 1

RESULT 190  
AX324818  
LOCUS AX324818 17 bp DNA linear PAT 02-SEP-2002  
DEFINITION Sequence 956 from Patent WO0192512.  
ACCESSION AX324818  
VERSION AX324818.1 GI:18095571  
KEYWORDS Eucalyptus camaldulensis (Murray red gum)  
SOURCE Eucalyptus camaldulensis  
ORGANISM Eucalyptus camaldulensis  
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
AUTHORS Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
TITLE Rosids; Myrtales; Myrtaceae; Eucalyptus.  
JOURNAL Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.  
FEATURES Targeted chromosomal genomic alterations in plants using modified  
source single stranded oligonucleotides  
/organism="Eucalyptus camaldulensis"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:34316"

Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1202 GGTCAACACGGTGG 1215  
Db 4 GGTCAACACGGTGG 17

RESULT 191  
AR039619

LOCUS AR039619 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 467 from patent US 5807743.  
ACCESSION AR039619  
VERSION AR039619.1 GI:5958982  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.  
TITLE Interleukin-2 receptor gamma-chain ribozymes  
JOURNAL Patent: US 5807743-A 467 15-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 693 CCTCAGTTCTTCTTTC 709  
Db 1 CCTCAGTTCTTCTTTC 17

RESULT 192  
AR081753  
LOCUS AR081753 17 bp DNA linear PAT 31-AUG-2000  
DEFINITION Sequence 25 from patent US 5972621.  
ACCESSION AR081753  
VERSION AR081753.1 GI:10008479  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 5972621-A 25 26-OCT-1999;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTACCTGCCCTTCAG 17

RESULT 193  
AR081755  
LOCUS AR081755 17 bp DNA linear PAT 31-AUG-2000  
DEFINITION Sequence 27 from patent US 5972621.  
ACCESSION AR081755  
VERSION AR081755.1 GI:10008481  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 5972621-A 27 26-OCT-1999;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"

/mol_type="unassigned DNA"		/mol_type="unassigned DNA"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;	Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	660 CACTACTGCGCTTCAG 676	QY	660 CACTACTGCGCTTCAG 676
Db	1 CACTATTGCGCTTCAG 17	Db	1 CACTATTGCGCTTCAG 17
RESULT 194		RESULT 197	
AR094983/C		BD254845	
LOCUS	AR094983	LOCUS	BD254845
DEFINITION	Sequence 21 from patent US 6001990.	DEFINITION	Regulation of repressor genes using nucleic acid molecules.
ACCESSION	AR094983	ACCESSION	BD254845
VERSION	AR094983.1	VERSION	BD254845.1
KEYWORDS	GI:10022419	KEYWORDS	JP 2002541795-A/2638.
SOURCE	Unknown.	SOURCE	unidentified
ORGANISM	Unknown.	ORGANISM	unclassified
REFERENCE	1 (bases 1 to 17)	REFERENCE	1 (bases 1 to 17)
AUTHORS	Wands, J.R., Wakita, T. and Moradpour, D.	AUTHORS	Blatt, L., Zwick, M., Pavco, P. and McSwiggen, J.
TITLE	Antisense inhibition of hepatitis C virus	TITLE	Regulation of repressor genes using nucleic acid molecules
JOURNAL	Patent: US 6001990-A 21 14-DEC-1999;	JOURNAL	Patent: JP 2002541795-A 2638 10-DEC-2002;
FEATURES	Location/Qualifiers	FEATURES	Location/Qualifiers
source	1. .17	source	1. .17
	/organism="unknown"		/organism="unknown"
	/mol_type="unassigned DNA"		/mol_type="unassigned DNA"
Query Match	0.8%; Score 13.8; DB 1; Length 17;	Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	222 CTCATGAGAAAACAAA 238	QY	116 CCAGACGGTCTCAGACA 132
Db	17 CTCAGAGAAAACAAA 1	Db	1 CCAGACGGTCTCAGTCA 17
RESULT 195		RESULT 198	
AR167985		CQ617155/c	
LOCUS	AR167985	LOCUS	CQ617155
DEFINITION	Sequence 25 from patent US 6287782.	DEFINITION	Sequence 27 from patent US 6287782.
ACCESSION	AR167985	ACCESSION	AR167987
VERSION	AR167985.1	VERSION	AR167987.1
KEYWORDS	GI:17903799	KEYWORDS	GI:17903801
SOURCE	Unknown.	SOURCE	Unknown.
ORGANISM	Unknown.	ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 17)	REFERENCE	1 (bases 1 to 17)
AUTHORS	Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.	AUTHORS	Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.
TITLE	Methods of using the Ob receptor to identify therapeutic compounds	TITLE	Methods of using the Ob receptor to identify therapeutic compounds
JOURNAL	Patent: US 6287782-A 25 11-SEP-2001;	JOURNAL	Patent: US 6287782-A 25 11-SEP-2001;
FEATURES	Location/Qualifiers	FEATURES	Location/Qualifiers
source	1. .17	source	1. .17
	/organism="unknown"		/organism="unknown"
	/mol_type="unassigned DNA"		/mol_type="unassigned DNA"
Query Match	0.8%; Score 13.8; DB 1; Length 17;	Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	660 CACTACTGCGCTTCAG 676	QY	116 CCAGACGGTCTCAGACA 132
Db	1 CACTATTGCGCTTCAG 17	Db	1 CCAGACGGTCTCAGTCA 17
RESULT 196		RESULT 199	
AR167987		CQ617155/c	
LOCUS	AR167987	LOCUS	CQ617155
DEFINITION	Sequence 27 from patent US 6287782.	DEFINITION	Sequence 27 from patent US 6287782.
ACCESSION	AR167987	ACCESSION	AR167987
VERSION	AR167987.1	VERSION	AR167987.1

AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 0192524-A 7355 06-DEC-2001;
FEATURES	Aeomica, Inc. (US)
source	Location/Qualifiers
	1..17
Query Match	/organism="Homo sapiens"
Best Local Similarity	88.2%; Score 13.8; DB 1; Length 17;
Matches	Pred. No. 1.3e+02; Indels 0; Gaps 0;
	Mismatches 2; Conservative 0;
QY	270 GAAGAAGCCACGAGAA 286
Db	1 GAAGAAGCCACGAGAA 17
RESULT 201	
CQ622745/c	
LOCUS	Sequence 7485 from Patent WO0192524.
DEFINITION	17 bp DNA linear PAT 02-FEB-2004
ACCESSION	CQ622745
VERSION	CQ622745.1 GI:41672963
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
AUTHORS	Myosin-like gene expressed in human heart and muscle
TITLE	Patent: WO 0192524-A 7485 06-DEC-2001;
JOURNAL	Aeomica, Inc. (US)
FEATURES	Location/Qualifiers
source	1..17
Query Match	/organism="Homo sapiens"
Best Local Similarity	88.2%; Score 13.8; DB 1; Length 17;
Matches	Pred. No. 1.3e+02; Indels 0; Gaps 0;
	Mismatches 2; Conservative 0;
QY	93 GAGAGTGGCGAGGTCTCT 109
Db	17 GAGAGTGGCGAGGTCTCT 1
RESULT 199	
CQ617903/c	
LOCUS	Sequence 2643 from Patent WO0192524.
DEFINITION	17 bp DNA linear PAT 02-FEB-2004
ACCESSION	CQ617903
VERSION	CQ617903.1 GI:41668121
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
AUTHORS	Myosin-like gene expressed in human heart and muscle
TITLE	Patent: WO 0192524-A 2643 06-DEC-2001;
JOURNAL	Aeomica, Inc. (US)
FEATURES	Location/Qualifiers
source	1..17
Query Match	/organism="Homo sapiens"
Best Local Similarity	88.2%; Score 13.8; DB 1; Length 17;
Matches	Pred. No. 1.3e+02; Indels 0; Gaps 0;
	Mismatches 2; Conservative 0;
QY	845 CTTCCAGCACC GCCCAA 861
Db	17 CTGCCAGCACC GCCCAA 1
RESULT 200	
CQ622615	
LOCUS	Sequence 7355 from Patent WO0192524.
DEFINITION	17 bp DNA linear PAT 02-FEB-2004
ACCESSION	CQ622615
VERSION	CQ622615.1 GI:41672833
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
AUTHORS	Myosin-like gene expressed in human heart and muscle
TITLE	Patent: WO 0192524-A 7355 06-DEC-2001;
JOURNAL	Aeomica, Inc. (US)
FEATURES	Location/Qualifiers
source	1..17
Query Match	/organism="Homo sapiens"
Best Local Similarity	88.2%; Score 13.8; DB 1; Length 17;
Matches	Pred. No. 1.3e+02; Indels 0; Gaps 0;
	Mismatches 2; Conservative 0;
QY	1530 GCCCAGCCTCTCCCGC 1546
Db	17 GTCAGGCCTCTCTCGC 1
RESULT 202	
CQ623828	
LOCUS	Sequence 8568 from Patent WO0192524.
DEFINITION	17 bp DNA linear PAT 02-FEB-2004
ACCESSION	CQ623828
VERSION	CQ623828.1 GI:41674046
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
AUTHORS	Myosin-like gene expressed in human heart and muscle
TITLE	Patent: WO 0192524-A 8568 06-DEC-2001;
JOURNAL	Aeomica, Inc. (US)
FEATURES	Location/Qualifiers
source	1..17
Query Match	/organism="Homo sapiens"
Best Local Similarity	88.2%; Score 13.8; DB 1; Length 17;
Matches	Pred. No. 1.3e+02; Indels 0; Gaps 0;
	Mismatches 2; Conservative 0;
QY	17 GTCCAGCCTCTCTCGC 1
Db	1 GTCCAGCCTCTCTCGC 1

```

/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 AGGATGCCCTAAATGAG 308
    ||||| ||| |||||
Db 1 AGGATGACCTGAATGAG 17

RESULT 203
LOCUS CQ623920
DEFINITION Sequence 8660 from Patent WO0192524.
ACCESSION CQ623920
VERSION CQ623920.1 GI:41674138
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8660 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 CTAGAAGAGCCCAAGAA 283
    ||||| ||| |||||
Db 1 CTGAGGAGCCCAAGAA 17

RESULT 204
LOCUS CQ623921
DEFINITION Sequence 8661 from Patent WO0192524.
ACCESSION CQ623921
VERSION CQ623921.1 GI:41674139
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8661 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 TAGAAGAGCCCAAGAA 284
    ||||| ||| |||||
Db 1 TGGAGGAGCCCAAGAA 17

RESULT 205
LOCUS CQ623923
DEFINITION Sequence 8663 from Patent WO0192524.
ACCESSION CQ623923
VERSION CQ623923.1 GI:41674141
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8663 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAA 286
    ||||| ||| |||||
Db 1 GAGGAAGCCCAAGAA 17

RESULT 206
LOCUS CQ623924
DEFINITION Sequence 8664 from Patent WO0192524.
ACCESSION CQ623924
VERSION CQ623924.1 GI:41674142
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8664 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAA 287
    ||||| ||| |||||
Db 1 AGGAAGCCCAAGAA 17

RESULT 207
LOCUS CQ624947/c
DEFINITION Sequence 9687 from Patent WO0192524.
ACCESSION CQ624947
VERSION CQ624947.1 GI:41675165
KEYWORDS

```

SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 9687 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 93 GGAGTGGCGCAGGTCTCT 109  
|||||  
Db 17 GAGAGTGGCGCCAGTCT 1  
RESULT 208  
LOCUS CQ624948/c 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 9688 from Patent WO0192524.  
ACCESSION CQ624948  
VERSION CQ624948.1 GI:41675166  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 9688 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 92 GGAGTGGCGCAGGTCTC 108  
|||||  
Db 17 GGAGTGGCGCCAGTCT 1  
RESULT 209  
LOCUS CQ624949/c 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 9689 from Patent WO0192524.  
ACCESSION CQ624949  
VERSION CQ624949.1 GI:41675167  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 9689 06-DEC-2001;

Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 91 GGGAGAGTGGCGCAGGTC 107  
|||||  
Db 17 GGGAGAGTGGCGCCAGTC 1  
RESULT 210  
LOCUS E65210/c 17 bp DNA linear PAT 18-JUN-2001  
DEFINITION Method for analyzing oligonucleotide.  
ACCESSION E65210  
VERSION E65210.1 GI:13025986  
KEYWORDS JP 1999046800-A/4.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
1 (bases 1 to 17)  
REFERENCE  
AUTHORS Leroy, E.H., Michael, W.H., Lloyd, M.S. and Tim, J.H.  
TITLE Method for analyzing oligonucleotide  
JOURNAL Patent: JP 1999046800-A 4 23-FEB-1999;  
CALIFORNIA INSTITUTE OF TECHNOLOGY  
COMMENT OS Artificial Sequence  
PN JP 1999046800-A/4  
PD 23-FEB-1999  
PF 12-FEB-1998 JP 1998030272  
PR 16-JAN-1984 US 570973  
PI LEROY E HOOD, MICHAEL W HANKAPILA, LLOYD M SMITH, TIM J HANKAPILA  
PC C12Q1/68, G01N21/76, G01N27/447, G01N33/50, G01N33/58//C12N15/09  
CC  
FH Key Location/Qualifiers  
FT source 1. .17 /organism='Artificial Sequence'.  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1357 AAGCGCTGCAGGAATAC 1373  
|||||  
Db 17 ATGCTCTGCAGGAATAC 1  
RESULT 211  
LOCUS AR192271 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 7759 from patent US 6346398.  
ACCESSION AR192271  
VERSION AR192271.1 GI:20238236  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
1 (bases 1 to 17)  
REFERENCE  
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions  
JOURNAL related to levels of vascular endothelial growth factor receptor  
FEATURES Patent: US 6346398-A 7759 12-FEB-2002;  
Location/Qualifiers



LOCUS	AR213318	17 bp	DNA	linear	PAT 25-SEP-2002
DEFINITION	Sequence 27 from patent US 6403552.				
ACCESSION	AR213318				
VERSION	AR213318.1	GI:23310501			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 17)				
AUTHORS	Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.				
TITLE	Ob receptor and methods for the diagnosis and treatment of body weight disorders				
JOURNAL	Patent: US 6403552-A	27 11-JUN-2002;			
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="genomic DNA"				
	/mol_type="genomic DNA"				
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;	
Best Local Similarity	88.2%;	Pred. No. 1.3e+02;			
Matches	15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
QY	660 CACTACTCTGCCCTTCAG	676			
Db	1 CACTATTGGCCCTTCAG	17			
RESULT 215					
AR256153					
LOCUS	AR256153	17 bp	DNA	linear	PAT 20-DEC-2002
DEFINITION	Sequence 25 from patent US 6482927.				
ACCESSION	AR256153				
VERSION	AR256153.1	GI:27305555			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 17)				
AUTHORS	Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.				
TITLE	Chimeric proteins comprising the extracellular domain of murine Ob receptor				
JOURNAL	Patent: US 6482927-A	25 19-NOV-2002;			
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="genomic DNA"				
	/mol_type="genomic DNA"				
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;	
Best Local Similarity	88.2%;	Pred. No. 1.3e+02;			
Matches	15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
QY	660 CACTACTCTGCCCTTCAG	676			
Db	1 CACTATTGGCCCTTCAG	17			
RESULT 216					
AR256155					
LOCUS	AR256155	17 bp	DNA	linear	PAT 20-DEC-2002
DEFINITION	Sequence 27 from patent US 6482927.				
ACCESSION	AR256155				
VERSION	AR256155.1	GI:27305557			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 17)				
AUTHORS	Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.				
TITLE	Chimeric proteins comprising the extracellular domain of murine Ob receptor				
JOURNAL	Patent: US 6482927-A	27 19-NOV-2002;			
FEATURES	Location/Qualifiers				
source	1..17				

```

/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCGCCCTTCAG 676
DB 1 CACTATTGGCCCTTCAG 17

RESULT 217
AR275110 17 bp DNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 25 from patent US 6506877.
ACCESSION AR275110
VERSION AR275110.1 GI:29708051
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor
JOURNAL Patent: US 6506877-A 25 14-JAN-2003;
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCGCCCTTCAG 676
DB 1 CACTATTGGCCCTTCAG 17

RESULT 218
AR275112 17 bp DNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 27 from patent US 6506877.
ACCESSION AR275112
VERSION AR275112.1 GI:29708053
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor
JOURNAL Patent: US 6506877-A 27 14-JAN-2003;
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCGCCCTTCAG 676
DB 1 CACTATTGGCCCTTCAG 17

RESULT 219
AR306243 17 bp DNA linear PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 25 from patent US 6548269.
ACCESSION AR306243

```

---

```

AR306243.1 GI:31695966
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia
JOURNAL Patent: US 6548269-A 25 15-APR-2003;
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCGCCCTTCAG 676
DB 1 CACTATTGGCCCTTCAG 17

RESULT 220
AR306245 17 bp DNA linear PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 27 from patent US 6548269.
ACCESSION AR306245
VERSION AR306245.1 GI:31695968
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.
TITLE Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia
JOURNAL Patent: US 6548269-A 27 15-APR-2003;
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCGCCCTTCAG 676
DB 1 CACTATTGGCCCTTCAG 17

RESULT 221
AR326141 17 bp RNA linear PAT 17-AUG-2003
LOCUS
DEFINITION Sequence 3543 from patent US 6566127.
ACCESSION AR326141
VERSION AR326141.1 GI:33711949
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3543 20-MAY-2003;
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1112 CTCTCTGCTGAGC 1128  
|||||  
Db 1 CTCCCCCTGCTGAGC 17

RESULT 222  
AR326780 AR326780 17 bp RNA linear PAT 17-AUG-2003  
LOCUS  
DEFINITION Sequence 4182 from patent US 6566127.  
ACCESSION AR326780  
VERSION AR326780.1 GI:33712588  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 4182 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1115 CTCTCTGCTGAGCAGC 1131  
|||||  
Db 1 CTCTGCTGAGCCGC 17

RESULT 223  
AR371631 AR371631 17 bp DNA linear PAT 12-SEP-2003  
LOCUS  
DEFINITION Sequence 25 from patent US 6395498.  
ACCESSION AR371631  
VERSION AR371631.1 GI:34608616  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 6395498-A 25 28-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676  
|||||  
Db 1 CACTATTGCTTCAG 17

RESULT 224  
AR371633 AR371633 17 bp DNA linear PAT 12-SEP-2003  
LOCUS  
DEFINITION Sequence 27 from patent US 6395498.  
ACCESSION AR371633  
VERSION AR371633.1 GI:34608618

KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 6395498-A 27 28-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676  
|||||  
Db 1 CACTATTGCTTCAG 17

RESULT 225  
AR458218 AR458218 17 bp DNA linear PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 1895 from patent US 6686188.  
ACCESSION AR458218  
VERSION AR458218.1 GI:42693275  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 1895 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 93 GAGAGTGGCAGTCTCT 109  
|||||  
Db 17 GAGAGAGCCAGTCTCT 1

RESULT 226  
AR458966 AR458966 17 bp DNA linear PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 2643 from patent US 6686188.  
ACCESSION AR458966  
VERSION AR458966.1 GI:42694023  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 2643 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	Indels	Gaps
Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	Indels	Gaps
845	CTTCCAGCACC	861	17 bp	DNA	linear	0	0
Db	17	CTGCCAGGACCCGCCAA	1				
RESULT 227	AR463678	Sequence 7355 from patent US 6686188.					
LOCUS	AR463678	Sequence 7355 from patent US 6686188.					
DEFINITION	AR463678	Sequence 7355 from patent US 6686188.					
ACCESSION	AR463678	Sequence 7355 from patent US 6686188.					
VERSION	AR463678.1	GI:42698735					
KEYWORDS							
SOURCE							
ORGANISM							
REFERENCE							
AUTHORS							
TITLE							
JOURNAL							
FEATURES							
source							
Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	Indels	Gaps
270	GAAGAAGCCAGCAAGAA	286	17 bp	DNA	linear	0	0
Db	1	GAAGAAGCCAGCAAGAA	17				
RESULT 228	AR463808/c	Sequence 7485 from patent US 6686188.					
LOCUS	AR463808	Sequence 7485 from patent US 6686188.					
DEFINITION	AR463808	Sequence 7485 from patent US 6686188.					
ACCESSION	AR463808	Sequence 7485 from patent US 6686188.					
VERSION	AR463808.1	GI:42698865					
KEYWORDS							
SOURCE							
ORGANISM							
REFERENCE							
AUTHORS							
TITLE							
JOURNAL							
FEATURES							
source							
Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	Indels	Gaps
1530	GCCAGCCTCTCCCGC	1546	17 bp	DNA	linear	0	0
Db	17	GTCAGCCTCTCTCTGC	1				
RESULT 229	AR464891	Sequence 8661 from patent US 6686188.					
LOCUS	AR464891	Sequence 8661 from patent US 6686188.					
DEFINITION	AR464891	Sequence 8661 from patent US 6686188.					
ACCESSION	AR464891	Sequence 8661 from patent US 6686188.					
VERSION	AR464891.1	GI:42700041					
KEYWORDS							
SOURCE							
ORGANISM							
REFERENCE							
AUTHORS							
TITLE							
JOURNAL							
FEATURES							
source							
Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	Indels	Gaps
267	CTAGAAGAACCAAGAA	283	17 bp	DNA	linear	0	0
Db	1	CTGAGGAGGACCAAGAA	17				
RESULT 231	AR464984	Sequence 8661 from patent US 6686188.					
LOCUS	AR464984	Sequence 8661 from patent US 6686188.					
DEFINITION	AR464984	Sequence 8661 from patent US 6686188.					
ACCESSION	AR464984	Sequence 8661 from patent US 6686188.					
VERSION	AR464984.1	GI:42700041					
KEYWORDS							
SOURCE							
ORGANISM							
REFERENCE							
AUTHORS							
TITLE							
JOURNAL							

FEATURES	Location/Qualifiers
source	1..17
/organism="unknown"	
/mol_type="genomic DNA"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	268 TAGAAGAAGCCCAAGAAG 284
Db	1 TGGAGGAGGCCCAAGAAG 17
RESULT 232	
LOCUS	AR464986
DEFINITION	Sequence 8663 from patent US 6686188.
ACCESSION	AR464986
VERSION	AR464986.1 GI:42700043
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 8663 03-FEB-2004;
FEATURES	Location/Qualifiers
source	1..17
/organism="unknown"	
/mol_type="genomic DNA"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	270 GAAGAAGCCCAAGAAGAA 286
Db	1 GAGGAAGCCCAAGAAGGA 17
RESULT 233	
LOCUS	AR464987
DEFINITION	Sequence 8664 from patent US 6686188.
ACCESSION	AR464987
VERSION	AR464987.1 GI:42700044
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 8664 03-FEB-2004;
FEATURES	Location/Qualifiers
source	1..17
/organism="unknown"	
/mol_type="genomic DNA"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	271 AAGAAGCCCAAGAAGAA 287
Db	1 AGGAAGCCCAAGAAGGAG 17

Shannon, M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 9689 03-FEB-2004;  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GGGAGAGTGGGAGGTC 107  
Db 17 GGGAGAGTGGGCGAGTC 1  
|||||  
/organism="Homo sapiens"  
/mol\_type="cDNA"

RESULT 237  
AX215611/c  
LOCUS AX215611 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1053 from Patent WO0159103.  
ACCESSION AX215611  
VERSION AX215611.1 GI:15525654  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE  
1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 1053 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1622 AATAAACTGCTGTGTG 1638  
Db 17 ATTAAACTGCTCTTTG 1  
|||||  
/organism="Homo sapiens"  
/mol\_type="cDNA"

RESULT 238  
AX216443/c  
LOCUS AX216443 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1885 from Patent WO0159103.  
ACCESSION AX216443  
VERSION AX216443.1 GI:15526504  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE  
1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 1885 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"

Shannon, M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 9689 03-FEB-2004;  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1621 CAATAAACTGCTGTGT 1637  
Db 17 CATTAAACTGCTCTTTT 1  
|||||  
/organism="Homo sapiens"  
/mol\_type="cDNA"

RESULT 239  
AX272871/c  
LOCUS AX272871 17 bp RNA linear PAT 29-OCT-2001  
DEFINITION Sequence 440 from Patent WO0162911.  
ACCESSION AX272871  
VERSION AX272871.1 GI:16545608  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
1  
AUTHORS Jarvis, T., von Carlowitz, I., McSwiggen, J.A., Hamblin, P.A. and Ellis, J.H.  
TITLE Method and reagent for the inhibition of grid  
JOURNAL Patent: WO 0162911-A 440 30-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1539 CTCCTCCGCTCTGGATCC 1555  
Db 17 CTCCTCCGCTGTGGAACC 1  
|||||  
/organism="Homo sapiens"  
/mol\_type="cDNA"

RESULT 240  
AX422540  
LOCUS AX422540 17 bp RNA linear PAT 18-JUN-2002  
DEFINITION Sequence 876 from Patent WO0188124.  
ACCESSION AX422540  
VERSION AX422540.1 GI:21525922  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
1  
AUTHORS Jarvis, T., von Carlowitz, I., McSwiggen, J.A., McLaughlin, F.G. and Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 876 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1504 GCCCCAGCTCCAGGCC 1520  
Db 1 GCCCCAGCTCCAGGCC 17  
|||||  
/organism="Homo sapiens"  
/mol\_type="cDNA"

RESULT 241  
AX423446  
LOCUS AX423446 17 bp RNA linear PAT 18-JUN-2002  
DEFINITION Sequence 1782 from Patent WO0189124.  
ACCESSION AX423446  
VERSION AX423446.1 GI:21526828  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and Randi,A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0189124-A 1782 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 218 GACTCTCATGAAAAA 234  
|||||  
Db 1 GACTCACAGAAAAA 17  
RESULT 242  
AX475287  
LOCUS AX475287 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 508 from Patent WO0224750.  
ACCESSION AX475287  
VERSION AX475287.1 GI:22214572  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 508 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 520 GCATCGACTCCCTGCTG 536  
|||||  
Db 1 GCATCTACTCCAGCTG 17  
RESULT 243  
AX475288  
LOCUS AX475288 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 509 from Patent WO0224750.  
ACCESSION AX475288  
VERSION AX475288.1 GI:22214573  
KEYWORDS  
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 509 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 521 CATCGACTCCCTGCTGG 537  
|||||  
Db 1 CATCTACTCCAGCTGG 17  
RESULT 244  
AX475289  
LOCUS AX475289 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 510 from Patent WO0224750.  
ACCESSION AX475289  
VERSION AX475289.1 GI:22214574  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 510 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 522 ATCGACTCCCTGCTGGA 538  
|||||  
Db 1 ATCTACTCCAGCTGGA 17  
RESULT 245  
AX475290  
LOCUS AX475290 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 511 from Patent WO0224750.  
ACCESSION AX475290  
VERSION AX475290.1 GI:22214575  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 511 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 TCAGCTCCCTGCTGGAG 539
Db 1 TCTACTCCAGCTGGAG 17

RESULT 246
AX475291
LOCUS AX475291 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 512 from Patent WO0224750.
ACCESSION AX475291
VERSION AX475291.1 GI:22214576
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 512 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 524 CGACTCCCTGCTGGAGA 540
Db 1 CTACTCCAGCTGGAGA 17

RESULT 247
AX475293
LOCUS AX475293 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 514 from Patent WO0224750.
ACCESSION AX475293
VERSION AX475293.1 GI:22214578
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 514 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 526 ACTCCCTGCTGGAGAC 542
Db 1 ACTCCAGCTGGAGACC 17

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 521 CATCGACTCCCTGCTGG 537
Db 1 CAGCGACTCACTGCTGG 17

RESULT 250
AX499442
LOCUS AX499442 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 749 from Patent EP1229046.
ACCESSION AX499442
VERSION AX499442.1 GI:23381735
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 748 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 521 CATCGACTCCCTGCTGG 537
Db 1 CAGCGACTCACTGCTGG 17

RESULT 249
AX499441
LOCUS AX499441 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 748 from Patent EP1229046.
ACCESSION AX499441
VERSION AX499441.1 GI:23381734
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 748 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1203 GTCACCCACGGTGGCTTC 1219
Db 1 GTCACCACTGTGGCTGC 17

RESULT 248
AX475720
LOCUS AX475720 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 941 from Patent WO0224750.
ACCESSION AX475720
VERSION AX475720.1 GI:22215005
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 941 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1203 GTCACCCACGGTGGCTTC 1219
Db 1 GTCACCACTGTGGCTGC 17
```



```

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Zhan,J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 749 07-AUG-2002;
              Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             source
               1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATCGACTCCTGCTGGA 538
Db 1 AGCGACTCACTGCTGGA 17

RESULT 251
AX687958
LOCUS      AX499931      17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1238 from Patent EP1229046.
ACCESSION AX499931
VERSION   AX499931.1 GI:23382224
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS    Zhan,J.
TITLE      Human testis expressed patched like protein
JOURNAL    Patent: EP 1229046-A 1238 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1273 TCTTGACTCTGATCCC 1289
Db 1 TCTTGACTCTGATCCC 17

RESULT 252
AX687958
LOCUS      AX687958      17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 690 from Patent EP1281758.
ACCESSION AX687958
VERSION   AX687958.1 GI:29410656
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS    Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE      Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
JOURNAL    Patent: EP 1281758-A 690 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Zhan,J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 749 07-AUG-2002;
              Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             source
               1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 788 CCTTGAGATGATACAG 804
Db 1 CCTGGAGATGAGACAG 17

RESULT 253
AX688721/c
LOCUS      AX688721      17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1453 from Patent EP1281758.
ACCESSION AX688721
VERSION   AX688721.1 GI:29411425
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS    Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE      Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
JOURNAL    Patent: EP 1281758-A 1453 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 926 GGGCTGCTCGCGATGA 942
Db 1 GTGCTGCTCGCGCTGA 1

RESULT 254
AX690667
LOCUS      AX690667      17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3399 from Patent EP1281758.
ACCESSION AX690667
VERSION   AX690667.1 GI:29413548
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS    Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE      Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
JOURNAL    Patent: EP 1281758-A 3399 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 464 GCTTGAGAGTTCCTGA 480
Db 1 GCTTGAGAGTTCCTGA 17
```

RESULT 255  
AX727197  
LOCUS AX727197 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 4884 from Patent WO03025176.  
ACCESSION AX727197  
VERSION AX727197.1 GI:30506540  
KEYWORDS Mus musculus (house mouse)  
SOURCE  
ORGANISM  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 4884 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2;  
QY 1551 GATCCTGCACTCTAACA 1567  
Db 1 GATCCTGACTCTAATA 17  
RESULT 256  
AX728423/C  
LOCUS AX728423 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 57 from Patent WO03025175.  
ACCESSION AX728423  
VERSION AX728423.1 GI:30507766  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025175-A 57 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2;  
QY 374 CTGGGAAGAGTGTAAGC 390  
Db 17 CTGGGAAGAGTGATGC 1  
RESULT 257  
AX731740  
LOCUS AX731740 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 3374 from Patent WO03025175.  
ACCESSION AX731740

VERSION AX731740.1 GI:30511083  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025175-A 3374 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2;  
QY 359 GACCATGATGCGCCTCT 375  
Db 1 GATCATGATGCGCCTCT 17  
RESULT 258  
AX734894  
LOCUS AX734894 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 484 from Patent WO03025177.  
ACCESSION AX734894  
VERSION AX734894.1 GI:30514171  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 484 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2;  
QY 1551 GATCCTGCACTCTAACA 1567  
Db 1 GATCCTGACTCTAATA 17  
RESULT 259  
AX756729/C  
LOCUS AX756729 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 50 from Patent WO03040369.  
ACCESSION AX756729  
VERSION AX756729.1 GI:32251283  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
REFERENCE 1  
AUTHORS Homo sapiens  
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 50 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. NO. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 91 GGGAGAGTGGGACGCTC 107  
||||| |||||||  
Db 17 GGGAGGTTGGGACATC 1  
RESULT 260  
161606  
LOCUS 161606 15 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 160 from patent US 5658780.  
ACCESSION 161606  
VERSION 161606.1 GI:2479554  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.  
TITLE Rel a targeted ribozymes  
JOURNAL Patent: US 5658780-A 160 19-AUG-1997;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1507 CCAGCCTCCAGGCC 1521  
||||| |||||||  
Db 1 CCAGCCTCCAGGCTC 15  
RESULT 261  
AR180106/c  
LOCUS AR180106 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 174 from patent US 6333152.  
ACCESSION AR180106  
VERSION AR180106.1 GI:20222139  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 174 25-DEC-2001;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 807 GCTCAGCAGGCCATG 821

Db 15 GCCCAGCAGGCCATG 1  
||||| |||||||  
RESULT 262  
AR180715/c  
LOCUS AR180715 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 783 from patent US 6333152.  
ACCESSION AR180715  
VERSION AR180715.1 GI:20222748  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 783 25-DEC-2001;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 807 GCTCAGCAGGCCATG 821  
||||| |||||||  
Db 15 GCCCAGCAGGCCATG 1  
RESULT 263  
AR532147/c  
LOCUS AR532147 15 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 75 from patent US 6727085.  
ACCESSION AR532147  
VERSION AR532147.1 GI:53920820  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Fano,T.S. and Mikkelsen,F.  
TITLE Subtilase variants having an improved wash performance on egg stains  
JOURNAL Patent: US 6727085-A 75 27-APR-2004;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1076 GCTGTAAAGTCCTA 1090  
||||| |||||||  
Db 15 GCTGTAAAGTCCTA 1  
RESULT 264  
AX167089/c  
LOCUS AX167089 15 bp DNA linear PAT 03-JUL-2001  
DEFINITION Sequence 75 from Patent WO0144452.  
ACCESSION AX167089  
VERSION AX167089.1 GI:14596577  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Fan,T.S. and Mikkelsen,F.F.

TITLE Subtilase variants having an improved wash performance on egg stains

JOURNAL Patent: WO 0144452-A 75 21-JUN-2001;

Novozymes A/S (DK)

FEATURES Location/Qualifiers

source 1..15

/organism="synthetic construct"

/mol\_type="unassigned DNA"

/db\_xref="taxon:32630"

/note="Antisense primer"

Query Match 0.8%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1076 GCTGCTAAAGTCCTA 1090

|||||

Db 15 GCTGTTAAAGTCCTA 1

RESULT 265

AX635964

LOCUS AX635964 15 bp RNA linear PAT 21-FEB-2003

DEFINITION Sequence 3103 from Patent EP1260586.

ACCESSION AX635964

VERSION AX635964.1 GI:28471578

KEYWORDS .

SOURCE unidentified

ORGANISM unidentified

REFERENCE 1 unclassified.

AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.

TITLE Method and reagent for inhibiting the expression of disease related genes

JOURNAL Patent: EP 1260586-A 3103 27-NOV-2002;

RIBOZYME PHARMACEUTICALS, INC. (US)

FEATURES Location/Qualifiers

source 1..15

/organism="unidentified"

/mol\_type="unassigned RNA"

/db\_xref="taxon:32644"

Query Match 0.8%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCCTCCAGGCC 1521

|||||

Db 1 CCAGCCTCCAGGCTC 15

RESULT 266

AR029843/c

LOCUS AR029843 16 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 32 from patent US 5861244.

ACCESSION AR029843

VERSION AR029843.1 GI:5943057

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Wang,C.-G. and Hepburn,A.G.

TITLE Genetic sequence assay using DNA triple strand formation

JOURNAL Patent: US 5861244-A 32 19-JAN-1999;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 271 AAGAGCCAGAAGA 285

|||||

Db 15 AAGAAGCAAGAAGA 1

RESULT 267

AR131574

LOCUS AR131574 16 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 67 from patent US 6194149.

ACCESSION AR131574

VERSION AR131574.1 GI:14120477

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.

TITLE Target-dependent reactions using structure-bridging oligonucleotides

JOURNAL Patent: US 6194149-A 67 27-FEB-2001;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522

|||||

Db 2 CAGCCTCCAGGACCC 16

RESULT 268

AR131575

LOCUS AR131575 16 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 68 from patent US 6194149.

ACCESSION AR131575

VERSION AR131575.1 GI:14120478

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.

TITLE Target-dependent reactions using structure-bridging oligonucleotides

JOURNAL Patent: US 6194149-A 68 27-FEB-2001;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522

|||||

Db 2 CAGCCTCCAGGACCC 16

RESULT 269

CQ796994/c

LOCUS CQ796994 16 bp DNA linear PAT 19-APR-2004

DEFINITION Sequence 11 from Patent WO2004027066.

ACCESSION CQ796994

VERSION CQ796994.1 GI:46408576  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.  
REFERENCE 1  
AUTHORS Letourneur,O.  
TITLE Chimeric recombinant protein and in vitro diagnosis  
JOURNAL Patent: WO 2004027066-A 11 01-APR-2004;  
Blomerieux (FR)  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="artificial sequence"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 476 CCTGAACCCAGAGCTC 490  
Db 15 CCTGAACCCGAGCTC 1

RESULT 270  
CQ858546/c  
LOCUS CQ858546 16 bp DNA linear PAT 31-AUG-2004  
DEFINITION Sequence 8 from Patent WO2004069991.  
ACCESSION CQ858546  
VERSION CQ858546.1 GI:51852513  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Hansen,B., Thruue,C.A., Petersen,K.D., Westergaard,M. and  
Wissenbach,M.  
TITLE Oligomeric compounds for the modulation of survivin expression  
JOURNAL Patent: WO 2004069991-A 8 19-AUG-2004;  
Santaris Pharma A/S (DK)  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 278 CAAGAAGAAGAAGA 292  
Db 16 CAATAAGAAGAAGA 2

RESULT 271  
AR199508  
LOCUS AR199508 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 67 from patent US 6355437.  
ACCESSION AR199508  
VERSION AR199508.1 GI:20249582  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging  
oligonucleotides  
JOURNAL Patent: US 6355437-A 67 12-MAR-2002;

VERSION CQ796994.1 GI:46408576  
KEYWORDS  
SOURCE unidentified  
unclassified.  
REFERENCE 1  
AUTHORS Letourneur,O.  
TITLE Chimeric recombinant protein and in vitro diagnosis  
JOURNAL Patent: WO 2004027066-A 11 01-APR-2004;  
Blomerieux (FR)  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="artificial sequence"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 476 CCTGAACCCAGAGCTC 490  
Db 15 CCTGAACCCGAGCTC 1

RESULT 270  
CQ858546/c  
LOCUS CQ858546 16 bp DNA linear PAT 31-AUG-2004  
DEFINITION Sequence 8 from Patent WO2004069991.  
ACCESSION CQ858546  
VERSION CQ858546.1 GI:51852513  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Hansen,B., Thruue,C.A., Petersen,K.D., Westergaard,M. and  
Wissenbach,M.  
TITLE Oligomeric compounds for the modulation of survivin expression  
JOURNAL Patent: WO 2004069991-A 8 19-AUG-2004;  
Santaris Pharma A/S (DK)  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 278 CAAGAAGAAGAAGA 292  
Db 16 CAATAAGAAGAAGA 2

RESULT 271  
AR199508  
LOCUS AR199508 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 67 from patent US 6355437.  
ACCESSION AR199508  
VERSION AR199508.1 GI:20249582  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging  
oligonucleotides  
JOURNAL Patent: US 6355437-A 67 12-MAR-2002;

FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16

RESULT 272  
AR199509  
LOCUS AR199509 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 68 from patent US 6355437.  
ACCESSION AR199509  
VERSION AR199509.1 GI:20249583  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging  
oligonucleotides  
JOURNAL Patent: US 6355437-A 68 12-MAR-2002;  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16

RESULT 273  
AR200979  
LOCUS AR200979 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 67 from patent US 6358691.  
ACCESSION AR200979  
VERSION AR200979.1 GI:20251867  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging  
oligonucleotides  
JOURNAL Patent: US 6358691-A 67 19-MAR-2002;  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16

RESULT 274  
AR199508  
LOCUS AR199508 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 67 from patent US 6355437.  
ACCESSION AR199508  
VERSION AR199508.1 GI:20249582  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging  
oligonucleotides  
JOURNAL Patent: US 6355437-A 67 12-MAR-2002;

AR200980 LOCUS AR200980 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 68 from patent US 6358691.  
ACCESSION AR200980  
VERSION AR200980.1 GI:20251868  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri, B., Dong, F., Lyamichev, V., Brow, M. Ann. D. and Fors, L.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6358691-A 68 19-MAR-2002;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 275  
AR488738 LOCUS AR488738 16 bp DNA linear PAT 15-MAY-2004  
DEFINITION Sequence 67 from patent US 6709815.  
ACCESSION AR488738  
VERSION AR488738.1 GI:47254936  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Dong, F., Lyamichev, V. I., Prudent, J. R., Fors, L., Neri, B. P.,  
Brow, M. A. D., Anderson, T. A. and Dahlberg, J. E.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6709815-A 67 23-MAR-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 276  
AR488739 LOCUS AR488739 16 bp DNA linear PAT 15-MAY-2004  
DEFINITION Sequence 68 from patent US 6709815.  
ACCESSION AR488739  
VERSION AR488739.1 GI:47254937  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Dong, F., Lyamichev, V. I., Prudent, J. R., Fors, L., Neri, B. P.,  
Brow, M. A. D., Anderson, T. A. and Dahlberg, J. E.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides

JOURNAL Patent: US 6709815-A 68 23-MAR-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 277  
AX419730 LOCUS AX419730 16 bp DNA linear PAT 18-JUN-2002  
DEFINITION Sequence 67 from Patent WO0198537.  
ACCESSION AX419730  
VERSION AX419730.1 GI:21524097  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 67 27-DEC-2001;  
THIRD WAVE TECHNOLOGIES, INC. (US)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 278  
AX419731 LOCUS AX419731 16 bp DNA linear PAT 18-JUN-2002  
DEFINITION Sequence 68 from Patent WO0198537.  
ACCESSION AX419731  
VERSION AX419731.1 GI:21524098  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 68 27-DEC-2001;  
THIRD WAVE TECHNOLOGIES, INC. (US)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 279  
AX419732 LOCUS AX419732 16 bp DNA linear PAT 18-JUN-2002  
DEFINITION Sequence 69 from Patent WO0198537.  
ACCESSION AX419732  
VERSION AX419732.1 GI:21524099  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 69 27-DEC-2001;  
THIRD WAVE TECHNOLOGIES, INC. (US)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

```

RESULT 279
BD084992
LOCUS
DEFINITION
    Target-dependent reactions using structure-bridging
    oligonucleotides.
ACCESSION
    BD084992
VERSION
    BD084992.1 GI:22630602
KEYWORDS
    JP 2001523111-A/67.
SOURCE
    unidentified
ORGANISM
    unidentified
REFERENCE
    1 (bases 1 to 16)
AUTHORS
    Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Neri,B.P.,
    Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.
TITLE
    Target-dependent reactions using structure-bridging
    oligonucleotides
JOURNAL
    Patent: JP 2001523111-A 67 20-NOV-2001;
COMMENT
    THIRD WAVE TECHNOLOGIES INC
OS   Unidentified
PN   JP 2001523111-A/67
PD   20-NOV-2001
PF   05-MAY-1998 JP 1998548047
PR   05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR
03-MAR-1998 US 09/034205
PI   FANG DONG,VICTOR I LYAMICHEV,JAMES R PRUDENT,LANCE FORS,BRUCE
PI   P NERI,
PI   MARY ANN D BROW,TODD A ANDERSON,JAMES E DAHLBERG PC
C07H21/04,C07H21/02,C12Q1/68
CC   Strandedness: Single;
CC   Topology: Linear;
CC   /desc = 'DNA'
FH   Key   Location/Qualifiers
FT   source   1..16
          Location/Qualifiers
          1..16
          /organism='Unidentified'.
          /mol_type='genomic DNA'
          /db_xref='taxon:32644'

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY   1508 CAGCCTCCAGGCC 1522
      |||||
DB   2 CAGCCTCCAGGCC 16

RESULT 280
BD084993
LOCUS
DEFINITION
    Target-dependent reactions using structure-bridging
    oligonucleotides.
ACCESSION
    BD084993
VERSION
    BD084993.1 GI:22630603
KEYWORDS
    JP 2001523111-A/68.
SOURCE
    unidentified
ORGANISM
    unidentified
REFERENCE
    1 (bases 1 to 16)
AUTHORS
    Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Neri,B.P.,
    Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.
TITLE
    Target-dependent reactions using structure-bridging
    oligonucleotides
JOURNAL
    Patent: JP 2001523111-A 68 20-NOV-2001;
COMMENT
    THIRD WAVE TECHNOLOGIES INC
OS   Unidentified
PN   JP 2001523111-A/68
PD   20-NOV-2001
PF   05-MAY-1998 JP 1998548047
PR   05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR
03-MAR-1998 US 09/034205
PI   FANG DONG,VICTOR I LYAMICHEV,JAMES R PRUDENT,LANCE FORS,BRUCE
PI   P NERI,
PI   MARY ANN D BROW,TODD A ANDERSON,JAMES E DAHLBERG PC
C07H21/04,C07H21/02,C12Q1/68
CC   Strandedness: Single;
CC   Topology: Linear;
CC   /desc = 'DNA'
FH   Key   Location/Qualifiers
FT   source   1..16
          Location/Qualifiers
          1..16
          /organism='Unidentified'.
          /mol_type='genomic DNA'
          /db_xref='taxon:32644'

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY   1508 CAGCCTCCAGGCC 1522
      |||||
DB   2 CAGCCTCCAGGCC 16

RESULT 281
S81287/c
LOCUS
DEFINITION
    Homo sapiens (human)
ACCESSION
    S81287
VERSION
    S81287.1 GI:245359
KEYWORDS
    Homo sapiens (human)
ORGANISM
    Homo sapiens
REFERENCE
    1 (bases 1 to 16)
AUTHORS
    Fukao,T., Yamaguchi,S., Orii,T., Schutgens,R.B., Osumi,T. and
    Hashimoto,T.
TITLE
    Identification of three mutant alleles of the gene for
    mitochondrial acetoacetyl-coenzyme A thiolase. A complete analysis
    of two generations of a family with 3-ketothiolase deficiency
JOURNAL
    J. Clin. Invest. 89 (2), 474-479 (1992)
MEDLINE
    92147861
PUBMED
    1346617
REMARK
    GenBank staff at the National Library of Medicine created this
    entry [NCBI gibbsq 81287] from the original journal article.
COMMENT
    A->C mutation at 3, splice site intron 10.
FEATURES
    source
    1..16
    /organism='Homo sapiens'
    /mol_type='genomic DNA'
    /db_xref='taxon:9606'

gene
    1..16
    /gene='mitochondrial acetoacetyl-coenzyme A thiolase'

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY   1323 AAGAACCCTAAATTT 1337
      |||||
DB   15 AAGAACCCTAAATTT 1

RESULT 282
AR066302/c
LOCUS
DEFINITION
    Sequence 1 from patent US 5849903.
ACCESSION
    AR066302
```

VERSION AR066302.1 GI:5996518  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 14)  
AUTHORS Pietrzowski, Z., Cieslak, D. and Olbina, G.  
TITLE Antisense oligonucleotides for IL-8 and IL-8 receptor  
JOURNAL Patent: US 5849903-A 1 15-DEC-1998;  
FEATURES Location/Qualifiers  
source  
1..14  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1239 GTTCCTCCGGTG 1251  
Db 13 GTTCCTCCGGTG 1  
RESULT 283  
AX377347/c  
LOCUS  
DEFINITION Sequence 11 from Patent WO0212499.  
ACCESSION AX377347  
VERSION AX377347.1 GI:19573633  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kliem, S.E., Koshy, B. and Lanz, E.M.  
TITLE Haplotypes of the ntfs3 gene  
JOURNAL Patent: WO 0212499-A 1 14-FEB-2002;  
Genaisance Pharmaceuticals, Inc. (US)  
FEATURES Location/Qualifiers  
source  
1..15  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 1.2e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1537 CTCCTCCCGCTCTGG 1551  
Db 15 CTCCTCCCGCTCTCGG 1  
RESULT 284  
ATH551605/c  
LOCUS  
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone  
282G05.  
ACCESSION AJ551605  
VERSION AJ551605.1 GI:29367738  
KEYWORDS left border; T-DNA flanking sequence.  
SOURCE Arabidopsis thaliana (thale cress)  
ORGANISM Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.  
REFERENCE 1  
AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,  
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,  
Lepiniec, L., Gaboche, M. and Lecharny, A.  
TITLE T-DNA integration into the Arabidopsis genome depends on sequences  
of pre-insertion sites

JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)  
MEDLINE 22363535  
PUBMED 12446565  
REFERENCE 2 (bases 1 to 15)  
AUTHORS Balzerque, S.  
TITLE Direct Submission  
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue  
Gaston Cremieux, 91057 Evry cedex, FRANCE  
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana  
plants from INRA (Versailles). The DNA fragment(s) resulting from  
the PCR were directly sequenced from the left or the right border  
to determine the genomic sequence flanking the insertion. T-DNA  
derived sequences were removed. Information to order the  
corresponding mutant line and a link to a database providing a  
graphical display of the insertion site are available at  
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has  
been generated in the framework of the French plant genomics  
program 'Genoplante' (http://www.genoplante.com and  
http://genoplante-info.infobiogen.fr).  
FEATURES Location/Qualifiers  
source  
1..15  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/cultivar="Wassiliewskaja"  
/db\_xref="taxon:3702"  
/clone="282G05"  
/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"  
misc\_feature 1..15  
/note="T-DNA flanking sequence  
left border"  
Query Match 0.8%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 229 AAAAAACAAACGA 241  
Db 14 AAAAAACAAACGA 2  
RESULT 285  
CQ806753  
LOCUS  
DEFINITION Sequence 203 from Patent WO2004035803.  
ACCESSION CQ806753  
VERSION CQ806753.1 GI:47112135  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Foekens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F.,  
Nimrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and  
Marx, A.  
TITLE Method and nucleic acids for the improved treatment of breast cell  
proliferative disorders  
JOURNAL Patent: WO 2004035803-A 203 29-APR-2004;  
Epigenomics AG (DE)  
FEATURES Location/Qualifiers  
source  
1..16  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1345 CCGTGGCGGAGAA 1357  
Db 3 CCGTGGCGGAGAA 15



RESULT 286  
A88141  
LOCUS A88141 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 289 from Patent WO9833904.  
ACCESSION A88141  
VERSION A88141.1 GI:6736711  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL PATENT: WO 9833904-A 289 06-AUG-1998;  
BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
FEATURES  
source  
1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 456 GGCGGCACCTTGAGG 471  
Db 1 GGCGGCACCTTGAGG 16  
RESULT 287  
A89435  
LOCUS A89435 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 1583 from Patent WO9833904.  
ACCESSION A89435  
VERSION A89435.1 GI:6738005  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL PATENT: WO 9833904-A 1583 06-AUG-1998;  
BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
FEATURES  
source  
1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 456 GGCGGCACCTTGAGG 471  
Db 1 GGCGGCACCTTGAGG 16  
RESULT 288  
A90108  
LOCUS A90108 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 289 from Patent EP0856579.  
ACCESSION A90108  
VERSION A90108.1 GI:6738622  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.

TITLE An antisense oligonucleotide preparation method  
JOURNAL PATENT: EP 0856579-A 289 05-AUG-1998;  
BIOGOSTIK GES (DE)  
FEATURES  
source  
1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 456 GGCGGCACCTTGAGG 471  
Db 1 GGCGGCACCTTGAGG 16  
RESULT 289  
AR104209/c  
LOCUS AR104209 16 bp DNA linear PAT 14-FEB-2001  
DEFINITION Sequence 25 from patent US 6093545.  
ACCESSION AR104209  
VERSION AR104209.1 GI:12816917  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Goodearl,A.D.J. and Glucksmann,M.Alexandra.  
TITLE Methods for detecting nucleic acid molecules encoding a member of the muscarinic family of receptors  
JOURNAL PATENT: US 6093545-A 25 25-JUL-2000;  
FEATURES  
source  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 72 GTGGGCTGCTGCTGA 87  
Db 16 GTGGGCTGCTGCTGA 1  
RESULT 290  
CQ786338/c  
LOCUS CQ786338 16 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 146 from Patent WO2004020668.  
ACCESSION CQ786338  
VERSION CQ786338.1 GI:45721440  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Nakamura,Y. and Katagiri,T.  
TITLE Method for treating synovial sarcoma  
JOURNAL PATENT: WO 2004020668-A 146 11-MAR-2004;  
Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)  
FEATURES  
source  
1..16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/notes="Description of Artificial Sequence: synthetic oligonucleotide"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

REFERENCE	1
AUTHORS	Waschuetza, S., Schnakenberg, E. and Lustig, M.
TITLE	Method and diagnostic kit for the molecular diagnosis of pharmacologically relevant genes
JOURNAL	Patent: WO 03018837-A 133 06-MAR-2003;
FEATURES	Adnagen AG (DE) Location/Qualifiers

```
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonukleotid"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 669 CCCTTCAGCTGCC 684
DB 1 CCCACGACCTGCC 16

RESULT 296
BD066948
LOCUS
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066948
VERSION BD066948.1 GI:22612551
KEYWORDS JP 2001511000-A/1583.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiefen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1583 07-AUG-2001;
COMMENT BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
PN JP 2001511000-A/1583
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source
FT Location/Qualifiers
1. .16
/organism="Unknown"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 630 TTCTTACCCGGAGC 645
DB 1 TTCTTACCCGGAGC 16

RESULT 298
BD086293/c
LOCUS
DEFINITION G protein-coupled receptor and utilization thereof.
ACCESSION BD086293
VERSION BD086293.1 GI:22631903
KEYWORDS JP 2001525174-A/9.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Goodearl,A.D.J., Glucksmann,A.M., Xie,M. and Distefano,P.
TITLE G protein-coupled receptor and utilization thereof
JOURNAL Patent: JP 2001525174-A 9 11-DEC-2001;
COMMENT MILLENNIUM PHARMACEUTICALS INC
PN JP 2001525174-A/9
PD 11-DEC-2001
PF 04-DEC-1998 JP 2000523346
PR 04-DEC-1997 US 08/985090,17-MAR-1998 US 09/042780 PI
ANDREW D J GOODEARL,ALEXANDRA M GLUCKSMANN,MICHAEL XIE,PETER PI
DISTEFANO
PC C12N15/09,C07K14/705,C07K16/28,C12N5/10,C12P21/02,C12Q1/68//
CC (C12P21/02,C12R1:91),C12N15/00,C12N5/00
CC Strandedness: Single;
CC Topology: Linear;
CC G protein-coupled receptor and utilization thereof FH Key
FT source
FT Location/Qualifiers
1. .16
/organism="Unidentified"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 72 GTGGGGCTGCTGCTGA 87
DB 16 GTGGGGCTGCTGCTCA 1

Search completed: September 13, 2005, 10:39:58
Job time : 7 secs
```

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:42:36 ; Search time 8 Seconds  
(without alignments)

3.180 Million cell updates/sec

Title: us-10-828-394-1

Perfect score: 1643

Sequence: 1 gaattccgcgcgtgaccgag.....taaaactgctgtgagctg 1643

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 411 seqs, 7741 residues

Total number of hits satisfying chosen parameters: 822

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 411 summaries

Database : rngdb:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	27.2	1.7	32	1	AAQ11501
2	26	1.6	26	1	ABK66659
3	25	1.5	25	1	ABK66660
4	25	1.5	25	1	ADP14589
5	25	1.5	25	1	ADP14593
6	25	1.5	25	1	ADP14578
7	25	1.5	25	1	ADP14583
8	25	1.5	25	1	ADP14590
9	25	1.5	25	1	ADP14585
10	25	1.5	25	1	ADP14587
11	25	1.5	25	1	ADP14582
12	25	1.5	25	1	ADP14584
13	25	1.5	25	1	ADP14586
14	25	1.5	25	1	ADP14588
15	25	1.5	25	1	ADP14592
16	25	1.5	25	1	ADP14579
17	25	1.5	25	1	ADP14581
18	25	1.5	25	1	ADP14591
19	25	1.5	25	1	ABN99658
20	23	1.4	23	1	ABN99658
21	23	1.4	23	1	ACF36411
22	23	1.4	23	1	ACF36410
23	23	1.4	23	1	ADM83082
24	23	1.4	23	1	ADM83081
25	23	1.4	23	1	ADL70521
26	23	1.4	23	1	ADL70512
27	23	1.4	23	1	ADL70515
28	23	1.4	23	1	ADL70518
29	21	1.3	21	1	AAAT39500
30	21	1.3	21	1	AAA52783
31	21	1.3	21	1	AAA94227
32	21	1.3	21	1	AAA94231
33	21	1.3	21	1	AAA94230

C 34	21	1.3	21	1	AAA94232	Human testosterone
C 35	21	1.3	21	1	AAA94233	Human testosterone
C 36	21	1.3	21	1	AAA94229	Human testosterone
C 37	21	1.3	21	1	AAA94226	Human testosterone
C 38	21	1.3	21	1	AAA94234	Human testosterone
C 39	21	1.3	21	1	AAA94228	Human testosterone
C 40	21	1.3	21	1	AAA94225	Human testosterone
C 41	21	1.3	21	1	AAF97658	Human gene single
C 42	21	1.3	21	1	AAF97656	Human gene single
C 43	21	1.3	21	1	AAF97657	Human gene single
C 44	21	1.3	21	1	AAF97659	Human gene single
C 45	21	1.3	21	1	ABN99659	Human clusterin PC
C 46	21	1.3	21	1	ACF36397	TRPM-2 antisense o
C 47	21	1.3	21	1	ACF36405	TRPM-2 antisense o
C 48	21	1.3	21	1	ACF36406	TRPM-2 antisense o
C 49	21	1.3	21	1	ACF36399	TRPM-2 antisense o
C 50	21	1.3	21	1	ACF36402	TRPM-2 antisense o
C 51	21	1.3	21	1	ACF36401	TRPM-2 antisense o
C 52	21	1.3	21	1	ACF36398	TRPM-2 antisense o
C 53	21	1.3	21	1	ACF36403	TRPM-2 antisense o
C 54	21	1.3	21	1	ACF36404	TRPM-2 antisense o
C 55	21	1.3	21	1	ACF36400	TRPM-2 antisense o
C 56	21	1.3	21	1	ADF75347	Human RT-PCR prime
C 57	21	1.3	21	1	ADF75348	Human TRPM-2 antis
C 58	21	1.3	21	1	ADM83075	Human TRPM-2 antis
C 59	21	1.3	21	1	ADM83072	Human TRPM-2 antis
C 60	21	1.3	21	1	ADM83074	Human TRPM-2 antis
C 61	21	1.3	21	1	ADM83076	Human TRPM-2 antis
C 62	21	1.3	21	1	ADM83068	Human TRPM-2 antis
C 63	21	1.3	21	1	ADM83069	Human TRPM-2 antis
C 64	21	1.3	21	1	ADM83070	Human TRPM-2 antis
C 65	21	1.3	21	1	ADM83073	Human TRPM-2 antis
C 66	21	1.3	21	1	ADM83071	Human TRPM-2 antis
C 67	21	1.3	21	1	ADL70456	RNAi for human clu
C 68	21	1.3	21	1	ADL70456	RNAi for human clu
C 69	21	1.3	21	1	ADL70450	RNAi for human clu
C 70	21	1.3	21	1	ADL70513	RNAi for human clu
C 71	21	1.3	21	1	ADL70458	RNAi for human clu
C 72	21	1.3	21	1	ADL70520	RNAi for human clu
C 73	21	1.3	21	1	ADL70461	RNAi for human clu
C 74	21	1.3	21	1	ADL70519	RNAi for human clu
C 75	21	1.3	21	1	ADL70517	RNAi for human clu
C 76	21	1.3	21	1	ADL70516	RNAi for human clu
C 77	21	1.3	21	1	ADL70457	RNAi for human clu
C 78	21	1.3	21	1	ADL70459	RNAi for human clu
C 79	21	1.3	21	1	ADL70514	Antisense oligonuc
C 80	21	1.3	21	1	ADL70410	RNAi for human clu
C 81	21	1.3	21	1	ADL70440	RNAi for human clu
C 82	21	1.3	21	1	ADL70422	Antisense oligonuc
C 83	21	1.3	21	1	ADL70413	Antisense oligonuc
C 84	21	1.3	21	1	ADL70408	Antisense oligonuc
C 85	21	1.3	21	1	ADL70412	RNAi for human clu
C 86	21	1.3	21	1	ADL70425	RNAi for human clu
C 87	21	1.3	21	1	ADL70442	Antisense oligonuc
C 88	21	1.3	21	1	ADL70406	Antisense oligonuc
C 89	21	1.3	21	1	ADL70423	RNAi for human clu
C 90	21	1.3	21	1	ADL70441	RNAi for human clu
C 91	21	1.3	21	1	ADL70443	Antisense oligonuc
C 92	21	1.3	21	1	ADL70411	RNAi for human clu
C 93	21	1.3	21	1	ADL70439	RNAi for human clu
C 94	21	1.3	21	1	ADL70438	Antisense oligonuc
C 95	21	1.3	21	1	ADL70414	Antisense oligonuc
C 96	21	1.3	21	1	ADL70409	RNAi for human clu
C 97	21	1.3	21	1	ADL70427	Antisense oligonuc
C 98	21	1.3	21	1	ADL70405	Antisense oligonuc
C 99	21	1.3	21	1	ADL70407	RNAi for human clu
C 100	21	1.3	21	1	ADL70424	RNAi for human clu
C 101	20.8	1.3	24	1	AAA66325	Dog genomic marker
C 102	20	1.2	20	1	ABN99680	Human clusterin in
C 103	20	1.2	20	1	ABN99682	Human clusterin in
C 104	20	1.2	20	1	ABN99684	Human clusterin in
C 105	20	1.2	20	1	ABN99686	Human clusterin in
C 106	20	1.2	20	1	ABN99709	Human clusterin in

C 107	20	1.2	20	1	ABN99711	Human clusterin in	C 180	18	1.1	18	1	AAT39501	Chromosome 8p clus
C 108	20	1.2	20	1	ABN99718	Human clusterin in	C 181	18	1.1	18	1	ABN99657	Human clusterin PC
C 109	20	1.2	20	1	ABN99677	Human clusterin in	C 182	17.8	1.1	21	1	ACF36409	DNA sequence of a
C 110	20	1.2	20	1	ABN99681	Human clusterin in	C 183	17.8	1.1	21	1	ACM83080	Control TRPM-2 mis
C 111	20	1.2	20	1	ABN99668	Human clusterin in	C 184	17	1.0	17	1	AAT41526	Human apolipoprote
C 112	20	1.2	20	1	ABN99675	Human clusterin in	C 185	17	1.0	17	1	AAT41542	Human apolipoprote
C 113	20	1.2	20	1	ABN99675	Human clusterin in	C 186	17	1.0	17	1	ABT34616	Tumour suppression
C 114	20	1.2	20	1	ABN99697	Human clusterin in	C 187	17	1.0	17	1	ADB45708	Tumour suppression
C 115	20	1.2	20	1	ABN99701	Human clusterin in	C 188	16.8	1.0	20	1	AAQ58405	Antisense oligonuc
C 116	20	1.2	20	1	ABN99702	Human clusterin in	C 189	16.8	1.0	20	1	ADN02449	Western equine enc
C 117	20	1.2	20	1	ABN99704	Human clusterin in	C 190	16	1.0	17	1	AAQ68062	Triple helix formi
C 118	20	1.2	20	1	ABN99716	Human clusterin in	C 191	16	1.0	17	1	AAQ68062	Duchenne muscular
C 119	20	1.2	20	1	ABN99726	Human clusterin in	C 192	16	1.0	19	1	ADN00161	DMD gene specific
C 120	20	1.2	20	1	ABN99727	Human clusterin in	C 193	16	1.0	19	1	ADN00161	Human PCTAIRE prot
C 121	20	1.2	20	1	ABN99670	Human clusterin in	C 194	16	1.0	20	1	ADN00161	Human PCTAIRE prot
C 122	20	1.2	20	1	ABN99672	Human clusterin in	C 195	16	1.0	20	1	ADN00161	Caenorhabditis ele
C 123	20	1.2	20	1	ABN99722	Human clusterin in	C 196	15.8	1.0	19	1	ADN00161	HCV coding region-
C 124	20	1.2	20	1	ABN99667	Human clusterin in	C 197	15.8	1.0	19	1	ADN00161	HCV coding region-
C 125	20	1.2	20	1	ABN99667	Human clusterin in	C 198	15.8	1.0	19	1	ADN00161	Hepatitis C virus
C 126	20	1.2	20	1	ABN99712	Human clusterin in	C 199	15.8	1.0	19	1	ADN00161	Hepatitis C virus
C 127	20	1.2	20	1	ABN99725	Human clusterin in	C 200	15.8	1.0	19	1	ADN00161	RNAi for human clu
C 128	20	1.2	20	1	ABN99671	Human clusterin in	C 201	15.8	1.0	19	1	ADN00161	RNAi for human clu
C 129	20	1.2	20	1	ABN99678	Human clusterin in	C 202	15.8	1.0	19	1	ADN00161	RNAi for human clu
C 130	20	1.2	20	1	ABN99694	Human clusterin in	C 203	15.8	1.0	19	1	ADN00161	Human apolipoprote
C 131	20	1.2	20	1	ABN99700	Human clusterin in	C 204	15.8	1.0	19	1	ADN00161	Human apolipoprote
C 132	20	1.2	20	1	ABN99721	Human clusterin in	C 205	15.8	1.0	19	1	ADN00161	Human apolipoprote
C 133	20	1.2	20	1	ABN99669	Human clusterin in	C 206	15.4	0.9	17	1	AAAT41543	Human apolipoprote
C 134	20	1.2	20	1	ABN99668	Human clusterin in	C 207	15.4	0.9	17	1	AAAT41543	Human apolipoprote
C 135	20	1.2	20	1	ABN99689	Human clusterin in	C 208	15.4	0.9	17	1	AAAT41543	Rabbit stromelysin
C 136	20	1.2	20	1	ABN99703	Human clusterin in	C 209	15.4	0.9	17	1	AAAT41543	Human NOD2 Hammett
C 137	20	1.2	20	1	ABN99720	Human clusterin in	C 210	15.4	0.9	17	1	ABN08674	Human MD23 scannin
C 138	20	1.2	20	1	ABN99691	Human clusterin in	C 211	15.4	0.9	17	1	ABN08674	HCV minus strand D
C 139	20	1.2	20	1	ABN99713	Human clusterin in	C 212	15.4	0.9	17	1	ABN08674	HCV DNazyme substr
C 140	20	1.2	20	1	ABN99724	Human clusterin in	C 213	15.4	0.9	17	1	ABN08674	Tumour suppression
C 141	20	1.2	20	1	ABN99690	Human clusterin in	C 214	15.4	0.9	17	1	ABN08674	HCV DNazyme substr
C 142	20	1.2	20	1	ABN99708	Human clusterin in	C 215	15.4	0.9	17	1	ABN08674	Human GDMPLP-1 prob
C 143	20	1.2	20	1	ABN99717	Human clusterin in	C 216	15.4	0.9	17	1	ABN08674	PCR primer for DNA
C 144	20	1.2	20	1	ABN99672	Human clusterin in	C 217	15.4	0.9	18	1	AAK85604	Allele specific pr
C 145	20	1.2	20	1	ABN99693	Human clusterin in	C 218	15.4	0.9	18	1	AAK85604	Peptide nucleic ac
C 146	20	1.2	20	1	ABN99698	Human clusterin in	C 219	15	0.9	15	1	AAV31968	HCV minus strand D
C 147	20	1.2	20	1	ABN99719	Human clusterin in	C 220	15	0.9	17	1	ACD62818	HCV DNazyme substr
C 148	20	1.2	20	1	ABN99728	Human clusterin in	C 221	15	0.9	17	1	ADN08768	Human GDMPLP-1 prob
C 149	20	1.2	20	1	ABN99733	Human clusterin in	C 222	15	0.9	17	1	ADN08768	Human GDMPLP-1 prob
C 150	20	1.2	20	1	ABN99673	Human clusterin in	C 223	14.8	0.9	18	1	AAQ35721	EIV primer EIVAI7
C 151	20	1.2	20	1	ABN99679	Human clusterin in	C 224	14.8	0.9	18	1	AAV95047	Mouse IL-2 recepto
C 152	20	1.2	20	1	ABN99696	Human clusterin in	C 225	14.8	0.9	18	1	AAH37505	SNP specific upper
C 153	20	1.2	20	1	ABN99696	Human clusterin in	C 226	14.8	0.9	18	1	ACC79773	Mouse PTPRB revers
C 154	20	1.2	20	1	ABN99706	Human clusterin in	C 227	14.6	0.9	18	1	ACF04428	Hepatitis C virus
C 155	20	1.2	20	1	ABN99706	Human clusterin in	C 228	14.4	0.9	17	1	AAK63904	Rabbit stromelysin
C 156	20	1.2	20	1	ABN99723	Human clusterin in	C 229	14.4	0.9	17	1	AAV93469	Human B-raf substr
C 157	20	1.2	20	1	ABN99731	Human clusterin in	C 230	14.4	0.9	17	1	ABK00171	Human NOD2 Hammett
C 158	20	1.2	20	1	ABN99674	Human clusterin in	C 231	14.4	0.9	17	1	ABN08360	Human GDMPLP-1 17-m
C 159	20	1.2	20	1	ABN99699	Human clusterin in	C 232	14.4	0.9	17	1	ABN08675	Human GDMPLP-1 17-m
C 160	20	1.2	20	1	ABN99714	Human clusterin in	C 233	14.4	0.9	17	1	ABN08675	Human GDMPLP-1 17-m
C 161	20	1.2	20	1	ABN99688	Human clusterin in	C 234	14.4	0.9	17	1	ABN08675	Human GDMPLP-1 17-m
C 162	20	1.2	20	1	ABN99710	Human clusterin in	C 235	14.4	0.9	17	1	ABN08673	Human GDMPLP-1 17-m
C 163	20	1.2	20	1	ABN99676	Human clusterin in	C 236	14.4	0.9	17	1	ABN10045	Human GDMPLP-1 17-m
C 164	20	1.2	20	1	ABN99692	Human clusterin in	C 237	14.4	0.9	17	1	ACN07603	Human GDMPLP-1 17-m
C 165	20	1.2	20	1	ABN99707	Human clusterin in	C 238	14.4	0.9	17	1	ACN09775	WNV minus strand H
C 166	20	1.2	20	1	ADN007105	CLU gene forward P	C 239	14.4	0.9	17	1	ACN07193	WNV minus strand I
C 167	20	1.2	20	1	ADN007106	CLU gene reverse P	C 240	14.4	0.9	17	1	ACN07193	WNV minus strand I
C 168	20	1.2	20	1	ADL70464	RNAi for human clu	C 241	14.4	0.9	17	1	ACN04500	WNV minus strand H
C 169	20	1.2	20	1	ADL70430	RNAi for human clu	C 242	14.4	0.9	17	1	ACN04500	WNV minus strand H
C 170	19.4	1.2	21	1	AA52782	Murine clusterin P	C 243	14.4	0.9	17	1	ABT38885	Tumour suppression
C 171	19	1.2	19	1	ADL70522	RNAi for human clu	C 244	14.4	0.9	17	1	ADN00466	Human MD23 scannin
C 172	19	1.2	19	1	ADL70523	RNAi for human clu	C 245	14.4	0.9	17	1	ADN00466	Human MD23 scannin
C 173	19	1.2	19	1	ADL70444	RNAi for human clu	C 246	14.4	0.9	17	1	ADN00466	Human H-Ras DNazym
C 174	19	1.2	19	1	ADL70445	RNAi for human clu	C 247	14.4	0.9	17	1	ADN00466	HCV DNazyme substr
C 175	19	1.2	21	1	ADL70465	RNAi for human clu	C 248	14.4	0.9	17	1	ADN00466	HCV DNazyme substr
C 176	19	1.2	21	1	ADL70431	RNAi for human clu	C 249	14.4	0.9	17	1	ADN00466	Tumour suppression
C 177	18.8	1.1	22	1	ADL70431	RNAi for human clu	C 250	14.4	0.9	17	1	ADN00466	Cholesterol homeos
C 178	18	1.1	18	1	AA741539	Human apolipoprote	C 251	14.4	0.9	17	1	ADN00466	Human Phe311leu mu
C 179	18	1.1	18	1	AA741527	Human apolipoprote	C 252	14.4	0.9	17	1	ADN00466	Human Phe311leu mu

253	14.4	0.9	17	1	ADL18587	RT-PCR primer HP6.	326	13.8	0.8	17	1	ABK18229	Human ERG hammerhe
254	14.4	0.9	17	1	ADMS9611	Hepatitis B virus	327	13.8	0.8	17	1	ABK19135	Human ERG Ambergzym
255	14.4	0.9	17	1	AD184297	HCV DNazyme subutr	328	13.8	0.8	17	1	AAD18269	Mouse Ob receptor
256	14.4	0.9	17	1	AD185767	HCV DNazyme subutr	329	13.8	0.8	17	1	AAD18271	Mouse Ob receptor
257	14.4	0.9	17	1	AD185767	HCV DNazyme subutr	330	13.8	0.8	17	1	ACN05936	WNV Ambergzyme subs
258	14.4	0.9	17	1	ACN71783	Human GMLP-1 prob	331	13.8	0.8	17	1	ACN08391	WNV minus strand H
259	14.4	0.9	17	1	ACN73136	Human GMLP-1 prob	332	13.8	0.8	17	1	ACN15008	WNV minus strand A
260	14.4	0.9	17	1	ACN73135	Human GMLP-1 prob	333	13.8	0.8	17	1	ACN00398	WNV Hammerhead Rib
261	14.4	0.9	17	1	ACN71451	Human GMLP-1 prob	334	13.8	0.8	17	1	ACN14016	WNV minus strand D
262	14.4	0.9	17	1	ACN71451	Human GMLP-1 prob	335	13.8	0.8	17	1	ACN15009	WNV minus strand A
263	14.4	0.9	17	1	ACN71765	Human GMLP-1 prob	336	13.8	0.8	17	1	ACN06460	WNV Ambergzyme subs
264	14.4	0.9	18	1	AAQ80949	PCR primer to gene	337	13.8	0.8	17	1	ACN06460	WNV Ambergzyme subs
265	14.4	0.9	18	1	ADMO6417	Human PCR primer S	338	13.8	0.8	17	1	ACN08392	WNV minus strand H
266	14.4	0.9	18	1	ADMS92954	SNP-containing car	339	13.8	0.8	17	1	ACN08392	WNV minus strand H
267	14.4	0.9	18	1	ADH71057	Human Vbeta point	340	13.8	0.8	17	1	ACN11835	WNV DNazyme subutr
268	14.4	0.9	15	1	AAAF47085	IGFBP3 oligonucleo	341	13.8	0.8	17	1	ACN05385	WNV minus strand H
269	14.4	0.9	15	1	AAAF47084	IGFBP3 oligonucleo	342	13.8	0.8	17	1	ACN08973	WNV minus strand H
270	14.4	0.9	17	1	ABK25595	Stress tolerance c	343	13.8	0.8	17	1	ABT34420	Tumour suppression
271	14.4	0.9	17	1	ABK25596	Stress tolerance c	344	13.8	0.8	17	1	ABT37737	Tumour suppression
272	14.4	0.9	17	1	ADCS9851	HCV DNazyme subutr	345	13.8	0.8	17	1	ACA06296	NFKB sub-unit modu
273	14.4	0.9	17	1	AD184295	HCV DNazyme subutr	346	13.8	0.8	17	1	ACA07700	NFKB sub-unit modu
274	14.4	0.9	17	1	ADN44286	Mutant cell identi	347	13.8	0.8	17	1	ACA08217	NFKB sub-unit modu
275	14.4	0.9	17	1	ADN44287	Mutant cell identi	348	13.8	0.8	17	1	ACA08217	NFKB sub-unit modu
276	14.4	0.9	17	1	AAU5231	Hepatitis C virus	349	13.8	0.8	17	1	ACA06298	NFKB sub-unit modu
277	13.8	0.8	17	1	AAU5231	Hepatitis C virus	350	13.8	0.8	17	1	ACA06394	NFKB sub-unit modu
278	13.8	0.8	17	1	AAU5231	Hepatitis C virus	351	13.8	0.8	17	1	ACA06394	NFKB sub-unit modu
279	13.8	0.8	17	1	AAU5231	Hepatitis C virus	352	13.8	0.8	17	1	ACA06517	NFKB sub-unit modu
280	13.8	0.8	17	1	AAU5231	Hepatitis C virus	353	13.8	0.8	17	1	ADA99701	Human MD23 scannin
281	13.8	0.8	17	1	AAU5231	Hepatitis C virus	354	13.8	0.8	17	1	ADB00467	Human MD23 scannin
282	13.8	0.8	17	1	AAU5231	Hepatitis C virus	355	13.8	0.8	17	1	ADB00467	Human MD23 scannin
283	13.8	0.8	17	1	AAU5231	Hepatitis C virus	356	13.8	0.8	17	1	ADB00467	Human MD23 scannin
284	13.8	0.8	17	1	AAU5231	Hepatitis C virus	357	13.8	0.8	17	1	ADB00467	Human MD23 scannin
285	13.8	0.8	17	1	AAU5231	Hepatitis C virus	358	13.8	0.8	17	1	ADB00467	Human MD23 scannin
286	13.8	0.8	17	1	AAU5231	Hepatitis C virus	359	13.8	0.8	17	1	ADB00467	Human MD23 scannin
287	13.8	0.8	17	1	AAU5231	Hepatitis C virus	360	13.8	0.8	17	1	ADB00467	Human MD23 scannin
288	13.8	0.8	17	1	AAU5231	Hepatitis C virus	361	13.8	0.8	17	1	ADB00467	Human MD23 scannin
289	13.8	0.8	17	1	AAU5231	Hepatitis C virus	362	13.8	0.8	17	1	ADB00467	Human MD23 scannin
290	13.8	0.8	17	1	AAU5231	Hepatitis C virus	363	13.8	0.8	17	1	ADB00467	Human MD23 scannin
291	13.8	0.8	17	1	AAU5231	Hepatitis C virus	364	13.8	0.8	17	1	ADB00467	Human MD23 scannin
292	13.8	0.8	17	1	AAU5231	Hepatitis C virus	365	13.8	0.8	17	1	ADB00467	Human MD23 scannin
293	13.8	0.8	17	1	AAU5231	Hepatitis C virus	366	13.8	0.8	17	1	ADB00467	Human MD23 scannin
294	13.8	0.8	17	1	AAU5231	Hepatitis C virus	367	13.8	0.8	17	1	ADB00467	Human MD23 scannin
295	13.8	0.8	17	1	AAU5231	Hepatitis C virus	368	13.8	0.8	17	1	ADB00467	Human MD23 scannin
296	13.8	0.8	17	1	AAU5231	Hepatitis C virus	369	13.8	0.8	17	1	ADB00467	Human MD23 scannin
297	13.8	0.8	17	1	AAU5231	Hepatitis C virus	370	13.8	0.8	17	1	ADB00467	Human MD23 scannin
298	13.8	0.8	17	1	AAU5231	Hepatitis C virus	371	13.8	0.8	17	1	ADB00467	Human MD23 scannin
299	13.8	0.8	17	1	AAU5231	Hepatitis C virus	372	13.8	0.8	17	1	ADB00467	Human MD23 scannin
300	13.8	0.8	17	1	AAU5231	Hepatitis C virus	373	13.8	0.8	17	1	ADB00467	Human MD23 scannin
301	13.8	0.8	17	1	AAU5231	Hepatitis C virus	374	13.8	0.8	17	1	ADB00467	Human MD23 scannin
302	13.8	0.8	17	1	AAU5231	Hepatitis C virus	375	13.8	0.8	17	1	ADB00467	Human MD23 scannin
303	13.8	0.8	17	1	AAU5231	Hepatitis C virus	376	13.8	0.8	17	1	ADB00467	Human MD23 scannin
304	13.8	0.8	17	1	AAU5231	Hepatitis C virus	377	13.8	0.8	17	1	ADB00467	Human MD23 scannin
305	13.8	0.8	17	1	AAU5231	Hepatitis C virus	378	13.8	0.8	17	1	ADB00467	Human MD23 scannin
306	13.8	0.8	17	1	AAU5231	Hepatitis C virus	379	13.8	0.8	17	1	ADB00467	Human MD23 scannin
307	13.8	0.8	17	1	AAU5231	Hepatitis C virus	380	13.8	0.8	17	1	ADB00467	Human MD23 scannin
308	13.8	0.8	17	1	AAU5231	Hepatitis C virus	381	13.8	0.8	17	1	ADB00467	Human MD23 scannin
309	13.8	0.8	17	1	AAU5231	Hepatitis C virus	382	13.8	0.8	17	1	ADB00467	Human MD23 scannin
310	13.8	0.8	17	1	AAU5231	Hepatitis C virus	383	13.8	0.8	17	1	ADB00467	Human MD23 scannin
311	13.8	0.8	17	1	AAU5231	Hepatitis C virus	384	13.8	0.8	17	1	ADB00467	Human MD23 scannin
312	13.8	0.8	17	1	AAU5231	Hepatitis C virus	385	13.8	0.8	17	1	ADB00467	Human MD23 scannin
313	13.8	0.8	17	1	AAU5231	Hepatitis C virus	386	13.8	0.8	17	1	ADB00467	Human MD23 scannin
314	13.8	0.8	17	1	AAU5231	Hepatitis C virus	387	13.8	0.8	17	1	ADB00467	Human MD23 scannin
315	13.8	0.8	17	1	AAU5231	Hepatitis C virus	388	13.8	0.8	17	1	ADB00467	Human MD23 scannin
316	13.8	0.8	17	1	AAU5231	Hepatitis C virus	389	13.8	0.8	17	1	ADB00467	Human MD23 scannin
317	13.8	0.8	17	1	AAU5231	Hepatitis C virus	390	13.8	0.8	17	1	ADB00467	Human MD23 scannin
318	13.8	0.8	17	1	AAU5231	Hepatitis C virus	391	13.8	0.8	17	1	ADB00467	Human MD23 scannin
319	13.8	0.8	17	1	AAU5231	Hepatitis C virus	392	13.8	0.8	17	1	ADB00467	Human MD23 scannin
320	13.8	0.8	17	1	AAU5231	Hepatitis C virus	393	13.8	0.8	17	1	ADB00467	Human MD23 scannin
321	13.8	0.8	17	1	AAU5231	Hepatitis C virus	394	13.8	0.8	17	1	ADB00467	Human MD23 scannin
322	13.8	0.8	17	1	AAU5231	Hepatitis C virus	395	13.8	0.8	17	1	ADB00467	Human MD23 scannin
323	13.8	0.8	17	1	AAU5231	Hepatitis C virus	396	13.8	0.8	17	1	ADB00467	Human MD23 scannin
324	13.8	0.8	17	1	AAU5231	Hepatitis C virus	397	13.8	0.8	17	1	ADB00467	Human MD23 scannin
325	13.8	0.8	17	1	AAU5231	Hepatitis C virus	398	13.8	0.8	17	1	ADB00467	Human MD23 scannin

399 13.4 0.8 15 1 ABX01804 Hepatitis C virus  
400 13.4 0.8 16 1 AAV70490 Sequence ID# 68 fr  
401 13.4 0.8 16 1 AAV70489 Sequence ID# 67 fr  
402 13.4 0.8 16 1 AAX14645 Triple helix third  
403 13.4 0.8 16 1 ABL46101 Hepatitis C virus  
404 13.4 0.8 16 1 ABL46100 Hepatitis C virus  
405 13.4 0.8 16 1 ADK82290 Nucleic acid analy  
406 13.4 0.8 16 1 ADK82291 Nucleic acid analy  
407 13.4 0.8 16 1 ADM80152 Linker peptide enc  
408 13.4 0.8 16 1 ADR32381 E. coli nicking ag  
409 13.4 0.8 16 1 ADR32430 E. coli fingerprin  
410 13.4 0.8 16 1 ADR33575 E. coli strain K12  
411 13.4 0.8 16 1 ADR69939 Human survivin gen

ALIGNMENTS

RESULT 1  
AAQ11501  
ID AAQ11501 standard; DNA; 32 BP.  
XX AC AAQ11501;  
DT 20-JUN-1991 (first entry)  
XX DE Probe based on amino acids 6-15 of the Cytolysis Inhibitor A-chain.  
XX KW cytolysis inhibitor; perforin; immunological effector molecule;  
XX KW infertility; ss.  
XX OS Homo sapiens.  
XX PN DE3933850-A.  
XX PD 18-APR-1991.  
XX PF 06-OCT-1989; 89DE-03933850.  
XX PR 06-OCT-1989; 89DE-03933850.  
XX PA (SCHD ) SCHERING AG.  
XX PI Tschopp J, Jenne D;  
XX DR WPI; 1991-118338/17.  
XX DNA sequence coding for cytolysis inhibitor - is strong inhibitor of  
XX terminal complement protein, e.g. perforin secreted by killer cells.  
XX Example 1; Page 4; 15pp; German.  
XX The partial amino acid sequences of both chains of the Cytolysis  
XX Inhibitor were known. This probe is one of two which were prepared based  
XX on the N-terminal sequences of the inhibitor. It corresponds to the  
XX sequence DNEIQEMSNQG. Both probes were radioactively labelled and used to  
XX screen a liver-specific cDNA library. One clone which hybridised  
XX positively to both probes was found to contain a 1.7kb BamHI-KpnI  
XX fragment. This was inserted into plasmid pGEM4, to give DSM 5269, and  
XX sequenced. See also AAQ11502 and AAQ11503  
XX Sequence 32 BP; 10 A; 7 C; 11 G; 4 T; 0 U; 0 Other;  
Query Match 1.7%; Score 27.2; DB 1; Length 32;  
Best Local Similarity 90.6%; Pred. No. 23;  
Matches 29; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 129 GACATGAGCTGCAGGAATGTCCCAATCAGG 160  
|||||  
Db 1 GACATGAGCTGCAGGAGATGTCCACACAGG 32  
|||||

RESULT 2

ABK66659  
ID ABK66659 standard; DNA; 26 BP.  
XX AC ABK66659;  
DT 02-JUL-2002 (first entry)  
XX Human gene specific PCR primer #747.  
XX Primer; ss; DNA microarray; differential expression analysis; human.  
XX OS Homo sapiens.  
XX PN US6352829-B1.  
XX PD 05-MAR-2002.  
XX PF 05-JAN-1999; 99US-00225928.  
XX PR 21-MAY-1997; 97US-00859998.  
XX PA (CLON-) CLONTECH LAB INC.  
XX PI Chenchik A, Johhadze G, Bibilashvili R;  
XX WPI; 2002-314699/35.  
XX Producing sub-population of labeled nucleic acids, useful for analyzing  
XX differences in RNA profiles between several different physiological  
XX sources, using set of distinct gene specific primers.  
XX Example 3; SEQ ID NO 747; 11pp; English.  
XX The invention relates to producing a sub-population of labeled nucleic  
XX acids (NAs) comprising contacting a NA sample from a physiological  
XX source with a pool of 50 distinct gene specific primers under suitable  
XX conditions to enzymatically generate sub-population of NAs, where each  
XX gene specific primer has a sequence complementary to a distinct mRNA, and  
XX each labeled NA is generated using a single gene specific primer. The  
XX method is useful for producing a sub-population of labeled NAs which is  
XX useful for analysing the differences in the RNA profiles between several  
XX different physiological sources, where the method comprises producing  
XX subpopulation of labeled NAs for the different physiological sources,  
XX comprising the populations for each physiological source to identify  
XX differences in the population, where the comparison is preferably  
XX performed by hybridising the labeled NAs for each of the distinct  
XX physiological sources to an array of probe NAs stably associated with the  
XX surface of a substrate to produce a hybridisation pattern for each of the  
XX sources, and comparing the patterns for each of the sources, where  
XX differential gene expression assays are utilised in differential  
XX expression analysis of diseased a normal tissue e.g. neoplastic a normal  
XX tissue, or different tissue or sub-tissue types. The present sequence is a  
XX human gene specific PCR primer used in the method of the invention. Note:  
XX The sequence data for this patent did not form part of the printed  
XX specification, but was obtained in electronic format directly from USPTO  
XX at http.wipo.segdata.uspto.gov/sequence.html?DocID=6352829B1  
XX Sequence 26 BP; 8 A; 4 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 16;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 934 TCGGATGAGGACCACTGTGACAAG 959  
|||||  
Db 1 TCGGATGAGGACCACTGTGACAAG 26  
|||||

RESULT 3  
ABK66660/C  
ID ABK66660 standard; DNA; 25 BP.  
XX AC ABK66660;



XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW head/neck cancer; differential expression; probe.  
XX Homo sapiens.  
XX WO2004048933-A2.  
XX 10-JUN-2004.  
XX 21-NOV-2003; 2003WO-US037481.  
XX 21-NOV-2002; 2002US-0427982P.  
XX 03-APR-2003; 2003US-0459782P.  
XX (AMHP ) WYETH.  
XX (TWIN/) TWINE N C.  
XX (BURC/) BURCZYNSKI M E.  
XX (TREP/) TREPICCHIO W L.  
XX (DORN/) DORNER A.  
XX (STOV/) STOVER J A.  
XX (SLON/) SLONI D K.  
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
PI Sloni DK;  
XX WPI; 2004-460799/43.  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
PT differential expression profile of specific genes in peripheral blood  
PT sample of subject with reference expression profile of specific genes.  
XX Disclosure; SEQ ID NO 1325; 350pp; English.  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
CC such as solid tumor by providing peripheral blood sample of human having  
CC non-blood disease, and comparing an expression profile of specific genes  
CC in the peripheral blood sample to reference expression profile of the  
CC genes, where each of the genes is differentially expressed in peripheral  
CC blood mononuclear cells (PBMCs) of patients having the disease as  
CC compared to PBMCs of normal humans. The method is useful for diagnosing  
CC non-blood disease such as solid tumor. The solid tumor is chosen from  
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood  
CC sample is a whole blood sample (claimed). (M1) is useful for identifying  
CC genes that are differentially expressed in peripheral blood samples  
CC isolated at different stages of progression, development or treatment of  
CC RCC and/or other solid tumors. This sequence corresponds to a probe to  
CC detect a gene that is differentially expressed and detected by the method  
CC of the invention.  
XX Sequence 25 BP; 6 A; 9 C; 4 G; 6 T; 0 U; 0 Other;  
SQ Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1550 GGATCTGCACTCTAACACTCGACT 1574  
DB 1 GGATCTGCACTCTAACACTCGACT 25  
RESULT 5  
ADP14593  
ID ADP14593 standard; DNA; 25 BP.  
XX AC ADP14593;  
XX 26-AUG-2004 (first entry)  
XX Renal cell carcinoma differentially expressed gene probe #998.  
DE XX

XX 02-JUL-2002 (first entry)  
XX Human gene specific PCR primer #748.  
XX Primer; ss; DNA microarray; differential expression analysis; human.  
XX Homo sapiens.  
XX US6352829-B1.  
XX 05-MAR-2002.  
XX 05-JAN-1999; 99US-00225928.  
XX 21-MAY-1997; 97US-00859998.  
XX (CLON-) CLONTECH LAB INC.  
XX Chenchik A, Johadze G, Bibilashvili R;  
XX WPI; 2002-314699/35.  
XX Producing sub-population of labeled nucleic acids, useful for analyzing  
PT differences in RNA profiles between several different physiological  
PT sources, using set of distinct gene specific primers.  
XX Example 3; SEQ ID NO 748; 11pp; English.  
XX The invention relates to producing a sub-population of labeled nucleic  
CC acids (NAs) comprising contacting a NA sample from a physiological  
CC source, with a pool of 50 distinct gene specific primers under suitable  
CC conditions to enzymatically generate sub-population of NAs, where each  
CC gene specific primer has a sequence complementary to a distinct mRNA, and  
CC each labeled NA is generated using a single gene specific primer. The  
CC method is useful for producing a sub-population of labeled NAs which is  
CC useful for analysing the differences in the RNA profiles between several  
CC different physiological sources, where the method comprises producing  
CC subpopulation of labeled NAs for the different physiological sources,  
CC comprising the populations for each physiological source to identify  
CC differences in the population, where the comparison is preferably  
CC performed by hybridising the labeled NAs for each of the distinct  
CC physiological sources to an array of probe NAs stably associated with the  
CC surface of a substrate to produce a hybridisation pattern for each of the  
CC sources, and comparing the patterns for each of the sources, where  
CC differential gene expression assays are utilised in differential  
CC expression analysis of diseased a normal tissue e.g. neoplastic a normal  
CC tissue, or different tissue or subtype types. The present sequence is a  
CC human gene specific PCR primer used in the method of the invention. Note:  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from USPTO  
CC at <http://wipo.seqdata.uspto.gov/sequence.html?docID=6352829B1>  
XX SQ Sequence 25 BP; 6 A; 8 C; 7 G; 4 T; 0 U; 0 Other;  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1190 GTACTATCTGGGGTCCACCGGTG 1214  
DB 25 GTACTATCTGGGGTCCACCGGTG 1  
RESULT 4  
ADP14589  
ID ADP14589 standard; DNA; 25 BP.  
XX AC ADP14589;  
XX 26-AUG-2004 (first entry)  
XX Renal cell carcinoma differentially expressed gene probe #994.  
DE XX

ss; diagnosis; non-blood disease; solid tumor; gene expression;  
peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
head/neck cancer; differential expression; probe.  
Homo sapiens.  
WO2004048933-A2.  
10-JUN-2004.  
21-NOV-2003; 2003WO-US037481.  
21-NOV-2002; 2002US-0427982P.  
03-APR-2003; 2003US-0459782P.  
(AMHP ) WYETH.  
(TWIN/) TWINE N C.  
(BURC/) BURCZYNSKI M E.  
(TREP/) TREPICCHIO W L.  
(DORN/) DORNER A.  
(STOV/) STOVER J A.  
(SLON/) SLONI D K.  
Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;  
Sloni DK;  
WPI; 2004-460799/43.  
Diagnosing non-blood disease such as solid tumor, involves comparing  
differential expression profile of specific genes in peripheral blood  
sample of subject with reference expression profile of specific genes.  
Disclosure; SEQ ID NO 1329; 350pp; English.  
The invention relate to a method of diagnosing (M1) non-blood disease  
such as solid tumor by providing peripheral blood sample of human having  
non-blood disease, and comparing an expression profile of specific genes  
in the peripheral blood sample to reference expression profile of the  
genes, where each of the genes is differentially expressed in peripheral  
blood mononuclear cells (PBMCs) of patients having the disease as  
compared to PBMCs of normal humans. The method is useful for diagnosing  
non-blood disease such as solid tumor. The solid tumor is chosen from  
renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
peripheral blood sample comprises enriched PBMCs. The peripheral blood  
sample is a whole blood sample (claimed). (M1) is useful for identifying  
genes that are differentially expressed in peripheral blood samples  
isolated at different stages of progression, development or treatment of  
RCC and/or other solid tumors. This sequence corresponds to a probe to  
detect a gene that is differentially expressed and detected by the method  
of the invention.  
Sequence 25 BP; 5 A; 8 C; 6 G; 6 T; 0 U; 0 Other;  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1564 AACACTCGACTCTGCTGCTCATGGG 1588  
DB 1 AACACTCGACTCTGCTGCTCATGGG 25  
RESULT 6  
ADP14578  
ID ADP14578 standard; DNA; 25 BP.  
XX AC  
XX ADP14578;  
XX 26-AUG-2004 (first entry)  
DT Renal cell carcinoma differentially expressed gene probe #983.  
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW ss; diagnosis; non-blood disease; solid tumor; gene expression;

peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
head/neck cancer; differential expression; probe.  
Homo sapiens.  
WO2004048933-A2.  
10-JUN-2004.  
21-NOV-2003; 2003WO-US037481.  
21-NOV-2002; 2002US-0427982P.  
03-APR-2003; 2003US-0459782P.  
(AMHP ) WYETH.  
(TWIN/) TWINE N C.  
(BURC/) BURCZYNSKI M E.  
(TREP/) TREPICCHIO W L.  
(DORN/) DORNER A.  
(STOV/) STOVER J A.  
(SLON/) SLONI D K.  
Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;  
Sloni DK;  
WPI; 2004-460799/43.  
Diagnosing non-blood disease such as solid tumor, involves comparing  
differential expression profile of specific genes in peripheral blood  
sample of subject with reference expression profile of specific genes.  
Disclosure; SEQ ID NO 1314; 350pp; English.  
The invention relate to a method of diagnosing (M1) non-blood disease  
such as solid tumor by providing peripheral blood sample of human having  
non-blood disease, and comparing an expression profile of specific genes  
in the peripheral blood sample to reference expression profile of the  
genes, where each of the genes is differentially expressed in peripheral  
blood mononuclear cells (PBMCs) of patients having the disease as  
compared to PBMCs of normal humans. The method is useful for diagnosing  
non-blood disease such as solid tumor. The solid tumor is chosen from  
renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
peripheral blood sample comprises enriched PBMCs. The peripheral blood  
sample is a whole blood sample (claimed). (M1) is useful for identifying  
genes that are differentially expressed in peripheral blood samples  
isolated at different stages of progression, development or treatment of  
RCC and/or other solid tumors. This sequence corresponds to a probe to  
detect a gene that is differentially expressed and detected by the method  
of the invention.  
Sequence 25 BP; 8 A; 8 C; 5 G; 4 T; 0 U; 0 Other;  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1088 CTACCACTGGAAGATGCTCAACACC 1112  
DB 1 CTACCACTGGAAGATGCTCAACACC 25  
RESULT 7  
ADP14583  
ID ADP14583 standard; DNA; 25 BP.  
XX AC  
XX ADP14583;  
XX 26-AUG-2004 (first entry)  
DT Renal cell carcinoma differentially expressed gene probe #988.  
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW ss; diagnosis; non-blood disease; solid tumor; gene expression;

KW head/neck cancer; differential expression; probe.  
XX Homo sapiens.  
OS WO2004048933-A2.  
XX 10-JUN-2004.  
XX 21-NOV-2003; 2003WO-US037481.  
XX 21-NOV-2002; 2002US-0427982P.  
XX 03-APR-2003; 2003US-0459782P.  
XX (AMHP ) WYETH.  
XX (TWIN/) TWINE N C.  
XX (BURC/) BURCZYNSKI M E.  
XX (TREP/) TREPICCHIO W L.  
XX (DORN/) DORNER A.  
XX (STOV/) STOVER J A.  
XX (SLOW/) SLONI D K.  
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
PI Sloni DK;  
XX WPI; 2004-460799/43.  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX differential expression profile of specific genes in peripheral blood  
XX sample of subject with reference expression profile of specific genes.  
XX Disclosure; SEQ ID NO 1319; 350pp; English.  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX such as solid tumor by providing peripheral blood sample of human having  
XX non-blood disease, and comparing an expression profile of specific genes  
XX in the peripheral blood sample to reference expression profile of the  
XX genes, where each of the genes is differentially expressed in peripheral  
XX blood mononuclear cells (PBMCs) of patients having the disease as  
XX compared to PBMCs of normal humans. The method is useful for diagnosing  
XX non-blood disease such as solid tumor. The solid tumor is chosen from  
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX genes that are differentially expressed in peripheral blood samples  
XX isolated at different stages of progression, development or treatment of  
XX RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX detect a gene that is differentially expressed and detected by the method  
XX of the invention.  
XX Sequence 25 BP; 5 A; 8 C; 4 G; 8 T; 0 U; 0 Other;  
SQ Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1268 GAAGCTCTTTGACTCTGATCCATC 1292  
DB 1 GAAGCTCTTTGACTCTGATCCATC 25  
RESULT 8  
ADP14580  
ID ADP14580 standard; DNA; 25 BP.  
XX ADP14580;  
XX 26-AUG-2004 (first entry)  
XX Renal cell carcinoma differentially expressed gene probe #995.  
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW head/neck cancer; differential expression; probe.

XX Homo sapiens.  
OS WO2004048933-A2.  
XX 10-JUN-2004.  
XX 21-NOV-2003; 2003WO-US037481.  
XX 21-NOV-2002; 2002US-0427982P.  
XX 03-APR-2003; 2003US-0459782P.  
XX (AMHP ) WYETH.  
XX (TWIN/) TWINE N C.  
XX (BURC/) BURCZYNSKI M E.  
XX (TREP/) TREPICCHIO W L.  
XX (DORN/) DORNER A.  
XX (STOV/) STOVER J A.  
XX (SLOW/) SLONI D K.  
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
PI Sloni DK;  
XX WPI; 2004-460799/43.  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX differential expression profile of specific genes in peripheral blood  
XX sample of subject with reference expression profile of specific genes.  
XX Disclosure; SEQ ID NO 1316; 350pp; English.  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX such as solid tumor by providing peripheral blood sample of human having  
XX non-blood disease, and comparing an expression profile of specific genes  
XX in the peripheral blood sample to reference expression profile of the  
XX genes, where each of the genes is differentially expressed in peripheral  
XX blood mononuclear cells (PBMCs) of patients having the disease as  
XX compared to PBMCs of normal humans. The method is useful for diagnosing  
XX non-blood disease such as solid tumor. The solid tumor is chosen from  
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX genes that are differentially expressed in peripheral blood samples  
XX isolated at different stages of progression, development or treatment of  
XX RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX detect a gene that is differentially expressed and detected by the method  
XX of the invention.  
XX Sequence 25 BP; 2 A; 9 C; 8 G; 6 T; 0 U; 0 Other;  
SQ Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1196 TCTCGGGTCACCCACCGTGGCTTCC 1220  
DB 1 TCTCGGGTCACCCACCGTGGCTTCC 25  
RESULT 9  
ADP14590  
ID ADP14590 standard; DNA; 25 BP.  
XX ADP14590;  
XX 26-AUG-2004 (first entry)  
XX Renal cell carcinoma differentially expressed gene probe #995.  
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW head/neck cancer; differential expression; probe.

OS	Homo sapiens.	
XX	WO2004048933-A2.	
PX	10-JUN-2004.	
PD		
PP		
XX	21-NOV-2003; 2003WO-US037481.	
XX		
XX	21-NOV-2002; 2002US-0427982P.	
PR	03-APR-2003; 2003US-0459782P.	
XX	(AMHP ) WYETH.	
PA	{TWIN/) TWINE N C.	
PA	(BURC/) BURCZYNSKI M E.	
PA	(TREP/) TREPICCHIO W L.	
PA	(DORN/) DORNER A.	
PA	(STOV/) STOVER J A.	
PA	(SLON/) SLONI D K.	
XX		
XX	Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;	
PI	Sloni DK;	
XX		
XX	WPI; 2004-460799/43.	
DR		
XX	Diagnosing non-blood disease such as solid tumor, involves comparing	
PT	differential expression profile of specific genes in peripheral blood	
PT	sample of subject with reference expression profile of specific genes.	
XX		
XX	Disclosure; SEQ ID NO 1326; 350pp; English.	
XX		
CC	The invention relate to a method of diagnosing (M1) non-blood disease	
CC	such as solid tumor by providing peripheral blood sample of human having	
CC	non-blood disease, and comparing an expression profile of specific genes	
CC	in the peripheral blood sample to reference expression profile of the	
CC	genes, where each of the genes is differentially expressed in peripheral	
CC	blood mononuclear cells (PBMCs) of patients having the disease as	
CC	compared to PBMCs of normal humans. The method is useful for diagnosing	
CC	non-blood disease such as solid tumor. The solid tumor is chosen from	
CC	renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The	
CC	peripheral blood sample comprises enriched PBMCs. The peripheral blood	
CC	sample is a whole blood sample (claimed). (M1) is useful for identifying	
CC	genes that are differentially expressed in peripheral blood samples	
CC	isolated at different stages of progression, development or treatment of	
CC	RCC and/or other solid tumors. This sequence corresponds to a probe to	
CC	detect a gene that is differentially expressed and detected by the method	
CC	of the invention.	
XX		
XX	Sequence 25 BP; 5 A; 9 C; 4 G; 7 T; 0 U; 0 Other;	
SQ		
Query Match            1.5%; Score 25; DB 1; Length 25;		
Best Local Similarity 100.0%; Pred. No. 19;		
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0		
QY	1556 TGCACCTTAACACTCGACTCTGCTG 1580	
DB	1 TGCACCTTAACACTCGACTCTGCTG 25	
RESULT 10		
ADP14585		
ID	ADP14585 standard; DNA; 25 BP.	
XX		
AC	ADP14585;	
XX		
DT	26-AUG-2004 (first entry)	
XX		
DE	Renal cell carcinoma differentially expressed gene probe #990.	
XX	as; diagnosis; non-blood disease; solid tumor; gene expression;	
KW	peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;	
KW	head/neck cancer; differential expression; probe.	
XX		
OS	Homo sapiens.	

P	N	WO2004048933-A2.
X	X	10-JUN-2004.
P	D	21-NOV-2003; 2003WO-US037481.
P	F	21-NOV-2002; 2002US-0427982P.
X	X	03-APR-2003; 2003US-0459782P.
P	R	(AMHP ) WYETH.
X	X	(TWIN/) TWINE N C.
P	A	(BURC/) BURCZYNSKI M E.
P	A	(TREP/) TREPICCHIO W L.
P	A	(DORN/) DORNER A.
P	A	(STOV/) STOVER J A.
P	A	(SLON/) SLONI D K.
X	X	Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
P	I	Sloni DK;
X	X	WPI; 2004-460799/43.
D	R	Diagnosing non-blood disease such as solid tumor, involves comparing
P	T	differential expression profile of specific genes in peripheral blood
P	T	sample of subject with reference expression profile of specific genes.
P	T	Disclosure; SEQ ID NO 1323; 350pp; English.
P	S	The invention relate to a method of diagnosing (M1) non-blood disease
X	X	such as solid tumor by providing peripheral blood sample of human having
C	C	non-blood disease, and comparing an expression profile of specific genes
C	C	in the peripheral blood sample to reference expression profile of the
C	C	genes, where each of the genes is differentially expressed in peripheral
C	C	blood mononuclear cells (PBMCs) of patients having the disease as
C	C	compared to PBMCs of normal humans. The method is useful for diagnosing
C	C	non-blood disease such as solid tumor. The solid tumor is chosen from
C	C	renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
C	C	peripheral blood sample comprises enriched PBMCs. The peripheral blood
C	C	sample is a whole blood sample (claimed). (M1) is useful for identifying
C	C	genes that are differentially expressed in peripheral blood samples
C	C	isolated at different stages of progression, development or treatment of
C	C	RCC and/or other solid tumors. This sequence corresponds to a probe to
C	C	detect a gene that is differentially expressed and detected by the method
C	C	of the invention.
X	X	Sequence 25 BP; 8 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
S	Q	Query Match 1.5%; Score 25; DB 1; Length 25;
		Best Local Similarity 100.0%; Pred. No. 19;
		Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Q	Y	1474 AGAGAGCTCTGCACGTCACCAAGTA 1498
D	b	1 AGAGAGCTCTGCACGTCACCAAGTA 25
		RESULT 12
		ID ADP14582
		ADP14582 standard; DNA; 25 BP.
		AC ADP14582;
		XX ADP14582;
		XX ADP14582;
		DT 26-AUG-2004 (first entry)
		DE Renal cell carcinoma differentially expressed gene probe #987.
		XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
		KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
		KW head/neck cancer; differential expression; probe.
		XX Homo sapiens.
		OS Homo sapiens.
		XX WO2004048933-A2.
		PN
		XX
		D
		WO2004048933-A2.
		PN
		XX
		OS
		Homo sapiens.
		XX
		DE
		Renal cell carcinoma differentially expressed gene probe #987.
		XX
		ss; diagnosis; non-blood disease; solid tumor; gene expression;
		KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
		KW head/neck cancer; differential expression; probe.
		XX
		OS
		Homo sapiens.
		XX
		PN
		WO2004048933-A2.
		PN
		XX
		OS
		Homo sapiens.
		XX
		DE
		Renal cell carcinoma differentially expressed gene probe #989.
		XX
		ss; diagnosis; non-blood disease; solid tumor; gene expression;
		KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
		KW head/neck cancer; differential expression; probe.
		XX
		OS
		Homo sapiens.
		XX
		PN
		WO2004048933-A2.
		PN
		XX
		OS
		Homo sapiens.
		XX
		DE
		Renal cell carcinoma differentially expressed gene probe #989.
		XX
		ss; diagnosis; non-blood disease; solid tumor; gene expression;
		KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
		KW head/neck cancer; differential expression; probe.
		XX
		OS
		Homo sapiens.
		XX
		PN
		WO2004048933-A2.
		PN
		XX
		OS
		Homo sapiens.
		XX
		DE
		Renal cell carcinoma differentially expressed gene probe #989.
		XX
		ss; diagnosis; non-blood disease; solid tumor; gene expression;
		KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
		KW head/neck cancer; differential expression; probe.
		XX
		OS
		Homo sapiens.
		XX
		PN
		WO2004048933-A2.
		PN
		XX
		OS
		Homo sapiens.
		XX
		DE
		Renal cell carcinoma differentially expressed gene probe #989.
		XX
		ss; diagnosis; non-blood disease; solid tumor; gene expression;
		KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
		KW head/neck cancer; differential expression; probe.
		XX
		OS
		Homo sapiens.
		XX
		PN
		WO2004048933-A2.
		PN
		XX
		OS
		Homo sapiens.
		XX
		DE
		Renal cell carcinoma differentially expressed gene probe #989.
		XX
		ss; diagnosis; non-blood disease; solid tumor; gene expression;
		KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
		KW head/neck cancer; differential expression; probe.

PD 10-JUN-2004.  
XX PF  
XX 21-NOV-2003; 2003WO-US037481.  
XX PR  
XX 21-NOV-2002; 2002US-0427982P.  
XX PR  
XX 03-APR-2003; 2003US-0459782P.  
XX PA  
XX (AMHP ) WYETH.  
XX PA (TWIN/) TWINE N C.  
XX PA (BURC/) BURCZYNSKI M E.  
XX PA (TREP/) TREPICCHIO W L.  
XX PA (DORN/) DORNER A.  
XX PA (STOV/) STOVER J A.  
XX PA (SLON/) SLONI D K.  
XX PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
XX PI Sloni DK;  
XX DR WPI; 2004-460799/43.  
XX  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX PT differential expression profile of specific genes in peripheral blood  
XX PT sample of subject with reference expression profile of specific genes.  
XX PS  
XX Disclosure; SEQ ID NO 1320; 350pp; English.  
XX  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX CC such as solid tumor by providing peripheral blood sample of human having  
XX CC non-blood disease, and comparing an expression profile of specific genes  
XX CC in the peripheral blood sample to reference expression profile of the  
XX CC genes, where each of the genes is differentially expressed in peripheral  
XX CC blood mononuclear cells (PBMCs) of patients having the disease as  
XX CC compared to PBMCs of normal humans. The method is useful for diagnosing  
XX CC non-blood disease such as solid tumor. The solid tumor is chosen from  
XX CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX CC peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX CC sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX CC genes that are differentially expressed in peripheral blood samples  
XX CC isolated at different stages of progression, development or treatment of  
XX CC RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX CC detect a gene that is differentially expressed and detected by the method  
XX CC of the invention.  
XX  
XX Sequence 25 BP; 4 A; 8 C; 4 G; 9 T; 0 U; 0 Other;  
SQ  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. NO. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1274 CTTTGACTCTGATCCCATCTGTG 1298  
DB 1 CTTTGACTCTGATCCCATCTGTG 25  
RESULT 14  
ADP14586  
ID ADP14586 standard; DNA; 25 BP.  
XX AC  
XX ADP14586;  
XX  
XX 26-AUG-2004 (first entry)  
XX DE Renal cell carcinoma differentially expressed gene probe #931.  
XX  
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
XX KW head/neck cancer; differential expression; probe.  
XX OS Homo sapiens.  
XX PN WO2004048933-A2.  
XX PN  
XX PD 10-JUN-2004.

XX 21-NOV-2003; 2003WO-US037481.  
XX PF  
XX 21-NOV-2002; 2002US-0427982P.  
XX PR  
XX 03-APR-2003; 2003US-0459782P.  
XX PA  
XX (AMHP ) WYETH.  
XX PA (TWIN/) TWINE N C.  
XX PA (BURC/) BURCZYNSKI M E.  
XX PA (TREP/) TREPICCHIO W L.  
XX PA (DORN/) DORNER A.  
XX PA (STOV/) STOVER J A.  
XX PA (SLON/) SLONI D K.  
XX PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
XX PI Sloni DK;  
XX DR WPI; 2004-460799/43.  
XX  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX PT differential expression profile of specific genes in peripheral blood  
XX PT sample of subject with reference expression profile of specific genes.  
XX PS  
XX Disclosure; SEQ ID NO 1322; 350pp; English.  
XX  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX CC such as solid tumor by providing peripheral blood sample of human having  
XX CC non-blood disease, and comparing an expression profile of specific genes  
XX CC in the peripheral blood sample to reference expression profile of the  
XX CC genes, where each of the genes is differentially expressed in peripheral  
XX CC blood mononuclear cells (PBMCs) of patients having the disease as  
XX CC compared to PBMCs of normal humans. The method is useful for diagnosing  
XX CC non-blood disease such as solid tumor. The solid tumor is chosen from  
XX CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX CC peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX CC sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX CC genes that are differentially expressed in peripheral blood samples  
XX CC isolated at different stages of progression, development or treatment of  
XX CC RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX CC detect a gene that is differentially expressed and detected by the method  
XX CC of the invention.  
XX  
XX Sequence 25 BP; 7 A; 9 C; 6 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. NO. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1470 CCAGAGAGAGCTCTGCACGTACCA 1494  
DB 1 CCAGAGAGAGCTCTGCACGTACCA 25  
RESULT 15  
ADP14588  
ID ADP14588 standard; DNA; 25 BP.  
XX AC  
XX ADP14588;  
XX  
XX 26-AUG-2004 (first entry)  
XX DE Renal cell carcinoma differentially expressed gene probe #993.  
XX  
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
XX KW head/neck cancer; differential expression; probe.  
XX OS Homo sapiens.  
XX PN WO2004048933-A2.  
XX PN  
XX PD 10-JUN-2004.

```
PF 21-NOV-2003; 2003WO-US037481.
XX
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX
PA (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX
PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1324; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
XX Sequence 25 BP; 7 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1480 CTCTGCACGTCCACCAAGTACCAGG 1504
DB 1 CTCTGCACGTCCACCAAGTACCAGG 25
RESULT 16
ADP14592
ID ADP14592 standard; DNA; 25 BP.
XX
XX ADP14592;
AC
XX
XX 26-AUG-2004 (first entry)
DT
XX
XX Renal cell carcinoma differentially expressed gene probe #997.
DE
XX
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
OS
XX
XX WO2004048933-A2.
PN
XX
XX 10-JUN-2004.
PD
XX
XX 21-NOV-2003; 2003WO-US037481.
PF
```

```
XX
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX
PA (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX
PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1324; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
XX Sequence 25 BP; 7 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1480 CTCTGCACGTCCACCAAGTACCAGG 1504
DB 1 CTCTGCACGTCCACCAAGTACCAGG 25
RESULT 16
ADP14592
ID ADP14592 standard; DNA; 25 BP.
XX
XX ADP14592;
AC
XX
XX 26-AUG-2004 (first entry)
DT
XX
XX Renal cell carcinoma differentially expressed gene probe #997.
DE
XX
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
OS
XX
XX WO2004048933-A2.
PN
XX
XX 10-JUN-2004.
PD
XX
XX 21-NOV-2003; 2003WO-US037481.
PF
```

```
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
PS Disclosure; SEQ ID NO 1315; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
SQ Sequence 25 BP; 8 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1177 AAGCGAAGACCAGTACTACTCTGCG 1201
Db 1 AAGCGAAGACCAGTACTACTCTGCG 25
RESULT 18
ADP14581
ID ADP14581 standard; DNA; 25 BP.
XX
AC ADP14581;
XX
XX 26-AUG-2004 (first entry)
DT
DE Renal cell carcinoma differentially expressed gene probe #986.
XX
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
OS
XX WO2004048933-A2.
PN
XX 10-JUN-2004.
PD
XX 21-NOV-2003; 2003WO-US037481.
XX
XX 21-NOV-2002; 2002US-0427982P.
PR
XX 21-NOV-2002; 2002US-0427982P.
```

```
PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
PS Disclosure; SEQ ID NO 1317; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
SQ Sequence 25 BP; 4 A; 4 C; 9 G; 8 T; 0 U; 0 Other;
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1256 TGAGGTGCTCGTGAAGCTCTTTGAC 1280
Db 1 TGAGGTGCTCGTGAAGCTCTTTGAC 25
RESULT 19
ADP14591
ID ADP14591 standard; DNA; 25 BP.
XX
AC ADP14591;
XX
XX 26-AUG-2004 (first entry)
DT
DE Renal cell carcinoma differentially expressed gene probe #996.
XX
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
XX Homo sapiens.
OS
XX WO2004048933-A2.
PN
XX 10-JUN-2004.
PD
XX 21-NOV-2003; 2003WO-US037481.
XX
XX 21-NOV-2002; 2002US-0427982P.
PR
XX 03-APR-2003; 2003US-0459782P.
```



XX (AMHP ) WYETH.  
PA (TWIN/) TWINE N C.  
PA (BURC/) BURCZYNSKI M E.  
PA (TREP/) TREPICCHIO W L.  
PA (DORN/) DORNER A.  
PA (STOV/) STOVER J A.  
PA (SLOW/) SLONI D K.  
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
PI Sloni DK;  
XX WPI; 2004-460799/43.  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
PT differential expression profile of specific genes in peripheral blood  
PT sample of subject with reference expression profile of specific genes.  
XX Disclosure; SEQ ID NO 1327; 350pp; English.  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
CC such as solid tumor by providing peripheral blood sample of human having  
CC non-blood disease, and comparing an expression profile of specific genes  
CC in the peripheral blood sample to reference expression profile of the  
CC genes, where each of the genes is differentially expressed in peripheral  
CC blood mononuclear cells (PBMCs) of patients having the disease as  
CC compared to PBMCs of normal humans. The method is useful for diagnosing  
CC non-blood disease such as solid tumor. The solid tumor is chosen from  
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood  
CC sample is a whole blood sample (claimed). (M1) is useful for identifying  
CC genes that are differentially expressed in peripheral blood samples  
CC isolated at different stages of progression, development or treatment of  
CC RCC and/or other solid tumors. This sequence corresponds to a probe to  
CC detect a gene that is differentially expressed and detected by the method  
CC of the invention.  
XX Sequence 25 BP; 5 A; 9 C; 4 G; 7 T; 0 U; 0 Other;  
SQ Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. NO. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1562 CTAACACTCGACTCTGCTGCTCATG 1586  
DB 1 CTAACACTCGACTCTGCTGCTCATG 25  
RESULT 20  
ABN99658/C  
ID ABN99658 standard; DNA; 23 BP.  
XX AC ABN99658;  
XX 16-AUG-2002 (first entry)  
XX Human clusterin PCR primer 2.  
DE Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss; PCR; primer;  
KW hyperproliferative disorder; hyperlipidemic disorder.  
XX Homo sapiens.  
OS WO200222635-A1.  
XX 21-MAR-2002.  
XX 10-SEP-2001; 2001WO-US028235.  
XX 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Example 13; Page 80; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a PCR primer used to amplify the human clusterin  
CC gene  
XX Sequence 23 BP; 5 A; 6 C; 5 G; 7 T; 0 U; 0 Other;  
SQ Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. NO. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 789 CTTGAGATGATACACGAGGCTCA 811  
DB 23 CTTGAGATGATACACGAGGCTCA 1  
RESULT 21  
ACF36411/C  
ID ACF36411 standard; DNA; 23 BP.  
XX AC ACF36411;  
XX 18-DEC-2003 (first entry)  
XX Human TRPM-2 cDNA amplifying RT-PCR antisense primer.  
DE TRPM-2; testosterone-repressed prostate message-2; cytostatic; RT-PCR;  
XX androgen; prostate cancer; anti-apoptotic protein; antisense; primer; ss.  
XX Homo sapiens.  
XX WO2003072591-A1.  
XX 04-SEP-2003.  
XX 20-FEB-2003; 2003WO-US005305.  
XX 22-FEB-2002; 2002US-00080794.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
XX WPI; 2003-689981/65.  
XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX Example 13; Page 20; 44pp; English.  
XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in

CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents a RT-  
CC PCR primer for amplifying the anti-apoptotic protein TRPM-2 (testosterone  
CC -repressed prostate message-2) cDNA

XX Sequence 23 BP; 7 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 AAGTCCGGGAGATCTTGCTGT 979  
|||  
Db 23 AAGTCCGGGAGATCTTGCTGT 1

RESULT 22  
ACF36410  
ID ACF36410 standard; DNA; 23 BP.

XX ACF36410;  
AC  
XX 18-DEC-2003 (first entry)  
DT  
XX Human TRPM-2 cDNA amplifying RT-PCR sense primer.

DE  
XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; RT-PCR;  
KW androgen; prostate cancer; anti-apoptotic protein; antisense; primer; ss.  
XX Homo sapiens.  
OS  
XX WO2003072591-A1.  
FN  
XX 04-SEP-2003.  
PD

XX 20-FEB-2003; 2003WO-US005305.

XX 22-FEB-2002; 2002US-00080794.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;

XX WPI; 2003-689981/65.

XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.

XX Example 13; Page 20; 44pp; English.

XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing of cancer  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents a RT-

CC PCR primer for amplifying the anti-apoptotic protein TRPM-2 (testosterone  
CC -repressed prostate message-2) cDNA

XX Sequence 23 BP; 11 A; 3 C; 4 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 177 AAGGAAATTCAAAATGCTGTCAA 199  
|||||  
Db 1 AAGGAAATTCAAAATGCTGTCAA 23

RESULT 23  
ADM83082/c  
ID ADM83082 standard; DNA; 23 BP.

XX ADM83082;  
AC  
XX 03-JUN-2004 (first entry)  
DT  
XX Human TRPM-2 amplifying antisense RT-PCR primer.

DE  
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW reverse transcription; RT-PCR; primer; ss.

XX Homo sapiens.

XX US2003158130-A1.

XX 21-AUG-2003.

XX 28-SEP-2001; 2001US-00967726.

XX 25-FEB-2000; 2000WO-US004875.

XX 28-SEP-2000; 2000US-0236301P.

XX 10-AUG-2001; 2001US-00913325.

XX (GLEA/) GLEAVE M.

XX (RENN/) RENNIE P S.

XX (MIYA/) MIYAKE H.

XX (NELS/) NELSON C.

XX (ZELL/) ZELLWEGER T.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

XX WPI; 2003-778017/73.

XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)

PT comprises administering a composition that inhibits expression of TRPM-2.

XX Disclosure; SEQ ID NO 17; 14pp; English.

XX The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) amplifying RT-PCR primer. The primer is used in the exemplification  
CC of the invention.

XX Sequence 23 BP; 7 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 957 AAGTCCGGGAGATCTTGTCTGT 979  
Db 23 AAGTCCGGGAGATCTTGTCTGT 1

RESULT 24  
ADM83081  
ID ADM83081 standard; DNA; 23 BP.  
XX AC  
XX ADM83081;  
XX AC  
XX 03-JUN-2004 (first entry)  
XX Human TRPM-2 amplifying sense RT-PCR primer.  
XX XX  
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW reverse transcription; RT-PCR; primer; ss.  
XX XX  
OS Homo sapiens.  
XX XX  
PN US2003158130-A1.  
XX XX  
PD 21-AUG-2003.  
XX XX  
XX 28-SEP-2001; 2001US-00967726.  
XX XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
PI WPI; 2003-778017/73.  
XX XX  
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX XX  
PS Disclosure; SEQ ID NO 16; 14pp; English.  
XX XX  
XX The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) amplifying RT-PCR primer. The primer is used in the exemplification  
CC of the invention.  
XX XX  
SQ Sequence 23 BP; 11 A; 3 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 177 AAGGAATTCAAATGCTGCA 199  
Db 1 AAGGAATTCAAATGCTGCA 23

RESULT 25  
ADL70521  
ID ADL70521 standard; cDNA; 23 BP.  
XX XX

AC ADL70521;  
XX XX  
XX 20-MAY-2004 (first entry)  
XX Human clusterin target for RNAi.  
XX XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytostatic; neuroprotective; neurotropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX XX  
OS Homo sapiens.  
OS Synthetic.  
XX XX  
XX WO2004018676-A2.  
XX XX  
XX 04-MAR-2004.  
XX XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX XX  
XX WPI; 2004-226852/21.  
XX XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX XX  
XX Example 6; SEQ ID NO 66; 63pp; English.  
XX XX  
XX The present sequence is a human clusterin cDNA target for a double-  
CC stranded short interfering RNA (siRNA) of the invention ADL70522-  
CC ADL70523. It was used in an example from the invention to demonstrate  
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also  
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapy or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX XX  
SQ Sequence 23 BP; 5 A; 5 C; 7 G; 6 T; 0 U; 0 Other;  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 46 GCATGATGAAGACTCTGCTG 68  
Db 1 GCATGATGAAGACTCTGCTG 23

RESULT 26  
ADL70512  
ID ADL70512 standard; cDNA; 23 BP.  
XX XX  
XX AC  
XX ADL70512;  
XX XX  
XX 20-MAY-2004 (first entry)  
XX Human clusterin target for RNAi.  
XX XX

KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX WO2004018676-A2.  
PN  
XX  
XX 04-MAR-2004.  
PD  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
PF  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR  
XX 03-SEP-2002; 2002US-0408152P.  
PR  
XX 20-MAY-2003; 2003US-0472387P.  
PR  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
PI  
XX WPI; 2004-226852/21.  
DR  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
PT  
XX  
XX Example 6; SEQ ID NO 57; 63pp; English.  
PS  
XX The present sequence is a human clusterin cDNA target for a double-  
CC stranded short interfering RNA (siRNA) of the invention to demonstrate  
CC ADL70514. It was used in an example from the invention to demonstrate  
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also  
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapies or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX  
XX Sequence 23 BP; 5 A; 9 C; 3 G; 6 T; 0 U; 0 Other;  
SQ  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 480 AACGAGCTCGCCCTTCTACTT 502  
DB 1 AACGAGCTCGCCCTTCTACTT 23  
RESULT 27  
ADL70515  
ID ADL70515 standard; cDNA; 23 BP.  
XX  
XX ADL70515;  
AC  
XX 20-MAY-2004 (first entry)  
DT  
XX  
XX Human clusterin target for RNAi.  
DE  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.

XX WO2004018676-A2.  
PN  
XX  
XX 04-MAR-2004.  
PD  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
PF  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR  
XX 03-SEP-2002; 2002US-0408152P.  
PR  
XX 20-MAY-2003; 2003US-0472387P.  
PR  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
PI  
XX WPI; 2004-226852/21.  
DR  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
PT  
XX  
XX Example 6; SEQ ID NO 60; 63pp; English.  
PS  
XX The present sequence is a human clusterin cDNA target for a double-  
CC stranded short interfering RNA (siRNA) of the invention to demonstrate  
CC ADL70517. It was used in an example from the invention to demonstrate  
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also  
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapies or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX  
XX Sequence 23 BP; 4 A; 9 C; 5 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 711 AAGTCCCGCATCGTCGCGAGCTT 733  
DB 1 AAGTCCCGCATCGTCGCGAGCTT 23  
RESULT 28  
ADL70518  
ID ADL70518 standard; cDNA; 23 BP.  
XX  
XX ADL70518;  
AC  
XX 20-MAY-2004 (first entry)  
DT  
XX  
XX Human clusterin target for RNAi.  
DE  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX WO2004018676-A2.  
PN  
XX 04-MAR-2004.  
PD  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
PF

XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX WPI; 2004-226852/21.  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX Example 6; SEQ ID NO 63; 63pp; English.  
XX The present sequence is a human clusterin cDNA target for a double-  
CC stranded short interfering RNA (siRNA) of the invention ADL70519-  
CC ADL70520. It was used in an example from the invention to demonstrate  
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also  
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapies or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX Sequence 23 BP; 10 A; 4 C; 1 G; 8 T; 0 U; 0 Other;  
SQ Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1613 AACTAATTCATTAATAAAGTGTCTT 1635  
DB 1 AACTAATTCATTAATAAAGTGTCTT 23  
RESULT 29  
AAT39500  
ID AAT39500 standard; DNA; 21 BP.  
XX AC AAT39500;  
XX 21-MAY-1997 (first entry)  
XX Chromosome 8p clusterin gene (CL1) specific primer (nt 2504-2524).  
XX Chromosome 8p; polymerase chain reaction; PCR; primer; CL1;  
KW Clusterin gene; human; steroidogenesis; acute regulatory protein;  
KW regional mapping; confirmation; hSTAR; ss.  
XX Synthetic.  
XX WO9629338-A1.  
XX 26-SEP-1996.  
XX 22-MAR-1996; 96WO-US003896.  
XX 23-MAR-1995; 95US-00410540.  
XX (REGC ) UNIV CALIFORNIA.  
PA (UYPE-) UNIV PENNSYLVANIA.  
XX Miller WL, Lin D, Strauss JF;

XX WPI; 1996-443130/44.  
XX Isolated human steroidogenesis acute regulatory protein gene - used for  
PT detection of mutation(s) of this gene that cause congenital lipoid  
PT adrenal hyperplasia.  
XX Example 7; Page 51; 89pp; English.  
XX The present sequence is a human chromosome 8p clusterin gene (CL1)  
CC specific PCR primer, which was used in the confirmation of the regional  
CC mapping of the human steroidogenesis acute regulatory protein (hSTAR)  
XX Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;  
SQ Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1354 AGAAAGCGCTGCAGGAATACC 1374  
DB 1 AGAAAGCGCTGCAGGAATACC 21  
RESULT 30  
AAA52783  
ID AAA52783 standard; DNA; 21 BP.  
XX AC AAA52783;  
XX 03-JAN-2001 (first entry)  
XX Porcine clusterin PCR primer #1.  
XX Pig; clusterin; cell migration; wound healing; angiogenesis; cancer;  
KW vascular trauma; vascular disease; atherosclerosis; restenosis;  
KW complement cytotoxicity inhibitor; SP-40; 40; apoJ;  
KW testosterone repressed prostate message-2; sulfated glycoprotein-2;  
KW PCR primer; ss.  
XX Sus scrofa.  
XX WO200034469-A1.  
XX 15-JUN-2000.  
XX 10-DEC-1999; 99WO-US029262.  
XX 11-DEC-1998; 98US-0111856P.  
XX (UYNY ) UNIV NEW YORK STATE RES FOUND.  
XX Millis AJT;  
XX WPI; 2000-431300/37.  
XX Clusterin and gp38K-related peptide capable of altering cell migration  
PT useful for treating atherosclerosis, cancer and stenosis following  
PT vascular trauma or disease.  
XX Disclosure; Page 12; 43pp; English.  
XX The present sequence is a PCR primer for the porcine clusterin gene.  
CC Clusterin (also known as complement cytotoxicity inhibitor, sulfated  
CC glycoprotein-2, testosterone repressed prostate message-2, SP-40, 40 and  
CC apoJ) is essential for the migration of vascular smooth muscle cells  
CC (VSMC). The gene and protein can, therefore, be used to promote wound  
CC healing, angiogenesis and vasculogenesis, in the treatment of stenosis  
CC following vascular trauma or disease and to treat atherosclerosis, and  
CC antisense sequences can be used to treat cancer, as angiogenesis is vital  
CC for tumour survival  
XX Sequence 21 BP; 12 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

DE	Human testosterone-repressed prostate message-2 antisense oligo #7.	XX	Human; testosterone-repressed prostate message-2; TRPM-2; clusterin; sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX		OS	Homo sapiens.
XX		PN	WO200049937-A2.
XX		PD	31-AUG-2000.
XX		XX	
PF	25-FEB-2000; 2000WO-US004875.	XX	
XX		XX	
PR	26-FEB-1999; 99US-0121726P.	XX	
XX		XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.	XX	
XX		XX	
PI	Gleave M, Rennie PS, Miyake H, Nelson C;	XX	
XX		XX	
DR	WPI; 2000-533132/48.	XX	
XX		XX	
PT	Treating prostatic tumors and renal cancers by antisense inhibition of sulfated glycoprotein-2 gene.	XX	
XX		XX	
PS	Example 5; Page 37; 38pp; English.	XX	
XX		XX	
CC	The present sequence is an antisense oligonucleotide directed at the human testosterone-repressed prostate message-2 (TRPM-2, also known as clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to promote the regression of tumours, and oligonucleotides directed at human TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2 gene. These include prostate cancer, renal cell cancer and some breast cancer cells. In addition to this, they also increase the chemosensitivity of the cells, meaning that conventional chemotherapy is more effective	XX	
XX		XX	
SQ	Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;	XX	
Query Match 1.3%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 39;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	916 ACAACTCCACGGGCTGCTGC 936	QY	
DB	21 ACAACTCCACGGGCTGCTGC 1	DB	
RESULT 33			
AAA94230/c			
ID	AAA94230 standard; DNA; 21 BP.	ID	
XX		XX	
AC	AAA94230;	AC	
XX		XX	
DT	12-JAN-2001 (first entry)	DT	
XX		XX	
DE	Human testosterone-repressed prostate message-2 antisense oligo #6.	XX	
XX		XX	
KW	Human; testosterone-repressed prostate message-2; TRPM-2; clusterin; sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.	KW	
OS	Homo sapiens.	OS	
XX		XX	
PN	WO200049937-A2.	PN	
XX		XX	
PD	31-AUG-2000.	PD	
XX		XX	
PF	25-FEB-2000; 2000WO-US004875.	PF	
XX		XX	
PR	26-FEB-1999; 99US-0121726P.	PR	
XX		XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.	XX	
XX		XX	
PI	Gleave M, Rennie PS, Miyake H, Nelson C;	XX	
XX		XX	
DR	WPI; 2000-533132/48.	XX	
XX		XX	
PT	Treating prostatic tumors and renal cancers by antisense inhibition of the testosterone-repressed prostate messenger-2 gene.	XX	
XX		XX	
PS	Claim 4; Page 36; 38pp; English.	XX	
XX		XX	
CC	The present sequence is an antisense oligonucleotide directed at the human testosterone-repressed prostate message-2 (TRPM-2, also known as clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to promote the regression of tumours, and oligonucleotides directed at human TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2 gene. These include prostate cancer, renal cell cancer and some breast cancer cells. In addition to this, they also increase the chemosensitivity of the cells, meaning that conventional chemotherapy is more effective	XX	
XX		XX	
SQ	Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;	XX	
Query Match 1.3%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 39;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	114 GACCAGCGGCTCAGACAAT 134	QY	
DB	21 GACCAGCGGCTCAGACAAT 1	DB	
RESULT 32			
AAA94231/c			
ID	AAA94231 standard; DNA; 21 BP.	ID	
XX		XX	
AC	AAA94231;	AC	
XX		XX	
DT	12-JAN-2001 (first entry)	DT	
XX		XX	

```
XX
DR WPI; 2000-533132/48.
PT Treating prostatic tumors and renal cancers by antisense inhibition of
PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Example 5; Page 37; 38pp; English.
PS
CC The present sequence is an antisense oligonucleotide directed at the
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
CC promote the regression of tumours, and oligonucleotides directed at human
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
CC gene. These include prostate cancer, renal cell cancer and some breast
CC cancer cells. In addition to this, they also increase the
CC chemosensitivity of the cells, meaning that conventional chemotherapy is
CC more effective
XX
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 716 CCGCATCGTCCGAGCTTGAT 736
Db 21 CCGCATCGTCCGAGCTTGAT 1
RESULT 34
AAA94232/c
ID AAA94232 standard; DNA; 21 BP.
AC AAA94232;
XX
DT 12-JAN-2001 (first entry)
XX
DE Human testosterone-repressed prostate message-2 antisense oligo #8.
XX
KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200049937-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004875.
XX
PR 26-FEB-1999; 99US-0121726P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX
PS WPI; 2000-533132/48.
XX
PT Treating prostatic tumors and renal cancers by antisense inhibition of
PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Example 5; Page 37; 38pp; English.
PS
CC The present sequence is an antisense oligonucleotide directed at the
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
CC promote the regression of tumours, and oligonucleotides directed at human
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
CC gene. These include prostate cancer, renal cell cancer and some breast
CC cancer cells. In addition to this, they also increase the
CC chemosensitivity of the cells, meaning that conventional chemotherapy is
CC more effective
XX
```

```
SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGGAGCAGCTGAA 1
RESULT 35
AAA94233/c
ID AAA94233 standard; DNA; 21 BP.
XX
AC AAA94233;
XX
DT 12-JAN-2001 (first entry)
XX
DE Human testosterone-repressed prostate message-2 antisense oligo #9.
XX
KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200049937-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004875.
XX
PR 26-FEB-1999; 99US-0121726P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX
PS WPI; 2000-533132/48.
XX
PT Treating prostatic tumors and renal cancers by antisense inhibition of
PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Example 5; Page 38; 38pp; English.
PS
CC The present sequence is an antisense oligonucleotide directed at the
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
CC promote the regression of tumours, and oligonucleotides directed at human
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
CC gene. These include prostate cancer, renal cell cancer and some breast
CC cancer cells. In addition to this, they also increase the
CC chemosensitivity of the cells, meaning that conventional chemotherapy is
CC more effective
XX
SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1316 CTCGAGGAGAACCTTAATTT 1336
Db 21 CTCGAGGAGAACCTTAATTT 1
RESULT 36
AAA94229/c
ID AAA94229 standard; DNA; 21 BP.
XX
AC AAA94229;
XX
DT 12-JAN-2001 (first entry)
```





XX SQ Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;  
 Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCACTCGGCCAGC 1536  
 Db 21' AGGCCCCCACTCGGCCAGC 1

RESULT 39  
 AAA94228/c  
 ID AAA94228 standard; DNA; 21 BP.  
 XX  
 AC AAA94228;  
 XX  
 DT 12-JAN-2001 (first entry)  
 XX Human testosterone-repressed prostate message-2 antisense oligo #4.  
 DE Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
 KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
 XX Homo sapiens.  
 OS  
 PN WO200049937-A2.  
 XX  
 PD 31-AUG-2000.  
 XX  
 PF 25-FEB-2000; 2000WO-US004875.  
 XX  
 PR 26-FEB-1999; 99US-0121726P.  
 XX  
 PA (UYBR-) UNIV BRITISH COLUMBIA.  
 XX  
 PI Gleave M, Rennie PS, Miyake H, Nelson C;  
 XX WPI; 2000-533132/48.  
 XX  
 PT Treating prostatic tumors and renal cancers by antisense inhibition of  
 the testosterone-repressed prostate messenger-2 gene.  
 XX  
 PS Example 5; Page 36; 38pp; English.  
 XX  
 CC The present sequence is an antisense oligonucleotide directed at the  
 human testosterone-repressed prostate message-2 (TRPM-2, also known as  
 clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
 promote the regression of tumours, and oligonucleotides directed at human  
 TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
 gene. These include prostate cancer, renal cell cancer and some breast  
 cancer cells. In addition to this, they also increase the  
 chemosensitivity of the cells, meaning that conventional chemotherapy is  
 more effective  
 XX  
 SQ Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGAGACAAGCTGAAGG 336  
 Db 21 AATCAGAGACAAGCTGAAGG 1

RESULT 40  
 AAA94225/c  
 ID AAA94225 standard; DNA; 21 BP.  
 XX  
 AC AAA94225;

DT 12-JAN-2001 (first entry)  
 XX Human testosterone-repressed prostate message-2 antisense oligo #1.  
 DE Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
 KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
 XX Homo sapiens.  
 OS  
 PN WO200049937-A2.  
 XX  
 PD 31-AUG-2000.  
 XX  
 PF 25-FEB-2000; 2000WO-US004875.  
 XX  
 PR 26-FEB-1999; 99US-0121726P.  
 XX  
 PA (UYBR-) UNIV BRITISH COLUMBIA.  
 XX  
 PI Gleave M, Rennie PS, Miyake H, Nelson C;  
 XX WPI; 2000-533132/48.  
 XX  
 PT Treating prostatic tumors and renal cancers by antisense inhibition of  
 the testosterone-repressed prostate messenger-2 gene.  
 XX  
 PS Example 5; Page 36; 38pp; English.  
 XX  
 CC The present sequence is an antisense oligonucleotide directed at the  
 human testosterone-repressed prostate message-2 (TRPM-2, also known as  
 clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
 promote the regression of tumours, and oligonucleotides directed at human  
 TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
 gene. These include prostate cancer, renal cell cancer and some breast  
 cancer cells. In addition to this, they also increase the  
 chemosensitivity of the cells, meaning that conventional chemotherapy is  
 more effective  
 XX  
 SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGCGGTGCAAAAGACTCCA 36  
 Db 21 CCGAGCGGTGCAAAAGACTCCA 1

RESULT 41  
 AAF97658  
 ID AAF97658 standard; DNA; 21 BP.  
 XX  
 AC AAF97658;  
 XX  
 DT 18-NOV-2004 (revised)  
 DT 06-JUN-2001 (first entry)  
 XX  
 DE Human gene single nucleotide polymorphism #2419.  
 XX  
 KW Human; variant thrombospondin 1; variant thrombospondin 4; SNP;  
 KW polymorphism; vascular disease; coronary artery disease; forensics;  
 KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;  
 KW pulmonary embolism; paternity test; ds.  
 XX  
 OS Homo sapiens.  
 OS Unidentified.  
 XX  
 PH Key Location/Qualifiers  
 FT variation 11  
 FT /\*tag= a  
 FT /standard\_name= "Single nucleotide polymorphism"  
 XX

```
PN WO200118250-A2.
XX
XX
PD 15-MAR-2001.
XX
XX PF 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX
XX WPI; 2001-226749/23.
DR
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 212; 242pp; English.
PS
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC
CC Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a captial V
XX
XX Sequence 21 BP; 7 A; 7 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1170 CTCACGCAAGCGGAGACCCAG 1190
DB 1 CTCACGCAAGCGGAGACCCAG 21
RESULT 42
AAF97656
ID AAF97656 standard; DNA; 21 BP.
XX
XX AAF97656;
AC
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #2417.
DE
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS Unidentified.
XX
XX Key Location/Qualifiers
FH variation 11
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"
```

```
XX WO200118250-A2.
XX
XX
PD 15-MAR-2001.
XX
XX PF 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX
XX WPI; 2001-226749/23.
DR
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 212; 242pp; English.
PS
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC
CC Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a captial V
XX
XX Sequence 21 BP; 8 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1050 GAGAGGTTGACCAGGAATAC 1070
DB 1 GAGAGGTTGACCAGGAATAC 21
RESULT 43
AAF97657
ID AAF97657 standard; DNA; 21 BP.
XX
XX AAF97657;
AC
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #2418.
DE
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS Unidentified.
XX
XX Key Location/Qualifiers
FH variation 11
FT /*tag= a
FT
```

```
FT      /standard_name= "Single nucleotide polymorphism"
XX      /*tag= a
XX      /standard_name= "Single nucleotide polymorphism"
PN      WO200118250-A2.
XX
XX      15-MAR-2001.
PD
XX
XX      07-SEP-2000; 2000WO-US024503.
XX
XX      10-SEP-1999; 99US-0153357P.
XX      26-JUL-2000; 2000US-0220947P.
PR      16-AUG-2000; 2000US-0225724P.
XX
XX      (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX      (MILL-) MILLENNIUM PHARM INC.
PA
XX      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX      WPI; 2001-226749/23.
DR
XX
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
XX      applications such as forensics, paternity testing, medicine, genetic
XX      analysis and phenotype correlations to diseases such as diabetes and
XX      atherosclerosis.
XX
XX      Example; Page 213; 242pp; English.
XX
XX      The present invention provides a method of diagnosing a vascular disease
XX      in an individual, involving determining the sequence at various
XX      polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX      genes. The sequences at a number of polymorphic sites are also provided
XX      in the specification. In particular, the method can be used in the
XX      diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX      disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX      pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX      useful in forensics, paternity testing, genetic analysis and phenotype
XX      correlations to diseases. The present sequence is an example of one of
XX      the human gene SNPs shown in the specification
XX
XX      Revised record issued on 18-NOV-2004 : The variation feature was
XX      incorrectly given a capital V
XX
XX      Sequence 21 BP; 3 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX      Query Match      1.3%; Score 21; DB 1; Length 21;
XX      Best Local Similarity 100.0%; Pred. No. 39;
XX      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY      1105 TCAACACCTCCTCTGCTGG 1125
Db      1 TCAACACCTCCTCTGCTGG 21

RESULT 45
ABN99659
ID      ABN99659 standard; DNA; 21 BP.
XX
XX      AC      ABN99659;
XX
XX      DT      16-AUG-2002 (first entry)
XX
XX      DE      Human clusterin PCR probe.
XX
XX      KW      Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX      hypercholesterolaemia; cardiovascular disorder; ss; PCR; probe;
XX      hyperproliferative disorder; hyperlipidemic disorder.
XX
XX      OS      Homo sapiens.
XX
XX      PN      WO200222635-A1.
XX
XX      PD      21-MAR-2002.
XX
```

```
FT      /standard_name= "Single nucleotide polymorphism"
XX      /*tag= a
XX      /standard_name= "Single nucleotide polymorphism"
PN      WO200118250-A2.
XX
XX      15-MAR-2001.
PD
XX
XX      07-SEP-2000; 2000WO-US024503.
XX
XX      10-SEP-1999; 99US-0153357P.
XX      26-JUL-2000; 2000US-0220947P.
PR      16-AUG-2000; 2000US-0225724P.
XX
XX      (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX      (MILL-) MILLENNIUM PHARM INC.
PA
XX      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX      WPI; 2001-226749/23.
DR
XX
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
XX      applications such as forensics, paternity testing, medicine, genetic
XX      analysis and phenotype correlations to diseases such as diabetes and
XX      atherosclerosis.
XX
XX      Example; Page 212; 242pp; English.
XX
XX      The present invention provides a method of diagnosing a vascular disease
XX      in an individual, involving determining the sequence at various
XX      polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX      genes. The sequences at a number of polymorphic sites are also provided
XX      in the specification. In particular, the method can be used in the
XX      diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX      disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX      pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX      useful in forensics, paternity testing, genetic analysis and phenotype
XX      correlations to diseases. The present sequence is an example of one of
XX      the human gene SNPs shown in the specification
XX
XX      Revised record issued on 18-NOV-2004 : The variation feature was
XX      incorrectly given a capital V
XX
XX      Sequence 21 BP; 3 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX      Query Match      1.3%; Score 21; DB 1; Length 21;
XX      Best Local Similarity 100.0%; Pred. No. 39;
XX      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY      999 CCTCCAGGCTAAGTCGG 1019
Db      1 CCTCCAGGCTAAGTCGG 21

RESULT 44
AAF97659
ID      AAF97659 standard; DNA; 21 BP.
XX
XX      AC      AAF97659;
XX
XX      DT      18-NOV-2004 (revised)
XX      06-JUN-2001 (first entry)
XX
XX      DE      Human gene single nucleotide polymorphism #2420.
XX
XX      KW      Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX      polymorphism; vascular disease; coronary artery disease; forensics;
XX      myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX      pulmonary embolism; paternity test; ds.
XX
XX      OS      Homo sapiens.
XX
XX      OS      Unidentified.
XX
XX      Key      Location/Qualifiers
XX      variation 11
XX
```

PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
DR WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Example 13; Page 80; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a PCR probe specific for the human clusterin  
CC gene. NOTE: The present sequence is labelled with a fluorescent reporter  
CC dye (FAM) and a quencher dye (TAMRA)  
XX  
SQ Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;  
  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 766 TCCACGCCATGTTCCAGCCCT 786  
DB 1 TCCACGCCATGTTCCAGCCCT 21  
  
RESULT 46  
ACF36397/c  
ID ACF36397 standard; DNA; 21 BP.  
XX  
AC ACF36397;  
XX  
XX 18-DEC-2003 (first entry)  
DT  
XX  
DE TRPM-2 antisense oligonucleotide.  
XX  
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
XX  
OS Synthetic.  
XX Homo sapiens.  
XX WO2003072591-A1.  
XX  
PD 04-SEP-2003.  
XX  
XX 20-FEB-2003; 2003WO-US005305.  
XX  
XX 22-FEB-2002; 2002US-00080794.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
PI  
XX WPI; 2003-689981/65.  
XX  
XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Example 5; Page 40; 44pp; English.

CC The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents an  
CC anti-apoptotic protein TRPM-2 (testosterone-repressed prostate message-2)  
CC antisense oligonucleotide  
XX  
SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;  
  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 16 CCGAGGCGTGCAAGACTCCA 36  
DB 21 CCGAGGCGTGCAAGACTCCA 1  
  
RESULT 47  
ACF36405/c  
ID ACF36405 standard; DNA; 21 BP.  
XX  
AC ACF36405;  
XX  
XX 18-DEC-2003 (first entry)  
DT  
XX  
DE TRPM-2 antisense oligonucleotide #11.  
XX  
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
XX  
OS Synthetic.  
XX Homo sapiens.  
XX WO2003072591-A1.  
XX  
PD 04-SEP-2003.  
XX  
XX 20-FEB-2003; 2003WO-US005305.  
XX  
XX 22-FEB-2002; 2002US-00080794.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
PI  
XX WPI; 2003-689981/65.  
XX  
XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Example 5; Page 42; 44pp; English.  
XX  
XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
XX

CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene  
XX  
SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCGAGGAGAACCTAAATT 1336

DB 21 CTCGAGGAGAACCTAAATT 1

RESULT 48

ACF36406/C

ID ACF36406 standard; DNA; 21 BP.

XX AC ACF36406;

DT 18-DEC-2003 (first entry)

XX TRPM-2 antisense oligonucleotide #12.

XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.

OS Synthetic.

OS Homo sapiens.

XX WO2003072591-A1.

XX 04-SEP-2003.

XX 20-FEB-2003; 2003WO-US005305.

XX 22-FEB-2002; 2002US-00080794.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;

XX WPI; 2003-689981/65.

XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.

XX Example 5; Page 42; 44pp; English.

XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent

CC antisense oligonucleotides targeted against human anti-apoptotic protein  
XX TRPM-2 (testosterone-repressed prostate message-2) gene  
SQ Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCAGC 1536

DB 21 AGGCCCCCAACTCCGCCAGC 1

RESULT 49

ACF36399/C

ID ACF36399 standard; DNA; 21 BP.

XX AC ACF36399;

XX 18-DEC-2003 (first entry)

XX TRPM-2 antisense oligonucleotide #5.

XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.

OS Synthetic.

OS Homo sapiens.

XX WO2003072591-A1.

XX 04-SEP-2003.

XX 20-FEB-2003; 2003WO-US005305.

XX 22-FEB-2002; 2002US-00080794.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;

XX WPI; 2003-689981/65.

XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.

XX Example 5; Page 40; 44pp; English.

XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene

XX Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

ID      114 GACCAGACGGTCTCAGACAAT 134
AC      |||||
XX      |||||
DT      |||||
DB      21 GACCAGACGGTCTCAGACAAT 1

RESULT 50
ACF36402/c
ID      ACF36402 standard; DNA; 21 BP.
XX
AC      ACF36402;
XX
DT      18-DEC-2003 (first entry)
XX
DE      TRPM-2 antisense oligonucleotide #8.
XX
KW      TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW      prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS      Synthetic.
OS      Homo sapiens.
XX
PN      WO2003072591-A1.
XX
PD      04-SEP-2003.
XX
PF      20-FEB-2003; 2003WO-US005305.
XX
PR      22-FEB-2002; 2002US-00080794.
XX
PA      (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI      Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX      WPI; 2003-689981/65.
XX
PT      New modified antisense oligonucleotide, useful particularly for treating
PT      prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
PS      Example 5; Page 41; 44pp; English.
XX
CC      The invention relates to a compound consisting of an oligonucleotide with
CC      a phosphorothioate backbone throughout, in which: (a) sugars on
CC      nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC      remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC      positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC      ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC      prostatic cancer cells to the androgen-independent state, in vivo or in
CC      vitro; (b) to treat prostatic cancer (after initially withdrawing of cancer
CC      androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC      cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC      ovarian and some breast cancer cells) that express abnormal levels of
CC      TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC      increase stability in vivo and activity (both in vivo or in vitro) and
CC      result in a synergistic increase in effect when (I) is used with
CC      chemotherapeutic agents or other antisense oligonucleotides directed
CC      against other antiapoptotic genes. Sequences ACF36399-406 represent
CC      antisense oligonucleotides targeted against human anti-apoptotic protein
CC      TRPM-2 (testosterone-repressed prostate message-2) gene
XX
SQ      Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      716 CCGCATCGTCCGAGCTTGAT 736
DB      |||||
        21 CCGCATCGTCCGAGCTTGAT 1

RESULT 51
ACF36401/c
ID      ACF36401 standard; DNA; 21 BP.
XX
AC      ACF36401;
XX
DT      18-DEC-2003 (first entry)
XX
DE      TRPM-2 antisense oligonucleotide #7.
XX
KW      TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW      prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS      Synthetic.
OS      Homo sapiens.
XX
PN      WO2003072591-A1.
XX
PD      04-SEP-2003.
XX
PF      20-FEB-2003; 2003WO-US005305.
XX
PR      22-FEB-2002; 2002US-00080794.
XX
PA      (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI      Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX      WPI; 2003-689981/65.
XX
PT      New modified antisense oligonucleotide, useful particularly for treating
PT      prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
PS      Example 5; Page 41; 44pp; English.
XX
CC      The invention relates to a compound consisting of an oligonucleotide with
CC      a phosphorothioate backbone throughout, in which: (a) sugars on
CC      nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC      remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC      positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC      ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC      prostatic cancer cells to the androgen-independent state, in vivo or in
CC      vitro; (b) to treat prostatic cancer (after initially withdrawing of cancer
CC      androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC      cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC      ovarian and some breast cancer cells) that express abnormal levels of
CC      TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC      increase stability in vivo and activity (both in vivo or in vitro) and
CC      result in a synergistic increase in effect when (I) is used with
CC      chemotherapeutic agents or other antisense oligonucleotides directed
CC      against other antiapoptotic genes. Sequences ACF36399-406 represent
CC      antisense oligonucleotides targeted against human anti-apoptotic protein
CC      TRPM-2 (testosterone-repressed prostate message-2) gene
XX
SQ      Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      515 TGACCGCATCGACTCCCTGCT 535
DB      |||||
        21 TGACCGCATCGACTCCCTGCT 1

RESULT 52
ACF36398/c
ID      ACF36398 standard; DNA; 21 BP.
XX
AC      ACF36398;
XX
DT      18-DEC-2003 (first entry)
XX
DE      TRPM-2 antisense oligonucleotide.
XX
```



PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
XX WPI; 2003-689981/65.  
XX  
XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Example 5; Page 41; 44pp; English.  
XX  
XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene  
XX  
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
DB 21 CTCCTTGCTGGAGCAGCTGAA 1  
RESULT 55  
ACF36400/C  
ID ACF36400 standard; DNA; 21 BP.  
XX  
XX ACF36400;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX TRPM-2 antisense oligonucleotide #6.  
XX  
XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
XX  
XX Synthetic.  
OS Homo sapiens.  
XX  
XX WO2003072591-A1.  
XX  
XX 04-SEP-2003.  
XX  
XX 20-FEB-2003; 2003WO-US005305.  
XX  
XX 22-FEB-2002; 2002US-00080794.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
PI WPI; 2003-689981/65.  
XX  
XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Example 5; Page 40; 44pp; English.  
PS  
The invention relates to a compound consisting of an oligonucleotide with  
a phosphorothioate backbone throughout, in which: (a) sugars on  
nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
prostatic cancer cells to the androgen-independent state, in vivo or in  
vitro; (b) to treat prostatic cancer (after initially withdrawing  
androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
cells (prostatic, renal, non-small cell lung, urothelial transitional,  
ovarian and some breast cancer cells) that express abnormal levels of  
TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
increase stability in vivo and activity (both in vivo or in vitro) and  
result in a synergistic increase in effect when (I) is used with  
chemotherapeutic agents or other antisense oligonucleotides directed  
against other antiapoptotic genes. Sequences ACF36399-406 represent  
antisense oligonucleotides targeted against human anti-apoptotic protein  
TRPM-2 (testosterone-repressed prostate message-2) gene  
Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 316 AATCAGACACAAAGCTGAAG 336  
DB 21 AATCAGACACAAAGCTGAAG 1  
RESULT 56  
ADP75347  
ID ADP75347 standard; DNA; 21 BP.  
XX  
XX ADP75347;  
XX  
XX 26-FEB-2004 (first entry)  
XX  
XX Human RT-PCR primer to amplify an epigenetically silenced gene (SeqID27).  
XX  
XX human; primer; RT-PCR; PCR; ss; epigenetically silenced gene;  
KW tumour suppressor; cancer; proliferative disorder; head and neck cancer;  
KW oesophageal squamous cell carcinoma; ESCC; gene therapy;  
KW methyltransferase inhibitor; 5Aza-dC; histone deacetylase inhibitor.  
XX  
XX Homo sapiens.  
XX  
XX WO2003076594-A2.  
XX  
XX 18-SEP-2003.  
XX  
XX 07-MAR-2003; 2003WO-US007245.  
XX  
XX 07-MAR-2002; 2002US-0362577P.  
XX  
XX (UYJO ) UNIV JOHNS HOPKINS.  
XX  
XX Sidransky D;  
XX  
XX WPI; 2003-756817/71.  
XX  
XX Identifying at least one epigenetically silenced gene associated with  
cancer useful for treating cancer comprises contacting an array of genome  
PT with nucleic acid molecule that reactivates expression of epigenetically  
PT silenced gene.  
XX  
XX Example 1; SEQ ID NO 27; 97pp; English.  
XX  
XX This invention relates to novel methods of screening to identify  
CC epigenetically silenced genes. Specifically, it refers to the detection  
CC of epigenetically silenced tumour suppressor genes in cancer cells, which  
CC are transcriptionally inactive due to aberrant methylation at normally



CC unmethylated CpG islands. Accordingly, these genes provide diagnostic  
CC markers for immortalised and transformed cells and hence can be used to  
CC diagnose various proliferative disorders, particularly oesophageal cancer  
CC and head and neck cancer. The present invention describes a genomic  
CC screening method to identify silenced genes in a cell suspected of a  
CC predisposition to, or exhibiting, unregulated growth. Accordingly,  
CC oligonucleotides of the genes identified herein are useful for detecting  
CC oesophageal squamous cell carcinoma (ESCC) or neck squamous cell  
CC carcinoma. Furthermore, treatment can occur via gene therapy, using a  
CC demethylation agent such as a methyltransferase inhibitor (5aza-dC) or a  
CC histone deacetylase inhibitor to restore expression of at least one  
CC methylation silenced gene in cancer cells. This oligonucleotide sequence  
CC is an RT-PCR primer used to amplify those genes that were up-regulated as  
CC a result of treatment with a demethylation agent i.e epigenetically  
CC silenced genes of the invention.

XX  
SQ Sequence 21 BP; 6 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 ACAACCCCTCCCGGCTAAGC 1014  
DB 1 ACAACCCCTCCCGGCTAAGC 21

RESULT 57  
ADF75348/c  
ID ADF75348 standard; DNA; 21 BP.  
XX  
AC ADF75348;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE Human RT-PCR primer to amplify an epigenetically silenced gene (SeqID28).  
XX  
DE human; primer; RT-PCR; PCR; ss; epigenetically silenced gene;  
KW tumour suppressor; cancer; proliferative disorder; head and neck cancer;  
KW oesophageal squamous cell carcinoma; ESCC; gene therapy;  
KW methyltransferase inhibitor; 5aza-dC; histone deacetylase inhibitor.  
XX  
OS Homo sapiens.  
XX  
PN WQ2003076594-A2.  
XX  
PD 18-SEP-2003.  
XX  
PF 07-MAR-2003; 2003WO-US007245.  
XX  
PR 07-MAR-2002; 2002US-0362577P.  
XX  
PA (UYJO ) UNIV JOHNS HOPKINS.  
XX  
PI Sidransky D;  
XX  
DR WPI; 2003-756817/71.  
XX  
PT Identifying at least one epigenetically silenced gene associated with  
PT cancer useful for treating cancer comprises contacting an array of genome  
PT with nucleic acid molecule that reactivates expression of epigenetically  
PT silenced gene.  
XX  
PS Example 1; SEQ ID NO 28; 97pp; English.  
XX  
CC This invention relates to novel methods of screening to identify  
CC epigenetically silenced genes. Specifically, it refers to the detection  
CC of epigenetically silenced tumour suppressor genes in cancer cells, which  
CC are transcriptionally inactive due to aberrant methylation at normally  
CC unmethylated CpG islands. Accordingly, these genes provide diagnostic  
CC markers for immortalised and transformed cells and hence can be used to  
CC diagnose various proliferative disorders, particularly oesophageal cancer  
CC and head and neck cancer. The present invention describes a genomic

CC screening method to identify silenced genes in a cell suspected of a  
CC predisposition to, or exhibiting, unregulated growth. Accordingly,  
CC oligonucleotides of the genes identified herein are useful for detecting  
CC oesophageal squamous cell carcinoma (ESCC) or neck squamous cell  
CC carcinoma. Furthermore, treatment can occur via gene therapy, using a  
CC demethylation agent such as a methyltransferase inhibitor (5aza-dC) or a  
CC histone deacetylase inhibitor to restore expression of at least one  
CC methylation silenced gene in cancer cells. This oligonucleotide sequence  
CC is an RT-PCR primer used to amplify those genes that were up-regulated as  
CC a result of treatment with a demethylation agent i.e epigenetically  
CC silenced genes of the invention.

XX  
SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1334 ATTTATGGAGACCGTGGCGGA 1354  
DB 21 ATTTATGGAGACCGTGGCGGA 1

RESULT 58  
ADM83075/c  
ID ADM83075 standard; DNA; 21 BP.  
XX  
AC ADM83075;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #10.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 10; 14pp; English.  
XX

CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
CC  
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1  
RESULT 59  
ADM83077/c  
ID ADM83077 standard; DNA; 21 BP.  
XX  
AC ADM83077;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #12.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US0004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Claim 6; SEQ ID NO 12; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
CC  
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
SQ

CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
CC  
XX Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1516 AGGCCCCCAACTCGCCGAGC 1536  
Db 21 AGGCCCCCAACTCGCCGAGC 1  
RESULT 60  
ADM83072/c  
ID ADM83072 standard; DNA; 21 BP.  
XX  
AC ADM83072;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #7.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US0004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 7; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The

CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX  
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 515 TGACCGCATCGACTCCCTGCT 535  
DB 21 TGACCGCATCGACTCCCTGCT 1  
RESULT 61  
ADM83074/c  
ID ADM83074 standard; DNA; 21 BP.  
XX  
AC  
XX  
AC  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #9.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 9; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
sensitivity of cancer cells for treating cancer such as prostate cancer,  
bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX

SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 916 ACAACTCCACGGCTGCTGTC 936  
DB 21 ACAACTCCACGGCTGCTGTC 1  
RESULT 62  
ADM83076/c  
ID ADM83076 standard; DNA; 21 BP.  
XX  
AC  
XX  
AC  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #11.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 11; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
sensitivity of cancer cells for treating cancer such as prostate cancer,  
bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX  
SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;		0; Indels 0; Gaps 0;	
Matches 21; Conservative 0; Mismatches			
Qy	1316 CTCCAGGAAGAACCTTAATT 1336		
Db	21 CTCCAGGAAGAACCTTAATT 1		
RESULT 63			
ADM83068/c			
ID	ADM83068 standard; DNA; 21 BP.		
XX			
AC	ADM83068;		
DT	03-JUN-2004 (first entry)		
DE	Human TRPM-2 antisense oligonucleotide #3.		
XX			
KW	Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;		
KW	radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;		
KW	lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;		
KW	antisense; ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
FH	Key Location/Qualifiers		
FT	modified_base 1..21		
FT	/*tag= a		
FT	/mod_base= OTHER		
FT	/note= "Phosphorothioate backbone"		
XX			
PN	US2003158130-A1.		
XX			
PD	21-AUG-2003.		
XX			
PF	28-SEP-2001; 2001US-00967726.		
XX			
PR	25-FEB-2000; 2000WO-US004875.		
PR	28-SEP-2000; 2000US-0236301P.		
PR	10-AUG-2001; 2001US-00913325.		
XX			
PA	(GLEA/) GLEAVE M.		
PA	(RENN/) RENNIE P S.		
PA	(MIYA/) MIYAKE H.		
PA	(NELS/) NELSON C.		
PA	(ZELL/) ZELLWEGER T.		
XX			
PI	Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;		
XX			
DR	WPI; 2003-778017/73.		
XX			
PT	Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells		
PT	that expresses testosterone-repressed prostate message-2 (TRPM-2)		
PT	comprises administering a composition that inhibits expression of TRPM-2.		
XX			
PS	Disclosure; SEQ ID NO 3; 14pp; English.		
XX			
CC	The present invention provides a method for treating cancer in which		
CC	cancer cells express testosterone-repressed prostate message-2 (TRPM-2).		
CC	The invention is useful for enhancing the chemo-sensitivity or radiation-		
CC	sensitivity of cancer cells for treating cancer such as prostate cancer,		
CC	bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma		
CC	(RCC). The invention is also useful in antisense gene therapy. The		
CC	present sequence is human testosterone-repressed prostate message-2 (TRPM		
CC	-2) antisense oligodeoxyribonucleotide (ODN).		
XX			
SQ	Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;		
Query Match 1.3%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 39;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	48 ATGATGAAGACTCTGCTGCTG 68		
Db	21 ATGATGAAGACTCTGCTGCTG 1		

Best Local Similarity 100.0%; Pred. No. 39;		0; Indels 0; Gaps 0;	
Matches 21; Conservative 0; Mismatches			
Qy	16 CCGAGGGCTGCAAAAGACTCCA 36		
Db	21 CCGAGGGCTGCAAAAGACTCCA 1		
RESULT 64			
ADM83069/c			
ID	ADM83069 standard; DNA; 21 BP.		
XX			
AC	ADM83069;		
DT	03-JUN-2004 (first entry)		
DE	Human TRPM-2 antisense oligonucleotide #4.		
XX			
KW	Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;		
KW	radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;		
KW	lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;		
KW	antisense; ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
FH	Key Location/Qualifiers		
FT	modified_base 1..21		
FT	/*tag= a		
FT	/mod_base= OTHER		
FT	/note= "Phosphorothioate backbone"		
XX			
PN	US2003158130-A1.		
XX			
PD	21-AUG-2003.		
XX			
PF	28-SEP-2001; 2001US-00967726.		
XX			
PR	25-FEB-2000; 2000WO-US004875.		
PR	28-SEP-2000; 2000US-0236301P.		
PR	10-AUG-2001; 2001US-00913325.		
XX			
PA	(GLEA/) GLEAVE M.		
PA	(RENN/) RENNIE P S.		
PA	(MIYA/) MIYAKE H.		
PA	(NELS/) NELSON C.		
PA	(ZELL/) ZELLWEGER T.		
XX			
PI	Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;		
XX			
DR	WPI; 2003-778017/73.		
XX			
PT	Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells		
PT	that expresses testosterone-repressed prostate message-2 (TRPM-2)		
PT	comprises administering a composition that inhibits expression of TRPM-2.		
XX			
PS	Claim 4; SEQ ID NO 4; 14pp; English.		
XX			
CC	The present invention provides a method for treating cancer in which		
CC	cancer cells express testosterone-repressed prostate message-2 (TRPM-2).		
CC	The invention is useful for enhancing the chemo-sensitivity or radiation-		
CC	sensitivity of cancer cells for treating cancer such as prostate cancer,		
CC	bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma		
CC	(RCC). The invention is also useful in antisense gene therapy. The		
CC	present sequence is human testosterone-repressed prostate message-2 (TRPM		
CC	-2) antisense oligodeoxyribonucleotide (ODN).		
XX			
SQ	Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;		
Query Match 1.3%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 39;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	48 ATGATGAAGACTCTGCTGCTG 68		
Db	21 ATGATGAAGACTCTGCTGCTG 1		

ADM83073/c  
ID ADM83073 standard; DNA; 21 BP.  
XX  
AC ADM83073;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #8.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX WPI; 2003-778017/73.  
XX  
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 8; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX  
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 716 CCGCATCGTCGCGAGCTTGAT 736  
Db 21 CCGCATCGTCGCGAGCTTGAT 1  
RESULT 67  
ADM83071/c  
ID ADM83071 standard; DNA; 21 BP.  
XX

RESULT 65  
ADM83070/c  
ID ADM83070 standard; DNA; 21 BP.  
XX  
AC ADM83070;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #5.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX WPI; 2003-778017/73.  
XX  
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Claim 5; SEQ ID NO 5; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX  
SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 114 GACCAGACGGTCTCAGACAAT 134  
Db 21 GACCAGACGGTCTCAGACAAT 1  
RESULT 66

AC ADM83071;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #6.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
XX WPI; 2003-778017/73.  
DR  
XX  
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX comprises administering a composition that inhibits expression of TRPM-2.  
XX  
XX Disclosure; SEQ ID NO 6; 14pp; English.  
PS  
XX The present invention provides a method for treating cancer in which  
XX cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
XX The invention is useful for enhancing the chemo-sensitivity or radiation-  
XX sensitivity of cancer cells for treating cancer such as prostate cancer,  
XX bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
XX (RCC). The invention is also useful in antisense gene therapy. The  
XX present sequence is human testosterone-repressed prostate message-2 (TRPM  
XX -2) antisense oligodeoxynucleotide (ODN).  
XX  
XX Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 316 AATCAGACAAAGCTGAAGG 336  
DB 21 AATCAGACAAAGCTGAAGG 1  
RESULT 68  
ADL70456  
ID ADL70456 standard; RNA; 21 BP.  
XX  
AC ADL70456;  
XX  
DT 20-MAY-2004 (first entry)

XX RNAi for human clusterin.  
DE  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
PN WO2004018676-A2.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001277.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX  
XX WPI; 2004-226852/21.  
DR  
XX New RNA molecule less than 49 bases and having a sequence effective to  
XX mediate degradation or block translation of mRNA that is the  
XX transcriptional product of a target gene, useful for treating Alzheimer's  
XX disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 1; 63pp; English.  
PS  
XX The present sequence is the sense strand of a short interfering RNA  
XX (siRNA) targeted to nucleotides 487-505 of human clusterin cDNA. The  
XX antisense strand is also provided ADL70457. The siRNA can be used to  
XX interfere with the expression of clusterin. Clusterin, also known as  
XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
XX tumour cells following androgen withdrawal, and has also been shown to be  
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.  
XX siRNAs of the invention can be used alone or in combination with other  
XX chemotherapies or apoptosis inducing treatments for the treatment of  
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
XX anaplastic large cell lymphoma and melanoma, and also for the treatment  
XX of Alzheimer's disease.  
XX  
XX Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 81.0%; Pred. No. 39;  
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 482 CCAGAGCTCGCCCTTCTACTT 502  
DB 1 CCAGAGCTCGCCCTTCTACTT 21  
RESULT 69  
ADL70460  
ID ADL70460 standard; RNA; 21 BP.  
XX  
AC ADL70460;  
XX  
XX 20-MAY-2004 (first entry)  
DT

XX RNAi for human clusterin.  
DE RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
OS Homo sapiens.  
OS Synthetic.  
XX Key Location/Qualifiers  
FH modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
PN WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
PI  
XX WPI; 2004-226852/21.  
DR  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 58; 63pp; English.  
XX  
XX The present sequence is the sense strand of a short interfering RNA  
CC (siRNA) targeted to a specific portion ADL70512 of human clusterin cDNA.  
CC The antisense strand is also provided ADL70514. The siRNA can be used to  
CC interfere with the expression of clusterin. Clusterin, also known as  
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapy or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease. In an example from the invention, the present  
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3  
CC prostate cancer cells. A reduction in clusterin transcript was observed.  
XX  
SQ Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 81.0%; Pred. No. 39;  
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 482 CCAGAGCTGCGCCCTTCTACTT 502  
DB 1 CCAGAGCTGCGCCCTTCTACTT 21  
RESULT 71  
ADL70458  
ID ADL70458 standard; RNA; 21 BP.  
XX  
AC ADL70458;

XX RNAi for human clusterin.  
DE RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
OS Homo sapiens.  
OS Synthetic.  
XX Key Location/Qualifiers  
FH modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
PN WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
PI  
XX WPI; 2004-226852/21.  
DR  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 5; 63pp; English.  
XX  
XX The present sequence is the sense strand of a short interfering RNA  
CC (siRNA) targeted to nucleotides 1620-1638 of human clusterin cDNA. The  
CC antisense strand is also provided ADL70461. The siRNA can be used to  
CC interfere with the expression of clusterin. Clusterin, also known as  
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapy or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX  
SQ Sequence 21 BP; 8 A; 4 C; 1 G; 2 T; 6 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 39;  
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 1615 CTAATTCATATAAACTGCTCT 1635  
DB 1 CUAUUUCAAUAAAACUGUCTT 21  
RESULT 70  
ADL70513  
ID ADL70513 standard; RNA; 21 BP.  
XX  
AC ADL70513;  
XX  
DT 20-MAY-2004 (first entry)

```
XX 20-MAY-2004 (first entry)
DT RNAi for human clusterin.
DE
DE RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX Homo sapiens.
OS Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dTdT"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Claim 4; SEQ ID NO 3; 63pp; English.
XX
XX The present sequence is the sense strand of a short interfering RNA
CC (siRNA) targeted to nucleotides 1105-1123 of human clusterin cDNA. The
CC antisense strand is also provided ADL70459. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease.
XX
XX Sequence 21 BP; 4 A; 9 C; 2 G; 2 T; 4 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1100 GATGCTCAACACCTCTCTT 1120
||:|||||:||||:||||
Db 1 GAUGUCUACACCUCCCTT 21
RESULT 72
ADL70520/c
ID ADL70520 standard; RNA; 21 BP.
XX
AC ADL70520;
```

```
XX 20-MAY-2004 (first entry)
DT RNAi for human clusterin.
DE
DE RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX Homo sapiens.
OS Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dTdT"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Claim 4; SEQ ID NO 65; 63pp; English.
XX
XX The present sequence is the antisense strand of a short interfering RNA
CC (siRNA) targeted to a specific portion ADL70518 of human clusterin cDNA.
CC The sense strand is also provided ADL70519. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease. In an example from the invention, the present
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC prostate cancer cells. A reduction in clusterin transcript was observed.
XX
XX Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1613 AACATAATTCAATAAACTGTC 1633
|||||:|||||:|||||
Db 21 AACATAATTCAATAAACTGTC 1
RESULT 73
ADL70461/c
ID ADL70461 standard; RNA; 21 BP.
```



RESULT 75

XX	ADL70461;
XX	20-MAY-2004 (first entry)
XX	RNAi for human clusterin.
DE	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX	cytostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
XX	58.
OS	Homo sapiens.
OS	Synthetic.
XX	Key
XX	Location/Qualifiers
FT	modified_base 20..21
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= dtdt"
XX	WO2004018676-A2.
XX	04-MAR-2004.
XX	21-AUG-2003; 2003WO-CA001277.
XX	21-AUG-2002; 2002US-0405193P.
PR	03-SEP-2002; 2002US-0408152P.
PR	20-MAY-2003; 2003US-0472387P.
XX	(UYBR-) UNIV BRITISH COLUMBIA.
XX	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI	Gonos ES;
XX	WPI; 2004-226852/21.
XX	New RNA molecule less than 49 bases and having a sequence effective to
DR	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
XX	Claim 4; SEQ ID NO 6; 63pp; English.
XX	The present sequence is the antisense strand of a short interfering RNA
CC	(siRNA) targeted to nucleotides 1620-1638 of human clusterin cDNA. The
CC	sense strand is also provided ADL70460. The siRNA can be used to
CC	interfere with the expression of clusterin. Clusterin, also known as
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC	tumour cells following androgen withdrawal, and has also been shown to be
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC	siRNAs of the invention can be used alone or in combination with other
CC	chemotherapy or apoptosis inducing treatments for the treatment of
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment
CC	of Alzheimer's disease.
XX	Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;
SQ	Query Match 1.3%; Score 21; DB 1; Length 21;
	Best Local Similarity 100.0%; Pred. No. 39;
	Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1613 AACTAATTCAATAAACTGTC 1633
Db	21 AACTAATTCAATAAACTGTC 1
RESULT 74	
ADL70519	
AD	ADL70519 standard; RNA; 21 BP.

RESULT 76	ADL70517/C	ADL70517 standard; RNA; 21 BP.
ID	ADL70516	ADL70516 standard; RNA; 21 BP.
XX	ADL70517	
AC	ADL70516;	
XX	20-MAY-2004 (first entry)	
DT		
XX	RNAi for human clusterin.	
DE		
XX	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;	
KW	cytostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;	
KW	ss.	
KW		
XX	Homo sapiens.	
OS	Synthetic.	
XX		
FH	Key	Location/Qualifiers
FT	modified_base	20..21
FT		/*tag= a
FT		/mod_base= OTHER
FT		/note= "OTHER= dtdt"
XX		
XX	WO2004018676-A2.	
PN		
XX		
PD	04-MAR-2004.	
XX		
PF	21-AUG-2003; 2003WO-CA001277.	
XX		
PR	21-AUG-2002; 2002US-0405193P.	
PR	03-SEP-2002; 2002US-0408152P.	
PR	20-MAY-2003; 2003US-0472387P.	
XX		
PA	(UYBR-) UNIV BRITISH COLUMBIA.	
XX		
XX	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;	
PI	Gonos ES;	
XX		
DR	WPI; 2004-226852/21.	
XX		
XX	New RNA molecule less than 49 bases and having a sequence effective to	
PT	mediate degradation or block translation of mRNA that is the	
PT	transcriptional product of a target gene, useful for treating Alzheimer's	
PT	disease or cancer.	
XX		
XX	Claim 4; SEQ ID NO 62; 63pp; English.	
PS		
XX	The present sequence is the antisense strand of a short interfering RNA	
CC	(siRNA) targeted to a specific portion ADL70515 of human clusterin cDNA.	
CC	The sense strand is also provided ADL70516. The siRNA can be used to	
CC	interfere with the expression of clusterin. Clusterin, also known as	
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated	
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate	
CC	tumour cells following androgen withdrawal, and has also been shown to be	
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.	
CC	siRNAs of the invention can be used alone or in combination with other	
CC	chemotherapy or apoptosis inducing treatments for the treatment of	
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,	
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,	
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment	
CC	of Alzheimer's disease. In an example from the invention, the present	
CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3	
CC	prostate cancer cells. A reduction in clusterin transcript was observed.	
XX		
XX	Sequence 21 BP; 3 A; 5 C; 9 G; 2 T; 2 U; 0 Other;	
SQ		
Query Match	1.3%; Score 21; DB 1; Length 21;	
Best Local Similarity	100.0%; Pred. No. 39;	
Matches	21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	711 AAGTCCCGCATCGTCCGAGC 731	
DB	21 AAGTCCCGCATCGTCCGAGC 1	

ADL70517/C	ADL70517 standard; RNA; 21 BP.
ID	ADL70517
XX	ADL70517
AC	ADL70517
XX	ADL70517
XX	ADL70517
DT	20-MAY-2004 (first entry)
XX	ADL70517
DE	RNAi for human clusterin.
XX	ADL70517
XX	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW	cytostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW	ss.
KW	ss.
XX	ADL70517
OS	Homo sapiens.
OS	Synthetic.
XX	ADL70517
FH	Key
FT	modified_base
FT	20..21
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= dtdt"
XX	ADL70517
PN	WO2004018676-A2.
XX	ADL70517
PD	04-MAR-2004.
XX	ADL70517
PF	21-AUG-2003; 2003WO-CA001277.
XX	ADL70517
PR	21-AUG-2002; 2002US-0405193P.
PR	03-SEP-2002; 2002US-0408152P.
PR	20-MAY-2003; 2003US-0472387P.
XX	ADL70517
PA	(UYBR-) UNIV BRITISH COLUMBIA.
XX	ADL70517
PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI	Gonos ES;
XX	ADL70517
DR	WPI; 2004-226852/21.
XX	ADL70517
XX	New RNA molecule less than 49 bases and having a sequence effective to
PT	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
XX	ADL70517
PS	Claim 4; SEQ ID NO 62; 63pp; English.
XX	ADL70517
CC	The present sequence is the antisense strand of a short interfering RNA
CC	(siRNA) targeted to a specific portion ADL70515 of human clusterin cDNA.
CC	The sense strand is also provided ADL70516. The siRNA can be used to
CC	interfere with the expression of clusterin. Clusterin, also known as
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC	tumour cells following androgen withdrawal, and has also been shown to be
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC	siRNAs of the invention can be used alone or in combination with other
CC	chemotherapy or apoptosis inducing treatments for the treatment of
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment
CC	of Alzheimer's disease. In an example from the invention, the present
CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC	prostate cancer cells. A reduction in clusterin transcript was observed.
XX	ADL70517
SQ	Sequence 21 BP; 3 A; 5 C; 9 G; 2 T; 2 U; 0 Other;
Query Match	1.3%; Score 21; DB 1; Length 21;
Best Local Similarity	100.0%; Pred. No. 39;
Matches	21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	711 AAGTCCCGCATCGTCCGAGC 731
DB	21 AAGTCCCGCATCGTCCGAGC 1

Db	1	GUCCCGCAUCGCGCAGCTT	21
RESULT 77			
ADL70457/C			
ID	ADL70457	standard; RNA; 21 BP.	
XX			
AC	ADL70457;		
XX			
DT	20-MAY-2004	(first entry)	
XX			
DE	RNAi for human clusterin.		
XX			
KW	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;		
KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;		
KW	ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FT	Key	Location/Qualifiers	
FT	modified_base	20..21	
FT		/*tag= a	
FT		/mod_base= OTHER	
FT		/note= "OTHER= dtdt"	
XX			
PN	WO2004018676-A2.		
XX			
PD	04-MAR-2004.		
XX			
PF	21-AUG-2003; 2003WO-CA001277.		
XX			
PR	21-AUG-2002; 2002US-0405193P.		
PR	03-SEP-2002; 2002US-0408152P.		
PR	20-MAY-2003; 2003US-0472387P.		
XX			
PA	(UYBR-) UNIV BRITISH COLUMBIA.		
XX			
PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;		
PI	Gonos ES;		
XX			
DR	WPI; 2004-226852/21.		
XX			
PT	New RNA molecule less than 49 bases and having a sequence effective to		
PT	mediate degradation or block translation of mRNA that is the		
PT	transcriptional product of a target gene, useful for treating Alzheimer's		
PT	disease or cancer.		
XX			
PS	Claim 4; SEQ ID NO 2; 63pp; English.		
XX			
CC	The present sequence is the antisense strand of a short interfering RNA		
CC	(siRNA) targeted to nucleotides 487-505 of human clusterin cDNA. The		
CC	sense strand is also provided ADL70456. The siRNA can be used to		
CC	interfere with the expression of clusterin. Clusterin, also known as		
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated		
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate		
CC	tumour cells following androgen withdrawal, and has also been shown to be		
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.		
CC	siRNAs of the invention can be used alone or in combination with other		
CC	chemotherapy or apoptosis inducing treatments for the treatment of		
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,		
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,		
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment		
CC	of Alzheimer's disease.		
XX			
SQ	Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;		
Query Match	1.3%;	Score 21; DB 1; Length 21;	
Best Local Similarity	100.0%;	Pred. No. 39;	
Matches	21; Conservative	0; Mismatches	0; Indels
			0; Gaps
			0;
Qy	480	AACCAGAGCTCGCCCTTCTAC	500

Db	21	AACCAGAGCTCGCCCTTCTAC	1
RESULT 78			
ADL70459/C			
ID	ADL70459	standard; RNA; 21 BP.	
XX			
AC	ADL70459;		
XX			
DT	20-MAY-2004	(first entry)	
XX			
DE	RNAi for human clusterin.		
XX			
KW	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;		
KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;		
KW	ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FT	Key	Location/Qualifiers	
FT	modified_base	20..21	
FT		/*tag= a	
FT		/mod_base= OTHER	
FT		/note= "OTHER= dtdt"	
XX			
PN	WO2004018676-A2.		
XX			
PD	04-MAR-2004.		
XX			
PF	21-AUG-2003; 2003WO-CA001277.		
XX			
PR	21-AUG-2002; 2002US-0405193P.		
PR	03-SEP-2002; 2002US-0408152P.		
PR	20-MAY-2003; 2003US-0472387P.		
XX			
PA	(UYBR-) UNIV BRITISH COLUMBIA.		
XX			
PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;		
PI	Gonos ES;		
XX			
DR	WPI; 2004-226852/21.		
XX			
PT	New RNA molecule less than 49 bases and having a sequence effective to		
PT	mediate degradation or block translation of mRNA that is the		
PT	transcriptional product of a target gene, useful for treating Alzheimer's		
PT	disease or cancer.		
XX			
PS	Claim 4; SEQ ID NO 4; 63pp; English.		
XX			
CC	The present sequence is the antisense strand of a short interfering RNA		
CC	(siRNA) targeted to nucleotides 1105-1123 of human clusterin cDNA. The		
CC	sense strand is also provided ADL70458. The siRNA can be used to		
CC	interfere with the expression of clusterin. Clusterin, also known as		
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated		
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate		
CC	tumour cells following androgen withdrawal, and has also been shown to be		
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.		
CC	siRNAs of the invention can be used alone or in combination with other		
CC	chemotherapy or apoptosis inducing treatments for the treatment of		
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,		
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,		
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment		
CC	of Alzheimer's disease.		
XX			
SQ	Sequence 21 BP; 4 A; 2 C; 9 G; 2 T; 4 U; 0 Other;		
Query Match	1.3%;	Score 21; DB 1; Length 21;	
Best Local Similarity	100.0%;	Pred. No. 39;	
Matches	21; Conservative	0; Mismatches	0; Indels
			0; Gaps
			0;
Qy	1098	AAGATGCTCAACACCTCTCC	1118

Db 21 AAGATGCTCAACACCTCCTCC 1

480 ACCAGAGCTCGCCTTCTAC 500  
 21 AACACAGAGCTCGCCTTCTAC 1

RESULT 79  
 ADL70514/c  
 ID ADL70514 standard; RNA; 21 BP.  
 AC ADL70514;  
 XX  
 XX 20-MAY-2004 (first entry)  
 DT  
 XX RNAi for human clusterin.  
 DE  
 XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
 KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
 KW ss.  
 KW  
 OS Homo sapiens.  
 OS Synthetic.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FH modified\_base 20..21  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= dTdT"  
 FT  
 XX WO2004018676-A2.  
 PN  
 XX  
 XX  
 XX 04-MAR-2004.  
 XX  
 XX 21-AUG-2003; 2003WO-CA001277.  
 XX  
 XX 21-AUG-2002; 2002US-0405193P.  
 PR 03-SEP-2002; 2002US-0408152P.  
 PR 20-MAY-2003; 2003US-0472387P.  
 PR  
 XX (UYBR-) UNIV BRITISH COLUMBIA.  
 PA  
 XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
 PI Gonos ES;  
 PI WPI; 2004-226852/21.  
 DR  
 XX New RNA molecule less than 49 bases and having a sequence effective to  
 PT mediate degradation or block translation of mRNA that is the  
 PT transcriptional product of a target gene, useful for treating Alzheimer's  
 PT disease or cancer.  
 PT  
 XX Claim 4; SEQ ID NO 59; 63pp; English.  
 PS  
 XX The present sequence is the antisense strand of a short interfering RNA  
 CC (siRNA) targeted to a specific portion ADL70512 of human clusterin cDNA.  
 CC The sense strand is also provided ADL70513. The siRNA can be used to  
 CC interfere with the expression of clusterin. Clusterin, also known as  
 CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
 CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
 CC tumour cells following androgen withdrawal, and has also been shown to be  
 CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
 CC siRNAs of the invention can be used alone or in combination with other  
 CC chemotherapies or apoptosis inducing treatments for the treatment of  
 CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
 CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
 CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
 CC of Alzheimer's disease. In an example from the invention, the present  
 CC siRNA was used to examine the effects of clusterin gene silencing in PC-3  
 CC prostate cancer cells. A reduction in clusterin transcript was observed.  
 XX  
 XX Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;  
 SQ

Best Match 1.3%; Score 21; DB 1; Length 21;  
 Query Local Similarity 100.0%; Pred. No. 39;  
 Matches 21; Conservative 0; Mismatches 0; Gaps 0;

480 ACCAGAGCTCGCCTTCTAC 500  
 21 AACACAGAGCTCGCCTTCTAC 1

RESULT 80  
 ADL70410/c  
 ID ADL70410 standard; DNA; 21 BP.  
 AC ADL70410;  
 XX  
 XX 20-MAY-2004 (first entry)  
 DT  
 XX Antisense oligonucleotide to human clusterin.  
 DE  
 XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
 KW  
 KW Homo sapiens.  
 OS Synthetic.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FH modified\_base 1..21  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= optional phosphorothioate nucleotides"  
 FT modified\_base 1..4  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"  
 FT modified\_base 18..21  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"  
 FT  
 XX WO2004018675-A1.  
 PN  
 XX  
 XX 04-MAR-2004.  
 XX  
 XX 21-AUG-2003; 2003WO-CA001276.  
 XX  
 XX 21-AUG-2002; 2002US-0405193P.  
 PR 03-SEP-2002; 2002US-0408152P.  
 PR 02-DEC-2002; 2002US-0319748P.  
 PR 20-MAY-2003; 2003US-0472387P.  
 PR  
 XX (UYBR-) UNIV BRITISH COLUMBIA.  
 PA (GLEA/) GLEAVE M E.  
 PA  
 XX Jansen B;  
 PI  
 XX WPI; 2004-226851/21.  
 DR  
 XX Treating melanoma in a mammalian subject comprises administering to the  
 PT subject a therapeutic agent effective to reduce the effective amount of  
 PT clusterin in the melanoma cells.  
 PT  
 XX Claim 6; SEQ ID NO 8; 32pp; English.  
 PS  
 XX The present sequence is that of an antisense oligonucleotide targeted to  
 CC human clusterin ADL70403. The invention relates to the treatment of  
 CC melanoma through reduction in the effective amount of clusterin. The  
 CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
 CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.  
 CC The antisense oligonucleotides are complementary to a region of the  
 CC clusterin mRNA spanning either the translation initiation site or the  
 CC termination site. They may be modified to increase stability in vivo,  
 CC e.g. they may be employed as phosphorothioate derivatives and may have 2  
 CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for  
 CC regulating expression of bcl-xL in a subject or cell line comprises  
 CC administering an agent effective to modulate the amount of clusterin  
 CC expression. In clusterin-expressing cells, expression of bcl-xL is down-  
 CC regulated when the effective amount of clusterin is reduced. Such  
 CC inhibition is significant because bcl-xL is known to act as an inhibitor

```

CC of apoptosis.
XX Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGCGAGCTTGAT 736
Db 21 CCGCATCGTCCGCGAGCTTGAT 1

RESULT 81
ADL70440
ID ADL70440 standard; RNA; 21 BP.
XX
AC ADL70440;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
XX
PR 03-SEP-2002; 2002US-0408152P.
XX
PR 02-DEC-2002; 2002US-0319748P.
XX
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 20; SEQ ID NO 38; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 2 A; 9 C; 5 G; 2 T; 3 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCCGCATCGTCCGCGAGCTT 733
Db 1 GUCCCGCAUCGUGCCGAGCTT 21

RESULT 82
ADL70422
ID ADL70422 standard; RNA; 21 BP.
XX
AC ADL70422;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
XX
PR 03-SEP-2002; 2002US-0408152P.
XX
PR 02-DEC-2002; 2002US-0319748P.
XX
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 10; SEQ ID NO 20; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```

Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGTCGCCCTTCTACTT 502  
|||||:||||:|:|:|

Db 1 CCAGAGCCUCCCUUUAUACTT 21

RESULT 83  
ADL70413/c  
ID ADL70413 standard; DNA; 21 BP.  
XX AC ADL70413;  
XX DT 20-MAY-2004 (first entry)  
XX DE Antisense oligonucleotide to human clusterin.  
XX KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional phosphorothioate nucleotides"  
FT modified\_base 1..4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
FT modified\_base 18..21  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
XX WO2004018675-A1.  
XX PN  
XX PD  
XX PD  
XX PD  
XX PF 21-AUG-2003; 2003WO-CA001276.  
XX PR 21-AUG-2002; 2002US-0405193P.  
XX PR 03-SEP-2002; 2002US-0408152P.  
XX PR 02-DEC-2002; 2002US-0319748P.  
XX PR 20-MAY-2003; 2003US-0472387P.  
XX PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX PA (GLEA/) GLEAVE M E.  
XX PI Jansen B;  
XX PI WPI; 2004-226851/21.  
XX DR  
XX PT Treating melanoma in a mammalian subject comprises administering to the  
XX PT subject a therapeutic agent effective to reduce the effective amount of  
XX PT clusterin in the melanoma cells.  
XX PS Claim 6; SEQ ID NO 11; 32pp; English.  
XX CC The present sequence is that of an antisense oligonucleotide targeted to  
XX CC human clusterin ADL70403. The invention relates to the treatment of  
XX CC melanoma through reduction in the effective amount of clusterin. The  
XX CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
XX CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.  
XX CC The antisense oligonucleotides are complementary to a region of the  
XX CC clusterin mRNA spanning either the translation initiation site or the  
XX CC termination site. They may be modified to increase stability in vivo,  
XX CC e.g. they may be employed as phosphorothioate derivatives and may have 2'  
XX CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for  
XX CC regulating expression of bcl-xL in a subject or cell line comprises  
XX CC administering an agent effective to modulate the amount of clusterin  
XX CC expression. In clusterin-expressing cells, expression of bcl-xL is down-

CC regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGGAAGAACCCCTAAATT 1336  
|||||:|||||:|:|:|

Db 21 CTCAGGAAGAACCCCTAAATT 1

RESULT 84  
ADL70408/c  
ID ADL70408 standard; DNA; 21 BP.  
XX AC ADL70408;  
XX DT 20-MAY-2004 (first entry)  
XX DE Antisense oligonucleotide to human clusterin.  
XX KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional phosphorothioate nucleotides"  
FT modified\_base 1..4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
FT modified\_base 18..21  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
XX WO2004018675-A1.  
XX PN  
XX PD  
XX PD  
XX PD  
XX PF 21-AUG-2003; 2003WO-CA001276.  
XX PR 21-AUG-2002; 2002US-0405193P.  
XX PR 03-SEP-2002; 2002US-0408152P.  
XX PR 02-DEC-2002; 2002US-0319748P.  
XX PR 20-MAY-2003; 2003US-0472387P.  
XX PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX PA (GLEA/) GLEAVE M E.  
XX PI Jansen B;  
XX PI WPI; 2004-226851/21.  
XX DR  
XX PT Treating melanoma in a mammalian subject comprises administering to the  
XX PT subject a therapeutic agent effective to reduce the effective amount of  
XX PT clusterin in the melanoma cells.  
XX PS Claim 6; SEQ ID NO 6; 32pp; English.  
XX CC The present sequence is that of an antisense oligonucleotide targeted to  
XX CC human clusterin ADL70403. The invention relates to the treatment of  
XX CC melanoma through reduction in the effective amount of clusterin. The  
XX CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
XX CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.

CC The antisense oligonucleotides are complementary to a region of the  
CC clusterin mRNA spanning either the translation initiation site or the  
CC termination site. They may be modified to increase stability in vivo,  
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'  
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for  
CC regulating expression of bcl-xL in a subject or cell line comprises  
CC administering an agent effective to modulate the amount of clusterin  
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-  
CC regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.

XX SQ Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;  
XX  
XX Query Match 1.3%; Score 21; DB 1; Length 21;  
XX Best Local Similarity 100.0%; Pred. No. 39;  
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGACAGCAAGCTGAAGG 336  
Db 21 AATCAGACAGCAAGCTGAAGG 1

RESULT 85  
ADL70412/c  
ID ADL70412 standard; DNA; 21 BP.  
XX  
XX AC ADL70412;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX Antisense oligonucleotide to human clusterin.  
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
XX Homo sapiens.  
XX Synthetic.

XX Key Location/Qualifiers  
XX modified\_base 1. .21  
XX /\*tag= b  
XX /mod\_base= OTHER  
XX /note= "OTHER= optional phosphorothioate nucleotides"  
XX modified\_base 1. .4  
XX /\*tag= a  
XX /mod\_base= OTHER  
XX /note= "OTHER= optional 2'O-methoxyethyl modifications"  
XX modified\_base 18. .21  
XX /\*tag= c  
XX /mod\_base= OTHER  
XX /note= "OTHER= optional 2'O-methoxyethyl modifications"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.

XX Claim 6; SEQ ID NO 10; 32pp; English.  
XX  
XX The present sequence is that of an antisense oligonucleotide targeted to  
XX human clusterin ADL70403. The invention relates to the treatment of  
XX melanoma through reduction in the effective amount of clusterin. The  
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.  
XX The antisense oligonucleotides are complementary to a region of the  
XX clusterin mRNA spanning either the translation initiation site or the  
XX termination site. They may be modified to increase stability in vivo,  
XX e.g. they may be employed as phosphorothioate derivatives and may have 2'  
XX -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for  
XX regulating expression of bcl-xL in a subject or cell line comprises  
XX administering an agent effective to modulate the amount of clusterin  
XX expression. In clusterin-expressing cells, expression of bcl-xL is down-  
XX regulated when the effective amount of clusterin is reduced. Such  
XX inhibition is significant because bcl-xL is known to act as an inhibitor  
XX of apoptosis.

XX SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
XX  
XX Query Match 1.3%; Score 21; DB 1; Length 21;  
XX Best Local Similarity 100.0%; Pred. No. 39;  
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 86  
ADL70425/c  
ID ADL70425 standard; RNA; 21 BP.  
XX  
XX AC ADL70425;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX RNAi for human clusterin.  
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
XX short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX Homo sapiens.  
XX Synthetic.

XX Key Location/Qualifiers  
XX modified\_base 20. .21  
XX /\*tag= a  
XX /mod\_base= OTHER  
XX /note= "OTHER= TT"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.

PT clusterin in the melanoma cells.  
PS Claim 10; SEQ ID NO 23; 32pp; English.  
XX  
CC The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 21 BP; 4 A; 2 C; 9 G; 2 T; 4 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1098 AGATGCTCAACACCTCTCC 1118  
Db 21 AGATGCTCAACACCTCTCC 1  
RESULT 87  
ADL70442  
ID ADL70442 standard; RNA; 21 BP.  
XX  
AC ADL70442;  
XX  
DT 20-MAY-2004 (first entry)  
DE RNAi for human clusterin.  
DE Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.  
XX  
PS Claim 20; SEQ ID NO 40; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 21 BP; 8 A; 4 C; 1 G; 2 T; 6 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 39;  
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 1615 CTAATTCAATAAACTGCTT 1635  
Db 1 CUAUUAUAAUAAACUGUCTT 21  
RESULT 88  
ADL70406/c  
ID ADL70406 standard; DNA; 21 BP.  
XX  
AC ADL70406;  
XX  
DT 20-MAY-2004 (first entry)  
DE Antisense oligonucleotide to human clusterin.  
DE Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= phosphorothioate nucleotides"  
XX  
FT modified\_base 1..4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'O-methoxyethyl modifications"  
XX  
FT modified\_base 18..21  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'O-methoxyethyl modifications"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT



subject a therapeutic agent effective to reduce the effective amount of bcl-xL in the melanoma cells.

Claim 7; SEQ ID NO 4; 32pp; English.

The present sequence is that of an antisense oligonucleotide targeted to human clusterin ADL70403. The invention relates to the treatment of melanoma through reduction in the effective amount of clusterin. The therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin. The antisense oligonucleotides are complementary to a region of the clusterin mRNA spanning either the translation initiation site or the termination site. They may be modified to increase stability in vivo, e.g. they may be employed as phosphorothioate derivatives and may have 2'-O-(2-methoxyethyl) (MOE) modifications in the 5' and 3' 'wings'. The present antisense oligonucleotide is particularly preferred. It is targeted to the translation initiation codon and next 6 codons of the human clusterin sequence. It has a phosphorothioate backbone throughout and MOE wings, the remaining nucleotides being 2'-deoxynucleotides. In an example from the invention, this antisense oligonucleotide provided a dose-dependent down-regulation of clusterin in human melanoma cells, leading to an increase in apoptotic cell death. In one melanoma cell line (607B) this alone was sufficient to lead to complete cell death. In another melanoma cell line, the surviving cells showed increased sensitivity to subsequent treatment with cisplatin. A claimed method for regulating expression of bcl-xL in a subject or cell line comprises administering an agent effective to modulate the amount of clusterin expression. In clusterin-expressing cells, expression of bcl-xL is down-regulated when the effective amount of clusterin is reduced. Such inhibition is significant because bcl-xL is known to act as an inhibitor of apoptosis.

Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGGTGCTG 68  
DB 21 ATGATGAAGACTCTGGTGCTG 1  
|||||

RESULT 89  
ADL70423/C  
ID ADL70423 standard; RNA; 21 BP.  
XX  
AC ADL70423;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21 /\*tag= a  
FT /\*mod\_base= OTHER  
FT /\*mod= "OTHER= TT"  
XX  
PN WO2004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
DP 03-SEP-2002; 2002US-0408152P.

PI Jansen B;  
XX WPI; 2004-226851/21.  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
PT  
XX  
PS Claim 20; SEQ ID NO 41; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1613 AACTAATTCAATAAACTGTC 1633  
DB 21 AACTAATTCAATAAACTGTC 1  
RESULT 92  
ADL70411/c  
ID ADL70411 standard; DNA; 21 BP.  
XX  
AC ADL70411;  
XX  
DT 20-MAY-2004 (first entry)  
DE Antisense oligonucleotide to human clusterin.  
XX  
KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional phosphorothioate nucleotides"  
FT modified\_base 1..4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"  
FT modified\_base 18..21  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"  
XX  
XX WO2004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.

PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
PT  
XX  
PS Claim 20; SEQ ID NO 39; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 21 BP; 3 A; 5 C; 9 G; 2 T; 2 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 711 AAGTCCGCGATCGTCGCGAGC 731  
DB 21 AAGTCCGCGATCGTCGCGAGC 1  
RESULT 91  
ADL70443/c  
ID ADL70443 standard; RNA; 21 BP.  
XX  
AC ADL70443;  
XX  
DT 20-MAY-2004 (first entry)  
DE RNAi for human clusterin.  
XX  
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
XX short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.

```
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 6; SEQ ID NO 9; 32pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 916 ACAATCCACGGGCTGCTGC 936
DB 21 ACAATCCACGGGCTGCTGC 1
RESULT 93
ADL70439/c
ID ADL70439 standard; RNA; 21 BP.
XX
AC ADL70439;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
XX WO2004018675-A1.
XX
PN 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX
XX 03-SEP-2002; 2002US-0408152P.
XX
XX 02-DEC-2002; 2002US-0319748P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
```

```
PR 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 20; SEQ ID NO 37; 32pp; English.
XX
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 480 AACGAGCTCGCCCTTCTAC 500
DB 21 AACGAGCTCGCCCTTCTAC 1
RESULT 94
ADL70438
ID ADL70438 standard; RNA; 21 BP.
XX
AC ADL70438;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
XX WO2004018675-A1.
XX
PN 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX
XX 03-SEP-2002; 2002US-0408152P.
XX
XX 02-DEC-2002; 2002US-0319748P.
XX
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
```

```
PA (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX Claim 20; SEQ ID NO 36; 32pp; English.
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 482 CCAGAGCTCGCCCTTCTACTT 502
DB 1 CCAGAGCUCGCCCUUUAUATT 21
RESULT 95
ID ADL70414/c
XX ADL70414;
XX 20-MAY-2004 (first entry)
XX Antisense oligonucleotide to human clusterin.
DE Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
FT modified_base 18..21
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
XX WO2004018675-A1.
XX 04-MAR-2004.
XX 21-AUG-2003; 2003WO-CA001276.
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
```

```
PR 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX Claim 6; SEQ ID NO 12; 32pp; English.
XX The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2',
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1516 AGGCCCCCAACTCCGCCGAGC 1536
DB 21 AGGCCCCCAACTCCGCCGAGC 1
RESULT 96
ID ADL70409/c
XX ADL70409 standard; DNA; 21 BP.
XX AC ADL70409;
XX 20-MAY-2004 (first entry)
XX Antisense oligonucleotide to human clusterin.
DE Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
FT modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-methoxyethyl modifications"
XX
```

```
PN WO2004018675-A1.
XX
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 6; SEQ ID NO 7; 32pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2',
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 515 TGACCGCATCGACTCCCTGCT 535
Db 21 TGACCGCATCGACTCCCTGCT 1
RESULT 97
ADL70427/c
ID ADL70427 standard; RNA; 21 BP.
XX
XX ADL70427;
AC
XX 20-MAY-2004 (first entry)
DT
XX RNAi for human clusterin.
DE
XX Human; clusterin; RNAi; melanoma; cytotostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
OS
XX Key Location/Qualifiers
PH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
FT
```

```
XX WO2004018675-A1.
XX
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 02-DEC-2002; 2002US-0319748P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 10; SEQ ID NO 25; 32pp; English.
XX
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNA molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1613 AACTAATTCAATAAAACTGTC 1633
Db 21 AACTAATTCAATAAAACTGTC 1
RESULT 98
ADL70405/c
ID ADL70405 standard; DNA; 21 BP.
XX
XX ADL70405;
AC
XX 20-MAY-2004 (first entry)
DT
XX Antisense oligonucleotide to human clusterin.
DE
XX Human; clusterin; antisense; melanoma; cytotostatic; gene silencing; ss.
KW
XX Homo sapiens.
OS
XX Synthetic.
OS
XX Key Location/Qualifiers
PH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"
FT
```



KW chromosome location; gene marker; polymorphic microsatellite marker;  
KW phenotype; behaviour; pedigree; ss.  
OS Canis familiaris.  
XX  
PN WO200029615-A2.  
XX  
PD 25-MAY-2000.  
XX  
PF 15-NOV-1999; 99WO-IB001907.  
XX  
PT 13-NOV-1998; 98US-0108193P.  
XX  
PA (CNRS ) CNRS CENT NAT RECH SCI.  
XX  
PI Galibert F, Andre C;  
XX  
DR WPI; 2000-387821/33.  
XX  
PT New radiation hybrid map of the dog, Canine familiaris, genome, useful  
PT for e.g. identifying genes implicated in phenotypic and behavioral traits  
PT or in genetic diseases and for studying dog pedigree.  
XX  
PS Claim 1; Page 61; 87pp; English.  
XX  
CC The present invention describes a radiation hybrid map of the dog (Canine  
CC familiaris) genome comprising the genome location of a marker selected  
CC from AA66139 to AA66942. The radiation hybrid map is useful for  
CC identifying and localising dog genes, since it covers approximately 80 %  
CC of the dog genome and provides a dense map integrating different types  
CC (i.e. Type I and Type II) of markers. The map and the dog genome markers  
CC (or complementary sequences) are especially useful to identify genes  
CC responsible for phenotypic and behavioural traits in dogs, to identify  
CC morbid genes, to analyse diseases and identify implicated genes in such  
CC diseases and their alleles, and to study dog pedigrees. They may also be  
CC useful for isolating corresponding human gene sequences e.g. genes  
CC involved in genetic diseases  
XX  
SQ Sequence 24 BP; 5 A; 8 C; 6 G; 5 T; 0 U; 0 Other;  
Query Match 1.3%; Score 20.8; DB 1; Length 24;  
Best Local Similarity 91.7%; Pred. No. 67;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1467 CCCCAGAGAGAGCTCTGCACGTC 1490  
Db 1 CCCCAGAGAGAGCTCTGCATGTC 24  
RESULT 102  
ABN99680/C  
ID ABN99680 standard; DNA; 20 BP.  
XX  
AC ABN99680;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 14.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.

DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN WO2004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 01-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
PS Claim 10; SEQ ID NO 22; 32pp; English.  
XX  
CC The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 21 BP; 4 A; 9 C; 2 G; 2 T; 4 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 81.0%; Pred. No. 39;  
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 1100 GATGCTCAACACCTCTCTCTT 1120  
Db 1 GAUGCUCAACACCUCCUCCCT 21  
RESULT 101  
AAA66325  
ID AAA66325 standard; DNA; 24 BP.  
XX  
AC AAA66325;  
XX  
DT 09-OCT-2000 (first entry)  
XX  
DE Dog genomic marker oligonucleotide sequence SEQ ID NO:187.  
XX  
KW Dog; genome; genomic marker; radiation hybrid map; identification;





Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTCATGAAGTTCTACGCAC 426  
 Db 20 CTCATGAAGTTCTACGCAC 1

RESULT 105  
 ABN99686/C  
 ID ABN99686 standard; DNA; 20 BP.  
 XX AC ABN99686;  
 AC AC  
 DT 16-AUG-2002 (first entry)  
 XX DE Human clusterin inhibiting antisense oligonucleotide 20.  
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX 21-MAR-2002.  
 XX 10-SEP-2001; 2001WO-US028235.  
 XX 11-SEP-2000; 2000US-00659791.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Monia BP, Freier SM;  
 XX WPI; 2002-404805/43.  
 XX Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX Claim 3; Page 83; 125pp; English.  
 XX The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the  
 CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 444 TCAGGCTGTGGTGGCCCA 463  
 Db 20 TCAGGCTGTGGTGGCCCA 1

RESULT 106  
 ABN99709/C  
 ID ABN99709 standard; DNA; 20 BP.  
 XX AC ABN99709;  
 XX 16-AUG-2002 (first entry)

XX Human clusterin inhibiting antisense oligonucleotide 43.  
 DE Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX 21-MAR-2002.  
 XX 10-SEP-2001; 2001WO-US028235.  
 XX 11-SEP-2000; 2000US-00659791.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Monia BP, Freier SM;  
 XX WPI; 2002-404805/43.  
 XX Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX Claim 3; Page 84; 125pp; English.  
 XX The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the  
 CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 SQ Sequence 20 BP; 2 A; 3 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 906 GAGATCGCCACAACTCCAC 925  
 Db 20 GAGATCGCCACAACTCCAC 1

RESULT 107  
 ABN99711/C  
 ID ABN99711 standard; DNA; 20 BP.  
 XX AC ABN99711;  
 XX 16-AUG-2002 (first entry)  
 XX DE Human clusterin inhibiting antisense oligonucleotide 45.  
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX 21-MAR-2002.



Query Match		1.2%; Score 20; DB 1; Length 20;
Best Local Similarity		100.0%; Pred. No. 45;
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	286 AGAAGAGGATGCCCTAAAT 305	
Db	20 AGAAGAGGATGCCCTAAAT 1	
RESULT 110		
ABN99681/c		
ID	ABN99681 standard; DNA; 20 BP.	
XX		
AC	ABN99681;	
XX		
DT	16-AUG-2002 (first entry)	
DE	Human clusterin inhibiting antisense oligonucleotide 15.	
XX		
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;	
KW	hypercholesterolaemia; cardiovascular disorder; ss;	
KW	hyperproliferative disorder; hyperlipidemic disorder;	
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200222635-A1.	
XX		
PD	21-MAR-2002.	
XX		
PF	10-SEP-2001; 2001WO-US028235.	
XX		
PR	11-SEP-2000; 2000US-00659791.	
XX		
PA	(ISIS-) ISIS PHARM INC.	
XX		
PI	Monia BP, Freier SM;	
XX		
DR	WPI; 2002-404805/43.	
XX		
PT	Novel antisense compound targeted to nucleic acid molecule encoding	
PT	clusterin, useful for treating animal having disease associated with	
PT	clusterin such as hyperlipidemic disorder, cardiovascular disorder.	
XX		
PS	Claim 3; Page 83; 125pp; English.	
XX		
CC	The invention comprises antisense oligonucleotides that are capable of	
CC	inhibiting expression of the human clusterin gene. The antisense	
CC	oligonucleotides of the invention are useful for inhibiting the	
CC	expression of clusterin in cells. The antisense oligonucleotides are also	
CC	useful for treating an animal with a disease or condition associated with	
CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;	
CC	hyperproliferative disorders; and hyperlipidemic disorders). The present	
CC	DNA sequence represents a clusterin antisense oligonucleotide of the	
CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone	
CC	and also contains 2'-O-methoxyethyl wings	
XX		
Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;		
Query Match 1.2%; Score 20; DB 1; Length 20;		
Best Local Similarity 100.0%; Pred. No. 45;		
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	359 GACCATGATGCCCTCTGGG 378	
Db	20 GACCATGATGCCCTCTGGG 1	
RESULT 111		
ABN99668/c		
ID	ABN99668 standard; DNA; 20 BP.	
XX		

Query Match		1.2%; Score 20; DB 1; Length 20;
Best Local Similarity		100.0%; Pred. No. 45;
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	21 GCCTGCAAGACTCCAGAT 40	
Db	20 GCCTGCAAGACTCCAGAT 1	
RESULT 112		
ABN99675/c		
ID	ABN99675 standard; DNA; 20 BP.	
XX		
AC	ABN99675;	
XX		
DT	16-AUG-2002 (first entry)	
DE	Human clusterin inhibiting antisense oligonucleotide 9.	
XX		
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;	
KW	hypercholesterolaemia; cardiovascular disorder; ss;	
KW	hyperproliferative disorder; hyperlipidemic disorder;	
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200222635-A1.	

ABN99668;

16-AUG-2002 (first entry)

Human clusterin inhibiting antisense oligonucleotide 2.

Human; antisense inhibition; antisense oligonucleotide; clusterin;

hypercholesterolaemia; cardiovascular disorder; ss;

hyperproliferative disorder; hyperlipidemic disorder;

phosphorothioate backbone; 2'-O-methoxyethyl wing.

Homo sapiens.

WO200222635-A1.

21-MAR-2002.

10-SEP-2001; 2001WO-US028235.

11-SEP-2000; 2000US-00659791.

(ISIS-) ISIS PHARM INC.

Monia BP, Freier SM;

WPI; 2002-404805/43.

Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.

Example 15; Page 83; 125pp; English.

The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 GCCTGCAAGACTCCAGAT 40

Db 20 GCCTGCAAGACTCCAGAT 1

RESULT 112

ABN99675/c

ID ABN99675 standard; DNA; 20 BP.

XX

AC ABN99675;

XX

DT 16-AUG-2002 (first entry)

DE Human clusterin inhibiting antisense oligonucleotide 9.

XX

KW Human; antisense inhibition; antisense oligonucleotide; clusterin;

KW hypercholesterolaemia; cardiovascular disorder; ss;

KW hyperproliferative disorder; hyperlipidemic disorder;

KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX

OS Homo sapiens.

XX

PN WO200222635-A1.

XX PD 21-MAR-2002.

XX XX 10-SEP-2001; 2001WO-US028235.

XX PF 11-SEP-2000; 2000US-00659791.

XX PR (ISIS-) ISIS PHARM INC.

XX PA Monia BP, Freier SM;

XX PI WPI; 2002-404805/43.

XX DR Novel antisense compound targeted to nucleic acid molecule encoding

XX PT clusterin, useful for treating animal having disease associated with

XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX XX Claim 3; Page 83; 125pp; English.

XX PS The invention comprises antisense oligonucleotides that are capable of

XX CC inhibiting expression of the human clusterin gene. The antisense

XX CC oligonucleotides of the invention are useful for inhibiting the

XX CC expression of clusterin in cells. The antisense oligonucleotides are also

XX CC useful for treating an animal with a disease or condition associated with

XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present

XX CC DNA sequence represents a clusterin antisense oligonucleotide of the

XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 2 A; 7 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 201 GGGGTGAACACAGATAAAGAC 220

Db 20 GGGGTGAACACAGATAAAGAC 1

RESULT 113

ABN99695/c

ID ABN99695 standard; DNA; 20 BP.

XX AC ABN99695;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 29.

XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;

XX KW hypercholesterolaemia; cardiovascular disorder; ss;

XX KW hyperproliferative disorder; hyperlipidemic disorder;

XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX XX WO200222635-A1.

XX XX 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX DR WPI; 2002-404805/43.

XX XX Novel antisense compound targeted to nucleic acid molecule encoding

XX PT clusterin, useful for treating animal having disease associated with

XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX XX Claim 3; Page 83; 125pp; English.

XX PS The invention comprises antisense oligonucleotides that are capable of

XX CC inhibiting expression of the human clusterin gene. The antisense

XX CC oligonucleotides of the invention are useful for inhibiting the

XX CC expression of clusterin in cells. The antisense oligonucleotides are also

XX CC useful for treating an animal with a disease or condition associated with

XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present

XX CC DNA sequence represents a clusterin antisense oligonucleotide of the

XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 2 A; 7 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 201 GGGGTGAACACAGATAAAGAC 220

Db 20 GGGGTGAACACAGATAAAGAC 1

RESULT 114

ABN99697/c

ID ABN99697 standard; DNA; 20 BP.

XX AC ABN99697;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 31.

XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;

XX KW hypercholesterolaemia; cardiovascular disorder; ss;

XX KW hyperproliferative disorder; hyperlipidemic disorder;

XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX XX WO200222635-A1.

XX XX 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX DR WPI; 2002-404805/43.

XX XX Novel antisense compound targeted to nucleic acid molecule encoding

XX PT clusterin, useful for treating animal having disease associated with

XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX XX Claim 3; Page 83; 125pp; English.

XX PS The invention comprises antisense oligonucleotides that are capable of

XX CC inhibiting expression of the human clusterin gene. The antisense

XX CC oligonucleotides of the invention are useful for inhibiting the

XX CC expression of clusterin in cells. The antisense oligonucleotides are also

XX CC useful for treating an animal with a disease or condition associated with

XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present

XX CC DNA sequence represents a clusterin antisense oligonucleotide of the

XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

CC and also contains 2'-O-methoxyethyl wings  
 XX Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;  
 SQ

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 608 AGACGAGCTTCCAGGACA 627  
 DB 20 AGACGAGCTTCCAGGACA 1

RESULT 115  
 ABN99701/c  
 ID ABN99701 standard; DNA; 20 BP.  
 XX AC  
 AC ABN99701;  
 XX DT 16-AUG-2002 (first entry)  
 XX DE Human clusterin inhibiting antisense oligonucleotide 35.  
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX PN 21-MAR-2002.  
 XX DT 10-SEP-2001; 2001WO-US028235.  
 XX PR 11-SEP-2000; 2000US-00659791.  
 XX PA (ISIS-) ISIS PHARM INC.  
 XX PI Monia BP, Freier SM;  
 XX WIPI; 2002-404805/43.  
 XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX Claim 3; Page 83; 125pp; English.  
 XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

QY 775 TGTTCCAGCCTTCTTGAG 794  
 DB 20 TGTTCCAGCCTTCTTGAG 1

RESULT 116  
 ABN99704/c  
 ID ABN99704 standard; DNA; 20 BP.  
 XX AC  
 AC ABN99704;  
 XX DT 16-AUG-2002 (first entry)  
 XX DE Human clusterin inhibiting antisense oligonucleotide 38.  
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX PN 21-MAR-2002.  
 XX DT 10-SEP-2001; 2001WO-US028235.  
 XX PR 11-SEP-2000; 2000US-00659791.  
 XX PA (ISIS-) ISIS PHARM INC.  
 XX PI Monia BP, Freier SM;  
 XX WIPI; 2002-404805/43.  
 XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX Claim 3; Page 83; 125pp; English.  
 XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

ABN99702/c  
 ID ABN99702 standard; DNA; 20 BP.  
 XX AC  
 AC ABN99702;  
 XX DT 16-AUG-2002 (first entry)  
 XX DE Human clusterin inhibiting antisense oligonucleotide 36.  
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX PN 21-MAR-2002.  
 XX DT 10-SEP-2001; 2001WO-US028235.  
 XX PR 11-SEP-2000; 2000US-00659791.  
 XX PA (ISIS-) ISIS PHARM INC.  
 XX PI Monia BP, Freier SM;  
 XX WIPI; 2002-404805/43.  
 XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX Claim 3; Page 83; 125pp; English.  
 XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

QY 776 GTTCCAGCCTTCTTGAGA 795  
 DB 20 GTTCCAGCCTTCTTGAGA 1

RESULT 117  
 ABN99704/c  
 ID ABN99704 standard; DNA; 20 BP.  
 XX AC  
 AC ABN99704;  
 XX DT 16-AUG-2002 (first entry)  
 XX DE Human clusterin inhibiting antisense oligonucleotide 38.  
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX PN 21-MAR-2002.  
 XX DT 10-SEP-2001; 2001WO-US028235.  
 XX PR 11-SEP-2000; 2000US-00659791.  
 XX PA (ISIS-) ISIS PHARM INC.  
 XX PI Monia BP, Freier SM;  
 XX WIPI; 2002-404805/43.  
 XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX Claim 3; Page 83; 125pp; English.  
 XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings

QY 777 GTTCCAGCCTTCTTGAGA 795  
 DB 20 GTTCCAGCCTTCTTGAGA 1

RESULT 118  
 ABN99704/c  
 ID ABN99704 standard; DNA; 20 BP.  
 XX AC  
 AC ABN99704;  
 XX DT 16-AUG-2002 (first entry)  
 XX DE Human clusterin inhibiting antisense oligonucleotide 38.  
 XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX OS Homo sapiens.  
 XX WO200222635-A1.  
 XX PN 21-MAR-2002.  
 XX DT 10-SEP-2001; 2001WO-US028235.  
 XX PR 11-SEP-2000; 2000US-00659791.  
 XX PA (ISIS-) ISIS PHARM INC.  
 XX PI Monia BP, Freier SM;  
 XX WIPI; 2002-404805/43.  
 XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX Claim 3; Page 83; 125pp; English.  
 XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings



CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 XX  
 SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGGATCCTGCACCTCTA 1564  
 |||||  
 DB 20 GCTCTGGATCCTGCACCTCTA 1

RESULT 120  
 ABN99727/c  
 ID ABN99727 standard; DNA; 20 BP.  
 XX  
 AC ABN99727;  
 XX  
 DT 16-AUG-2002 (first entry)  
 DE Human clusterin inhibiting antisense oligonucleotide 61.  
 XX  
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200222635-A1.  
 XX  
 PD 21-MAR-2002.  
 XX  
 PF 10-SEP-2001; 2001WO-US028235.  
 XX  
 PR 11-SEP-2000; 2000US-00659791.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Monia BP, Freier SM;  
 XX  
 DR WPI; 2002-404805/43.  
 XX  
 PT Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX  
 PS Claim 3; Page 84; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the  
 CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 XX  
 SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCTGCATGCACTAAT 1619  
 |||||  
 DB 20 TGCTCTGCATGCACTAAT 1

RESULT 121  
 ABN99670/c  
 ID ABN99670 standard; DNA; 20 BP.  
 XX  
 AC ABN99670;  
 XX  
 DT 16-AUG-2002 (first entry)  
 DE Human clusterin inhibiting antisense oligonucleotide 4.  
 XX  
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200222635-A1.  
 XX  
 PD 21-MAR-2002.  
 XX  
 PF 10-SEP-2001; 2001WO-US028235.  
 XX  
 PR 11-SEP-2000; 2000US-00659791.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Monia BP, Freier SM;  
 XX  
 DR WPI; 2002-404805/43.  
 XX  
 PT Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX  
 PS Example 15; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the  
 CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 XX  
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCTGCTGCTGACCTGGGAGA 96  
 |||||  
 DB 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 122  
 ABN99683/c  
 ID ABN99683 standard; DNA; 20 BP.  
 XX  
 AC ABN99683;  
 XX  
 DT 16-AUG-2002 (first entry)  
 DE Human clusterin inhibiting antisense oligonucleotide 17.  
 XX  
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;

KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
XX WO200222635-A1.  
XX 21-MAR-2002.  
XX 10-SEP-2001; 2001WO-US028235.  
XX 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
XX  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 380 AGAGTGTAAAGCCCTGCCTGA 399  
XX Db 20 AGAGTGTAAAGCCCTGCCTGA 1  
XX  
XX RESULT 123  
XX ABN99722/c  
XX ID ABN99722 standard; DNA; 20 BP.  
XX AC ABN99722;  
XX XX  
XX DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 56.  
XX XX  
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
XX OS  
XX WO200222635-A1.  
XX PN  
XX PD 21-MAR-2002.  
XX XX  
XX PF 10-SEP-2001; 2001WO-US028235.  
XX PR 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.  
XX PA

XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Claim 3; Page 84; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;  
XX  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 1275 TTTCAGTCTGATCCCATCAC 1294  
XX Db 20 TTTCAGTCTGATCCCATCAC 1  
XX  
XX RESULT 124  
XX ABN99667/c  
XX ID ABN99667 standard; DNA; 20 BP.  
XX AC ABN99667;  
XX XX  
XX DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 1.  
XX XX  
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
XX OS  
XX WO200222635-A1.  
XX PN  
XX PD 21-MAR-2002.  
XX XX  
XX PF 10-SEP-2001; 2001WO-US028235.  
XX PR 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Example 15; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the



CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGCGCTGCAAGAC 32  
Db 20 TGACCGAGCGCTGCAAGAC 1

RESULT 125  
ABN99687/c  
ID ABN99687 standard; DNA; 20 BP.

XX  
AC ABN99687;

XX  
DT 16-AUG-2002 (first entry)

XX  
DE Human clusterin inhibiting antisense oligonucleotide 21.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX  
OS Homo sapiens.

XX  
PN WO200222635-A1.

XX  
PD 21-MAR-2002.

XX  
PF 10-SEP-2001; 2001WO-US028235.

XX  
PR 11-SEP-2000; 2000US-00659791.

XX  
PA (ISIS-) ISIS PHARM INC.

XX  
PI Monia BP, Freier SM;

XX  
DR WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX  
PS Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings

XX  
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TGGCCCCCAGCTTGAGGAGT 474  
Db 20 TGGCCCCCAGCTTGAGGAGT 1

RESULT 126  
ABN99712/c

ID ABN99712 standard; DNA; 20 BP.

XX  
AC ABN99712;

XX  
DT 16-AUG-2002 (first entry)

XX  
DE Human clusterin inhibiting antisense oligonucleotide 46.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX  
OS Homo sapiens.

XX  
PN WO200222635-A1.

XX  
PD 21-MAR-2002.

XX  
PF 10-SEP-2001; 2001WO-US028235.

XX  
PR 11-SEP-2000; 2000US-00659791.

XX  
PA (ISIS-) ISIS PHARM INC.

XX  
PI Monia BP, Freier SM;

XX  
DR WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX  
PS Claim 3; Page 84; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings

XX  
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTGCGCGGAGCTC 1028  
Db 20 CTAAGCTGCGCGGAGCTC 1

RESULT 127  
ABN99725/c

ID ABN99725 standard; DNA; 20 BP.

XX  
AC ABN99725;

XX  
DT 16-AUG-2002 (first entry)

XX  
DE Human clusterin inhibiting antisense oligonucleotide 59.

```
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
PN WO200222635-A1.
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
PR 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
PA Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 84; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 9 A; 7 C; 2 G; 2 T; 0 U; 0 Other;
XX
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Oy 1398 GATCTGATGTTGCTTTTC 1417
Db 20 GATCTGATGTTGCTTTTC 1
XX
RESULT 128
ABN99671/c
ID ABN99671 standard; DNA; 20 BP.
XX
AC ABN99671;
XX
XX 16-AUG-2002 (first entry)
XX Human clusterin inhibiting antisense oligonucleotide 5.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
XX
PD 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
```

```
PR 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Oy 101 GCAGGTCTCTGGGGGACCAGA 120
Db 20 GCAGGTCTCTGGGGGACCAGA 1
XX
RESULT 129
ABN99678/c
ID ABN99678 standard; DNA; 20 BP.
XX
AC ABN99678;
XX
XX 16-AUG-2002 (first entry)
XX Human clusterin inhibiting antisense oligonucleotide 12.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Freier SM;
XX WPI; 2002-404805/43.
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
PS Claim 3; Page 83; 125pp; English.
XX
```

CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCTAATGAGACGACGGAA 317  
DB 20 CCTAATGAGACGACGGAA 1  
|||||

RESULT 130  
ABN99694/C  
ID ABN99694 standard; DNA; 20 BP.  
XX  
AC ABN99694;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 28.  
XX  
DE Human, antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCAGGACCCAC 584  
DB 20 TGGATGTCATGCAGGACCCAC 1  
|||||

RESULT 131  
ABN99700/C  
ID ABN99700 standard; DNA; 20 BP.  
XX  
AC ABN99700;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 34.  
XX  
KW Human, antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 TCGTCCGACGCTTGATGCC 740  
DB 20 TCGTCCGACGCTTGATGCC 1  
|||||

RESULT 132  
ABN99721/C  
ID ABN99721 standard; DNA; 20 BP.  
XX  
AC ABN99721;  
XX

DT 16-AUG-2002 (first entry)  
DE Human clusterin inhibiting antisense oligonucleotide 55.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
PN  
XX 21-MAR-2002.  
PD  
XX 10-SEP-2001; 2001WO-US028235.  
PF  
XX 11-SEP-2000; 2000US-00659791.  
PR  
XX (ISIS-) ISIS PHARM INC.  
PA  
XX Monia BP, Freier SM;  
PI  
XX WPI; 2002-404805/43.  
DR  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 84; 125pp; English.  
PS  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
XX Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;  
SQ  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1216 CTTCCACACTTCTGACTCG 1235  
Db 20 CTTCCACACTTCTGACTCG 1  
  
RESULT 133  
ABN99669/C  
ID ABN99669 standard; DNA; 20 BP.  
XX  
XX AC ABN99669;  
XX  
XX 16-AUG-2002 (first entry)  
DT  
XX  
XX DE Human clusterin inhibiting antisense oligonucleotide 3.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX OS Homo sapiens.  
XX  
XX WO200222635-A1.  
PN  
XX 21-MAR-2002.  
PD

XX 10-SEP-2001; 2001WO-US028235.  
PF  
XX 11-SEP-2000; 2000US-00659791.  
PR  
XX (ISIS-) ISIS PHARM INC.  
PA  
XX Monia BP, Freier SM;  
PI  
XX WPI; 2002-404805/43.  
DR  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Example 15; Page 83; 125pp; English.  
PS  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
XX Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;  
SQ  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 39 ATTGGAGGCATGATGAGAC 58  
Db 20 ATTGGAGGCATGATGAGAC 1  
  
RESULT 134  
ABN99685/C  
ID ABN99685 standard; DNA; 20 BP.  
XX  
XX AC ABN99685;  
XX  
XX 16-AUG-2002 (first entry)  
DT  
XX  
XX DE Human clusterin inhibiting antisense oligonucleotide 19.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX OS Homo sapiens.  
XX  
XX WO200222635-A1.  
PN  
XX 21-MAR-2002.  
PD  
XX 10-SEP-2001; 2001WO-US028235.  
PF  
XX 11-SEP-2000; 2000US-00659791.  
PR  
XX (ISIS-) ISIS PHARM INC.  
PA  
XX Monia BP, Freier SM;  
PI  
XX WPI; 2002-404805/43.  
DR  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
PT

XX PS Claim 3; Page 83; 125pp; English.

CC The invention comprises antisense oligonucleotides that are capable of

CC inhibiting expression of the human clusterin gene. The antisense

CC oligonucleotides of the invention are useful for inhibiting the

CC expression of clusterin in cells. The antisense oligonucleotides are also

CC useful for treating an animal with a disease or condition associated with

CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

CC hyperproliferative disorders; and hyperlipidemic disorders). The present

CC DNA sequence represents a clusterin antisense oligonucleotide of the

CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 443 CTCAGGCTGGTTGGCGCC 462

Db 20 CTCAGGCTGGTTGGCGCC 1

RESULT 135

ABN99689/c

ID ABN99689 standard; DNA; 20 BP.

XX AC ABN99689;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 23.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;

KW hypercholesterolaemia; cardiovascular disorder; ss;

KW hyperproliferative disorder; hyperlipidemic disorder;

KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX WO200222635-A1.

XX 21-MAR-2002.

XX 10-SEP-2001; 2001WO-US028235.

XX 11-SEP-2000; 2000US-00659791.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Freier SM;

XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding

XX clusterin, useful for treating animal having disease associated with

XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of

XX inhibiting expression of the human clusterin gene. The antisense

XX oligonucleotides of the invention are useful for inhibiting the

XX expression of clusterin in cells. The antisense oligonucleotides are also

XX useful for treating an animal with a disease or condition associated with

XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX hyperproliferative disorders; and hyperlipidemic disorders). The present

XX DNA sequence represents a clusterin antisense oligonucleotide of the

XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX and also contains 2'-O-methoxyethyl wings

SQ Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 492 CCCTTCTACTTCTGGATGAA 511

Db 20 CCCTTCTACTTCTGGATGAA 1

RESULT 136

ABN99703/c

ID ABN99703 standard; DNA; 20 BP.

XX AC ABN99703;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 37.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;

KW hypercholesterolaemia; cardiovascular disorder; ss;

KW hyperproliferative disorder; hyperlipidemic disorder;

KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX WO200222635-A1.

XX 21-MAR-2002.

XX 10-SEP-2001; 2001WO-US028235.

XX 11-SEP-2000; 2000US-00659791.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Freier SM;

XX WPI; 2002-404805/43.

XX Novel antisense compound targeted to nucleic acid molecule encoding

XX clusterin, useful for treating animal having disease associated with

XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of

XX inhibiting expression of the human clusterin gene. The antisense

XX oligonucleotides of the invention are useful for inhibiting the

XX expression of clusterin in cells. The antisense oligonucleotides are also

XX useful for treating an animal with a disease or condition associated with

XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX hyperproliferative disorders; and hyperlipidemic disorders). The present

XX DNA sequence represents a clusterin antisense oligonucleotide of the

XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 783 CCCTTCTCTGAGATGATACA 802

Db 20 CCCTTCTCTGAGATGATACA 1

RESULT 137

ABN99720/c

ID ABN99720 standard; DNA; 20 BP.

```
XX AC ABN99720;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 54.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX DR Novel antisense compound targeted to nucleic acid molecule encoding
XX PT clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 84; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1194 TATCTGCGGGTACCACGGT 1213
DB 20 TATCTGCGGGTACCACGGT 1

RESULT 138
ABN99691/C
ID ABN99691 standard; DNA; 20 BP.
XX AC ABN99691;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 25.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX
```

```
PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX DR Novel antisense compound targeted to nucleic acid molecule encoding
XX PT clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 83; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 533 GCTGGAGAACGACCGCGCAGC 552
DB 20 GCTGGAGAACGACCGCGCAGC 1

RESULT 139
ABN99713/C
ID ABN99713 standard; DNA; 20 BP.
XX AC ABN99713;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 47.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX
```

CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1332 AAATTTATGGAGACCGTGGC 1351  
DB 20 AAATTTATGGAGACCGTGGC 1  
RESULT 141  
ABN99690/c  
ID ABN99690 standard; DNA; 20 BP.  
XX AC ABN99690;  
XX DT 16-AUG-2002 (first entry)  
XX XX Human clusterin inhibiting antisense oligonucleotide 24.  
DE Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX Homo sapiens.  
OS  
XX WO200222635-A1.  
FN 21-MAR-2002.  
XX  
PD 10-SEP-2001; 2001WO-US028235.  
XX PF 11-SEP-2000; 2000US-00659791.  
XX PR (ISIS-) ISIS PHARM INC.  
XX PA Monia BP, Freier SM;  
XX PI WPI; 2002-404805/43.  
XX DR  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 83; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 517 ACCGATCGACTCCCTGCTG 536  
DB 20 ACCGATCGACTCCCTGCTG 1

XX	Homo sapiens.
OS	WO200222635-A1.
PN	21-MAR-2002.
PD	10-SEP-2001; 2001WO-US028235.
PX	11-SEP-2000; 2000US-00659791.
PA	(ISIS-) ISIS PHARM INC.
PI	Monia BP, Freier SM;
PP	WPI; 2002-404805/43.
PS	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
PT	Claim 3; Page 84; 125pp; English.
QY	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
DB	Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
DE	Query Match 1.2%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 45; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DI	1121 GCTGGAGCAGCTGTAACGAGC 1140 20 GCTGGAGCAGCTGTAACGAGC 1
DJ	RESULT 144 ABN99672/c
DK	ID ABN99672 standard; DNA; 20 BP.
DL	AC ABN99672;
DM	XX 16-AUG-2002 (first entry)
DN	Human clusterin inhibiting antisense oligonucleotide 6.
DO	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.
DP	Homo sapiens.
DQ	WO200222635-A1.
DR	21-MAR-2002.
DS	10-SEP-2001; 2001WO-US028235.
DT	11-SEP-2000; 2000US-00659791.
DU	(ISIS-) ISIS PHARM INC.
DV	Monia BP, Freier SM;
DW	WPI; 2002-404805/43.
DX	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
DY	Claim 3; Page 83; 125pp; English.
EA	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
EB	Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
EC	Query Match 1.2%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 45; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
ED	894 ACTGTGTCCCGGAGATCCG 913 20 ACTGTGTCCCGGAGATCCG 1
EE	RESULT 143 ABN99717/c
EF	ID ABN99717 standard; DNA; 20 BP.
EG	AC ABN99717;
EH	16-AUG-2002 (first entry)
EI	Human clusterin inhibiting antisense oligonucleotide 51.
EJ	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.



CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC	hyperproliferative disorders; and hyperlipidemic disorders). The present
CC	DNA sequence represents a clusterin antisense oligonucleotide of the
CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC	and also contains 2'-O-methoxyethyl wings
XX	
SQL	Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
	Query Match 1.2%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 45;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	553 AGACGCACATGCTGGATGTC 572
DB	20 AGACGCACATGCTGGATGTC 1
RESULT 146	
ABN99698/c	
ID	ABN99698 standard; DNA; 20 BP.
XX	
XX	ABN99698;
XX	
XX	16-AUG-2002 (first entry)
XX	
XX	Human clusterin inhibiting antisense oligonucleotide 32.
DE	
XX	
XX	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolaemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	
OS	Homo sapiens.
OS	
PN	WO200222635-A1.
PN	
PD	21-MAR-2002.
XX	
XX	10-SEP-2001; 2001WO-US028235.
XX	
XX	11-SEP-2000; 2000US-00659791.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
XX	Monia BP, Freier SM;
XX	
XX	WPI; 2002-404805/43.
DR	
PT	Novel antisense compound targeted to nucleic acid molecule encoding
PT	clusterin, useful for treating animal having disease associated with
PT	clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
PS	Claim 3; Page 83; 125pp; English.
XX	
XX	The invention comprises antisense oligonucleotides that are capable of
CC	inhibiting expression of the human clusterin gene. The antisense
CC	oligonucleotides of the invention are useful for inhibiting the
CC	expression of clusterin in cells. The antisense oligonucleotides are also
CC	useful for treating an animal with a disease or condition associated with
CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC	hyperproliferative disorders; and hyperlipidemic disorders). The present
CC	DNA sequence represents a clusterin antisense oligonucleotide of the
CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC	and also contains 2'-O-methoxyethyl wings
XX	
SQL	Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
	Query Match 1.2%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 45;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	613 AGCTCTCCAGGACAGGTTTC 632

Db	20	AGCTCTTCCAGGACAGGTTTC 1	KW	hypercholesterolaemia; cardiovascular disorder; ss;
			KW	hyperproliferative disorder; hyperlipidemic disorder;
			KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
			XX	
			OS	Homo sapiens.
			XX	
			XX	
			PN	WO200222635-A1.
			XX	
			AC	ABN99715;
			XX	
			DT	16-AUG-2002 (first entry)
			XX	
			DE	Human clusterin inhibiting antisense oligonucleotide 49.
			XX	
			KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
			KW	hypercholesterolaemia; cardiovascular disorder; ss;
			KW	hyperproliferative disorder; hyperlipidemic disorder;
			KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
			XX	
			OS	Homo sapiens.
			XX	
			PN	WO200222635-A1.
			XX	
			PD	21-MAR-2002.
			XX	
			PF	10-SEP-2001; 2001WO-US028235.
			XX	
			PR	11-SEP-2000; 2000US-00659791.
			XX	
			PA	(ISIS-) ISIS PHARM INC.
			XX	
			PI	Monia BP, Freier SM;
			XX	
			DR	WPI; 2002-404805/43.
			XX	
			PT	Novel antisense compound targeted to nucleic acid molecule encoding
			PT	clusterin, useful for treating animal having disease associated with
			PT	clusterin such as hyperlipidemic disorder, cardiovascular disorder.
			XX	
			PS	Claim 3; Page 84; 125pp; English.
			XX	
			CC	The invention comprises antisense oligonucleotides that are capable of
			CC	inhibiting expression of the human clusterin gene. The antisense
			CC	oligonucleotides of the invention are useful for inhibiting the
			CC	expression of clusterin in cells. The antisense oligonucleotides are also
			CC	useful for treating an animal with a disease or condition associated with
			CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
			CC	hyperproliferative disorders; and hyperlipidemic disorders). The present
			CC	DNA sequence represents a clusterin antisense oligonucleotide of the
			CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone
			CC	and also contains 2'-O-methoxyethyl wings
			SQ	Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
			PS	Claim 3; Page 84; 125pp; English.
			XX	
			CC	The invention comprises antisense oligonucleotides that are capable of
			CC	inhibiting expression of the human clusterin gene. The antisense
			CC	oligonucleotides of the invention are useful for inhibiting the
			CC	expression of clusterin in cells. The antisense oligonucleotides are also
			CC	useful for treating an animal with a disease or condition associated with
			CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
			CC	hyperproliferative disorders; and hyperlipidemic disorders). The present
			CC	DNA sequence represents a clusterin antisense oligonucleotide of the
			CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone
			CC	and also contains 2'-O-methoxyethyl wings
			SQ	Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
			XX	
			Query Match	1.2%; Score 20; DB 1; Length 20;
			Best Local Similarity	100.0%; Pred. No. 45;
			Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
			QY	1091 CCAGTGGAGAGATGCTCAACA 1110
			DB	20 CCAGTGGAGAGATGCTCAACA 1
			XX	
			RESULT 148	
			ABN99719/c	
			ID	ABN99719 standard; DNA; 20 BP.
			XX	
			AC	ABN99719;
			XX	
			DT	16-AUG-2002 (first entry)
			XX	
			DE	Human clusterin inhibiting antisense oligonucleotide 53.
			XX	
			XX	Human; antisense inhibition; antisense oligonucleotide; clusterin;
			KW	
			Query Match	1.2%; Score 20; DB 1; Length 20;
			Best Local Similarity	100.0%; Pred. No. 45;
			Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
			QY	1182 GAAGACCAGTACTACTGCG 1201
			DB	20 GAAGACCAGTACTACTGCG 1
			XX	
			RESULT 149	
			ABN99728/c	
			ID	ABN99728 standard; DNA; 20 BP.
			XX	
			AC	ABN99728;
			XX	
			DT	16-AUG-2002 (first entry)
			XX	
			DE	Human clusterin inhibiting antisense oligonucleotide 62.
			XX	
			KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
			KW	hypercholesterolaemia; cardiovascular disorder; ss;
			KW	hyperproliferative disorder; hyperlipidemic disorder;
			KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
			XX	
			OS	Homo sapiens.
			XX	
			PN	WO200222635-A1.
			XX	
			PD	21-MAR-2002.
			XX	
			PF	10-SEP-2001; 2001WO-US028235.
			XX	
			PR	11-SEP-2000; 2000US-00659791.
			XX	
			PA	(ISIS-) ISIS PHARM INC.
			XX	
			PI	Monia BP, Freier SM;
			XX	
			DR	WPI; 2002-404805/43.
			XX	
			PT	Novel antisense compound targeted to nucleic acid molecule encoding
			PT	clusterin, useful for treating animal having disease associated with
			PT	clusterin such as hyperlipidemic disorder, cardiovascular disorder.
			XX	
			PS	Claim 3; Page 84; 125pp; English.
			XX	
			CC	The invention comprises antisense oligonucleotides that are capable of
			CC	inhibiting expression of the human clusterin gene. The antisense
			CC	oligonucleotides of the invention are useful for inhibiting the
			CC	expression of clusterin in cells. The antisense oligonucleotides are also
			CC	useful for treating an animal with a disease or condition associated with
			CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
			CC	hyperproliferative disorders; and hyperlipidemic disorders). The present
			CC	DNA sequence represents a clusterin antisense oligonucleotide of the
			CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone
			CC	and also contains 2'-O-methoxyethyl wings
			SQ	Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;



DE Human clusterin inhibiting antisense oligonucleotide 30.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
DR WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 604 TCATAGACGAGCTCTCCAG 623  
DB 20 TCATAGACGAGCTCTCCAG 1  
RESULT 154  
ABN99705/C  
ID ABN99705 standard; DNA; 20 BP.  
XX  
AC ABN99705;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 39.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.

OY 149 GTCCAATCAGGAACTAAGT 168  
DB 20 GTCCAATCAGGAACTAAGT 1  
RESULT 152  
ABN99679/C  
ID ABN99679 standard; DNA; 20 BP.  
XX  
AC ABN99679;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 13.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
DR WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 307 AGACCAGGGAATCAGAGACA 326  
DB 20 AGACCAGGGAATCAGAGACA 1  
RESULT 153  
ABN99696/C  
ID ABN99696 standard; DNA; 20 BP.  
XX  
AC ABN99696;  
XX  
DT 16-AUG-2002 (first entry)  
XX

XX 11-SEP-2000; 2000US-00659791.  
PR (ISIS-) ISIS PHARM INC.  
XX  
XX  
PI Monia BP, Freier SM;  
XX  
DR WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 1 A; 3 C; 9 G; 7 T; 0 U; 0 Other;  
XX  
XX  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
QY 848 CCAGCACCAGCAAT 867  
DB 20 CCAGCACCAGCAAT 1  
XX  
XX  
XX RESULT 155  
XX ABN99706/C  
XX ID ABN99706 standard; DNA; 20 BP.  
XX  
XX AC ABN99706;  
XX  
XX DT 16-AUG-2002 (first entry)  
XX  
XX DE Human clusterin inhibiting antisense oligonucleotide 40.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX PD 21-MAR-2002.  
XX  
XX PF 10-SEP-2001; 2001WO-US028235.  
XX  
XX PR 11-SEP-2000; 2000US-00659791.  
XX  
XX PA (ISIS-) ISIS PHARM INC.  
XX  
XX PI Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 3 A; 2 C; 7 G; 8 T; 0 U; 0 Other;  
XX  
XX  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
QY 853 ACCGCCAACAGATTCATA 872  
DB 20 ACCGCCAACAGATTCATA 1  
XX  
XX  
XX RESULT 156  
XX ABN99723/C  
XX ID ABN99723 standard; DNA; 20 BP.  
XX  
XX AC ABN99723;  
XX  
XX DT 16-AUG-2002 (first entry)  
XX  
XX DE Human clusterin inhibiting antisense oligonucleotide 57.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX PD 21-MAR-2002.  
XX  
XX PF 10-SEP-2001; 2001WO-US028235.  
XX  
XX PR 11-SEP-2000; 2000US-00659791.  
XX  
XX PA (ISIS-) ISIS PHARM INC.  
XX  
XX PI Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 84; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGTCCCTGTAGAGTCTCC 1319  
Db 20 CGTCCCTGTAGAGTCTCC 1

RESULT 157  
ABN99731/c  
ID ABN99731 standard; DNA; 20 BP.  
AC ABN99731;  
XX  
XX 16-AUG-2002 (first entry)  
XX Human clusterin inhibiting antisense oligonucleotide 65.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
OS  
XX WO200222635-A1.  
PN  
XX  
XX AC ABN99731;  
XX  
XX 16-AUG-2002 (first entry)  
XX Human clusterin inhibiting antisense oligonucleotide 65.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
OS  
XX WO200222635-A1.  
PN  
XX  
XX 21-MAR-2002.  
XX 10-SEP-2001; 2001WO-US028235.  
XX 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
PT  
XX  
XX Claim 3; Page 84; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings  
XX  
XX Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 TGGACTGTTCACCAACAC 998  
Db 20 TGGACTGTTCACCAACAC 1

RESULT 158  
ABN99699/c  
ID ABN99699 standard; DNA; 20 BP.  
XX  
XX AC ABN99699;

XX 16-AUG-2002 (first entry)  
XX Human clusterin inhibiting antisense oligonucleotide 33.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
OS  
XX WO200222635-A1.  
PN  
XX  
XX 21-MAR-2002.  
XX 10-SEP-2001; 2001WO-US028235.  
XX 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
PT  
XX  
XX Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings  
XX  
XX Sequence 20 BP; 8 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 AGCCCTCACTTCTTCTTCC 709  
Db 20 AGCCCTCACTTCTTCTTCC 1

RESULT 159  
ABN99714/c  
ID ABN99714 standard; DNA; 20 BP.  
XX  
XX AC ABN99714;  
XX  
XX 16-AUG-2002 (first entry)  
XX Human clusterin inhibiting antisense oligonucleotide 48.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
OS  
XX WO200222635-A1.  
XX

PD 21-MAR-2002.  
XX  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
XX  
PI Monia BP, Freier SM;  
XX  
XX  
DR WPI; 2002-404805/43.  
XX  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX  
PS Claim 3; Page 84; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
XX Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;  
SQ  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1083 AAGTCCTACCAGTGGAGAT 1102  
DB 20 AAGTCCTACCAGTGGAGAT 1  
RESULT 160  
ABN99674/c  
ID ABN99674 standard; DNA; 20 BP.  
XX  
XX  
AC ABN99674;  
XX  
XX 16-AUG-2002 (first entry)  
XX  
XX Human clusterin inhibiting antisense oligonucleotide 8.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX 21-MAR-2002.  
XX  
XX 10-SEP-2001; 2001WO-US028235.  
XX  
XX 11-SEP-2000; 2000US-00659791.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with

PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 83; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
XX Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
SQ  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 166 AGTACGCTCAATAGGAAAT 185  
DB 20 AGTACGCTCAATAGGAAAT 1  
RESULT 161  
ABN99688/c  
ID ABN99688 standard; DNA; 20 BP.  
XX  
XX  
AC ABN99688;  
XX  
XX 16-AUG-2002 (first entry)  
XX  
XX Human clusterin inhibiting antisense oligonucleotide 22.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX 21-MAR-2002.  
XX  
XX 10-SEP-2001; 2001WO-US028235.  
XX  
XX 11-SEP-2000; 2000US-00659791.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 83; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
XX Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
SQ

XX	SQ	Sequence	20 BP; 5 A; 3 C; 9 G; 3 T; 0 U; 0 Other;	
XX	Query Match	1.2%; Score 20; DB 1; Length 20;		
XX	Best Local Similarity	100.0%; Pred. No. 45;		
XX	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	482	CCAGAGCTCGCCCTTCTACT 501		
Db	20	CCAGAGCTCGCCCTTCTACT 1		
XX	RESULT 162			
XX	ABN99710/c			
XX	ID	ABN99710 standard; DNA; 20 BP.		
XX	AC	ABN99710;		
XX	DT	16-AUG-2002 (first entry)		
XX	DE	Human clusterin inhibiting antisense oligonucleotide 44.		
XX	Human; antisense inhibition; antisense oligonucleotide; clusterin;			
KW	hypercholesterolaemia; cardiovascular disorder; ss;			
KW	hyperproliferative disorder; hyperlipidemic disorder;			
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.			
XX	Homo sapiens.			
OS	WO200222635-A1.			
XX	PN	21-MAR-2002.		
XX	PD	10-SEP-2001; 2001WO-US028235.		
XX	PF	11-SEP-2000; 2000US-00659791.		
XX	PR	(ISIS-) ISIS PHARM INC.		
XX	PA	Monia BP, Freier SM;		
XX	PI	WPI; 2002-404805/43.		
XX	DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.		
XX	PT	Claim 3; Page 83; 125pp; English.		
XX	PS	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings		
XX	SQ	Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;		
XX	Query Match	1.2%; Score 20; DB 1; Length 20;		
XX	Best Local Similarity	100.0%; Pred. No. 45;		
XX	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	281	GAAGAAGAAAGAGGATGCC 300		
Db	20	GAAGAAGAAAGAGGATGCC 1		
XX	RESULT 164			
XX	ABN99692/c			
XX	ID	ABN99692 standard; DNA; 20 BP.		
XX	AC	ABN99692;		
XX	DT	16-AUG-2002 (first entry)		
XX	DE	Human clusterin inhibiting antisense oligonucleotide 26.		
XX	Human; antisense inhibition; antisense oligonucleotide; clusterin;			
KW	hypercholesterolaemia; cardiovascular disorder; ss;			
KW	hyperproliferative disorder; hyperlipidemic disorder;			
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.			
XX	Homo sapiens.			
OS				



XX PN WO200222635-A1.  
XX PD 21-MAR-2002.  
XX PF 10-SEP-2001; 2001WO-US028235.  
XX PR 11-SEP-2000; 2000US-00659791.  
XX PA (ISIS-) ISIS PHARM INC.  
XX PI Monia BP, Freier SM;  
XX DR WPI; 2002-404805/43.  
XX XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX PS Claim 3; Page 83; 125pp; English.  
XX CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;  
PS Claim 3; Page 83; 125pp; English.  
XX CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 551 GCAGACGCACATGCTGGATG 570  
DB 20 GCAGACGCACATGCTGGATG 1  
RESULT 165  
ABN99707/C  
ID ABN99707 standard; DNA; 20 BP.  
XX AC ABN99707;  
XX DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 41.  
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX KW hypercholesterolaemia; cardiovascular disorder; ss;  
XX KW hyperproliferative disorder; hyperlipidemic disorder;  
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX OS Homo sapiens.  
XX XX WO200222635-A1.  
XX PN 21-MAR-2002.  
XX PF 10-SEP-2001; 2001WO-US028235.  
XX PR 11-SEP-2000; 2000US-00659791.  
XX PA (ISIS-) ISIS PHARM INC.  
XX PI Monia BP, Freier SM;  
XX DR WPI; 2002-404805/43.  
XX XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX PS Claim 3; Page 83; 125pp; English.  
XX CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 551 GCAGACGCACATGCTGGATG 570  
DB 20 GCAGACGCACATGCTGGATG 1  
RESULT 165  
ABN99707/C  
ID ABN99707 standard; DNA; 20 BP.  
XX AC ABN99707;  
XX DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 41.  
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX KW hypercholesterolaemia; cardiovascular disorder; ss;  
XX KW hyperproliferative disorder; hyperlipidemic disorder;  
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX OS Homo sapiens.  
XX XX WO200222635-A1.  
XX PN 21-MAR-2002.  
XX PF 10-SEP-2001; 2001WO-US028235.  
XX PR 11-SEP-2000; 2000US-00659791.  
XX PA (ISIS-) ISIS PHARM INC.  
XX PI Monia BP, Freier SM;  
XX DR WPI; 2002-404805/43.  
XX XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX PS Claim 3; Page 83; 125pp; English.  
XX CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 893 GACTGTGTGCGGAGATCC 912  
DB 20 GACTGTGTGCGGAGATCC 1  
RESULT 166  
ADO071105  
ID ADO071105 standard; DNA; 20 BP.  
XX AC ADO071105;  
XX DT 15-JUL-2004 (first entry)  
XX DE CUU gene forward PCR primer.  
XX KW Rheumatoid arthritis; osteoarthritis; microarray; molecular profiling;  
XX KW diagnosis; antiarthritic; CUU; PCR; primer; human; ss.  
XX OS Homo sapiens.  
XX XX WO2004035827-A2.  
XX PN 29-APR-2004.  
XX PD 20-OCT-2003; 2003WO-IB005143.  
XX PF 18-OCT-2002; 2002US-0419650P.  
XX PR (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.  
XX PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.  
XX PA (COMS ) COMMISSARIAT ENERGIE ATOMIQUE.  
XX PI Breban M, Gidrol X, Marion S, Chicocchia G;  
XX DR WPI; 2004-348476/32.  
XX XX New library of polynucleotide sequences expressed in cells from synovial  
PT tissues, useful for diagnosing and treating rheumatoid arthritis or  
PT osteoarthritis.  
XX PS Disclosure; SEQ ID NO 5; 71pp; English.  
XX XX The present invention concerns an analysis of genes differentially  
CC expressed in synovial tissues from rheumatoid arthritis (RA) and  
CC osteoarthritis (OA) patients. Microarray technology was used to compare  
CC gene expression profiles, and sets of genes were identified based on over  
CC -expression or under-expression in RA samples compared to OA samples.  
CC Results for 6 of the selected genes (GAP1,CLU, RH70, GLO1, DXS and CTSL)  
CC were verified by real-time, quantitative PCR using samples identical to



Matches	15;	Conservative	5;	Mismatches	0;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

  

QY	48	ATGATGAAGACTCTGCTGCT	67
Db	1	AUGAUGAAGACUCGUGCT	20

  

RESULT 170	
AAAS2782	
ID	AAAS2782 standard; DNA; 21 BP.
XX	
AC	AAAS2782;
XX	
DT	03-JAN-2001 (first entry)
XX	
DE	Murine clusterin PCR primer #2.
XX	
KW	Mouse; clusterin; cell migration; wound healing; angiogenesis; cancer;
KW	vascular trauma; vascular disease; atherosclerosis; restenosis;
KW	complement cytolytic inhibitor; SP-40; 40; apoJ;
KW	testosterone repressed prostate message-2; sulfated glycoprotein-2;
KW	PCR primer; ss.
XX	
OS	Mus sp.
XX	
PN	WO200034469-A1.
XX	
PD	15-JUN-2000.
XX	
PF	10-DEC-1999; 99WO-US029262.
XX	
PR	11-DEC-1998; 98US-0111856P.
XX	
PA	(UWNY ) UNIV NEW YORK STATE RES FOUND.
XX	
PI	Millis AJT;
XX	
DR	WPI; 2000-431300/37.
XX	
PT	Clusterin and gp38K-related peptide capable of altering cell migration
PT	useful for treating atherosclerosis, cancer and stenosis following
PT	vascular trauma or disease.
XX	
PS	Disclosure; Page 12; 43pp; English.
XX	
CC	The present sequence is a PCR primer for the murine clusterin gene.
CC	Clusterin (also known as complement cytolysis inhibitor, sulfated
CC	glycoprotein-2, testosterone repressed prostate message-2, SP-40, 40 and
CC	apoJ) is essential for the migration of vascular smooth muscle cells
CC	(VSMC). The gene and protein can, therefore, be used to promote wound
CC	healing, angiogenesis and vasculogenesis, in the treatment of stenosis
CC	following vascular trauma or disease and to treat atherosclerosis, and
CC	antisense sequences can be used to treat cancer, as angiogenesis is vital
CC	for tumour survival
XX	
SQ	Sequence 21 BP; 12 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

  

Query Match	1.2%;	Score 19.4;	DB 1;	Length 21;
Best Local Similarity	95.2%;	Pred. No. 66;		
Matches	20;	Conservative	0;	Mismatches 1;
				Indels 0;
				Gaps 0;

  

QY	271	AAGAAGCCAGAGAAGAAAG	291
Db	1	AGGAAGCCAGAGAAGAAAG	21

  

RESULT 171	
ADL70522	
ID	ADL70522 standard; RNA; 19 BP.
XX	
AC	ADL70522;
XX	
DT	20-MAY-2004 (first entry)
XX	

XX	DE	DT	20-MAY-2004	(first entry)	XX	DE	DT	20-MAY-2004	(first entry)
XX	KW	KW	RNAi for human clusterin.		XX	KW	KW	RNAi for human clusterin.	
XX	KW	KW	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;		XX	KW	KW	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;	
XX	KW	KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;		XX	KW	KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;	
XX	OS	OS	ss.		XX	OS	OS	ss.	
XX	OS	OS	Homo sapiens.		XX	OS	OS	Homo sapiens.	
XX	OS	OS	Synthetic.		XX	OS	OS	Synthetic.	
XX	PH	PH	Key	Location/Qualifiers	XX	PH	PH	Key	Location/Qualifiers
XX	FT	FT	modified_base	18..19	XX	FT	FT	modified_base	18..19
XX	FT	FT	/tag= a		XX	FT	FT	/tag= a	
XX	FT	FT	/mod_base= OTHER		XX	FT	FT	/mod_base= OTHER	
XX	FT	FT	/note= "OTHER= dtdt"		XX	FT	FT	/note= "OTHER= dtdt"	
XX	PN	PN	WO2004018676-A2.		XX	PN	PN	WO2004018676-A2.	
XX	PD	PD	04-MAR-2004.		XX	PD	PD	04-MAR-2004.	
XX	PF	PF	21-AUG-2003; 2003WO-CA001277.		XX	PF	PF	21-AUG-2003; 2003WO-CA001277.	
XX	PR	PR	21-AUG-2002; 2002US-0405193P.		XX	PR	PR	21-AUG-2002; 2002US-0405193P.	
XX	PR	PR	03-SEP-2002; 2002US-0408152P.		XX	PR	PR	03-SEP-2002; 2002US-0408152P.	
XX	PR	PR	20-MAY-2003; 2003US-0472387P.		XX	PR	PR	20-MAY-2003; 2003US-0472387P.	
XX	PA	PA	(UYBR-) UNIV BRITISH COLUMBIA.		XX	PA	PA	(UYBR-) UNIV BRITISH COLUMBIA.	
XX	PI	PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;		XX	PI	PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;	
XX	PI	PI	Gonos ES;		XX	PI	PI	Gonos ES;	
XX	PI	PI	WPI; 2004-226852/21.		XX	PI	PI	WPI; 2004-226852/21.	
XX	DR	DR	New RNA molecule less than 49 bases and having a sequence effective to		XX	DR	DR	New RNA molecule less than 49 bases and having a sequence effective to	
XX	PT	PT	mediate degradation or block translation of mRNA that is the		XX	PT	PT	mediate degradation or block translation of mRNA that is the	
XX	PT	PT	transcriptional product of a target gene, useful for treating Alzheimer's		XX	PT	PT	transcriptional product of a target gene, useful for treating Alzheimer's	
XX	PT	PT	disease or cancer.		XX	PT	PT	disease or cancer.	
XX	PS	PS	Claim 4; SEQ ID NO 67; 63pp; English.		XX	PS	PS	Claim 4; SEQ ID NO 67; 63pp; English.	
XX	CC	CC	The present sequence is the sense strand of a short interfering RNA		XX	CC	CC	The present sequence is the sense strand of a short interfering RNA	
XX	CC	CC	(siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.		XX	CC	CC	(siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.	
XX	CC	CC	The antisense strand is also provided ADL70523. The siRNA can be used to		XX	CC	CC	The antisense strand is also provided ADL70523. The siRNA can be used to	
XX	CC	CC	interfere with the expression of clusterin. Clusterin, also known as		XX	CC	CC	interfere with the expression of clusterin. Clusterin, also known as	
XX	CC	CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated		XX	CC	CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated	
XX	CC	CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate		XX	CC	CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate	
XX	CC	CC	tumour cells following androgen withdrawal, and has also been shown to be		XX	CC	CC	tumour cells following androgen withdrawal, and has also been shown to be	
XX	CC	CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.		XX	CC	CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.	
XX	CC	CC	siRNAs of the invention can be used alone or in combination with other		XX	CC	CC	siRNAs of the invention can be used alone or in combination with other	
XX	CC	CC	chemotherapy or apoptosis inducing treatments for the treatment of		XX	CC	CC	chemotherapy or apoptosis inducing treatments for the treatment of	
XX	CC	CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,		XX	CC	CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,	
XX	CC	CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,		XX	CC	CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,	
XX	CC	CC	anaplastic large cell lymphoma and melanoma, and also for the treatment		XX	CC	CC	anaplastic large cell lymphoma and melanoma, and also for the treatment	
XX	CC	CC	of Alzheimer's disease. In an example from the invention, the present		XX	CC	CC	of Alzheimer's disease. In an example from the invention, the present	
XX	CC	CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3		XX	CC	CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3	
XX	CC	CC	prostate cancer cells. A reduction in clusterin transcript was observed.		XX	CC	CC	prostate cancer cells. A reduction in clusterin transcript was observed.	
XX	CC	CC	Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;		XX	CC	CC	Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;	
XX	CC	CC	Query Match	1.2%; Score 19; DB 1; Length 19;	XX	CC	CC	Query Match	1.2%; Score 19; DB 1; Length 19;
XX	CC	CC	Best Local Similarity	73.7%; Pred. No. 52;	XX	CC	CC	Best Local Similarity	73.7%; Pred. No. 52;
XX	CC	CC	Matches	14; Conservative	XX	CC	CC		

XX	RNAi for human clusterin.
DE	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KW	ss.
KW	Homo sapiens.
OS	Synthetic.
FH	Key Location/Qualifiers
FT	modified_base 18..19
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= dTdT"
XX	WO2004018676-A2.
PN	04-MAR-2004.
PD	21-AUG-2003; 2003WO-CA001277.
XX	21-AUG-2002; 2002US-0405193P.
XX	03-SEP-2002; 2002US-0408152P.
PR	20-MAY-2003; 2003US-0472387P.
PR	(UYBR-) UNIV BRITISH COLUMBIA.
XX	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
XX	Gonos ES;
PI	WPI; 2004-226852/21.
DR	New RNA molecule less than 49 bases and having a sequence effective to
PT	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
PS	Claim 4; SEQ ID NO 67; 63pp; English.
XX	The present sequence is the sense strand of a short interfering RNA
CC	(siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.
CC	The antisense strand is also provided ADL70523. The siRNA can be used to
CC	interfere with the expression of clusterin. Clusterin, also known as
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC	tumour cells following androgen withdrawal, and has also been shown to be
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC	siRNAs of the invention can be used alone or in combination with other
CC	chemotherapy or apoptosis inducing treatments for the treatment of
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment
CC	of Alzheimer's disease. In an example from the invention, the present
CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC	prostate cancer cells. A reduction in clusterin transcript was observed.
XX	Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
SQ	Query Match 1.2%; Score 19; DB 1; Length 19;
	Best Local Similarity 73.7%; Pred. No. 52;
	Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY	48 ATGATGAAGACTCTGTCTGC 66
	:   :   :   :   :   :   :   :
Db	1 AUGAUGAGACUCUGCUGC 19
	:   :   :   :   :   :   :   :
RESULT 172	
ID ADL70523/c	
ID ADL70523 standard; RNA; 19 BP.	
XX	

XX	20-MAY-2004 (first entry)
DT	RNAi for human clusterin.
DE	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KW	ss.
KW	Homo sapiens.
OS	Synthetic.
FH	Key Location/Qualifiers
FT	modified_base 18..19
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= dTdT"
XX	WO2004018676-A2.
PN	04-MAR-2004.
PD	21-AUG-2003; 2003WO-CA001277.
XX	21-AUG-2002; 2002US-0405193P.
XX	03-SEP-2002; 2002US-0408152P.
PR	20-MAY-2003; 2003US-0472387P.
PR	(UYBR-) UNIV BRITISH COLUMBIA.
XX	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
XX	Gonos ES;
PI	WPI; 2004-226852/21.
DR	New RNA molecule less than 49 bases and having a sequence effective to
PT	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
PS	Claim 4; SEQ ID NO 68; 63pp; English.
XX	The present sequence is the antisense strand of a short interfering RNA
CC	(siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.
CC	The sense strand is also provided ADL70522. The siRNA can be used to
CC	interfere with the expression of clusterin. Clusterin, also known as
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC	tumour cells following androgen withdrawal, and has also been shown to be
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC	siRNAs of the invention can be used alone or in combination with other
CC	chemotherapy or apoptosis inducing treatments for the treatment of
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment
CC	of Alzheimer's disease. In an example from the invention, the present
CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC	prostate cancer cells. A reduction in clusterin transcript was observed.
XX	Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
SQ	Query Match 1.2%; Score 19; DB 1; Length 19;
	Best Local Similarity 100.0%; Pred. No. 52;
	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	48 ATGATGAAGACTCTGTCTGC 66
Db	19 ATGATGAAGACTCTGTCTGC 1
RESULT 173	
ID ADL70444	
ID ADL70444 standard; RNA; 19 BP.	
XX	

```
XX AC ADL70444;
XX DT 20-MAY-2004 (first entry)
XX DE RNAi for human clusterin.
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
XX DE short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 18..19
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= TT"
XX PN WO2004018675-A1.
XX PD 04-MAR-2004.
XX PF 21-AUG-2003; 2003WO-CA001276.
XX PF 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI Jansen B;
XX PI WPI; 2004-226851/21.
XX DR
XX PT Treating melanoma in a mammalian subject comprises administering to the
XX PT subject a therapeutic agent effective to reduce the effective amount of
XX PT clusterin in the melanoma cells.
XX PS Claim 20; SEQ ID NO 42; 32pp; English.
XX PS
XX CC The present sequence is that of a short interfering RNA (siRNA) molecule
XX CC targeted to human clusterin ADL70403. The invention relates to the
XX CC treatment of melanoma through reduction in the effective amount of
XX CC clusterin. The therapeutic agent may be an antisense oligonucleotide
XX CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX CC line comprises administering an agent effective to modulate the amount of
XX CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX CC is down-regulated when the effective amount of clusterin is reduced. Such
XX CC inhibition is significant because bcl-xL is known to act as an inhibitor
XX CC of apoptosis.
XX SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 52;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGC 66
DB 1 AUGAUGAAGACUCUGCUGC 19
RESULT 174
ADL70445/C
ID ADL70445 standard; RNA; 19 BP.
XX AC ADL70445;
XX DE RNAi for human clusterin.
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
XX DE short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 18..19
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= TT"
XX PN WO2004018675-A1.
XX PD 04-MAR-2004.
XX PF 21-AUG-2003; 2003WO-CA001276.
XX PF 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI Jansen B;
XX PI WPI; 2004-226851/21.
XX DR
XX PT Treating melanoma in a mammalian subject comprises administering to the
XX PT subject a therapeutic agent effective to reduce the effective amount of
XX PT clusterin in the melanoma cells.
XX PS Claim 20; SEQ ID NO 42; 32pp; English.
XX PS
XX CC The present sequence is that of a short interfering RNA (siRNA) molecule
XX CC targeted to human clusterin ADL70403. The invention relates to the
XX CC treatment of melanoma through reduction in the effective amount of
XX CC clusterin. The therapeutic agent may be an antisense oligonucleotide
XX CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX CC line comprises administering an agent effective to modulate the amount of
XX CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX CC is down-regulated when the effective amount of clusterin is reduced. Such
XX CC inhibition is significant because bcl-xL is known to act as an inhibitor
XX CC of apoptosis.
XX SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 52;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGC 66
DB 1 AUGAUGAAGACUCUCUGCUGC 19
RESULT 174
ADL70445/C
ID ADL70445 standard; RNA; 19 BP.
XX AC ADL70445;
XX DE RNAi for human clusterin.
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
XX DE short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 18..19
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= TT"
XX PN WO2004018675-A1.
XX PD 04-MAR-2004.
XX PF 21-AUG-2003; 2003WO-CA001276.
XX PF 21-AUG-2002; 2002US-0405193P.
XX PR 03-SEP-2002; 2002US-0408152P.
XX PR 02-DEC-2002; 2002US-0319748P.
XX PR 20-MAY-2003; 2003US-0472387P.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (GLEA/) GLEAVE M E.
XX PI Jansen B;
XX PI WPI; 2004-226851/21.
XX DR
XX PT Treating melanoma in a mammalian subject comprises administering to the
XX PT subject a therapeutic agent effective to reduce the effective amount of
XX PT clusterin in the melanoma cells.
XX PS Claim 20; SEQ ID NO 43; 32pp; English.
XX PS
XX CC The present sequence is that of a short interfering RNA (siRNA) molecule
XX CC targeted to human clusterin ADL70403. The invention relates to the
XX CC treatment of melanoma through reduction in the effective amount of
XX CC clusterin. The therapeutic agent may be an antisense oligonucleotide
XX CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
XX CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
XX CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
XX CC line comprises administering an agent effective to modulate the amount of
XX CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
XX CC is down-regulated when the effective amount of clusterin is reduced. Such
XX CC inhibition is significant because bcl-xL is known to act as an inhibitor
XX CC of apoptosis.
XX SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGC 66
DB 19 ATGATGAAGACTCTGCTGC 1
RESULT 175
ADL70465/C
ID ADL70465 standard; RNA; 21 BP.
XX AC ADL70465;
XX XX
XX DT 20-MAY-2004 (first entry)
XX DE RNAi for human clusterin.
```

KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
PN WO2004018676-A2.  
XX  
XX  
PD 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
PI  
XX  
XX WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
XX mediate degradation or block translation of mRNA that is the  
XX transcriptional product of a target gene, useful for treating Alzheimer's  
XX disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 10; 63pp; English.  
XX  
XX The present sequence is the antisense strand of a short interfering RNA  
XX (siRNA) targeted to human clusterin. The sense strand is also provided  
XX ADL70464. The siRNA can be used to interfere with the expression of  
XX clusterin. Clusterin, also known as testosterone-repressed prostate  
XX message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
XX increased amounts by prostate tumour cells following androgen withdrawal,  
XX and has also been shown to be critical for neuritic toxicity in mouse  
XX models of Alzheimer's disease. siRNAs of the invention can be used alone  
XX or in combination with other chemotherapy or apoptosis inducing  
XX treatments for the treatment of prostate cancer, sarcomas such as  
XX osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
XX cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
XX melanoma, and also for the treatment of Alzheimer's disease.  
XX  
XX Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;  
SQ  
Query Match 1.2%; Score 19; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 75;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 48 ATGATGAAGACTCTGCTGC 66  
Db 19 ATGATGAAGACTCTGCTGC 1  
RESULT 176  
ADL70431/c  
ID ADL70431 standard; RNA; 21 BP.  
XX  
XX ADL70431;  
XX  
XX 20-MAY-2004 (first entry)  
DT  
XX RNAi for human clusterin.  
XX

KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN WO2004018675-A1.  
XX  
XX  
PD 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
PI  
XX  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.  
XX  
XX Claim 20; SEQ ID NO 29; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
XX targeted to human clusterin ADL70403. The invention relates to the  
XX treatment of melanoma through reduction in the effective amount of  
XX clusterin. The therapeutic agent may be an antisense oligonucleotide  
XX ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
XX targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
XX mRNA. A method for regulating expression of bcl-xL in a subject or cell  
XX line comprises administering an agent effective to modulate the amount of  
XX clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
XX is down-regulated when the effective amount of clusterin is reduced. Such  
XX inhibition is significant because bcl-xL is known to act as an inhibitor  
XX of apoptosis.  
XX  
XX Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;  
SQ  
Query Match 1.2%; Score 19; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 75;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 48 ATGATGAAGACTCTGCTGC 66  
Db 19 ATGATGAAGACTCTGCTGC 1  
RESULT 177  
ADC10398/c  
ID ADC10398 standard; DNA; 22 BP.  
XX  
XX ADC10398;  
XX  
XX 18-DEC-2003 (first entry)  
DT  
XX  
XX Human NOVX polypeptide gene reverse primer SEQ ID NO: 417.  
XX  
XX ss; primer; cytostatic; antidiabetic; anorectic; cerebroprotective;  
KW neuroprotective; antiinflammatory; gene therapy; antisense therapy;  
KW thyromimetic; NOVX; pathology; cancer; diabetes; obesity;  
KW

endocrine disorder; CNS disorder; inflammatory disorder;  
chromosome mapping; tissue typing; predictive medicine.

Homo sapiens.

W02003000842-A2.

03-JAN-2003.

04-JUN-2002; 2002WO-US017443.

04-JUN-2001; 2001US-0295607P.

06-JUN-2001; 2001US-0296404P.

06-JUN-2001; 2001US-0296418P.

07-JUN-2001; 2001US-0296575P.

11-JUN-2001; 2001US-0297414P.

12-JUN-2001; 2001US-0295573P.

14-JUN-2001; 2001US-0297567P.

15-JUN-2001; 2001US-0298285P.

18-JUN-2001; 2001US-0299133P.

19-JUN-2001; 2001US-0299230P.

21-JUN-2001; 2001US-0299949P.

22-JUN-2001; 2001US-0300177P.

26-JUN-2001; 2001US-0300883P.

28-JUN-2001; 2001US-0301530P.

03-JUL-2001; 2001US-0302951P.

31-JUL-2001; 2001US-0308909P.

14-SEP-2001; 2001US-0322297P.

25-SEP-2001; 2001US-0324669P.

03-DEC-2001; 2001US-0337477P.

14-DEC-2001; 2001US-0341562P.

21-FEB-2002; 2002US-0358656P.

21-FEB-2002; 2002US-0359122P.

22-FEB-2002; 2002US-0358978P.

22-FEB-2002; 2002US-0359034P.

22-FEB-2002; 2002US-0359035P.

27-FEB-2002; 2002US-0359121P.

27-FEB-2002; 2002US-0359964P.

01-MAR-2002; 2002US-0360858P.

12-MAR-2002; 2002US-0363430P.

12-MAR-2002; 2002US-0363767P.

10-APR-2002; 2002US-0371346P.

10-MAY-2002; 2002US-0379444P.

04-JUN-2002; 2002US-00379444.

(CURA-) CURAGEN CORP.

Agee ML, Anderson DW, Berghs C, Casman SJ, Catterton E,

Dipippo VA, Edinger SR, Eisen A, Ellerman K, Gangolli EA;

Gerlach VL, Gorman L, Guo X, Herrmann JL, Hjalt T, Ji W, Kekuda R;

Khrantsov NV, Li L, Liu X, Malyankar UM, Miller CE, Millet I;

Ort T, Padigar M, Pattarajan M, Pena CE, Rastelli L, Rieger DK;

Rothenberg ME, Shenoy SG, Shinkets RA, Smithson G, Spaderna SK;

Spytek KA, Stone DJ, Vernet CM, Zhong H, Zhong M, Alsbrook JP;

Burgess CE, Lepley DM;

WPI; 2003-210149/20.

New isolated NOVX polypeptides and nucleic acid molecules useful for

treating, preventing and diagnosing pathological conditions with NOVX-

associated disorders, such as cancer, obesity, diabetes and inflammatory

or CNS diseases.

Example B; SEQ ID NO 417; 772pp; English.

The invention relates to novel isolated polypeptides, mature form of the

polypeptide, a sequence that is 95% identical to the polypeptide or the

polypeptide comprising one or more conservative substitutions. The NOVX

polypeptide is useful for treating or preventing a pathology associated

with the polypeptide e.g. disorders associated with aberrant expression

or activity of the polypeptide, such as cancer, diabetes, obesity, and  
endocrine, CNS and inflammatory disorders. They can also be used in  
various detection and screening assays, chromosome mapping, tissue typing  
and predictive medicine. This sequence corresponds to a primer used to  
amplify and isolate the coding sequence for one of the polypeptides of  
the invention.

Sequence 22 BP; 1 A; 7 C; 3 G; 11 T; 0 U; 0 Other;

Query Match 1.1%; Score 18.8; DB 1; Length 22;

Best Local Similarity 90.9%; Pred. No. 94;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 AACCTAGAGAGCCCAAGA 285

Db 22 AAGCTAGAGAGCCCAAGA 1

RESULT 178

AAT41539/C

ID AAT41539 standard; DNA; 18 BP.

XX AAT41539;

AC AAT41539;

XX 24-JUN-1997 (first entry)

DE Human apolipoprotein-J gene exon 7-specific 3' PCR primer.

XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;

KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;

KW diagnosis; ss.

XX Synthetic.

XX WO9632502-A1.

XX 17-OCT-1996.

XX 02-APR-1996; 96WO-US004510.

XX 11-APR-1995; 95US-00420291.

XX (UYCO ) UNIV COLUMBIA NEW YORK.

XX Mayeux R, Tycko B;

XX WPI; 1996-477152/47.

XX New oligonucleotide specific for apolipoprotein-J polymorphisms - used

to identify patients susceptible to Alzheimer's disease or prostate

cancer.

XX Example 1; Page 20; 62pp; English.

XX AAT41527-T41541 are exon-specific PCR primers used for the amplification

of exons 2-8 of the human apolipoprotein-J (ApoJ) gene. The primers were

used in a method for detecting polymorphisms associated with an allelic

variation in the ApoJ gene. The oligonucleotide (OG) detects the

probability of a person developing Alzheimer's disease (AD), preferably

in patients of African or Hispanic descent. The OG also detects the

probability of a person developing a cognitive disorder, or a prostatic

carcinoma. Transgenic mammals expressing an allelic variant of an ApoJ

gene may be used as a prognostic and diagnostic means for studying AD,

and to determine the effectiveness of therapeutic drugs

Sequence 18 BP; 3 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.1%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 60;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1070 CAACGAGCTGCTAAAGTC 1087

|||||







QY 48 ATGATGAAGACTCTGCTGCTG 68  
 DB 21 ATGATAAATACTCTGCTGCTG 1

RESULT 184  
 AAT41526  
 ID AAT41526 standard; DNA; 17 BP.  
 XX  
 AC AAT41526;  
 XX  
 DT 24-JUN-1997 (first entry)  
 XX  
 DE Human apolipoprotein-J gene J3-allelic variant primer/probe.  
 XX  
 KW Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;  
 KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;  
 KW diagnosis; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9632502-A1.  
 XX  
 PD 17-OCT-1996.  
 XX  
 PF 02-APR-1996; 96WO-US004510.  
 XX  
 PR 11-APR-1995; 95US-00420291.  
 XX  
 PA (UYCO ) UNIV COLUMBIA NEW YORK.  
 XX  
 PI Mayeux R, Tycko B;  
 XX  
 DR WPI; 1996-477152/47.  
 XX  
 PT New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
 PT to identify patients susceptible to Alzheimer's disease or prostate  
 PT cancer.  
 XX  
 PS Example 1; Page 21; 62pp; English.  
 XX  
 CC AAT41542 and AAT41543 are J1 allele-specific primer/probes used as  
 CC controls in an example of a method for detecting polymorphisms associated  
 CC with an allelic variation in the human apolipoprotein-J (ApoJ) gene. The  
 CC oligonucleotide (OG) detects the probability of a person developing  
 CC Alzheimer's disease (AD), preferably in patients of African or Hispanic  
 CC descent. The OG also detects the probability of a person developing a  
 CC cognitive disorder, or a prostatic carcinoma. Transgenic mammals  
 CC expressing an allelic variant of an ApoJ gene may be used as a prognostic  
 CC and diagnostic means for studying AD, and to determine the effectiveness  
 CC of therapeutic drugs  
 XX  
 SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 68;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 984 TGTTCACCAACAACCC 1000  
 DB 1 TGTTCACCAACAACCC 17

RESULT 186  
 ABT34616  
 ID ABT34616 standard; DNA; 17 BP.  
 XX  
 AC ABT34616;  
 XX  
 DT 12-JUN-2003 (first entry)  
 XX  
 DE Tumour suppression related human fukutin oligo SEQ ID No 253.  
 XX  
 KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;  
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; protein chip; gene therapy; tumour suppression;  
 KW human fukutin; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003025175-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004208.  
 XX  
 PR 17-SEP-2001; 2001FR-00011978.  
 XX

QY 1023 GAGCTCGACGAATCCCT 1039  
 DB 1 GAGCTCGACGAATCCCT 17

RESULT 185  
 AAT41542  
 ID AAT41542 standard; DNA; 17 BP.  
 XX  
 AC AAT41542;  
 XX  
 DT 24-JUN-1997 (first entry)  
 XX  
 DE Human apolipoprotein-J gene J1-allelic specific primer/probe.  
 XX

Query Match 1.0%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 68;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1023 GAGCTCGACGAATCCCT 1039  
 DB 1 GAGCTCGACGAATCCCT 17

RESULT 185  
 AAT41542  
 ID AAT41542 standard; DNA; 17 BP.  
 XX  
 AC AAT41542;  
 XX  
 DT 24-JUN-1997 (first entry)  
 XX  
 DE Human apolipoprotein-J gene J1-allelic specific primer/probe.  
 XX

PI Telerman A, Amson R, Tuijnder M;  
 XX WPI; 2003-441574/41.  
 XX  
 PT New nucleic acid encoding human prostate membrane-specific antigen,  
 PT useful e.g. for treatment of tumors and viral infection, also related  
 PT polypeptide and antibodies.  
 XX  
 XX Disclosure; Page 737; 771pp; French.  
 PS  
 CC The invention relates to the isolation of 6327 nucleotide sequences,  
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
 CC sequence having at least 80% identity, after optimal alignment, with the  
 CC nucleotides, a sequence that hybridizes under stringent conditions with  
 CC the nucleotides, or the complement, or corresponding RNA, of the  
 CC nucleotides. The nucleotides are used as probes or primers for detecting,  
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
 CC sense and antisense sequences, of nucleotides involved in tumour  
 CC suppression or reversion, apoptosis and or viral resistance, to produce  
 CC recombinant polypeptides, and to prepare transgenic animals, as  
 CC experimental models. The nucleotides (also vectors containing them and  
 CC cells containing the vectors), the encoded polypeptides and antibodies  
 CC (Ab) against the polypeptide are useful for prevention and/or treatment  
 CC of viral infections or diseases characterized by development of tumours  
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
 CC Analysis of the expression of the nucleotides can be used for diagnosis  
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
 CC also be used to screen for their specific interactive molecules,  
 CC potentially useful for treating diseases associated with abnormal  
 CC expression of the nucleotides.  
 XX  
 SQ Sequence 17 BP; 5 A; 6 C; 2 G; 4 T; 0 U; 0 Other;  
 Query Match 1.0%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 68;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1551 GATCCTGCCTCTTAACA 1567  
 DB 1 GATCCTGCCTCTTAACA 17  
 RESULT 188  
 AAQ58405/c  
 ID AAQ58405 standard; DNA; 20 BP.  
 XX  
 AC AAQ58405;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 04-OCT-1994 (first entry)  
 XX  
 DE Antisense oligonucleotide CAS-110-G-119 to HCV 5'-UTR.  
 XX  
 KW Hepatitis C virus; HCV; non-A, non-B hepatitis virus; NANBHV;  
 KW antisense oligonucleotide; translation inhibition; therapy; 5'-UTR;  
 KW 5'-untranslated region; loop C; ss.  
 XX  
 OS Synthetic.  
 OS  
 XX WO9405813-A1.  
 XX  
 PD 17-MAR-1994.  
 XX  
 PF 10-SEP-1993; 93WO-JP001293.  
 XX  
 PR 10-SEP-1992; 92US-00945289.  
 PR 14-APR-1993; 93JP-00087195.  
 XX  
 PA (MOCH ) MOCHIDA PHARM CO LTD.  
 PA (KAGA ) CHEMO SERO THERAPEUTIC RES INST.  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 XX Anderson KP, Hanecak RC, Hoshiko K, Nozaki C, Nishihara T;

PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX WPI; 2003-313353/30.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 XX Disclosure; Page 63; 720pp; French.  
 PS  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterized by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 XX  
 SQ Sequence 17 BP; 5 A; 6 C; 2 G; 4 T; 0 U; 0 Other;  
 Query Match 1.0%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 68;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1551 GATCCTGCCTCTTAACA 1567  
 DB 1 GATCCTGCCTCTTAACA 17  
 RESULT 187  
 ADB45708  
 ID ADB45708 standard; DNA; 17 BP.  
 XX  
 AC ADB45708;  
 XX  
 DT 18-DEC-2003 (first entry)  
 DE Tumour suppression/reversion associated nucleotide #6031.  
 XX  
 KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
 KW diagnosis.  
 XX  
 OS Homo sapiens.  
 OS  
 XX WO2003040369-A2.  
 XX  
 PD 15-MAY-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004219.  
 XX  
 PR 17-SEP-2001; 2001FR-00011981.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX

PI Nakatake H, Hamada F, Eto T, Furukawa S;  
XX WPI; 1994-101217/12.  
XX  
PT Antisense oligo:nucleotide(s) complementary to hepatitis C viral genome  
PT - useful for inhibiting HCV replication, to treat related diseases.  
XX  
XX Example 7; Page 24; 91pp; English.  
XX  
XX Antisense oligonucleotides were synthesised which are complementary to  
CC target sequences located at 10-nucleotide intervals from nucleotide 1 to  
CC 339 in the HCV RNA 5'-untranslated region. Of these sequences (CAS-1 to  
CC CAS-320), oligonucleotide CAS-110 (AAQ58403), which is complementary to a  
CC portion of loop C, was found to cause greater than 80% inhibition of core  
CC protein translation. The nucleotide at position 119 in loop C has a high  
CC variation rate among HCV strains so oligonucleotide CAS-110-I-119 was  
CC synthesised in which inosine replaced the T (corresp. to A at position  
CC 119) in CAS-110. The CAS-110-I-119 showed an inhibitory activity of more  
CC than 70%. A control oligonucleotide (CAS-110-G-119) showed much lower  
CC activity. See AAQ58388-Q58422, AAQ44885-Q44892 and AAQ58383. (Updated on  
CC 25-MAR-2003 to correct PN field.)  
XX  
XX Sequence 20 BP; 2 A; 3 C; 14 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 1.0%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 1.3e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1510 GCCTCAGGCCCCCACTCC 1529  
DB 20 GCCTCAGGCCCCCCCTCC 1  
RESULT 189  
ADN02449/C  
ID ADN02449 standard; DNA; 20 BP.  
XX  
XX ADN02449;  
AC  
DT 17-JUN-2004 (first entry)  
XX  
DE Western equine encephalomyelitis virus 26S region PCR primer WEEP2.  
XX  
XX ss; expression vector; Western equine encephalitis; WEE;  
KW anti-encephalitis; Venezuelan equine encephalitis virus; encephalitis;  
KW PCR; primer.  
XX  
XX Western equine encephalomyelitis virus.  
OS  
XX CA2327189-A1.  
XX  
XX 21-JUN-2002.  
PD  
XX 21-DEC-2000; 2000CA-02327189.  
PF  
XX 21-DEC-2000; 2000CA-02327189.  
PR  
XX (MIND ) CANADA MIN NAT DEFENCE.  
PA  
XX  
XX Wong JP, Negata LP;  
PI  
XX WPI; 2002-600289/65.  
DR  
XX A western equine encephalitis (WEE) virus strain used to develop DNA  
PT vaccines to WEE virus and related alphaviruses.  
FT  
XX Disclosure; Page 28; 52pp; English.  
PS  
XX The invention relates to a novel mammalian expression vector, under which  
XX expression of the structural genes of western equine encephalitis (WEE)  
CC virus strain 71V-1658 have been placed under the control of a eukaryotic  
CC promoter. The expression vector has anti-encephalitis activity. The  
CC invention provides a means of developing a vaccine to the WEE virus which

CC is important for protection against an aerosol challenge of WEE used in  
CC biological warfare. The prophylactic method of the invention is used for  
CC inducing a protective immune response to eastern equine encephalitis  
CC virus and Venezuelan equine encephalitis virus in a mammal. The present  
CC sequence represents a WEE virus 26S region PCR primer.  
XX  
XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.0%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 1.3e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 524 CGACTCCCTGCTGGAGAACG 543  
DB 20 CGACACGCTGCTGGAGAACG 1  
RESULT 190  
AAQ68062/C  
ID AAQ68062 standard; DNA; 16 BP.  
XX  
XX AAQ68062;  
AC  
XX 25-MAR-2003 (revised)  
DT 19-DEC-1994 (first entry)  
XX  
DE Antisense probe 155 for HCV LipA typing.  
XX  
XX Hepatitis C virus; HCV; probe; genotyping; hybridisation;  
KW non-A, non-B hepatitis; NANBH; amplification; primer;  
KW polymerase chain reaction; PCR; line probe assay; LipA; ss.  
XX  
XX Synthetic.  
OS  
XX WO9412670-A2.  
XX  
XX 09-JUN-1994.  
PD  
XX 26-NOV-1993; 93WO-EP003325.  
PF  
XX 27-NOV-1992; 92EP-00403222.  
PR  
XX 31-AUG-1993; 93EP-00402129.  
PR  
XX (INNO-) INNOGENETICS NV SA.  
PA  
XX Maertens G, Stuyver L, Rossau R, Van Heuverswyn H;  
PI WPI; 1994-200296/24.  
XX  
XX Process for genotyping Hepatitis C virus (HCV) isolates - utilises probes  
PT hybridising to HCV isolate domains.  
PT  
XX Disclosure; Page 29; 96pp; English.  
PS  
XX Genotyping HCV utilises probes hybridising to HCV isolate domains. HCV  
CC types 2, 3, 4, 5 or 6 and subtypes 1a, 1b, 2a, 2b, 3a, 3b, 3c, 4a, 4b,  
CC 4c, 4d, 4e, 4f, 4g and 4h can be typed. Antisense probe 155 was used in  
CC the identification of type 4 isolates. (Updated on 25-MAR-2003 to correct  
CC PN field.)  
XX  
XX Sequence 16 BP; 1 A; 3 C; 10 G; 2 T; 0 U; 0 Other;  
SQ  
Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 75;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCCC 1523  
DB 16 CAGCCTCCAGGCCCCC 1  
RESULT 191  
AAI14650

ID	AAAX14650 standard; DNA; 17 BP.	XX	Key	Location/Qualifiers
XX	AAAX14650;	FT	modified_base	1..19
XX		FT		/tag= a
DT	24-MAR-1999 (first entry)	FT	/mod_base= OTHER	
XX	Triple helix forming nucleotides 5967-5983 of the dystrophin gene.	FT	/note= "OTHER = Phosphorothioate backbone"	
DE	XX	XX		
XX	Triple-helix forming region; Triplex formation; DNA detection;	XX		
KW	identification; bacteria; oncogene; virus; ds.	XX		
XX		XX		
OS	Homo sapiens.	XX		
XX		XX		
XX	US5861244-A.	XX		
XX	19-JAN-1999.	XX		
XX		XX		
XX	22-DEC-1993; 93US-00173489.	XX		
XX		XX		
XX	29-OCT-1992; 92US-00968436.	XX		
XX	(PROF-) PROFILE DIAGNOSTIC SCI INC.	XX		
PA	Hepburn AG, Wang C;	XX		
PI		XX		
XX	WPI; 1999-130384/11.	XX		
XX		XX		
XX	Assay of genetic sequences based on triplex formation from double	XX		
PT	stranded analyte - and hybrid of anchor and reporter sequences, with	XX		
PT	reporter released if triplex formation occurs, used e.g. to identify	XX		
PT	bacteria.	XX		
XX		XX		
XX	Disclosure; Col 15-16; 169pp; English.	XX		
XX		XX		
XX	The present sequence represents a potential triple-helix forming region.	XX		
CC	It can be used to demonstrate the assay of the invention. The assay	XX		
CC	comprises adding a sample containing double-stranded DNA test sequences,	XX		
CC	e.g. containing the present sequence, to an aqueous medium containing at	XX		
CC	least one complex of anchor DNA, attached to a solid support, and	XX		
CC	reporter DNA, where either a part of the anchor DNA or reporter DNA is	XX		
CC	designed to form a triple-strand structure with part of the test	XX		
CC	sequence. Triplex formation results in displacement of the reporter DNA	XX		
CC	which is detected as an indication of the presence of the DNA test	XX		
CC	sequence. The method is used to detect DNA sequences, particularly for	XX		
CC	identification of bacteria (by detecting genes for ribosomal RNA) in	XX		
CC	clinical samples, but also detection of oncogenes and Hepatitis B virus	XX		
XX		XX		
SQ	Sequence 17 BP; 10 A; 0 C; 7 G; 0 T; 0 U; 0 Other;	XX		
	Query Match 1.0%; Score 16; DB 1; Length 17;			
	Best Local Similarity 100.0%; Pred. No. 94;			
	Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	280 AGAAGAAGAAAGAGGA 295	QY	280 AGAAGAAGAAAGAGGA 295	
Db	1 AGAAGAAGAAAGAGGA 16	Db	17 AGAAGAAGAAAGAGGA 2	
RESULT 192		RESULT 193		
ADS00161/c		ADS73873/c		
ID	ADS00161 standard; RNA; 19 BP.	ID	ADS73873 standard; RNA; 19 BP.	
XX		XX		
AC	ADS00161;	AC	ADS73873;	
XX		XX		
DT	16-DEC-2004 (first entry)	DT	16-DEC-2004 (first entry)	
XX		XX		
DE	Duchenne muscular dystrophy gene-specific antisense oligonucleotide #7.	DE	DMD gene specific antisense oligonucleotide h41AON1.	
XX		XX		
KW	antisense oligonucleotide; Duchenne muscular dystrophy gene; DMD gene;	XX	DMD; Duchenne muscular dystrophy; collagen VI alpha 1; COL6A1;	
KW	pre-mRNA recognition alteration; inherited disease;	KW	myotubular myopathy 1; MTM1; dysferlin; DYSF; laminin-alpha 2; LAMA2;	
KW	pre-mRNA exon skipping induction; splicing machinery efficiency; ss.	KW	emery-dreyfuss muscular dystrophy; EMD; calpain 3; CAPN3; antisense; ss.	
XX		XX		
OS	Unidentified.	XX		

XX	DT	22-APR-2004	(first entry)	
XX	DE	Human PCTAIRE protein kinase 2 antisense oligonucleotide #71.		
XX	KW	gene therapy; PCTAIRE technology; PCTAIRE protein kinase 2; neurological disorder; human; PCTAIRE protein kinase 2; ss.		
XX	OS	Homo sapiens.		
XX	FT	Key	Location/Qualifiers	
FT	FT	modified_base	1. .20	
FT	FT		/*tag= b	
FT	FT		/mod_base= OTHER	
FT	FT		/note= "OTHER= Phosphorothioate backbone. All cytidines are 5-methylcytidines"	
FT	FT	modified_base	1. .5	
FT	FT		/*tag= a	
FT	FT		/mod_base= OTHER	
FT	FT		/note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"	
FT	FT	modified_base	15. .20	
FT	FT		/*tag= c	
FT	FT		/mod_base= OTHER	
FT	FT		/note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"	
XX	PN	US2003225256-A1.		
XX	PD	04-DEC-2003.		
XX	PF	31-MAY-2002; 2002US-00160787.		
XX	PR	31-MAY-2002; 2002US-00160787.		
XX	PA	(ISIS-) ISIS PHARM INC.		
XX	PI	Watt AT;		
XX	DR	WPI; 2004-022085/02.		
XX	PT	New antisense oligonucleotide, having a sequence targeted to a nucleic acid encoding PCTAIRE protein kinase 2, useful for preparing a composition for treating neurological disorders.		
XX	PS	Claim 1; SEQ ID NO 84; 58pp; English.		
XX	CC	The invention describes a new antisense oligonucleotide, having a sequence comprising 8-80 bp targeted to a nucleic acid encoding PCTAIRE protein kinase 2, that specifically hybridizes with the nucleic acid encoding PCTAIRE protein kinase 2 and having a sequence comprising 20 bp.		
XX	CC	The antisense oligonucleotide is useful for preparing a composition for treating e.g., neurological disorders. This sequence represents a human PCTAIRE protein kinase 2 antisense oligonucleotide.		
XX	SQ	Sequence 20 BP; 1 A; 8 C; 2 G; 9 T; 0 U; 0 Other;		
		Query Match	1.0%; Score 16; DB 1; Length 20;	
		Best Local Similarity	100.0%; Pred. No. 1.6e+02;	
		Matches	16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	Db	1583 CATGGGAGACAGAA 1598		
		17 CATGGGAGACAGAA 2		
RESULT 195				
AD119270				
ID	AD119270	standard; DNA; 20 BP.		
XX	AC	AD119270;		
XX	DT	22-APR-2004 (first entry)		
XX	DE	Human PCTAIRE protein kinase 2 antisense oligonucleotide #124.		

XX gene therapy; antisense technology; PCTAIRE protein kinase 2;  
KW neurological disorder; human; PCTAIRE protein kinase 2; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= Phosphorothioate backbone. All cytidines  
FT are 5-methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
FT modified\_base 15..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
XX US2003225256-A1.  
XX 04-DEC-2003.  
XX  
XX 31-MAY-2002; 2002US-00160787.  
XX  
XX 31-MAY-2002; 2002US-00160787.  
XX (ISIS-) ISIS PHARM INC.  
XX Watt AT;  
XX WPI; 2004-022085/02.  
XX  
XX New antisense oligonucleotide, having a sequence targeted to a nucleic  
PT acid encoding PCTAIRE protein kinase 2, useful for preparing a  
PT composition for treating neurological disorders.  
XX  
XX Example 15; SEQ ID NO 137; 58pp; English.  
XX  
XX The invention describes a new antisense oligonucleotide, having a  
CC sequence comprising 8-80 bp targeted to a nucleic acid encoding PCTAIRE  
CC protein kinase 2, that specifically hybridises with the nucleic acid  
CC encoding PCTAIRE protein kinase 2 and having a sequence comprising 20 bp.  
CC The antisense oligonucleotide is useful for preparing a composition for  
CC treating e.g., neurological disorders. This sequence represents a human  
CC PCTAIRE protein kinase 2 antisense oligonucleotide.  
XX  
SQ Sequence 20 BP; 9 A; 2 C; 8 G; 1 T; 0 U; 0 Other;  
Query Match 1.0%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1583 CATGGGAAGAACAGAA 1598  
Db |||||  
4 CATGGGAAGAACAGAA 19  
RESULT 196  
ABN88070  
ID ABN88070 standard; DNA; 19 BP.  
XX  
AC ABN88070;  
XX  
DT 12-AUG-2002 (first entry)  
XX  
DE Caenorhabditis elegans related dsRNA2 upstream primer.  
XX  
KW Caenorhabditis elegans; C. elegans; reproduction; development;  
KW antineurotic; nematocyst; plant protectant; gene therapy; infection;  
KW calabar swelling; lymphatic filariasis; elephantiasis; onchocercosis;  
KW

KW primer; ss.  
XX Caenorhabditis elegans.  
OS Synthetic.  
XX  
DN WO200238600-A2.  
XX  
PD 16-MAY-2002.  
XX  
XX 09-NOV-2001; 2001WO-EP013038.  
XX  
XX 09-NOV-2000; 2000US-0246721P.  
XX  
XX (CENI-) CENIX BIOSCIENCE GMBH.  
XX  
XX Echeverri C, Goenczy P, Hyman A, Coulson A, Jones S, Oegema K;  
PI Kirkham M;  
XX  
XX WPI; 2002-471547/50.  
XX  
XX New Caenorhabditis elegans genes required for viability, growth or  
PT reproduction of nematodes, useful for diagnosing or treating e.g.  
PT onchocercosis or elephantiasis in humans or animals, or plant diseases  
PT caused by e.g. Heterodera.  
XX  
XX Example 2; Page 28; 35pp; English.  
XX  
XX The present invention describes an isolated nucleic acid molecule (I),  
CC which encodes a polypeptide (II) required for the viability and/or growth  
CC and/or reproduction of nematodes (Caenorhabditis elegans), or its  
CC fragment. (I) and (II) have nematocyst and plant protectant activities,  
CC and can be used in gene therapy. (I) is useful for producing (II)  
CC required for the viability, growth and/or reproduction of nematodes.  
CC Nucleic acids, probes, polypeptides, fusion proteins and antibodies from  
CC the present invention are also useful in a screening assay for  
CC interacting drugs that inhibit, stimulate or affect worm growth,  
CC viability or reproduction. They are useful for diagnosing or treating  
CC human or animal diseases associated with the infection or presence of  
CC nematode worms, e.g. Wuchereria bancrofti, Brugia malayi, Loa loa or  
CC Onchocerca volvulus. These diseases include calabar swellings, lymphatic  
CC filariasis (elephantiasis) or onchocercosis. The nucleic acids, probes,  
CC polypeptides, fusion proteins and antibodies are also useful for  
CC diagnosing or treating plant diseases associated with the infection or  
CC presence of nematode worms. Furthermore, the nucleic acid and amino acid  
CC sequences are useful for developing computational models, structural  
CC models or other models for evaluating drug binding and efficacy. The  
CC present sequence represents a primer which is used in an example from the  
CC present invention in RNAi experiments  
XX  
SQ Sequence 19 BP; 6 A; 3 C; 7 G; 3 T; 0 U; 0 Other;  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 551 GCAGACGCACATGCTGGAT 569  
Db |||||  
1 GCAGACGCACATGCTGGAT 19  
RESULT 197  
ADD00110  
ID ADD00110 standard; RNA; 19 BP.  
XX  
XX AC ADD00110;  
XX  
XX 01-JAN-2004 (first entry)  
XX  
XX HCV coding region-derived 60% conserved RNA sequence 56.  
XX  
XX HCV infection; replication; pathogenesis; virucide; vaccine;  
KW gene therapy; db.  
XX







XX WPI; 2004-226952/21.  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 7; 63pp; English.  
XX  
XX The present sequence is the sense strand of a short interfering RNA  
CC (siRNA) targeted to human clusterin. The antisense strand is also  
CC provided ADL70463. The siRNA can be used to interfere with the expression  
CC of clusterin. Clusterin, also known as testosterone-repressed prostate  
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
CC increased amounts by prostate tumour cells following androgen withdrawal,  
CC and has also been shown to be critical for neuritic toxicity in mouse  
CC models of Alzheimer's disease. siRNAs of the invention can be used alone  
CC or in combination with other chemotherapy or apoptosis inducing  
CC treatments for the treatment of prostate cancer, sarcomas such as  
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
CC melanoma, and also for the treatment of Alzheimer's disease.  
XX  
XX Sequence 19 BP; 8 A; 3 C; 1 G; 2 T; 5 U; 0 Other;  
SQ  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 1.5e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 1616 TAATTCAATTAATAACTGCT 1634  
DB 1 UAAUUCACACAAACUGUTT 19  
RESULT 202  
ADL70463/C  
ID ADL70463 standard; RNA; 19 BP.  
XX  
XX ADL70463;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX RNAi for human clusterin.  
DE  
DE RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
FT  
XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX

DR WPI; 2004-226952/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 8; 63pp; English.  
XX  
XX The present sequence is the antisense strand of a short interfering RNA  
CC (siRNA) targeted to human clusterin. The sense strand is also provided  
CC ADL70462. The siRNA can be used to interfere with the expression of  
CC clusterin. Clusterin, also known as testosterone-repressed prostate  
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
CC increased amounts by prostate tumour cells following androgen withdrawal,  
CC and has also been shown to be critical for neuritic toxicity in mouse  
CC models of Alzheimer's disease. siRNAs of the invention can be used alone  
CC or in combination with other chemotherapy or apoptosis inducing  
CC treatments for the treatment of prostate cancer, sarcomas such as  
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
CC melanoma, and also for the treatment of Alzheimer's disease.  
XX  
XX Sequence 19 BP; 5 A; 1 C; 3 G; 2 T; 8 U; 0 Other;  
SQ  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1614 ACTAATTCATATAAACTGCT 1632  
DB 19 AATAATTCACAAACTGCT 1  
RESULT 203  
ADL70429/C  
ID ADL70429 standard; RNA; 19 BP.  
XX  
XX ADL70429;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX RNAi for human clusterin.  
DE  
DE Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
PI  
XX WPI; 2004-226951/21.  
DR

XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PPT clusterin in the melanoma cells.  
  
XX  
PPS Claim 20; SEQ ID NO 27; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CCC targeted to human clusterin ADL70403. The invention relates to the  
CCC treatment of melanoma through reduction in the effective amount of  
CCC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CCC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CCC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CCC mRNA. A method for regulating expression of bcl-xl in a subject or cell  
CCC line comprises administering an agent effective to modulate the amount of  
CCC clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
CCC is down-regulated when the effective amount of clusterin is reduced. Such  
CCC inhibition is significant because bcl-Xl is known to act as an inhibitor  
XXX of apoptosis.

XX Sequence 19 BP; 5 A; 1 C; 3 G; 2 T; 8 U; 0 Other;

Query Match            1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity     89.5%; Pred. No. 1.5e+02;  
Matches       17; Conservative      0; Mismatches    2; Indels    0; Gaps    0;

OY          1614 ACTAATTCAATAAACTGT 1632

Db          | ||||| ||||||  
            19 RATNATTCACAAAAGTGT 1

RESULT 204

ID ADL70426

ADL70426 standard; RNA; 19 BP.

XX AC

XX ADL70426;

XX DT

XX 20-MAY-2004 (first entry)

XX RNAi for human clusterin.

DE Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;

KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.

XK Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FH modified\_base 18..19

FT FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "OTHER= TT"

XX WO2004018675-A1.

PX PN

PN PD

PD PP

PP 21-AUG-2003; 2003WO-CR001276.

XX 21-AUG-2002; 2002US-0405193P.

PR 03-SEP-2002; 2002US-0408152P.

PR 02-DEC-2002; 2002US-0319748P.

PR 20-MAY-2003; 2003US-0472387P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

PA (GLEAVE/) GLEAVE M E.

XX Jansen B;

PI WFI; 2004-226851/21.

XX DR

XX PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of

PT	clusterin in the melanoma cells.
XX	
PPS	Claim 10; SEQ ID NO 24; 32pp; English.
CC	The present sequence is that of a short interfering RNA (siRNA) molecule targeted to human clusterin ADL70403. The invention relates to the treatment of melanoma through reduction in the effective amount of clusterin. The therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin. The siRNAs molecules direct cleavage of clusterin mRNA. A method for regulating expression of bcl-xl in a subject or cell line comprises administering an agent effective to modulate the amount of clusterin expression. In clusterin-expressing cells, expression of bcl-xl is down-regulated when the effective amount of clusterin is reduced. Such inhibition is significant because bcl-xl is known to act as an inhibitor of apoptosis.
CC	
XX	
SQ	Sequence 19 BP; 8 A; 3 C; 1 G; 2 T; 5 U; 0 Other;
	Query Match            1.0%; Score 15.8; DB 1; Length 19;
	Best Local Similarity   63.2%; Pred. No. 1.5e+02;
	Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
OY	1616 TAATTCAATAAACTGTCT 1634 : :::     :: :
Dn	1 UAUUUCACAAAACUGUTT 19
RESULT 205	
ADL70428	
ID	ADL70428 standard; RNA; 19 BP.
XX	
AC	ADL70428;
XX	
DT	20-MAY-2004 (first entry)
XX	
DE	RNAi for human clusterin.
XX	
KW	Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KX	short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XN	
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	modified_base 18..19
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= TT"
XX	
PV	WO2004018675-A1.
XX	
PD	04-MAR-2004.
XX	
PF	21-AUG-2003; 2003WO-CAN001276.
XX	
PR	21-AUG-2002; 2002US-0405193P.
PR	03-SEP-2002; 2002US-0408152P.
PR	02-DEC-2002; 2002US-0319748P.
PR	20-MAY-2003; 2003US-0472387P.
XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.
PA	(GLEA/) GLEAVE M E.
PI	Jansen B;
XX	
DR	WIPI; 2004-226951/21.
XX	
PT	Treating melanoma in a mammalian subject comprising administering to the subject a therapeutic agent effective to reduce the effective amount of clusterin in the melanoma cells.
PS	Claim 20; SEQ ID NO 26; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 19 BP; 8 A; 3 C; 1 G; 2 T; 5 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 1.5e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1616 TAATTCATAATAAACTGTCT 1634  
Db :||:|||||:|  
1 UAAUUAACAACAACUGUTT 19

RESULT 206  
AAT41543  
ID AAT41543 standard; DNA; 17 BP.  
XX  
AC AAT41543;  
XX  
DT 24-JUN-1997 (first entry)  
XX Human apolipoprotein-J gene J1-allelic specific primer/probe.  
XX  
XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;  
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;  
KW diagnosis; ss.  
XX  
XX Synthetic.  
OS  
XX WO9632502-Al.  
XX  
XX 17-OCT-1996.  
XX  
XX 02-APR-1996; 96WO-US004510.  
XX  
XX 11-APR-1995; 95US-00420291.  
XX (UYCO ) UNIV COLUMBIA NEW YORK.  
XX  
XX Mayeux R, Tycko B;  
XX WPI; 1996-477152/47.  
XX  
XX New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
PT to identify patients susceptible to Alzheimer's disease or prostate  
PT cancer.

PS Example 1; Page 21; 62pp; English.  
XX  
XX AAT41542 and AAT41543 are J1 allele-specific primer/probes used as  
CC controls in an example of a method for detecting polymorphisms associated  
CC with an allelic variation in the human apolipoprotein-J (ApoJ) gene. The  
CC oligonucleotide (OG) detects the probability of a person developing  
CC Alzheimer's disease (AD), preferably in patients of African or Hispanic  
CC descent. The OG also detects the probability of a person developing a  
CC cognitive disorder, or a prostatic carcinoma. Transgenic mammals  
CC expressing an allelic variant of an ApoJ gene may be used as a prognostic  
CC and diagnostic means for studying AD, and to determine the effectiveness  
CC of therapeutic drugs  
XX  
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1023 GAGCTCGACCAATCCCT 1039  
Db :||:|||||:|  
1 GAGCTCAACGAATCCCT 17  
RESULT 207  
AAT41525  
ID AAT41525 standard; DNA; 17 BP.  
XX  
AC AAT41525;  
XX  
DT 24-JUN-1997 (first entry)  
XX Human apolipoprotein-J gene J2-allelic variant primer/probe.  
XX  
XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;  
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;  
KW diagnosis; ss.  
XX  
XX Synthetic.  
OS  
XX WO9632502-Al.  
XX  
XX 17-OCT-1996.  
XX  
XX 02-APR-1996; 96WO-US004510.  
XX  
XX 11-APR-1995; 95US-00420291.  
XX (UYCO ) UNIV COLUMBIA NEW YORK.  
XX  
XX Mayeux R, Tycko B;  
XX WPI; 1996-477152/47.  
XX  
XX New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
PT to identify patients susceptible to Alzheimer's disease or prostate  
PT cancer.

PS Claim 27; Page 40; 62pp; English.  
XX  
XX AAT41525 is a primer/probe used to detect a J2 allelic variation in the  
CC human apolipoprotein-J (ApoJ) gene. The primer/probe is used for  
CC detecting polymorphisms associated with an allelic variation in the ApoJ  
CC gene. The oligonucleotide (OG) detects the probability of a person  
CC developing Alzheimer's disease (AD), preferably in patients of African or  
CC Hispanic descent. The OG also detects the probability of a person  
CC developing a cognitive disorder, or a prostatic carcinoma. Transgenic  
CC mammals expressing an allelic variant of an ApoJ gene may be used as a  
CC prognostic and diagnostic means for studying AD, and to determine the  
CC effectiveness of therapeutic drugs  
XX  
SQ Sequence 17 BP; 4 A; 9 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 984 TGTTCACCAACCAACCC 1000  
Db :||:|||||:|  
1 TGTTCACCAACCAACCC 17

RESULT 208  
AAX63903/C  
ID AAX63903 standard; RNA; 17 BP.  
XX  
AC AAX63903;

XX	DT	20-JUL-1999	(first entry)
XX	DE	Rabbit stromelysin hammerhead target SEQ ID NO:535.	
XX	XX	Arthritic condition; graft tolerance; immune response; target; cleavage;	
KW	KW	hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;	
KW	KW	stromelysin; synovial membrane; joint; arthritis; osteoarthritis;	
KW	KW	rheumatoid arthritis; autoimmune disease; allergy; inflammation;	
KW	KW	diagnosis; ss.	
XX	OS	Oryctolagus cuniculus.	
XX	PN	WO9618736-A2.	
XX	XX	20-JUN-1996.	
XX	XX	22-NOV-1995; 95WO-US015516.	
XX	PR	13-DEC-1994; 94US-00354920.	
PR	PR	23-DEC-1994; 94US-00363253.	
PR	PR	23-DEC-1994; 94US-00363254.	
PR	PR	17-FEB-1995; 95US-00390850.	
PR	PR	20-APR-1995; 95US-00426124.	
PR	PR	02-MAY-1995; 95US-00432874.	
PR	PR	04-MAY-1995; 95US-00434509.	
PR	PR	07-JUL-1995; 95US-0000951P.	
PR	PR	07-JUL-1995; 95US-0000974P.	
PR	PR	07-AUG-1995; 95US-00512861.	
PR	PR	05-OCT-1995; 95US-00541365.	
XX	XX	(RIBO-) RIBOZYME PHARM INC.	
PA	PA	Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;	
XX	PI	McSwiggen J, Gustafson J, Usman N, Wincott F, Matulic-Adamic J;	
PI	PI	Karpeisky A, Thompson JD, Modak A, Burgin A;	
XX	XX	WPI; 1996-300653/30.	
XX	XX	Enzymatic nucleic acid molecules having a hammer-head motif - used for	
PT	PT	the treatment of arthritis, induction of graft tolerance or treatment of	
PT	PT	auto-immune diseases.	
XX	XX	Example 1; Page 154; 307pp; English.	
XX	XX	The present invention describes a novel enzymatic nucleic acid (ENA)	
CC	CC	having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues	
CC	CC	; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least	
CC	CC	ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's	
CC	CC	can inhibit collagenase and stromelysin production in the synovial	
CC	CC	membrane of joints for the treatment or prevention of arthritis,	
CC	CC	particularly osteoarthritis or rheumatoid arthritis. The ENA's can also	
CC	CC	be used to treat antigen presenting cells of a donor to induce tolerance	
CC	CC	in a recipient to an alloantigen of a donor. They can also be used for	
CC	CC	enhancing graft tolerance or for treating autoimmune disease, and for	
CC	CC	treating allergies and other inflammatory conditions. The ENA's can also	
CC	CC	be used in diagnosis. Ribozyme therapy impacts on the expression of	
CC	CC	stromelysin without introducing the non-specific effects upon gene	
CC	CC	expression which accompany treatment with retinoids and dexamethasone.	
CC	CC	The concentration of ribozyme required to affect a therapeutic treatment	
CC	CC	is lower than that required of antisense molecules, and is highly	
CC	CC	specific. The present sequence is used in the exemplification of the	
CC	CC	present invention	
XX	XX	Sequence 17 BP; 4 A; 2 C; 4 G; 0 T; 7 U; 0 Other;	
SQ	SQ	Query Match 0.9%; Score 15.4; DB 1; Length 17;	
		Best Local Similarity 94.1%; Pred. No. 1.1e+02;	
		Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	QY	1589 AAGAACAGATTGCTCC 1605	
DB	DB	17 AAGAACAGATTCTCC 1	

RESULT 209	
ABK00170/c	
ID ABK00170 standard; RNA; 17 BP.	
XX	
AC ABK00170;	
XX	
DT 12-MAR-2002 (first entry)	
XX	
DE Human NOGO Hammerhead Ribozyme #170.	
XX	
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;	
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;	
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;	
KW DNzyme; inozyme; G-cleaver; amberyzyme; zinzyme; lymphoma; leukaemia;	
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;	
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;	
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;	
KW inflammatory arthropathy; central nervous system injury;	
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;	
KW Parkinson's disease; ataxia; Huntington's disease;	
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.	
XX	
OS Homo sapiens.	
OS Synthetic.	
XX	
PN WO200159103-A2.	
XX	
PD 16-AUG-2001.	
XX	
PF 09-FEB-2001; 2001WO-US004273.	
XX	
PR 11-FEB-2000; 2000US-0181797P.	
PR 28-FEB-2000; 2000US-0185516P.	
PR 06-MAR-2000; 2000US-0187128P.	
XX	
PA (RIBO-) RIBOZYME PHARM INC.	
PA (BLAT/) BLATT L.	
PA (MCSW/) MCSWIGGEN J.	
PA (CHOW/) CHOWRIRA B M.	
XX	
PI Blatt L, Mcswiggen J, Chowrira BM;	
XX	
XX WPI; 2001-607195/69.	
XX	
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense	
PT constructs, which down regulate expression of a CD20 gene or neurite	
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and	
PT central nervous system injury.	
XX	
PS Claim 88; Page 68; 200pp; English.	
XX	
XX The invention relates to a nucleic acid molecule which down regulates	
CC expression of a CD20 gene and a nucleic acid molecule which down	
CC regulates expression of a neurite growth inhibitor gene (NOGO). The	
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a	
CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule	
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or	
CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA	
CC with a YGV motif). The CD20-targeting nucleic acid is used to cleave RNA	
CC of CD20 in the presence of a divalent cation that is preferably Mg <sup>2+</sup> .	
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of	
CC the cell and treat a patient having a condition associated with the level	
CC of CD20. The treatment may further comprise the use of one or more	
CC therapies. In particular, the CD20 targeting nucleic acid may be used to	
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-	
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic	
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell	
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,	
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-	
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the	



PA (BLA1// BLA11 P:

XX

Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
Draper K. Roberts E;

PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
XX  
XX Blatt L, Macejak D, Mcawiggen J, Morrissey J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
XX  
XX WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
XX Claim 1; Page 261; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNzyme or minus strand DNzyme sequences disclosed in the present  
CC invention  
XX  
XX Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;  
SQ  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 1.1e+02;  
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
QY 766 TCCACGCCATGTTCCAG 782  
DB 1 UCCACGCCAUGUCCGG 17  
RESULT 214  
ADB45503  
ID ADB45503 standard; DNA; 17 BP.  
XX  
XX ADB45503;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX Tumour suppression/reversion associated nucleotide #5826.  
XX  
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX  
XX Homo sapiens.  
OS  
XX WO2003040369-A2.  
PN  
XX 15-MAY-2003.  
PD  
XX 17-SEP-2002; 2002WO-IB004219.  
PF  
XX 17-SEP-2001; 2001FR-00011981.  
PR

XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
XX Telerman A, Amson R, Tuijnder M;  
XX  
XX WPI; 2003-441574/41.  
XX  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX  
XX Disclosure; Page 713; 771pp; French.  
XX  
XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
XX Sequence 17 BP; 4 A; 7 C; 2 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1551 GATCTGCACTCTTACCA 1567  
DB 1 GATCTGCACTCTTACCA 17  
RESULT 215  
ADI84296  
ID ADI84296 standard; RNA; 17 BP.  
XX  
XX ADI84296;  
XX  
XX 03-JUN-2004 (first entry)  
XX  
XX HCV DNzyme substrate sequence #1542.  
XX  
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
KW HCV infection; type I interferon; DNzyme.  
XX  
XX Hepatitis C virus.  
OS  
XX US2003125270-A1.  
PN  
XX 03-JUL-2003.  
PD  
XX 18-DEC-2000; 2000US-00740332.  
PF  
XX 18-DEC-2000; 2000US-00740332.  
PR  
XX (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (ROBE/) ROBERTS E.  
PA (PAVC/) PAVCO P A.  
PA (MACE/) MACEJACK D.  
PA



```
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1542; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNase substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 766 TCCACGCCATGTCCAG 782
DB :|||||:|:|
1 UCCACGCCAGUUCGCG 17
RESULT 216
ACNT1764
ID ACNT1764 standard; DNA; 17 BP.
XX
XX ACNT1764;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:8666.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX
XX (JIY/) JI Y.
XX
XX (PENN/) PENN S G.
PA
(HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 8666; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 273 GAAGCCCAAGGAAGAA 289
DB :|||||:|:|
1 GAAGCCCAAGGAAGAA 17
RESULT 217
AA85604/C
ID AA85604 standard; DNA; 18 BP.
XX
XX AA85604;
XX
XX 06-SEP-1999 (first entry)
XX
XX PCR primer for DNA encoding a human growth factor designated zapol.
XX
XX Human; growth factor; zapol; angiopoietin homologue; cell growth;
XX tissue development; multimeric protein; hematopoietic; angiogenic;
XX tissue revascularization; full-thickness skin wound; venous stasis ulcer;
XX fracture repair; skin grafting; reconstructive surgery;
XX transplanted cell; PCR primer; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX W99932515-A2.
XX
XX 01-JUL-1999.
XX
XX 17-DEC-1998; 98WO-US027055.
XX
XX 19-DEC-1997; 97US-0068268P.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX Presnell SR, Conklin DC;
XX
XX WPI; 1999-405158/34.
XX
XX Zapol, a novel angiopoietin homologue, and related DNA, useful for the
```

(comprising at least 8 contiguous nucleotides where one of the nucleotides is an SNP as cited above, or their complement), an isolated polypeptide comprising an amino acid sequence selected from any of the 696 amino acid sequences (not defined in the specification), an antibody that specifically binds to the polypeptide (or its antigen-binding fragment), an amplified polynucleotide containing the SNP as cited (where the amplified polynucleotide is between about 16 and about 1,000 nucleotides in length), an isolated polynucleotide which specifically hybridises to a nucleic acid molecule containing the SNP, a kit for detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid molecule, detecting a variant polypeptide and identifying an agent useful in therapeutically or prophylactically treating stenosis. The detection step of the method is carried out by a process selected from allele-specific probe hybridisation, allele-specific primer extension, molecular specific amplification, sequencing, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism. The method is useful for identifying an individual who has altered risk for developing coronary stenosis, which can lead to angina (ischaemic chest pain), myocardial infarction and ultimately sudden cardiac death. The present sequence is an allele specific primer for amplifying a SNP-containing region of a human marker gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the specification but are provided on a CD-R named CL001510CDR which was not supplied with the specification.

XX Sequence 18 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 1 Other;

QY 500 CTTCTGGATGATGGTGA 517

DB 1 CTTCTGCANGAATGGTGA 18

RESULT 219

AAV31968/C

ID AAV31968 standard; DNA; 15 BP.

XX

AC AAV31968;

DT 21-AUG-1998 (first entry)

XX

DE Peptide nucleic acid probe 111.

XX

KW Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;

KW ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.

XX

OS Synthetic.

OS Mycobacterium sp.

XX

XX Key Location/Qualifiers

FT modified\_base 1..15

FT /\*tag= a

FT /note= "This sequence contains a polyamide backbone

FT instead of a deoxyribose backbone"

XX

XX WO9815648-A1.

XX

XX 16-APR-1998.

XX

XX 03-OCT-1997; 97WO-DK000425.

XX

XX 04-OCT-1996; 96DK-00001096.

XX 18-OCT-1996; 96DK-00001156.

XX 05-MAY-1997; 97DK-00000512.

XX (DAKO-) DAKO AS.

XX Stender H, Lund K, Mollerup TA;

XX WPI; 1998-240831/21.

study and regulation of angiogenesis and for developing inhibitors.

XX

PS Example 3; Page 55; 56pp; English.

XX

CC PCR primers AAX85603-04 were used to amplify DNA encoding a human growth factor designated zapol. Zapol is an angiotensin homologue. The polypeptide is used to stimulate cell growth and tissue development. The polypeptides form multimeric proteins. Zapol has angiogenic or hematopoietic activity. The proteins can be used in assays for angiogenic activity. Zapol proteins may be used therapeutically to stimulate revascularization of tissue. Specific applications include treatment of chronic, non-healing wounds, as well as fracture repair, skin grafting, reconstructive surgery, and establishment of vascular networks in transplanted cells and tissues. Zapol is also useful as a research agent, such as in the expansion of hematopoietic cells (including stem cells) and endothelial cells. The polypeptides are added to tissue culture media for these cell types

XX

XX Sequence 18 BP; 1 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

QY 284 GAAGAAGAGCGTCC 300

DB 18 GAAGAAGAGCGTCC 2

RESULT 218

ADR74784

ID ADR74784 standard; DNA; 18 BP.

XX

AC ADR74784;

DT 16-DEC-2004 (first entry)

XX

DE Allele specific primer A for human stenosis marker hCV25612495.

XX

KW Human; ss; PCR; primer; Allele specific primer; coronary stenosis; angina; ischaemic chest pain; myocardial infarction;

KW sudden cardiac death; SNP; single nucleotide polymorphism.

XX

OS Homo sapiens.

XX

XX WO2004081186-A2.

XX

XX 23-SEP-2004.

XX

XX 10-MAR-2004; 2004WO-US007140.

XX

XX 10-MAR-2003; 2003US-0453050P.

XX 30-APR-2003; 2003US-0466437P.

XX

XX (APPL-) APPLERA CORP.

XX

XX Cargill M, Devlin J, Luke MW;

XX

XX WPI; 2004-668949/65.

XX

XX Identifying an individual who has altered risk for developing stenosis comprises detecting single nucleotide polymorphism (SNP), in the individual's nucleic acids.

XX

XX Claim 19; SEQ ID NO 68096; 146pp; English.

XX

CC The invention relates to identifying an individual who has altered risk for developing coronary stenosis comprising detecting a single nucleotide polymorphism (SNP) in any one of the 67073 nucleotide sequences (not given in the specification), in the individual's nucleic acids, where the presence of the SNP is correlated with an altered risk for stenosis in the individual. Also included are an isolated nucleic acid molecule

XX Peptide nucleic acid probes for detection of ribosomal nucleic acid of  
PT mycobacteria - allow differentiation between species of tuberculosis  
PT complex and others and can penetrate cell membranes without pretreatment.  
XX  
XX  
PS Claim 22; Page 67; 106pp; English.  
XX  
XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe  
CC used in the method of the invention, to detect ribosomal nucleic acid of  
CC mycobacteria. The probes are used, in situ or in vitro, for detection of  
CC the Mycobacterium tuberculosis complex (MTC), specifically M.  
CC tuberculosis, and especially in sputum samples, but also in other body  
CC fluids, biopsy specimens, foods, soil, air and water. Particularly, they  
CC are used to diagnose, stage or monitor infection, or for identification  
CC of drug-resistant strains (which generally have mutations in rRNA)  
XX  
SQ Sequence 15 BP; 3 A; 2 C; 1 G; 9 T; 0 U; 0 Other;  
Query Match 0.9%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 83;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 177 AAGGAATTCAAAAT 191  
DB 15 AAGGAATTCAAAAT 1  
RESULT 220  
ACD62818/c  
ID ACD62818 standard; RNA; 17 BP.  
XX  
XX ACD62818;  
XX  
XX 24-SEP-2003 (first entry)  
XX  
XX HCV minus strand DNazyme substrate sequence #737.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
XX RNA stability; RNA expression; RNA synthesis; antisense;  
XX enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
XX HBV reverse transcriptase; Enhancer I region; viral replication;  
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
XX virucide; antiinflammatory; substrate; ss.  
XX  
XX Hepatitis C virus.  
XX  
XX WO200281494-A1.  
XX  
XX 17-OCT-2002.  
XX  
XX 26-MAR-2002; 2002WO-US009187.  
XX  
XX 26-MAR-2001; 2001US-00817879.  
XX  
XX 08-JUN-2001; 2001US-00877478.  
XX  
XX 08-JUN-2001; 2001US-0296876P.  
XX  
XX 24-OCT-2001; 2001US-0335059P.  
XX  
XX 05-DEC-2001; 2001US-0337055P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX (BLAT/) BLATT L.  
XX  
XX (MACE/) MACEJACK D.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (MORR/) MORRISSEY D.  
XX  
XX (PVC/) PAVCO P.  
XX  
XX (LEEP/) LEE P.  
XX  
XX (DRAP/) DRAPER K.  
XX  
XX (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
PI  
PT  
XX

DR WPI; 2003-229207/22.  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
XX Claim 1; Page 288; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNazyme or minus strand DNazyme sequences disclosed in the present  
CC invention  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;  
Query Match 0.9%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 766 TCCACGCCATGTTC 780  
DB 15 TCCACGCCATGTTC 1  
RESULT 221  
AD185768/c  
ID AD185768 standard; RNA; 17 BP.  
XX  
XX AD185768;  
XX  
XX 03-JUN-2004 (first entry)  
XX  
XX HCV DNazyme substrate sequence #3014.  
XX  
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
XX HCV infection; type I interferon; DNazyme.  
XX  
XX Hepatitis C virus.  
XX  
XX US2003125270-A1.  
XX  
XX 03-JUL-2003.  
XX  
XX 18-DEC-2000; 2000US-00740332.  
XX  
XX 18-DEC-2000; 2000US-00740332.  
XX  
XX (BLAT/) BLATT L.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (ROBE/) ROBERTS E.  
XX  
XX (PVC/) PAVCO P A.  
XX  
XX (MACE/) MACEJACK D.  
XX  
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
PI  
XX WPI; 2004-031273/03.  
XX  
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived  
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
PT

```
PT especially in combination with type I interferon therapy.
XX Claim 1; SEQ ID NO 3014; 198pp; English.
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNase substrate
CC sequence.
XX Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
SQ
Query Match 0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 766 TCCACGCCATGTTCC 780
Db 15 TCCACGCCATGTTCC 1
RESULT 223
AD079635/c
ID AD079635 standard; DNA; 17 BP.
XX AC AD079635;
XX DT 26-AUG-2004 (first entry)
XX DE KIAA0783 extend primer #27.
XX KW Cytostatic; Gene therapy; breast cancer; human; DLG1; KIAA0783; DPf3;
XX KX CENPC1; SNP; single nucleotide polymorphism; PHF14;
XX KW PHD finger protein 14; chromosome 7p21.3; zinc finger protein;
XX KW transcription factor; extend; primer; ss.
XX OS Homo sapiens.
XX OS WO2004047514-A2.
XX FN 10-JUN-2004.
XX PD 25-NOV-2003; 2003WO-US037943.
XX PF 25-NOV-2002; 2002US-0429136P.
XX PR 24-JUL-2003; 2003US-0490234P.
XX PA (SEQU-) SEQUENOM INC.
XX PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WI WPI; 2004-441037/41.
XX DR
XX PT Identifying a subject at risk of breast cancer by detecting the presence
XX of polymorphic variations in the DLG1, KIAA0783, DPf3 or CENPC1 regions
XX PT which are associated with breast cancer in a nucleic acid sample from a
XX PT subject.
XX PS Example 4; Page 78; 227pp; English.
XX
XX The present invention relates to a method for identifying a subject at
XX risk of breast cancer. The method comprising detecting the presence or
XX absence of one or more polymorphic variations associated with breast
XX cancer in a nucleic acid sample from a subject. The nucleic acid sample
XX comprises the DLG1 region (AD079402), KIAA0783 region (AD079403), DPf3
XX region (AD079404) or CENPC1 region (AD079405). The gene DLG1 (discs,
XX large homolog 1 (Drosophila)) is also known as synapse-associated protein
XX 97, hdlg or SAP97. DLG1 has been mapped to chromosomal position 3q29. The
XX gene KIAA0783 is also known as PHF14 and PHD finger protein 14. KIAA0783
XX has been mapped to chromosomal position 7p21.3. The KIAA0783 protein is a
CC
```

```
CC novel gene with unknown function, however, being a zinc finger protein,
CC it likely to be a transcription factor. The gene DPf3 (D4, zinc and
CC double PHD fingers, family 3) is also known as CERD4, cer-4d, FLJ14079
CC and 2810403B03Rik. DPf3 is a Rho family guanine-nucleotide exchange
CC factor. DPf3 has been mapped to chromosomal position 14q24.3-q31.1. The
CC gene CENPC1 (centromere protein C1) is also known as Centromere
CC autoantigen C1. CENPC1 has been mapped to chromosomal position 4q12-
CC q13.3. CENPC1 is a centromere autoantigen and a component of the inner
CC kinetochore plate. The CENPC1 protein is required for maintaining proper
CC kinetochore size and a timely transition to anaphase. The method is
CC useful for identifying a subject at risk of breast cancer, for early
CC diagnosis, prevention and treatment of breast cancer, to analyze and
CC predict a response to a breast cancer treatment, and in clinical drug
CC trials. The present sequence was used in an example from the invention.
XX
XX Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 438 AGTGGCTCAGGCTG 452
Db 15 AGTGGCTCAGGCTG 1
RESULT 223
AAQ35721/c
ID AAQ35721 standard; DNA; 18 BP.
XX AC AAQ35721;
XX DT 25-MAR-2003 (revised)
XX DT 24-FEB-1993 (first entry)
XX DE EIV primer EIVAIP7A.
XX DE Expression cassette; equine influenza virus; EIV; hemagglutinin; HA;
XX KW Al/Prague/56; NYVAC; ALVAC; recombinant vector; PCR; amplify; pCPV1;
XX KW polymerase chain reaction; pRW764.2; H6 promoter; canarypox virus;
XX KW Copenhagen vaccine; vaccinia virus; virulence factors; deletion loci;
XX KW recipient loci; ss.
XX OS Synthetic.
XX OS WO9215672-A1.
XX FN 17-SEP-1992.
XX PD 09-MAR-1992; 92WO-US001906.
XX PF 07-MAR-1991; 91US-00666056.
XX PR 11-JUN-1991; 91US-00713967.
XX PR 06-MAR-1992; 92US-00847951.
XX PA (VIRO-) VIROGENETICS CORP.
XX PI Paoletti E, Perkus ME, Taylor J, Tartaglia J, Norton EK;
XX PI Riviere M, De Taisne C, Lambach KJ, Johnson GP, Pincus SE, Cox WI;
XX PI Francis J, Gettig RR;
XX WI WPI; 1992-331718/40.
XX
XX Vaccine comprises recombinant, attenuated pox-virus - use for vaccinating
XX against viral infections such as rabies, hepatitis B, HIV, HSV, EBV, CMV,
XX mumps etc.
XX PS Disclosure; Page 220; 456pp; English.
XX
XX The sequences given in AAQ35720-23 were used to generate an expression
XX cassette for the insertion of the equine influenza virus (EIV)
XX hemagglutinin (HA) (Al/Prague/56) into NYVAC and ALVAC recombinant
XX vectors. The HA gene sequence was isolated from an EIV cDNA library and
CC
```

CC was amplified by polymerase chain reaction. The amplified sequence was  
CC inserted into the linearised plasmid pRW764.2. The resultant plasmid was  
CC designated pPCV1 and contains the vaccinia virus H6 promoter followed by  
CC a polylinker region and flanked by canarypox virus homologous sequences.  
CC NRVAC is derived from a Copenhagen vaccine strain of vaccinia virus and  
CC AIVAC is derived from a canarypox virus which has been modified by  
CC deletion of non-essential regions of the genome encoding known or  
CC potential virulence factors. The deletion loci of both vectors were  
CC engineered as recipient loci for the insertion of foreign genes. See also  
CC AAQ35501-864. (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 18 BP; 2 A; 1 C; 4 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTAATAGAAAAAACAAC 239  
DB 18 CTAATAGAAAAAACAAC 1  
|| |||||

RESULT 224  
ID AAV95047 standard; RNA; 18 BP.  
AC AAV95047;  
XX  
XX 24-FEB-1999 (first entry)  
XX  
XX Mouse IL-2 receptor g-chain substrate position 51.  
XX  
XX Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;  
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;  
KW autoimmune disease; psoriasis; allergy; inflammatory disease;  
KW graft rejection; ss.  
XX  
XX Mus sp.  
XX  
XX WO9824913-A2.  
XX  
XX 11-JUN-1998.  
XX  
XX 02-DEC-1997; 97WO-US021748.  
XX  
XX 03-DEC-1996; 96US-00758306.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Stinchcomb DT, Mcswigen JA;  
XX  
XX WPI; 1998-333332/29.  
XX  
XX Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,  
PT autoimmune disease and allergies.  
XX  
XX Claim 4; Page 44; 61pp; English.

CC The present sequence invention describes ribozymes targeted to modulate  
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.  
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and  
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences  
CC from the present invention. The ribozymes can be used for the treatment  
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy  
CC and other inflammatory conditions. The ribozymes are also used to induce  
CC tolerance in a recipient to alloantigen from a donor  
XX  
SQ Sequence 18 BP; 1 A; 8 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 GCTGGAGCAGCTGAACGA 1138  
DB 18 GCAGGAGCAGCTGAACGA 1  
|| |||||

RESULT 225  
AAH37505  
ID AAH37505 standard; DNA; 18 BP.  
XX  
XX AAH37505;  
XX  
XX 14-AUG-2001 (first entry)  
XX

SNP specific upper PCR primer SEQ ID 301.  
XX  
XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;  
KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;  
KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;  
KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;  
KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;  
KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO200129262-A2.  
XX  
XX 26-APR-2001.  
XX  
XX 13-OCT-2000; 2000WO-US028436.  
XX  
XX 15-OCT-1999; 99US-0160096P.  
XX  
XX (ORCH-) ORCHID BIOSCIENCES INC.  
XX  
XX Picoult-Newburg L, Pohl M;  
XX  
XX WPI; 2001-290930/30.  
XX  
XX New genotyping oligonucleotide, useful for detecting the presence,  
PT absence or identity of single polynucleotide polymorphism in a nucleic  
PT acid sample.

Claim 1; Page 51; 83pp; English.  
XX  
XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide  
CC primer extension (SNPE) primers, and the sequences of regions flanking  
CC sites of single nucleotide polymorphisms SNPs. The present invention  
CC includes kits for determining the presence or absence of a SNP, using the  
CC oligonucleotides of the invention. The PCR primers are used to amplify a  
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.  
CC The oligonucleotides are useful for genotyping a nucleic acid sample by  
CC performing a single-nucleotide primer extension reaction. The  
CC oligonucleotides are useful for determining the presence, absence or  
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to  
CC assess by association analysis the genotype of an individual or group of  
CC individuals, having a pathological phenotypic trait suspected of being  
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.  
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular  
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,  
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic  
CC traits also include symptoms of or susceptibility to multifactorial  
CC diseases of which a component is or may be genetic such as autoimmune  
CC diseases, including, rheumatoid arthritis, multiple sclerosis,  
CC inflammation, cancer, nervous system diseases and infection by pathogenic  
CC microorganism. The method is also useful in forensic investigations and  
CC paternity analysis. The present sequence represents a PCR primer specific  
CC for a human SNP containing DNA sequence

SQ Sequence 18 BP; 4 A; 8 C; 5 G; 1 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC PTP10D, Tec or EDPH homologous polypeptide. The nucleic acid molecule of  
CC PTP10D, Tec, or EDPH family or their fragments, may be used in the  
CC preparation of a non-human animal which over- or under-expresses the  
CC PTP10D, Tec, or EDPH gene product. The present sequence represents a PCR  
CC primer for mouse protein tyrosine phosphatase receptor type B precursor  
CC (PTPRB), which is used in an example from the present invention  
XX  
SQ Sequence 18 BP; 3 A; 10 C; 1 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 764 CTTCACGCCCATGTTCCA 781  
DB 1 CTCCACGCCCATGTTCCA 18  
  
RESULT 227  
ACF04428  
ID ACF04428 standard; DNA; 18 BP.  
XX  
AC ACF04428;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Hepatitis C virus RNA probe.  
XX  
KW Silicon; silicon containing magnetic particle; superparamagnetic;  
KW silicon dioxide; nucleic acid isolation; probe; ss; RCV.  
XX  
OS Hepatitis C virus.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1 /\*tag= a  
FT /\*mod\_base= OTHER  
FT /\*note= "modified by FAM"  
FT modified\_base 18 /\*tag= b  
FT /\*mod\_base= OTHER  
FT /\*note= "modified by TAMRA"  
XX  
PN WO2003058649-A1.  
XX  
PD 17-JUL-2003.  
XX  
PP 07-JAN-2003; 2003WO-EP000054.  
XX  
PR 14-JAN-2002; 2002DE-01001084.  
XX  
PA (FARB ) BAYER AG.  
XX  
PI Hennig G, Hildenbrand K;  
XX  
DR WPI; 2003-542203/51.  
XX  
PT Silicon-coated magnetic particles, useful for purification of nucleic  
PT acid from body samples, do not need to be separated before quantification  
PT by polymerase chain reaction.  
XX  
PS Example 7; Page 23; 35pp; German.  
XX  
CC The present invention relates to silicon-coated magnetic particles in  
CC which the silicon content is less than 20wt.% of total. These can be used  
CC to isolate nucleic acids from body samples, especially serum,  
CC particularly for diagnostic detection of RNA from hepatitis C virus or  
CC HIV. The present sequence is a probe used to isolate RNA from hepatitis C  
CC virus from serum in the exemplification of the invention  
XX  
SQ Sequence 18 BP; 2 A; 11 C; 3 G; 1 T; 0 U; 1 Other;  
  
Query Match 0.9%; Score 14.6; DB 1; Length 18;

QY 1492 CCAAGTAACAGGCCCA 1509  
DB 1 CCAAGTGACAGGCCCA 18  
  
RESULT 226  
ACC79773  
ID ACC79773 standard; DNA; 18 BP.  
XX  
AC ACC79773;  
XX  
DT 02-SEP-2003 (first entry)  
XX  
DE Mouse PTPRB reverse PCR primer SEQ ID NO:11.  
XX  
KW Tec; protein tyrosine kinase; protein tyrosine phosphatase; PTP10D;  
KW egg derived tyrosine phosphatase; EDPH; antidiabetic; hypotensive;  
KW cardiant; antilipidemic; osteopathic; cytostatic; anorectic; obesity;  
KW immunomodulator; gene therapy; metabolic disease; eating disorder;  
KW body weight regulation disorder; cachexia; diabetes mellitus; cancer;  
KW hypertension; coronary heart disease; hypercholesterolaemia; gallstone;  
KW dyslipidaemia; osteoarthritis; sleep apnea; mouse; PTPRB;  
KW protein tyrosine phosphatase receptor type B precursor; PCR primer; ss.  
XX  
OS Mus BP.  
OS Synthetic.  
XX  
PN WO2003047611-A2.  
XX  
PD 12-JUN-2003.  
XX  
PF 04-DEC-2002; 2002WO-EP013744.  
XX  
PR 04-DEC-2001; 2001EP-00128844.  
PR 07-DEC-2001; 2001EP-00129138.  
PR 02-JAN-2002; 2002EP-00000010.  
XX  
PA (DEVE-) DEVELOPENTWICKLUNGSBIOLOGISCHE FORSCH.  
XX  
PI Meise M, Eulenberger K, Fritsch R, Haeder T, Broenner G;  
PI Steuernagel A;  
XX  
XX WPI; 2003-532801/50.  
XX  
XX New compositions comprising tyrosine phosphatase PTP10D, protein tyrosine  
XX kinase Tec or egg-derived tyrosine phosphatase genes or proteins, useful  
XX for treating or preventing metabolic diseases, e.g. as obesity or  
XX cachexia.  
XX  
XX Example 4; Page 52; 83pp; English.  
XX  
CC The present invention describes a pharmaceutical composition comprising a  
CC nucleic acid (I) protein tyrosine phosphatase PTP10D, non-receptor  
CC protein tyrosine kinase Tec, egg derived tyrosine phosphatase (EDPH) gene  
CC family or encoded polypeptide, fragment or variant of nucleic acid  
CC molecule or polypeptide, an antibody, an aptamer or receptor recognising  
CC a nucleic acid molecule of PTP10D, Tec, or EDPH gene family or encoded  
CC polypeptide, and a carrier; diluent and/or adjuvant. The pharmaceutical  
CC composition can have antidiabetic, hypotensive, cardiant, antilipidemic,  
CC osteopathic, cytostatic, anorectic and immunomodulator activities, and  
CC can be used in gene therapy. The composition is useful for the  
CC manufacture of an agent for detecting and/or verifying, for treating and  
CC alleviating and/or preventing a disorder, including metabolic diseases  
CC such as obesity and other body weight regulation disorders, as well as  
CC related disorders such as eating disorder, cachexia, diabetes mellitus,  
CC hypertension, coronary heart disease, hypercholesterolaemia.  
CC dyslipidaemia, osteoarthritis, gallstones, cancers (cancers of the  
CC reproductive organ), sleep apnea, and other diseases, in cells, cell  
CC masses, organs and/or subjects. The components of the composition may  
CC also be used in controlling the function of a gene and/or gene product  
CC which is influenced and/or modified by a PTP10D, Tec, or EDPH homologous  
CC polypeptide, and for identifying substances capable of interacting with a

Best Local Similarity 93.3%; Pred. No. 1.8e+02; Mismatches 1; Mismatches 0; Indels 0; Gaps 0;

QY 1509 AGCTCCAGGCCCCC 1523  
DB 1 AGCTCCAGGCCCCC 15

RESULT 228  
AAV93469/c  
ID AAV93469 standard; RNA; 17 BP.  
XX AAV93469;  
AC AAV93469;  
XX  
XX 20-JUL-1999 (first entry)  
DE Rabbit stromelysin hammerhead target SEQ ID NO:536.  
XX  
XX Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
XX diagnosis; ss.  
XX  
XX Oryctolagus cuniculus.  
OS  
XX  
XX WO9618736-A2.  
PN  
XX  
XX 20-JUN-1996.  
PD  
XX  
XX 22-NOV-1995; 95WO-US015516.  
PF  
XX  
XX 13-DEC-1994; 94US-00354920.  
PR  
XX 23-DEC-1994; 94US-00363253.  
PR  
XX 23-DEC-1994; 94US-00363254.  
PR  
XX 17-FEB-1995; 95US-00390850.  
PR  
XX 20-APR-1995; 95US-00426124.  
PR  
XX 02-MAY-1995; 95US-00432874.  
PR  
XX 04-MAY-1995; 95US-00434509.  
PR  
XX 07-JUL-1995; 95US-0000951P.  
PR  
XX 07-JUL-1995; 95US-0000974P.  
PR  
XX 07-AUG-1995; 95US-00512861.  
PR  
XX 05-OCT-1995; 95US-00541365.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpelesky A, Thompson JD, Modak A, Burgin A;  
XX  
XX WPI; 1996-300653/30.  
DR  
XX  
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
XX Example 1; Page 154; 307pp; English.  
PS  
XX  
XX The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment

CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention

XX  
SQ Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAGAAATTCCTC 1604  
DB 16 AAGAACAGAAATTCCTC 1

RESULT 229  
AAV93469  
ID AAV93469 standard; RNA; 17 BP.  
XX  
XX AAV93469;  
AC AAV93469;  
XX  
XX 18-FEB-1999 (first entry)  
DT  
XX  
XX Human B-raf substrate nucleotide position 1085.  
DE  
XX  
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;  
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;  
KW screening; identification; synthesis; deprotection; purification; cancer;  
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;  
KW restenosis; rheumatoid arthritis; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO9850530-A2.  
PN  
XX  
XX 12-NOV-1998.  
PD  
XX  
XX 05-MAY-1998; 98WO-US009249.  
PF  
XX  
XX 09-MAY-1997; 97US-0046059P.  
PR  
XX 03-JUN-1997; 97US-0049002P.  
PR  
XX 03-JUL-1997; 97US-0051718P.  
PR  
XX 22-AUG-1997; 97US-0056808P.  
PR  
XX 02-OCT-1997; 97US-0061321P.  
PR  
XX 02-OCT-1997; 97US-0061324P.  
PR  
XX 05-NOV-1997; 97US-0064866P.  
PR  
XX 19-DEC-1997; 97US-0068212P.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;  
PI Parry T, Beigelman L, McSwiggen JA, Karpelesky A, Burgin A;  
PI Thompson J, Workman CT, Beaudry A, Sweedler D;  
XX  
XX WPI; 1999-009494/01.  
DR  
XX  
XX Identifying new catalytic nucleic acid that modulates selected processes  
PT - especially ribozymes that cleave Raf RNA for treating cancer.  
PT restenosis, and also new ribozymes and modified nucleoside triphosphates  
PT used as antiviral agents and synthons.  
XX  
XX Claim 177; Page 168; 259pp; English.  
PS  
XX  
XX A method has been developed for the identification of a nucleic acid  
CC capable of modulating a process in a biological system. The method  
CC comprises: (a) introducing into the system a random library of nucleic  
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising  
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC  
CC in systems where modulation has occurred and/or determining the sequence  
CC of at least part of the SBDs in such systems. Nucleic acid molecules with  
CC endonuclease activity and catalytic activity, from the present invention,  
CC are used to modulate gene expression in plant and mammalian cells and to  
CC cleave target nucleic acid, particularly for treating systemic diseases







XX 25-MAY-2001; 2001WO-US016981.  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8667; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 274 AAGCCAAGAGAGAGAA 289  
DB 1 AAGCCAAGAGAGAGAA 16  
RESULT 233  
ABN08361/c  
ID ABN08361 standard; DNA; 17 BP.  
XX  
XX AC AEN08361;  
XX  
XX DT 29-MAY-2002 (first entry)  
XX

PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8352; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 CAGCTCTCTCTTGCTG 1124  
DB 17 CAGCTCTCTCTTGCTG 2  
RESULT 232  
ABN08675  
ID AEN08675 standard; DNA; 17 BP.  
XX  
XX AC AEN08675;  
XX  
XX DT 29-MAY-2002 (first entry)  
XX  
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8667.  
XX  
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
OS Homo sapiens.  
XX  
XX PN WO200192524-A2.  
XX  
XX PD 06-DEC-2001.

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8353.  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
OS Homo sapiens.  
XX  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
PI WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8353; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 CAGCTCCTCTTGTCTG 1124  
|||||

Db 16 CAGCTCCTCTTGTCTG 1  
RESULT 234  
ABN10046/C  
ID ABN10046 standard; DNA; 17 BP.  
XX  
XX AC ABN10046;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10038.  
XX  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
PI WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 10038; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 CAGCTCCTCTTGTCTG 1124  
|||||

CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 715 CCGCATCGTCCGAG 730  
Db 16 CCGCATCGTCCGAG 1  
  
RESULT 235  
ABN08673  
ID ABN08673 standard; DNA; 17 BP.  
XX  
AC ABN08673;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8665.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
KW New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
or as specific biomolecule capture probes for surface-enhanced laser  
desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 8665; 214pp; English.  
XX  
SS  
CC The present invention describes a human genome-derived myosin-like  
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
nucleic acids can be used as probes to detect, characterise and quantify  
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
provide initial substrates for the recombinant engineering of hGDMPLP-1  
protein variants having desired phenotypic improvements, and for  
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
used as immunogens to raise antibodies that specifically recognise hGDMPLP

-1 proteins, as standards in assays used to determine the concentration  
and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
capture probes for surface-enhanced laser desorption ionisation, as  
therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
production, and in vaccines or for replacement therapy. The  
polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
disorder associated with the expression of hGDMPLP-1, in particular heart  
and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
The present sequence represents an oligomer used in the screening of the  
hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
The sequence data for this patent did not form part of the printed  
specification, but was obtained in electronic format directly from WIPO  
at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 273 GAAGCCCAAGAAGAAGA 288  
Db 2 GAAGCCCAAGAAGAAGA 17  
  
RESULT 236  
ABN10045/c  
ID ABN10045 standard; DNA; 17 BP.  
XX  
AC ABN10045;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10037.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
KW New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
or as specific biomolecule capture probes for surface-enhanced laser  
desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX

```
PS Disclosure; SEQ ID NO 10037; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 715 CCGCATCGTCCGCG 730
DB 17 CCGCATCGTCCACAG 2
RESULT 237
ACN07604
ID ACN07604 standard; RNA; 17 BP.
XX
XX ACN07604;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7607.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PT
```

```
PS Claim 23; SEQ ID NO 7607; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1234 CGACGTCCTTCGCG 1249
DB 1 CGACGUCCAUCCGG 16
RESULT 238
ACN09975
ID ACN09975 standard; RNA; 17 BP.
XX
XX ACN09975;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand Inozyme substrate SEQ ID NO 9978.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PT
```

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

XX Sequence 17 BP; 2 A; 9 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 1.6e+02;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACCTCTCTCT 1119  
DB 1 CUCGACACCUCCUCCU 16

RESULT 239  
ACN07053/c  
ID ACN07053 standard; RNA; 17 BP.  
XX ACN07053;  
XX 22-APR-2004 (first entry)  
XX WNV Amberzyme substrate SEQ ID NO 7056.  
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.  
XX West Nile Virus.  
XX WO200268637-A2.  
XX 06-SEP-2002.  
XX 19-OCT-2001; 2001WO-US048350.  
XX 20-OCT-2000; 2000US-0242411P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX (BLAT/) BLATT L.  
XX (MCSW/) MCSWIGGEN J A.  
XX Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.  
XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX Claim 23; SEQ ID NO 7056; 495pp; English.  
XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

CC Sequence 17 BP; 2 A; 9 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACCTCTCTCT 1119  
DB 17 CTCGACACCTCTCTCT 2

RESULT 240  
ACN07193/c  
ID ACN07193 standard; RNA; 17 BP.  
XX ACN07193;  
XX 22-APR-2004 (first entry)  
XX WNV Amberzyme substrate SEQ ID NO 7196.  
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.  
XX West Nile Virus.  
XX WO200268637-A2.  
XX 06-SEP-2002.  
XX 19-OCT-2001; 2001WO-US048350.  
XX 20-OCT-2000; 2000US-0242411P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX (BLAT/) BLATT L.  
XX (MCSW/) MCSWIGGEN J A.  
XX Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.  
XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX Claim 23; SEQ ID NO 7196; 495pp; English.  
XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

CC Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02; Mismatches 1; Indels 0; Gaps 0; Matches 15; Conservative 0;	
OY	1234 CGGACGTTCTTCCCG 1249
Db	17 CGGACGTTCCATCCG 2
RESULT 241	
ACN04500/C	
ID	ACN04500 standard; RNA; 17 BP.
XX	ACN04500;
XX	22-APR-2004 (first entry)
XX	WNV Zinzyme substrate SEQ ID NO 4503.
XX	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; viricide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.
XX	West Nile Virus.
XX	WO200268637-A2.
XX	06-SEP-2002.
XX	19-OCT-2001; 2001WO-US048350.
XX	20-OCT-2000; 2000US-0242411P.
XX	(RIBO-) RIBOZYME PHARM INC.
XX	(BLAT/) BLATT L.
XX	(MCSW/) MCSWIGGEN J A.
XX	Blatt L, Mcswiggen JA;
XX	WPI; 2002-706994/76.
XX	New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX	Claim 23; SEQ ID NO 4503; 495pp; English.
XX	The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention
XX	Sequence 17 BP; 4 A; 1 C; 10 G; 0 T; 2 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;	
Best Local Similarity 93.8%; Pred. No. 1.6e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
OY	1104 CTCACACCTCTCTCT 1119
Db	16 CTCGACACTCTCTCT 1

Best Local Similarity 93.8%; Pred. No. 1.6e+02; Mismatches 1; Indels 0; Gaps 0; Matches 15; Conservative 0;	
OY	1234 CGGACGTTCTTCCCG 1249
Db	2 CGGACGUUCCAUCCG 17
RESULT 243	
ABT38885/C	
ID	ABT38885 standard; DNA; 17 BP.
XX	ABT38885;
XX	

DT 12-JUN-2003 (first entry)  
DE XX Tumour suppression related human fukutin oligo SEQ ID NO 4522.  
XX  
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025175-A2.  
XX  
PD 27-MAR-2003.  
XX  
XX 17-SEP-2002; 2002WO-IB004208.  
XX  
PF 17-SEP-2001; 2001FR-00011978.  
XX  
PR (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PA Telerman A, Amson R, Tuijnder M;  
XX  
PI WPI; 2003-313353/30.  
XX  
DR New isolated nucleic acid, useful for treating viral diseases associated  
XX with tumors and cell degeneration, also related polypeptides, antibodies  
XX PT and transfected cells.  
XX PT  
XX PS Disclosure; Page 562; 720pp; French.  
XX  
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
XX given in the specification, a sequence containing at least 15 consecutive  
XX nucleotides from the 17 mer sequence, a sequence with, after optimal  
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
XX hybridizes to them under highly stringent conditions, or the complement  
XX of any of them, or the corresponding RNA. The novel isolated nucleic  
XX acids of the invention are useful as probes and primers for detecting,  
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
XX component of a gene chip, in vitro as (anti)sense reagents, and for  
XX production of recombinant polypeptides. Any of the nucleic acids,  
XX polypeptides, vectors containing the nucleic acids, cells containing the  
XX vector or antibodies directed against the polypeptides are useful for  
XX preparation of pharmaceuticals for prevention and/or treatment of viral  
XX diseases that are characterised by development of tumours or cell  
XX degeneration, specifically cancer but also Alzheimer's disease and  
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
XX patient samples is useful for diagnosis and/or prognosis of these  
XX diseases. The polypeptides can also be used to generate antibodies, and  
XX both the polypeptide and antibodies are useful as components of protein  
XX chips. The nucleic acid sequences of the invention can be used in gene  
XX therapy. This polynucleotide sequence represents a tumour suppression  
XX related human fukutin oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 2 G; 7 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 326 AAAGCTGAAGGAGCTC 341  
|||||  
DB 16 AAAGCTGAAGGAGATC 1

RESULT 244  
ADB00466/c  
ID ADB00466 standard; DNA; 17 BP.  
XX  
AC ADB00466;  
XX  
XX 20-NOV-2003 (first entry)  
XX  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
XX developmental disorder; ss.  
XX  
OS Homo sapiens.

Human MD23 scanning oligonucleotide SEQ ID 1452.  
Cytostatic; immunostimulant; gene therapy; vaccine; human;  
zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
developmental disorder; ss.  
Homo sapiens.  
EP1281758-A2.  
05-FEB-2003.  
30-JUL-2002; 2002EP-00016874.  
02-AUG-2001; 2001US-00922181.  
(AEOM-) AEOMICA INC.  
Shannon M, Gu Y, Nguyen C;  
WPI; 2003-423107/40.  
New zinc finger-containing proteins and nucleic acids, useful in  
manufacturing a medicament for treating or preventing a disorder  
associated with decreased or increased expression or activity of MD23,  
MD24, MD27 or MD212, e.g. cancer.  
Example 8; SEQ ID NO 1452; 103pp; English.  
The present invention relates to novel human zinc finger-containing  
proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
or in manufacturing a medicament for treating or preventing a disorder  
associated with decreased or increased expression or activity of MD23  
MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
acids and proteins are also useful for diagnosing or monitoring a disease  
caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
acids can also be used as probes to detect and characterize gross  
alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
useful in constructing microarrays for measuring gene expression. The  
proteins are useful as therapeutic agents for gene therapy or as  
vaccines. The present sequence was used to illustrate the invention.  
Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0

QY 928 GCTGCCTCGCGATGAA 943  
|||||  
DB 16 GCTGCCTCGCGTGAA 1

RESULT 245  
ADB00464/c  
ID ADB00464 standard; DNA; 17 BP.  
XX  
AC ADB00464;  
XX  
XX 20-NOV-2003 (first entry)  
XX  
XX Human MD23 scanning oligonucleotide SEQ ID 1450.  
XX  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
XX developmental disorder; ss.  
XX  
OS Homo sapiens.



XX PF1281758-A2.  
XX 05-FEB-2003.  
XX 30-JUL-2002; 2002EP-00016874.  
XX 02-AUG-2001; 2001US-00922181.  
XX (AEOM-) AEOMICA INC.  
XX Shannon M, Gu Y, Nguyen C;  
XX WPI; 2003-423107/40.  
XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MD23,  
PT MD24, MD27 or MD212, e.g. cancer.  
XX Example 8; SEQ ID NO 1450; 103pp; English.  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
CC encoded at chromosome 7q22.1. MD24 is encoded at chromosome 6p21.3-22.2,  
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MD23,  
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 929 CTGCTCGGATGAAG 944  
Db 17 CTGCTCGGCTGAAG 2  
RESULT 246  
ABZ61479/c  
ID ABZ61479 standard; RNA; 17 BP.  
XX AC ABZ61479;  
XX 21-MAR-2003 (first entry)  
XX Human H-Ras DNAzyme target #270.  
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;  
KW anti-rheumatic; cancer; AIDS; ss.  
XX Homo sapiens.  
XX WO200297114-A2.  
XX 05-DEC-2002.  
XX 29-MAY-2002; 2002WO-US016840.  
XX 29-MAY-2001; 2001US-0294140P.  
PR 06-JUN-2001; 2001US-0296249P.

PR 10-SEP-2001; 2001US-0318471P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Mcswiggen J;  
XX WPI; 2003-140484/13.  
XX Novel short interfering RNA and enzymatic nucleic acid useful for  
PT treating cancer, modulates the expression of a nucleic acid encoding  
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
XX Claim 58; Page 116; 185pp; English.  
XX The invention relates to a novel short interfering RNA (siRNA) nucleic  
CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
CC rheumatic activity. The nucleic acid molecules are useful for reducing  
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,  
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human  
CC ribozymes of the invention  
XX SQ Sequence 17 BP; 1 A; 5 C; 9 G; 0 T; 2 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1507 CCAGCTCCAGGCCCC 1522  
Db 17 CCAGCTCCAGGCCCC 2  
RESULT 247  
ACD59853  
ID ACD59853 standard; RNA; 17 BP.  
XX AC ACD59853;  
XX 24-SEP-2003 (first entry)  
XX HCV DNAzyme substrate sequence #1543.  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX Hepatitis C virus.  
XX WO200281494-A1.  
XX 17-OCT-2002.  
XX 26-MAR-2002; 2002WO-US009187.  
XX 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.



```
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 261; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.8%; Pred. No. 1.6e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
XX
QY 768 CAGCCCATGTTCCAGC 783
Db 1 CAGCCCAUGUCCGCG 16
|||||:|:|:|
XX
RESULT 248
ACD53920/c
ID ACD53920 standard; RNA; 17 BP.
XX
AC ACD53920;
XX
XX 24-SEP-2003 (first entry)
XX
XX HBV zinzyme substrate sequence #90.
DE
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN WO200281494-A1.
XX
XX 17-OCT-2002.
PD
```

```
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX 08-JUN-2001; 2001US-0296876P.
XX
XX 24-OCT-2001; 2001US-0335059P.
XX
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BLAT/) BLATT L.
XX
XX (MACE/) MACEJAK D.
XX
XX (MCSW/) MCSWIGGEN J.
XX
XX (MORR/) MORRISSEY D.
XX
XX (PAVC/) PAVCO P.
XX
XX (LEEP/) LEE P.
XX
XX (DRAP/) DRAPER K.
XX
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.
XX
XX Example 1; Page 175; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 3 A; 0 C; 11 G; 0 T; 3 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1519 CCCCCAACTCCGCCCA 1534
Db 16 CCCCCAACTCCTCCCA 1
|||||:|:|:|
XX
RESULT 249
ADB43621
ID ADB43621 standard; DNA; 17 BP.
XX
XX ADB43621;
AC ADB43621;
XX
XX 18-DEC-2003 (revised)
XX
XX 04-DEC-2003 (first entry)
XX
XX Tumour suppression/reversion associated nucleotide #3944.
DE
XX
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX primer; probe; tumour suppression; tumour reversion; apoptosis;
KW
```

KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
XX diagnosis.  
OS Homo sapiens.  
XX WO2003040369-A2.  
PN 15-MAY-2003.  
XX 17-SEP-2002; 2002WO-IB004219.  
PF 17-SEP-2001; 2001FR-00011981.  
PR (MOLE-) MOLECULAR ENGINES LAB.  
XX Telerman A, Amson R, Tuijnder M;  
PI WPI; 2003-441574/41.  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX Disclosure; Page 493; 771pp; French.  
XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 154 ATCAGGGAAGTAAGTA 169  
Db ||||||| |||||  
2 ATCAGGGAAGTAAGTA 17  
RESULT 250  
ADE30979  
ID ADE30979 standard; DNA; 17 BP.  
XX ADE30979;  
AC ADE30979;  
XX 29-JAN-2004 (first entry)  
DT Cholesterol homeostasis/adipogenesis related DNA seq id 366.  
XX expression vector; anorectic; antiarteriosclerotic; cardiant;  
XX anti-diabetic; elevated cholesterol; elevated lipid; adipogenesis;  
KW obesity; atherosclerosis; diabetes mellitus;  
KW coronary artery heart disease; cholesterol homeostasis; ss;  
KW differential expression.  
XX

OS Homo sapiens.  
XX US2003180764-A1.  
XX 25-SEP-2003.  
XX 08-JAN-2003; 2003US-00339793.  
PF 09-JAN-2002; 2002US-0347286P.  
PR (LYNX-) LYNX THERAPEUTICS INC.  
XX Shang J, Bowen B;  
PI WPI; 2003-830986/77.  
XX Polynucleotides differentially regulated in response to cholesterol and  
PT adipogenesis are useful to detect and treat associated conditions such as  
PT obesity, atherosclerosis, diabetes mellitus and coronary artery heart  
PT disease.  
XX Claim 8; SEQ ID NO 366; 59pp; English.  
XX The invention describes a composition comprising at least one expression  
CC vector comprising a polynucleotide of the invention. The composition has  
CC anorectic, antiarteriosclerotic, cardiant and anti-diabetic properties.  
CC The invention is used to detect and treat conditions associated with  
CC elevated cholesterol and lipid or during adipogenesis, particularly  
CC obesity, atherosclerosis, diabetes mellitus or coronary artery heart  
CC disease. This sequence represents a polynucleotide differentially  
CC expressed during cholesterol homeostasis and adipogenesis.  
XX Sequence 17 BP; 5 A; 9 C; 1 G; 2 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 990 ACCAACACCCCTCCC 1005  
Db ||||||| |||||  
2 ATCAACACCCCTCCC 17  
RESULT 251  
ABX95832  
ID ABX95832 standard; DNA; 17 BP.  
XX AC ABX95832;  
XX 24-JUL-2003 (first entry)  
DT Human Phe311Leu mutant Abl kinase, allele specific PCR primer F311T.  
DE Human; Abl kinase domain; tyrosine kinase activity; leukaemia;  
XX N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4-;  
KW (4-methyl-piperazin-1-ylmethyl)-benzamide; PCR; primer; ss.  
XX Homo sapiens.  
OS Synthetic.  
OS WO2003031608-A2.  
XX 17-APR-2003.  
XX 04-OCT-2002; 2002WO-EP011144.  
XX 05-OCT-2001; 2001US-0327389P.  
PR 12-OCT-2001; 2001US-0328740P.  
PR 11-JAN-2002; 2002US-0347351P.  
XX (NOVS ) NOVARTIS AG.  
PA (UYBO-) UNIV BORDEAUX 2 SEGALEN VICTOR.  
PA (UYMU-) UNIV TECH MUEENCHEN.  
PA

```
PA (UYOR-) UNIV OREGON HEALTH SCI.
PA (UYHE-) UNIV HEIDELBERG.
PA (CHRU-) CHRU LILLE.
PA (MEDV-) MEDVET SCI PTY LTD.
XX
XX Barthe C, Branford S, Corbin A, Druker BJ, Duyster J, Hochhaus A;
PI Hughes T, Kreil S, Leguay T, Mahon F, Marit G, Mueller M;
PI Peschel C, Preudhomme C, Roche Lestienne C, Rudzki Z;
XX WPI; 2003-363366/34.
XX
XX New isolated polypeptide having mutated native human Abl kinase domains,
PT useful for screening compounds that inhibit tyrosine kinase activity and
PT for diagnosing leukemias.
XX
XX Example 6; Page 34; 57pp; English.
XX
XX The present invention relates to mutated human Abl kinase domains that
CC are functional and resistant to inhibition of their tyrosine kinase
CC activity by N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4
CC -(4-methyl-piperazin-1-ylmethyl)-benzamide, or its salt. The mutant Abl
CC polypeptides are useful in screening for compounds that inhibit the
CC tyrosine kinase activity of such polypeptides. Polynucleotide sequences
CC encoding the mutant polypeptides are useful for the production of the
CC mutant polypeptides. The mutant polypeptides are also useful in the
CC diagnosis of leukemias. The present sequence represents a PCR primer
CC used in the examples of the present invention
XX
XX Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 635 CACCCGGAGCCCCG 650
DB 1 CACCCGGAGCCCCG 16
RESULT 252
ABX95833
ID ABX95833 standard; DNA; 17 BP.
XX
XX ABX95833;
DT 24-JUL-2003 (first entry)
XX
XX Human Phe311Leu mutant Abl kinase, allele specific PCR primer F311C.
DE
XX Human; Abl kinase domain; tyrosine kinase activity; leukaemia;
KW N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4-;
KW (4-methyl-piperazin-1-ylmethyl)-benzamide; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO2003031608-A2.
XX
XX 17-APR-2003.
XX
XX 04-OCT-2002; 2002WO-EP011144.
XX
XX 05-OCT-2001; 2001US-0327389P.
PR 12-OCT-2001; 2001US-0328740P.
PR 11-JAN-2002; 2002US-0347351P.
XX
XX (NOVS ) NOVARTIS AG.
PA (UYBO-) UNIV BORDEAUX 2 SEGALEN VICTOR.
PA (UYMU-) UNIV TECH MUENCHEN.
PA (UYOR-) UNIV OREGON HEALTH SCI.
PA (UYHE-) UNIV HEIDELBERG.
PA (CHRU-) CHRU LILLE.
PA (MEDV-) MEDVET SCI PTY LTD.
XX
XX Barthe C, Branford S, Corbin A, Druker BJ, Duyster J, Hochhaus A;
PI Hughes T, Kreil S, Leguay T, Mahon F, Marit G, Mueller M;
PI Peschel C, Preudhomme C, Roche Lestienne C, Rudzki Z;
XX WPI; 2003-363366/34.
XX
XX New isolated polypeptide having mutated native human Abl kinase domains,
PT useful for screening compounds that inhibit tyrosine kinase activity and
PT for diagnosing leukemias.
XX
XX Example 6; Page 34; 57pp; English.
XX
XX The present invention relates to mutated human Abl kinase domains that
CC are functional and resistant to inhibition of their tyrosine kinase
CC activity by N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4
CC -(4-methyl-piperazin-1-ylmethyl)-benzamide, or its salt. The mutant Abl
CC polypeptides are useful in screening for compounds that inhibit the
CC tyrosine kinase activity of such polypeptides. Polynucleotide sequences
CC encoding the mutant polypeptides are useful for the production of the
CC mutant polypeptides. The mutant polypeptides are also useful in the
CC diagnosis of leukemias. The present sequence represents a PCR primer
CC used in the examples of the present invention
XX
XX Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 635 CACCCGGAGCCCCG 650
DB 1 CACCCGGAGCCCCG 16
RESULT 253
ADL18587
ID ADL18587 standard; DNA; 17 BP.
XX
XX ADL18587;
DT 06-MAY-2004 (first entry)
XX
XX RT-PCR primer HP6.
DE
XX DNA storage; DNA analysis; virus identification; bacteria identification;
KW reverse transcriptase; RT-PCR; primer; ss; HP6.
XX
XX Synthetic.
XX
XX US20031134312-A1.
XX
XX 17-JUL-2003.
XX
XX 15-NOV-2002; 2002US-00298255.
XX
XX 15-NOV-2001; 2001US-0336005P.
XX
XX (WHAT-) WHATMAN INC.
XX
XX Burgoyne LA;
XX
XX WPI; 2003-843261/78.
XX
XX New device comprising a filter layer comprising a dry solid medium
PT comprising a hydrophilic solid matrix, and an isolation layer, useful for
PT storing and analyzing a nucleic acid containing moiety.
XX
XX Example 1; SEQ ID NO 4; 14pp; English.
XX
XX The invention relates to a device for storage and analysis of a nucleic
CC acid containing a moiety in a biological sample, comprising a filter
CC layer comprising a dry solid medium comprising a hydrophilic solid
```

CC matrix, and an isolation layer comprising a dry solid medium comprising a  
CC neutral solid matrix attached to a composition comprising a detergent.  
CC storing and analysing a nucleic acid containing a moiety in a biological  
CC sample comprises applying a biological sample to the filter layer,  
CC filtering the components of the biological sample through the filter  
CC layer to the isolation layer, retaining the nucleic acid components in  
CC the isolation layer while removing the non-nucleic acid components,  
CC drying the isolation layer, providing a primer and analysing the nucleic  
CC acid components using at least one primer. The device and method are  
CC useful for storing and analysing a nucleic acid containing a moiety in a  
CC biological sample. They are also useful for identifying known or unknown  
CC virions or bacteria contained in a fluid. This sequence represents a  
CC reverse transcriptase PCR (RT-PCR) primer used in the scope of the  
CC invention.  
XX  
SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1523  
|||||  
Db 1 CAGCCTCCAGGCCCC 16  
RESULT 254  
ADM59611/c  
ID ADM59611 standard; RNA; 17 BP.  
XX  
AC ADM59611;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Hepatitis B virus (HBV) RNA target sequence #1745.  
XX  
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;  
KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;  
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;  
KW virucide; hepatotropic; antiinflammatory; cytostatic.  
XX  
OS Hepatitis B virus.  
XX  
PN US2004054156-A1.  
XX  
PD 18-MAR-2004.  
XX  
PF 15-JAN-2003; 2003US-00342902.  
XX  
PR 14-MAY-1992; 92US-00882712.  
PR 07-FEB-1994; 94US-00193627.  
PR 08-NOV-1999; 99US-00436430.  
PR 20-MAR-2000; 2000US-00531025.  
PR 09-AUG-2000; 2000US-00636395.  
PR 24-OCT-2000; 2000US-00696347.  
PR 08-JUN-2001; 2001US-00877478.  
XX  
PA (DRAP/) DRAPER K.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
PA (MORR/) MORRISSEY D.  
XX  
PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;  
XX  
DR WPI; 2004-247781/23.  
XX  
PT Novel enzymatic nucleic acid molecule such as DNazymes and inozymes  
PT specifically cleaving RNA derived from hepatitis B virus and comprising  
PT one or more binding arms, useful for treating hepatitis and cirrhosis.  
XX  
PS Disclosure; SEQ ID NO 1745; 122pp; English.  
XX  
CC The invention relates to an enzymatic nucleic acid molecule that

CC specifically cleaves RNA derived from hepatitis B virus (HBV) and  
CC comprising one or more binding arms, without requiring the presence of a  
CC 2'-OH group within the molecule for activity. The nucleic acids are  
CC useful for treating hepatitis B virus infection, hepatitis,  
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in  
CC combination with other therapies such as lamivudine and interferons. The  
CC nucleic acids are useful as diagnostic tools to examine genetic drift and  
CC mutations within diseased cells, for detecting the presence of HBV RNA in  
CC a cell, for the study of RNA and for down-regulating gene expression of  
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This  
CC sequence represents an HBV RNA target sequence, used in the scope of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 17 BP; 3 A; 0 C; 11 G; 0 T; 3 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1519 CCCCCCACTCCGCCA 1534  
|||||  
Db 16 CCCCCCACTCCGCCA 1  
RESULT 255  
ADI84297  
ID ADI84297 standard; RNA; 17 BP.  
XX  
AC ADI84297;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE HCV DNzyme substrate sequence #1543.  
XX  
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
KW HCV infection; type I interferon; DNzyme.  
XX  
OS Hepatitis C virus.  
XX  
PN US2003125270-A1.  
XX  
PD 03-JUL-2003.  
XX  
PF 18-DEC-2000; 2000US-00740332.  
XX  
PR 18-DEC-2000; 2000US-00740332.  
XX  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (ROBE/) ROBERTS E.  
PA (PAVC/) PAVCO P A.  
PA (MACE/) MACEJACK D.  
XX  
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
XX  
DR WPI; 2004-031273/03.  
XX  
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived  
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
PT especially in combination with type I interferon therapy.  
XX  
PS Claim 1; SEQ ID NO 1543; 198pp; English.  
XX  
CC The invention relates to an enzymatic nucleic acid molecule which  
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
CC the binding arms of the enzymatic nucleic acid molecule comprises  
CC sequences complementary to any of the defined substrate sequences given  
CC in the specification. The nucleic acid molecule may be administered for  
CC the treatment of HCV infections, especially in combination with type I  
CC interferons. The present sequence represents a HCV DNzyme substrate  
CC sequence.  
XX

SQ	Sequence	17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;	
XX	AC	ACN71763;	
XX	DT	02-DEC-2004 (first entry)	
XX	DE	Human GDMPLP-1 probe SEQ ID NO:8665.	
XX	KW	Human; ss; probe; myosin-like protein-1; hGDMPLP-1;	
XX	KW	hGDMPLP-1 agonist; hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;	
XX	OS	skeletal muscle function.	
XX	OS	Homo sapiens.	
XX	PN	US2004137589-A1.	
XX	PD	15-JUL-2004.	
XX	PF	26-NOV-2003; 2003US-00723361.	
XX	PR	26-MAY-2000; 2000US-0207456P.	
XX	PR	21-SEP-2000; 2000US-0234687P.	
XX	PR	27-SEP-2000; 2000US-0236359P.	
XX	PR	04-OCT-2000; 2000GB-00024263.	
XX	PR	30-JAN-2001; 2001WO-US000661.	
XX	PR	30-JAN-2001; 2001WO-US000662.	
XX	PR	30-JAN-2001; 2001WO-US000663.	
XX	PR	30-JAN-2001; 2001WO-US000664.	
XX	PR	30-JAN-2001; 2001WO-US000665.	
XX	PR	30-JAN-2001; 2001WO-US000666.	
XX	PR	30-JAN-2001; 2001WO-US000667.	
XX	PR	30-JAN-2001; 2001WO-US000668.	
XX	PR	30-JAN-2001; 2001WO-US000669.	
XX	PR	05-FEB-2001; 2001WO-US000670.	
XX	PR	25-MAY-2001; 2001US-0266860P.	
XX	PA	(GUY/) GU Y.	
XX	PA	(JIY/) JI Y.	
XX	PA	(PENN/) PENN S G.	
XX	PA	(HANZ/) HANZEL D K.	
XX	PA	(RANK/) RANK D.	
XX	PA	(CHEN/) CHEN W.	
XX	PA	(SHAN/) SHANNON M E.	
XX	PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;	
XX	DR	WPI; 2004-533378/51.	
XX	PT	Novel myosin-like protein-1, useful for treating or preventing disorder	
XX	PT	associated with decreased expression or activity of human genome-derived	
XX	PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle	
XX	PS	function.	
XX	PS	Disclosure; SEQ ID NO 8665; Opp; English.	
XX	CC	The invention relates to a novel polypeptide (I) comprising a sequence	
XX	CC	(SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully	
XX	CC	defined in the specification, a fragment of at least 8 amino acids of	
XX	CC	(SI), 95% deviation from (SI) which are conservative substitutions, and	
XX	CC	65% identity to (SI). A polypeptide of the invention acts as an agonist or	
XX	CC	antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A	
XX	CC	pharmaceutical composition of the invention is useful for treating or	
XX	CC	preventing a disorder associated with decreased expression or activity of	
XX	CC	hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.	
XX	CC	The present sequence represents a 17-mer nucleotide, used in the	
XX	CC	invention for scanning the sequence represented in ACN63103	
XX	XX	Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;	
XX	XX	Query Match 0.9%; Score 14.4; DB 1; Length 17;	
XX	XX	Best Local Similarity 93.8%; Pred. No. 1.6e+02;	
XX	XX	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	768	CACGCCATGTTCCAGC 783	
DB	1	CACGCCAUGUUCGCGC 16	
RESULT 256			
AD185767/C			
ID	ADI85767	standard; RNA; 17 BP.	
XX	AC	ADI85767;	
XX	DT	03-JUN-2004 (first entry)	
XX	DE	HCV DNasey substrate sequence #3013.	
XX	SS	ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;	
KW	KW	HCV infection; type I interferon; DNasey.	
XX	OS	Hepatitis C virus.	
XX	PN	US2003125270-A1.	
XX	PD	03-JUL-2003.	
XX	PR	18-DEC-2000; 2000US-00740332.	
XX	PR	18-DEC-2000; 2000US-00740332.	
XX	PA	(BLAT/) BLATT L.	
XX	PA	(MCSW/) MCSWIGEN J.	
XX	PA	(ROBE/) ROBERTS E.	
XX	PA	(PAVC/) PAVCO P A.	
XX	PA	(MACE/) MACEJACK D.	
XX	PI	Blatt L, Meswigen J, Roberts E, Pavco PA, Macejack D;	
XX	DR	WPI; 2004-031273/03.	
XX	PT	Enzymatic nucleic acid molecules which specifically cleave RNA derived	
XX	PT	from hepatitis C virus (HCV), useful for the treatment of HCV infections,	
XX	PT	especially in combination with type I interferon therapy.	
XX	PS	Claim 1; SEQ ID NO 3013; 198pp; English.	
XX	CC	The invention relates to an enzymatic nucleic acid molecule which	
XX	CC	specifically cleaves RNA derived from hepatitis C virus (HCV), in which	
XX	CC	the binding arms of the enzymatic nucleic acid molecule comprises	
XX	CC	sequences complementary to any of the defined substrate sequences given	
XX	CC	in the specification. The nucleic acid molecule may be administered for	
XX	CC	the treatment of HCV infections, especially in combination with type I	
XX	CC	interferons. The present sequence represents a HCV DNasey substrate	
XX	CC	sequence.	
XX	XX	Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;	
XX	XX	Query Match 0.9%; Score 14.4; DB 1; Length 17;	
XX	XX	Best Local Similarity 93.8%; Pred. No. 1.6e+02;	
XX	XX	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	768	CACGCCATGTTCCAGC 783	
DB	16	CACGCCATGTTCCGCGC 1	
RESULT 257			
ACN71763			
ID	ACN71763	standard; DNA; 17 BP.	

CC	invention for scanning the sequence represented in ACN63103									
XX										
QQ	Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;									
	Query Match	0.9%;	Score 14.4;	DB 1;	Length 17;					
	Best Local Similarity	93.8%;	Pred. No. 1.6e+02;							
	Matches 15;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;					
QY	715	CCCGCATCGTCCGAC	730							
DB	16	CCCGCATCGTCCACAG	1							
RESULT 259										
ACN73135/c										
ID	ACN73135 standard; DNA; 17 BP.									
XX										
AC	ACN73135;									
XX										
DT	02-DEC-2004 (first entry)									
XX										
DE	Human GDMPLP-1 probe SEQ ID NO:10037.									
XX										
KW	Human; ss; probe; myosin-like protein-1; hGDMPLP-1;									
KW	hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;									
XX	skeletal muscle function.									
XX										
OS	Homo sapiens.									
PN	US2004137589-A1.									
XX										
PD	15-JUL-2004.									
XX										
PF	26-NOV-2003; 2003US-00723361.									
XX										
PR	26-MAY-2000; 2000US-0207456P.									
PR	21-SEP-2000; 2000US-0234687P.									
PR	27-SEP-2000; 2000US-0236359P.									
PR	04-OCT-2000; 2000GB-00024263.									
PR	30-JAN-2001; 2001WO-US0000661.									
PR	30-JAN-2001; 2001WO-US0000662.									
PR	30-JAN-2001; 2001WO-US0000663.									
PR	30-JAN-2001; 2001WO-US0000664.									
PR	30-JAN-2001; 2001WO-US0000665.									
PR	30-JAN-2001; 2001WO-US0000666.									
PR	30-JAN-2001; 2001WO-US0000667.									
PR	30-JAN-2001; 2001WO-US0000668.									
PR	30-JAN-2001; 2001WO-US0000669.									
PR	30-JAN-2001; 2001WO-US0000670.									
PR	05-FEB-2001; 2001US-0266860P.									
PR	25-MAY-2001; 2001US-00866108.									
XX										
PA	(GUY/) GU Y.									
PA	(JIY/) JI Y.									
PA	(PENN/) PENN S G.									
PA	(HANZ/) HANZEL D K.									
PA	(RANK/) RANK D.									
PA	(CHEN/) CHEN W.									
PA	(SHAN/) SHANNON M E.									
XX										
XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;									
PI	WPI; 2004-533378/51.									
DR										
XX										
PT	Novel myosin-like protein-1, useful for treating or preventing disorder									
PT	associated with decreased expression or activity of human genome-derived									
PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle									
PT	function.									
XX										
PS	Disclosure; SEQ ID NO 10037; opp; English.									
XX										
CC	The invention relates to a novel polypeptide (I) comprising a sequence									
CC	(SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully									

CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103

XX  
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 715 CCGCATCGTCCGAC 730  
Db |||||

RESULT 260  
ACN71450/c  
ID ACN71450 standard; DNA; 17 BP.  
XX AC ACN71450;  
XX  
XX  
DT 02-DEC-2004 (first entry)  
XX  
XX Human GDMPLP-1 probe SEQ ID NO:8352.  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.

XX Homo sapiens.  
XX  
XX US2004137589-A1.  
XX  
XX 15-JUL-2004.  
XX  
XX 26-NOV-2003; 2003US-00723361.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.  
XX (JIY/) JI Y.  
XX (PENN/) PENN S G.  
XX (HANK/) HANZEL D K.  
XX (CHEN/) CHEN W.  
XX (SHAN/) SHANNON M E.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
XX function.  
XX  
XX Disclosure; SEQ ID NO 8352; Opp; English.  
XX  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103

XX  
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 CACCTCCTCTGCTG 1124  
Db |||||

RESULT 261  
ACN71451/c  
ID ACN71451 standard; DNA; 17 BP.  
XX AC ACN71451;  
XX  
XX  
DT 02-DEC-2004 (first entry)  
XX  
XX Human GDMPLP-1 probe SEQ ID NO:8353.  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.

XX Homo sapiens.  
XX  
XX US2004137589-A1.  
XX  
XX 15-JUL-2004.  
XX  
XX 26-NOV-2003; 2003US-00723361.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.  
XX (JIY/) JI Y.  
XX (PENN/) PENN S G.  
XX (HANK/) HANZEL D K.  
XX (SHAN/) SHANNON M E.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder

```
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8353; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1109 CACCTCTCTCTTGCTG 1124
DB 16 CAGCTCTCTCTTGCTG 1
XX
RESULT 262
ACN71765
ID ACN71765 standard; DNA; 17 BP.
XX
AC ACN71765;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:8667.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8667; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 274 AAGCCCAAGGAAGAA 289
DB 1 AAGCCCAAGGAAGGA 16
XX
RESULT 263
AAQ80949/c
ID AAQ80949 standard; DNA; 18 BP.
XX
AC AAQ80949;
XX
DT 25-MAR-2003 (revised)
DT 24-AUG-1995 (first entry)
XX
DE PCR primer to generate probe flanking the sCos-1 T7 promoter site.
XX
XX sequence sampled mapping; genomic analysis; complex genome mapping;
XX cosmid library; Giardia lamblia; T7 promoter; ss.
XX
XX Synthetic.
XX
XX WO9429486-A1.
XX
XX 22-DEC-1994.
XX
XX 15-JUN-1994; 94WO-US006810.
XX
XX 15-JUN-1993; 93US-00078471.
XX 07-SEP-1993; 93US-00117952.
XX
XX (SALK ) SALK INST BIOLOGICAL STUDIES.
XX
XX Evans GA, Smith MW;
XX
PI
```



XX WPI; 1995-036508/05.  
XX Sequencing complex genomes, present as fragments in a cosmid library - by  
PT sequencing end-specific nucleotides of each clone then correlating with  
PT spatial relationship of cosmid, esp. for mammalian chromosomes.

XX Example 3; Page 44; 128pp; English.

XX In a sequence-sample mapping procedure using a Giardia lamblia 20-genome  
XX equivalent cosmid library, each end of the genomic insert in a cosmid was  
CC detected as a vector/genomic chimera by hybridisation with probes  
CC flanking the T3 and T7 promoter sites of sCos-1. The 1046 bp T3 probe was  
CC amplified from sCos-1 with the primers AAQ80946 and AAQ80947 and the 1004  
CC bp T7 probe was amplified with primers AAQ80948 and AAQ80949. The T7  
CC probe was labelled with 35S- dATP and the T3 probe with 33P-dATP for dual  
CC -label hybridisations. Maps were constructed by determining an order of  
CC fragments with no gaps using a computer program. (Updated on 25-MAR-2003  
CC to correct PN field.)

XX Sequence 18 BP; 4 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1520 CCCCAACTCGCCCGAC 1535  
DB 18 CCTTAATCGCCCGAC 3

RESULT 264  
ADM06417  
ID ADM06417 standard; DNA; 18 BP.  
XX  
XX ADM06417;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX Human PCR primer SEQ ID NO:5102.  
XX  
XX human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.  
XX  
XX Homo sapiens.  
XX  
XX EPI347046-A1.  
XX  
XX 24-SEP-2003.  
XX  
XX 12-APR-2002; 2002EP-00008400.  
XX  
XX 22-MAR-2002; 2002JP-00137785.  
XX  
XX (REAS-) RES ASSOC BIOTECHNOLOGY.  
XX  
XX Isoqai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;  
XX Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;  
XX Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;  
XX WPI; 2003-723558/69.  
XX  
XX New polynucleotides and polypeptides are useful in gene therapy, for  
XX developing a diagnostic marker or medicines for regulating their  
XX expression and activity, or as a target of gene therapy.

XX Example 8; SEQ ID NO 5102; 305pp; English.

XX The invention relates to a novel human polynucleotide and the encoded  
XX polypeptide. A polynucleotide of the invention may have a use in gene  
XX therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful  
XX as a primer for synthesizing the polynucleotide or as a probe for  
XX detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are  
XX useful in gene therapy, for developing a diagnostic marker or medicines

XX for regulating their expression and activity, or as a target of gene  
XX therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides  
XX are useful as pharmaceutical agents. The present sequence represents an  
XX oligonucleotide used in the invention.

XX Sequence 18 BP; 4 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1094 GTGGAAGATGCTCAAC 1109  
DB 1 GTGGAAGATGCTCGAC 16

RESULT 265  
ADM92954  
ID ADM92954 standard; DNA; 18 BP.  
XX  
XX ADM92954;  
XX  
XX 03-JUN-2004 (first entry)  
XX  
XX SNP-containing cardiovascular associated gene primer #285.  
XX  
XX SNP; single nucleotide polymorphism; cardiovascular associated gene;  
XX allelic variation; atherosclerosis; ischemia; reperfusion; hypertension;  
XX restenosis; arterial inflammation; myocardial infarction; stroke; primer;  
XX ss.

XX Homo sapiens.  
XX  
XX WO2003057911-A2.  
XX  
XX 17-JUL-2003.  
XX  
XX 07-JAN-2003; 2003WO-EP000060.  
XX  
XX 08-JAN-2002; 2002EP-00000153.  
XX  
XX (FARB ) BAYER AG.  
XX  
XX Stropp U, Schwiers S, Kallabis H;  
XX WPI; 2003-577532/54.  
XX  
XX New isolated polynucleotides comprising single nucleotide polymorphisms  
XX of the cardiovascular gene, useful for assessing predisposition or  
XX susceptibility to a cardiovascular disease, e.g. atherosclerosis,  
XX restenosis or stroke.

XX Disclosure; Page 78; 187pp; English.

XX The invention relates an isolated polynucleotide (I) encoded by a  
XX cardiovascular associated (CA) gene, having allelic variation contained  
XX in a functional surrounding like full length cDNA for CA gene  
XX polypeptide, and with or without the CA gene promoter sequence. (I) is a  
XX polynucleotide comprising single nucleotide polymorphisms predicting  
XX cardiovascular disease. The polynucleotides are useful for assessing  
XX predisposition or susceptibility to a cardiovascular disease, e.g.  
XX atherosclerosis, ischemia/reperfusion, hypertension, restenosis, arterial  
XX inflammation, myocardial infarction, and stroke. These may also be used  
XX to predict personal medication schemes omitting adverse drug reactions,  
XX or as probes for detecting genetic polymorphisms and as templates for the  
XX recombinant production of normal or variant peptides/polypeptides encoded  
XX by the genes. This sequence corresponds to a PCR primer to amplify one of  
XX the genes of the invention.

XX Sequence 18 BP; 8 A; 5 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	1488 GTCACCAAGTAACGAG 1503 	
Db	1 GTCACCAATTAACGAG 16	
RESULT 266		
ADH71057/c		
ID	ADH71057 standard; DNA; 18 BP.	
XX	ADH71057;	
AC	XX	
XX	XX	
DT	25-MAR-2004 (first entry)	
XX	Human Vbeta point mutation PCR primer #10.	
DE	XX	
XX	human; T-cell associated disease; Vbeta; autoimmune disease;	
KW	degenerative nervous system disease; graft versus host disease;	
KW	hypersensitivity disease; infectious disease; neoplastic disease;	
KW	Addison's disease; atrophic gastritis;	
KW	degenerative nervous system disease; multiple sclerosis;	
KW	Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;	
KW	allergy; type II hypersensitivity; Goodpasture's syndrome;	
KW	type IV hypersensitivity; leprosy; infectious disease; viral infection;	
KW	HIV; fungal infection; Candida; parasitic infection; schistosoma;	
KW	filaria; bacterial infection; Mycobacterium; neoplastic disease;	
KW	lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;	
KW	breast cancer; ss; PCR; primer.	
XX	XX	
OS	Homo sapiens.	
XX	US2002150891-A1.	
PN	17-OCT-2002.	
XX	XX	
XX	05-MAR-1999; 99US-00263959.	
PF	19-SEP-1994; 94US-00309335.	
PR	19-SEP-1995; 95US-00531241.	
XX	(HOOD/) HOOD L E.	
PA	(ROWE/) ROWEN L.	
XX	Hood LE, Rowen L;	
PI	WPI; 2004-059052/06.	
XX	Kit for diagnosing and treating T-cell associated diseases e.g.	
PT	autoimmune, degenerative nervous system and infectious disease, comprises	
PT	nucleic acid primers specifically priming and allowing amplification of a	
PT	Vbeta gene.	
XX	Disclosure; SEQ ID NO 1251; 164pp; English.	
PS	XX	
XX	The invention relates to a kit for diagnosing and treating T-cell	
CC	associated diseases which comprises a panel of nucleic acid primers	
CC	specifically priming and allowing amplification of each Vbeta gene,	
CC	VbetarNA or cDNA. The kit is useful for diagnosing organ transplant	
CC	rejection and diagnosing and treating T-cell associated diseases	
CC	including autoimmune diseases, degenerative nervous system diseases,	
CC	graft versus host disease, hypersensitivity diseases, infectious diseases	
CC	and neoplastic diseases. Autoimmune diseases include Addison's disease,	
CC	atrophic gastritis. Degenerative nervous system diseases include multiple	
CC	sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type	
CC	I hypersensitivities such as contact with allergens that lead to	
CC	allergies, Type II hypersensitivities such as those present in	
CC	Goodpasture's syndrome and type IV hypersensitivities such as those	
CC	manifested in leprosy. Infectious diseases include viral infections	
CC	caused by viruses such as HIV, fungal infections such as those caused by	
CC	the yeast genus Candida, parasitic infections such as those caused by	
CC	schistosomes, filaria and bacterial infections such as those caused by	
CC	Mycobacterium. Neoplastic diseases include lymphoproliferative diseases	
CC	XX	
such as leukaemias, lymphomas and cancers such as cancer of the brain,		
breast. The present sequence represents a Vbeta point mutation PCR		
primer.		
XX	Sequence 18 BP; 1 A; 4 C; 9 G; 4 T; 0 U; 0 Other;	
SQ	Query Match 0.9%; Score 14.4; DB 1; Length 18;	
	Best Local Similarity 93.8%; Pred. No. 1.9e-02;	
	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	634 TCACCCGGGAGCCCA 649 	
Db	17 TCACCCGGGAGCCCA 2 	
RESULT 267		
AAF47085		
ID	AAF47085 standard; DNA; 15 BP.	
XX	AAF47085;	
AC	XX	
XX	30-MAR-2001 (first entry)	
DT	IGFBP3 oligonucleotide #505.	
DE	XX	
XX	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;	
KW	cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;	
KW	skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pteryiasis;	
KW	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;	
KW	growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;	
KW	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;	
KW	hyperneovascular condition; hyperplasia; kidney disease;	
KW	neovascular condition of the retina; ss.	
XX	XX	
OS	Homo sapiens.	
XX	WO200078341-A1.	
PN	28-DEC-2000.	
XX	21-JUN-2000; 2000WO-AU000693.	
PF	21-JUN-1999; 99US-0140345P.	
PR	(MURD-) MURDOCH CHILDRENS RES INST.	
XX	Wright CJ, Werther GA, Edmondson SR;	
XX	WPI; 2001-041421/05.	
XX	Ameliorating the effects of a disorder, e.g. psoriasis, by administering	
PT	UV (ultra-violet) treatment (optional) and an antisense nucleic acid that	
PT	inhibits or reduces growth factor mediated cell proliferation and/or	
PT	inflammation.	
XX	Example 7; Page 47; 201pp; English.	
PS	XX	
XX	The present invention relates to a method for ameliorating the effects of	
CC	skin disorders. The method comprises contacting the skin with an	
CC	antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1	
CC	receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of	
CC	inhibiting or reducing growth factor mediated cell proliferation,	
CC	inflammation and/or other disorders. The present sequence is an	
CC	oligonucleotide which can be used to design the antisense	
CC	oligonucleotides of the present invention (see AAF45151 and AAF45153-	
CC	F45161). The method is useful for ameliorating the effects of psoriasis,	
CC	ichthyosis, pteryiasis, ruba, pilaris, serborrhea, keloids, keratosis,	
CC	neoplasias, scleroderma, warts, benign growths, cancers of the skin, a	
CC	hyperneovascular condition such as a neovascular condition of the retina,	
CC	brain or skin, growth factor-mediated malignancies, other sclerotic	
CC	disease, kidney disease, hyperproliferation of the inside of blood	
CC	vessels or any other hyperplasia	
XX	XX	

SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 136 AGCTCCAGGAAATG 149  
 |||||  
 DB 2 AGCTCCAGGAAATG 15

RESULT 269  
 ABK25595/c  
 ID ABK25595 standard; DNA; 17 BP.  
 XX  
 AC ABK25595;  
 XX  
 DT 09-APR-2002 (first entry)  
 XX  
 DE Stress tolerance conferring genome altering oligonucleotide #63.  
 XX  
 KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;  
 KW o-methyl modification; LNA modification; phosphorothioate linkage;  
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;  
 KW abiotic stress tolerance; improved nutritional value; hygromycin-B;  
 KW amino acid over production; herbicide resistance; glyphosate resistance;  
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;  
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;  
 KW modified oil production; modified starch production; waxy starch;  
 KW altered floral morphology; male-sterile plant; albino mutant;  
 KW modified fatty acid content; reduced palmitate production; albino plant;  
 KW increased stearate production; reduced linolenic acid production;  
 KW photosynthetic process.  
 XX  
 OS Rucalyptus camaldulensis.  
 OS Synthetic.  
 XX  
 PN WO200192512-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 XX 01-JUN-2001; 2001WO-US017672.  
 XX  
 XX 01-JUN-2000; 2000US-0208538P.  
 PR 30-OCT-2000; 2000US-024989P.  
 PR 27-MAR-2001; 2001US-00818875.  
 XX  
 XX (UYDE ) UNIV DELAWARE.  
 XX  
 XX Kmiec EB, Gamper HB, Rice MC, Kim J;  
 XX  
 DR WPI; 2002-106307/14.  
 XX  
 PT New oligonucleotides with modified nuclease-resistant termini, useful for  
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved  
 PT nutritional value, herbicide or disease resistance, or modified oil  
 PT production.  
 PT  
 XX Claim 7; Page 100; 220pp; English.  
 PS  
 XX The invention relates to an oligonucleotide for targeted alteration of a  
 CC genetic sequence, which comprises a single-stranded oligonucleotide  
 CC having a DNA domain. The DNA domain has at least one mismatch with  
 CC respect to the genetic sequence to be altered and further comprises  
 CC chemical modifications of the oligonucleotide. The chemical modifications  
 CC consist of o-methyl modification, an LNA modification, two or more  
 CC phosphorothioate linkages on a terminus, or a combination of any two or  
 CC more of these modifications. The oligonucleotides are useful for  
 CC directing repair or alteration of plant genetic information. The  
 CC oligonucleotides are particularly useful for creating plants with desired  
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved  
 CC nutritional value (e.g. altering amino acid content of plants or  
 CC conferring amino acid over production), herbicide resistance (e.g.  
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide  
 CC resistance, porphyrin herbicide resistance or triazine resistance),  
 CC disease resistance, modified oil production, modified starch production  
 CC (e.g. increased starch or production of waxy starch), altered floral

SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 136 AGCTCCAGGAAATG 149  
 |||||  
 DB 1 AGCTCCAGGAAATG 14

RESULT 268  
 AAF47084  
 ID AAF47084 standard; DNA; 15 BP.  
 XX  
 AC AAF47084;  
 XX  
 DT 30-MAR-2001 (first entry)  
 XX  
 DE IGFBP3 oligonucleotide #504.  
 XX  
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;  
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;  
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;  
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
 KW hyperneovascular condition; hyperplasia; kidney disease;  
 KW neovascular condition of the retina; ss.  
 XX  
 OS Homo sapiens.  
 OS  
 XX WO200078341-A1.  
 PN  
 XX 28-DEC-2000.  
 PD  
 XX 21-JUN-2000; 2000WO-AU000693.  
 XX  
 XX 21-JUN-1999; 99US-0140345P.  
 PR  
 XX (MURD-) MURDOCH CHILDRENS RES INST.  
 PA  
 XX Wraight CJ, Werther GA, Edmondson SR;  
 XX  
 XX WPI; 2001-041421/05.  
 XX  
 DR  
 XX  
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
 PT inhibits or reduces growth factor mediated cell proliferation and/or  
 PT inflammation.  
 PT  
 XX Example 7; Page 47; 201pp; English.  
 PS  
 XX The present invention relates to a method for ameliorating the effects of  
 CC skin disorders. The method comprises contacting the skin with an  
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
 CC inhibiting or reducing growth factor mediated cell proliferation,  
 CC inflammation and/or other disorders. The present sequence is an  
 CC oligonucleotide which can be used to design the antisense  
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-  
 CC F45161). The method is useful for ameliorating the effects of psoriasis,  
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,  
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
 CC hyperneovascular condition such as a neovascular condition of the retina,  
 CC brain or skin, growth factor-mediated malignancies, other sclerotic  
 CC disease, kidney disease, hyperproliferation of the inside of blood  
 CC vessels or any other hyperplasia  
 XX  
 SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;

CC morphology (e.g. male-sterile plants) or modified fatty acid content  
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).  
CC The oligonucleotides are also useful for producing albino mutants for the  
CC analysis of photosynthetic processes. This sequence represents a genome  
CC altering oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1202 GGTCACACGGTGG 1215  
DB 14 GGTCACACGGTGG 1  
  
RESULT 270  
ABK25596  
ID ABK25596 standard; DNA; 17 BP.  
XX  
AC ABK25596;  
XX  
DT 09-APR-2002 (first entry)  
XX  
DE Stress tolerance conferring genome altering oligonucleotide #64.  
XX  
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;  
KW o-methyl modification; LNA modification; phosphorothioate linkage;  
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;  
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;  
KW amino acid over production; herbicide resistance; glyphosate resistance;  
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;  
KW porphyrin herbicide resistance; triazine resistance; disease resistance;  
KW modified oil production; modified starch production; waxy starch;  
KW altered floral morphology; male-sterile plant; albino mutant;  
KW modified fatty acid content; reduced palmitate production; albino plant;  
KW increased stearate production; reduced linolenic acid production;  
KW photosynthetic process.  
XX  
XX Eucalyptus camaldulensis.  
OS Synthetic.  
OS  
XX  
PN WO200192512-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 01-JUN-2001; 2001WO-US017672.  
XX  
PR 01-JUN-2000; 2000US-0208538P.  
PR 30-OCT-2000; 2000US-0244989P.  
PR 27-MAR-2001; 2001US-00818875.  
XX  
XX (UYDE ) UNIV DELAWARE.  
PA  
XX Kmiec EB, Gamper HB, Rice MC, Kim J;  
PI  
XX WPI; 2002-106307/14.  
XX  
XX New oligonucleotides with modified nuclease-resistant termini, useful for  
PT creating plants with desired phenotypes, e.g. stress tolerance, improved  
PT nutritional value, herbicide or disease resistance, or modified oil  
PT production.  
XX  
XX Claim 7; Page 100; 220pp; English.  
PS  
XX The invention relates to an oligonucleotide for targeted alteration of a  
CC genetic sequence, which comprises a single-stranded oligonucleotide  
CC having a DNA domain. The DNA domain has at least one mismatch with  
CC respect to the genetic sequence to be altered and further comprises  
CC chemical modifications of the oligonucleotide. The chemical modifications  
CC consist of o-methyl modification, an LNA modification, two or more  
CC phosphorothioate linkages on a terminus, or a combination of any two or

CC more of these modifications. The oligonucleotides are useful for  
CC directing repair or alteration of plant genetic information. The  
CC oligonucleotides are particularly useful for creating plants with desired  
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved  
CC nutritional value (e.g. altering amino acid content of plants or  
CC conferring amino acid over production), herbicide resistance (e.g.  
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide  
CC resistance, porphyrin herbicide resistance or triazine resistance),  
CC disease resistance, modified oil production, modified starch production  
CC (e.g. increased starch or production of waxy starch), altered floral  
CC morphology (e.g. male-sterile plants) or modified fatty acid content  
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).  
CC The oligonucleotides are also useful for producing albino mutants for the  
CC analysis of photosynthetic processes. This sequence represents a genome  
CC altering oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1202 GGTCACACGGTGG 1215  
DB 4 GGTCACACGGTGG 17  
  
RESULT 271  
ACD59851  
ID ACD59851 standard; RNA; 17 BP.  
XX  
AC ACD59851;  
XX  
DT 24-SEP-2003 (first entry)  
XX  
DE HCV DNAzyme substrate sequence #1541.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinczyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer; replication;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX  
OS Hepatitis C virus.  
XX  
XX WO200281494-A1.  
XX  
PD 17-OCT-2002.  
XX  
XX 26-MAR-2002; 2002WO-US009187.  
PF  
XX 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (NACE/) MACRIK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey J, Pavco P, Lee P;  
PI Draper K, Roberts E;  
XX

DR WPI; 2003-229207/22.  
 XX Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 XX  
 XX Claim 1; Page 261; 387pp; English.  
 XX  
 CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, ambezymes, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNazyme or minus strand DNazyme sequences disclosed in the present  
 CC invention  
 XX  
 XX Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;  
 SQ  
 Query Match 0.9%; Score 14; DB 1; Length 17;  
 Best Local Similarity 71.4%; Pred. No. 1.8e+02;  
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
 QY 766 TCACGCCCATGTC 779  
 Db :|||||:|:|:  
 4 UCCACGCCCAUGUUC 17  
 RESULT 272  
 AD184295  
 ID AD184295 standard; RNA; 17 BP.  
 XX  
 AC AD184295;  
 XX  
 DT 03-JUN-2004 (first entry)  
 XX  
 DE HCV DNazyme substrate sequence #1541.  
 XX  
 KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
 KW HCV infection; type I interferon; DNazyme.  
 XX  
 OS Hepatitis C virus.  
 XX  
 PN US2003125270-A1.  
 XX  
 PD 03-JUL-2003.  
 XX  
 XX 18-DEC-2000; 2000US-00740332.  
 XX  
 XX 18-DEC-2000; 2000US-00740332.  
 XX  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (ROBE/) ROBERTS E.  
 PA (PACV/) PAVCO P A.  
 PA (MACE/) MACEJACK D.  
 XX  
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
 XX  
 DR WPI; 2004-031273/03.  
 XX  
 PT Enzymatic nucleic acid molecules which specifically cleave RNA derived  
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
 PT especially in combination with type I interferon therapy.  
 XX  
 XX Claim 1; SEQ ID NO 1541; 198pp; English.  
 CC  
 CC The invention relates to an enzymatic nucleic acid molecule which  
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
 CC the binding arms of the enzymatic nucleic acid molecule comprises  
 CC sequences complementary to any of the defined substrate sequences given  
 CC in the specification. The nucleic acid molecule may be administered for  
 CC the treatment of HCV infections, especially in combination with type I  
 CC interferons. The present sequence represents a HCV DNazyme substrate  
 CC sequence.  
 XX  
 XX Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;  
 SQ  
 Query Match 0.9%; Score 14; DB 1; Length 17;  
 Best Local Similarity 71.4%; Pred. No. 1.8e+02;  
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
 QY 766 TCACGCCCATGTC 779  
 Db :|||||:|:|:  
 4 UCCACGCCCAUGUUC 17  
 RESULT 273  
 ADN44286/c  
 ID ADN44286 standard; DNA; 17 BP.  
 XX  
 AC ADN44286;  
 XX  
 DT 15-JUL-2004 (first entry)  
 XX  
 DE Mutant cell identification-related mutagenic oligonucleotide SeqID955.  
 XX  
 KW cell identification; oligonucleotide-directed sequence alteration;  
 KW selectable phenotype; transgenic plant; herbicide resistance;  
 KW sterile plant; abiotic stress tolerance; albino plant;  
 KW amino acid production; ss.  
 XX  
 OS Eucalyptus camaldulensis.  
 OS Synthetic.  
 XX  
 PN WO2004033708-A2.  
 XX  
 PD 22-APR-2004.  
 XX  
 XX 07-OCT-2003; 2003WO-US031862.  
 PF  
 XX 07-OCT-2002; 2002US-0416983P.  
 PR  
 PR 07-MAR-2003; 2003US-0453360P.  
 XX  
 XX (UYDE ) UNIV DELAWARE.  
 PA (NAPR-) NAPRO BIO THERAPEUTICS INC.  
 PA  
 XX Kmiec EB, Van Brabant A;  
 XX  
 XX WPI; 2004-340941/31.  
 DR  
 XX  
 XX Identifying a cell with a desired oligonucleotide-directed sequence  
 PT alteration at a nucleic acid target site within the cell by identifying  
 PT the desired sequence alteration in cells selected for the presence of a  
 PT selectable phenotype.  
 XX  
 XX Example 25; SEQ ID NO 955; 303pp; English.  
 PS  
 XX This invention relates to a novel method of identifying a cell having a  
 CC desired oligonucleotide-directed sequence alteration at a first nucleic  
 CC acid target site within the cell. The method comprises identifying the  
 CC desired sequence alteration in cells that have been selected for the  
 CC presence of a selectable phenotype conferred by a concurrent  
 CC oligonucleotide-directed sequence alteration at a second nucleic acid  
 CC target site within the cells. The method is useful in identifying a cell  
 CC having a desired oligonucleotide-directed sequence alteration at a first

CC nucleic acid target site within the cell. The method may be useful for  
CC the production of plants with herbicide resistance, male or female  
CC sterile plants, abiotic stress tolerance, albino plants or plants with  
CC altered amino acid production as well as for use in mammalian cell lines.  
CC The present sequence is that of a mutagenic oligonucleotide which was  
CC used in the exemplification of the invention.  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1202 GGTCAACCGGTGG 1215  
Db 14 GGTCAACCGGTGG 1  
RESULT 274  
ADN44287  
ID ADN44287 standard; DNA; 17 BP.  
XX  
AC ADN44287;  
XX  
DT 15-JUL-2004 (first entry)  
XX  
DE Mutant cell identification-related mutagenic oligonucleotide SeqID956.  
XX  
KW cell identification; oligonucleotide-directed sequence alteration;  
KW selectable phenotype; transgenic plant; herbicide resistance;  
KW sterile plant; abiotic stress tolerance; albino plant;  
KW amino acid production; ss.  
XX  
OS Eucalyptus camaldulensis.  
OS  
OS Synthetic.  
PN WO2004033708-A2.  
XX  
XX 22-APR-2004.  
XX  
XX 07-OCT-2003; 2003WO-US031862.  
XX  
XX 07-OCT-2002; 2002US-0416983P.  
PR  
PR 07-MAR-2003; 2003US-0453360P.  
XX  
XX (UYDE ) UNIV DELAWARE.  
PA  
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.  
XX  
XX Kmiec EB, Van Brabant A;  
PI  
DR WPI; 2004-340941/31.  
XX  
XX Identifying a cell with a desired oligonucleotide-directed sequence  
PT alteration at a nucleic acid target site within the cell by identifying  
PT the desired sequence alteration in cells selected for the presence of a  
PT selectable phenotype.  
XX  
XX Example 25; SEQ ID NO 956; 303pp; English.  
PS  
XX  
XX This invention relates to a novel method of identifying a cell having a  
CC desired oligonucleotide-directed sequence alteration at a first nucleic  
CC acid target site within the cell. The method comprises identifying the  
CC desired sequence alteration in cells that have been selected for the  
CC presence of a selectable phenotype conferred by a concurrent  
CC oligonucleotide-directed sequence alteration at a second nucleic acid  
CC target site within the cells. The method is useful in identifying a cell  
CC having a desired oligonucleotide-directed sequence alteration at a first  
CC nucleic acid target site within the cell. The method may be useful for  
CC the production of plants with herbicide resistance, male or female  
CC sterile plants, abiotic stress tolerance, albino plants or plants with  
CC altered amino acid production as well as for use in mammalian cell lines.  
CC The present sequence is that of a mutagenic oligonucleotide which was  
CC used in the exemplification of the invention.

XX  
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1202 GGTCAACCGGTGG 1215  
Db 4 GGTCAACCGGTGG 17  
RESULT 275  
AAT05231/C  
ID AAT05231 standard; DNA; 17 BP.  
XX  
AC AAT05231;  
XX  
DT 13-JUN-1996 (first entry)  
XX  
DE Hepatitis C virus antisense oligonucleotide A377 (17) .  
XX  
KW Inhibition; expression; hepatitis C virus; HCV; non-A; non-B; RNA;  
KW translation; in vivo; ex vivo; in vitro; treatment; prevention;  
KW infection; antisense; non coding; region; NCR; core region; ss.  
XX  
OS Synthetic.  
OS  
PN WO9530746-A1.  
XX  
PD 16-NOV-1995.  
XX  
PF 08-MAY-1995; 95WO-US005812.  
XX  
PR 10-MAY-1994; 94US-00240382.  
XX  
XX (GEHO ) GEN HOSPITAL CORP.  
XX  
XX Wakita T, Wands JR;  
PI  
XX WPI; 1995-404113/51.  
XX  
XX New anti-sense hepatitis C virus oligonucleotide(s) - used for  
PT inhibiting HCV RNA translation, for the treatment or prevention of HCV  
PT infection.  
XX  
XX Claim 1; Page 31; 50pp; English.  
PS  
XX The present oligonucleotide (ON) inhibits the expression of hepatitis C  
CC virus (HCV) RNA, specifically HCV type II protein synthesis is inhibited  
CC by about 50%. The ONs of the invention inhibit translation of HCV types I  
CC -V RNA in vivo, ex vivo or in vitro, and can therefore be used to treat  
CC or prevent HCV infection. The antisense ONs comprise 10-28 nucleotides  
CC complementary to the entire HCV 5'-non-coding and part of the core  
CC region. The A or S in the ONs name denotes antisense or sense, and the  
CC no. indicates the position of the 5'-end of the ON. The ON was tested at  
CC 10 fold molar excess to HCV RNA  
XX  
XX Sequence 17 BP; 1 A; 1 C; 4 G; 11 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAACAAA 238  
Db 17 CTCAAAGAAAAACAAA 1  
RESULT 276  
AAX75009  
ID AAX75009 standard; RNA; 17 BP.  
XX

AC	AAX75009;	
XX		
DT	28-JUL-1999	(first entry)
XX		
DE	Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #537.	
XX		
KW	Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;	
KW	KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;	
KW	tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;	
KW	fms-like tyrosine kinase 1; kinase insert domain containing receptor;	
KW	foetal liver kinase 1; ss.	
XX		
OS	Mus sp.	
XX		
PN	WO9715662-A2.	
XX		
PD	01-MAY-1997.	
XX		
XX	25-OCT-1996;	96WO-US017480.
PF		
XX	26-OCT-1995;	95US-0005974P.
PR		
PR	11-JAN-1996;	96US-00584040.
XX		
PA	(RIBO-) RIBOZYME PHARM INC.	
PA	(CHIR-) CHIRON CORP.	
XX		
PI	Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;	
XX		
DR	WPI; 1997-259017/23.	
XX		
PT	Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA	
PT	stability - useful for treating e.g. tumour angiogenesis, psoriasis,	
PT	rheumatoid arthritis, etc., in a human patient.	
XX		
PS	Claim 4; Page 171; 219pp; English.	
XX		
CC	The present invention describes nucleic acid molecules which modulate the	
CC	synthesis, expression and/or stability of a mRNA encoding 1 or more	
CC	receptors of vascular endothelial growth factor (VEGF). A patient	
CC	(preferably human) having a condition associated with the level of the	
CC	fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing	
CC	receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour	
CC	angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be	
CC	treated by administering the nucleic acid molecule or the expression	
CC	vector to the patient. AAX67275 to AAX75752 represent specific examples	
CC	of nucleic acid molecules from the present invention	
XX		
SQ	Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;	
	Query Match	0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity	64.7%; Pred. No. 1.9e+02;
	Matches 11; Conservative	4; Mismatches 2; Indels 0; Gaps 0;
Qy	1112 CTCCTCTCTGCTGGAGC 1128	
	:   :   :   :	
Db	1 CUCCCCCUUGCUGAAGC 17	
RESULT 277		
AAX62812/C		
ID	AAX62812 standard; RNA; 17 BP.	
XX		
AC	AAX62812;	
XX		
DT	16-JUL-1999	(first entry)
XX		
DE	Delta-9 desaturase hammerhead ribozyme target SEQ ID NO:687.	
XX		
KW	Maize; corn; Zea mays; delta-9 desaturase; GBS5; target; substrate;.	
KW	granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;	
KW	modulation; gene expression; transgenic plant; cleavage; canola plant;	
KW	caffeine synthesis; coffee plant; nicotine production; tobacco;	
KW	fruit ripening; flower pigmentation; lignin production; ss	





PT Treating respiratory disease with antisense sequences directed against  
PT adenosine or bradykinin receptors - with localised delivery to the  
PT respiratory system, suitable for long term treatment of asthma, adult  
PT respiratory distress syndrome etc.  
XX  
PS Claim 12; Page 8-24; 47pp; English.  
XX  
CC Sequences AAV46501-V47446 are anti-sense oligonucleotides that target the  
CC human adenosine A1 receptor, the design of which required the secondary  
CC structure of this targets mRNA. The adenosine receptor mRNA secondary  
CC structure was both analysed and used to construct antisense  
CC oligonucleotides containing a phosphorothioate backbone. Once the  
CC antisense molecules are created they can be used to target their  
CC antisense molecules containing a phosphorothioate backbone. The  
CC predetermined target, thus causing the gene product to decrease. The  
CC antisense oligonucleotides were targeted to specific mRNA regions  
CC containing either a junction between the intron and exon, or where they  
CC may overlap the initiation codon. The receptor is a member of the G-  
CC protein coupled family of cell surface receptors that have 7-  
CC transmembrane segments. These oligonucleotides can be used to treat or  
CC prevent conditions associated with bronchoconstriction and/or lung  
CC inflammation in humans or other animals e.g. asthma, pulmonary disease,  
CC allergy, emphysema and cystic fibrosis  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCACGCTCTCCCGC 1546  
|||||||  
DB 17 GCCACGCTGTGCCGC 1  
  
RESULT 281  
AAV46535/C  
ID AAV46535 standard; DNA; 17 BP.  
XX  
AC AAV46535;  
XX  
DT 10-NOV-1998 (first entry)  
XX  
DE Antisense oligonucleotide 35, targeting adenosine A1 receptor.  
XX  
KW Secondary structure; mRNA; phosphorothioate backbone; G-protein;  
KW bronchoconstriction; lung inflammation; asthma; pulmonary disease;  
KW allergy; emphysema; cystic fibrosis; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..17  
FT /\*tag= a  
FT /note= "contains phosphorothioate internucleotide  
FT linkages"  
XX  
PN WO9823294-A1.  
XX  
PD 04-JUN-1998.  
XX  
XX 26-NOV-1997; 97WO-US022017.  
XX  
XX 26-NOV-1996; 96US-00757024.  
XX  
XX (UYEC-) UNIV EAST CAROLINA.  
XX  
XX Nyce JW;  
XX  
XX WPI; 1998-322464/28.  
XX  
XX Treating respiratory disease with antisense sequences directed against  
PT adenosine or bradykinin receptors - with localised delivery to the

PT respiratory system, suitable for long term treatment of asthma, adult  
PT respiratory distress syndrome etc.  
XX  
PS Claim 12; Page 8-24; 47pp; English.  
XX  
CC Sequences AAV46501-V47446 are anti-sense oligonucleotides that target the  
CC human adenosine A1 receptor, the design of which required the secondary  
CC structure of this targets mRNA. The adenosine receptor mRNA secondary  
CC structure was both analysed and used to construct antisense  
CC oligonucleotides containing a phosphorothioate backbone. Once the  
CC antisense molecules are created they can be used to target their  
CC predetermined target, thus causing the gene product to decrease. The  
CC antisense oligonucleotides were targeted to specific mRNA regions  
CC containing either a junction between the intron and exon, or where they  
CC may overlap the initiation codon. The receptor is a member of the G-  
CC protein coupled family of cell surface receptors that have 7-  
CC transmembrane segments. These oligonucleotides can be used to treat or  
CC prevent conditions associated with bronchoconstriction and/or lung  
CC inflammation in humans or other animals e.g. asthma, pulmonary disease,  
CC allergy, emphysema and cystic fibrosis  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCACGCTCTCCCGC 1546  
|||||||  
DB 17 GCCACGCTGTGCCGC 1  
  
RESULT 282  
AAV94804  
ID AAV94804 standard; RNA; 17 BP.  
XX  
AC AAV94804;  
XX  
DT 24-FEB-1999 (first entry)  
XX  
DE Human IL-2 receptor g-chain substrate position 1385.  
XX  
KW Human; IL-2 receptor g-chain; Interleukin 2 receptor gamma chain;  
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;  
KW autoimmune disease; psoriasis; allergy; inflammatory disease;  
KW graft rejection; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9824913-A2.  
XX  
PD 11-JUN-1998.  
XX  
PF 02-DEC-1997; 97WO-US021748.  
XX  
PR 03-DEC-1996; 96US-00758306.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Stinchcomb DT, Meswigen JA;  
XX  
XX WPI; 1998-333332/29.  
XX  
XX Ribozymes targeted to interleukin 2 - useful for treating e.g. cancer,  
PT autoimmune disease and allergies.  
XX  
PS Claim 4; Page 37; 61pp; English.  
XX  
XX The present sequence invention describes ribozymes targeted to modulate  
XX the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.  
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and  
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences  
CC from the present invention. The ribozymes can be used for the treatment

CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy  
CC and other inflammatory conditions. The ribozymes are also used to induce  
CC tolerance in a recipient to alloantigen from a donor  
XX  
SQ Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.9e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
QY 693 CCTCATTCTTCTTTCC 709  
DB 1 CCUCCUCCUCCUCC 17  
RESULT 283  
AAV92651/c  
ID AAV92651 standard; RNA; 17 BP.  
XX  
AC AAV92651;  
XX  
DT 18-FEB-1999 (first entry)  
DE Human A-Raf substrate position 2271.  
XX  
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;  
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;  
KW screening; identification; synthesis; deprotection; purification; cancer;  
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;  
KW restenosis; rheumatoid arthritis; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO9850530-A2.  
PN  
XX  
PD 12-NOV-1998.  
XX  
XX 05-MAY-1998; 98WO-US009249.  
XX  
XX 09-MAY-1997; 97US-0046059P.  
PR 09-JUN-1997; 97US-0049002P.  
PR 03-JUL-1997; 97US-0051718P.  
PR 22-AUG-1997; 97US-0056808P.  
PR 02-OCT-1997; 97US-0061321P.  
PR 02-OCT-1997; 97US-0061324P.  
PR 05-NOV-1997; 97US-0064866P.  
PR 19-DEC-1997; 97US-0068212P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;  
PI Parry T, Beigelman L, Meswigen JA, Karpeisky A, Burgin A;  
PI Thompson J, Workman CT, Beaudry A, Sweedler D;  
XX  
XX WPI; 1999-009494/01.  
DR  
XX  
XX Identifying new catalytic nucleic acid that modulates selected processes  
PT - especially ribozymes that cleave Raf RNA for treating cancer,  
PT restenosis, and also new ribozymes and modified nucleoside triphosphates  
PT used as antiviral agents and synthons.  
XX  
XX  
PS Claim 177; Page 162; 259pp; English.  
XX  
XX A method has been developed for the identification of a nucleic acid  
CC capable of modulating a process in a biological system. The method  
CC comprises: (a) introducing into the system a random library of nucleic  
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising  
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC  
CC in systems where modulation has occurred and/or determining the sequence  
CC of at least part of the SBDs in such systems. Nucleic acid molecules with  
CC endonuclease activity and catalytic activity, from the present invention,  
CC are used to modulate gene expression in plant and mammalian cells and to  
CC cleave target nucleic acid, particularly for treating systemic diseases

CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic  
CC ascites and infection. They may also be used to detect genetic drift and  
CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs  
CC with RNA-cleaving activity that modulate expression of the Raf gene, are  
CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or  
CC generally any condition associated with the level of c-raf. Introduction  
CC of sugar/phosphate modifications increases stability against nuclease and  
CC activity. AAV90922 to AAV93877 represent NACs that can be used in the  
CC method, specifically for modulating the expression of a Raf gene  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 328 AGCTGAGGAGCTCCCA 344  
DB 17 AGATGGAGGAGCTCCCA 1  
RESULT 284  
AAV53788/c  
ID AAV53788 standard; DNA; 17 BP.  
XX  
AC AAV53788;  
XX  
DT 05-JUL-1999 (first entry)  
DE Human adenosine A1 receptor antisense oligonucleotide fragment.  
XX  
XX Antisense oligonucleotide; multiple target; antisense treatment;  
KW impaired respiration; inflammation; lung disease;  
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;  
KW acute asthma; allergy; asthma; impeded respiration;  
KW respiratory distress syndrome; pain; cystic fibrosis;  
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;  
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;  
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;  
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;  
KW prostate cancer; ss.  
XX  
XX Synthetic.  
XX WO9913886-A1.  
PN  
XX 25-MAR-1999.  
PD  
XX 17-SEP-1998; 98WO-US019419.  
PR 17-SEP-1997; 97US-0059160P.  
PR 09-JUN-1998; 98US-00093972.  
XX  
XX (UYEC-) UNIV EAST CAROLINA.  
XX  
XX Nyce JW;  
PI  
XX WPI; 1999-229400/19.  
DR  
XX  
XX New antisense oligonucleotides used in treatment of, e.g. pulmonary  
PT vasoconstriction.  
XX  
XX Disclosure; Page 41; 120pp; English.  
XX  
XX The specification describes antisense oligonucleotides (AAV52869-X55271)  
CC directed against at least 2 mRNAs selected from target genes, coding and  
CC non-coding regions of RNAs corresponding to target genes, gene initiation  
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-  
CC end and the juxta-section between coding and non-coding regions and all  
CC segments of RNAs encoding proteins associated with one or more diseases,  
CC conditions or mixtures. The antisense oligonucleotides may be derived  
CC from sequences AAV55272-74. These multiple target oligonucleotides  
CC (specifically AAV55180-271) can be used for the antisense treatment of

CC	diseases and conditions. Typical diseases and conditions are those	CC	from sequences AAX5272-74. These multiple target oligonucleotides
CC	associated with impaired respiration and inflammation, including lung	CC	(specifically AAX5180-271) can be used for the antisense treatment of
CC	diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,	CC	diseases and conditions. Typical diseases and conditions are those
CC	acute asthma, allergies, asthma, impeded respiration, respiratory	CC	associated with impaired respiration and inflammation, including lung
CC	distress syndrome, pain, cystic fibrosis, pulmonary hypertension,	CC	diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC	pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary	CC	acute asthma, allergies, asthma, impeded respiration, respiratory
CC	disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.	CC	distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC	colon cancer, breast cancer, lung cancer, pancreatic cancer,	CC	pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC	hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as	CC	disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC	well as all types of cancers which may metastasize or have metastasized	CC	colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC	to the lungs, including breast and prostate cancer	CC	hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
XX		CC	well as all types of cancers which may metastasize or have metastasized
SQ	Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;	CC	to the lungs, including breast and prostate cancer
Query Match 0.8%; Score 13.8; DB 1; Length 17;			
Best Local Similarity 88.2%; Pred. No. 1.9e+02;			
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1530 GCCCAGCCTCTCCCGC 1546	QY	1530 GCCCAGCCTCTCCCGC 1546
DB	17 GCCCAGCCTGTGCCGC 1	DB	17 GCCCAGCCTGTGCCGC 1
RESULT 286			
ID	AAX52912/c	AA33231/c	
XX	AAX52912 standard; DNA; 17 BP.	XX	AAA33231 standard; DNA; 17 BP.
AC	AAX52912;	AC	AAA33231;
XX		XX	
DT	05-JUL-1999 (first entry)	DT	28-JUL-2000 (first entry)
XX	Human adenosine A1 receptor antisense oligonucleotide fragment.	XX	Low adenosine antisense oligonucleotide SEQ ID NO:920.
XX	Antisense oligonucleotide; multiple target; antisense treatment;	XX	Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW	impaired respiration; inflammation; lung disease;	KW	phosphorothioate; impaired respiration; inflammation; allergy;
KW	pulmonary vasoconstriction; inflammation; allergic rhinitis;	KW	allergic disease; bronchoconstriction; inhibitor; anti-inflammatory;
KW	acute asthma; allergy; asthma; impeded respiration;	KW	antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW	respiratory distress syndrome; pain; cystic fibrosis;	KW	lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW	pulmonary hypertension; pulmonary vasoconstriction; emphysema;	KW	respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW	chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;	KW	pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW	colon cancer; breast cancer; lung cancer; pancreatic cancer;	KW	hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW	prostate cancer; ss.	KW	cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX		XX	
OS	Synthetic.	OS	Homo sapiens.
XX		XX	
PN	WO9913886-A1.	PN	WO200009525-A2.
XX		XX	
PD	25-MAR-1999.	PD	24-FEB-2000.
XX		XX	
PF	17-SEP-1998; 98WO-US019419.	PF	03-AUG-1999; 99WO-US017712.
XX		XX	
PR	17-SEP-1997; 97US-0059160P.	PR	03-AUG-1998; 98US-0095212P.
PR	09-JUN-1998; 98US-00093972.	XX	
XX		XX	
XX		PA	(UYEC-) UNIV EAST CAROLINA.
PA	(UYEC-) UNIV EAST CAROLINA.	XX	
XX		PI	Nyce JW;
PI	Nyce JW;	XX	
XX		XX	
XX		DR	WPI; 2000-205971/18.
XX		XX	
DR	WPI; 1999-229400/19.	XX	
XX		PT	New antisense oligonucleotides useful for treating e.g. pulmonary
PT	New antisense oligonucleotides used in treatment of, e.g. pulmonary	PT	vasoconstriction, inflammation, allergies, asthma, hypertension,
PT	vasoconstriction.	PT	bronchitis, emphysema, respiratory distress syndrome, ischemia or
XX		PT	cancers.
XX		XX	
PS	Disclosure; Page 28; 120pp; English.	PS	Claim 18; Page 380; 1343pp; English.
XX		XX	
CC	The specification describes antisense oligonucleotides (AAX52869-X55271)	XX	The present invention describes a new composition comprising an antisense
CC	directed against at least 2 mRNAs selected from target genes, coding and	CC	oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC	non-coding regions of RNAs corresponding to target genes, gene initiation	CC	nucleic acids involved in bronchoconstriction, allergies, and/or
CC	codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'	CC	inflammation. The ON can have antiinflammatory, antiallergic,
CC	-end and the juxta-section between coding and non-coding regions and all	CC	antiasthmatic, cytostatic and analgesic activities. The compositions are
CC	segments of RNAs encoding proteins associated with one or more diseases,	CC	useful for the treatment of diseases associated with inflammation,
CC	conditions or mixtures. The antisense oligonucleotides may be derived	CC	

CC impaired airways, including lung disease and diseases whose secondary  
CC effects afflict the lungs of a subject. They can be used for treating  
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
CC impeded respiration, respiratory distress syndrome, pain, cystic  
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,  
CC carcinomas, and cancers which may metastasise to the lungs, including  
CC breast and prostate cancer. The reduction of the adenosine content of the  
CC ONS reduces side effects. The A-containing ONS break down with the  
CC release of deoxyadenosine which activates adenosine receptors causing  
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the  
CC nucleotide sequences given in the sequence listing from the present  
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to  
CC AAA33992) are specifically claimed ONS from the present invention. N.B.  
CC Sequences given in the disclosure of the present invention do not match  
CC up with their corresponding SEQ ID NO: sequences given in the sequence  
CC listing  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCACGCTCTCCCGC 1546  
Db 17 GCCACGCTGTGCGGC 1  
  
RESULT 287  
AAA32356/c  
ID AAA32356 standard; DNA; 17 BP.  
XX  
AC AAA32356;  
XX  
DT 28-JUL-2000 (first entry)  
XX  
DE Low adenosine antisense oligonucleotide SEQ ID NO:44.  
XX  
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;  
KW phosphorothioate; impaired respiration; inflammation; allergy;  
KW allergic disease; bronchoconstriction; inhibitor; anti-inflammatory;  
KW anti-allergic; antiasthmatic; cytostatic; analgesic; impaired airway;  
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;  
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;  
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;  
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200009525-A2.  
XX  
PD 24-FEB-2000.  
XX  
PF 03-AUG-1999; 99WO-US017712.  
XX  
PR 03-AUG-1998; 98US-0095212P.  
XX  
PA (UYEC-) UNIV EAST CAROLINA.  
XX  
PI Nyce JW;  
XX  
DR WPI; 2000-205971/18.  
XX  
PT New antisense oligonucleotides useful for treating e.g. pulmonary  
PT vasoconstriction, inflammation, allergies, asthma, hypertension,  
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or  
PT cancers.  
XX  
PS Claim 18; Page 272; 1343pp; English.  
XX

CC The present invention describes a new composition comprising an antisense  
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets  
CC nucleic acids involved in bronchoconstriction, allergies, and/or  
CC inflammation. The ON can have anti-inflammatory, anti-allergic,  
CC antiasthmatic, cytostatic and analgesic activities. The compositions are  
CC useful for the treatment of diseases associated with inflammation,  
CC impaired airways, including lung disease and diseases whose secondary  
CC effects afflict the lungs of a subject. They can be used for treating  
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
CC impeded respiration, respiratory distress syndrome, pain, cystic  
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,  
CC carcinomas, and cancers which may metastasise to the lungs, including  
CC breast and prostate cancer. The reduction of the adenosine content of the  
CC ONS reduces side effects. The A-containing ONS break down with the  
CC release of deoxyadenosine which activates adenosine receptors causing  
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the  
CC nucleotide sequences given in the sequence listing from the present  
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to  
CC AAA33992) are specifically claimed ONS from the present invention. N.B.  
CC Sequences given in the disclosure of the present invention do not match  
CC up with their corresponding SEQ ID NO: sequences given in the sequence  
CC listing  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCACGCTCTCCCGC 1546  
Db 17 GCCACGCTGTGCGGC 1  
  
RESULT 288  
AAZ57766/c  
ID AAZ57766 standard; DNA; 17 BP.  
XX  
AC AAZ57766;  
XX  
DT 05-APR-2000 (first entry)  
XX  
DE Hepatitis C virus antisense inhibitor oligonucleotide #21.  
XX  
KW Hepatitis C virus; HCV; antisense oligonucleotide; hepatotropic; ss;  
KW anti-inflammatory; translation inhibition; HCV infection; virucide.  
XX  
OS Hepatitis C virus.  
XX  
PN US6001990-A.  
XX  
PD 14-DEC-1999.  
XX  
PF 07-JUN-1995; 95US-00474700.  
XX  
PR 10-MAY-1994; 94US-00240382.  
XX  
PA (GEHO ) GEN HOSPITAL CORP.  
XX  
PI Moradpour D, Wands JR, Wakita T;  
XX  
DR WPI; 2000-104900/09.  
XX  
PT Antisense oligonucleotide to Hepatitis C virus RNA, useful for treating  
PT Hepatitis C virus infections.  
XX  
PS Claim 24; Col 25; 31pp; English.  
XX  
CC This sequence is an antisense oligonucleotide that hybridises to  
CC Hepatitis C virus (HCV) RNA, under physiological conditions. The

invention relates to HCV antisense oligonucleotides, and also for a vector comprising a nucleotide sequence which is transcribed in an animal cell to generate an antisense oligonucleotide. The oligonucleotides have virucide, hepatotropic and anti-inflammatory activity, and are useful for treating HCV infection by inhibiting translation of type I-V HCV RNA. Hepatitis C virus is a positive strand RNA virus, and is the major causative agent of post-transfusion hepatitis. Persistent HCV infection can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma

Sequence 17 BP; 1 A; 1 C; 4 G; 11 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

222 CTCATAGAAACAA 238  
17 CTCATAGAAACAA 1

RESULT 289  
AAA03590/c  
ID AAA03590 standard; DNA; 17 BP.  
XX  
AC AAA03590;  
XX  
19-MAY-2000 (first entry)

Human adenosine A1 receptor antisense oligonucleotide SEQ ID NO:874.  
Human; adenosine A1 receptor; antisense oligonucleotide; hypoxia;  
adenosine A2a receptor; adenosine Ab receptor; adenosine A3 receptor;  
phosphorothioate; cardiopulmonary failure; renal failure; ischaemia;  
endotoxin release; ARDS; acute respiratory distress syndrome;  
cytoprotective; anti-allergic; anti-inflammatory; anti-hypoxic;  
supraventricular tachycardia; allergic rhinitis; acute inflammation;  
chronic obstructive pulmonary disease; ss.

Homo sapiens.  
Synthetic.  
WO9963938-A2.  
16-DEC-1999.  
08-JUN-1999; 99WO-US012775.

08-JUN-1998; 98US-0088501P.  
09-JUN-1998; 98US-00093972.  
09-JUN-1998; 98US-0088657P.  
(EPIG-) EPIGENESIS PHARM INC.  
Nyce JW, Hill JL;  
WPI; 2000-116433/10.

Novel composition for treating or preventing e.g. cardiopulmonary and renal injury.  
Claim 17; Page 36; 252pp; English.

The present invention describes a pharmaceutical composition, comprising at least one agent (I) that prevents, alleviates and/or inhibits adenosine-mediated cardiopulmonary and/or renal damage and/or failure. (I) is an adenosine A2a receptor agonist (Ia), or an oligonucleotide (Ib), containing less than 15% adenosine (A), that is antisense to target genes or corresponding RNA, to genomic flanking regions (i.e. 5' or 3' ends or segments between coding and non-coding sequences), or to all segments of mRNA encoding the adenosine A1, A2a, A2b or A3 receptors, and has A1, A2b or A3 agonist activity or A2a antagonist activity (or at least no agonist activity at this receptor). (I) may be a mixture of (Ia) and (Ib), and optionally also contains one or more surfactants. The

compositions are used to prevent, alleviate and/or treat adenosine receptor-mediated cardiac, lung and/or renal damage or failure (particularly where associated with ischaemia, toxin release and/or administration of drugs or imaging agents, e.g. adenosine for treating supraventricular tachycardia); (adult) respiratory distress syndrome (e.g. associated with sepsis); allergic rhinitis; chronic obstructive pulmonary disease; cardiopulmonary hypoxia associated with administration of stress-test agents, particularly where such conditions are associated with acute inflammation. AAA02717, AAA02719, AAA02721 and AAA02723 to AAA03715 represent specifically claimed phosphorothioate antisense oligonucleotides for use in the composition of the present invention. Other phosphorothioate oligonucleotides used in the exemplification of the present invention

Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1530 GCCAGCCTCTCCCGC 1546  
17 GCCAGCCTGTGCCGC 1

RESULT 290  
AAA03660/c  
ID AAA03660 standard; DNA; 17 BP.  
XX  
AC AAA03660;  
XX  
19-MAY-2000 (first entry)

Human adenosine A1 receptor antisense oligonucleotide SEQ ID NO:944.  
Human; adenosine A1 receptor; antisense oligonucleotide; hypoxia;  
adenosine A2a receptor; adenosine Ab receptor; adenosine A3 receptor;  
phosphorothioate; cardiopulmonary failure; renal failure; ischaemia;  
endotoxin release; ARDS; acute respiratory distress syndrome;  
cytoprotective; anti-allergic; anti-inflammatory; anti-hypoxic;  
supraventricular tachycardia; allergic rhinitis; acute inflammation;  
chronic obstructive pulmonary disease; ss.

Homo sapiens.  
Synthetic.  
WO9963938-A2.  
16-DEC-1999.  
08-JUN-1999; 99WO-US012775.

08-JUN-1998; 98US-0088501P.  
09-JUN-1998; 98US-00093972.  
09-JUN-1998; 98US-0088657P.  
(EPIG-) EPIGENESIS PHARM INC.  
Nyce JW, Hill JL;  
WPI; 2000-116433/10.

Novel composition for treating or preventing e.g. cardiopulmonary and renal injury.  
Claim 17; Page 37; 252pp; English.

The present invention describes a pharmaceutical composition, comprising at least one agent (I) that prevents, alleviates and/or inhibits adenosine-mediated cardiopulmonary and/or renal damage and/or failure. (I) is an adenosine A2a receptor agonist (Ia), or an oligonucleotide (Ib), containing less than 15% adenosine (A), that is antisense to target

CC genes or corresponding RNA, to genomic flanking regions (i.e. 5' or 3'  
CC ends or segments between coding and non-coding sequences), or to all  
CC segments of mRNA encoding the adenosine A1, A2a, A2b or A3 receptors, and  
CC has A1, A2b or A3 agonist activity or A2a antagonist activity (or at  
CC least no agonist activity at this receptor). (I) may be a mixture of (Ia)  
CC and (Ib), and optionally also contains one or more surfactants. The  
CC compositions are used to prevent, alleviate and/or treat adenosine  
CC receptor-mediated cardiac, lung and/or renal damage or failure  
CC (particularly where associated with ischaemia, toxin release and/or  
CC administration of drugs or imaging agents, e.g. adenosine for treating  
CC supraventricular tachycardia); (adult) respiratory distress syndrome  
CC (e.g. associated with sepsis); allergic rhinitis; chronic obstructive  
CC pulmonary disease; cardiopulmonary hypoxia associated with administration  
CC of stress-test agents, particularly where such conditions are associated  
CC with acute inflammation. AAA02717, AAA02719, AAA02721 and AAA02723 to  
CC AAA03715 represent specifically claimed phosphorothioate antisense  
CC oligonucleotides for use in the composition of the present invention.  
CC AAA02718, AAA02720, AAA02722 and AAA03716 to AAA03720 represent other  
CC phosphorothioate oligonucleotides used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCAGCCTCTCCCGC 1546  
Db 17 GCCAGCCTGTGCCGC 1  
  
RESULT 291  
AAF19353/C  
ID AAF19353 standard; DNA; 17 BP.  
XX  
AC AAF19353;  
XX  
DT 14-MAR-2001 (first entry)  
XX  
DE Human adenosine A1 receptor polynucleotide fragment #920.  
XX  
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
KW human; airway disorder; bronchoconstriction; lung inflammation;  
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cyostatic;  
KW respiratory obstruction; pulmonary obstruction; impeded respiration;  
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;  
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
KW cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200062736-A2.  
XX  
PD 26-OCT-2000.  
XX  
PF 24-MAR-2000; 2000WO-US008020.  
XX  
PR 06-APR-1999; 99US-0127958P.  
XX  
PA (UYEC-) UNIV EAST CAROLINA.  
PA (NYCE/) NYCE J W.  
XX  
XX Nyce JW;  
XX  
XX WPI; 2000-679539/66.  
XX  
XX Low adenosine (A) content antisense oligonucleotides which do not trigger  
XX adenosine receptors during metabolism, useful e.g. for treating cancers  
XX and respiratory obstructions.

XX Claim 14; Page 120; 1592pp; English.  
PS  
XX The present invention describes low adenosine (A) content antisense  
CC oligonucleotides and compositions (I) comprising them. In the antisense  
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.  
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
CC immunosuppressive, antiasthmatic, hypotensive and cyostatic activities.  
CC The antisense oligonucleotides and (I) can be used to down-regulate the  
CC expression and or activity of target polypeptides associated with  
CC lung/respiratory disorders and malignancies, such as stimulating and  
CC activating peptide factors and transmitters, transcription factors,  
CC immunoglobulins and antibodies, antibody receptors, cytokines and  
CC chemokines, endogenously produced specific and non-specific enzymes,  
CC binding proteins, adhesion molecules and their receptors, cytokine and  
CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
CC nervous system (CNS) and peripheral nervous and non-nervous system  
CC receptors, CNS and peripheral nervous and non-nervous system peptide  
CC transmitters, defensins growth factors, vasoactive peptides and  
CC receptors, binding proteins and malignancy associated proteins. The  
CC antisense oligonucleotides may be used in this way to treat disorders  
CC including respiratory obstruction (especially pulmonary obstruction  
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or  
CC surfactant hypoproduction which are associated with a disease or  
CC condition selected from pulmonary vasoconstriction, inflammation,  
CC allergies, asthma, impeded respiration, respiratory distress syndrome  
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
CC fragments and antisense oligonucleotides used in the exemplification of  
CC the present invention  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCAGCCTCTCCCGC 1546  
Db 17 GCCAGCCTGTGCCGC 1  
  
RESULT 292  
AAF18477/C  
ID AAF18477 standard; DNA; 17 BP.  
XX  
AC AAF18477;  
XX  
DT 14-MAR-2001 (first entry)  
XX  
DE Human adenosine A1 receptor polynucleotide fragment #44.  
XX  
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
KW human; airway disorder; bronchoconstriction; lung inflammation;  
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cyostatic;  
KW respiratory obstruction; pulmonary obstruction; impeded respiration;  
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;  
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
KW cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200062736-A2.  
XX  
PD 26-OCT-2000.  
XX  
PF 24-MAR-2000; 2000WO-US008020.  
XX

PR 06-APR-1999; 99US-0127958P.  
XX (UYEC-) UNIV EAST CAROLINA.  
PA (NYCE/) NYCE J W.  
XX  
XX Nyce JW;  
XX WPI; 2000-679539/66.  
XX  
XX Low adenosine (A) content antisense oligonucleotides which do not trigger  
PT adenosine receptors during metabolism, useful e.g. for treating cancers  
PT and respiratory obstructions.  
XX  
XX Claim 14; Page 106; 1592pp; English.  
XX  
XX The present invention describes low adenosine (A) content antisense  
CC oligonucleotides and compositions (i) comprising them. In the antisense  
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.  
CC (i) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
CC immunosuppressive, antiaesthetic, hypotensive and cytostatic activities.  
CC The antisense oligonucleotides and (i) can be used to down-regulate the  
CC expression and or activity of target polypeptides associated with  
CC lung/respiratory disorders and malignancies, such as stimulating and  
CC activating peptide factors and transmitters, transcription factors,  
CC immunoglobulins and antibodies, antibody receptors, cytokines and  
CC chemokines, endogenously produced specific and non-specific enzymes,  
CC binding proteins, adhesion molecules and their receptors, cytokine and  
CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
CC nervous system (CNS) and peripheral nervous and non-nervous system  
CC receptors, CNS and peripheral nervous and non-nervous system peptide  
CC transmitters, defensins, growth factors, vasoactive peptides and  
CC receptors, binding proteins and malignancy associated proteins. The  
CC antisense oligonucleotides may be used in this way to treat disorders  
CC including respiratory obstruction (especially pulmonary obstruction  
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or  
CC surfactant hypoproduction which are associated with a disease or  
CC condition selected from pulmonary vasoconstriction, inflammation,  
CC allergies, asthma, impeded respiration, respiratory distress syndrome  
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
CC fragments and antisense oligonucleotides used in the exemplification of  
CC the present invention  
XX  
XX Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCAGCCTCTCCCGC 1546  
Db 17 GCCAGCCTGTGCCCGC 1

RESULT 293  
AAF02647  
ID AAF02647 standard; DNA; 17 BP.  
XX  
XX AAF02647;  
AC  
XX  
XX 16-FEB-2001 (first entry)  
DT  
XX  
XX Hammerhead ribozyme substrate #942.  
DE  
XX  
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX W0200061729-A2.  
PN

PD 19-OCT-2000.  
XX  
XX 11-APR-2000; 2000WO-US009721.  
XX  
XX 12-APR-1999; 99US-0129390P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;  
PI  
XX WPI; 2000-647423/62.  
DR  
XX  
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
XX  
XX Claim 37; Page 77; 164pp; English.  
XX  
XX The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).  
CC Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX  
XX Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 116 CCAGACGGTCTCAGACA 132  
Db 1 CCAGACGGTCTCAGTCA 17

RESULT 294  
ABK01885/C  
ID ABK01885 standard; RNA; 17 BP.  
XX  
XX ABK01885;  
AC  
XX  
XX 12-MAR-2002 (first entry)  
DT  
XX  
XX Human NOGO Zinzyne #207.  
DE  
XX  
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberyne; zinzyne; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
XX Homo sapiens.  
OS  
XX  
XX Synthetic.  
XX  
XX W0200159103-A2.  
PN  
XX  
XX 16-AUG-2001.  
PD  
XX  
XX 09-FEB-2001; 2001WO-US004273.  
PR  
XX  
XX 11-FEB-2000; 2000US-0181797P.  
PR 28-FEB-2000; 2000US-0185516P.  
PR 06-MAR-2000; 2000US-0187128P.  
PR



XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
XX Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
XX  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
XX Claim 88; Page 99; 200pp; English.  
XX  
XX The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA  
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a zynzyme molecule of the invention  
XX  
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.6; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1621 CAATAAACGTCTTGT 1637  
Db |||||||  
17 CATTAAACGTCTTTT 1  
RESULT 295  
ABK01053/c  
ID ABK01053 standard; RNA; 17 BP.  
XX  
XX ABK01053;  
AC  
XX 12-MAR-2002 (first entry)  
DT  
XX Human NOGO Inozyme #323.  
DE  
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;



Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1622 AATAAACTGCTCTTG 1638  
17 AATAAACTGCTCTTTG 1

Db

RESULT 296

AAD20527  
ID AAD20527 standard; DNA; 17 BP.  
XX  
AC AAD20527;  
XX  
DT 03-JAN-2002 (first entry)  
XX  
DE Mouse Obr genomic DNA amplifying forward PCR primer #2.  
XX  
KW Mouse; obese receptor; Obr; anorectic; anabolic; body weight disorder;  
KW therapy; obesity; cachexia; anorexia; PCR primer; ss.  
XX  
OS Mus sp.  
XX  
PN US6287782-B1.  
XX  
PD 11-SEP-2001.  
XX  
PF 29-APR-1998; 98US-00069781.  
XX  
PR 27-NOV-1995; 95US-00562663.  
PR 04-DEC-1995; 95US-00566622.  
PR 08-DEC-1995; 95US-00569485.  
PR 11-DEC-1995; 95US-00570142.  
PR 28-DEC-1995; 95US-00583153.  
PR 22-JAN-1996; 96US-00599455.  
PR 26-APR-1996; 96US-00638524.  
PR 03-SEP-1996; 96US-00708123.  
PR 28-MAY-1997; 97US-00864564.  
XX  
PA (MILL-) MILLENNIUM PHARM INC.  
XX  
PI Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2001-624489/72.  
XX  
PT Identifying compounds for treating body weight disorder, e.g. obesity,  
PT anorexia or cachexia, comprises contacting cell expressing mammalian Ob  
PT receptor protein, JAK2 protein and mammalian SOCS-1 protein with test  
PT compound.  
XX  
PS Example; Col 62; 109pp; English.  
XX  
CC The patent discloses obese receptor (Obr) proteins and nucleic acids  
CC encoding them. Obr protein participates in the regulation of mammalian  
CC body weight. The invention also relates to a method of identifying  
CC therapeutic compounds for the treatment of a body weight disorder. The  
CC method involves contacting a cell that expresses a mammalian Obr protein,  
CC a JAK2 protein and a mammalian SOCS-1 protein with a test compound. The  
CC method is useful for identifying compounds which modulate Obr gene  
CC expression and gene product activity, which can be used as agents to  
CC control body weight particularly as therapeutic agents for treating body  
CC weight disorders, including obesity, cachexia and anorexia. The present  
CC DNA sequence is a forward PCR primer which is used for amplifying mouse  
CC Obr genomic DNA  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676

Db

Db

1 CACTATTTCCTTCAG 17

RESULT 297

AAD20529  
ID AAD20529 standard; DNA; 17 BP.  
XX  
AC AAD20529;  
XX  
DT 03-JAN-2002 (first entry)  
XX  
DE Mouse famj5312 Obr cDNA amplifying forward PCR primer.  
XX  
KW Mouse; obese receptor; Obr; anorectic; anabolic; body weight disorder;  
KW therapy; obesity; cachexia; anorexia; PCR primer; ss.  
XX  
OS Mus spretus.  
XX  
PN US6287782-B1.  
XX  
PD 11-SEP-2001.  
XX  
PF 29-APR-1998; 98US-00069781.  
XX  
PR 27-NOV-1995; 95US-00562663.  
PR 04-DEC-1995; 95US-00566622.  
PR 08-DEC-1995; 95US-00569485.  
PR 11-DEC-1995; 95US-00570142.  
PR 28-DEC-1995; 95US-00583153.  
PR 22-JAN-1996; 96US-00599455.  
PR 26-APR-1996; 96US-00638524.  
PR 03-SEP-1996; 96US-00708123.  
PR 28-MAY-1997; 97US-00864564.  
XX  
PA (MILL-) MILLENNIUM PHARM INC.  
XX  
PI Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2001-624489/72.  
XX  
PT Identifying compounds for treating body weight disorder, e.g. obesity,  
PT anorexia or cachexia, comprises contacting cell expressing mammalian Ob  
PT receptor protein, JAK2 protein and mammalian SOCS-1 protein with test  
PT compound.  
XX  
PS Example; Col 63; 109pp; English.  
XX  
CC The patent discloses obese receptor (Obr) proteins and nucleic acids  
CC encoding them. Obr protein participates in the regulation of mammalian  
CC body weight. The invention also relates to a method of identifying  
CC therapeutic compounds for the treatment of a body weight disorder. The  
CC method involves contacting a cell that expresses a mammalian Obr protein,  
CC a JAK2 protein and a mammalian SOCS-1 protein with a test compound. The  
CC method is useful for identifying compounds which modulate Obr gene  
CC expression and gene product activity, which can be used as agents to  
CC control body weight particularly as therapeutic agents for treating body  
CC weight disorders, including obesity, cachexia and anorexia. The present  
CC DNA sequence is a forward PCR primer which is used for amplifying mouse  
CC famj5312 Obr cDNA  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676

Db

1 CACTATTTCCTTCAG 17

RESULT 298

AAF79852  
ID AAF79852 standard; DNA; 17 BP.  
XX  
AC AAF79852;  
XX  
DT 30-MAY-2001 (first entry)  
XX  
DE DNA sequencing method DNA fragment.  
XX  
DE DNA sequencing; sequence analysis; chromosome; fluorophore; ds.  
XX  
KW Synthetic.  
XX  
OS  
XX  
PN US6200748-B1.  
XX  
PD 13-MAR-2001.  
XX  
PF 07-JUN-1995; 95US-00484340.  
XX  
PR 16-JAN-1984; 84US-00570973.  
XX  
PR 02-JAN-1985; 85US-00689013.  
XX  
PR 11-APR-1985; 85US-00722742.  
XX  
PR 07-OCT-1987; 87US-00106232.  
XX  
PR 21-FEB-1991; 91US-00660160.  
XX  
PR 12-JUN-1992; 92US-00899019.  
XX  
PR 21-DEC-1994; 94US-00361176.  
XX  
PA (CALY ) CALIFORNIA INST OF TECHNOLOGY.  
XX  
PI Smith LM, Hood LE, Hunkapiller MW, Hunkapiller TJ, Connell CR;  
XX  
DR WPI; 2001-256466/26.  
XX  
DT Novel duplex useful in sequencing reactions, comprising an  
PT oligonucleotide primer covalently coupled to a chromosome or fluorophore  
PT so as to allow chain extension by a polymerase, and a template.  
XX  
PS Disclosure; Fig 1A; 15pp; English.  
XX  
CC The present invention describes a duplex comprising a template and a  
CC primer joined to a chromosome or fluorophore to enable chain extension  
CC by a polymerase. Also described is a method of sequencing a nucleic acid  
CC using said primer, where the chromosome or fluorophore is used to  
CC determine the sequence of the oligonucleotide. This is useful in sequence  
CC analysis. The present sequence was used to demonstrate the method of the  
CC invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1357 AACGGCTGCAGGAATAC 1373  
Db 1 ATGCTCTGCAGGAATAC 17  
RESULT 299  
ABL46807/c  
ID ABL46807 standard; RNA; 17 BP.  
XX  
AC ABL46807;  
XX  
DT 27-JUN-2003 (first entry)  
XX  
DE Human GRID NCH ribozyme substrate oligonucleotide #261.  
XX  
KW Human; Grb2-related with Insert Domain; GRID; T-cell;  
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;  
KW leukemia; cytostatic; ss.  
XX  
OS Homo sapiens.

XX WO200162911-A2.  
PN  
XX  
PD 30-AUG-2001.  
XX  
PF 23-FEB-2001; 2001WO-US005957.  
XX  
PR 24-FEB-2000; 2000US-0184594P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (GLAX ) GLAXO GROUP LTD.  
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;  
XX  
XX WPI; 2001-550088/61.  
DR  
XX  
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain  
PT (GRID) gene comprises using antisense and enzymatic nucleic acid  
PT molecules such as hammerhead ribozymes.  
XX  
PS Claim 4; Page 67; 108pp; English.  
XX  
CC The present invention relates to oligonucleotides that downregulate the  
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is  
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful  
CC for modulating the expression of GRID, to treat conditions such as  
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be  
CC administered in conjunction with other therapies such as radiation,  
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was  
CC used to illustrate the invention  
XX  
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1539 CTCCTCGCTCTCGATCC 1555  
Db 17 CTCCTCGCTCTCGAACC 1  
RESULT 300  
AAD41482  
ID AAD41482 standard; DNA; 17 BP.  
XX  
AC AAD41482;  
XX  
DT 30-OCT-2002 (first entry)  
XX  
DE Mouse Ob receptor (OBR) gene amplifying forward PCR primer #2.  
XX  
KW Mouse; obese receptor; OBR; receptor; body weight disorder; obesity;  
KW cachexia; anorexia; anorectic; anabolic; immunomodulator; PCR; primer;  
KW ss.  
XX  
OS Mus sp.  
XX  
PN US6395498-B1.  
XX  
PD 28-MAY-2002.  
XX  
PF 28-MAY-1997; 97US-00864564.  
XX  
PR 27-NOV-1995; 95US-00562663.  
XX  
PR 04-DEC-1995; 95US-00566622.  
XX  
PR 08-DEC-1995; 95US-00569485.  
XX  
PR 11-DEC-1995; 95US-00570142.  
XX  
PR 28-DEC-1995; 95US-00583153.  
XX  
PR 22-JAN-1996; 96US-00599455.  
XX  
PR 26-APR-1996; 96US-00638524.  
XX  
PR 03-SEP-1996; 96US-00708123.  
XX

XX Identifying candidate therapeutic agents for treating body weight  
PT disorders, comprises contacting test compound with cell expressing  
PT mammalian obese receptor and reporter protein, and measuring expression  
PT of reporter protein.  
XX  
XX Example; Col 121; 110pp; English.  
XX  
XX The present invention relates to novel obese (Ob) receptor (OBR) proteins  
CC and polynucleotides encoding them. The invention relates to a method of  
CC identifying candidate therapeutic agents to treat body weight disorder.  
CC  
CC The method involves providing a cell which expresses a mammalian OBR on  
CC the cell surface, binds leptin, the cell harbouring a reporter construct  
CC comprising a sequence encoding a reporter protein, contacting the cell  
CC with a test compound and measuring the expression of the reporter protein  
CC in the presence of the test compound. The method is useful to identify an  
CC agent, preferably a small molecule or antibody for the treatment of body  
CC weight disorders such as obesity, cachexia, and anorexia. The present DNA  
CC sequence is a PCR primer which is used for amplifying mouse OBR genomic  
CC DNA. This sequence is used in the exemplification of the invention  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
  
RESULT 302  
AAD42341  
ID AAD42341 standard; DNA; 17 BP.  
XX  
AC AAD42341;  
XX  
DT 04-NOV-2002 (first entry)  
XX  
DE Mouse obesity receptor (Obr) gene amplifying forward primer #3.  
XX  
KW Obesity receptor; Obr; body weight disorder; therapy; food intake;  
KW anorexia; cachexia; acquired immune deficiency syndrome; cytostatic;  
KW AIDS-related wasting; cancer-related wasting; metabolic; anti-HIV;  
KW immunomodulator; human immunodeficiency virus; mouse; PCR; primer; ss.  
XX  
OS Mus sp.  
XX  
XX US6403552-B1.  
XX  
XX 11-JUN-2002.  
XX  
XX 09-JUN-1998; 98US-00094410.  
XX  
XX 27-NOV-1995; 95US-00562663.  
XX  
XX 04-DEC-1995; 95US-00566622.  
XX  
XX 08-DEC-1995; 95US-00569485.  
XX  
XX 11-DEC-1995; 95US-00570142.  
XX  
XX 28-DEC-1995; 95US-00583153.  
XX  
XX 22-JAN-1996; 96US-00599455.  
XX  
XX 26-APR-1996; 96US-00638524.  
XX  
XX 03-SEP-1996; 96US-00708123.  
XX  
XX 28-MAY-1997; 97US-00864564.  
XX  
XX (MILL-) MILLENNIUM PHARM INC.  
XX  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX  
XX WPI; 2002-536045/57.  
XX  
XX Increasing food intake in a mammal having a low body weight disorder such  
PT as anorexia, involves administering to the mammal a soluble polypeptide

PA (MILL-) MILLENNIUM PHARM INC.  
XX  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX  
XX WPI; 2002-535640/57.  
XX  
XX Identifying candidate therapeutic agents for treating body weight  
PT disorders, comprises contacting test compound with cell expressing  
PT mammalian obese receptor and reporter protein, and measuring expression  
PT of reporter protein.  
XX  
XX Example; Col 119; 110pp; English.  
XX  
XX The present invention relates to novel obese (Ob) receptor (OBR) proteins  
CC and polynucleotides encoding them. The invention relates to a method of  
CC identifying candidate therapeutic agents to treat body weight disorder.  
CC  
CC The method involves providing a cell which expresses a mammalian OBR on  
CC the cell surface, binds leptin, the cell harbouring a reporter construct  
CC comprising a sequence encoding a reporter protein, contacting the cell  
CC with a test compound and measuring the expression of the reporter protein  
CC in the presence of the test compound. The method is useful to identify an  
CC agent, preferably a small molecule or antibody for the treatment of body  
CC weight disorders such as obesity, cachexia, and anorexia. The present DNA  
CC sequence is a PCR primer which is used for amplifying mouse OBR genomic  
CC DNA. This sequence is used in the exemplification of the invention  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
  
RESULT 301  
AAD41484  
ID AAD41484 standard; DNA; 17 BP.  
XX  
AC AAD41484;  
XX  
DT 30-OCT-2002 (first entry)  
XX  
DE Mouse Ob receptor (Obr) gene amplifying forward PCR primer #3.  
XX  
XX Mouse; obese receptor; Obr; receptor; body weight disorder; obesity;  
KW cachexia; anorexia; anorectic; anabolic; immunomodulator; PCR; primer;  
KW ss.  
XX  
XX Mus sp.  
XX  
XX US6395498-B1.  
XX  
XX 28-MAY-2002.  
XX  
XX 28-MAY-1997; 97US-00864564.  
XX  
XX 27-NOV-1995; 95US-00562663.  
XX  
XX 04-DEC-1995; 95US-00566622.  
XX  
XX 08-DEC-1995; 95US-00569485.  
XX  
XX 11-DEC-1995; 95US-00570142.  
XX  
XX 28-DEC-1995; 95US-00583153.  
XX  
XX 22-JAN-1996; 96US-00599455.  
XX  
XX 26-APR-1996; 96US-00638524.  
XX  
XX 03-SEP-1996; 96US-00708123.  
XX  
XX (MILL-) MILLENNIUM PHARM INC.  
XX  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX  
XX WPI; 2002-535640/57.  
XX  
XX

comprising the extracellular domain of an obesity receptor protein.  
Example; Col 63; 114pp; English.  
The invention relates to obesity receptor (Obr) protein and its corresponding nucleic acid. The invention also relates to a method for the diagnosis and treatment of body weight disorders. The method is useful for increasing food intake in a mammal having a disorder characterised by low body weight, where the disorder is anorexia, cachexia, acquired immunodeficiency syndrome (AIDS)-related wasting or cancer-related wasting. The present sequence is a PCR primer used for amplifying mouse Obr gene. This sequence is used in the exemplification of the invention  
Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
RESULT 303  
AAD42339  
ID AAD42339 standard; DNA; 17 BP.  
XX AAD42339;  
XX  
XX 04-NOV-2002 (first entry)  
XX Mouse obesity receptor (Obr) gene amplifying forward primer #2.  
XX  
XX Obesity receptor; Obr; body weight disorder; therapy; food intake;  
XX anorexia; cachexia; acquired immune deficiency syndrome; cytostatic;  
XX AIDS-related wasting; cancer-related wasting; metabolic; anti-HIV;  
XX immunomodulator; human immunodeficiency virus; mouse; PCR; primer; ss.  
XX Mus sp.  
XX  
XX US6403552-B1.  
XX 11-JUN-2002.  
XX 09-JUN-1998; 98US-00094410.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENIUM PHARM INC.  
XX  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2002-536045/57.  
XX  
XX Increasing food intake in a mammal having a low body weight disorder such as anorexia, involves administering to the mammal a soluble polypeptide comprising the extracellular domain of an obesity receptor protein.  
XX Example; Col 62; 114pp; English.  
XX  
XX The invention relates to obesity receptor (Obr) protein and its corresponding nucleic acid. The invention also relates to a method for the diagnosis and treatment of body weight disorders. The method is

useful for increasing food intake in a mammal having a disorder characterised by low body weight, where the disorder is anorexia, cachexia, acquired immunodeficiency syndrome (AIDS)-related wasting or cancer-related wasting. The present sequence is a PCR primer used for amplifying mouse Obr gene  
Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
RESULT 304  
ABN01903/c  
ID ABN01903 standard; DNA; 17 BP.  
XX ABN01903;  
XX  
XX 29-MAY-2002 (first entry)  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1895.  
XX  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 1895; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1

CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 93 GAGAGTGGCAGGTCT 109  
Db 17 GAGAGAGCCAGGTCT 1  
  
RESULT 305  
ABN07493/C  
ID ABN07493 standard; DNA; 17 BP.  
XX AC ABN07493;  
XX DT  
XX 29-MAY-2002 (first entry)  
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7485.  
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN W0200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPT; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT

PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.  
XX Disclosure; SEQ ID NO 7485; 21app; English.  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1530 GCCCAGCCTCTCCCGC 1546  
Db 17 GTCCAGCCTCTCTCGC 1  
  
RESULT 306  
ABN08576  
ID ABN08576 standard; DNA; 17 BP.  
XX AC ABN08576;  
XX DT  
XX 29-MAY-2002 (first entry)  
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8568.  
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN W0200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 30-JAN-2001; 2001WO-US000667.  
XX PR 30-JAN-2001; 2001WO-US000668.



ABN09696/c  
ID ABN09696 standard; DNA; 17 BP.  
XX AC ABN09696;  
XX DT 29-MAY-2002 (first entry)  
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9688.  
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
XX KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX KW skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 30-JAN-2001; 2001WO-US000667.  
XX PR 30-JAN-2001; 2001WO-US000668.  
XX PR 30-JAN-2001; 2001WO-US000669.  
XX PR 30-JAN-2001; 2001WO-US000670.  
XX PR 05-FEB-2001; 2001US-0266860P.  
XX PA (AEOM-) AEOMICA INC.  
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX DR WPI; 2002-179446/23.  
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX PT or as specific biomolecule capture probes for surface-enhanced laser  
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX PS Disclosure; SEQ ID NO 9688; 214pp; English.  
XX CC The present invention describes a human genome-derived myosin-like  
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX CC nucleic acids can be used as probes to detect, characterise and quantify  
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX CC protein variants having desired phenotypic improvements, and for  
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX CC -1 proteins, as standards in assays used to determine the concentration  
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX CC capture probes for surface-enhanced laser desorption ionisation, as  
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX CC production, and in vaccines or for replacement therapy. The  
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart  
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX CC The present sequence represents an oligomer used in the screening of the  
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX CC The sequence data for this patent did not form part of the printed  
XX CC specification, but was obtained in electronic format directly from WIPO  
XX CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX CC Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 30-JAN-2001; 2001WO-US000667.  
XX PR 30-JAN-2001; 2001WO-US000668.  
XX PR 30-JAN-2001; 2001WO-US000669.  
XX PR 30-JAN-2001; 2001WO-US000670.  
XX PR 05-FEB-2001; 2001US-0266860P.  
XX PA (AEOM-) AEOMICA INC.  
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX DR WPI; 2002-179446/23.  
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX PT or as specific biomolecule capture probes for surface-enhanced laser  
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX PS Disclosure; SEQ ID NO 8663; 214pp; English.  
XX CC The present invention describes a human genome-derived myosin-like  
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX CC nucleic acids can be used as probes to detect, characterise and quantify  
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX CC protein variants having desired phenotypic improvements, and for  
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX CC -1 proteins, as standards in assays used to determine the concentration  
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX CC capture probes for surface-enhanced laser desorption ionisation, as  
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX CC production, and in vaccines or for replacement therapy. The  
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart  
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX CC The present sequence represents an oligomer used in the screening of the  
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX CC The sequence data for this patent did not form part of the printed  
XX CC specification, but was obtained in electronic format directly from WIPO  
XX CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX CC Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. NO. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Oy 270 GAAGAGCCAGAGAA 286  
Db 1 GAGGAGCCAGAGAA 17  
RESULT 309

CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 91 GGGAGAGTGGGCGAGTCC 107  
Db 17 GGGAGAGTGGGCGAGTCC 1  
  
RESULT 311  
ABN09697/C  
ID ABN09697 standard; DNA; 17 BP.  
XX  
AC ABN09697;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7355.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 9689; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 92 GGAGAGTGGGCGAGTCC 108  
Db 17 GGAGAGTGGGCGAGTCC 1  
  
RESULT 310  
ABN09697/C  
ID ABN09697 standard; DNA; 17 BP.  
XX  
AC ABN09697;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9689.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 9689; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1



CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 270 GAAGAAGCCCAAGAGAA 286  
DB 1 GAAGAAGCCCAAGAGAA 17  
|||||

RESULT 312  
ABN08672  
ID ABN08672 standard; DNA; 17 BP.  
XX  
AC ABN08672;  
XX  
XX 29-MAY-2002 (first entry)  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8664.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) ASOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8664; 214pp; English.

XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX nucleic acids can be used as probes to detect, characterise and quantify  
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX protein variants having desired phenotypic improvements, and for  
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX -1 proteins, as standards in assays used to determine the concentration  
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX capture probes for surface-enhanced laser desorption/ionisation, as  
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX production, and in vaccines or for replacement therapy. The  
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX disorder associated with the expression of hGDMPLP-1, in particular heart  
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX The present sequence represents an oligomer used in the screening of the  
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX The sequence data for this patent did not form part of the printed  
XX specification, but was obtained in electronic format directly from WIPO  
XX at ftp.wipo.int/pub/published\_pct\_sequence

XX SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAGAG 287  
DB 1 AGGAAGCCCAAGAGAG 17  
|||||

RESULT 313  
ABN08669  
ID ABN08669 standard; DNA; 17 BP.

XX  
XX AC ABN08669;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8661.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US0000665.  
PR 30-JAN-2001; 2001WO-US0000666.  
PR 30-JAN-2001; 2001WO-US0000667.  
PR 30-JAN-2001; 2001WO-US0000668.  
PR 30-JAN-2001; 2001WO-US0000669.  
PR 30-JAN-2001; 2001WO-US0000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
PA  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8661; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterize and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 268 TAGAAGAGCCCAAGAG 284  
DB 1 TGGAGGAGCCCAAGAG 17  
RESULT 314  
ABN02651/c  
ID ABN02651 standard; DNA; 17 BP.  
XX  
XX ABN02651;  
XX  
XX 29-MAY-2002 (first entry)  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2643.  
XX  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US0000661.  
PR 30-JAN-2001; 2001WO-US0000662.  
PR 30-JAN-2001; 2001WO-US0000663.  
PR 30-JAN-2001; 2001WO-US0000664.  
PR 30-JAN-2001; 2001WO-US0000665.  
PR 30-JAN-2001; 2001WO-US0000666.  
PR 30-JAN-2001; 2001WO-US0000667.  
PR 30-JAN-2001; 2001WO-US0000668.  
PR 30-JAN-2001; 2001WO-US0000669.  
PR 30-JAN-2001; 2001WO-US0000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 2643; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterize and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 1 A; 4 C; 8 G; 4 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 845 CTTCCAGCACCCGCCAA 861  
DB 17 CTGCCAGCACCCGCCAA 1  
RESULT 315  
ABN08668  
ID ABN08668 standard; DNA; 17 BP.  
XX  
XX ABN08668;  
XX  
XX 29-MAY-2002 (first entry)  
XX

DE	Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8660.
XX	Human; genome-derived myosin-like protein 1; hGDMPLP-1; hGDMPLP-1; heart;
XX	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	skeletal muscle disorder; amplicon; screening; ss.
XX	Homo sapiens.
OS	WO200192524-A2.
PN	06-DEC-2001.
PP	25-MAY-2001; 2001WO-US016981.
PR	26-MAY-2000; 2000US-0207456P.
PR	27-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000666.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000669.
PR	30-JAN-2001; 2001WO-US000670.
PR	05-FEB-2001; 2001US-0266860P.
XX	(AEOM-) AEOMICA INC.
PA	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI	WPI; 2002-179446/23.
DR	New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX	or as specific biomolecule capture probes for surface-enhanced laser
XX	desorption ionization, comprises human myosin-like protein hGDMPLP-1.
PS	Disclosure; SEQ ID NO 8660; 214pp; English.
CC	The present invention describes a human genome-derived myosin-like
CC	protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC	1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC	nucleic acids can be used as probes to detect, characterize and quantify
CC	hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substrates for the recombinant engineering of hGDMPLP-1
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption/ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGDMPLP-1, in particular heart
CC	and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
XX	Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
..	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	267 CTAGAAGAACCAAGAA 283 
DB	1 CTGGAGGAAGCCAAGAA 17
RESULT	316
ABO63736	
ID	ABO63736 standard; DNA; 17 BP.
XX	ABO63736;
AC	ABO63736;
XX	20-AUG-2002 (first entry)
DT	
XX	Human KTOM1a portion (ABO63232) probe # 449.
DE	
XX	Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX	Homo sapiens.
OS	WO200224750-A2.
PN	28-MAR-2002.
XX	
PD	21-SEP-2001; 2001WO-US029656.
PF	
XX	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000666.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000669.
PR	30-JAN-2001; 2001WO-US000670.
PR	23-MAY-2001; 2001US-00864761.
PR	28-AUG-2001; 2001US-0315676P.
XX	
XX	(AEOM-) AEOMICA INC.
PA	Zhang J;
PI	WPI; 2002-479509/51.
DR	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX	acids encoding the protein, useful for treating subjects having defects
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT	e.g., liver or bone.
XX	Example 2; Page 216; 418pp; English.
PS	The invention relates to a novel isolated nucleic acid encoding human
XX	KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
CC	invention has cytostatic activity. The nucleotide may have a use in gene
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC	monitor a disease caused by altered expression of human KTOM1.
CC	Compositions comprising the nucleic acids, proteins or antibodies may be
CC	used to treat subjects having defects in KTOM1 which can manifest as
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC	function. The sequence represents a probe used in the invention to scan
CC	the nt 1-1001 portion of human KTOM1a (ASQ63232)
XX	Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
..	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	524 CGACTCCTCGTGGAGA 540 

Qy 522 ATCGACTCCCTGCTGGA 538  
Db 1 ATCTACTCCAGCTGGA 17

RESULT 318  
ABQ63732  
ID ABQ63732 standard; DNA; 17 BP.  
XX  
AC ABQ63732;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 445.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhang J;  
XX  
XX WPI; 2002-479509/51.  
XX  
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
XX Example 2; Page 216; 418pp; English.  
XX  
XX The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1 ATCTACTCCAGCTGGA 17

RESULT 317  
ABQ63734  
ID ABQ63734 standard; DNA; 17 BP.  
XX  
AC ABQ63734;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 447.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhang J;  
XX  
XX WPI; 2002-479509/51.  
XX  
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
XX Example 2; Page 216; 418pp; English.  
XX  
XX The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 521 CATCGACTCCCTGCTG 537  
|||||  
Db 1 CATCTACTCCAGCTG 17

RESULT 320  
ABQ63735  
ID ABQ63735 standard; DNA; 17 BP.  
XX  
AC ABQ63735;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 448.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (ABOM-) ABOMICA INC.  
XX  
PI Zhang J;  
XX  
DR WPI; 2002-479509/51.  
XX  
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
PS Example 2; Page 216; 418pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Qy 520 GCATCGACTCCCTGCTG 536  
|||||  
Db 1 GCATCTACTCCAGCTG 17

RESULT 319  
ABQ63733  
ID ABQ63733 standard; DNA; 17 BP.  
XX  
AC ABQ63733;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 446.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (ABOM-) ABOMICA INC.  
XX  
PI Zhang J;  
XX  
DR WPI; 2002-479509/51.  
XX  
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
PS Example 2; Page 216; 418pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Query Match		0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity		88.2%;	Pred. No. 1.9e+02;		
Matches 15;		Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Qy	523	TCGACTCCCTGCTGGAG	539		
	1	TCTACTCCAGCTGGAG	17		
Db					
	1	ACTCCAGCTGGAGACC	17		
RESULT 322					
ABQ64165					
ID	ABQ64165	standard; DNA; 17 BP.			
XX					
AC	ABQ64165;				
XX					
DT	20-AUG-2002	(first entry)			
XX					
DE	Human KTOM1a portion (ABQ63232) probe # 878.				
XX					
KW	Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;				
KW	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;				
KW	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.				
XX					
OS	Homo sapiens.				
XX					
PN	WO200224750-A2.				
XX					
PD	28-MAR-2002.				
XX					
PF	21-SEP-2001; 2001WO-US029656.				
XX					
PR	21-SEP-2000; 2000US-0234687P.				
PR	27-SEP-2000; 2000US-0236359P.				
PR	04-OCT-2000; 2000GB-00024263.				
PR	30-JAN-2001; 2001WO-US000661.				
PR	30-JAN-2001; 2001WO-US000662.				
PR	30-JAN-2001; 2001WO-US000663.				
PR	30-JAN-2001; 2001WO-US000664.				
PR	30-JAN-2001; 2001WO-US000665.				
PR	30-JAN-2001; 2001WO-US000666.				
PR	30-JAN-2001; 2001WO-US000667.				
PR	30-JAN-2001; 2001WO-US000668.				
PR	30-JAN-2001; 2001WO-US000669.				
PR	30-JAN-2001; 2001WO-US000670.				
PR	23-MAY-2001; 2001US-00864761.				
PR	28-AUG-2001; 2001US-0315676P.				
XX	(AEOM-) AEOMICA INC.				
PA					
XX					
PI	Zhang J;				
XX					
DR	WPI; 2002-479509/51.				
XX					
PT	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic				
PT	acids encoding the protein, useful for treating subjects having defects				
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of				
PT	e.g., liver or bone.				
XX					
PS	Example 2; Page 272; 418pp; English.				
XX					
CC	The invention relates to a novel isolated nucleic acid encoding human				
CC	KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the				
CC	invention has cytostatic activity. The nucleotide may have a use in gene				
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or				
CC	monitor a disease caused by altered expression of human KTOM1.				
CC	Compositions comprising the nucleic acids, proteins or antibodies may be				
CC	used to treat subjects having defects in KTOM1 which can manifest as				
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,				
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta				
CC	function. The sequence represents a probe used in the invention to scan				
CC	the nt 1-1001 portion of human KTOM1a (ABQ63232)				
XX					
SQ	Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;				

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 1.9e+02;		
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Qy	526	ACTCCCTGCTGGAGAAC	542	
Db	1	ACTCCAGCTGGAGACC	17	
RESULT 322				
ABQ64165				
ID	ABQ64165	standard; DNA; 17 BP.		
XX				
AC	ABQ64165;			
XX				
DT	20-AUG-2002	(first entry)		
XX				
DE	Human KTOM1a portion	(ABQ63232) probe # 878.		
XX				
KW	Human; KTOM1a; KTOM1;	kidney tumour overexpressed membrane; cytostatic;		
KW	gene therapy; cancer;	kidney; liver; bone marrow; brain; heart; lung;		
KW	kidney; colon;	skeletal muscle; testis; uterus; placenta; probe; ss.		
XX				
OS	Homo sapiens.			
XX				
PN	WO200224750-A2.			
XX				
PD	28-MAR-2002.			
XX				
PF	21-SEP-2001;	2001WO-US029656.		
XX				
PR	21-SEP-2000;	2000US-0234687P.		
PR	27-SEP-2000;	2000US-0236359P.		
PR	04-OCT-2000;	2000GB-00024263.		
PR	30-JAN-2001;	2001WO-US000661.		
PR	30-JAN-2001;	2001WO-US000662.		
PR	30-JAN-2001;	2001WO-US000663.		
PR	30-JAN-2001;	2001WO-US000664.		
PR	30-JAN-2001;	2001WO-US000665.		
PR	30-JAN-2001;	2001WO-US000666.		
PR	30-JAN-2001;	2001WO-US000667.		
PR	30-JAN-2001;	2001WO-US000668.		
PR	30-JAN-2001;	2001WO-US000669.		
PR	30-JAN-2001;	2001WO-US000670.		
PR	23-MAY-2001;	2001US-00864761.		
PR	28-AUG-2001;	2001US-0315676P.		
XX				
PA	(AEOM-) AEOMICA INC.			
XX				
PI	Zhang J;			
XX				
DR	WPI; 2002-479509/51.			
XX				
PT	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic			
PT	acids encoding the protein, useful for treating subjects having defects			
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of			
PT	e.g., liver or bone.			
XX				
PS	Example 2; Page 272; 418pp; English.			
XX				
CC	The invention relates to a novel isolated nucleic acid encoding human			
CC	KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the			
CC	invention has cytostatic activity. The nucleotide may have a use in gene			
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or			
CC	monitor a disease caused by altered expression of human KTOM1.			
CC	Compositions comprising the nucleic acids, proteins or antibodies may be			
CC	used to treat subjects having defects in KTOM1 which can manifest as			
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,			
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta			
CC	function. The sequence represents a probe used in the invention to scan			
CC	the nt 1-1001 portion of human KTOM1a (ABQ63232)			
XX				
SQ	Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;			

```
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
SQ Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1203 GTCACACGGTGGCTTC 1219
Db 1 GTCACCACTGTGGCTGC 17

RESULT 323
ABV79503
ID ABV79503 standard; DNA; 17 BP.
XX
AC ABV79503;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 749.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) ABOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 162; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
```

```
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
SQ Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 522 ATCGACTCCCTGCTCGA 538
Db 1 AGCGACTCACTGCTGGA 17

RESULT 324
ABV79992
ID ABV79992 standard; DNA; 17 BP.
XX
AC ABV79992;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 1238.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) ABOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 226; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
```



CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 4 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1273 TCTTTGACTCTGATCCC 1289  
||| ||||| ||||| |||||  
Db 1 TCTGTGACTGTGATCCC 17  
RESULT 325  
ABV79502  
ID ABV79502 standard; DNA; 17 BP.  
XX  
AC ABV79502;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 748.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
XN EPI229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US0000663.  
PR 30-JAN-2001; 2001WO-US0000664.  
PR 30-JAN-2001; 2001WO-US0000665.  
PR 30-JAN-2001; 2001WO-US0000667.  
PR 30-JAN-2001; 2001WO-US0000668.  
PR 30-JAN-2001; 2001WO-US0000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 09-OCT-2001; 2001US-0327898P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhan J;  
XX  
XX WPI; 2002-676582/73.  
XX  
DR Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX  
PS Example 2; Page 161; 718pp; English.  
XX  
CC The present invention relates to human testis expressed Patched like  
CC protein (HTPL), see ABV78759 to ABV78762 and ABV98519 to ABV98520. HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC important in regulating male germ cell development, and the HTPL gene was  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,

CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 521 CATGACTCCCTGCTGG 537  
||| ||||| ||||| |||||  
Db 1 CAGCGACTCACTGCTGG 17  
RESULT 326  
ABK18229  
ID ABK18229 standard; RNA; 17 BP.  
XX  
AC ABK18229;  
XX  
DT 09-APR-2002 (first entry)  
XX  
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 876.  
XX  
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;  
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;  
KW amberzyme.  
XX  
OS Homo sapiens.  
XX  
XN WO2001188124-A2.  
XX  
PD 22-NOV-2001.  
XX  
PF 16-MAY-2001; 2001WO-US015866.  
XX  
PR 16-MAY-2000; 2000US-00572021.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (GLAX ) GLAXO GROUP LTD.  
XX  
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
XX  
XX WPI; 2002-082995/11.  
XX  
DR Novel polynucleotide which down regulates expression of Ets-related gene,  
XX useful for treating cancer, diabetic retinopathy, macular degeneration,  
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
PT  
XX  
PS Claim 4; Page 74; 149pp; English.  
XX  
CC The invention relates to a nucleic acid molecule (I) which down regulates  
CC expression of an Ets-related gene (ERG). (I) is useful for treating  
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,  
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge  
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu  
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
CC treating a patient having a condition associated with the level of ERG  
CC by contacting cells of the patient with (I) under conditions suitable for  
CC the treatment. The method comprises the use of one or more therapies  
CC under conditions suitable for the treatment. Leukaemia or tumour  
CC angiogenesis is treated by administering (I) to the patient in  
CC conjunction with one or more of other therapies such as radiation or



CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
CC cation such as Mg<sup>2+</sup>. (I) is useful for diagnosis of conditions and  
CC diseases related to the expression of ERG, and as diagnostic tool to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of ERG RNA in a cell. (I) is useful for specifically  
CC targeting genes that share homology with ERG gene or ERG fusion genes.  
CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
CC related PCR primers of the invention  
XX  
SQ Sequence 17 BP; 2 A; 12 C; 2 G; 0 T; 1 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1504 GCCCAGCCTCCAGGCC 1520  
Db 1 GCCCAGCCTCCAGGCC 17  
  
RESULT 327  
ABK19135  
ID ABK19135 standard; RNA; 17 BP.  
XX  
AC ABK19135;  
XX  
DT 09-APR-2002 (first entry)  
XX  
DE Human ERG Amberzyme target sequence Seq ID No 1782.  
XX  
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;  
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNazyme; inozyme;  
KW amberzyme.  
XX  
OS Homo sapiens.  
XX  
PN WO200188124-A2.  
XX  
PD 22-NOV-2001.  
XX  
PF 16-MAY-2001; 2001WO-US015866.  
XX  
PR 16-MAY-2000; 2000US-00572021.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (GLAX) GLAXO GROUP LTD.  
XX  
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
XX WPI; 2002-082995/11.  
XX  
PT Novel polynucleotide which down regulates expression of Ets-related gene,  
PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
PS Claim 4; Page 120; 149pp; English.  
XX  
CC The invention relates to a nucleic acid molecule (I) which down regulates  
CC expression of an Ets-related gene (ERG). (I) is useful for treating  
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,  
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge  
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu

CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
CC treating a patient having a condition associated with the level of ERG,  
CC by contacting cells of the patient with (I) under conditions suitable for  
CC the treatment. The method comprises the use of one or more therapies  
CC under conditions suitable for the treatment. Leukaemia or tumour  
CC angiogenesis is treated by administering (I) to the patient in  
CC conjunction with one or more of other therapies such as radiation or  
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
CC cation such as Mg<sup>2+</sup>. (I) is useful for diagnosis of conditions and  
CC diseases related to the expression of ERG, and as diagnostic tool to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of ERG RNA in a cell. (I) is useful for specifically  
CC targeting genes that share homology with ERG gene or ERG fusion genes.  
CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
CC related PCR primers of the invention  
XX  
SQ Sequence 17 BP; 10 A; 3 C; 3 G; 0 T; 1 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 218 GACTTCTCATGAAAAA 234  
Db 1 GACUCACAGAGAAAAA 17  
  
RESULT 328  
AAD38269  
ID AAD38269 standard; DNA; 17 BP.  
XX  
AC AAD38269;  
XX  
DT 10-SEP-2002 (first entry)  
XX  
DE Mouse Ob receptor genomic DNA amplifying forward PCR primer #2.  
XX  
KW Mouse; Ob receptor; OBR; leptin; body weight disorder; drug screening;  
KW gene therapy; obesity; cachexia; anorexia; anorectic; anabolic; PCR;  
KW primer; ss.  
XX  
OS Mus sp.  
XX  
PN US6380363-B1.  
XX  
PD 30-APR-2002.  
XX  
PF 19-AUG-1998; 98US-00137132.  
XX  
PR 27-NOV-1995; 95US-00562663.  
PR 04-DEC-1995; 95US-00566622.  
PR 08-DEC-1995; 95US-00569485.  
PR 11-DEC-1995; 95US-00570142.  
PR 28-DEC-1995; 95US-00583153.  
PR 22-JAN-1996; 96US-00599455.  
PR 26-APR-1996; 96US-00638524.  
PR 03-SEP-1996; 96US-00708123.  
PR 28-MAY-1997; 97US-00864564.  
XX  
PA (TART/) TARTAGLIA L A.  
PA (TEPP/) TEPPER R I.  
PA (CULP/) CULPEPPER J A.  
PA (WHIT/) WHITE D W.  
XX  
PI Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2002-413726/44.  
XX  
PT Antibodies which selectively bind mammalian Ob receptors and inhibits the  
PT binding of leptin to the mammalian Ob receptor, useful for diagnosing and

```

PT treating weight disorders.
XX Example; Col 62; 108pp; English.
XX The present invention relates to novel antibodies which selectively bind
CC mammalian Ob receptors (ObR) and inhibit the binding of leptin to the
CC mammalian Ob receptor. ObR sequences are novel receptor proteins that
CC participate in the control of mammalian body weight. The antibodies of
CC the invention may be used to detect of Ob receptor in a biological sample
CC and utilised as a part of diagnostic or prognostic technique in which
CC patients may be tested for abnormal amounts of Ob receptors. They may be
CC utilised in conjunction with, for example, compound screening schemes for
CC the evaluation of the effect of test compounds on expression and/or
CC activity of the Ob receptor gene product. The antibodies can be used in
CC conjunction with the gene therapy techniques, for example, to evaluate
CC the normal and/or engineered Ob receptor-expressing cells prior to their
CC introduction into the patient. They may be used in the method for the
CC inhibition of abnormal Ob receptor activity and can be used for drug
CC screening, clinical trial monitoring and/or the treatment of body weight
CC disorders including but not limited to obesity, cachexia and anorexia.
CC The present DNA sequence is a PCR primer which is used for amplifying
CC mouse ObR genomic DNA. This sequence is used in the exemplification of
CC the invention
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 329
AAD38271
ID AAD38271 standard; DNA; 17 BP.
XX AAD38271;
AC AAD38271;
XX 10-SEP-2002 (first entry)
XX Mouse Ob receptor genomic DNA amplifying forward PCR primer #3.
XX Mouse; Ob receptor; ObR; leptin; body weight disorder; drug screening;
KW gene therapy; obesity; cachexia; anorexia; anorectic; anabolic; PCR;
KW primer; ss.
XX Mus sp.
XX US6380363-B1.
XX 30-APR-2002.
XX 19-AUG-1998; 98US-00137132.
XX 27-NOV-1995; 95US-00562663.
XX 04-DEC-1995; 95US-00566622.
XX 08-DEC-1995; 95US-00569485.
XX 11-DEC-1995; 95US-00570142.
XX 28-DEC-1995; 95US-00583153.
XX 22-JAN-1996; 96US-00599455.
XX 26-APR-1996; 96US-00638524.
XX 03-SEP-1996; 96US-00708123.
XX 28-MAY-1997; 97US-00864564.
XX (TART/) TARTAGLIA L A.
XX (TEPP/) TEPPER R I.
XX (CULP/) CULPEPPER J A.
XX (WHIT/) WHITE D W.
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;

```

```

XX WPI; 2002-413726/44.
XX Antibodies which selectively bind mammalian Ob receptors and inhibits the
PT binding of leptin to the mammalian Ob receptor, useful for diagnosing and
PT treating weight disorders.
XX Example; Col 62; 108pp; English.
XX The present invention relates to novel antibodies which selectively bind
CC mammalian Ob receptors (ObR) and inhibit the binding of leptin to the
CC mammalian Ob receptor. ObR sequences are novel receptor proteins that
CC participate in the control of mammalian body weight. The antibodies of
CC the invention may be used to detect of Ob receptor in a biological sample
CC and utilised as a part of diagnostic or prognostic technique in which
CC patients may be tested for abnormal amounts of Ob receptors. They may be
CC utilised in conjunction with, for example, compound screening schemes for
CC the evaluation of the effect of test compounds on expression and/or
CC activity of the Ob receptor gene product. The antibodies can be used in
CC conjunction with the gene therapy techniques, for example, to evaluate
CC the normal and/or engineered Ob receptor-expressing cells prior to their
CC introduction into the patient. They may be used in the method for the
CC inhibition of abnormal Ob receptor activity and can be used for drug
CC screening, clinical trial monitoring and/or the treatment of body weight
CC disorders including but not limited to obesity, cachexia and anorexia.
CC The present DNA sequence is a PCR primer which is used for amplifying
CC mouse ObR genomic DNA. This sequence is used in the exemplification of
CC the invention
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 330
ACN05936/C
ID ACN05936 standard; RNA; 17 BP.
XX ACN05936;
AC ACN05936;
XX 22-APR-2004 (first entry)
XX WNV Amberzyme substrate SEQ ID NO 5939.
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAsyme;
KW Amberzyme; Zinzyme; ss.
XX West Nile Virus.
XX WO200268637-A2.
XX 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.

```

Mon Nov 7 09:26:58 2005

XX	New nucleic acid molecule that modulates replication of West Nile Virus
PT	(WNV), useful for treating a condition related to WNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX	
XX	Claim 23; SEQ ID NO 5939; 495pp; English.
XX	
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-cleaver, DNAYzyme, Amberzyme and Zinzyme. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
XX	
SQ	Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;

The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

Sequence 17 BP; 0 A; 9 C; 0 G; 0 T; 8 U; 0 Other;

# I

CC	nucleic acid molecules further comprise at least five ribose residues, at	XX	Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at	SQ	
CC	least three of the 5' terminal nucleotides and a 3' end modification of a		
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080	Query Match	0.8%; Score 13.8; DB 1; Length 17;
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given	Best Local Similarity	88.2%; Pred. NO. 1.9e+02;
CC	in the specification. The present sequence is that of a nucleic acid	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CC	molecule of the invention		
XX		QY	1228 CTGACTCGGAGTTCCT 1244
SQ	Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;	Db	17 CTGAGTCGACATTCCT 1
		RESULT 334	
		ACN00398/c	
ID	ACN00398 standard; RNA; 17 BP.	ID	ACN14016 standard; RNA; 17 BP.
XX		XX	
AC	ACN00398;	AC	ACN14016;
XX		XX	
DT	22-APR-2004 (first entry)	DT	22-APR-2004 (first entry)
XX		XX	
DE	WNV Hammerhead Ribozyme substrate SEQ ID NO 388.	DE	WNV minus strand DNazyme substrate SEQ ID NO 14019.
XX		XX	
KW	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;	KW	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;	KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;	KW	encephalitis; myocarditis; meningitis; infection; hepatitis;
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;	KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW	Amberzyme; Zinzyme; ss.	KW	Amberzyme; Zinzyme; ss.
XX		XX	
OS	West Nile Virus.	OS	West Nile Virus.
XX		XX	
PN	WO200268637-A2.	PN	WO200268637-A2.
XX		XX	
PD	06-SEP-2002.	PD	06-SEP-2002.
XX		XX	
PF	19-OCT-2001; 2001WO-US048350.	PF	19-OCT-2001; 2001WO-US048350.
XX		XX	
PR	20-OCT-2000; 2000US-0242411P.	PR	20-OCT-2000; 2000US-0242411P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.	PA	(BLAT/) BLATT L.
PA	(MCSW/) MCSWIGGEN J A.	PA	(MCSW/) MCSWIGGEN J A.
XX		XX	
PI	Blatt L, Mcswiggen JA;	PI	Blatt L, Mcswiggen JA;
XX		XX	
DR	WPI; 2002-706994/76.	DR	WPI; 2002-706994/76.
XX		XX	
XX	New nucleic acid molecule that modulates replication of West Nile Virus	XX	New nucleic acid molecule that modulates replication of West Nile Virus
XX	(WNV), useful for treating a condition related to WNV infection e.g.	XX	(WNV), useful for treating a condition related to WNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.	PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX		XX	
PS	Claim 23; SEQ ID NO 388; 495pp; English.	PS	Claim 23; SEQ ID NO 14019; 495pp; English.
XX		XX	
CC	The invention relates to nucleic acid molecules that modulate replication	CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for	CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,	CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,	CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid	CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of	CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The	CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC	nucleic acid molecules further comprise at least five ribose residues, at	CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at	CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a	CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080	CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given	CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid	CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention	CC	molecule of the invention
XX		XX	
SQ	Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;
		Query Match	0.8%; Score 13.8; DB 1; Length 17;
		Best Local Similarity	52.9%; Pred. NO. 1.9e+02;
		Matches	9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```
Qy 1229 TGACTCGGACGTTCTT 1245
Db 1 UGAGUGCGACAUCCU 17

RESULT 335
ACN15009
ID ACN15009 standard; RNA; 17 BP.
AC ACN15009;
XX
XX
DT 22-APR-2004 (first entry)
XX
XX WNV minus strand Amberzyme substrate SEQ ID NO 15012.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 15012; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 58.8%; Pred. No. 1.9e+02;
XX Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1228 CTGACTCGGACGTTCTT 1244
Db 1 CUGAGUGCGACAUCCU 17

RESULT 336
ACN06460/c
ID ACN06460 standard; RNA; 17 BP.
AC ACN06460;
XX
XX
DT 22-APR-2004 (first entry)
XX
XX WNV Amberzyme substrate SEQ ID NO 6463.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 6463; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 8 A; 1 C; 8 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 489 TCGCCCTTCTACTCTG 505
Db 17 TCTCCCTTCTCTCTG 1

RESULT 337
ACN01953/c
ID ACN01953 standard; RNA; 17 BP.
XX
XX ACN01953;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Inozyme substrate SEQ ID NO 1943.
```

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
XX WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 1943; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1227 TCTGACTCGGACGTTCC 1243  
DB 17 TCTGACTCGGACATTCC 1  
RESULT 338  
ACN08392  
ID ACN08392 standard; RNA; 17 BP.  
XX  
AC ACN08392;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8395.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX

OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
XX WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 8395; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 0 A; 8 C; 1 G; 0 T; 8 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.9e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
QY 489 TCGCCCTTCTACTTCTG 505  
DB 1 UCUCUCCUCCUCCUCCUG 17  
RESULT 339  
ACN11835/C  
ID ACN11835 standard; RNA; 17 BP.  
XX  
AC ACN11835;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Inozyme substrate SEQ ID NO 11838.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX

XX 20-OCT-2000; 2000US-0242411P.  
PR (RIBO-) RIBOZYME PHARM INC.  
XX (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
XX Blatt L, Mcswiggen JA;  
PI WPI; 2002-706994/76.  
DR  
XX  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
XX Claim 23; SEQ ID NO 11838; 495pp; English.  
PS  
XX  
XX The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
XX Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1470 CCAGAGAGAGCTCTGCA 1486  
Db 17 CAAGAGGAGGCTCTGCA 1

RESULT 340  
ACN05385/C  
ID ACN05385 standard; RNA; 17 BP.  
XX  
XX ACN05385;  
XX  
XX 22-APR-2004 (first entry)  
XX  
XX WNV DNazyme substrate SEQ ID NO 5388.  
XX  
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyne; ss.  
XX  
XX West Nile Virus.  
OS  
XX  
XX WO200268637-A2.  
PN  
XX  
XX 06-SEP-2002.  
PD  
XX  
XX 19-OCT-2001; 2001WO-US048350.  
PF  
XX  
XX 20-OCT-2000; 2000US-0242411P.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
XX Blatt L, Mcswiggen JA;  
PI WPI; 2002-706994/76..  
DR  
XX  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX

PI Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.  
XX  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
XX Claim 23; SEQ ID NO 5388; 495pp; English.  
PS  
XX  
XX The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1232 CTCGGAGCTTCCTCCG 1248  
Db 17 CGCGAGCGTTCATCCG 1

RESULT 341  
ACN08973  
ID ACN08973 standard; RNA; 17 BP.  
XX  
XX ACN08973;  
XX  
XX 22-APR-2004 (first entry)  
XX  
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8976.  
XX  
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyne; ss.  
XX  
XX West Nile Virus.  
OS  
XX  
XX WO200268637-A2.  
PN  
XX  
XX 06-SEP-2002.  
PD  
XX  
XX 19-OCT-2001; 2001WO-US048350.  
PF  
XX  
XX 20-OCT-2000; 2000US-0242411P.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
XX Blatt L, Mcswiggen JA;  
PI WPI; 2002-706994/76..  
DR  
XX  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
XX Sequence 17 BP; 4 A; 7 C; 2 G; 4 T; 0 U; 0 Other;  
SQ  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 374 CTGGGAAGAGTCTAAGC 390  
Db 17 CTGGGAAGAGTCTGATC 1  
|||||||  
  
RESULT 343  
ABT37737  
ID ABT37737 standard; DNA; 17 BP.  
XX  
AC ABT37737;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
DE Tumour suppression related human fukutin oligo SEQ ID No 3374.  
XX  
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025175-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004208.  
XX  
PR 17-SEP-2001; 2001FR-00011978.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
XX WPI; 2003-313353/30.  
XX  
DR New isolated nucleic acid, useful for treating viral diseases associated  
XX with tumors and cell degeneration, also related polypeptides, antibodies  
XX and transfected cells.  
XX  
PS Disclosure; Page 428; 720pp; French.  
XX  
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
XX given in the specification, a sequence containing at least 15 consecutive  
XX nucleotides from the 17 mer sequence, a sequence with, after optimal  
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
XX hybridizes to them under highly stringent conditions, or the complement  
XX of any of them, or the corresponding RNA. The novel isolated nucleic  
XX acids of the invention are useful as probes and primers for detecting,  
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
XX component of a gene chip, in vitro as (anti)sense reagents, and for

XX Claim 23; SEQ ID NO 8976; 495pp; English.  
XX  
XX The invention relates to nucleic acid molecules that modulate replication  
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
XX treating a condition related to WNV infection e.g. pancreatitis,  
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
XX molecule is selected from the group of ribozymes consisting of  
XX Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
XX nucleic acid molecules further comprise at least five ribose residues, at  
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
XX least three of the 5' terminal nucleotides and a 3' end modification of a  
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
XX in the specification. The present sequence is that of a nucleic acid  
XX molecule of the invention  
XX  
XX Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;  
SQ  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 1.9e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1226 TTCTGACTCGGACGTTC 1242  
Db 1 UUCUGAGCGGACAUC 17  
::||::|::|::|::|::|::|  
  
RESULT 342  
ABT34420/c  
ID ABT34420 standard; DNA; 17 BP.  
XX  
AC ABT34420;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
DE Tumour suppression related human fukutin oligo SEQ ID No 57.  
XX  
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025175-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004208.  
XX  
PR 17-SEP-2001; 2001FR-00011978.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
XX WPI; 2003-313353/30.  
XX  
DR New isolated nucleic acid, useful for treating viral diseases associated  
XX with tumors and cell degeneration, also related polypeptides, antibodies  
XX and transfected cells.  
XX  
PS Disclosure; Page 40; 720pp; French.  
XX  
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
XX given in the specification, a sequence containing at least 15 consecutive  
XX nucleotides from the 17 mer sequence, a sequence with, after optimal  
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
XX hybridizes to them under highly stringent conditions, or the complement  
XX of any of them, or the corresponding RNA. The novel isolated nucleic  
XX acids of the invention are useful as probes and primers for detecting,



CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 359 GACCATGATGCCCTCT 375  
Db 1 GATCATGATGCCCTCT 17  
RESULT 344  
ACA06296  
ID ACA06296 standard; RNA; 17 BP.  
AC ACA06296;  
XX  
DT 03-JUN-2003 (first entry)  
XX  
DE NFKB sub-unit modulating inozyme substrate #115.  
XX  
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2002177568-A1.  
XX  
PD 28-NOV-2002.  
XX  
PF 23-MAY-2001; 2001US-00864785.  
XX  
PR 07-DEC-1992; 92US-00987132.  
PR 18-MAY-1994; 94US-00245466.  
PR 15-AUG-1994; 94US-00291932.  
PR 23-DEC-1996; 96US-00777916.  
XX  
PA (STIN)/ STINCHOMB D T.  
PA (MCSW)/ MCSWIGGEN J.  
PA (DRAP)/ DRAPER K G.  
XX  
PI Stinchcomb DT, Mcswiggen J, Draper KG;  
XX  
DR WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
PT a sequence encoding a subunit of nuclear factor kappa B useful for  
PT treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 29; 72pp; English.  
XX  
CC The invention describes an enzymatic nucleic acid molecule (I) which down  
CC regulates expression of a sequence encoding a subunit of nuclear factor  
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
CC cancer and is useful for down-regulating REL-A activity in a cell, for  
CC treating a patient having a condition associated with the level of REL-A.  
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
CC antisense nucleic acid molecules are useful for treating breast, lung,  
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
CC multidrug resistant cancer. The method involves use of other drug  
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
CC gencitabine or radiation therapy. The enzymatic and antisense nucleic  
CC acid molecules are also useful for treating inflammatory disease such as  
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
CC rejection, gene therapy applications, ischaemia/reperfusion injury  
CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
CC infection. This sequence represents the substrate of a novel enzymatic  
CC nucleic acid molecule  
XX  
SQ Sequence 17 BP; 6 A; 9 C; 0 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 988 CCACCAACACCCCTCC 1004

Db 1 CCACCAACACCCCUUC 17

RESULT 345

ACA07700

ID ACA07700 standard; RNA; 17 BP.

AC ACA07700;

XX  
DT 03-JUN-2003 (first entry)

XX NFKB sub-unit modulating zinzyme substrate #99.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

XX OS  
XX US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245466.

PR	15-AUG-1994;	94US-00291932.	
PR	23-DEC-1996;	96US-00777916.	
XX			
PA	(STIN/) STINCHCOMB D T.		
PA	(MCSW/) MCSWIGGEN J.		
PA	(DRAP/) DRAPER K G.		
XX			
PI	Stinchcomb DT, Mcswiggen J, Draper KG;		
XX			
DR	WPI; 2003-340953/32.		
XX			
PT	Novel enzymatic nucleic acid molecules which down regulates expression of		
PT	a sequence encoding a subunit of nuclear factor kappa B useful for		
PT	treating cancer, inflammatory disorders and autoimmune diseases.		
XX			
XX	Claim 3; Page 39; 72pp; English.		
XX			
CC	The invention describes an enzymatic nucleic acid molecule (I) which down		
CC	regulates expression of a sequence encoding a subunit of nuclear factor		
CC	kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme		
CC	configuration. The enzymatic nucleic acid molecule is adapted to treat		
CC	cancer and is useful for down-regulating REL-A activity in a cell, for		
CC	treating a patient having a condition associated with the level of REL-A.		
CC	(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in		
CC	the presence of a divalent cation, especially Mg <sup>2+</sup> . The enzymatic and		
CC	antisense nucleic acid molecules are useful for treating breast, lung,		
CC	prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,		
CC	cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or		
CC	multidrug resistant cancer. The method involves use of other drug		
CC	therapies such as monoclonal antibodies, REL-A-specific inhibitors or		
CC	chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,		
CC	cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,		
CC	gemcitabine or radiation therapy. The enzymatic and antisense nucleic		
CC	acid molecules are also useful for treating inflammatory disease such as		
CC	rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,		
CC	obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft		
CC	rejection, gene therapy applications, ischaemia/reperfusion injury		
CC	(central nervous system (CNS) and myocardial), glomerulonephritis,		
CC	sepsis, allergic airway inflammation, inflammatory bowel disease or		
CC	infection. This sequence represents the substrate of a novel enzymatic		
CC	nucleic acid molecule		
XX			
SQ	Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;		
	Query Match 0.8%; Score 13.8; DB 1; Length 17;		
	Best Local Similarity 82.4%; Pred. No. 1.9e+02;		
	Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;		
QY	1502 AGGCCCCAGCCTCCAGG 1518		
Db	1 AGACCCCGAGCCGCGAGG 17		
	:		
	1 AGACCCCGAGCCGCGAGG 17		
	RESULT 346		
	ACA07701		
ID	ACA07701 standard; RNA; 17 BP.		
XX			
AC	ACA07701;		
XX			
DT	03-JUN-2003 (first entry)		
XX			
DE	NFKB sub-unit modulating zinzyme substrate #100.		
XX			
KW	Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;		
KW	G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;		
KW	lung cancer; prostate cancer; colorectal cancer; brain cancer;		
KW	oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;		
KW	cervical cancer; head and neck cancer; ovarian cancer; melanoma;		
KW	lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;		
KW	chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;		
KW	cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;		
KW	gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;		
KW	rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;		

03-JUN-2003 (first entry)  
NFKB sub-unit modulating DNzyme substrate #24.  
Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
lung cancer; prostate cancer; colorectal cancer; brain cancer;  
oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
transplant/graft rejection; reperfusion injury; glomerulonephritis;  
allergic airway inflammation; inflammatory bowel disease; infection; ss.  
Homo sapiens.  
US2002177568-A1.  
28-NOV-2002.  
23-MAY-2001; 2001US-00864785.  
07-DEC-1992; 92US-00987132.  
18-MAY-1994; 94US-00245466.  
15-AUG-1994; 94US-00291932.  
23-DEC-1996; 96US-00777916.  
(STIN/) STINCHCOMB D T.  
(MCSW/) MCSWIGGEN J.  
(DRAP/) DRAPER K G.  
Stinchcomb DT, Mcswiggen J, Draper KG;  
WPI; 2003-340953/32.  
Novel enzymatic nucleic acid molecules which down regulates expression of  
a sequence encoding a subunit of nuclear factor kappa B useful for  
treating cancer, inflammatory disorders and autoimmune diseases.  
Claim 3; Page 43; 72pp; English.  
The invention describes an enzymatic nucleic acid molecule (I) which down  
regulates expression of a sequence encoding a subunit of nuclear factor  
kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
configuration. The enzymatic nucleic acid molecule is adapted to treat  
cancer and is useful for down-regulating REL-A activity in a cell, for  
treating a patient having a condition associated with the level of REL-A.  
(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
antisense nucleic acid molecules are useful for treating breast, lung,  
prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
multidrug resistant cancer. The method involves use of other drug  
therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
acid molecules are also useful for treating inflammatory disease such as  
rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
rejection, gene therapy applications, ischaemia/reperfusion injury  
(central nervous system (CNS) and myocardial), glomerulonephritis,  
sepsis, allergic airway inflammation, inflammatory bowel disease or  
infection. This sequence represents the substrate of a novel enzymatic  
nucleic acid molecule  
Sequence 17 BP; 6 A; 9 C; 0 G; 0 T; 2 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
QY 989 CACCAACAACCCCTCCC 1005  
||| ||||| |||  
Db 1 CAACACAACCCCUCC 17  
RESULT 348  
ACA06298  
ID ACA06298 standard; RNA; 17 BP.  
AC ACA06298;  
XX  
XX 03-JUN-2003 (first entry)  
XX NFKB sub-unit modulating inozyme substrate #117.  
XX  
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
lung cancer; prostate cancer; colorectal cancer; brain cancer;  
oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
transplant/graft rejection; reperfusion injury; glomerulonephritis;  
allergic airway inflammation; inflammatory bowel disease; infection; ss.  
Homo sapiens.  
US2002177568-A1.  
28-NOV-2002.  
23-MAY-2001; 2001US-00864785.  
07-DEC-1992; 92US-00987132.  
18-MAY-1994; 94US-00245466.  
15-AUG-1994; 94US-00291932.  
23-DEC-1996; 96US-00777916.  
(STIN/) STINCHCOMB D T.  
(MCSW/) MCSWIGGEN J.  
(DRAP/) DRAPER K G.  
Stinchcomb DT, Mcswiggen J, Draper KG;  
WPI; 2003-340953/32.  
Novel enzymatic nucleic acid molecules which down regulates expression of  
a sequence encoding a subunit of nuclear factor kappa B useful for  
treating cancer, inflammatory disorders and autoimmune diseases.  
Claim 3; Page 29; 72pp; English.  
The invention describes an enzymatic nucleic acid molecule (I) which down  
regulates expression of a sequence encoding a subunit of nuclear factor  
kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
configuration. The enzymatic nucleic acid molecule is adapted to treat  
cancer and is useful for down-regulating REL-A activity in a cell, for  
treating a patient having a condition associated with the level of REL-A.  
(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
antisense nucleic acid molecules are useful for treating breast, lung,  
prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
multidrug resistant cancer. The method involves use of other drug  
therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,

CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,  
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
CC acid molecules are also useful for treating inflammatory disease such as  
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes  
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
CC rejection, gene therapy applications, ischaemia/reperfusion injury  
CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
CC infection. This sequence represents the substrate of a novel enzymatic  
CC nucleic acid molecule  
XX  
SQ Sequence 17 BP; 6 A; 8 C; 1 G; 0 T; 2 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
QY 992 CAACAACCCCTCCAGG 1008  
Db 1 CAACAACCCCTCCAGG 17  
  
RESULT 349  
ACA06394  
ID ACA06394 standard; RNA; 17 BP.  
XX  
AC ACA06394;  
XX  
DT 03-JUN-2003 (first entry)  
XX  
DE NFKB sub-unit modulating inozyme substrate #213.  
XX  
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
KW chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;  
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;  
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2002177568-A1.  
XX  
PD 28-NOV-2002.  
XX  
PF 23-MAY-2001; 2001US-00864785.  
XX  
PR 07-DEC-1992; 92US-00987132.  
XX  
PR 18-MAY-1994; 94US-00245466.  
XX  
PR 15-AUG-1994; 94US-00291932.  
XX  
PR 23-DEC-1996; 96US-00777916.  
XX  
PA (STIN)/ STINCHOMB D T.  
PA (MCSW)/ MCSWIGGEN J.  
PA (DRAP)/ DRAPER K G.  
XX  
PI Stinchcomb DT, Mcswiggen J, Draper KG;  
XX  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX PT a sequence encoding a subunit of nuclear factor kappa B useful for  
XX PT treating cancer, inflammatory disorders and autoimmune diseases.  
XX  
XX  
XX Claim 3; Page 30; 72pp; English.

CC The invention describes an enzymatic nucleic acid molecule (I) which down  
CC regulates expression of a sequence encoding a subunit of nuclear factor  
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
CC cancer and is useful for down-regulating REL-A activity in a cell, for  
CC treating a patient having a condition associated with the level of REL-A.  
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
CC antisense nucleic acid molecules are useful for treating breast, lung,  
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
CC multidrug resistant cancer. The method involves use of other drug  
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,  
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
CC acid molecules are also useful for treating inflammatory disease such as  
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
CC rejection, gene therapy applications, ischaemia/reperfusion injury  
CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
CC infection. This sequence represents the substrate of a novel enzymatic  
CC nucleic acid molecule  
XX  
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 0 T; 1 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1501 CAGGCCCCAGCTCCAG 1517  
Db 1 CAGGCCCCAGCTCCAG 17  
  
RESULT 350  
ACA06396  
ID ACA06396 standard; RNA; 17 BP.  
XX  
AC ACA06396;  
XX  
DT 03-JUN-2003 (first entry)  
XX  
DE NFKB sub-unit modulating inozyme substrate #215.  
XX  
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
KW chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;  
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;  
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2002177568-A1.  
XX  
PD 28-NOV-2002.  
XX  
PF 23-MAY-2001; 2001US-00864785.  
XX  
PR 07-DEC-1992; 92US-00987132.  
XX  
PR 18-MAY-1994; 94US-00245466.  
XX  
PR 15-AUG-1994; 94US-00291932.  
XX  
PR 23-DEC-1996; 96US-00777916.  
XX

PA (STIN/) STINCHOMB D T.  
PA (MCSW/) MCSWIGGEN J.  
PA (DRAP/) DRAPER K G.  
XX  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX a sequence encoding a subunit of nuclear factor kappa B useful for  
XX treating cancer, inflammatory disorders and autoimmune diseases.  
XX  
XX Claim 3; Page 30; 72pp; English.  
XX  
XX The invention describes an enzymatic nucleic acid molecule (I) which down  
XX regulates expression of a sequence encoding a subunit of nuclear factor  
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
XX configuration. The enzymatic nucleic acid molecule is adapted to treat  
XX cancer and is useful for down-regulating REL-A activity in a cell, for  
XX treating a patient having a condition associated with the level of REL-A.  
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
XX the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
XX antisense nucleic acid molecules are useful for treating breast, lung,  
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
XX multidrug resistant cancer. The method involves use of other drug  
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
XX gencitabine or radiation therapy. The enzymatic and antisense nucleic  
XX acid molecules are also useful for treating inflammatory disease such as  
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
XX rejection, gene therapy applications, ischaemia/reperfusion injury  
XX (central nervous system (CNS) and myocardial), glomerulonephritis,  
XX sepsis, allergic airway inflammation, inflammatory bowel disease or  
XX infection. This sequence represents the substrate of a novel enzymatic  
XX nucleic acid molecule  
XX  
XX Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
XX Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
XX Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
XX Qy 1505 CCCGAGCTCCAGGCC 1521  
XX |||||:|||||  
XX 1 CCCGAGCTCCAGGCC 17  
XX  
XX RESULT 351  
XX ACA06517 standard; RNA; 17 BP.  
XX  
XX AC A06517;  
XX  
XX 03-JUN-2003 (first entry)  
XX  
XX NFkB sub-unit modulating inozyme substrate #336.  
XX  
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
XX G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
XX lung cancer; prostate cancer; colorectal cancer; brain cancer;  
XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
XX cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
XX gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
XX transplant/graft rejection; reperfusion injury; glomerulonephritis;  
XX allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.  
XX  
XX US2002177568-A1.  
XX  
XX 28-NOV-2002.  
XX  
XX 23-MAY-2001; 2001US-00864785.  
XX  
XX 07-DEC-1992; 92US-00987132.  
XX 18-MAY-1994; 94US-00245466.  
XX 15-AUG-1994; 94US-00291932.  
XX 23-DEC-1996; 96US-0077916.  
XX  
XX (STIN/) STINCHOMB D T.  
XX (MCSW/) MCSWIGGEN J.  
XX (DRAP/) DRAPER K G.  
XX  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX a sequence encoding a subunit of nuclear factor kappa B useful for  
XX treating cancer, inflammatory disorders and autoimmune diseases.  
XX  
XX Claim 3; Page 32; 72pp; English.  
XX  
XX The invention describes an enzymatic nucleic acid molecule (I) which down  
XX regulates expression of a sequence encoding a subunit of nuclear factor  
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
XX configuration. The enzymatic nucleic acid molecule is adapted to treat  
XX cancer and is useful for down-regulating REL-A activity in a cell, for  
XX treating a patient having a condition associated with the level of REL-A.  
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
XX the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
XX antisense nucleic acid molecules are useful for treating breast, lung,  
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
XX multidrug resistant cancer. The method involves use of other drug  
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
XX gencitabine or radiation therapy. The enzymatic and antisense nucleic  
XX acid molecules are also useful for treating inflammatory disease such as  
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
XX rejection, gene therapy applications, ischaemia/reperfusion injury  
XX (central nervous system (CNS) and myocardial), glomerulonephritis,  
XX sepsis, allergic airway inflammation, inflammatory bowel disease or  
XX infection. This sequence represents the substrate of a novel enzymatic  
XX nucleic acid molecule  
XX  
XX Sequence 17 BP; 2 A; 11 C; 3 G; 0 T; 1 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
XX Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
XX Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
XX Qy 1505 CCCGAGCTCCAGGCC 1521  
XX |||||:|||||  
XX 1 CCCGAGCTCCAGGCC 17  
XX  
XX RESULT 352  
XX ADA99701 standard; DNA; 17 BP.  
XX  
XX ADA99701;  
XX  
XX 20-NOV-2003 (first entry)  
XX  
XX Human MD23 scanning oligonucleotide SEQ ID 690.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX Homo sapiens.  
XX EP1281758-A2.  
XX 05-FEB-2003.  
XX 30-JUL-2002; 2002EP-00016874.  
XX 02-AUG-2001; 2001US-00922181.  
XX (AEOM-) AEOMICA INC.  
XX Shannon M, Gu Y, Nguyen C;  
XX WPI; 2003-423107/40.  
XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MD23,  
PT MD24, MD27 or MD212, e.g. cancer.  
XX Example 8; SEQ ID NO 690; 103pp; English.  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MD23,  
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 788 CTTGAGATGATACACG 804  
Db 1 CTTGAGATGAGACACG 17  
RESULT 353  
ADB00467/C  
ID ADB00467 standard; DNA; 17 BP.  
XX AC ADB00467;  
XX 20-NOV-2003 (first entry)  
XX Homo sapiens.  
XX Human MD23 scanning oligonucleotide SEQ ID 1453.  
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX Homo sapiens.  
XX

PN EP1281758-A2.  
XX 05-FEB-2003.  
XX 30-JUL-2002; 2002EP-00016874.  
XX 02-AUG-2001; 2001US-00922181.  
XX (AEOM-) AEOMICA INC.  
XX Shannon M, Gu Y, Nguyen C;  
XX WPI; 2003-423107/40.  
XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MD23,  
PT MD24, MD27 or MD212, e.g. cancer.  
XX Example 8; SEQ ID NO 1453; 103pp; English.  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MD23,  
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 926 GSGCTGCTCGCGATCA 942  
Db 17 GTGCTGCTCGCGCTGA 1  
RESULT 354  
ADB02413  
ID ADB02413 standard; DNA; 17 BP.  
XX AC ADB02413;  
XX 20-NOV-2003 (first entry)  
XX Human MD24 scanning oligonucleotide SEQ ID 3399.  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX Homo sapiens.  
XX EP1281758-A2.  
XX 05-FEB-2003.  
XX 30-JUL-2002; 2002EP-00016874.  
XX 02-AUG-2001; 2001US-00922181.  
XX

```
PA (ABOM-) ABOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 3399; 103pp; English.
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 464 GCTTGAGGAGTCTCTGA 480
DB 1 GCTGAGCAGTCTCTGA 17
RESULT 355
ACD58046
ID ACD58046 standard; RNA; 17 BP.
AC ACD58046;
XX
XX 23-SEP-2003 (first entry)
DT
DE HCV DNazyme substrate sequence #632.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
PN
XX 17-OCT-2002.
PD
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX 08-JUN-2001; 2001US-0296876P.
XX
XX 24-OCT-2001; 2001US-0335059P.
XX
XX 05-DEC-2001; 2001US-0337055P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MACE/) MACEJAK D.
XX (MCSW/) MCSWIGGEN J.
XX (MORR/) MORRISSEY D.
XX (PAVC/) PAVCO P.
XX (LEEP/) LEE P.
XX (DRAP/) DRAPER K.
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 245; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNazyme or minus strand DNazyme sequences disclosed in the present
CC invention
XX
XX Sequence 17 BP; 2 A; 1 C; 7 G; 0 T; 7 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 1400 TGTGGATGTTGCTTTTG 1416
DB 1 UGUGGAUGAUGCGUUG 17
RESULT 356
ACD61087
ID ACD61087 standard; RNA; 17 BP.
XX
XX ACD61087;
AC
XX
XX 24-SEP-2003 (first entry)
DT
DE HCV DNazyme substrate sequence #2161.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
OS
XX WO200281494-A1.
PN
```



RNA stability; RNA expression; RNA synthesis; antisense; enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme; amberyne; G-cleaver ribozyme; decoy molecule; aptamer; HBV reverse transcriptase; Enhancer I region; viral replication; degenerative; disease state; HBV infection; HCV infection; cirrhosis; liver failure; hepatocellular carcinoma; hepatotropic; cytostatic; virucide; antiinflammatory; substrate; ss.

Hepatitis C virus.

WO200281494-A1.

17-OCT-2002.

26-MAR-2002; 2002WO-US009187.

26-MAR-2001; 2001US-00817879.

08-JUN-2001; 2001US-00877478.

08-JUN-2001; 2001US-0296876P.

24-OCT-2001; 2001US-0335059P.

05-DEC-2001; 2001US-0337055P.

(RIBO-) RIBOZYME PHARM INC.

(BLAT/) BLATT L.

(MACE/) MACEJAK D.

(MCSW/) MCSWIGGEN J.

(MORR/) MORRISSEY J.

(PAVC/) PAVCO P.

(LEEF/) LEE P.

(DRAP/) DRAPER K.

(ROBE/) ROBERTS E.

Blatt L, Macejak D, Mcswiggen J, Morrissey J, Morrissey D, Pavco P, Lee P; Draper K, Roberts E; WPI; 2003-229207/22.

Novel compound useful for treating cirrhosis, liver failure, hepatocellular carcinoma, or condition associated with hepatitis C virus infection.

Claim 1; Page 272; 387pp; English.

The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of Hepatitis C virus (HCV) or Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes, inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed are nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences, as well as oligonucleotides that specifically bind the Enhancer I region of HBV DNA. The nucleic acids may be used to modulate the expression of HBV genes and HBV viral replication. Also disclosed is a method for screening compounds and/or potential therapies directed against HBV, and compounds that modulate the expression and/or replication of HCV. The compounds and methods of the invention are useful for the treatment of degenerative and disease states related to HBV and HCV infection, replication and gene expression such as cirrhosis, liver failure, and hepatocellular carcinoma. The present sequence represents a substrate for one of the HCV DNazyme or minus strand DNazyme sequences disclosed in the present invention

Sequence 17 BP; 3 A; 5 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 52.2%; Pred. No. 1.9e+02; Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

689 GAGGCTCACTTCTTCT 705

1 GAUGACUCACUUCUUCU 17

RESULT 357

ACD62816/C

ID ACD62816 standard; RNA; 17 BP.

ACD62816;

24-SEP-2003 (first entry)

HCV minus strand DNazyme substrate sequence #735.

Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;



RESULT 358  
ACC67637  
ID ACC67637 standard; DNA; 17 BP.  
XX  
XX ACC67637;  
AC  
XX  
XX 01-JUL-2003 (first entry)  
DT  
XX  
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4884.  
XX  
XX Cytostatic; virucide; neuroprotective; neuroleptic; murine;  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; ss.  
XX  
XX Mus musculus.  
OS  
XX  
XX WO2003025176-A2.  
PN  
XX  
XX 27-MAR-2003.  
PD  
XX  
XX 17-SEP-2002; 2002WO-IB004210.  
PF  
XX  
XX 17-SEP-2001; 2001FR-00011979.  
PR  
XX  
XX (MOLE-) MOLECULAR ENGINES LAB.  
PA  
XX  
XX Telexman A, Amson R, Tuijnder M;  
PI  
XX  
XX WPI; 2003-333167/31.  
DR  
XX  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
PT  
XX  
XX Disclosure; Page 602; 738pp; French.  
PS  
XX  
XX The present invention relates to murine oligonucleotides (ACC62754-  
CC ACC6806), which are associated with tumour suppression, tumour  
CC reversion, apoptosis and virus resistance. The oligonucleotides are  
CC useful as (1) as probes and primers for detecting, identifying,  
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
CC recombinant polypeptides. The oligonucleotides are useful for preparation  
CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia  
CC  
XX  
XX Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1551 GATCCTGCACTTAACA 1567  
DB 1 GATCCTGACTTAATA 17  
RESULT 359  
ADB39727/c  
ID ADB39727 standard; DNA; 17 BP.  
XX  
XX ADB39727;  
AC  
XX  
XX 18-DEC-2003 (revised)  
DT  
XX 04-DEC-2003 (first entry)  
DT  
XX Tumour suppression/reversion associated nucleotide #50.  
DE  
XX  
XX Cytostatic; antiviral; neuroprotective; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW

diagnosis.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2003040369-A2.  
PN  
XX  
XX 15-MAY-2003.  
PD  
XX  
XX 17-SEP-2002; 2002WO-IB004219.  
PF  
XX  
XX 17-SEP-2001; 2001FR-00011981.  
PR  
XX  
XX (MOLE-) MOLECULAR ENGINES LAB.  
PA  
XX  
XX Telexman A, Amson R, Tuijnder M;  
PI  
XX  
XX WPI; 2003-441574/41.  
DR  
XX  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
PT  
XX  
XX Disclosure; Page 37; 771pp; French.  
PS  
XX  
XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
XX Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 91 GGGAGAGTGGCAGGTC 107  
DB 17 GGGAGGTTGGCAGATC 1  
RESULT 360  
ADI47981  
ID ADI47981 standard; DNA; 17 BP.  
XX  
XX ADI47981;  
AC  
XX  
XX 15-APR-2004 (first entry)  
DT  
XX  
XX Human tumour suppression/reversion-related DNA sequence SeqID484.  
DE  
XX  
XX Tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytosstatic; virucide; neuroprotective; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
XX  
XX Homo sapiens.  
OS  
XX

PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 484; 30pp; French.  
XX  
CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, indentifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1551 GATCCTGCACTCTAACA 1567  
DB 1 GATCCTGTACTCTAATA 17  
  
RESULT 361  
ABZ94171/C  
ID ABZ94171 standard; DNA; 17 BP.  
XX  
AC ABZ94171;  
XX  
DT 17-OCT-2003 (first entry)  
XX  
DE Human adenosine A1 receptor antisense fragment no.34.  
XX  
KW Human; antisense; lung dysfunction; nasal airway dysfunction;  
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KW lung inflammation; respiratory disease; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO200285308-A2.  
XX  
PD 31-OCT-2002.  
XX  
PF 23-APR-2002; 2002WO-US013135.  
XX

PR 24-APR-2001; 2001US-0286137P.  
XX  
PA (EPIG-) EPIGENESIS PHARM INC.  
XX  
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahabuddin S;  
XX  
DR WPI; 2003-229219/22.  
XX  
PT Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.  
XX  
PS Disclosure; SEQ ID NO 9413; 872pp; English.  
XX  
CC The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiquinone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, have a  
CC immunosuppressive, and cytostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of ubiquinone or  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCCAGCCTCTCCCGC 1546  
DB 17 GCCCAGCCTGTCCCGC 1  
  
RESULT 362  
ABZ95047/C  
ID ABZ95047 standard; DNA; 17 BP.  
XX  
AC ABZ95047;  
XX  
DT 17-OCT-2003 (first entry)  
XX  
DE Human adenosine A1 receptor antisense fragment no.910.  
XX  
KW Human; antisense; lung dysfunction; nasal airway dysfunction;  
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KW lung inflammation; respiratory disease; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO200285308-A2.  
XX  
PD 31-OCT-2002.  
XX  
PF 23-APR-2002; 2002WO-US013135.  
XX

PR 24-APR-2001; 2001US-0286137P.  
XX (EPIG-) EPIGENESIS PHARM INC.  
XX  
XX Nycse JW, Li Y, Sandrasaga A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahabuddin S;  
PI  
XX WPI; 2003-229219/22.  
XX  
XX Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.  
XX  
XX  
PS Disclosure; SEQ ID NO 10289; 872pp; English.  
XX  
XX The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding regions, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiquinone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,  
CC immunosuppressive, and cytostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
XX Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCAGCCTCTCCCGC 1546  
DB ||||| |  
17 GCCAGCCTGTGCCGC 1  
  
RESULT 363  
ADL48005  
ID ADL48005 standard; RNA; 17 BP.  
XX  
XX ADL48005;  
AC  
XX 20-MAY-2004 (first entry)  
DT  
XX Human IKK-gamma substrate sequence #515.  
DE  
XX  
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;  
KW substrate; ds.  
XX  
XX Unidentified.  
OS  
XX WO200281628-A2.  
PN  
XX

PD 17-OCT-2002.  
XX  
XX 03-APR-2002; 2002WO-US010512.  
PF  
XX  
XX 05-APR-2001; 2001US-00827395.  
PR  
XX 29-MAY-2001; 2001US-0294412P.  
PR  
XX 28-AUG-2001; 2001US-0315315P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
PI WPI; 2003-058513/05.  
XX  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
XX Claim 59; SEQ ID NO 1538; 317pp; English.  
PS  
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human IKK-  
CC gamma substrate sequence.  
XX  
XX Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.9e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
  
QY 697 ACTTCTCTTCCCAAG 713  
DB ||:::|:|:|  
1 ACUUCUGCUGCCCAAG 17  
  
RESULT 364  
ADL50256/c  
ID ADL50256 standard; RNA; 17 BP.  
XX  
XX ADL50256;  
AC  
XX 20-MAY-2004 (first entry)  
DT  
XX Human PKR substrate sequence #1370.  
DE  
XX  
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
XX Unidentified.  
OS  
XX WO200281628-A2.  
PN  
XX

```
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3789; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 8 A; 6 C; 1 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1400 TGTGGATGTTGCTTTG 1416
DB 17 TGTGGATGTTGCTTTG 1
RESULT 365
ADL48380
ID ADL48380 standard; RNA; 17 BP.
XX
XX ADL48380;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #890.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
```

```
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1913; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.9e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 698 CTTCTCTCTTCCCAAGT 714
DB 1 CUUCUGUGUGCCCAAGU 17
RESULT 366
ADM09485
ID ADM09485 standard; RNA; 17 BP.
XX
XX ADM09485;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor amberzyme substrate sequence #40.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor amberzyme; substrate; ss.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
```

PD	17-OCT-2002.
XX	
PF	03-APR-2002; 2002WO-USO10512.
XX	
XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
XX	
XX	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-059513/05.
XX	
DR	Noel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	
XX	Claim 9; SEQ ID NO 880; 317pp; English.
PS	
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	KappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human NOGO
CC	receptor amberzyme substrate sequence.
XX	
SQ	Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 70.6%; Pred. No. 1.9e+02;
	Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0
QY	1117 CCTTGCTGGAGCAGCTG 1133    :        : D6 1 CCCUCCUGGACGACUC 17
RESULT 367	
ADM54165/c	
ID	ADM54165 standard; mRNA; 17 BP.
XX	
AC	ADM54165;
XX	
DT	03-JUN-2004 (first entry)
XX	
DE	Human GRID mRNA substrate sequence #440.
DE	
KW	Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
KW	NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNazyme; amberyzyme; Inozyne;
KW	hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX	
OS	Homo sapiens.
OS	
FN	US2003134806-A1.
XX	
PD	17-JUL-2003.
XX	
PF	23-FEB-2001; 2001US-00792818.
XX	
PR	10-FEB-2000; 2000US-0181594P.
XX	

emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ds.  
Homo sapiens.  
WO200285309-A2.  
31-OCT-2002.  
23-APR-2002; 2002WO-US013143.  
24-APR-2001; 2001US-0286036P.  
(EPTG-) EPIGENESIS PHARM INC.  
Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S; WPI; 2003-093058/08.  
Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.  
Claim 15; SEQ ID NO 10289; 763pp; English.  
This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, cancer. Transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it  
Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1530 GCCCAGCCTCTCCCGC 1546  
Db 17 GCCCAGCCTGTGCCGC 1  
RESULT 370  
ADG63002  
ID ADG63002 standard; DNA; 17 BP.  
XX

(EPTG-) EPIGENESIS PHARM INC.  
Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S; WPI; 2003-093058/08.  
Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.  
Claim 15; SEQ ID NO 9413; 763pp; English.  
This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, cancer. Transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it  
Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1530 GCCCAGCCTCTCCCGC 1546  
Db 17 GCCCAGCCTGTGCCGC 1  
RESULT 369  
ABD18895/C  
ID ABD18895 standard; DNA; 17 BP.  
XX  
AC ABD18895;  
XX  
XX 29-JUL-2004 (first entry)  
XX  
DE Human adenosine A1 receptor oligonucleotide fragment 910.  
XX  
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;  
XX

AC ADG63002;  
XX 11-MAR-2004 (first entry)  
XX Mouse genomic DNA amplifying famj5312-derived forward PCR primer #3.  
DE Obese receptor gene; OBR gene; body weight regulation; diagnosis;  
XX prognosis; body weight disorder; obesity; cachexia; anorexia; bulimia;  
KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.  
XX Mus sp.  
OS US2002182676-A1.  
XX 05-DEC-2002.  
XX 19-FEB-2002; 2002US-00079625.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Teppner RI, Culpepper JA, White DW;  
XX WPI; 2004-050987/05.  
XX New nucleic acid encoding an Ob receptor protein is useful to provide  
XX treatment for weight disorders, particularly anorexia, cachexia, bulimia,  
XX AIDS-related wasting or cancer-related wasting, or obesity.  
XX Example 8; SEQ ID NO 27; 112pp; English.  
XX The present invention relates to the identification and characterisation  
XX of nucleotides that encode obese receptor (OBR), a receptor protein that  
XX participates in mammalian body weight regulation. The invention is useful  
XX for diagnosis and prognosis of body weight disorders including obesity,  
XX cachexia, anorexia, bulimia, AIDS (acquired immune deficiency syndrome)-  
XX related and cancer-related wasting. The present sequence is mouse genomic  
XX DNA amplifying famj5312-derived PCR primer. This primer is used in the  
XX exemplification of the invention.  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 660 CACTACCTGCGCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17  
RESULT 371  
ADG63000  
ID ADG63000 standard; DNA; 17 BP.  
XX AC ADG63000;  
XX 11-MAR-2004 (first entry)  
XX Mouse genomic DNA amplifying famj5312-derived forward PCR primer #2.  
DE Obese receptor gene; OBR gene; body weight regulation; diagnosis;  
XX prognosis; body weight disorder; obesity; cachexia; anorexia; bulimia;  
KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.

KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.  
XX Mus sp.  
XX US2002182676-A1.  
XX 05-DEC-2002.  
XX 19-FEB-2002; 2002US-00079625.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Teppner RI, Culpepper JA, White DW;  
XX WPI; 2004-050987/05.  
XX New nucleic acid encoding an Ob receptor protein is useful to provide  
XX treatment for weight disorders, particularly anorexia, cachexia, bulimia,  
XX AIDS-related wasting or cancer-related wasting, or obesity.  
XX Example 8; SEQ ID NO 25; 112pp; English.  
XX The present invention relates to the identification and characterisation  
XX of nucleotides that encode obese receptor (OBR), a receptor protein that  
XX participates in mammalian body weight regulation. The invention is useful  
XX for diagnosis and prognosis of body weight disorders including obesity,  
XX cachexia, anorexia, bulimia, AIDS (acquired immune deficiency syndrome)-  
XX related and cancer-related wasting. The present sequence is mouse genomic  
XX DNA amplifying famj5312-derived PCR primer. This primer is used in the  
XX exemplification of the invention.  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 660 CACTACCTGCGCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17  
RESULT 372  
ADK98279/C  
ID ADK98279 standard; DNA; 17 BP.  
XX AC ADK98279;  
XX 06-MAY-2004 (first entry)  
XX Primer of the invention #3999.  
XX human; single nucleotide polymorphism; SNP; ss; primer.  
XX Synthetic.  
XX JP2003259875-A.  
XX 16-SEP-2003.  
XX 08-MAR-2002; 2002JP-00064373.  
XX







Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGTCCT 109  
Db 17 GAGAGAGCCAGGTCCT 1

RESULT 376  
ACN71759  
ID ACN71759 standard; DNA; 17 BP.  
XX AC ACN71759;  
XX AC ACN71759;  
DT 02-DEC-2004 (first entry)  
XX Human GDMPLP-1 probe SEQ ID NO:8661.  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX Homo sapiens.  
XX US2004137589-A1.  
XX 15-JUL-2004.  
XX 26-NOV-2003; 2003US-00723361.  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001WO-US000670.  
PR 25-MAY-2001; 2001US-00866108.  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
XX associated with decreased expression or activity of human genome-derived  
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
XX function.  
XX Disclosure; SEQ ID NO 8661; Opp; English.  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
XX defined in the specification, a fragment of at least 8 amino acids of  
XX (S1); 95% deviation from (S1) which are conservative substitutions, and  
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A

RESULT 375  
ACN64993/c  
ID ACN64993 standard; DNA; 17 BP.  
XX AC ACN64993;  
XX AC ACN64993;  
DT 02-DEC-2004 (first entry)  
XX Human GDMPLP-1 probe SEQ ID NO:1895.  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX Homo sapiens.  
XX US2004137589-A1.  
XX 15-JUL-2004.  
XX 26-NOV-2003; 2003US-00723361.  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001WO-US000670.  
PR 25-MAY-2001; 2001US-00866108.  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
XX associated with decreased expression or activity of human genome-derived  
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
XX function.  
XX Disclosure; SEQ ID NO 1895; Opp; English.  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
XX defined in the specification, a fragment of at least 8 amino acids of  
XX (S1); 95% deviation from (S1) which are conservative substitutions, and  
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
XX pharmaceutical composition of the invention is useful for treating or  
XX preventing a disorder associated with decreased expression or activity of  
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
XX The present sequence represents a 17-mer nucleotide, used in the  
XX invention for scanning the sequence represented in ACN63102  
XX Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 268 TAGAAGACCCCAAGAG 284  
DB 1 TGGAGGAGCCCAAGAG 17  
  
RESULT 377  
ACN72785/c  
ID ACN72785 standard; DNA; 17 BP.  
XX  
AC ACN72785;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:9687.  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX

PS Disclosure; SEQ ID NO 9687; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 93 GAGAGTGGCGAGTCTCT 109  
DB 17 GAGAGTGGCGCAGTCTCT 1  
  
RESULT 378  
ACN72787/c  
ID ACN72787 standard; DNA; 17 BP.  
XX  
AC ACN72787;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:9689.  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI

XX  
DR WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
XX Disclosure; SEQ ID NO 9689; Opp; English.  
XX  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 91 GGGAGAGTGGCGCAGTGC 107  
|||||||  
DB 17 GGGAGAGTGGCGCAGTGC 1  
RESULT 379  
ACN71758  
ID ACN71758 standard; DNA; 17 BP.  
XX  
AC ACN71758;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:8660.  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
XX Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PP 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
XX (GUY/) GU Y.

PA (JIYX/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANK/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
XX Disclosure; SEQ ID NO 8660; Opp; English.  
XX  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 267 CTAGAAGAAGCCCAAGAA 283  
|||||||  
DB 1 CTGGAGAGCCCAAGAA 17  
RESULT 380  
ACN71761  
ID ACN71761 standard; DNA; 17 BP.  
XX  
AC ACN71761;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:8663.  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
XX Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PP 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
XX

```
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8663; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 9% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 270 GAAGAGCCCAAGAGAA 286
DB 1 GAGAGAGCCCAAGAGGA 17
XX
XX RESULT 381
XX ACN65741/C
XX ID ACN65741 standard; DNA; 17 BP.
XX
XX ACN65741;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:2643.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
```

```
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 2643; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 9% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as a agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 1 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 845 CTTCCAGCACCAGCCCA 861
DB 17 CTGCCAGGACCCGCCAA 1
XX
XX RESULT 382
XX ACN70453
XX ID ACN70453 standard; DNA; 17 BP.
XX
XX ACN70453;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:7355.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
```

PN	US2004137589-A1.	DE	Human GDMPLP-1 probe SEQ ID NO:7485.
XX	15-JUL-2004.	XX	Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX	26-NOV-2003; 2003US-00723361.	KW	hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX	26-MAY-2000; 2000US-0207456P.	XX	skeletal muscle function.
PR	21-SEP-2000; 2000US-0234687P.	OS	Homo sapiens.
PR	27-SEP-2000; 2000US-0236359P.	XX	US2004137589-A1.
PR	04-OCT-2000; 2000GB-00024263.	XX	15-JUL-2004.
PR	30-JAN-2001; 2001WO-US000661.	XX	26-NOV-2003; 2003US-00723361.
PR	30-JAN-2001; 2001WO-US000662.	XX	26-MAY-2000; 2000US-0207456P.
PR	30-JAN-2001; 2001WO-US000663.	PR	21-SEP-2000; 2000US-0234687P.
PR	30-JAN-2001; 2001WO-US000664.	PR	27-SEP-2000; 2000US-0236359P.
PR	30-JAN-2001; 2001WO-US000665.	PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000666.	PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000667.	PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000668.	PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000669.	PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000670.	PR	30-JAN-2001; 2001WO-US000665.
PR	05-FEB-2001; 2001US-0266860P.	PR	30-JAN-2001; 2001WO-US000666.
PR	25-MAY-2001; 2001US-00866108.	PR	30-JAN-2001; 2001WO-US000667.
XX	(GUY/) GU Y.	XX	30-JAN-2001; 2001WO-US000668.
PA	(JIY/) JI Y.	XX	30-JAN-2001; 2001WO-US000669.
PA	(PENN/) PENN S G.	XX	30-JAN-2001; 2001WO-US000670.
PA	(HANZ/) HANZEL D K.	PI	05-FEB-2001; 2001US-0266860P.
PA	(RANK/) RANK D.	XX	25-MAY-2001; 2001US-00866108.
PA	(CHEN/) CHEN W.	XX	(GUY/) GU Y.
PA	(SHAN/) SHANNON M E.	PA	(JIY/) JI Y.
XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;	PA	(PENN/) PENN S G.
PI	WPI; 2004-533378/51.	PA	(HANZ/) HANZEL D K.
XX	Novel myosin-like protein-1, useful for treating or preventing disorder	PA	(RANK/) RANK D.
PT	associated with decreased expression or activity of human genome-derived	PA	(CHEN/) CHEN W.
PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle	PA	(SHAN/) SHANNON M E.
PT	function.	XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX	Disclosure; SEQ ID NO 7355; Opp; English.	XX	WPI; 2004-533378/51.
XX	The invention relates to a novel polypeptide (I) comprising a sequence	XX	Novel myosin-like protein-1, useful for treating or preventing disorder
CC	(S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully	XX	associated with decreased expression or activity of human genome-derived
CC	defined in the specification, a fragment of at least 8 amino acids of	PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle
CC	(S1), 95% deviation from (S1) which are conservative substitutions, and	PT	function.
CC	65% identity to (S1). A polypeptide of the invention acts as an agonist or	XX	Disclosure; SEQ ID NO 7485; Opp; English.
CC	antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A	XX	The invention relates to a novel polypeptide (I) comprising a sequence
CC	pharmaceutical composition of the invention is useful for treating or	CC	(S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC	preventing a disorder associated with decreased expression or activity of	CC	defined in the specification, a fragment of at least 8 amino acids of
CC	hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.	CC	(S1), 95% deviation from (S1) which are conservative substitutions, and
CC	The present sequence represents a 17-mer nucleotide, used in the	CC	65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC	invention for scanning the sequence represented in ACN63103	CC	antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX	Sequence 17 BP; 8 A; 4 C; 5 G; 0 T; 0 U; 0 Other;	CC	pharmaceutical composition of the invention is useful for treating or
XX	Query Match 0.8%; Score 13.8; DB 1; Length 17;	CC	preventing a disorder associated with decreased expression or activity of
XX	Best Local Similarity 88.2%; Pred. No. 1.9e+02;	CC	hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	CC	The present sequence represents a 17-mer nucleotide, used in the
QY	270 GAAGAGCCCAAGAGAA 286	CC	invention for scanning the sequence represented in ACN63103
DB	1 GAAGAGCCCAAGAGAA 17	XX	Sequence 17 BP; 8 A; 4 C; 5 G; 0 T; 0 U; 0 Other;
XX	Query Match 0.8%; Score 13.8; DB 1; Length 17;	XX	Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX	Best Local Similarity 88.2%; Pred. No. 1.9e+02;	XX	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX	RESULT 383	XX	Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX	ACN70583/c	XX	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX	ACN70583 standard; DNA; 17 BP.	XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX	ACN70583;	XX	Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX	02-DEC-2004 (first entry)	XX	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX		XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 384  
ACN71762  
ID ACN71762 standard; DNA; 17 BP.  
XX  
AC ACN71762;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:8664.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 08-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUIYU/) GU Y.  
PA (JIYU/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANKZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
GU Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
WPI; 2004-533378/51.  
XX  
Novel myosin-like protein-1, useful for treating or preventing disorder  
associated with decreased expression or activity of human genome-derived  
myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
function.  
XX  
Disclosure; SEQ ID NO 8664; Opp; English.  
XX  
The invention relates to a novel polypeptide (I) comprising a sequence  
(S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
defined in the specification, a fragment of at least 8 amino acids of  
(S1), 95% deviation from (S1) which are conservative substitutions, and  
(S1), 95% deviation from (S1) which are conservative substitutions, and  
65% identity to (S1). A polypeptide of the invention acts as an agonist or  
antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
pharmaceutical composition of the invention is useful for treating or  
preventing a disorder associated with decreased expression or activity of  
hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
XX  
The present sequence represents a 17-mer nucleotide, used in the  
invention for scanning the sequence represented in ACN63103  
XX  
Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 271 AAGAAGCCCAAGAAGAG 287  
Db 1 AGGAAGCCCAAGAAGAG 17  
RESULT 385  
ACN71666  
ID ACN71666 standard; DNA; 17 BP.  
XX  
AC ACN71666;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:8568.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUIYU/) GU Y.  
PA (JIYU/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANKZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
GU Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
WPI; 2004-533378/51.  
XX  
Novel myosin-like protein-1, useful for treating or preventing disorder  
associated with decreased expression or activity of human genome-derived  
myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
function.  
XX  
Disclosure; SEQ ID NO 8568; Opp; English.  
XX  
The invention relates to a novel polypeptide (I) comprising a sequence  
(S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
defined in the specification, a fragment of at least 8 amino acids of  
(S1), 95% deviation from (S1) which are conservative substitutions, and  
65% identity to (S1). A polypeptide of the invention acts as an agonist or  
antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103

SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 292 AGGATGCCCTAAATGAG 308

Db 1 AGGATGACCTGAATGAG 17

RESULT 386

ACN72786/c

ID ACN72786 standard; DNA; 17 BP.

XX AC

XX AC

XX AC

DT 02-DEC-2004 (first entry)

DE Human GDMLP-1 probe SEQ ID NO:9688.

XX AC

XX AC

KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;

KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

KW skeletal muscle function.

XX OS

XX Homo sapiens.

XX US2004137589-A1.

XX PD 15-JUL-2004.

XX PF 26-NOV-2003; 2003US-00723361.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 30-JAN-2001; 2001WO-US000670.

XX PR 05-FEB-2001; 2001US-0266860P.

XX PR 25-MAY-2001; 2001US-00866108.

XX PA (GUY/) GU Y.

XX PA (JIY/) JI Y.

XX PA (PENN/) PENN S G.

XX PA (HANZ/) HANZEL D K.

XX PA (RANK/) RANK D.

XX PA (CHEN/) CHEN W.

XX PA (SHAN/) SHANNON M E.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX DR

XX Novel myosin-like protein-1, useful for treating or preventing disorder

XX associated with decreased expression or activity of human genome-derived

XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle

XX function.

XX PT

XX Disclosure; SEQ ID NO 9688; Opp; English.

XX PS

XX

CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103

XX SQ

Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 92 GGAGAGTGGGCGAGTCC 108

Db 17 GGAGAGTGGGCGAGTCC 1

RESULT 387

ABL52123/c

ID ABL52123 standard; DNA; 15 BP.

XX AC

XX ABL52123;

XX 12-JUL-2002 (first entry)

XX DT

XX DE Human PER1 allele specific oligonucleotide primer SEQ ID NO:48.

XX KW Human; period (Drosophila) homologue 1; PER1; polymorphic variant;

XX KW polymorphic site; genotyping; haplotyping; circadian rhythm regulation;

XX KW single nucleotide polymorphism; SNP; gene; primer; ss.

XX OS

XX Homo sapiens.

XX FH

Key Location/Qualifiers

FT misc\_feature 14

FT /\*tag= a

FT /note= "polymorphic site indicated by an ambiguity base"

XX W0200222650-A2.

XX PD 21-MAR-2002.

XX PF 13-SEP-2001; 2001WO-US028780.

XX PR 13-SEP-2000; 2000US-0232468P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Duda A, Kliem SE, Koshy B;

XX WPI; 2002-393941/42.

XX DR

XX Novel isolated human period Drosophila homolog 1 polynucleotide, useful

XX for therapeutic purposes, for studying the expression and function of the

XX polynucleotide, and for expressing the homolog.

XX Claim 17; Page 15; 162pp; English.

XX PS

XX The present invention describes an isolated human period (Drosophila)

XX homologue 1, (PER1) polynucleotide (I) comprising a sequence which is a

XX polymorphic variant for a reference sequence (ABL52077) for the PER1 gene

XX or its fragment, or a polymorphic variant of a reference sequence

XX (ABL52078) for a PER1 cDNA or its fragment. The present invention also

XX describes methods for genotyping and haplotyping the PER1 gene of an

XX individual. (I) is useful in studying the expression and function of

XX PER1, and in expressing PER1 protein for use in screening for candidate

CC drugs to treat diseases related to PER1 activity. (I) is useful for  
CC therapeutic purposes. A recombinant non-human organism transformed or  
CC transfected with (I) can be used for studying expression of the PER1  
CC isogenes in vivo, for in vivo screening and testing of drugs targeted  
CC against PER1 protein, and for testing the efficacy of therapeutic agents  
CC and compounds for disorders associated with circadian rhythm regulation.  
CC The present sequence represents an allele specific oligonucleotide primer  
CC for human PER1, which is used in the exemplification of the present  
CC invention  
XX  
XX  
SQ Sequence 15 BP; 1 A; 3 C; 8 G; 2 T; 0 U; 1 Other;  
Query Match 0.8%; Score 13.6; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1500 CCAGGCCCCAGCCT 1513  
DB 14 YCAGGCCCCAGCCT 1  
RESULT 388  
AAS95535  
ID AAS95535 standard; DNA; 15 BP.  
XX  
AC AAS95535;  
XX  
AC AAS95535;  
XX  
DT 14-FEB-2002 (first entry)  
XX  
DE Human IL8RB gene allele-specific oligonucleotide probe #11.  
XX  
XX Human; interleukin 8 receptor beta; IL8RB; ss; antiinflammatory; probe;  
KW haplotyping; haplotype pair; single nucleotide polymorphism; genotyping;  
KW gene therapy; drug screening; chronic obstructive pulmonary disease;  
KW inflammatory disease; sequencing primer; PCR primer.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200179221-A2.  
PN  
XX  
XX 25-OCT-2001.  
PD  
XX  
XX 12-APR-2001; 2001WO-US011942.  
PF  
XX  
XX 12-APR-2000; 2000US-0196734P.  
PR  
XX  
XX (GENA-) GENAISSANCE PHARM INC.  
PA  
XX  
XX Bentivegna SC, Chew A, Choi JY, Denton RR, Nandabalan K;  
PI  
XX  
XX WPI; 2002-055250/07.  
DR  
XX  
XX New polymorphic variants comprising interleukin-8 receptor beta (IL8RB)  
PT isogene, useful in expressing IL8RB protein for use in screening for  
PT candidate drugs to treat diseases related to IL8RB activity, e.g.  
PT inflammatory disorders.  
PT  
XX  
XX Claim 16; Page 13; 74pp; English.  
PS  
XX  
XX The invention relates to single nucleotide polymorphisms in the human  
CC interleukin 8 receptor beta (IL8RB) gene. A method for haplotyping the  
CC IL8RB gene in an individual comprises identifying the nucleotide at one  
CC or more polymorphic sites and determining whether one of the copies of  
CC the gene is defined by one of the IL8RB haplotypes given in the  
CC specification or whether both copies are defined by a haplotype pair.  
CC This method is useful in genotyping, whereby all possible haplotype pairs  
CC can be assigned to specific genotypes. An association between a trait and  
CC a haplotype or haplotype pair of the IL8RB gene can be identified by  
CC comparing the frequency of the haplotype or haplotype pair in a  
CC population exhibiting the trait with the frequency of the haplotype or  
CC haplotype pair in a reference population, where a higher haplotype  
CC frequency in the trait population indicates the trait is associated with  
CC the haplotype or haplotype pair. IL8RB and its corresponding DNA are used

CC for studying the expression and function of IL8RB, for use in screening  
CC for candidate drugs to treat diseases related to IL8RB activity, such as  
CC chronic obstructive pulmonary disease and other inflammatory disorders.  
CC The sequences are also useful for studying the effect of variation on the  
CC biological activity of IL8RB as well as on the binding affinity of  
CC candidate drugs targeting IL8RB. Sequences AAS95525-AAS95579 represent  
CC allele-specific oligonucleotide probes, sequencing primers and PCR  
CC primers used to detect IL8RB gene polymorphisms  
XX  
XX Sequence 15 BP; 5 A; 4 C; 4 G; 1 T; 0 U; 1 Other;  
SQ  
Query Match 0.8%; Score 13.6; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.3e+02;  
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 197 CAACGGGGTGAAC 210  
DB 1 CAACGGGGTGAAC 14  
RESULT 389  
AAT54903  
ID AAT54903 standard; RNA; 15 BP.  
XX  
AC AAT54903;  
XX  
XX 25-MAR-2003 (revised)  
DT 07-APR-1997 (first entry)  
XX  
XX Mouse rela hammerhead ribozyme target sequence (nt. position 1250).  
DE  
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;  
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;  
KW intercellular adhesion molecule; rel A; tumour necrosis factor;  
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;  
KW translocation; chronic myelogenous leukaemia; CML; cancer;  
KW Philadelphia chromosome; inflammation; autoimmune disease;  
KW atherosclerosis; myocardial infarction; stroke; restenosis;  
KW transplant rejection; rheumatoid arthritis; psoriasis;  
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;  
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;  
SS.  
XX Mus musculus.  
OS  
XX  
XX WO9523225-A2.  
PN  
XX  
XX 31-AUG-1995.  
PD  
XX  
XX 23-FEB-1995; 95WO-IB000156.  
PF  
XX  
XX 23-FEB-1994; 94US-00201109.  
PR  
XX 29-MAR-1994; 94US-00218934.  
PR  
XX 04-APR-1994; 94US-00222795.  
PR  
XX 07-APR-1994; 94US-00224483.  
PR  
XX 15-APR-1994; 94US-00227958.  
PR  
XX 15-APR-1994; 94US-00228041.  
PR  
XX 18-MAY-1994; 94US-00245736.  
PR  
XX 06-JUL-1994; 94US-00271280.  
PR  
XX 15-AUG-1994; 94US-00291932.  
PR  
XX 16-AUG-1994; 94US-00291433.  
PR  
XX 17-AUG-1994; 94US-00292620.  
PR  
XX 19-AUG-1994; 94US-00293520.  
PR  
XX 02-SEP-1994; 94US-00300000.  
PR  
XX 08-SEP-1994; 94US-00303039.  
PR  
XX 23-SEP-1994; 94US-00311486.  
PR  
XX 23-SEP-1994; 94US-00311749.  
PR  
XX 28-SEP-1994; 94US-00314397.  
PR  
XX 03-OCT-1994; 94US-00316771.  
PR  
XX 07-OCT-1994; 94US-00319492.  
PR  
XX 11-OCT-1994; 94US-00321993.  
PR  
XX 04-NOV-1994; 94US-00334847.  
PR  
XX 10-NOV-1994; 94US-00337608.



```
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX (RIBO-) RIBOZYME PHARM INC.
XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Uzman N, Wincott PE, Woolf T;
XX WPI; 1995-351090/45.
XX Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX Claim 2; Page 226; 407pp; English.
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves rRNA at the
XX nucleotide base position indicated in the DE line. The rRNA gene product
XX is a subunit of the transcriptional regulator NF-kappaB and is implicated
XX specifically in the induction of inflammatory responses. Regions of the
XX mRNA that do not form secondary folding structures and that contain
XX potential hammerhead and hairpin ribozyme cleavage sites were identified
XX by computer analysis. Ribozymes directed against these mRNA sequences
XX were designed and synthesised with modifications that improve their
XX nuclease resistance. The ribozymes are designed to cleave the target
XX sequences and thereby inhibit rRNA expression, making them potentially
XX useful for treating rheumatoid arthritis, restenosis and asthma as well
XX as for increasing tolerance to transplanted tissues. The potential
XX immunosuppressive properties of a ribozyme that cleaves rRNA means
XX that uses are limited to local delivery, acute indications or ex vivo
XX treatment. (Updated on 25-MAR-2003 to correct PI field.)
XX SQ Sequence 15 BP; 2 A; 8 C; 3 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 86.7%; Pred. No. 1.4e+02;
XX Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 1507 CCAGCCTCCAGGCC 1521
Db 1 CCAGCCUCCAGGCUC 15
XX
RESULT 390
AAV31969/c
ID AAV31969 standard; DNA; 15 BP.
XX
XX AAV31969;
XX
XX 21-AUG-1998 (first entry)
XX
XX Peptide nucleic acid probe 112.
XX
XX Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
XX ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
XX
XX Synthetic.
XX Mycobacterium sp.
XX
XX Key Location/Qualifiers
XX modified_base 1..15
XX /tag= a
XX /note= "This sequence contains a polyamide backbone
XX instead of a deoxyribose backbone"
XX
XX WO9815648-A1.
XX
XX 16-APR-1998.
XX
XX Stender H, Lund K, Mollerup TA;
XX
```

```
PF 03-OCT-1997; 97WO-DK000425.
XX
XX 04-OCT-1996; 96DK-00001096.
XX 18-OCT-1996; 96DK-00001156.
XX 05-MAY-1997; 97DK-00000512.
XX (DAKO-) DAKO AS.
XX
XX Stender H, Lund K, Mollerup TA;
XX WPI; 1998-240831/21.
XX
XX Peptide nucleic acid probes for detection of ribosomal nucleic acid of
XX mycobacteria - allow differentiation between species of tuberculosis
XX complex and others and can penetrate cell membranes without pretreatment.
XX Claim 22; Page 67; 106pp; English.
XX
XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe
XX used in the method of the invention, to detect ribosomal nucleic acid of
XX mycobacteria. The probes are used, in situ or in vitro, for detection of
XX the Mycobacterium tuberculosis complex (MTC), specifically M.
XX tuberculosis, and especially in sputum samples, but also in other body
XX fluids, biopsy specimens, foods, soil, air and water. Particularly, they
XX are used to diagnose, stage or monitor infection, or for identification
XX of drug-resistant strains (which generally have mutations in rRNA)
XX
XX SQ Sequence 15 BP; 2 A; 3 C; 1 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 1.4e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 177 AAGGAATTCAAAAT 191
Db 15 AAGGAATTCAAAAT 1
XX
RESULT 391
AAV31970/c
ID AAV31970 standard; DNA; 15 BP.
XX
XX AAV31970;
XX
XX 21-AUG-1998 (first entry)
XX
XX Peptide nucleic acid probe 113.
XX
XX Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
XX ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
XX
XX Synthetic.
XX Mycobacterium sp.
XX
XX Key Location/Qualifiers
XX modified_base 1..15
XX /tag= a
XX /note= "This sequence contains a polyamide backbone
XX instead of a deoxyribose backbone"
XX
XX WO9815648-A1.
XX
XX 16-APR-1998.
XX
XX 03-OCT-1997; 97WO-DK000425.
XX
XX 04-OCT-1996; 96DK-00001096.
XX 18-OCT-1996; 96DK-00001156.
XX 05-MAY-1997; 97DK-00000512.
XX (DAKO-) DAKO AS.
XX
XX Stender H, Lund K, Mollerup TA;
XX
```



```
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1

RESULT 394
AAAX31728/c
ID AAAX31728 standard; DNA; 15 BP.
XX
XX
AC AAAX31728,
XX
XX 21-MAY-1999 (first entry)
XX
XX
XX Transcript tag sequence increased in pancreatic and colorectal cancer.
XX
XX Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
XX diagnosis; prognosis; treatment; ss.
XX
XX Homo sapiens.
XX
XX W09853319-A2.
XX
XX 26-NOV-1998.
XX
XX 20-MAY-1998; 98WO-US010277.
XX
XX 21-MAY-1997; 97US-0047352P.
XX
XX (UYJO ) UNIV JOHNS HOPKINS.
XX
XX Vogelstein B, Kinzler KW;
XX
XX WPI; 1999-070161/06.
XX
XX Use of isolated gene transcripts - useful for developing products for the
XX diagnosis, prognosis and treatment of cancers, particularly colon and
XX pancreatic cancer.
XX
XX Disclosure; Page 73; 120pp; English.
XX
XX AAAX30947-31815 represent tag sequences of transcripts that are
XX differentially expressed in colorectal cancer, in pancreatic cancer, or
XX in both. The tag sequences can be used to identify genes by matching the
XX tag to a gen data base member, or by using the tag sequences as probes to
XX isolate unidentified genes from cDNA libraries. The tag sequences can
XX also be used in a method for diagnosing colon or pancreatic cancer in a
XX sample suspected of being neoplastic. The method comprises comparing the
XX level of at least one transcript in a first sample of a tissue to a
XX second sample, where the first sample is a colonic tissue suspected of
XX being neoplastic and the second sample is a normal human colonic tissue.
XX The transcript is identified by a tag selected from AAAX30947-31815. The
XX methods of the invention can be used in the diagnosis, prognosis and
XX treatment of cancer
XX
XX Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1

RESULT 395
AAF50848
ID AAF50848 standard; DNA; 15 BP.
XX
XX AAF50848;
AC AAF50848;
XX
```

```
DT 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #1808.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antiporiatic;
XX cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX W0200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 72; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 1.4e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 532 TGCTGGAGAACGACC 546
Db 1 TGCTGGAGAACGACC 15

RESULT 396
ABK32682/c
ID ABK32682 standard; DNA; 15 BP.
XX
XX ABK32682;
XX
XX 23-APR-2002 (first entry)
XX
XX Human colorectal and pancreatic cancer SAGE tag #49.
XX
```

KW	Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;	
KW	serial analysis of gene expression; diagnostic; prognostic; probe;	
KW	cancer marker; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	US6333152-B1.	
XX		
PD	25-DEC-2001.	
XX		
PF	20-MAY-1998; 98US-00081646.	
XX		
PR	20-MAY-1998; 98US-00081646.	
XX		
PA	(UYJO ) UNIV JOHNS HOPKINS.	
XX		
PI	Vogelstein B, Kinzler KW, Zhang L, Zhou W;	
XX		
DR	WPI; 2002-153821/20.	
XX		
PT	New human nucleic acid containing specific SAGE tags, useful as	
PT	diagnostic markers for cancer, also derived probes.	
XX		
PS	Disclosure; Col 87; 161pp; English.	
XX		
CC	The invention relates to an isolated, purified human nucleic acid (I)	
CC	that has the same sequence as a mRNA found in humans and is a SAGE	
CC	(serial analysis of gene expression) tag comprising a single stranded	
CC	probe containing at least 10 consecutive nucleotides. SAGE tags, are	
CC	diagnostic and prognostic markers of cancer, especially of the colon and	
CC	pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer	
CC	SAGE tags of the invention	
XX		
SQ	Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;	
	Query Match 0.8%; Score 13.4; DB 1; Length 15;	
	Best Local Similarity 93.3%; Pred. No. 1.4e+02;	
	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	807 GCTCAGCAGGCCATG 821	
Db	15 GCCCAGCAGGCCATG 1	
RESULT 398		
ABX01805		
ID	ABX01805 standard; RNA; 15 BP.	
XX		
AC	ABX01805;	
XX		
DT	23-DEC-2002 (first entry)	
XX		
DE	Hepatitis C virus (HCV) ribozyme related RNA sequence #74.	
XX		
KW	Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;	
KW	HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;	
KW	liver failure; hepatocellular carcinoma; HCV infection; drug therapy;	
KW	type I interferon; interferon alpha; interferon beta; cytostatic; ss;	
KW	interferon gamma; consensus interferon; hepatotropic; antiinflammatory.	
XX		
OS	Unidentified.	
XX		
PN	US2002082225-A1.	
XX		
PD	27-JUN-2002.	
XX		
PF	23-MAR-1999; 99US-00274553.	
XX		
PR	23-MAR-1999; 99US-00274553.	
XX		
PA	(BLAT/) BLATT L.	
PA	(MCSW/) MCSWIGGEN J A.	
PA	(ROBE/) ROBERTS B.	
PA	(PAVC/) PAVCO P A.	
PA	(MACE/) MACEJACK D.	
XX		
PI	Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;	
XX		
DR	WPI; 2002-617759/66.	
XX		
PT	New ribozymes targeting RNA derived from hepatitis C virus inhibit viral	
PT	replication and are useful to treat hepatitis C virus infections and	
PT	cirrhosis, liver failure or hepatocellular carcinoma.	
XX		
PS	Disclosure; SEQ ID NO 1587; 80pp; English.	
XX		
CC	The present invention relates to enzymatic nucleic acids which	
CC	specifically cleave RNA derived from Hepatitis C virus (HCV). The	
CC	enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin	
CC	(HP) motif where the binding arms comprise sequences complementary to one	
CC	of the substrate sequences defined in the specification. The HCV	
CC	ribozymes are useful for modulating the expression and/or replication of	

KW	Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;	
KW	serial analysis of gene expression; diagnostic; prognostic; probe;	
KW	cancer marker; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	US6333152-B1.	
XX		
PD	25-DEC-2001.	
XX		
PF	20-MAY-1998; 98US-00081646.	
XX		
PR	20-MAY-1998; 98US-00081646.	
XX		
PA	(UYJO ) UNIV JOHNS HOPKINS.	
XX		
PI	Vogelstein B, Kinzler KW, Zhang L, Zhou W;	
XX		
DR	WPI; 2002-153821/20.	
XX		
PT	New human nucleic acid containing specific SAGE tags, useful as	
PT	diagnostic markers for cancer, also derived probes.	
XX		
PS	Disclosure; Col 87; 161pp; English.	
XX		
CC	The invention relates to an isolated, purified human nucleic acid (I)	
CC	that has the same sequence as a mRNA found in humans and is a SAGE	
CC	(serial analysis of gene expression) tag comprising a single stranded	
CC	probe containing at least 10 consecutive nucleotides. SAGE tags, are	
CC	diagnostic and prognostic markers of cancer, especially of the colon and	
CC	pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer	
CC	SAGE tags of the invention	
XX		
SQ	Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;	
	Query Match 0.8%; Score 13.4; DB 1; Length 15;	
	Best Local Similarity 93.3%; Pred. No. 1.4e+02;	
	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	807 GCTCAGCAGGCCATG 821	
Db	15 GCCCAGCAGGCCATG 1	
RESULT 397		
ABK32073/c		
ID	ABK32073 standard; DNA; 15 BP.	
XX		
AC	ABK32073;	
XX		
DT	23-APR-2002 (first entry)	
XX		
DE	Human colon cancer SAGE tag #174.	
XX		
KW	Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;	
KW	serial analysis of gene expression; diagnostic; prognostic; probe;	
KW	cancer marker; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	US6333152-B1.	
XX		
PD	25-DEC-2001.	
XX		
PF	20-MAY-1998; 98US-00081646.	
XX		
PR	20-MAY-1998; 98US-00081646.	
XX		
PA	(UYJO ) UNIV JOHNS HOPKINS.	
XX		
PI	Vogelstein B, Kinzler KW, Zhang L, Zhou W;	
XX		
DR	WPI; 2002-153821/20.	

CC HCV. They can be used to treat cirrhosis, liver failure and/or  
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating  
 CC a condition associated with HCV infection in conjunction with one or more  
 CC other drug therapies, particularly type I interferon, especially  
 CC interferon alpha, beta or gamma or consensus interferon. The present  
 CC sequence represents a RNA sequence of unknown function. Note: The present  
 CC sequence is given in the sequence data but is not mentioned elsewhere in  
 CC the specification. The complete sequence data for this patent was  
 CC obtained in electronic format directly from the USPTO web site at  
 CC seqdata.uspto.gov/psipdIDEntry.html  
 XX  
 SQ Sequence 15 BP; 3 A; 8 C; 3 G; 0 T; 1 U; 0 Other;  
 Query Match 0.8%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 1.4e+02;  
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 1509 AGCTCCAGGCCCC 1523  
 Db 1 AGCCUCCAGGACCC 15  
 RESULT 399  
 ID ABX01804  
 AC ABX01804 standard; RNA; 15 BP.  
 XX  
 AC ABX01804;  
 XX  
 DT 23-DEC-2002 (first entry)  
 XX  
 DE Hepatitis C virus (HCV) ribozyme related RNA sequence #73.  
 XX  
 KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;  
 KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;  
 KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;  
 KW type I interferon; interferon alpha; interferon beta; cytostatic; ss;  
 KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory.  
 XX  
 OS Unidentified.  
 XX  
 PN US2002082225-A1.  
 XX  
 PD 27-JUN-2002.  
 XX  
 PF 23-MAR-1999; 99US-00274553.  
 XX  
 PR 23-MAR-1999; 99US-00274553.  
 XX  
 PA (BLATT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 PA (ROBE/) ROBERTS B.  
 PA (PAVC/) PAVCO P A.  
 PA (MACE/) MACEJACK D.  
 XX  
 PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;  
 XX  
 DR WPI; 2002-617759/66.  
 XX  
 PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral  
 PT replication and are useful to treat hepatitis C virus infections and  
 PT cirrhosis, liver failure or hepatocellular carcinoma.  
 XX  
 PS Disclosure; SEQ ID NO 1586; 80pp; English.  
 XX  
 CC The present invention relates to enzymatic nucleic acids which  
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The  
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin  
 CC (HP) motif where the binding arms comprise sequences complementary to one  
 CC of the substrate sequences defined in the specification. The HCV  
 CC ribozymes are useful for modulating the expression and/or replication of  
 CC HCV. They can be used to treat cirrhosis, liver failure and/or  
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating  
 CC a condition associated with HCV infection in conjunction with one or more

CC other drug therapies, particularly type I interferon, especially  
 CC interferon alpha, beta or gamma or consensus interferon. The present  
 CC sequence represents a RNA sequence of unknown function. Note: The present  
 CC sequence is given in the sequence data but is not mentioned elsewhere in  
 CC the specification. The complete sequence data for this patent was  
 CC obtained in electronic format directly from the USPTO web site at  
 CC seqdata.uspto.gov/psipdIDEntry.html  
 XX  
 SQ Sequence 15 BP; 3 A; 8 C; 3 G; 0 T; 1 U; 0 Other;  
 Query Match 0.8%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 1.4e+02;  
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 1508 CAGCTCCAGGCCCC 1522  
 Db 1 CAGCCUCCAGGACCC 15  
 RESULT 400  
 ID AAV70490  
 AC AAV70490 standard; DNA; 16 BP.  
 XX  
 AC AAV70490;  
 XX  
 DT 08-APR-1999 (first entry)  
 XX  
 DE Sequence ID# 68 from patent specification WO9850403.  
 XX  
 KW Nucleic acid detection; nucleic acid characterisation; hybridisation;  
 KW infection; disease; cancer; forensic; paternity; multiplexing; ss.  
 XX  
 OS Unidentified.  
 XX  
 PN WO9850403-A1.  
 XX  
 PD 12-NOV-1998.  
 XX  
 PF 05-MAY-1998; 98WO-US003194.  
 XX  
 PR 05-MAY-1997; 97US-00851588.  
 PR 19-SEP-1997; 97US-00934097.  
 PR 03-MAR-1998; 98US-00034205.  
 XX  
 PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
 XX  
 PI Dong F, Lyamichiev VI, Prudent JR, Fors L, Neri BP, Brow MAD;  
 PI Anderson TA, Dahlberg JE;  
 XX  
 DR WPI; 1998-610317/51.  
 XX  
 PT Detection and characterisation of nucleic acid sequences - by mixing a  
 PT folded target and one or more probes to form a probe/folded target  
 PT complex and detecting and characterising the complexes.  
 XX  
 PS Disclosure; Page 180; 279pp; English.  
 XX  
 CC The invention relates to methods and compositions of detection and  
 CC characterisation of nucleic acid sequences and sequence changes. One  
 CC method of detection and characterisation comprises: (a) providing: (i) a  
 CC folded target having a DNA sequence comprising at least 1 double stranded  
 CC region and at least 1 single stranded region; and (ii) at least 1 probe  
 CC complementary to at least a portion of the folded target; and (b) mixing  
 CC the target and probes so that the probe hybridises to form a probe  
 CC /folded target complex. Also provided are methods for determination of  
 CC structure formation in nucleic acid targets; for analysing folded nucleic  
 CC acids targets; and for analysis of nucleic acid structures. The methods  
 CC can be used for the detection and characterisation of nucleic acid  
 CC sequences to detect the presence of pathogenic nucleic acid sequences  
 CC indicative of an infection, the presence of variants or alleles of  
 CC mammalian genes associated with disease and cancers, and the  
 CC identification of the source of nucleic acids found in forensic samples,  
 CC as well as in paternity determinations. The methods allow simultaneous

CC	analysis of both strands (e.g. the sense and antisense strands) and are	CC	as well as in paternity determinations. The methods allow simultaneous
CC	ideal for high-level multiplexing. The products produced are amenable to	CC	analysis of both strands (e.g. the sense and antisense strands) and are
CC	qualitative, quantitative and positional analysis. The methods may be	CC	ideal for high-level multiplexing. The products produced are amenable to
CC	performed in solution or in the solid phase (e.g. on a solid support).	CC	qualitative, quantitative and positional analysis. The methods may be
CC	The methods are powerful in that they allow for analysis of longer	CC	performed in solution or in the solid phase (e.g. on a solid support).
CC	fragments of nucleic acid than current methodologies. The present	CC	The methods are powerful in that they allow for analysis of longer
CC	sequence represents the sequence no:68 in the specification for which no	CC	fragments of nucleic acid than current methodologies. The present
CC	information is provided	CC	sequence represents the sequence no:67 in the specification for which no
XX	Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;	XX	information is provided
SQ	Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;	SQ	Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 16;			
Best Local Similarity 93.3%; Pred. No. 1.7e+02;			
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
QY	1508 CAGCCTCCAGGCCCC 1522	QY	1508 CAGCCTCCAGGCCCC 1522
DB	2 CAGCCTCCAGGCCCC 16	DB	2 CAGCCTCCAGGCCCC 16
RESULT 401			
AAV70489	AAV70489 standard; DNA; 16 BP.	AAV70489	AAV70489 standard; DNA; 16 BP.
XX	AAV70489;	XX	AAV70489;
AC	AAV70489;	AC	AAV70489;
DT	08-APR-1999 (first entry)	DT	08-APR-1999 (first entry)
XX	Sequence ID# 67 from patent specification WO9850403.	XX	24-MAR-1999 (first entry)
DE	Nucleic acid detection; nucleic acid characterisation; hybridisation;	DE	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	infection; disease; cancer; forensic; paternity; multiplexing; ss.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
KW	Unidentified.	KW	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	Unidentified.	KW	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
OS	Unidentified.	KW	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	Unidentified.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PN	WO9850403-A1.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	WO9850403-A1.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PD	12-NOV-1998.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	12-NOV-1998.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PF	05-MAY-1998; 98WO-US003194.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	05-MAY-1998; 98WO-US003194.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PR	05-MAY-1997; 97US-00851588.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PR	19-SEP-1997; 97US-00934097.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PR	03-MAR-1998; 98US-00034205.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	03-MAR-1998; 98US-00034205.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	(THIR-) THIRD WAVE TECHNOLOGIES INC.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PA	(THIR-) THIRD WAVE TECHNOLOGIES INC.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	(THIR-) THIRD WAVE TECHNOLOGIES INC.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PI	Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PI	Anderson TA, Dahlberg JE;	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	Anderson TA, Dahlberg JE;	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
DR	WPI; 1998-610317/51.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	WPI; 1998-610317/51.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	WPI; 1998-610317/51.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PT	Detection and characterisation of nucleic acid sequences - by mixing a	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PT	folded target and one or more probes to form a probe/folded target	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PT	complex and detecting and characterising the complexes.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	complex and detecting and characterising the complexes.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	complex and detecting and characterising the complexes.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
PS	Disclosure; Page 180; 279pp; English.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	Disclosure; Page 180; 279pp; English.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX	Disclosure; Page 180; 279pp; English.	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	The invention relates to methods and compositions of detection and	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	characterisation of nucleic acid sequences and sequence changes. One	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	method of detection and characterisation comprises: (a) providing: (i) a	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	folded target having a DNA sequence comprising at least 1 double stranded	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	region and at least 1 single stranded region; and (ii) at least 1 probe	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	complementary to at least a portion of the folded target; and (b) mixing	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	the target and probes so that the probe hybridises to form a probe	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	/folded target complex. Also provided are methods for determination of	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	structure formation in nucleic acid targets; for analysing folded nucleic	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	acids targets; and for analysis of nucleic acid structures. The methods	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	can be used for the detection and characterisation of nucleic acid	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	sequences to detect the presence of pathogenic nucleic acid sequences	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	indicative of an infection, the presence of variants or alleles of	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	mammalian genes associated with disease and cancers, and the	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
CC	identification of the source of nucleic acids found in forensic samples,	XX	Triple helix third strand of dystrophin gene nucleotides 4480-4495.

XX SQ Sequence 16 BP; 0 A; 4 C; 1 G; 11 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 271 AAGAAGCCAGAGA 285  
Db 15 AAGAAGCCAGAGA 1  
RESULT 403  
ABL46101  
ID ABL46101 standard; DNA; 16 BP.  
XX AC ABL46101;  
XX DT 26-APR-2002 (first entry)  
XX DE Hepatitis C virus PCR primer SEQ ID NO:68.  
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;  
KW characterisation; identification; nucleic acid structure; diagnosis;  
KW PCR primer; probe; ss.  
XX OS Hepatitis C virus.  
OS Synthetic.  
XX WO200198537-A2.  
XX PN 27-DEC-2001.  
XX PD 15-JUN-2001; 2001WO-US019401.  
XX PF 17-JUN-2000; 2000US-0212308P.  
XX PR 15-JUN-2001; 2001US-00212308.  
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX LYamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX WPI; 2002-049698/06.  
XX PT Identifying oligonucleotides hybridizing to nucleic acids containing  
PT secondary structure, useful in clinical diagnosis, comprises identifying  
PT primers that interact with the target to form an extension product under  
PT amplification conditions.  
XX PS Example 8; Page 370; 409pp; English.  
XX The present invention describes a method for identifying oligonucleotides  
CC with desired hybridisation properties to nucleic acid targets containing  
CC secondary structure. The method comprises amplifying a target nucleic  
CC acid having at least one accessible and one inaccessible site. Primers  
CC that form an extension product are identified as the oligonucleotides  
CC which can interact with the folded target nucleic acid. Oligonucleotides  
CC from the present invention can be used in novel detection methods for  
CC clinical diagnostic purposes, including the detection and identification  
CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
CC sequences used in the exemplification of the present invention  
XX SQ Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16  
RESULT 405  
ADK82290  
ID ADK82290 standard; DNA; 16 BP.  
XX AC ADK82290;  
XX DT 03-JUN-2004 (first entry)  
XX DE Nucleic acid analysis method associated oligonucleotide seqid 67.  
XX

RESULT 404  
ABL46100  
ID ABL46100 standard; DNA; 16 BP.  
XX AC ABL46100;  
XX DT 26-APR-2002 (first entry)  
XX DE Hepatitis C virus PCR primer SEQ ID NO:67.  
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;  
KW characterisation; identification; nucleic acid structure; diagnosis;  
KW PCR primer; probe; ss.  
XX OS Hepatitis C virus.  
OS Synthetic.  
XX WO200198537-A2.  
XX PN 27-DEC-2001.  
XX PD 15-JUN-2001; 2001WO-US019401.  
XX PF 17-JUN-2000; 2000US-0212308P.  
XX PR 15-JUN-2001; 2001US-00212308.  
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX LYamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX WPI; 2002-049698/06.  
XX PT Identifying oligonucleotides hybridizing to nucleic acids containing  
PT secondary structure, useful in clinical diagnosis, comprises identifying  
PT primers that interact with the target to form an extension product under  
PT amplification conditions.  
XX PS Example 8; Page 370; 409pp; English.  
XX The present invention describes a method for identifying oligonucleotides  
CC with desired hybridisation properties to nucleic acid targets containing  
CC secondary structure. The method comprises amplifying a target nucleic  
CC acid having at least one accessible and one inaccessible site. Primers  
CC that form an extension product are identified as the oligonucleotides  
CC which can interact with the folded target nucleic acid. Oligonucleotides  
CC from the present invention can be used in novel detection methods for  
CC clinical diagnostic purposes, including the detection and identification  
CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
CC sequences used in the exemplification of the present invention  
XX SQ Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16  
RESULT 405  
ADK82290  
ID ADK82290 standard; DNA; 16 BP.  
XX AC ADK82290;  
XX DT 03-JUN-2004 (first entry)  
XX DE Nucleic acid analysis method associated oligonucleotide seqid 67.  
XX

KW	nucleic acid analysis; hepatitis C virus;	XX	18-JUL-2000; 2000US-00402618.	PF
KW	non-contiguous single-stranded region; NCSR; cleavage structure;	XX		PF
KW	clinical; diagnostic; microorganism detection;	PR	05-MAY-1997; 97US-00851588.	PR
KW	microorganism identification; ss.	PR	19-SEP-1997; 97US-00934097.	PR
XX		PR	03-MAR-1998; 98US-00034205.	PR
OS	Synthetic.	XX		XX
PN	US6709815-B1.	PA	(THIR-) THIRD WAVE TECHNOLOGIES INC.	PA
PN		XX		XX
PD	23-MAR-2004.	PI	Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;	PI
XX		PI	Anderson TA, Dahlberg JE;	PI
XX		XX	WPI; 2004-256067/24.	XX
PF	18-JUL-2000; 2000US-00402618.	DR		DR
XX		XX		XX
PR	05-MAY-1997; 97US-00851588.	XX	Analyzing nucleic acids, comprises mixing target nucleic acid such as	XX
PR	19-SEP-1997; 97US-00934097.	PT	hepatitis C virus nucleic acid, bridging oligonucleotide, second	PT
PR	03-MAR-1998; 98US-00034205.	PT	oligonucleotide and cleavage agent to form cleavage structure.	PT
XX		XX	Disclosure; SEQ ID NO 67; 143pp; English.	XX
PA	(THIR-) THIRD WAVE TECHNOLOGIES INC.	XX	The invention describes a method of analysing nucleic acids comprising	XX
XX		CC	providing a target nucleic acid, e.g. hepatitis C virus nucleic acid	CC
PI	Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;	CC	having non-contiguous single-stranded regions (NCSR) separated by an	CC
PI	Anderson TA, Dahlberg JE;	CC	intervening region, a bridging oligonucleotide capable of binding to the	CC
XX		CC	first and second NCSR; a second oligonucleotide binding to a portion of	CC
XX	WPI; 2004-256067/24.	CC	the first NCSR and a cleavage agent, and mixing the contents to form a	CC
XX	Analyzing nucleic acids, comprises mixing target nucleic acid such as	CC	cleavage structure. The method is useful for analysing nucleic acids,	CC
PT	hepatitis C virus nucleic acid, bridging oligonucleotide, second	CC	e.g. hepatitis C virus nucleic acid useful for clinical diagnostic	CC
PT	oligonucleotide and cleavage agent to form cleavage structure.	CC	purposes and detection and identification of pathogenic microorganisms	CC
XX		CC	such as hepatitis C virus. This sequence represents an oligonucleotide	CC
XX	Disclosure; SEQ ID NO 67; 143pp; English.	CC	associated with the nucleic acid analysis method of the invention.	CC
XX	The invention describes a method of analysing nucleic acids comprising	XX	Sequence 16 BP; 3 A; 8 C; 3 G; 1 T; 0 U; 0 Other;	XX
CC	providing a target nucleic acid, e.g. hepatitis C virus nucleic acid	XX	Query Match 0.8%; Score 13.4; DB 1; Length 16;	XX
CC	having non-contiguous single-stranded regions (NCSR) separated by an	XX	Best Local Similarity 93.3%; Pred. No. 1.7e+02;	XX
CC	intervening region, a bridging oligonucleotide capable of binding to the	XX	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	XX
CC	first and second NCSR; a second oligonucleotide binding to a portion of	QY	1508 CAGCCTCCAGGCC 1522	QY
CC	the first NCSR and a cleavage agent, and mixing the contents to form a	DB		DB
CC	cleavage structure. The method is useful for analysing nucleic acids,		2 CAGCCTCCAGGCC 16	
CC	e.g. hepatitis C virus nucleic acid useful for clinical diagnostic			
CC	purposes and detection and identification of pathogenic microorganisms			
CC	such as hepatitis C virus. This sequence represents an oligonucleotide			
CC	associated with the nucleic acid analysis method of the invention.			
XX	Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;			
XX	Query Match 0.8%; Score 13.4; DB 1; Length 16;			
XX	Best Local Similarity 93.3%; Pred. No. 1.7e+02;			
XX	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
QY	1508 CAGCCTCCAGGCC 1522			
DB				
	2 CAGCCTCCAGGCC 16			
RESULT 406				
ADK82291				
ID	ADK82291 standard; DNA; 16 BP.			
XX				
AC	ADK82291;			
XX				
DT	03-JUN-2004 (first entry)			
XX				
DE	Nucleic acid analysis method associated oligonucleotide seqid 68.			
XX				
KW	nucleic acid analysis; hepatitis C virus;			
KW	non-contiguous single-stranded region; NCSR; cleavage structure;			
KW	clinical; diagnostic; microorganism detection;			
KW	microorganism identification; ss.			
XX				
OS	Synthetic.			
XX				
PN	US6709815-B1.			
XX				
PD	23-MAR-2004.			



XX Letourneur O;  
PI WPI; 2004-259482/25.  
DR P-PSDB; ADM80153.  
XX  
PT New recombinant DNA encoding chimeric protein, useful for in vitro  
PT diagnosis of viral infections, comprises sequences encoding epitopic  
PT regions, a linker and a binding region.  
XX  
PS Claim 5; SEQ ID NO 11; 33pp; French.  
XX  
CC The invention relates to a novel recombinant DNA (I) encoding a  
CC recombinant chimeric protein (II). The protein consists of at least two  
CC nucleotide fragments, each encoding an epitopic region of at least one  
CC microorganism; at least one sequence encoding a linker, and at least one  
CC sequence encoding a binding region. The DNA and/or protein are used for  
CC in vitro diagnosis, especially of virus-related diseases, specifically  
CC HIV-1 or -2 infections. The protein is easy to purify and synthesize, and  
CC has strong immunoreactivity with sera from virus-infected subjects. The  
CC present sequence encodes a linker of the recombinant chimeric peptide of  
CC the invention.  
XX  
SQ Sequence 16 BP; 2 A; 5 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 476 CCTGAACCGAGCTC 490  
Db 15 CCTGAACCGAGCTC 1  
RESULT 408  
ADR32381  
ID ADR32381 standard; DNA; 16 BP.  
XX  
AC ADR32381;  
XX  
DT 04-NOV-2004 (first entry)  
XX  
DE E. coli nicking agent target DNA #26.  
XX  
SS; nicking agent; assay panel; diagnosis; expression pattern;  
KW DNA fingerprinting; nosocomial infection; microbiological assay;  
KW bacterial contamination; genome mapping; bioremediation.  
XX  
OS Escherichia coli.  
XX  
PN WO2004067765-A2.  
XX  
PD 12-AUG-2004.  
XX  
XX 29-JAN-2004; 2004WO-US002720.  
XX  
XX 29-JAN-2003; 2003US-0443811P.  
XX  
XX (KECK-) KECK GRADUATE INST.  
XX  
XX Van Ness J, Galas DJ, Van Ness LK;  
XX  
XX WPI; 2004-581010/56.  
XX  
PT Identifying nucleic acid sample source, useful for identifying bacterial  
PT strains involved in nosocomial infections, comprises treating the nucleic  
PT acid sample with components comprising a nicking agent under nicking  
PT conditions.  
XX  
XX Example 1; Page 65; 238pp; English.  
XX  
XX The invention relates to a method of treating a nucleic acid sample with  
CC components under nicking conditions, where the components comprise a

CC nicking agent, and the conditions cause the nicking agent to nick the  
CC nucleic acid sample to thus produce a family of initiating  
CC oligonucleotide fragments, and subjecting one or more members of the  
CC family of initiating oligonucleotide fragments to a characterization  
CC process to thus provide results. The method is useful for creating an  
CC assay panel of diagnostic oligonucleotides that can identify any organism  
CC or individual. The method is useful for characterizing other DNA  
CC molecules e.g., cDNA, and for characterizing cDNA expression patterns.  
CC The method, kit or composition is useful for identifying the source  
CC organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,  
CC non-human animal or human. The method is particularly useful for rapidly  
CC fingerprinting DNA to identifying prokaryotic and eukaryotic species.  
CC subspecies, and especially strains or individuals of the subspecies. It  
CC is especially useful for identifying different bacterial strains involved  
CC in e.g., nosocomial infections. Furthermore, the method is useful for  
CC diagnosing bacterial disease in plants and humans, monitoring for  
CC bacterial content and/or contamination in the environment, monitoring for  
CC food for bacterial contamination, monitoring quality assurance/quality control of  
CC bacterial contamination, monitoring microbiological assays, tracing bacterial  
CC laboratory tests involving microbiological assays, tracing bacterial  
CC contamination and/or outbreaks of bacterial infections, genome mapping,  
CC monitoring bioremediation sites, and for monitoring agricultural sites  
CC for test crops, bacteria and recombinant molecules. This sequence  
CC corresponds to nucleic acid used in the method of the invention.  
XX  
SQ Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 501 TTCTGGATGAATGGT 515  
Db 1 TTCTGGATGAATGGT 15  
RESULT 409  
ADR32430  
ID ADR32430 standard; DNA; 16 BP.  
XX  
AC ADR32430;  
XX  
DT 04-NOV-2004 (first entry)  
XX  
DE E. coli fingerprint oligonucleotide #12.  
XX  
SS; nicking agent; assay panel; diagnosis; expression pattern;  
KW DNA fingerprinting; nosocomial infection; microbiological assay;  
KW bacterial contamination; genome mapping; bioremediation.  
XX  
OS Escherichia coli.  
XX  
PN WO2004067765-A2.  
XX  
PD 12-AUG-2004.  
XX  
XX 29-JAN-2004; 2004WO-US002720.  
XX  
XX 29-JAN-2003; 2003US-0443811P.  
XX  
XX (KECK-) KECK GRADUATE INST.  
XX  
XX Van Ness J, Galas DJ, Van Ness LK;  
XX  
XX WPI; 2004-581010/56.  
XX  
PT Identifying nucleic acid sample source, useful for identifying bacterial  
PT strains involved in nosocomial infections, comprises treating the nucleic  
PT acid sample with components comprising a nicking agent under nicking  
PT conditions.  
XX  
XX Example 1; Page 70; 238pp; English.  
XX

	The invention relates to a method of treating a nucleic acid sample with components under nicking conditions, where the components comprise a nicking agent, and the conditions cause the nicking agent to nick the nucleic acid sample to thus produce a family of initiating oligonucleotide fragments, and subjecting one or more members of the family of initiating oligonucleotide fragments to a characterization process so as to provide results. The method is useful for creating an assay panel of diagnostic oligonucleotides that can identify any organism or individual. The method is useful for characterizing other DNA molecules e.g., cDNA, and for characterizing cDNA expression patterns.
	The method, kit or composition is useful for identifying the source organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant, non-human animal or human. The method is particularly useful for rapidly fingerprinting DNA to identifying prokaryotic and eukaryotic species,
	CC subspecies, and especially strains or individuals of the subspecies. It CC
	is especially useful for identifying different bacterial strains involved in e.g., nosocomial infections. Furthermore, the method is useful for
	diagnosing bacterial disease in plants and humans, monitoring for bacterial content and/or contamination in the environment, monitoring food for bacterial contamination, monitoring quality assurance/control of laboratory tests involving microbiological assays, tracing bacterial contamination and/or outbreaks of bacterial infections, genome mapping, monitoring bioremediation sites, and for monitoring agricultural sites for test crops, bacteria and recombinant molecules. This sequence corresponds to nucleic acid used in the method of the invention.
XX	
SQ	Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
	Query Match           0.8%; Score 13.4; DB 1; Length 16; Best Local Similarity    93.3%; Pred. No. 1.7e+02; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	501 TTCTGGATGAATGTT 515         Db      1 TTCTGGATGAATGTT 15
Dd	
	RESULT 410
ID	ADR3357S standard; DNB; 16 BP.
AC	ADR3357S;
DT	04-NOV-2004 (first entry)
DE	E. coli strain K12 detection oligonucleotide K12-558515.
KW	ss; nicking agent; assay panel; diagnosis; expression pattern;
KW	DNA fingerprinting; nosocomial infection; microbiological assay;
KW	bacterial contamination; genome mapping; bioremediation.  
OS	Escherichia coli.
PN	WO2004067765-A2.
PD	12-AUG-2004.
PF	29-JAN-2004; 2004WO-USO02720.
PR	29-JAN-2003; 2003US-0443811P.
PA	(KECK-) KECK GRADUATE INST.
PI	Van Ness J, Galas DJ, Van Ness LK;
DR	WPT; 2004-581010/56.
FT	Identifying nucleic acid sample source, useful for identifying bacterial strains involved in nosocomial infections, comprises treating the nucleic acid sample with components comprising a nicking agent under nicking conditions.
PS	Example 2; Page 94; 239pp; English.
XX	The invention relates to a method of treating a nucleic acid sample with components under nicking conditions, where the components comprise a nicking agent, and the conditions cause the nicking agent to nick the nucleic acid sample to thus produce a family of initiating oligonucleotide fragments, and subjecting one or more members of the family of initiating oligonucleotide fragments to a characterization process so as to provide results. The method is useful for creating an assay panel of diagnostic oligonucleotides that can identify any organism or individual. The method is useful for characterizing other DNA molecules e.g., cDNA, and for characterizing cDNA expression patterns.
CC	The method, kit or composition is useful for identifying the source organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant, non-human animal or human. The method is particularly useful for rapidly fingerprinting DNA to identifying prokaryotic and eukaryotic species,
CC	subspecies, and especially strains or individuals of the subspecies. It
CC	is especially useful for identifying different bacterial strains involved in e.g., nosocomial infections. Furthermore, the method is useful for
CC	diagnosing bacterial disease in plants and humans, monitoring for bacterial content and/or contamination in the environment, monitoring food for bacterial contamination, monitoring manufacturing processes for laboratory tests involving microbiological assays, tracing bacterial contamination and/or outbreaks of bacterial infections, genome mapping, monitoring bioremediation sites, and for monitoring agricultural sites for test crops, bacteria and recombinant molecules. This sequence corresponds to nucleic acid used in the method of the invention to detect an E. coli strain K12 sequence.
XX	
SQ	Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
	Query Match           0.8%; Score 13.4; DB 1; Length 16; Best Local Similarity    93.3%; Pred. No. 1.7e+02; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	501 TTCTGGATGAATGTT 515         DB    1 TTCTGGATGAATGTT 15
DE	
DE	Result 411
ID	ADR69939/C
AC	ADR69939 standard; DNA; 16 BP.
AC	ADR69939;
DT	04-NOV-2004 (First Entry)
DE	Human survivin gene modulatory oligonucleotide #7.
SS	ss; antiangiogenic; cytostatic; antiarteriosclerotic; antipsoriatic;
KW	anti-diabetic; ophthalmologic; antiarthritic; anti-neumatic;
KW	antiasthmatic; anti-allergic; anti-inflammatory; dermatological; anti-HIV;
KW	viruside; survivin antagonist; apoptosis inhibitor;
KW	cellular proliferation inhibitor; survivin; gene expression;
KW	abnormal angiogenesis; chemotherapeutic agent; busulfan; myleran;
KW	carbolatin; paraplalin; Taxol; doxorubicin; adriamycin; atherosclerosis;
KW	psoriasis; diabetic retinopathy; rheumatoid arthritis; asthma; warts;
KW	allergic dermatitis; cancer; tumour; sarcoma; glioma; carcinoma;
KW	melanoma; osteosarcoma; Ewing's sarcoma; chondrosarcoma;
KW	malignant fibrous histiocytoma; fibrosarcoma; Kaposi's sarcoma;
KW	Faciitaxel; Docetaxel.
OS	Homo sapiens.
OS	Synthetic.
PH	Key Location/Qualifiers
FT	modified_base 1..16 /tag= b
FT	/mod_base= OTHER
FT	/note= "OTHER = phosphorothioate internucleotide linkages, all locked nucleic acid (LNA) residues are 5'-

QY 278 CAAGAAGAGAAAGA 292  
| | | | | | | | | |  
Db 16 CAATAGAGAGAAAGA 2

Search completed: September 13, 2005, 10:42:46  
Job time : 10 secs

FT modified\_base methyl cytosine residues"  
FT 1..4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER = beta-D-oxy-locked nucleic acid but  
FT optionally DNA nucleotides, optionally phosphate  
FT internucleotide linkages"  
FT modified\_base  
FT 13..16  
FT /\*tag= C  
FT /mod\_base= OTHER  
FT /note= "OTHER = beta-D-oxy-locked nucleic acid but  
FT optionally DNA nucleotides, optionally phosphate  
FT internucleotide linkages"  
PN WO2004069991-A2.  
XX  
XX 19-AUG-2004.  
XX  
XX 10-FEB-2004; 2004WO-DK000096.  
XX  
XX 10-FEB-2003; 2003DK-00000183.  
PR 18-NOV-2003; 2003DK-00001708.  
XX  
XX (SANT-) SANTARIS PHARMA AS.  
XX Hansen B, Thru CA, Petersen KD, Westergaard M, Wissenbach M;  
PI WPI; 2004-625494/60.  
XX  
XX New locked nucleic acid containing oligomeric compound capable of  
PT modulating survivin expression, useful for treating cancer such as breast  
PT carcinoma, lung carcinoma, etc.  
XX  
XX Claim 1; SEQ ID NO 8; 122pp; English.  
XX  
XX The invention relates to an oligomeric compound (I) capable of modulating  
CC survivin expression, having 8-50 nucleotides and/or nucleotide analogues,  
CC where the compound comprises a subsequence of at least 8 nucleotides or  
CC nucleotide analogues, where the subsequence is located within a sequence  
CC chosen from one of 143 sequences given in the specification. (I) is  
CC useful for treating a mammal suffering from or susceptible from a disease  
CC caused by abnormal angiogenesis, by administering (I) containing one or  
CC more LNA units that are targeted to survivin. (I) is useful as a  
CC medicament and for the manufacture of a medicament for the treatment of  
CC cancer, in combination with chemotherapeutic agent such as busulfan  
CC (myleran), carboplatin (paraplatin), Taxol, doxorubicin (adriamycin),  
CC etc. (I) or a conjugate (II) containing (I) is useful in the preparation  
CC of a medicament for the treatment of atherosclerosis, psoriasis, diabetic  
CC retinopathy, rheumatoid arthritis, asthma, warts and allergic dermatitis.  
CC (I), (II) or a pharmaceutical (III) containing (I) is useful for treating  
CC cancer in the form of a solid tumour, sarcoma, glioma or carcinoma chosen  
CC from malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast  
CC carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder  
CC carcinoma, recurrent superficial bladder cancer, stomach carcinoma,  
CC prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical  
CC carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma,  
CC colorectal carcinoma and carcinoma tumours. The malignant melanoma is  
CC chosen from superficial spreading melanoma, nodular melanoma, lentigo  
CC maligna melanoma, acral melanoma, amelanotic melanoma, and desmoplastic  
CC melanoma. The sarcoma is chosen from osteosarcoma, Ewing's sarcoma,  
CC chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's  
CC sarcoma. The treatment further involves administration of a  
CC chemotherapeutic agent such as taxanes, preferably Taxol, Paclitaxel or  
CC Docetaxel. (I), (II) or (III) is also useful for preventing or limiting  
CC apoptosis or for preventing cellular proliferation. This sequence  
CC corresponds to an antisense oligonucleotide targeted to the human  
CC survivin gene.  
XX  
XX Sequence 16 BP; 1 A; 3 C; 1 G; 11 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:46:55 ; Search time 10 Seconds  
(without alignments)  
3.440 Million cell updates/sec

Title: us-10-828-394-1  
Perfect score: 1643  
Sequence: 1 gaattccgcgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 497 seqs, 10470 residues

Total number of hits satisfying chosen parameters: 994

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 497 summaries

Database : rnpbdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	25	1.5	25	1	US-10-717-597-1314
2	25	1.5	25	1	US-10-717-597-1315
3	25	1.5	25	1	US-10-717-597-1316
4	25	1.5	25	1	US-10-717-597-1317
5	25	1.5	25	1	US-10-717-597-1318
6	25	1.5	25	1	US-10-717-597-1319
7	25	1.5	25	1	US-10-717-597-1320
8	25	1.5	25	1	US-10-717-597-1321
9	25	1.5	25	1	US-10-717-597-1322
10	25	1.5	25	1	US-10-717-597-1323
11	25	1.5	25	1	US-10-717-597-1324
12	25	1.5	25	1	US-10-717-597-1325
13	25	1.5	25	1	US-10-717-597-1326
14	25	1.5	25	1	US-10-717-597-1327
15	25	1.5	25	1	US-10-717-597-1328
16	25	1.5	25	1	US-10-717-597-1329
17	25	1.5	25	1	US-10-717-597-1330
18	25	1.5	25	1	US-10-956-157-25933
19	25	1.5	25	1	US-10-956-157-25934
20	25	1.5	25	1	US-10-956-157-25935
21	25	1.5	25	1	US-10-956-157-25936
22	25	1.5	25	1	US-10-956-157-25937
23	25	1.5	25	1	US-10-956-157-25938
24	25	1.5	25	1	US-10-956-157-25939
25	25	1.5	25	1	US-10-956-157-25940
26	25	1.5	25	1	US-10-956-157-25941
27	25	1.5	25	1	US-10-956-157-25942
28	25	1.5	25	1	US-10-956-157-25943
29	25	1.5	25	1	US-10-956-157-25944
30	25	1.5	25	1	US-10-956-157-25945
31	25	1.5	25	1	US-10-956-157-25946
32	25	1.5	25	1	US-10-956-157-25947
33	25	1.5	25	1	US-10-956-157-25948
					US-10-956-157-25949
					Sequence 1314, Ap
					Sequence 1315, Ap
					Sequence 1316, Ap
					Sequence 1317, Ap
					Sequence 1318, Ap
					Sequence 1319, Ap
					Sequence 1320, Ap
					Sequence 1321, Ap
					Sequence 1322, Ap
					Sequence 1323, Ap
					Sequence 1324, Ap
					Sequence 1325, Ap
					Sequence 1326, Ap
					Sequence 1327, Ap
					Sequence 1328, Ap
					Sequence 1329, Ap
					Sequence 1330, Ap
					Sequence 25933, A
					Sequence 25934, A
					Sequence 25935, A
					Sequence 25936, A
					Sequence 25937, A
					Sequence 25938, A
					Sequence 25939, A
					Sequence 25940, A
					Sequence 25941, A
					Sequence 25942, A
					Sequence 25943, A
					Sequence 25944, A
					Sequence 25945, A
					Sequence 25946, A
					Sequence 25947, A
					Sequence 25948, A
					Sequence 25949, A

1	US-10-956-157-25950	1.5	25	1	Sequence 25950, A
2	US-10-956-157-25951	1.5	25	1	Sequence 25951, A
3	US-10-956-157-25952	1.5	25	1	Sequence 25952, A
4	US-10-956-157-25953	1.5	25	1	Sequence 25953, A
5	US-10-956-157-25954	1.5	25	1	Sequence 25954, A
6	US-10-956-157-25955	1.5	25	1	Sequence 25955, A
7	US-10-956-157-25956	1.5	25	1	Sequence 25956, A
8	US-10-956-157-25957	1.5	25	1	Sequence 25957, A
9	US-10-956-157-25958	1.5	25	1	Sequence 25958, A
10	US-10-956-157-25959	1.5	25	1	Sequence 25959, A
11	US-10-956-157-25960	1.5	25	1	Sequence 25960, A
12	US-10-956-157-25961	1.5	25	1	Sequence 25961, A
13	US-10-956-157-25962	1.5	25	1	Sequence 25962, A
14	US-10-956-157-25963	1.5	25	1	Sequence 25963, A
15	US-10-956-157-25964	1.5	25	1	Sequence 25964, A
16	US-10-956-157-25965	1.5	25	1	Sequence 25965, A
17	US-10-956-157-25966	1.5	25	1	Sequence 25966, A
18	US-10-956-157-25967	1.5	25	1	Sequence 25967, A
19	US-10-956-157-25968	1.5	25	1	Sequence 25968, A
20	US-10-956-157-25969	1.5	25	1	Sequence 25969, A
21	US-10-956-157-25970	1.5	25	1	Sequence 25970, A
22	US-10-956-157-25971	1.5	25	1	Sequence 25971, A
23	US-10-956-157-25972	1.5	25	1	Sequence 25972, A
24	US-10-956-157-25973	1.5	25	1	Sequence 25973, A
25	US-10-956-157-25974	1.5	25	1	Sequence 25974, A
26	US-10-956-157-25975	1.5	25	1	Sequence 25975, A
27	US-10-956-157-25976	1.5	25	1	Sequence 25976, A
28	US-10-956-157-25977	1.5	25	1	Sequence 25977, A
29	US-10-956-157-25978	1.5	25	1	Sequence 25978, A
30	US-10-956-157-25979	1.5	25	1	Sequence 25979, A
31	US-10-956-157-25980	1.5	25	1	Sequence 25980, A
32	US-10-956-157-25981	1.5	25	1	Sequence 25981, A
33	US-10-956-157-25982	1.5	25	1	Sequence 25982, A
	US-10-956-157-25983	1.5	25	1	Sequence 25983, A
	US-10-956-157-25984	1.5	25	1	Sequence 25984, A
	US-10-956-157-25985	1.5	25	1	Sequence 25985, A
	US-10-956-157-25986	1.5	25	1	Sequence 25986, A
	US-10-956-157-25987	1.5	25	1	Sequence 25987, A
	US-10-956-157-25988	1.5	25	1	Sequence 25988, A
	US-10-956-157-25989	1.5	25	1	Sequence 25989, A
	US-10-956-157-25990	1.5	25	1	Sequence 25990, A
	US-10-956-157-25991	1.5	25	1	Sequence 25991, A
	US-10-956-157-25992	1.5	25	1	Sequence 25992, A
	US-10-956-157-25993	1.5	25	1	Sequence 25993, A
	US-10-956-157-25994	1.5	25	1	Sequence 25994, A
	US-10-956-157-25995	1.5	25	1	Sequence 25995, A
	US-10-956-157-25996	1.5	25	1	Sequence 25996, A
	US-10-956-157-25997	1.5	25	1	Sequence 25997, A
	US-10-956-157-25998	1.5	25	1	Sequence 25998, A
	US-10-956-157-25999	1.5	25	1	Sequence 25999, A

107	25	1.5	25	1	US-10-956-157-252760	Sequence 252760,	c 180	21	1.3	21	1	US-09-967-726A-12	Sequence 12, Appl
108	25	1.5	25	1	US-10-956-157-253138	Sequence 253138,	181	21	1.3	21	1	US-10-270-871-14	Sequence 14, Appl
109	25	1.5	25	1	US-10-956-157-255424	Sequence 255424,	c 182	21	1.3	21	1	US-10-080-794-3	Sequence 3, Appl
110	25	1.5	25	1	US-10-956-157-255957	Sequence 255957,	c 183	21	1.3	21	1	US-10-080-794-4	Sequence 4, Appl
111	25	1.5	25	1	US-10-956-157-256203	Sequence 256203,	c 184	21	1.3	21	1	US-10-080-794-5	Sequence 5, Appl
112	25	1.5	25	1	US-10-956-157-261789	Sequence 261789,	c 185	21	1.3	21	1	US-10-080-794-6	Sequence 6, Appl
113	25	1.5	25	1	US-10-956-157-266662	Sequence 266662,	c 186	21	1.3	21	1	US-10-080-794-7	Sequence 7, Appl
114	25	1.5	25	1	US-10-956-157-268124	Sequence 268124,	c 187	21	1.3	21	1	US-10-080-794-8	Sequence 8, Appl
115	25	1.5	25	1	US-10-956-157-269972	Sequence 269972,	c 188	21	1.3	21	1	US-10-080-794-9	Sequence 9, Appl
116	25	1.5	25	1	US-10-956-157-273702	Sequence 273702,	c 189	21	1.3	21	1	US-10-080-794-10	Sequence 10, Appl
117	25	1.5	25	1	US-10-956-157-274079	Sequence 274079,	c 190	21	1.3	21	1	US-10-080-794-11	Sequence 11, Appl
118	25	1.5	25	1	US-10-956-157-274264	Sequence 274264,	c 191	21	1.3	21	1	US-10-080-794-12	Sequence 12, Appl
119	25	1.5	25	1	US-10-956-157-274647	Sequence 274647,	192	21	1.3	21	1	US-10-380-124-6	Sequence 6, Appl
120	25	1.5	25	1	US-10-956-157-279222	Sequence 279222,	193	21	1.3	21	1	US-10-383-864-27	Sequence 27, Appl
121	25	1.5	25	1	US-10-956-157-281215	Sequence 281215,	c 194	21	1.3	21	1	US-10-383-864-28	Sequence 28, Appl
122	25	1.5	25	1	US-10-956-157-285427	Sequence 285427,	c 195	21	1.3	21	1	US-10-646-391A-3	Sequence 3, Appl
123	25	1.5	25	1	US-10-956-157-285561	Sequence 285561,	c 196	21	1.3	21	1	US-10-646-391A-4	Sequence 4, Appl
124	25	1.5	25	1	US-10-956-157-285688	Sequence 285688,	c 197	21	1.3	21	1	US-10-646-391A-5	Sequence 5, Appl
125	25	1.5	25	1	US-10-956-157-287832	Sequence 287832,	c 198	21	1.3	21	1	US-10-646-391A-6	Sequence 6, Appl
126	25	1.5	25	1	US-10-956-157-291738	Sequence 291738,	c 199	21	1.3	21	1	US-10-646-391A-7	Sequence 7, Appl
127	25	1.5	25	1	US-10-956-157-292100	Sequence 292100,	c 200	21	1.3	21	1	US-10-646-391A-8	Sequence 8, Appl
128	25	1.5	25	1	US-10-956-157-292272	Sequence 292272,	c 201	21	1.3	21	1	US-10-646-391A-9	Sequence 9, Appl
129	25	1.5	25	1	US-10-956-157-297166	Sequence 297166,	c 202	21	1.3	21	1	US-10-646-391A-10	Sequence 10, Appl
130	25	1.5	25	1	US-10-956-157-302171	Sequence 302171,	c 203	21	1.3	21	1	US-10-646-391A-11	Sequence 11, Appl
131	25	1.5	25	1	US-10-956-157-316681	Sequence 316681,	c 204	21	1.3	21	1	US-10-646-391A-12	Sequence 12, Appl
132	25	1.5	25	1	US-10-956-157-317598	Sequence 317598,	c 205	21	1.3	21	1	US-10-646-391A-20	Sequence 20, Appl
133	24	1.5	25	1	US-10-956-157-287991	Sequence 287991,	c 206	21	1.3	21	1	US-10-646-391A-21	Sequence 21, Appl
134	23	1.4	25	1	US-10-719-956-187214	Sequence 187214,	c 207	21	1.3	21	1	US-10-646-391A-22	Sequence 22, Appl
135	23	1.4	23	1	US-10-080-794-16	Sequence 16, Appl	c 208	21	1.3	21	1	US-10-646-391A-23	Sequence 23, Appl
136	23	1.4	23	1	US-10-080-794-17	Sequence 17, Appl	c 209	21	1.3	21	1	US-10-646-391A-25	Sequence 25, Appl
137	23	1.4	23	1	US-10-380-124-5	Sequence 5, Appl	c 210	21	1.3	21	1	US-10-646-391A-36	Sequence 36, Appl
138	23	1.4	23	1	US-10-646-436-57	Sequence 57, Appl	c 211	21	1.3	21	1	US-10-646-391A-37	Sequence 37, Appl
139	23	1.4	23	1	US-10-646-436-60	Sequence 60, Appl	c 212	21	1.3	21	1	US-10-646-391A-38	Sequence 38, Appl
140	23	1.4	23	1	US-10-646-436-63	Sequence 63, Appl	c 213	21	1.3	21	1	US-10-646-391A-39	Sequence 39, Appl
141	23	1.4	23	1	US-10-646-436-66	Sequence 66, Appl	c 214	21	1.3	21	1	US-10-646-391A-40	Sequence 40, Appl
142	23	1.4	25	1	US-10-956-157-291041	Sequence 291041,	c 215	21	1.3	21	1	US-10-646-391A-41	Sequence 41, Appl
143	22	1.3	22	1	US-10-980-850-34	Sequence 34, Appl	c 216	21	1.3	21	1	US-10-646-436-1	Sequence 1, Appl
144	22	1.3	25	1	US-10-956-157-167169	Sequence 167169,	c 217	21	1.3	21	1	US-10-646-436-2	Sequence 2, Appl
145	22	1.3	25	1	US-10-956-157-167170	Sequence 167170,	c 218	21	1.3	21	1	US-10-646-436-3	Sequence 3, Appl
146	22	1.3	25	1	US-10-956-157-167171	Sequence 167171,	c 219	21	1.3	21	1	US-10-646-436-4	Sequence 4, Appl
147	22	1.3	25	1	US-10-956-157-228788	Sequence 228788,	c 220	21	1.3	21	1	US-10-646-436-5	Sequence 5, Appl
148	22	1.3	25	1	US-10-956-157-279365	Sequence 279365,	c 221	21	1.3	21	1	US-10-646-436-6	Sequence 6, Appl
149	21.8	1.3	25	1	US-10-719-900-56804	Sequence 56804, A	c 222	21	1.3	21	1	US-10-646-436-58	Sequence 58, Appl
150	21.8	1.3	25	1	US-10-719-900-417945	Sequence 417945,	c 223	21	1.3	21	1	US-10-646-436-59	Sequence 59, Appl
151	21.8	1.3	25	1	US-10-719-900-417946	Sequence 417946,	c 224	21	1.3	21	1	US-10-646-436-61	Sequence 61, Appl
152	21.8	1.3	25	1	US-10-719-900-815718	Sequence 815718,	c 225	21	1.3	21	1	US-10-646-436-62	Sequence 62, Appl
153	21.8	1.3	25	1	US-10-719-900-892165	Sequence 892165,	c 226	21	1.3	21	1	US-10-646-436-64	Sequence 64, Appl
154	21.8	1.3	25	1	US-10-909-189-31760	Sequence 31760, A	c 227	21	1.3	21	1	US-10-646-436-65	Sequence 65, Appl
155	21.8	1.3	25	1	US-10-719-956-30749	Sequence 30749, A	c 228	21	1.3	21	1	US-10-828-394-4	Sequence 4, Appl
156	21.8	1.3	25	1	US-10-719-956-187213	Sequence 187213,	c 229	21	1.3	21	1	US-10-828-394-5	Sequence 5, Appl
157	21.8	1.3	25	1	US-10-719-956-374026	Sequence 374026,	c 230	21	1.3	21	1	US-10-828-394-6	Sequence 6, Appl
158	21.8	1.3	25	1	US-10-719-956-501381	Sequence 501381,	c 231	21	1.3	21	1	US-10-828-394-7	Sequence 7, Appl
159	21.8	1.3	25	1	US-10-719-956-612442	Sequence 612442,	c 232	21	1.3	21	1	US-10-828-394-8	Sequence 8, Appl
160	21	1.3	21	1	US-09-944-326-3	Sequence 3, Appl	c 233	21	1.3	21	1	US-10-828-394-9	Sequence 9, Appl
161	21	1.3	21	1	US-09-944-326-4	Sequence 4, Appl	c 234	21	1.3	21	1	US-10-828-394-10	Sequence 10, Appl
162	21	1.3	21	1	US-09-944-326-5	Sequence 5, Appl	c 235	21	1.3	21	1	US-10-828-394-11	Sequence 11, Appl
163	21	1.3	21	1	US-09-944-326-6	Sequence 6, Appl	c 236	21	1.3	21	1	US-10-828-394-12	Sequence 12, Appl
164	21	1.3	21	1	US-09-944-326-7	Sequence 7, Appl	c 237	21	1.3	21	1	US-10-828-394-13	Sequence 13, Appl
165	21	1.3	21	1	US-09-944-326-8	Sequence 8, Appl	c 238	21	1.3	21	1	US-10-828-395-4	Sequence 4, Appl
166	21	1.3	21	1	US-09-944-326-9	Sequence 9, Appl	c 239	21	1.3	21	1	US-10-828-395-5	Sequence 5, Appl
167	21	1.3	21	1	US-09-944-326-10	Sequence 10, Appl	c 240	21	1.3	21	1	US-10-828-395-6	Sequence 6, Appl
168	21	1.3	21	1	US-09-944-326-11	Sequence 11, Appl	c 241	21	1.3	21	1	US-10-828-395-7	Sequence 7, Appl
169	21	1.3	21	1	US-09-944-326-12	Sequence 12, Appl	c 242	21	1.3	21	1	US-10-828-395-8	Sequence 8, Appl
170	21	1.3	21	1	US-09-459-749D-14	Sequence 14, Appl	c 243	21	1.3	21	1	US-10-828-395-9	Sequence 9, Appl
171	21	1.3	21	1	US-09-967-726A-3	Sequence 3, Appl	c 244	21	1.3	21	1	US-10-828-395-10	Sequence 10, Appl
172	21	1.3	21	1	US-09-967-726A-4	Sequence 4, Appl	c 245	21	1.3	21	1	US-10-828-395-11	Sequence 11, Appl
173	21	1.3	21	1	US-09-967-726A-5	Sequence 5, Appl	c 246	21	1.3	21	1	US-10-828-395-12	Sequence 12, Appl
174	21	1.3	21	1	US-09-967-726A-6	Sequence 6, Appl	c 247	21	1.3	21	1	US-10-828-395-13	Sequence 13, Appl
175	21	1.3	21	1	US-09-967-726A-7	Sequence 7, Appl	c 248	20.8	1.3	25	1	US-10-719-900-695781	Sequence 695781, A
176	21	1.3	21	1	US-09-967-726A-8	Sequence 8, Appl	c 249	20.2	1.2	25	1	US-10-719-900-56803	Sequence 56803, A
177	21	1.3	21	1	US-09-967-726A-9	Sequence 9, Appl	c 250	20.2	1.2	25	1	US-10-719-900-452919	Sequence 452919, A
178	21	1.3	21	1	US-09-967-726A-10	Sequence 10, Appl	c 251	20.2	1.2	25	1	US-10-719-900-815717	Sequence 815717, A
179	21	1.3	21	1	US-09-967-726A-11	Sequence 11, Appl	c 252	20.2	1.2	25	1	US-10-719-900-892166	Sequence 892166, A

253	20.2	1.2	25	1	US-10-809-189-31758	Sequence 31758, A	c 326	20	1.2	20	1	US-10-380-124-80	Sequence 80, Appl
254	20.2	1.2	25	1	US-10-956-157-271151	Sequence 271151, A	327	20	1.2	20	1	US-10-980-850-17	Sequence 17, Appl
255	20.2	1.2	25	1	US-10-719-956-30750	Sequence 30750, A	c 328	20	1.2	20	1	US-10-980-850-18	Sequence 18, Appl
256	20.2	1.2	25	1	US-10-719-956-70566	Sequence 70566, A	329	20	1.2	20	1	US-10-980-850-33	Sequence 33, Appl
257	20.2	1.2	25	1	US-10-719-956-355802	Sequence 355802, A	330	20	1.2	21	1	US-10-646-391A-28	Sequence 28, Appl
258	20.2	1.2	25	1	US-10-719-956-374027	Sequence 374027, A	331	20	1.2	21	1	US-10-646-436-9	Sequence 9, Appl
259	20.2	1.2	25	1	US-10-719-956-501380	Sequence 501380, A	332	19.4	1.2	21	1	US-09-459-749D-13	Sequence 13, Appl
260	20.2	1.2	25	1	US-10-719-956-517912	Sequence 517912, A	333	19.4	1.2	21	1	US-10-270-871-13	Sequence 13, Appl
261	20.2	1.2	25	1	US-10-719-956-604881	Sequence 604881, A	334	19	1.2	19	1	US-10-646-391A-42	Sequence 42, Appl
262	20.2	1.2	25	1	US-10-719-956-612441	Sequence 612441, A	c 335	19	1.2	19	1	US-10-646-391A-43	Sequence 43, Appl
263	20	1.2	20	1	US-10-380-124-14	Sequence 14, Appl	336	19	1.2	19	1	US-10-646-436-67	Sequence 67, Appl
264	20	1.2	20	1	US-10-380-124-15	Sequence 15, Appl	c 337	19	1.2	19	1	US-10-646-436-68	Sequence 68, Appl
265	20	1.2	20	1	US-10-380-124-16	Sequence 16, Appl	338	19	1.2	19	1	US-10-828-394-16	Sequence 16, Appl
266	20	1.2	20	1	US-10-380-124-17	Sequence 17, Appl	339	19	1.2	19	1	US-10-828-394-17	Sequence 17, Appl
267	20	1.2	20	1	US-10-380-124-18	Sequence 18, Appl	340	19	1.2	19	1	US-10-828-394-18	Sequence 18, Appl
268	20	1.2	20	1	US-10-380-124-19	Sequence 19, Appl	341	19	1.2	19	1	US-10-828-395-16	Sequence 16, Appl
269	20	1.2	20	1	US-10-380-124-20	Sequence 20, Appl	342	19	1.2	19	1	US-10-828-395-17	Sequence 17, Appl
270	20	1.2	20	1	US-10-380-124-21	Sequence 21, Appl	343	19	1.2	19	1	US-10-828-395-18	Sequence 18, Appl
271	20	1.2	20	1	US-10-380-124-22	Sequence 22, Appl	c 344	19	1.2	21	1	US-10-646-391A-29	Sequence 29, Appl
272	20	1.2	20	1	US-10-380-124-23	Sequence 23, Appl	345	19	1.2	21	1	US-10-646-436-10	Sequence 10, Appl
273	20	1.2	20	1	US-10-380-124-24	Sequence 24, Appl	346	18	1.1	18	1	US-10-380-124-4	Sequence 4, Appl
274	20	1.2	20	1	US-10-380-124-25	Sequence 25, Appl	c 347	17.8	1.1	21	1	US-09-967-726A-15	Sequence 15, Appl
275	20	1.2	20	1	US-10-380-124-26	Sequence 26, Appl	348	17.8	1.1	21	1	US-10-080-794-15	Sequence 15, Appl
276	20	1.2	20	1	US-10-380-124-27	Sequence 27, Appl	349	17.8	1.1	21	1	US-10-751-736-11047	Sequence 11047, A
277	20	1.2	20	1	US-10-380-124-28	Sequence 28, Appl	c 350	16.8	1.0	20	1	US-10-921-868A-37	Sequence 37, Appl
278	20	1.2	20	1	US-10-380-124-29	Sequence 29, Appl	c 351	16.8	1.0	21	1	US-10-786-720-3371	Sequence 3371, Ap
279	20	1.2	20	1	US-10-380-124-30	Sequence 30, Appl	c 352	16.8	1.0	21	1	US-10-786-720-4073	Sequence 4073, Ap
280	20	1.2	20	1	US-10-380-124-31	Sequence 31, Appl	c 353	16.8	1.0	21	1	US-10-786-720-4811	Sequence 4811, Ap
281	20	1.2	20	1	US-10-380-124-32	Sequence 32, Appl	c 354	16.8	1.0	21	1	US-10-751-736-24026	Sequence 24026, A
282	20	1.2	20	1	US-10-380-124-33	Sequence 33, Appl	c 355	16.8	1.0	21	1	US-10-911-318-81	Sequence 81, Appl
283	20	1.2	20	1	US-10-380-124-34	Sequence 34, Appl	c 356	16	1.0	16	1	US-09-294-121A-97	Sequence 97, Appl
284	20	1.2	20	1	US-10-380-124-35	Sequence 35, Appl	c 357	16	1.0	16	1	US-09-899-082A-97	Sequence 97, Appl
285	20	1.2	20	1	US-10-380-124-36	Sequence 36, Appl	c 358	16	1.0	16	1	US-09-899-302-97	Sequence 97, Appl
286	20	1.2	20	1	US-10-380-124-37	Sequence 37, Appl	c 359	16	1.0	16	1	US-09-899-044-97	Sequence 97, Appl
287	20	1.2	20	1	US-10-380-124-38	Sequence 38, Appl	c 360	16	1.0	16	1	US-10-822-711-97	Sequence 97, Appl
288	20	1.2	20	1	US-10-380-124-39	Sequence 39, Appl	c 361	16	1.0	20	1	US-10-160-787-84	Sequence 84, Appl
289	20	1.2	20	1	US-10-380-124-40	Sequence 40, Appl	362	16	1.0	20	1	US-10-160-787-137	Sequence 137, App
290	20	1.2	20	1	US-10-380-124-41	Sequence 41, Appl	363	15.8	1.0	19	1	US-10-646-391A-24	Sequence 24, Appl
291	20	1.2	20	1	US-10-380-124-42	Sequence 42, Appl	364	15.8	1.0	19	1	US-10-646-391A-26	Sequence 26, Appl
292	20	1.2	20	1	US-10-380-124-43	Sequence 43, Appl	c 365	15.8	1.0	19	1	US-10-646-391A-27	Sequence 27, Appl
293	20	1.2	20	1	US-10-380-124-44	Sequence 44, Appl	c 366	15.8	1.0	19	1	US-10-646-436-7	Sequence 7, Appl
294	20	1.2	20	1	US-10-380-124-45	Sequence 45, Appl	c 367	15.8	1.0	19	1	US-10-646-436-8	Sequence 8, Appl
295	20	1.2	20	1	US-10-380-124-46	Sequence 46, Appl	c 368	15.8	1.0	19	1	US-10-667-271-1001	Sequence 1001, App
296	20	1.2	20	1	US-10-380-124-47	Sequence 47, Appl	c 369	15.8	1.0	19	1	US-10-667-271-305	Sequence 305, App
297	20	1.2	20	1	US-10-380-124-48	Sequence 48, Appl	370	15.4	0.9	17	1	US-09-866-108-8666	Sequence 8666, Ap
298	20	1.2	20	1	US-10-380-124-49	Sequence 49, Appl	c 371	15.4	0.9	17	1	US-09-866-108-8666	Sequence 170, App
299	20	1.2	20	1	US-10-380-124-50	Sequence 50, Appl	c 372	15.4	0.9	17	1	US-09-740-332-1542	Sequence 1542, Ap
300	20	1.2	20	1	US-10-380-124-51	Sequence 51, Appl	c 373	15.4	0.9	17	1	US-09-740-332-3013	Sequence 3013, Ap
301	20	1.2	20	1	US-10-380-124-52	Sequence 52, Appl	374	15.4	0.9	17	1	US-09-817-879-1542	Sequence 1542, Ap
302	20	1.2	20	1	US-10-380-124-53	Sequence 53, Appl	c 375	15.4	0.9	17	1	US-09-817-879-3013	Sequence 3013, Ap
303	20	1.2	20	1	US-10-380-124-54	Sequence 54, Appl	376	15.4	0.9	17	1	US-10-669-841-4135	Sequence 4135, Ap
304	20	1.2	20	1	US-10-380-124-55	Sequence 55, Appl	c 377	15.4	0.9	17	1	US-10-669-841-5606	Sequence 5606, Ap
305	20	1.2	20	1	US-10-380-124-56	Sequence 56, Appl	c 378	15.4	0.9	17	1	US-10-723-361-8666	Sequence 8666, Ap
306	20	1.2	20	1	US-10-380-124-57	Sequence 57, Appl	c 379	15.4	0.9	17	1	US-10-828-394-19	Sequence 19, Appl
307	20	1.2	20	1	US-10-380-124-58	Sequence 58, Appl	c 380	15.4	0.9	17	1	US-10-828-395-19	Sequence 19, Appl
308	20	1.2	20	1	US-10-380-124-59	Sequence 59, Appl	c 381	15	0.9	15	1	US-10-758-451-883	Sequence 883, App
309	20	1.2	20	1	US-10-380-124-60	Sequence 60, Appl	c 382	15	0.9	17	1	US-09-740-332-3014	Sequence 3014, Ap
310	20	1.2	20	1	US-10-380-124-61	Sequence 61, Appl	c 383	15	0.9	17	1	US-09-817-879-3014	Sequence 3014, Ap
311	20	1.2	20	1	US-10-380-124-62	Sequence 62, Appl	c 384	15	0.9	17	1	US-10-669-841-5607	Sequence 5607, Ap
312	20	1.2	20	1	US-10-380-124-63	Sequence 63, Appl	385	14.8	0.9	18	1	US-10-497-692-11	Sequence 11, Appl
313	20	1.2	20	1	US-10-380-124-64	Sequence 64, Appl	c 386	14.4	0.9	17	1	US-09-866-108-8352	Sequence 8352, Ap
314	20	1.2	20	1	US-10-380-124-65	Sequence 65, Appl	c 387	14.4	0.9	17	1	US-09-866-108-8353	Sequence 8353, Ap
315	20	1.2	20	1	US-10-380-124-66	Sequence 66, Appl	c 388	14.4	0.9	17	1	US-09-866-108-8665	Sequence 8665, Ap
316	20	1.2	20	1	US-10-380-124-67	Sequence 67, Appl	389	14.4	0.9	17	1	US-09-866-108-8667	Sequence 8667, Ap
317	20	1.2	20	1	US-10-380-124-68	Sequence 68, Appl	c 390	14.4	0.9	17	1	US-09-866-108-10037	Sequence 10037, A
318	20	1.2	20	1	US-10-380-124-69	Sequence 69, Appl	c 391	14.4	0.9	17	1	US-09-866-108-10038	Sequence 10038, A
319	20	1.2	20	1	US-10-380-124-70	Sequence 70, Appl	c 392	14.4	0.9	17	1	US-09-928-412-7	Sequence 7, Appl
320	20	1.2	20	1	US-10-380-124-71	Sequence 71, Appl	c 393	14.4	0.9	17	1	US-09-780-533A-171	Sequence 171, App
321	20	1.2	20	1	US-10-380-124-72	Sequence 72, Appl	c 394	14.4	0.9	17	1	US-09-877-478-1745	Sequence 1745, Ap
322	20	1.2	20	1	US-10-380-124-73	Sequence 73, Appl	c 395	14.4	0.9	17	1	US-09-740-332-1543	Sequence 1543, Ap
323	20	1.2	20	1	US-10-380-124-74	Sequence 74, Appl	396	14.4	0.9	17	1	US-09-817-879-1543	Sequence 1543, Ap
324	20	1.2	20	1	US-10-380-124-75	Sequence 75, Appl	c 397	14.4	0.9	17	1	US-10-298-255-4	Sequence 4, Appl
325	20	1.2	20	1	US-10-380-124-76	Sequence 76, Appl	c 398	14.4	0.9	17	1	US-10-238-700-2912	Sequence 2912, Ap
					Sequence 78, Appl								





```
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1315
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1315

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1177 AAGCGAAGACCACTACTCTGCG 1201
Db 1 AAGCGAAGACCACTACTCTGCG 25

RESULT 3
US-10-717-597-1316
; Sequence 1316, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1316
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1316

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1196 TCTCGGGTACCACGGTGGCTCC 1220
Db 1 TCTCGGGTACCACGGTGGCTCC 25

RESULT 4
US-10-717-597-1317
; Sequence 1317, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1317
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1317

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1262 GGTCGTGAAGCTCTTTGACTCTGAT 1286
Db 1 GGTCGTGAAGCTCTTTGACTCTGAT 25

RESULT 6
US-10-717-597-1319
; Sequence 1319, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1318
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1318

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1262 GGTCGTGAAGCTCTTTGACTCTGAT 1286
Db 1 GGTCGTGAAGCTCTTTGACTCTGAT 25
```

```

; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1319
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1319

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1268 GAAGCTCTTTGACTCTGATCCCATC 1292
Db 1 GAAGCTCTTTGACTCTGATCCCATC 25

RESULT 7
US-10-717-597-1320
; Sequence 1320, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1320
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1320

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1274 CTTTGACTCTGATCCCATCACTGTG 1298
Db 1 CTTTGACTCTGATCCCATCACTGTG 25

RESULT 8
US-10-717-597-1321
; Sequence 1321, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1321
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1321

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1470 CCAGAGAGAGCTCTGCACGTCACCA 1494
Db 1 CCAGAGAGAGCTCTGCACGTCACCA 25

RESULT 10
US-10-717-597-1322
; Sequence 1322, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1322
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1322

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1397 AGATGTGGATGTTGCTTTTGACCT 1421
Db 1 AGATGTGGATGTTGCTTTTGACCT 25

RESULT 9
US-10-717-597-1322
; Sequence 1322, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1322
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1322

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1397 AGATGTGGATGTTGCTTTTGACCT 1421
Db 1 AGATGTGGATGTTGCTTTTGACCT 25
```

```

RESULT 13
US-10-717-597-1326
; Sequence 1326, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCES: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1326
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1326

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1556  TGCACCTTAACACTCGACTCTGCTG 1580
Db      1      TGCACCTTAACACTCGACTCTGCTG 25

```

RESULT 14  
US-10-717-597-1327  
; Sequence 1327, Application US/10717597  
; Publication No. US20040110221A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Burczynski, Michael E.  
; APPLICANT: Twine, Natalie C.  
; APPLICANT: Dörner, Andrew J.  
; APPLICANT: Trepicchio, William L.  
; APPLICANT: Slonim, Donna K.  
; APPLICANT: Stover, Jennifer A.  
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS  
; FILE REFERENCE: AM101080L  
; CURRENT APPLICATION NUMBER: US/10/717,597  
; CURRENT FILING DATE: 2003-11-21  
; PRIOR APPLICATION NUMBER: US 60/459,782  
; PRIOR FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: US 60/427,982  
; PRIOR FILING DATE: 2002-11-21  
; NUMBER OF SEQ ID NOS: 4904  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1327  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-717-597-1327

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1562 CTAACACTCGACTCTGCTGCTCATG 1586  
DB 1 CTAACACTCGACTCTGCTGCTCATG 25

RESULT 15  
US-10-717-597-1328  
; Sequence 1328, Application US/10717597  
; Publication No. US20040110221A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Burczynski, Michael E.  
; APPLICANT: Twine, Natalie C.  
; APPLICANT: Dörner, Andrew J.  
; APPLICANT: Trepicchio, William L.  
; APPLICANT: Slonim, Donna K.  
; APPLICANT: Stover, Jennifer A.  
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS  
; FILE REFERENCE: AM101080L  
; CURRENT APPLICATION NUMBER: US/10/717,597  
; CURRENT FILING DATE: 2003-11-21  
; PRIOR APPLICATION NUMBER: US 60/459,782  
; PRIOR FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: US 60/427,982  
; PRIOR FILING DATE: 2002-11-21  
; NUMBER OF SEQ ID NOS: 4904  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1328  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-717-597-1328

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1563 TAACACTCGACTCTGCTGCTCATGG 1587  
DB 1 TAACACTCGACTCTGCTGCTCATGG 25

RESULT 16  
US-10-717-597-1329  
; Sequence 1329, Application US/10717597  
; Publication No. US20040110221A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Burczynski, Michael E.  
; APPLICANT: Twine, Natalie C.  
; APPLICANT: Dörner, Andrew J.  
; APPLICANT: Trepicchio, William L.  
; APPLICANT: Slonim, Donna K.  
; APPLICANT: Stover, Jennifer A.  
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS  
; FILE REFERENCE: AM101080L  
; CURRENT APPLICATION NUMBER: US/10/717,597  
; CURRENT FILING DATE: 2003-11-21  
; PRIOR APPLICATION NUMBER: US 60/459,782  
; PRIOR FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: US 60/427,982  
; PRIOR FILING DATE: 2002-11-21  
; NUMBER OF SEQ ID NOS: 4904  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1329  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-717-597-1329

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1564 AACACTCGACTCTGCTGCTCATGGG 1588  
DB 1 AACACTCGACTCTGCTGCTCATGGG 25

RESULT 17  
US-10-956-157-25933  
; Sequence 25933, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25933  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25933

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 494 CTTCTACTTCTGGATGAATGGTGAC 518  
DB 1 CTTCTACTTCTGGATGAATGGTGAC 25

RESULT 18  
US-10-956-157-25934  
; Sequence 25934, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

```
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25934
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25934

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 493 CCTTCTACTTCTGGATGAATGGTGA 517
Db 1 CCTTCTACTTCTGGATGAATGGTGA 25

RESULT 19
US-10-956-157-25935
; Sequence 25935, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25935
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25935

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 495 TTCTACTTCTGGATGAATGGTGACC 519
Db 1 TTCTACTTCTGGATGAATGGTGACC 25

RESULT 20
US-10-956-157-25936
; Sequence 25936, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25936
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25936
```

```
Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 300 CTAATGAGACCAAGGGAATCAGAGA 324
Db 1 CTAATGAGACCAAGGGAATCAGAGA 25

RESULT 21
US-10-956-157-25937
; Sequence 25937, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25937
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25937

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 301 TAAATGAGACCAAGGGAATCAGAGAC 325
Db 1 TAAATGAGACCAAGGGAATCAGAGAC 25

RESULT 22
US-10-956-157-25938
; Sequence 25938, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25938
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25938

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 281 GAAGAAGAAAGAGATGCCCTAAAT 305
Db 1 GAAGAAGAAAGAGATGCCCTAAAT 25

RESULT 23
US-10-956-157-25939
; Sequence 25939, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25939
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25939

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 282 AAGAAGAAAGAGGATGCCCTAAATG 306
      |||||
Db 1 AAGAAGAAAGAGGATGCCCTAAATG 25

RESULT 24
US-10-956-157-25940
; Sequence 25940, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25940
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25940

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 284 GAAGAAGAGGATGCCCTAAATGAG 308
      |||||
Db 1 GAAGAAGAGGATGCCCTAAATGAG 25

RESULT 25
US-10-956-157-25941
; Sequence 25941, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25941
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25941

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 284 GAAGAAGAGGATGCCCTAAATGAG 308
      |||||
Db 1 GAAGAAGAGGATGCCCTAAATGAG 25

RESULT 26
US-10-956-157-25942
; Sequence 25942, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25942
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25942

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 AGAAGAAAGAGGATGCCCTAAATGA 307
      |||||
Db 1 AGAAGAAAGAGGATGCCCTAAATGA 25

RESULT 27
US-10-956-157-25943
; Sequence 25943, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25943
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25943

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAAGAGGATGCCCTAAA 304
      |||||
Db 1 AGAAGAAAGAGGATGCCCTAAA 25

RESULT 28
US-10-956-157-25944
; Sequence 25944, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```

Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 AAGAAGAGGATGCCCTAAATGAGA 309
      |||||
Db 1 AAGAAGAGGATGCCCTAAATGAGA 25

RESULT 26
US-10-956-157-25942
; Sequence 25942, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25942
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25942

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 AGAAGAAAGAGGATGCCCTAAATGA 307
      |||||
Db 1 AGAAGAAAGAGGATGCCCTAAATGA 25

RESULT 27
US-10-956-157-25943
; Sequence 25943, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25943
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25943

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAAGAGGATGCCCTAAA 304
      |||||
Db 1 AGAAGAAAGAGGATGCCCTAAA 25

RESULT 28
US-10-956-157-25944
; Sequence 25944, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25944
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25944

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 279 AAGAAGAAGAAGAGGATGCCCTAA 303
      |||||
Db 1 AAGAAGAAGAAGAGGATGCCCTAA 25

RESULT 29
US-10-956-157-25945
; Sequence 25945, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25945
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25945

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 492 CCCTTCTACTTCTGGATGAATGGTG 516
      |||||
Db 1 CCCTTCTACTTCTGGATGAATGGTG 25

RESULT 30
US-10-956-157-25946
; Sequence 25946, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25946
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25946

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 492 CCCTTCTACTTCTGGATGAATGGTG 516
      |||||
Db 1 CCCTTCTACTTCTGGATGAATGGTG 25

```

```

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 496 TCTACTTCTGGATGAATGGTGACCG 520
      |||||
Db 1 TCTACTTCTGGATGAATGGTGACCG 25

RESULT 31
US-10-956-157-25947
; Sequence 25947, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25947
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25947

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 286 AGAAGAGGATGCCCTAAATGAGAC 310
      |||||
Db 1 AGAAGAGGATGCCCTAAATGAGAC 25

RESULT 32
US-10-956-157-25948
; Sequence 25948, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25948
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25948

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 278 CAAGAAGAGAGGATGCCCTA 302
      |||||
Db 1 CAAGAAGAGAGGATGCCCTA 25

RESULT 33
US-10-956-157-25949
; Sequence 25949, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

```

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25949  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25949

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1066 AATACAACGAGCTGCTAAAGTCCTA 1090  
|||||  
Db 1 AATACAACGAGCTGCTAAAGTCCTA 25

RESULT 34

US-10-956-157-25950  
; Sequence 25950, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25950  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25950

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 299 CCTAAATGAGACCGAGGAATCAGAG 323  
|||||  
Db 1 CCTAAATGAGACCGAGGAATCAGAG 25

RESULT 35

US-10-956-157-25951  
; Sequence 25951, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25951  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25951

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1048 CTGAGAGTTGACCGAGGAATACAA 1072  
|||||  
Db 1 CTGAGAGTTGACCGAGGAATACAA 25

RESULT 36

US-10-956-157-25952  
; Sequence 25952, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25952  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25952

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1064 GAAATACAACGAGCTGCTAAAGTCC 1088  
|||||  
Db 1 GAAATACAACGAGCTGCTAAAGTCC 25

RESULT 37

US-10-956-157-25953  
; Sequence 25953, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25953  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25953

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1063 GGAATACAACGAGCTGCTAAAGTC 1087  
|||||  
Db 1 GGAATACAACGAGCTGCTAAAGTC 25

RESULT 38

US-10-956-157-25954  
; Sequence 25954, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES



; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25954  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25954

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1067 ATACAAGAGCTGCTAAAGTCTTAC 1091  
Db 1 ATACAAGAGCTGCTAAAGTCTTAC 25

## RESULT 39

US-10-956-157-25955  
; Sequence 25955, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 25955

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-25955

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 398 GAAACAGACCTGCATGAAGTCTTAC 422  
Db 1 GAAACAGACCTGCATGAAGTCTTAC 25

## RESULT 40

US-10-956-157-25956  
; Sequence 25956, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 25956

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-25956

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 304 ATGAGACCAGGGGAATCAGAGACAAA 328  
Db 1 ATGAGACCAGGGGAATCAGAGACAAA 25

## RESULT 41

US-10-956-157-122144  
; Sequence 122144, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 122144

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-122144

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 850 AGACCCGCCCAACAGATTTCATCG 874  
Db 1 AGACCCGCCCAACAGATTTCATCG 25

## RESULT 42

US-10-956-157-127897  
; Sequence 127897, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 127897

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-127897

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 411 ATGAAGTTCTACGACCGCTCTGCA 435  
Db 1 ATGAAGTTCTACGACCGCTCTGCA 25

## RESULT 43

US-10-956-157-131009  
; Sequence 131009, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

```

; CURRENT APPLICATION NUMBER: US/10/956,157
;
; CURRENT FILING DATE: 2004-10-04
;
; NUMBER OF SEQ ID NOS: 319805
;
; SOFTWARE: PatentIn version 3.2
;
; SEQ ID NO 131009
;
; LENGTH: 25
;
; TYPE: DNA
;
; ORGANISM: Probe Sequence
;
US-10-956-157-131009

```

Query Match	1.5%;	Score 25;	DB 1;	Length 25;
Best Local Similarity	100.0%;	Pred. No. 72;		
Matches 25;	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;

Qy 561 ATGCTGGATGTCATGCAGGACCACT 585  
|||  
Db 1 ATGCTGGATGTCATGCAGGACCACT 25

RESULT 44  
US-10-956-157-134947  
; Sequence 134947, Application US/10956157  
; Publication No. US20050118625A1

[illegible]

```

; CURRENT APPLICATION NUMBER: US/10/956,15
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 134947

```

; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-134947

Query Match	1.5%;	Score 25;	DB 1;	Length 25;
Best Local Similarity	100.0%;	Pred. No. 72;		
Matches	25;	Conservative	0;	Mismatches
			0;	Indels
			0;	Gaps

Qy 334 AGGAGCTCCAGGAGTGTGCAATGA 358  
|||  
Db 1 AGGAGCTCCAGGAGTGTGCAATGA 25

RESULT 45  
US-10-956-157-135244  
; Sequence 135244, Application US/10956157  
; Publication No. US20050118625A1

```

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

```

```

; FILE REFERENCE: 001050-0150000 (AM) 10100805
;
; CURRENT APPLICATION NUMBER: US/10/956,15
;
; CURRENT FILING DATE: 2004-10-04
;
; NUMBER OF SEQ ID NOS: 319805
;
; SOFTWARE: PatentIn version 3.2
;
; SEQ ID NO 115244

```

```

; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-135244

```

Query Match	1.5%;	Score 25;	DB 1;	Length 25;
Best Local Similarity	100.0%;	Pred. No. 72;		
Matches	25;	Conservative	0;	Mismatches
			0;	Indels
			0;	Gaps

Qy 292 AGGATGCCCTAAATGAGACCAGGGA 316

REF ID: A7

US-10-956-157-140752  
; Sequence 140752, Application US/10956157  
; Publication No. US20050118625A1

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 334 AGGAGCTCCAGGAGTGTGCAATGA 358  
|||  
Db 1 AGGAGCTCCAGGAGTGTGCAATGA 25

SEQ ID	LENGTH
1	10
2	10
3	10
4	10
5	10
6	10
7	10
8	10
9	10
10	10
11	10
12	10
13	10
14	10
15	10
16	10
17	10
18	10
19	10
20	10
21	10
22	10
23	10
24	10
25	10
26	10
27	10
28	10
29	10
30	10
31	10
32	10
33	10
34	10
35	10
36	10
37	10
38	10
39	10
40	10
41	10
42	10
43	10
44	10
45	10
46	10
47	10
48	10
49	10
50	10
51	10
52	10
53	10
54	10
55	10
56	10
57	10
58	10
59	10
60	10
61	10
62	10
63	10
64	10
65	10
66	10
67	10
68	10
69	10
70	10
71	10
72	10
73	10
74	10
75	10
76	10
77	10
78	10
79	10
80	10
81	10
82	10
83	10
84	10
85	10
86	10
87	10
88	10
89	10
90	10
91	10
92	10
93	10
94	10
95	10
96	10
97	10
98	10
99	10
100	10

```

; LENGTH: 23
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-140752

```

```

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

```

```

; FILE REFERENCE: 001050-0150000 (AM) 10100805
;
; CURRENT APPLICATION NUMBER: US/10/956,15
;
; CURRENT FILING DATE: 2004-10-04
;
; NUMBER OF SEQ ID NOS: 319805
;
; SOFTWARE: PatentIn version 3.2
;
; SEQ ID NO 115244

```

; Sequenc

; PUBLICATION NO. US20050118625A1  
 ;  
 ; GENERAL INFORMATION:  
 ;  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Mounts William

Best Local Similarity 100.0%; Pred. NO. /2;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 292 AGGATGCCCTAAATGAGACCAGGGA 316

; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 141327  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-141327

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1299 ACGTCCCTGTAGAGTCTCCAGCA 1323  
Db 1 ACGTCCCTGTAGAGTCTCCAGCA 25

## RESULT 49

US-10-956-157-146594  
; Sequence 146594, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 146594  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-146594

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 889 ACCGGACTGTGTCCGGGAGATCCG 913  
Db 1 ACCGGACTGTGTCCGGGAGATCCG 25

## RESULT 50

US-10-956-157-146923  
; Sequence 146923, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 146923  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-146923

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 544 ACCGGCAGCAGCACATGCTGGA 568  
|||||

Db 1 ACCGGCAGCAGCACATGCTGGA 25

## RESULT 51

US-10-956-157-156812  
; Sequence 156812, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 156812  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-156812

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1379 AAAGCACCGGGAGGTGAGATGTG 1403  
Db 1 AAAGCACCGGGAGGTGAGATGTG 25

## RESULT 52

US-10-956-157-158656  
; Sequence 158656, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 158656  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-158656

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1083 AAGTCCTACCAGTGGGAAGATGCTCA 1107  
Db 1 AAGTCCTACCAGTGGGAAGATGCTCA 25

## RESULT 53

US-10-956-157-159440  
; Sequence 159440, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 159440  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-159440

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1071 AACGAGCTGCTAAAGTCTACCACT 1095  
|||||  
Db 1 AACGAGCTGCTAAAGTCTACCACT 25

## RESULT 54

US-10-956-157-168291  
; Sequence 168291, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 168291  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-168291

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 182 AATTCAAATGCTGTCAACGGGTG 206  
|||||  
Db 1 AATTCAAATGCTGTCAACGGGTG 25

## RESULT 55

US-10-956-157-172467  
; Sequence 172467, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 172467  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-172467

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1140 CAGTTTAAGTGGGTGTCGGCTGG 1164  
|||||  
Db 1 CAGTTTAAGTGGGTGTCGGCTGG 25

## RESULT 56

US-10-956-157-174696  
; Sequence 174696, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 174696  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-174696

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 462 CAGCTTGAGGAGTTCCTGAACACG 486  
|||||  
Db 1 CAGCTTGAGGAGTTCCTGAACACG 25

## RESULT 57

US-10-956-157-174708  
; Sequence 174708, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 174708  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-174708

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 780 CAGCCCTTCCTTGAGATGATACACG 804  
|||||  
Db 1 CAGCCCTTCCTTGAGATGATACACG 25

## RESULT 58

US-10-956-157-174902  
; Sequence 174902, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 174902  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-174902

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1441 CAGCTCCCCCAAGATGAGCTGCAG 1465  
|||||  
Db 1 CAGCTCCCCCAAGATGAGCTGCAG 25

## RESULT 59

US-10-956-157-176821  
; Sequence 176821, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 176821  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-176821

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 948 CAGTGTGACAAAGTCCCGGAGATCT 972  
|||||  
Db 1 CAGTGTGACAAAGTCCCGGAGATCT 25

## RESULT 60

US-10-956-157-178550  
; Sequence 178550, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 178550  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-178550

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 602 CATCATAGACGAGCTCTCCAGGAC 626  
|||||  
Db 1 CATCATAGACGAGCTCTCCAGGAC 25

## RESULT 61

US-10-956-157-178867  
; Sequence 178867, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 178867  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-178867

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1289 CATCACTGTGACGGTCCCTGTAGAA 1313  
|||||  
Db 1 CATCACTGTGACGGTCCCTGTAGAA 25

## RESULT 62

US-10-956-157-186901  
; Sequence 186901, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 186901  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186901

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1602 CTCCTGCATGCAACTAATTCATAA 1626  
|||||  
Db 1 CTCCTGCATGCAACTAATTCATAA 25

## RESULT 63

US-10-956-157-186902  
; Sequence 186902, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 186902  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186902

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1602 CTCCTGCATGCAACTAATTCAATAA 1626  
|||||  
Db 1 CTCCTGCATGCAACTAATTCAATAA 25

## RESULT 64

US-10-956-157-186903  
; Sequence 186903, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 186903  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186903

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1602 CTCCTGCATGCAACTAATTCAATAA 1626  
|||||  
Db 1 CTCCTGCATGCAACTAATTCAATAA 25

## RESULT 65

US-10-956-157-186908  
; Sequence 186908, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 186908  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186908

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1482 CTCGACGTCCACCAAGTAACAGGCC 1506  
|||||  
Db 1 CTCGACGTCCACCAAGTAACAGGCC 25

## RESULT 66

US-10-956-157-186914  
; Sequence 186914, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 186914  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186914

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 CTCGAGTCGCTGAGAGGTTGACCA 1062  
|||||  
Db 1 CTCGAGTCGCTGAGAGGTTGACCA 25

## RESULT 67

US-10-956-157-188008  
; Sequence 188008, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 188008  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-188008

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 78 CTGCTGCTGACCTGGGAGAGTGGGC 102  
|||||  
Db 1 CTGCTGCTGACCTGGGAGAGTGGGC 25

## RESULT 68

US-10-956-157-188038  
; Sequence 188038, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 188038

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-188038

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 407 CTGCATGAAGTTCTACGACCGTC 431
      |||||
Db 1 CTGCATGAAGTTCTACGACCGTC 25

RESULT 69
US-10-956-157-189641
; Sequence 189641, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189641
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-189641

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 976 CTGTGGACTGTTCCACCACCAACCC 1000
      |||||
Db 1 CTGTGGACTGTTCCACCACCAACCC 25

RESULT 70
US-10-956-157-191487
; Sequence 191487, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 191487
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-191487

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 884 CGATGACCGGACTGTGTCGGGGAG 908
      |||||
Db 1 CGATGACCGGACTGTGTCGGGGAG 25

RESULT 71
```

```

US-10-956-157-193107
; Sequence 193107, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193107
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193107

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 490 CGCCTTCTACTTCTGGATGATCG 514
      |||||
Db 1 CGCCTTCTACTTCTGGATGATCG 25

RESULT 72
US-10-956-157-193726
; Sequence 193726, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193726
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193726

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 341 CCCAGGAGTGTGCAATGAGACCATG 365
      |||||
Db 1 CCCAGGAGTGTGCAATGAGACCATG 25

RESULT 73
US-10-956-157-194937
; Sequence 194937, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 194937
; LENGTH: 25
```

```
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-194937

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 390 CCTGCTGAAACAGACCTGCATGA 414
      |||||
Db 1 CCCTGCTGAAACAGACCTGCATGA 25

RESULT 74
US-10-956-157-195328
; Sequence 195328, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-195328

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 854 CCCGCCAACAGATTTCATACGAGAA 878
      |||||
Db 1 CCCGCCAACAGATTTCATACGAGAA 25

RESULT 75
US-10-956-157-195368
; Sequence 195368, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195368
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-195368

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1467 CCCCAGAGAGAGCTCTGCACGTCA 1491
      |||||
Db 1 CCCCAGAGAGAGCTCTGCACGTCA 25

RESULT 76
US-10-956-157-196424
```

```
; Sequence 196424, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 196424
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-196424

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 590 CCGCGGTCGACGATCATAGACGAG 614
      |||||
Db 1 CCGCGGTCGACGATCATAGACGAG 25

RESULT 77
US-10-956-157-199713
; Sequence 199713, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 199713
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-199713

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 106 TCCTGGGGACCGACGCTCTCAGA 130
      |||||
Db 1 TCCTGGGGACCGACGCTCTCAGA 25

RESULT 78
US-10-956-157-206442
; Sequence 206442, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 206442
; LENGTH: 25
; TYPE: DNA
```



```
; ORGANISM: Probe Sequence
US-10-956-157-206442

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 782 GCCCTTCCTTGAGATGATACACGAG 806
      |||
Db 1 GCCCTTCCTTGAGATGATACACGAG 25

RESULT 79
US-10-956-157-208499
; Sequence 208499, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208499
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-208499

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1121 GCTGGAGCAGCTGACGACGAGTGT 1145
      |||
Db 1 GCTGGAGCAGCTGACGACGAGTGT 25

RESULT 80
US-10-956-157-212934
; Sequence 212934, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212934
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212934

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1364 GCAGGAATACCGCAAAAGCACCGG 1388
      |||
Db 1 GCAGGAATACCGCAAAAGCACCGG 25

RESULT 81
US-10-956-157-215054
; Sequence 215054, Application US/10956157
```

```
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 215054
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-215054

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 GCAGACGCACATGCTGGATGTCATG 575
      |||
Db 1 GCAGACGCACATGCTGGATGTCATG 25

RESULT 82
US-10-956-157-216983
; Sequence 216983, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216983
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216983

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 247 GCAGACACTGCTCAGCAACCTAGA 271
      |||
Db 1 GCAAGACACTGCTCAGCAACCTAGA 25

RESULT 83
US-10-956-157-218349
; Sequence 218349, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218349
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
```

## US-10-956-157-218349

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1596 GAATTGCTCTGCGATGCAACTAATT 1620  
|||||  
Db 1 GAATTGCTCTGCGATGCAACTAATT 25

## RESULT 84

US-10-956-157-218350  
; Sequence 218350, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 218350

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-218350

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1596 GAATTGCTCTGCGATGCAACTAATT 1620  
|||||  
Db 1 GAATTGCTCTGCGATGCAACTAATT 25

## RESULT 85

US-10-956-157-218351  
; Sequence 218351, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 218351

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-218351

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1596 GAATTGCTCTGCGATGCAACTAATT 1620  
|||||  
Db 1 GAATTGCTCTGCGATGCAACTAATT 25

## RESULT 86

US-10-956-157-219734  
; Sequence 219734, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 219734

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-219734

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1311 GAAGTCTCCAGGAAGAACCTTAAT 1335  
|||||  
Db 1 GAAGTCTCCAGGAAGAACCTTAAT 25

## RESULT 87

US-10-956-157-220245  
; Sequence 220245, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 220245

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-220245

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 941 GAAGGACCAGTGTGACAAGTCCGG 965  
|||||  
Db 1 GAAGGACCAGTGTGACAAGTCCGG 25

## RESULT 88

US-10-956-157-221279  
; Sequence 221279, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 221279

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-221279

```

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1588 GAAGAACAGAAATTCCTCTGCATGC 1612
Db 1 GAAGAACAGAAATTCCTCTGCATGC 25

RESULT 89
US-10-956-157-221280
; Sequence 221280, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 221280
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-221280

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1588 GAAGAACAGAAATTCCTCTGCATGC 1612
Db 1 GAAGAACAGAAATTCCTCTGCATGC 25

RESULT 90
US-10-956-157-222407
; Sequence 222407, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 222407
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-222407

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1325 GAACCCCTAAATTTATGGACACCGTG 1349
Db 1 GAACCCCTAAATTTATGGACACCGTG 25

RESULT 91
US-10-956-157-225352
; Sequence 225352, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 225352
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-225352

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1355 GAAAGCGCTGCAGGAATACCGCAA 1379
Db 1 GAAAGCGCTGCAGGAATACCGCAA 25

RESULT 92
US-10-956-157-228789
; Sequence 228789, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 228789
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228789

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1571 GACTCTGCTGCTCATGGGAAGAACA 1595
Db 1 GACTCTGCTGCTCATGGGAAGAACA 25

RESULT 93
US-10-956-157-229312
; Sequence 229312, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 229312
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-229312

```

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 119 GAGGCTCTCAGCAATGAGTCCAG 143  
|||||  
Db 1 GAGGCTCTCAGCAATGAGTCCAG 25

## RESULT 94

US-10-956-157-230136  
; Sequence 230136, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 230136

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-230136

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 404 GACTGTCATGAGTTCTACGACGC 428  
|||||  
Db 1 GACTGTCATGAGTTCTACGACGC 25

## RESULT 95

US-10-956-157-230317  
; Sequence 230317, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 230317

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-230317

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1185 GACCAGTACTATCTCGGGGTACCA 1209  
|||||  
Db 1 GACCAGTACTATCTCGGGGTACCA 25

## RESULT 96

US-10-956-157-231573  
; Sequence 231573, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 231573  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-231573

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 135 GAGCTCCAGGAAATGTCCAATCAGG 159  
|||||  
Db 1 GAGCTCCAGGAAATGTCCAATCAGG 25

## RESULT 97

US-10-956-157-231724  
; Sequence 231724, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 231724

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-231724

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1074 GAGCTGCTAAAGTCCTACCAGTGGG 1098  
|||||  
Db 1 GAGCTGCTAAAGTCCTACCAGTGGG 25

## RESULT 98

US-10-956-157-231783  
; Sequence 231783, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 231783

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-231783

Query Match 1.5%; Score 25; DB 1; Length 25;

```
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1137 GAGCAGTTTAACTGGGTGTCCTCCGCG 1161
      |||||
Db 1 GAGCAGTTTAACTGGGTGTCCTCCGCG 25

RESULT 99
US-10-956-157-232704
; Sequence 232704, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 232704
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-232704

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1341 GAGACCGTGGCGGAGAAAGCGCTGC 1365
      |||||
Db 1 GAGACCGTGGCGGAGAAAGCGCTGC 25

RESULT 100
US-10-956-157-233030
; Sequence 233030, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233030
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233030

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 GAGACAAAGCTGAAGAGCTCCAG 345
      |||||
Db 1 GAGACAAAGCTGAAGAGCTCCAG 25

RESULT 101
US-10-956-157-233762
; Sequence 233762, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233762
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233762

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 966 GAGATCTTGCTGTGGACTGTTCGA 990
      |||||
Db 1 GAGATCTTGCTGTGGACTGTTCGA 25

RESULT 102
US-10-956-157-235882
; Sequence 235882, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 235882
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-235882

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 GAGGAGTTCTCTGAACACGAGCTCG 492
      |||||
Db 1 GAGGAGTTCTCTGAACACGAGCTCG 25

RESULT 103
US-10-956-157-236817
; Sequence 236817, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236817
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-236817

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 GAGGAGTTCTCTGAACACGAGCTCG 492
      |||||
Db 1 GAGGAGTTCTCTGAACACGAGCTCG 25
```

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 GAGCATGATGAAGACTCTGCTGCT 67  
|||||

Db 1 GAGCATGATGAAGACTCTGCTGCT 25

## RESULT 104

US-10-956-157-237638  
; Sequence 237638, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 237638

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-237638

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 794 GATGATACACGAGGCTCAGCAGGCC 818

|||||

Db 1 GATGATACACGAGGCTCAGCAGGCC 25

## RESULT 105

US-10-956-157-238337  
; Sequence 238337, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 238337

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-238337

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 506 GATGAATGGTGACCGCATCGACTCC 530

|||||

Db 1 GATGAATGGTGACCGCATCGACTCC 25

## RESULT 106

US-10-956-157-243092  
; Sequence 243092, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 243092

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-243092

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 416 GTTCTACGCACGCGTCTGCAGAGT 440

|||||

Db 1 GTTCTACGCACGCGTCTGCAGAGT 25

## RESULT 107

US-10-956-157-252760  
; Sequence 252760, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 252760

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-252760

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1044 GTCGCTGAGAGTTGACCAAGAAAT 1068

|||||

Db 1 GTCGCTGAGAGTTGACCAAGAAAT 25

## RESULT 108

US-10-956-157-253138  
; Sequence 253138, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 253138

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-253138

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 596 GTCCAGCATCATGACGAGCTCTTC 620  
| | | | | | | | | | | | | | | | | |  
Db 1 GTCCAGCATCATGACGAGCTCTTC 25

RESULT 109  
US-10-956-157-255424  
; Sequence 255424, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 255424  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-255424

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1394 GTGAGATGTGGATGTTGCTTTTGCA 1418  
| | | | | | | | | | | | | | | | | |  
Db 1 GTGAGATGTGGATGTTGCTTTTGCA 25

RESULT 110  
US-10-956-157-255957  
; Sequence 255957, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 255957  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-255957

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 383 GTGTAAGCCCTGCCTGAAACAGACC 407  
| | | | | | | | | | | | | | | | | |  
Db 1 GTGTAAGCCCTGCCTGAAACAGACC 25

RESULT 111  
US-10-956-157-256203  
; Sequence 256203, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 256203  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-256203

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 348 GTGTGCAATGAGACCATGATGGCCC 372  
| | | | | | | | | | | | | | | | | |  
Db 1 GTGTGCAATGAGACCATGATGGCCC 25

RESULT 112  
US-10-956-157-261789  
; Sequence 261789, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 261789  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-261789

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1259 GGTGTCGTGAAGCTCTTTGACTCT 1283  
| | | | | | | | | | | | | | | | | |  
Db 1 GGTGTCGTGAAGCTCTTTGACTCT 25

RESULT 113  
US-10-956-157-266662  
; Sequence 266662, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 266662  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-266662

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 566 GGATGTCATCAGGACCACCTTCAGC 590  
| | | | | | | | | | | | | | | | | | | |  
Db 1 GGATGTCATCAGGACCACCTTCAGC 25

RESULT 114  
US-10-956-157-268124  
; Sequence 268124, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 268124  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-268124

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 GGAGAGTGGCAGGTCTCTGGGGAC 116  
| | | | | | | | | | | | | | | | | | | |  
Db 1 GGAGAGTGGCAGGTCTCTGGGGAC 25

RESULT 115  
US-10-956-157-269972  
; Sequence 269972, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 269972  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-269972

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1163 GGCAAACTCACCAGGCGGAAGAC 1187  
| | | | | | | | | | | | | | | | | | | |  
Db 1 GGCAAACTCACCAGGCGGAAGAC 25

RESULT 116  
US-10-956-157-273702  
; Sequence 273702, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 273702  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-273702

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 879 GCGCAGCATGACCGGACTGTGTGCC 903  
| | | | | | | | | | | | | | | | | | | |  
Db 1 GCGCAGCATGACCGGACTGTGTGCC 25

RESULT 117  
US-10-956-157-274079  
; Sequence 274079, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 274079  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-274079

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 927 GGCTGCTCGGATGAAGGACCACT 951  
| | | | | | | | | | | | | | | | | | | |  
Db 1 GGCTGCTCGGATGAAGGACCACT 25

RESULT 118  
US-10-956-157-274264  
; Sequence 274264, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 274264  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-274264

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1179 GCGGAAGACCACTACTATCTCGGG 1203



Db 1 GGCAGAACCTAGTACTATCTGCGGG 25  
|||||  
RESULT 119  
US-10-956-157-274647  
; Sequence 274647, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 274647  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-274647  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 20 GCGGTGCAAGACTCCAGAAATTGGA 44  
|||||  
Db 1 GCGGTGCAAGACTCCAGAAATTGGA 25  
|||||  
RESULT 120  
US-10-956-157-279222  
; Sequence 279222, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 279222  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-279222  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1295 TGTGACGGTCCCTGTAGAAGTCTCC 1319  
|||||  
Db 1 TGTGACGGTCCCTGTAGAAGTCTCC 25  
|||||  
RESULT 121  
US-10-956-157-281215  
; Sequence 281215, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157

; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 281215  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-281215  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 150 TCCAATCAGGGAAGTAAGTAGGTCA 174  
|||||  
Db 1 TCCAATCAGGGAAGTAAGTAGGTCA 25  
|||||  
RESULT 122  
US-10-956-157-285427  
; Sequence 285427, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 285427  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-285427  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 52 TGAAGACTCTGCTGCTGCTTTGTGGG 76  
|||||  
Db 1 TGAAGACTCTGCTGCTGCTTTGTGGG 25  
|||||  
RESULT 123  
US-10-956-157-285561  
; Sequence 285561, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 285561  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-285561  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 351 TGCATGAGACCATGATGCGCCCTCT 375  
|||||

Db 1 TGCATGAGACCATGATGGCCCTCT 25

RESULT 124

US-10-956-157-285688

; Sequence 285688, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 285688

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-285688

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 256 TGCTCAGCAACCTAGAGAGCCAA 280

Db 1 TGCTCAGCAACCTAGAGAGCCAA 25

RESULT 125

US-10-956-157-287832

; Sequence 287832, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 287832

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-287832

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 960 TGCCGGGAGATCTGTCTGTGGACT 984

Db 1 TGCCGGGAGATCTGTCTGTGGACT 25

RESULT 126

US-10-956-157-291738

; Sequence 291738, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 291738

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-291738

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1002 TCCAGGCTAAGCTGCGGGGAGC 1026

Db 1 TCCAGGCTAAGCTGCGGGGAGC 25

RESULT 127

US-10-956-157-292100

; Sequence 292100, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 292100

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-292100

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1264 TCGTGAAGCTCTTTGACTCTGATCC 1288

Db 1 TCGTGAAGCTCTTTGACTCTGATCC 25

RESULT 128

US-10-956-157-292272

; Sequence 292272, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 292272

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-292272

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1569 TCGACTCTCTGCTCATGGAAGAA 1593

Db 1 TCGACTCTCTGCTCATGGAAGAA 25

```
RESULT 129
US-10-956-157-297166
; Sequence 297166, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297166
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297166

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1171 TCACGCAAGGCGAAGACCAAGTACTA 1195
Db      1 TCACGCAAGGCGAAGACCAAGTACTA 25

RESULT 130
US-10-956-157-302171
; Sequence 302171, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 302171
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-302171

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      871 TACGAGAAGGCGACGATGACCGGAC 895
Db      1 TACGAGAAGGCGACGATGACCGGAC 25

RESULT 131
US-10-956-157-316681
; Sequence 316681, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 316681
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-316681

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1244 TTCGGGTGTCACGTGAGGTGTCGTG 1268
Db      1 TTCGGGTGTCACGTGAGGTGTCGTG 25

RESULT 132
US-10-956-157-317598
; Sequence 317598, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 317598
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-317598

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1240 TTCCTCCGGTGTCACTGAGGTGCT 1264
Db      1 TTCCTCCGGTGTCACTGAGGTGCT 25

RESULT 133
US-10-956-157-287991
; Sequence 287991, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287991
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287991

Query Match      1.5%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      8 GCCGCTGACCGAGCGGTGCAAGA 31
Db      2 GCCGCTGACCGAGCGGTGCAAGA 25
```

```
RESULT 134
US-10-719-956-187214
; Sequence 187214, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 187214
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-187214

Query Match      1.4%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 969 ATCTGCTGTGGACTGTTCCACCA 993
Db 1 ATCTGCTGTGGACTGTTCCACCA 25

RESULT 135
US-10-080-794-16
; Sequence 16, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 23
; TYPE: DNA
; ORGANISM: HUMAN
US-10-080-794-16

Query Match      1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 177 AAGAAATTCAAAATGCTGCA 199
Db 1 AAGAAATTCAAAATGCTGCA 23

RESULT 136
US-10-080-794-17/c
; Sequence 17, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 23
; TYPE: DNA
; ORGANISM: HUMAN
US-10-080-794-17

Query Match      1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 AAGTCCGGGAGATCTTGCTGT 979
Db 23 AAGTCCGGGAGATCTTGCTGT 1

RESULT 137
US-10-380-124-5/c
; Sequence 5, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 5
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-380-124-5

Query Match      1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 789 CTTGAGATGATACACGAGGCTCA 811
Db 23 CTTGAGATGATACACGAGGCTCA 1

RESULT 138
US-10-646-436-57
; Sequence 57, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
```

```

; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
; US-10-646-436-57

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AACGAGCTCGCCCTTCTACTT 502
      |||||
Db 1 AACGAGCTCGCCCTTCTACTT 23

RESULT 139
US-10-646-436-60
; Sequence 60, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
; US-10-646-436-60

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCGCGAGCTT 733
      |||||
Db 1 AAGTCCCGCATCGTCGCGAGCTT 23

RESULT 140
US-10-646-436-63
; Sequence 63, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 63
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
; US-10-646-436-63

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCGCGAGCTT 733
      |||||
Db 1 AAGTCCCGCATCGTCGCGAGCTT 23

RESULT 141
US-10-646-436-66
; Sequence 66, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
; US-10-646-436-66

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATATAAACTGCTT 1635
      |||||
Db 1 AACTAATTCATATAAACTGCTT 23

RESULT 142
US-10-646-436-68
; Sequence 68, Application US/10646436
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 68
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
; US-10-646-436-68

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 46 GCATGATGAAGACTCTGCTGCTG 68
      |||||
Db 1 GCATGATGAAGACTCTGCTGCTG 23

RESULT 143
US-10-956-157-291041
; Sequence 291041, Application US/10956157
; Publication No. US20050118625A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291041
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-291041

Query Match      1.4%; Score 23; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1114 CCTCCTTGCTGGAGCAGCTGAAC 1136
      |||||
Db 3 CCTCCTTGCTGGAGCAGCTGAAC 25

RESULT 143
US-10-980-850-34/c
; Sequence 34, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Reverse Primer for OAS1
US-10-980-850-34

Query Match      1.3%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1072 ACGAGCTGCTAAAGTCCTACCA 1093
      |||||
Db 22 ACGAGCTGCTAAAGTCCTACCA 1

RESULT 144
US-10-956-157-167169
; Sequence 167169, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167169
; LENGTH: 25
; TYPE: DNA
```

```
; ORGANISM: Probe Sequence
US-10-956-157-167169

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1622 AATAAACTGCTCTGTGAGCTG 1643
      |||||
Db 1 AATAAACTGCTCTGTGAGCTG 22

RESULT 145
US-10-956-157-167170
; Sequence 167170, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167170
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-167170

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1622 AATAAACTGCTCTGTGAGCTG 1643
      |||||
Db 1 AATAAACTGCTCTGTGAGCTG 22

RESULT 146
US-10-956-157-167171
; Sequence 167171, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167171
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-167171

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1622 AATAAACTGCTCTGTGAGCTG 1643
      |||||
Db 1 AATAAACTGCTCTGTGAGCTG 22

RESULT 147
US-10-956-157-228788
; Sequence 228788, Application US/10956157
```

```

; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228788
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228788

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1571 GACTCTGCTGCTCATGGAGA 1592
Db      1 GACTCTGCTGCTCATGGAGA 22

RESULT 148
US-10-956-157-279365
; Sequence 279365, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 279365
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-279365

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1400 TGTGATGTTGCTTTTGACCT 1421
Db      1 TGTGATGTTGCTTTTGACCT 22

RESULT 149
US-10-900-56804
; Sequence 56804, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 56804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-56804

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1133 GAACGACGAGTTTAACCTGGGTGTC 1157
Db      1 GAACGACGAGTTTAACCTGGGTGTC 25

RESULT 150
US-10-719-900-417945
; Sequence 417945, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417945
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417945

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1133 GAACGACGAGTTTAACCTGGGTGTC 1157
Db      1 GAACGACGAGTTTAACCTGGGTGTC 25

RESULT 151
US-10-719-900-417946
; Sequence 417946, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417946
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417946

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1133 GAACGACGAGTTTAACCTGGGTGTC 1157
Db      1 GAACGACGAGTTTAACCTGGGTGTC 25

RESULT 152
US-10-719-900-815718
; Sequence 815718, Application US/10719900
; Publication No. US20050026164A1
```

```

US-10-719-900-56804

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1269 AACCTCTTTGACCTCTGATCCCATCA 1293
Db      1 AAGCTGTTTGACCTCTGATCCCATCA 25

RESULT 150
US-10-719-900-417945
; Sequence 417945, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417945
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417945

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1133 GAACGACGAGTTTAACCTGGGTGTC 1157
Db      1 GAACGACGAGTTTAACCTGGGTGTC 25

RESULT 151
US-10-719-900-417946
; Sequence 417946, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417946
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417946

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1133 GAACGACGAGTTTAACCTGGGTGTC 1157
Db      1 GAACGACGAGTTTAACCTGGGTGTC 25

RESULT 152
US-10-719-900-815718
; Sequence 815718, Application US/10719900
; Publication No. US20050026164A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 815718
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-815718

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1245 TCCGGTGTCACTGAGGTGGTGGTGA 1269
      ||| ||||| ||||| ||||| |||||
Db 1 TCCGGTGTCACTGAGGTGGTGGTGA 25

RESULT 153
US-10-719-900-892165
; Sequence 892165, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 892165
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-892165

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 TGGGTGTCCGGTGGCAACCTCA 1173
      ||| ||||| ||||| ||||| |||||
Db 1 TGGGTGTCCAGCTGGCTAACCTCA 25

RESULT 154
US-10-809-189-31760
; Sequence 31760, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
```

```
; SEQ ID NO 31760
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31760

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1270 AGCTCTTTGACTCTGATCCCATCAC 1294
      ||| ||||| ||||| ||||| |||||
Db 1 AGCTGTTTGACTCTGACCCCATCAC 25

RESULT 155
US-10-719-956-30749/c
; Sequence 30749, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 30749
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-30749

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1120 TGCTGGAGCAGCTGAACGAGCAGTT 1144
      ||||| ||||| ||||| ||||| |||||
Db 25 TGCTGGACAGCTGAACGACCAGTT 1

RESULT 156
US-10-719-956-187213
; Sequence 187213, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 187213
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-187213

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 ATCTTGCTGTGTGCACTGTTCCACCA 993
      ||||| ||||| ||||| ||||| |||||
Db 1 ATCTTGCTGTGCACTGTTCCACCA 25
```



```

RESULT 157
US-10-719-956-374026/c
; Sequence 374026, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 374026
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-374026

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      975 TCTGTGGACTTTCCACCAACACC 999
Db      25 TCTGTGGACTTTCCACCAACATC 1

RESULT 158
US-10-719-956-501381
; Sequence 501381, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 501381
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-501381

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1266 GTGAAGCTCTTTGACTCTGATCCCA 1290
Db      1 GTGAAGCTCTTTGACTCTGATCCCA 25

RESULT 159
US-10-719-956-612442/c
; Sequence 612442, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 612442
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-612442

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1149 TGGGTGTCCTCCGCTGCAACACTCA 1173
Db      25 TGGGTGTCCTCCGCTGCTTAACCTCA 1

RESULT 160
US-09-944-326-3/c
; Sequence 3, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-3

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      16 CCGAGGCGCTGCAAGACTCCA 36
Db      21 CCGAGGCGCTGCAAGACTCCA 1

RESULT 161
US-09-944-326-4/c
; Sequence 4, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
US-09-944-326-4/c

```

; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-4

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 48 ATGATGAAGACTCTGCTGCTG 68  
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 162  
US-09-944-326-5/c  
; Sequence 5, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-5

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 114 GACCAGACGGTCTCAGACAAT 134  
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 163  
US-09-944-326-6/c  
; Sequence 6, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 6  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN

; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-6

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 316 AATCAGACAAAGCTGAAGG 336  
Db 21 AATCAGACAAAGCTGAAGG 1

RESULT 164  
US-09-944-326-7/c  
; Sequence 7, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 7  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-7

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 515 TGACCGCATCGACTCCCTGCT 535  
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 165  
US-09-944-326-8/c  
; Sequence 8, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 8  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN

US-09-944-326-8

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 716 CCGCATGCTCCGAGCTTGAT 736  
 Db 21 CCGCATGCTCCGAGCTTGAT 1

RESULT 166

US-09-944-326-9/c  
 ; Sequence 9, Application US/09944326  
 ; Patent No. US20020128220A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Gleave, Martin  
 ; APPLICANT: Rennie, Paul S.  
 ; APPLICANT: Miyake, Hideaki  
 ; APPLICANT: Nelson, Colleen  
 ; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
 ; FILE REFERENCE: UBC P-020-2  
 ; CURRENT APPLICATION NUMBER: US/09/944,326  
 ; CURRENT FILING DATE: 2001-08-30  
 ; PRIOR APPLICATION NUMBER: 60/121,726  
 ; PRIOR FILING DATE: 1999-02-26  
 ; PRIOR APPLICATION NUMBER: 09/913,325  
 ; PRIOR FILING DATE: 2001-08-10  
 ; NUMBER OF SEQ ID NOS: 14  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 9  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: HUMAN  
 ; FEATURE:  
 ; OTHER INFORMATION: antisense TRPM-2 ODN  
 US-09-944-326-9

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 916 ACAACTCCACGGGCTGCTGC 936  
 Db 21 ACAACTCCACGGGCTGCTGC 1

RESULT 167

US-09-944-326-10/c  
 ; Sequence 10, Application US/09944326  
 ; Patent No. US20020128220A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Gleave, Martin  
 ; APPLICANT: Rennie, Paul S.  
 ; APPLICANT: Miyake, Hideaki  
 ; APPLICANT: Nelson, Colleen  
 ; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
 ; FILE REFERENCE: UBC P-020-2  
 ; CURRENT APPLICATION NUMBER: US/09/944,326  
 ; CURRENT FILING DATE: 2001-08-30  
 ; PRIOR APPLICATION NUMBER: 60/121,726  
 ; PRIOR FILING DATE: 1999-02-26  
 ; PRIOR APPLICATION NUMBER: 09/913,325  
 ; PRIOR FILING DATE: 2001-08-10  
 ; NUMBER OF SEQ ID NOS: 14  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 10  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: HUMAN  
 ; FEATURE:  
 ; OTHER INFORMATION: antisense TRPM-2 ODN  
 US-09-944-326-10

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
 Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 168

US-09-944-326-11/c  
 ; Sequence 11, Application US/09944326  
 ; Patent No. US20020128220A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Gleave, Martin  
 ; APPLICANT: Rennie, Paul S.  
 ; APPLICANT: Miyake, Hideaki  
 ; APPLICANT: Nelson, Colleen  
 ; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
 ; FILE REFERENCE: UBC P-020-2  
 ; CURRENT APPLICATION NUMBER: US/09/944,326  
 ; CURRENT FILING DATE: 2001-08-30  
 ; PRIOR APPLICATION NUMBER: 60/121,726  
 ; PRIOR FILING DATE: 1999-02-26  
 ; PRIOR APPLICATION NUMBER: 09/913,325  
 ; PRIOR FILING DATE: 2001-08-10  
 ; NUMBER OF SEQ ID NOS: 14  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 11  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: HUMAN  
 ; FEATURE:  
 ; OTHER INFORMATION: antisense TRPM-2 ODN  
 US-09-944-326-11

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1316 CTCGAGGAAGAACCCCTAAATT 1336  
 Db 21 CTCGAGGAAGAACCCCTAAATT 1

RESULT 169

US-09-944-326-12/c  
 ; Sequence 12, Application US/09944326  
 ; Patent No. US20020128220A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Gleave, Martin  
 ; APPLICANT: Rennie, Paul S.  
 ; APPLICANT: Miyake, Hideaki  
 ; APPLICANT: Nelson, Colleen  
 ; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
 ; FILE REFERENCE: UBC P-020-2  
 ; CURRENT APPLICATION NUMBER: US/09/944,326  
 ; CURRENT FILING DATE: 2001-08-30  
 ; PRIOR APPLICATION NUMBER: 60/121,726  
 ; PRIOR FILING DATE: 1999-02-26  
 ; PRIOR APPLICATION NUMBER: 09/913,325  
 ; PRIOR FILING DATE: 2001-08-10  
 ; NUMBER OF SEQ ID NOS: 14  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 12  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: HUMAN  
 ; FEATURE:  
 ; OTHER INFORMATION: antisense TRPM-2 ODN  
 US-09-944-326-12

```
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCACTCGGCCAGC 1536
Db 21 AGGCCCCCACTCGGCCAGC 1

RESULT 170
US-09-459-749D-14
; Sequence 14, Application US/09459749D
; Patent No. US20020136716A1
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; CURRENT FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer bind
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-09-459-749D-14

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCAAGAGAAGAAAGAGG 294
Db 1 AAGCCAAGAGAAGAAAGAGG 21

RESULT 171
US-09-967-726A-3/c
; Sequence 3, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-3

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGCGTGCAAGACTCCA 36
Db 21 CCGAGGCGTGCAAGACTCCA 1

RESULT 172
US-09-967-726A-4/c
; Sequence 4, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-4

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 173
US-09-967-726A-5/c
; Sequence 5, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-5

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 174
US-09-967-726A-6/c
; Sequence 6, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
```

```
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      316 AATCAGAGACAAAGCTGAAGG 336
Db      21 AATCAGAGACAAAGCTGAAGG 1
|||||

RESULT 175
US-09-967-726A-7/c
; Sequence 7, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      515 TGACCGCATCGACTCCCTGCT 535
Db      21 TGACCGCATCGACTCCCTGCT 1
|||||

RESULT 176
US-09-967-726A-8/c
; Sequence 8, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
```

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      716 CCGCATCGTCCGACGCTTGAT 736
Db      21 CCGCATCGTCCGACGCTTGAT 1
|||||

RESULT 177
US-09-967-726A-9/c
; Sequence 9, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      916 ACAACTCCAGGGCTGCCTGC 936
Db      21 ACAACTCCAGGGCTGCCTGC 1
|||||

RESULT 178
US-09-967-726A-10/c
; Sequence 10, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-10

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 179
US-09-967-726A-11/c
; Sequence 11, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-11

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCGAGGAGAACCTTAAATT 1336
Db 21 CTCGAGGAGAACCTTAAATT 1

RESULT 180
US-09-967-726A-12/c
; Sequence 12, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-12

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCACG 1536
Db 21 AGGCCCCCAACTCCGCCACG 1

RESULT 181
US-10-270-871-14
; Sequence 14, Application US/10270871
; Publication No. US20030162702A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/10/270,871
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: US/09/459,749D
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer_bind
; FEATURE:
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-10-270-871-14

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCAAGAGAGAAAGAGG 294
Db 1 AAGCCAAGAGAGAAAGAGG 21

RESULT 182
US-10-080-794-3/c
; Sequence 3, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-3

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGCGGTGCAAGACTCCA 36
Db 21 CCGAGCGGTGCAAGACTCCA 1

RESULT 183
US-10-080-794-4/c
```

Sequence 4, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: Patent In Ver. 2.1  
SEQ ID NO 4  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-4

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTGCTGCTG 68  
Db 21 ATGATGAAGACTGCTGCTG 1

RESULT 184  
US-10-080-794-5/c  
Sequence 5, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: Patent In Ver. 2.1  
SEQ ID NO 5  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-5

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 114 GACCAGACGGTCTCAGACAAAT 134  
Db 21 GACCAGACGGTCTCAGACAAAT 1

RESULT 185  
US-10-080-794-6/c  
Sequence 6, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: Patent In Ver. 2.1  
SEQ ID NO 6  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-6

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 316 AATCAGACAAAGCTGAAGG 336  
Db 21 AATCAGACAAAGCTGAAGG 1

RESULT 186  
US-10-080-794-7/c  
Sequence 7, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: Patent In Ver. 2.1  
SEQ ID NO 7  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:

```
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 187
US-10-080-794-8/c
; Sequence 8, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; PRIOR FILING DATE: 2002-02-22
; PRIOR FILING DATE: 1999-02-26
; PRIOR FILING DATE: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR FILING DATE: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGAGCTTGAT 736
Db 21 CCGCATCGTCCGAGCTTGAT 1

RESULT 188
US-10-080-794-9/c
; Sequence 9, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; PRIOR FILING DATE: 2002-02-22
; PRIOR FILING DATE: 09/913,325
; PRIOR FILING DATE: 1999-02-26
; PRIOR FILING DATE: 2001-08-10
; PRIOR FILING DATE: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 190
US-10-080-794-11/c
; Sequence 11, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; PRIOR FILING DATE: 2002-02-22
; PRIOR FILING DATE: 09/913,325
; PRIOR FILING DATE: 1999-02-26
; PRIOR FILING DATE: 2001-08-10
; PRIOR FILING DATE: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-10

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 190
US-10-080-794-11/c
; Sequence 11, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; PRIOR FILING DATE: 2002-02-22
; PRIOR FILING DATE: 09/913,325
; PRIOR FILING DATE: 1999-02-26
; PRIOR FILING DATE: 2001-08-10
; PRIOR FILING DATE: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-10
```



```
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-11

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1316 CTCGAGGAAGAACCTAAATT 1336
Db 21 CTCGAGGAAGAACCTAAATT 1

RESULT 191
US-10-080-794-12/c
; Sequence 12, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: USC P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-12

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1516 AGGCCCCCAACTCGCCGAGC 1536
Db 21 AGGCCCCCAACTCGCCGAGC 1

RESULT 192
US-10-380-124-6
; Sequence 6, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
```

```
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-380-124-6

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCACGCCATGTTCCAGCCCT 786
Db 1 TCCACGCCATGTTCCAGCCCT 21

RESULT 193
US-10-383-864-27
; Sequence 27, Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SIDRANSKY, David
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-27

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 994 ACAACCCCTCCAGGCTAAGC 1014
Db 1 ACAACCCCTCCAGGCTAAGC 21

RESULT 194
US-10-383-864-28/c
; Sequence 28, Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SIDRANSKY, David
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA
```

```
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-28

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1334 ATTTATGGAGACCGTGGCGGA 1354
      |||||
Db 21 ATTTATGGAGACCGTGGCGGA 1

RESULT 195
US-10-646-391A-3/c
; Sequence 3, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-3

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGCGTGCAAGACTCCA 36
      |||||
Db 21 CCGAGGCGTGCAAGACTCCA 1

RESULT 196
US-10-646-391A-4/c
; Sequence 4, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-4

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
      |||||
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 198
US-10-646-391A-6/c
; Sequence 6, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-6

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
      |||||
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 197
US-10-646-391A-5/c
; Sequence 5, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-5

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
      |||||
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 198
US-10-646-391A-6/c
; Sequence 6, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-6
```

```

; ORGANISM: human
US-10-646-391A-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 316 AATCAGAGACAAAGCTGAAGG 336
      |||||
Db 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 199
US-10-646-391A-7/c
; Sequence 7, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 515 TGACCGCATCGACTCCCTGCT 535
      |||||
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 200
US-10-646-391A-8/c
; Sequence 8, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 716 CCGCATCGTCGGCAGCTTGAT 736
      |||||
Db 21 CCGCATCGTCGGCAGCTTGAT 1

RESULT 201
US-10-646-391A-9/c
; Sequence 9, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 916 ACAACTCCACGGCTGCTGC 936
      |||||
Db 21 ACAACTCCACGGCTGCTGC 1

RESULT 202
US-10-646-391A-10/c
; Sequence 10, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-10

```

```
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTGCTGAGCAGCTGAA 1135
DB 21 CTCCTGCTGAGCAGCTGAA 1

RESULT 203
US-10-646-391A-11/c
; Sequence 11, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-11

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCGAGGAAGACCTAAATT 1336
DB 21 CTCGAGGAAGACCTAAATT 1

RESULT 204
US-10-646-391A-12/c
; Sequence 12, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-12

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCACTCCGCCGAGC 1536
DB 21 AGGCCCCCACTCCGCCGAGC 1

RESULT 205
US-10-646-391A-20
; Sequence 20, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-20

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
DB 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 206
US-10-646-391A-21/c
; Sequence 21, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
```

```

; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-21

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AACGAGCTCGCCCTTCTAC 500
    |||||
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 207
US-10-646-391A-22
; Sequence 22, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-22

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1100 GATGCTCAACACCTCCTT 1120
    ||:|||||:|||||:|||||
Db 1 GAUGCUCACACCCUCCCTT 21

RESULT 208
US-10-646-391A-23/c
; Sequence 23, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-23/c

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATAAACTGTC 1633
    |||||
Db 21 AACTAATTCATAAACTGTC 1

RESULT 210
US-10-646-391A-36
; Sequence 36, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-25

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATAAACTGTC 1633
    |||||
Db 21 AACTAATTCATAAACTGTC 1

```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-36

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 502
      |||||:||||:|:|||||
Db 1 CCAGAGCUGCGCCCUUUAU 21

RESULT 211
US-10-646-391A-37/c
; Sequence 37, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-37

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGAGCTCGCCCTTCTAC 500
      |||||:|||||:|||||
Db 21 AACGAGAGCTCGCCCTTCTAC 1

RESULT 212
US-10-646-391A-38
; Sequence 38, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-38

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AGTCCCGCATCGTCGCGAGC 731
      |||||:|||||:|||||
Db 21 AGTCCCGCATCGTCGCGAGC 1

RESULT 214
US-10-646-391A-40
; Sequence 40, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCGCGCATCGTCGCGAGCTT 733
      |||||:|||||:|||||
Db 1 GUCCCGCAUGGUCGCGAGCTT 21

RESULT 213
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCGCGCATCGTCGCGAGCTT 733
      |||||:|||||:|||||
Db 1 GUCCCGCAUGGUCGCGAGCTT 21

RESULT 213
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCGCGCATCGTCGCGAGCTT 733
      |||||:|||||:|||||
Db 1 GUCCCGCAUGGUCGCGAGCTT 21

RESULT 213
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AGTCCCGCATCGTCGCGAGC 731
      |||||:|||||:|||||
Db 21 AGTCCCGCATCGTCGCGAGC 1

RESULT 214
US-10-646-391A-40
; Sequence 40, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
```

```

; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-40

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1615 CTAATTCAATAAAACTGTCTT 1635
Db 1 CUAUAUCAUAAACUGUCTT 21

RESULT 215
US-10-646-391A-41/c
; Sequence 41, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646.391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-41

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCAATAAAAGTGC 1633
Db 21 AACTAATTCAATAAAAGTGC 1

RESULT 216
US-10-646-436-1
; Sequence 1, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios

```

```

; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646.436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-1

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCUCGCCCUUCUACTT 21

RESULT 217
US-10-646-436-2/c
; Sequence 2, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646.436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-2

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AACGAGAGCTCGCCCTTCTAC 500
Db 21 AACGAGAGCTCGCCCTTCTAC 1

RESULT 218
US-10-646-436-3
; Sequence 3, Application US/10646436
; Publication No. US20040096882A1

```

```
/ GENERAL INFORMATION:
/ APPLICANT: Jansen, Burkhard
/ APPLICANT: Gleave, Martin
/ APPLICANT: Signaevsky, Maxim
/ APPLICANT: Beraldi, Eliana
/ APPLICANT: Trougakos, Ioannis
/ APPLICANT: Gonos, Efsthios
/ TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
/ FILE REFERENCE: UBC.P-030
/ CURRENT APPLICATION NUMBER: US/10/646,436
/ CURRENT FILING DATE: 2003-08-21
/ PRIOR APPLICATION NUMBER: US 60/405,193
/ PRIOR FILING DATE: 2002-08-21
/ PRIOR APPLICATION NUMBER: US 60/408,152
/ PRIOR FILING DATE: 2002-09-03
/ PRIOR APPLICATION NUMBER: US 60/473,387
/ PRIOR FILING DATE: 2003-05-20
/ NUMBER OF SEQ ID NOS: 68
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 3
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-3

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GATGCTCAACACCTCTCTCTT 1120
||:|||||:|||||
Db 1 GAUGCUCAACACCUCCUCCTT 21

RESULT 219
US-10-646-436-4/c
/ Sequence 4, Application US/10646436
/ Publication No. US20040096882A1
/ GENERAL INFORMATION:
/ APPLICANT: Jansen, Burkhard
/ APPLICANT: Gleave, Martin
/ APPLICANT: Signaevsky, Maxim
/ APPLICANT: Beraldi, Eliana
/ APPLICANT: Trougakos, Ioannis
/ APPLICANT: Gonos, Efsthios
/ TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
/ FILE REFERENCE: UBC.P-030
/ CURRENT APPLICATION NUMBER: US/10/646,436
/ CURRENT FILING DATE: 2003-08-21
/ PRIOR APPLICATION NUMBER: US 60/405,193
/ PRIOR FILING DATE: 2002-08-21
/ PRIOR APPLICATION NUMBER: US 60/408,152
/ PRIOR FILING DATE: 2002-09-03
/ PRIOR APPLICATION NUMBER: US 60/473,387
/ PRIOR FILING DATE: 2003-05-20
/ NUMBER OF SEQ ID NOS: 68
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 4
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-4

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1098 AGATGCTCAACACCTCTCTCC 1118
|||||
```

```
Db 21 AAGATGCTCAACACCTCTCTCC 1

RESULT 220
US-10-646-436-5
/ Sequence 5, Application US/10646436
/ Publication No. US20040096882A1
/ GENERAL INFORMATION:
/ APPLICANT: Jansen, Burkhard
/ APPLICANT: Gleave, Martin
/ APPLICANT: Signaevsky, Maxim
/ APPLICANT: Beraldi, Eliana
/ APPLICANT: Trougakos, Ioannis
/ APPLICANT: Gonos, Efsthios
/ TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
/ FILE REFERENCE: UBC.P-030
/ CURRENT APPLICATION NUMBER: US/10/646,436
/ CURRENT FILING DATE: 2003-08-21
/ PRIOR APPLICATION NUMBER: US 60/405,193
/ PRIOR FILING DATE: 2002-08-21
/ PRIOR APPLICATION NUMBER: US 60/408,152
/ PRIOR FILING DATE: 2002-09-03
/ PRIOR APPLICATION NUMBER: US 60/473,387
/ PRIOR FILING DATE: 2003-05-20
/ NUMBER OF SEQ ID NOS: 68
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 5
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-5

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCAATAAAACTGTCTT 1635
||:|||||:|||||
Db 1 CUAUUCUAUAAACUGUCCTT 21

RESULT 221
US-10-646-436-6/c
/ Sequence 6, Application US/10646436
/ Publication No. US20040096882A1
/ GENERAL INFORMATION:
/ APPLICANT: Jansen, Burkhard
/ APPLICANT: Gleave, Martin
/ APPLICANT: Signaevsky, Maxim
/ APPLICANT: Beraldi, Eliana
/ APPLICANT: Trougakos, Ioannis
/ APPLICANT: Gonos, Efsthios
/ TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
/ FILE REFERENCE: UBC.P-030
/ CURRENT APPLICATION NUMBER: US/10/646,436
/ CURRENT FILING DATE: 2003-08-21
/ PRIOR APPLICATION NUMBER: US 60/405,193
/ PRIOR FILING DATE: 2002-08-21
/ PRIOR APPLICATION NUMBER: US 60/408,152
/ PRIOR FILING DATE: 2002-09-03
/ PRIOR APPLICATION NUMBER: US 60/473,387
/ PRIOR FILING DATE: 2003-05-20
/ NUMBER OF SEQ ID NOS: 68
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 6
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-6
```



```

; SEQ ID NO 59
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-59

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATTAATAAACTGTC 1633
Db 21 AACTAATTCATTAATAAACTGTC 1

RESULT 222
US-10-646-436-58
; Sequence 58, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 58
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-58

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 482 CCAGAGTCGCGCTTCTACTT 502
Db 1 CCAGAGTCGCGCTTCTACTT 21

RESULT 223
US-10-646-436-59/c
; Sequence 59, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-61

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 713 GTCCCGCATCGTCGCGAGCTT 733
Db 1 GUCCCGCAUCGUCGCGAGCTT 21

RESULT 225
US-10-646-436-62/c
; Sequence 62, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-61
```

```
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-62

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AAGTCCGCGCATCGTCGCGAGC 731
Db 21 AAGTCCGCGCATCGTCGCGAGC 1

RESULT 226
US-10-646-436-64
; Sequence 64, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-64

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCAATAAAAGTGTCTT 1635
Db 1 CUAUUCAUAUAAAACUGUCTT 21

RESULT 227
US-10-646-436-65/c
; Sequence 65, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
```

```
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 65
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-65

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAATAAACTGTC 1633
Db 21 AACTAATTCATAATAAACTGTC 1

RESULT 228
US-10-828-394-4/c
; Sequence 4, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-4

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGCGGTGCAGAGACTCCA 36
Db 21 CCGAGCGGTGCAGAGACTCCA 1

RESULT 229
US-10-828-394-5/c
; Sequence 5, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
```

; FILE REFERENCE: UBC.P-033  
; CURRENT APPLICATION NUMBER: US/10/828,394  
; PRIOR FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-394-5

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTCTGCTGCTG 68  
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 230  
US-10-828-394-6/c  
; Sequence 6, Application US/10828394  
; Publication No. US20040220131A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
; FILE REFERENCE: UBC.P-033  
; CURRENT APPLICATION NUMBER: US/10/828,394  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 6  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-394-6

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 114 GACCAGACGGTCTCAGACAAT 134  
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 231  
US-10-828-394-7/c  
; Sequence 7, Application US/10828394  
; Publication No. US20040220131A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
; FILE REFERENCE: UBC.P-033  
; CURRENT APPLICATION NUMBER: US/10/828,394  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 21

; TYPE: DNA  
; ORGANISM: human  
US-10-828-394-7

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 316 AATCAGACAAAGCTGAAGG 336  
Db 21 AATCAGACAAAGCTGAAGG 1

RESULT 232  
US-10-828-394-8/c  
; Sequence 8, Application US/10828394  
; Publication No. US20040220131A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
; FILE REFERENCE: UBC.P-033  
; CURRENT APPLICATION NUMBER: US/10/828,394  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 8  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-394-8

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 515 TGACCGCATCGACTCCCTGCT 535  
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 233  
US-10-828-394-9/c  
; Sequence 9, Application US/10828394  
; Publication No. US20040220131A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
; FILE REFERENCE: UBC.P-033  
; CURRENT APPLICATION NUMBER: US/10/828,394  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 9  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-394-9

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 716 CCGCATCGTCCGACGCTTGAT 736

```
Db      21  CCGCATGCTCCGACGCTGAT 1
|||||
RESULT 234
US-10-828-394-10/c
; Sequence 10, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-10
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      916  ACAACTCCAGCGGCTGCCTGC 936
|||||
Db      21  ACAACTCCAGCGGCTGCCTGC 1

RESULT 235
US-10-828-394-11/c
; Sequence 11, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-11
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1115 CTCCTTGCTGGACGAGCTGAA 1135
|||||
Db      21  CTCCTTGCTGGACGAGCTGAA 1

RESULT 236
US-10-828-394-12/c
; Sequence 12, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; PRIOR FILING DATE: 2004-04-19
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-12
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1516 AGGCCCCCAACTCCGCCGACG 1536
|||||
Db      21  AGGCCCCCAACTCCGCCGACG 1

RESULT 237
US-10-828-394-13/c
; Sequence 13, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR FILING DATE: 2003-04-18
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-13
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1316 CTCGAGGAAGAACCTTAATT 1336
|||||
Db      21  CTCGAGGAAGAACCTTAATT 1

RESULT 238
US-10-828-395-4/c
; Sequence 4, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; PRIOR FILING DATE: 2004-04-19
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-4/c
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1516 AGGCCCCCAACTCCGCCGACG 1536
|||||
Db      21  AGGCCCCCAACTCCGCCGACG 1
```

```
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-4

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      16 CCGAGGGCTGCAAGACTCCA 36
Db      21 CCGAGGGCTGCAAGACTCCA 1

RESULT 239
US-10-828-395-5/c
; Sequence 5, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-5

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      48 ATGATGAAGACTCTGCTGCTG 68
Db      21 ATGATGAAGACTCTGCTGCTG 1

RESULT 240
US-10-828-395-6/c
; Sequence 6, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      114 GACCAGACGGTCTCAGACAAT 134
Db      21 GACCAGACGGTCTCAGACAAT 1

RESULT 241
US-10-828-395-7/c
; Sequence 7, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      316 AATCAGAGACAAAGCTGAAGG 336
Db      21 AATCAGAGACAAAGCTGAAGG 1

RESULT 242
US-10-828-395-8/c
; Sequence 8, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-8
```

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535  
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 243  
US-10-828-395-9/c  
; Sequence 9, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 9  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-9

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGCGAGCTTGAT 736  
Db 21 CCGCATCGTCCGCGAGCTTGAT 1

RESULT 244  
US-10-828-395-10/c  
; Sequence 10, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 10  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-10

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGGCTGCCTGC 936  
Db 21 ACAACTCCACGGGCTGCCTGC 1

RESULT 245  
US-10-828-395-11/c  
; Sequence 11, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 11  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-11

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 246  
US-10-828-395-12/c  
; Sequence 12, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 12  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-12

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGGAAGAACCTTAATTT 1336  
Db 21 CTCAGGAAGAACCTTAATTT 1

```

RESULT 247
US-10-828-395-13/c
; Sequence 13, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Sprigate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: URC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-13

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1516 AGGCCCCCACTCGCCGAGC 1536
      |||||||
Db 21 AGGCCCCCACTCGCCGAGC 1

RESULT 248
US-10-719-900-695781/c
; Sequence 695781, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 695781
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-695781

Query Match      1.3%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 TGCATGTCATGACGAGCACCCTCA 588
      |||||||
Db 25 TGCATGTCATGACGAGCACCCTCA 2

RESULT 249
US-10-719-900-56803
; Sequence 56803, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20

```

```

; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 56803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-56803

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1269 AAGCTCTTTGACTCTGATCCCATCA 1293
      |||||||
Db 1 AAGCTGTTTGACACTGACCCCATCA 25

RESULT 250
US-10-719-900-452919
; Sequence 452919, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 452919
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-452919

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1137 GAGCAGTTTAACTGGGTGTCGCCGC 1161
      |||||||
Db 1 GACCAGTTCAACTGGGTGTCGCCAGC 25

RESULT 251
US-10-719-900-815717
; Sequence 815717, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 815717
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-815717

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1245 TCCGGTGTCACTGAGGTGTCGTGA 1269

```

```
Db 1 TCCCGTGTCACTCAGGTGGTGA 25
|||||
RESULT 252
US-10-719-900-892166
; Sequence 892166, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 892166
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-892166

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1149 TGGGTGTCCCGGTGGCAACCTCA 1173
|||||
Db 1 TGGGTGTCCCGGTGGCTAACCTCA 25
|||||

RESULT 253
US-10-809-189-31758
; Sequence 31758, Application US/10809189
; Publication No. US2005004851A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31758
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31758

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1171 TCACGGAAGCGAAGACCACTACTA 1195
|||||
Db 1 TCACACAGGCGAAGACCACTACTA 25
|||||

RESULT 254
US-10-956-157-271151
; Sequence 271151, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

---

```
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 271151
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-271151

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1588 GAAGAACAGAAATTGCTCTGCATGC 1612
|||||
Db 1 GGAAGACAGAAATTGCTCTGCATGC 25
|||||

RESULT 255
US-10-719-956-30750/c
; Sequence 30750, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 30750
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-30750

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1120 TGCTGGAGCAGCTGAACGACGAGTT 1144
|||||
Db 25 TGCTGGACAGCAGACGACGAGTT 1
|||||

RESULT 256
US-10-719-956-70566/c
; Sequence 70566, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 70566
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-70566

Query Match 1.2%; Score 20.2; DB 1; Length 25;
```



Best Local Similarity 88.0%; Pred. No. 2e+02; Indels 3; Mismatches 0; Gaps 0;  
Matches 22; Conservative 0;

Qy 951 TGTGACAAAGTCCGGGAGATCTTCT 975  
Db 25 TGTGAGAAGTGCCAAAGAGATCTTGT 1

## RESULT 257

US-10-719-956-355802/c  
; Sequence 355802, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat  
; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 355802  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-355802

Query Match 1.2%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 2e+02; Indels 3; Mismatches 0; Gaps 0;  
Matches 22; Conservative 0;

Qy 898 TGTGCGGGAGATCGCCCAACATC 922  
Db 25 TGTGCAAGGAGATCCGCCATATC 1

## RESULT 258

US-10-719-956-374027/c  
; Sequence 374027, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat  
; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 374027  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-374027

Query Match 1.2%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 2e+02; Indels 3; Mismatches 0; Gaps 0;  
Matches 22; Conservative 0;

Qy 975 TCTGTGGACTGTTCCACCAACAC 999  
Db 25 TCTGTGGACTGTACCAACCAATC 1

## RESULT 259

US-10-719-956-501380  
; Sequence 501380, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat

; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 501380  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-501380

Query Match 1.2%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 2e+02; Indels 3; Mismatches 0; Gaps 0;  
Matches 22; Conservative 0;

Qy 1266 GTGAAGCTCTTGTGACTCTGATCCCA 1290  
Db 1 GTGAAGCTGTTTCACTCTGACCCCA 25

## RESULT 260

US-10-719-956-517912  
; Sequence 517912, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat  
; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 517912  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-517912

Query Match 1.2%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 2e+02; Indels 3; Mismatches 0; Gaps 0;  
Matches 22; Conservative 0;

Qy 897 GTGTGCGGGAGATCGCCCAACT 921  
Db 1 GTGTGCAAGGAGATCCGCCATATC 25

## RESULT 261

US-10-719-956-604881/c  
; Sequence 604881, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat  
; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 604881  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-604881

Query Match 1.2%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 2e+02;

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 778 TCCAGCCCTTCCTTGAGATGATACA 802  
||||| ||||||| ||||||| |||

Db 25 TCCAGCCCTTCCTTGAGTTGATCA 1

## RESULT 262

US-10-719-956-612441/c  
; Sequence 612441, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat  
; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 612441  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-612441

Query Match 1.2%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 3; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1149 TGGGTGTCCCGGTGGCAACCTCA 1173  
||||| ||||||| ||||||| |||

Db 25 TGGGTGTCCCGGTGGCTAACCTCA 1

## RESULT 263

US-10-380-124-14/c  
; Sequence 14, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 14  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-14

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGCGGTGCAAGAC 32  
||||| ||||||| ||||||| |||

Db 20 TGACCGAGCGGTGCAAGAC 1

## RESULT 264

US-10-380-124-15/c  
; Sequence 15, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 15  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-15

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 GCGTGCAAGACTCCAGAAT 40  
||||| ||||||| ||||||| |||

Db 20 GCGTGCAAGACTCCAGAAT 1

## RESULT 265

US-10-380-124-16/c  
; Sequence 16, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 16  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-16

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 ATTGGAGGCATGATGAAGAC 58  
||||| ||||||| ||||||| |||

Db 20 ATTGGAGGCATGATGAAGAC 1

## RESULT 266

US-10-380-124-17/c  
; Sequence 17, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 17  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-17

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 77 GCTGCTGCTGACCTGGGAGA 96  
|||||  
Db 20 GCTGCTGCTGACCTGGGAGA 1

## RESULT 267

US-10-380-124-18/c  
; Sequence 18, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 18  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-18

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 101 GCAGTCTCTGGGGACCAGA 120  
|||||  
Db 20 GCAGTCTCTGGGGACCAGA 1

## RESULT 268

US-10-380-124-19/c  
; Sequence 19, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 19  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-19

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 122 GGTCTCAGACAATGAGCTCC 141  
|||||  
Db 20 GGTCTCAGACAATGAGCTCC 1

## RESULT 269

US-10-380-124-20/c  
; Sequence 20, Application US/10380124

Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 20  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-20

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 GTCCAATCAGGGAAGTAAGT 168  
|||||  
Db 20 GTCCAATCAGGGAAGTAAGT 1

## RESULT 270

US-10-380-124-21/c  
; Sequence 21, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 21  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-21

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 166 AGTACGTCAATAAGGAATT 185  
|||||  
Db 20 AGTACGTCAATAAGGAATT 1

## RESULT 271

US-10-380-124-22/c  
; Sequence 22, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 22  
; LENGTH: 20  
; TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-22

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 201 GGGGTGAACAGATAAAGAC 220
Db 20 GGGGTGAACAGATAAAGAC 1

RESULT 272
US-10-380-124-23/c
; Sequence 23, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-23

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 GAAGAAGAAAGAGATGCC 300
Db 20 GAAGAAGAAAGAGATGCC 1

RESULT 273
US-10-380-124-24/c
; Sequence 24, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-24

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 AGAAGAGAGATGCCCTAAAT 305
Db 20 AGAAGAGAGATGCCCTAAAT 1

RESULT 274
US-10-380-124-25/c
; Sequence 25, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-25

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCTTAATCAGACCGGAA 317
Db 20 CCTTAATCAGACCGGAA 1

RESULT 275
US-10-380-124-26/c
; Sequence 26, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-26

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCGAGGAATCAGAGACA 326
Db 20 AGACCGAGGAATCAGAGACA 1

RESULT 276
US-10-380-124-27/c
; Sequence 27, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
```

NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 27  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-27

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 324 ACAAGCTGAAGGAGCTCCC 343  
Db 20 ACAAGCTGAAGGAGCTCCC 1

RESULT 277  
US-10-380-124-28/c  
; Sequence 28, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 28  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-28

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 359 GACCATGATGCCCTCTGGG 378  
Db 20 GACCATGATGCCCTCTGGG 1

RESULT 278  
US-10-380-124-29/c  
; Sequence 29, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 29  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-29

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 364 TGATGCCCTCTCGGAAGAG 383  
Db 20 TGATGCCCTCTCGGAAGAG 1

RESULT 279  
US-10-380-124-30/c  
; Sequence 30, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 30  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-30

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 380 AGAGTGTAAGCCCTGCCTGA 399  
Db 20 AGAGTGTAAGCCCTGCCTGA 1

RESULT 280  
US-10-380-124-31/c  
; Sequence 31, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 31  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-31

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTGCATGAAGTTCTACGCAC 426  
Db 20 CTGCATGAAGTTCTACGCAC 1

RESULT 281  
US-10-380-124-32/c  
; Sequence 32, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier



```

; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-37

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 ACCGATCGACTCCTCTGCTG 536
Db 20 ACCGATCGACTCCTCTGCTG 1

RESULT 287
US-10-380-124-38/c
; Sequence 38, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-38

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 533 GCTGGAGAACGACCGGCAGC 552
Db 20 GCTGGAGAACGACCGGCAGC 1

RESULT 288
US-10-380-124-39/c
; Sequence 39, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-39

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 GCAGCGCACATGCTGGATG 570
Db 20 GCAGCGCACATGCTGGATG 1

RESULT 289
US-10-380-124-40/c
; Sequence 40, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-40

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGACGCGACATGCTGGATGC 572
Db 20 AGACGCGACATGCTGGATGC 1

RESULT 290
US-10-380-124-41/c
; Sequence 41, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-41

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCGAGGACCAC 584
Db 20 TGGATGTCATGCGAGGACCAC 1

```

```

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCGAGGACCAC 584
Db 20 TGGATGTCATGCGAGGACCAC 1

```

```
RESULT 291
US-10-380-124-42/c
; Sequence 42, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-42

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 567 GATGTCATGCAGACCACTT 586
Db 20 GATGTCATGCAGACCACTT 1

RESULT 292
US-10-380-124-43/c
; Sequence 43, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-43

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 TCATAGCAGCTCTTCCAG 623
Db 20 TCATAGCAGCTCTTCCAG 1

RESULT 293
US-10-380-124-44/c
; Sequence 44, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
```

```
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-44

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 608 AGACGAGCTCTTCCAGACA 627
Db 20 AGACGAGCTCTTCCAGACA 1

RESULT 294
US-10-380-124-45/c
; Sequence 45, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-45

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 613 AGCTCTTCCAGCAGGTTTC 632
Db 20 AGCTCTTCCAGCAGGTTTC 1

RESULT 295
US-10-380-124-46/c
; Sequence 46, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-46

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 AGGCCTCACTTCTTCTTCC 709
```



```

; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-49

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      776 GTTCCAGCCCTTCCTTGAG 795
Db      20 GTTCCAGCCCTTCCTTGAG 1

RESULT 299
US-10-380-124-50/c
; Sequence 50, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-50

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      783 CCCTTCCTTGAGATGATACA 802
Db      20 CCCTTCCTTGAGATGATACA 1

RESULT 300
US-10-380-124-51/c
; Sequence 51, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-51

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      775 TGTTCAGCCCTTCCTTGAG 794
Db      20 TGTTCAGCCCTTCCTTGAG 1

RESULT 298
US-10-380-124-49/c
; Sequence 49, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
US-10-380-124-49

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      775 TGTTCAGCCCTTCCTTGAG 794
Db      20 TGTTCAGCCCTTCCTTGAG 1

RESULT 297
US-10-380-124-48/c
; Sequence 48, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-48

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      721 TCGTCCGAGCTTGATGCC 740
Db      20 TCGTCCGAGCTTGATGCC 1

RESULT 296
US-10-380-124-47/c
; Sequence 47, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-47

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      721 TCGTCCGAGCTTGATGCC 740
Db      20 TCGTCCGAGCTTGATGCC 1

```

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 820 TGGACATCCACTTCCACAGC 839
Db 20 TGGACATCCACTTCCACAGC 1

RESULT 301
US-10-380-124-52/c
; Sequence 52, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-54

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 GACTGTGTGCCGGGAGATCC 912
Db 20 GACTGTGTGCCGGGAGATCC 1

RESULT 304
US-10-380-124-55/c
; Sequence 55, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-55

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 894 ACTGTGTGCCGGGAGATCCG 913
Db 20 ACTGTGTGCCGGGAGATCCG 1

RESULT 305
US-10-380-124-56/c
; Sequence 56, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

---

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 820 TGGACATCCACTTCCACAGC 839
Db 20 TGGACATCCACTTCCACAGC 1

RESULT 301
US-10-380-124-52/c
; Sequence 52, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-52

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 848 CCAGCACCCGCCAACAGAAAT 867
Db 20 CCAGCACCCGCCAACAGAAAT 1

RESULT 302
US-10-380-124-53/c
; Sequence 53, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-53

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 ACCCGCCAAACAGAAATTCATA 872
Db 20 ACCCGCCAAACAGAAATTCATA 1

RESULT 303
US-10-380-124-54/c
; Sequence 54, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
```

OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-56

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 906 GAGATCGCGCAGCACTCCAC 925  
DB 20 GAGATCGCGCAGCACTCCAC 1

RESULT 306

US-10-380-124-57/C  
Sequence 57, Application US/10380124  
Publication No. US20040053874A1  
GENERAL INFORMATION:  
APPLICANT: Isis Pharmaceuticals, Inc.  
APPLICANT: Brett P. Monia  
TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
FILE REFERENCE: RTS-0156  
CURRENT APPLICATION NUMBER: US/10/380,124  
CURRENT FILING DATE: 2003-03-10  
NUMBER OF SEQ ID NOS: 90  
SEQ ID NO 57  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-57

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 GCTGCTCGCGATGAAGAC 947  
DB 20 GCTGCTCGCGATGAAGAC 1

RESULT 307  
US-10-380-124-58/C  
Sequence 58, Application US/10380124  
Publication No. US20040053874A1  
GENERAL INFORMATION:  
APPLICANT: Isis Pharmaceuticals, Inc.  
APPLICANT: Brett P. Monia  
TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
FILE REFERENCE: RTS-0156  
CURRENT APPLICATION NUMBER: US/10/380,124  
CURRENT FILING DATE: 2003-03-10  
NUMBER OF SEQ ID NOS: 90  
SEQ ID NO 58  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-58

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 967 AGATCTGTCTGTGACTGT 986  
DB 20 AGATCTGTCTGTGACTGT 1

RESULT 308

US-10-380-124-59/C  
Sequence 59, Application US/10380124  
Publication No. US20040053874A1  
GENERAL INFORMATION:  
APPLICANT: Isis Pharmaceuticals, Inc.  
APPLICANT: Brett P. Monia

TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
FILE REFERENCE: RTS-0156  
CURRENT APPLICATION NUMBER: US/10/380,124  
CURRENT FILING DATE: 2003-03-10  
NUMBER OF SEQ ID NOS: 90  
SEQ ID NO 59  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-59

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTGCGCGGAGCTC 1028  
DB 20 CTAAGCTGCGCGGAGCTC 1

RESULT 309  
US-10-380-124-60/C  
Sequence 60, Application US/10380124  
Publication No. US20040053874A1  
GENERAL INFORMATION:  
APPLICANT: Isis Pharmaceuticals, Inc.  
APPLICANT: Brett P. Monia  
TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
FILE REFERENCE: RTS-0156  
CURRENT APPLICATION NUMBER: US/10/380,124  
CURRENT FILING DATE: 2003-03-10  
NUMBER OF SEQ ID NOS: 90  
SEQ ID NO 60  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-60

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1022 GGAGCTCGACGATCCTCC 1041  
DB 20 GGAGCTCGACGATCCTCC 1

RESULT 310  
US-10-380-124-61/C  
Sequence 61, Application US/10380124  
Publication No. US20040053874A1  
GENERAL INFORMATION:  
APPLICANT: Isis Pharmaceuticals, Inc.  
APPLICANT: Brett P. Monia  
TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
FILE REFERENCE: RTS-0156  
CURRENT APPLICATION NUMBER: US/10/380,124  
CURRENT FILING DATE: 2003-03-10  
NUMBER OF SEQ ID NOS: 90  
SEQ ID NO 61

```
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-61

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 AAGTCTACCACTGAGAGAT 1102
DB 20 AAGTCTACCACTGAGAGAT 1

RESULT 311
US-10-380-124-62/c
/ Sequence 62, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 62
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-62

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 CCAGTGAAGATGCTCAACA 1110
DB 20 CCAGTGAAGATGCTCAACA 1

RESULT 312
US-10-380-124-63/c
/ Sequence 63, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 63
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-63

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1113 TCCTCTTGTGAGGAGCT 1132
DB 20 TCCTCTTGTGAGGAGCT 1132
```

```
DB 20 TCCTCTTGTGAGGAGCT 1

RESULT 313
US-10-380-124-64/c
/ Sequence 64, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 64
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-64

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 GCTGAGCAGCTGACGAGC 1140
DB 20 GCTGAGCAGCTGACGAGC 1

RESULT 314
US-10-380-124-65/c
/ Sequence 65, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 65
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-65

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 CTGGGTGTCCCGGCTGGCAA 1167
DB 20 CTGGGTGTCCCGGCTGGCAA 1

RESULT 315
US-10-380-124-66/c
/ Sequence 66, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
```

```

; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-66

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 GAAGACGAGTACTATCTGCG 1201
DB 20 GAAGACGAGTACTATCTGCG 1

RESULT 316
US-10-380-124-67/c
; Sequence 67, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-67

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1194 TATCTGCGGTCACGCGT 1213
DB 20 TATCTGCGGTCACGCGT 1

RESULT 317
US-10-380-124-68/c
; Sequence 68, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-68

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1200 TATCTGCGGTCACGCGT 1213
DB 20 TATCTGCGGTCACGCGT 1

RESULT 318
US-10-380-124-69/c
; Sequence 69, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-69

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1275 TTGACTCTGATCCGATCAC 1294
DB 20 TTGACTCTGATCCGATCAC 1

RESULT 319
US-10-380-124-70/c
; Sequence 70, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-70

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAGTCTCC 1319
DB 20 CGGTCCCTGTAGAGTCTCC 1

RESULT 320
US-10-380-124-71/c
; Sequence 71, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
```

```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1216 CTCCACACTTCTGACTCG 1235
DB 20 CTCCACACTTCTGACTCG 1

RESULT 318
US-10-380-124-69/c
; Sequence 69, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-69

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1275 TTGACTCTGATCCGATCAC 1294
DB 20 TTGACTCTGATCCGATCAC 1

RESULT 319
US-10-380-124-70/c
; Sequence 70, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-70

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAGTCTCC 1319
DB 20 CGGTCCCTGTAGAGTCTCC 1

RESULT 320
US-10-380-124-71/c
; Sequence 71, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
```

```
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-380-124-71

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1332 AATTATGAGACCGTGGC 1351
Db 20 AATTATGAGACCGTGGC 1

RESULT 321
US-10-380-124-72/c
; Sequence 72, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-380-124-72

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GATGTGATGCTCTTTC 1417
Db 20 GATGTGATGCTCTTTC 1

RESULT 322
US-10-380-124-73/c
; Sequence 73, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

```
US-10-380-124-73

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGATCTCGACTCTA 1564
Db 20 GCTCTGATCTCGACTCTA 1

RESULT 323
US-10-380-124-74/c
; Sequence 74, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-380-124-74

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCTGCATGCACTAAT 1619
Db 20 TGCTCTGCATGCACTAAT 1

RESULT 324
US-10-380-124-75/c
; Sequence 75, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-380-124-75

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCATAAACTGTCT 1634
Db 20 CTAATTCATAAACTGTCT 1

RESULT 325
US-10-380-124-76/c
```

```
; Sequence 78, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RFS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-78

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      979 TGGACTGTCACCAACAC 998
DB      20 TGGACTGTCACCAACAC 1

RESULT 326
US-10-380-124-80/c
; Sequence 80, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RFS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-80

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1383 CACCGGAGAGTGATGT 1402
DB      20 CACCGGAGAGTGATGT 1

RESULT 327
US-10-980-850-17
; Sequence 17, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Forward Primer for CLU
US-10-980-850-17

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      762 AACTTCACGCCATGTTCCA 781
DB      1 AACTTCACGCCATGTTCCA 20

RESULT 328
US-10-980-850-18/c
; Sequence 18, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Reverse Primer for CLU
US-10-980-850-18

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      870 ATACGAGAGCGACGATGA 889
DB      20 ATACGAGAGCGACGATGA 1

RESULT 329
US-10-980-850-33
; Sequence 33, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Forward Primer for OAS1
US-10-980-850-33

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      977 TGTGACTGTTCCACCACA 996
          |||||
Db      1 TGTGACTGTTCCACCACA 20

```

```

RESULT 330
US-10-646-391A-28
; Sequence 28, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Martin
; APPLICANT: Gleave, Barthard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: USC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-28

```

Query Match	1.2%	Score 20	DB 1	Length 21
Best Local Similarity	75.0%	Pred. No.	1.4e+02	
Matches 15	Conservative	5	Mismatches 0	Indels 0
			Gaps	0

QY	48	ATGATGAGACTCTGCTGCT	67
		: : : : : : : : : :	
Db	1	AUGAUGAAGACUCUGCUGCT	20

```

RESULT 331
US-10-646-436-9
; Sequence 9, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beratali, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Elefathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: USC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
; US-10-646-436-9

```

Query Match	1.2%	Score 20;	DB 1;	Length 21;
Best Local Similarity	75.0%;	Pred. No. 1.4e+02;		
Matches 15; Conservative	5;	Mismatches 0;	Indels 0;	Gaps 0;

```
QY      48 ATGATGAAGACTCTGCTGCT 67
        ||:||:||:||:||:||
Db       1 AUGAUGAAGACUCUGCUGCT 20
```

```

RESULT 332
US-09-459-749D-13
; Sequence 13. Application US/09459749D
Patent No. US20020136716A1
; GENERAL INFORMATION:
; APPLICANT: Mills, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0799.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; CURRENT FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1.
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer bind
; OTHER INFORMATION: synthetic antisense primer based on murine clusterin
US-09-459-749D-13

```

Query Match	1.2%	Score 19.4;	DB 1;	length 21;
Best Local Similarity	95.2%	Pred. No. 1.6e+02;		
Matches 20; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

QY		271	AAGAGCCAGAAGAAGAAAG	291
Db		1	AGGAGCCAAGAAGAAGAAAG	21

```

RESULT 333
US-10-270-871-13
? Sequence 13, Application US/10270871
? Publication No. US20030162702A1
? GENERAL INFORMATION:
? APPLICANT: M1118, Albert J. T.
? TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
? FILE REFERENCE: 0794.016A
? CURRENT APPLICATION NUMBER: US/10/270, 871
? CURRENT FILING DATE: 2002-10-15
? PRIOR APPLICATION NUMBER: US/09/459,749D
? PRIOR FILING DATE: 1999-12-10
? PRIOR APPLICATION NUMBER: 60/111,856
? PRIOR FILING DATE: 1998-12-11
? NUMBER OF SEQ ID NOS: 17
? SOFTWARE: Patentrin Ver. 2.1
? SEQ ID NO 13
? LENGTH: 21
? TYPE: DNA
? ORGANISM: Artificial Sequence
? FEATURE:
? OTHER INFORMATION: Description of Artificial Sequence:primer_bind
? FEATURE:
? OTHER INFORMATION: synthetic antisense primer based on murine clusterin
? US-10-270-871-13

```

Query March	1.2%	Score 19.4	DB 1	Length 21
Best Local Similarity	95.2%	Pred. No. 1.6e+02		
Matches 20; Conservative	0	Mismatches 1	Indels 0	Gaps 0

QY 271 AAGAAGCCAGAAGAAGAAG 291



Db 1 AGGAGCCAGAGAGAGAAG 21

RESULT 334

US-10-646-391A-42  
; Sequence 42, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 42  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-42

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 73.7%; Pred. No. 1.4e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 48 ATGATGAAGACTCTGCTGC 66  
Db 1 AUGAUGAAGACUUCUCUC 19

RESULT 335

US-10-646-391A-43/c  
; Sequence 43, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 43  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-43

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 48 ATGATGAAGACTCTGCTGC 66  
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 336

US-10-646-436-67  
; Sequence 67, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 67  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-436-67

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 73.7%; Pred. No. 1.4e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 48 ATGATGAAGACTCTGCTGC 66  
Db 1 AUGAUGAAGACUUCUCUC 19

RESULT 337

US-10-646-436-68/c  
; Sequence 68, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; APPLICANT: Efstathiou  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 68  
; LENGTH: 19  
; TYPE: RNA

```
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi fo rhuman clusterin
US-10-646-436-68
```

```
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 48 ATGATGAAGACTGCTGTC 66
DB 19 ATGATGAAGACTGCTGTC 1
```

```
RESULT 338
US-10-828-394-16
; Sequence 16, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-10-828-394-16
```

```
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 482 CCAGAGCTCGCCCTTCTAC 500
DB 1 CCAGAGCTCGCCCTTCTAC 19
```

```
RESULT 339
US-10-828-394-17
; Sequence 17, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-394-17
```

```
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1100 GATGCTCAACACCTCTCC 1118
DB 1 GAUGCCCAACACCTCTCC 19
```

```
RESULT 340
US-10-828-394-18
; Sequence 18, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-394-18
```

```
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.4e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1615 CTATTCATTAATAACTGTC 1633
DB 1 CTAATTCATTAATAACTGTC 19
```

```
RESULT 341
US-10-828-395-16
; Sequence 16, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-10-828-395-16
```

```
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 482 CCAGAGCTCGCCCTTCTAC 500
DB 1 CCAGAGCTCGCCCTTCTAC 19
```

```
RESULT 342
US-10-828-395-17
```

```
; Sequence 17, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-395-17

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1100 GATGCTCAACACCTCTCTCC 1118
DB      1 GAUGCUCAACACCCUCCUCC 19

RESULT 343
US-10-828-395-18
; Sequence 18, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-395-18

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.4e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1615 CTAATTCATTAATAACTGTC 1633
DB      1 CUAUUCUCAAUAAAACUCUC 19

RESULT 344
US-10-646-391A-29/c
; Sequence 29, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
```

```
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC-P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-29

Query Match          1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 ATGATGAAGACTCTGCTGC 66
DB      19 ATGATGAAGACTCTGCTGC 1

RESULT 345
US-10-646-436-10/c
; Sequence 10, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Sigalevsky, Maxim
; APPLICANT: Betaldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC-P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-10

Query Match          1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 ATGATGAAGACTCTGCTGC 66
DB      19 ATGATGAAGACTCTGCTGC 1

RESULT 346
US-10-380-124-4
```

```
; Sequence 4, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-380-124-4
```

```
Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 746 TCCGTACGAGCCCTGAA 763
Db 1 TCCGTACGAGCCCTGAA 18
```

```
RESULT 347
US-09-967-726A-15/c
; Sequence 15, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: 2 base mismatch primer from human TRPM-2
US-09-967-726A-15
```

```
Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 48 ATGATGAAGACTGCTGCTG 68
Db 21 ATGATAAATCTGCTGCTG 1
```

```
RESULT 348
US-10-080-794-15/c
; Sequence 15, Application US/10080794
; Publication No. US20030165591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
```

```
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
US-10-080-794-15
```

```
Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 48 ATGATGAAGACTGCTGCTG 68
Db 21 ATGATAAATCTGCTGCTG 1
```

```
RESULT 349
US-10-751-736-11047
; Sequence 11047, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wylech
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11047
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11047
```

```
Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 35 CAGAAATGGAGCATGATGAA 55
Db 1 CAGTAATTGAGCATGATGAA 21
```

```
RESULT 350
US-10-921-868A-37/c
; Sequence 37, Application US/10921868A
; Publication No. US20050118251A1
; GENERAL INFORMATION:
; APPLICANT: Nagata, Leslie P.
; APPLICANT: Wong, Jonathan P.
; TITLE OF INVENTION: NOVEL DNA-BASED VACCINE AGAINST THE ENCEPHALITIS ALPHAVIRUSES
; FILE REFERENCE: NEL-0001/DV1
; CURRENT APPLICATION NUMBER: US/10/921,868A
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: 10/023,649
; PRIOR FILING DATE: 2001-12-21
```

PRIOR APPLICATION NUMBER: 60/256,948  
PRIOR FILING DATE: 2000-12-21  
NUMBER OF SEQ ID NOS: 49  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 37  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: DNA Primer  
US-10-921-868A-37

Query Match 1.0%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 2.5e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 524 CGACTCCCTGCTGGAGAAGC 543  
DB 20 CGACACGCTGCTGGAGAAGC 1

RESULT 351  
US-10-786-720-3371/c  
Sequence 3371, Application US/10786720  
Publication No. US20040191818A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: O'Toole, Margot  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
FILE REFERENCE: 031896-023000 (AM101331L)  
CURRENT APPLICATION NUMBER: US/10/786,720  
CURRENT FILING DATE: 2004-02-26  
NUMBER OF SEQ ID NOS: 2135  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 3371  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI-sense strand  
US-10-786-720-3371

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 583 ACTTCAGCCGCGCTCCAGC 602  
DB 20 ACTTCAGCCGCTCCTCCAGC 1

RESULT 352  
US-10-786-720-4073/c  
Sequence 4073, Application US/10786720  
Publication No. US20040191818A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: O'Toole, Margot  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
FILE REFERENCE: 031896-023000 (AM101331L)  
CURRENT APPLICATION NUMBER: US/10/786,720  
CURRENT FILING DATE: 2004-02-26  
NUMBER OF SEQ ID NOS: 21135  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 4073  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI-sense strand  
US-10-786-720-4073

Query Match 1.0%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 583 ACTTCAGCCGCGCTCCAGC 602  
DB 20 ACTTCAGCCGCTCCTCCAGC 1

RESULT 353  
US-10-786-720-4811/c  
Sequence 4811, Application US/10786720  
Publication No. US20040191818A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: O'Toole, Margot  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
FILE REFERENCE: 031896-023000 (AM101331L)  
CURRENT APPLICATION NUMBER: US/10/786,720  
CURRENT FILING DATE: 2004-02-26  
NUMBER OF SEQ ID NOS: 21135  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 4811  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI-sense strand  
US-10-786-720-4811

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 583 ACTTCAGCCGCGCTCCAGC 602  
DB 20 ACTTCAGCCGCTCCTCCAGC 1

RESULT 354  
US-10-751-736-24026/c  
Sequence 24026, Application US/10751736  
Publication No. US20040265230A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: Martinez, Robert  
APPLICANT: Brown, Eugene  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
FILE REFERENCE: AM100927 (031896-002000)  
CURRENT APPLICATION NUMBER: US/10/751,736  
CURRENT FILING DATE: 2003-01-06  
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
PRIOR FILING DATE: 2003-01-06  
NUMBER OF SEQ ID NOS: 54873  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 24026  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI  
US-10-751-736-24026

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 136 AGCTCAGAGAAATGTCAT 155  
DB 20 AGCTCAGAGAAATGTCAT 1

RESULT 355  
US-10-911-318-81/c

/ Sequence 81, Application US/10911318  
/ Publication No. US20050130185A1  
/ GENERAL INFORMATION:  
/ APPLICANT: We Gene Technologies, Inc.  
/ TITLE OF INVENTION: MENINGITIS DETECTION CHIP AND FABRICATION METHOD THEROF AND  
/ TITLE OF INVENTION: METHOD OF DETECTING MENINGITIS AND PRIMER SET FOR MENINGITIS  
/ TITLE OF INVENTION: DETECTION  
/ FILE REFERENCE: 12333-US-PA  
/ CURRENT APPLICATION NUMBER: US/10/911,318  
/ CURRENT FILING DATE: 2004-08-03  
/ PRIOR APPLICATION NUMBER: TW 92135134  
/ PRIOR FILING DATE: 2003-12-12  
/ NUMBER OF SEQ ID NOS: 134  
/ SOFTWARE: PatentIn version 3.3  
/ SEQ ID NO 81  
/ LENGTH: 21  
/ TYPE: DNA  
/ ORGANISM: artificial sequence  
/ FEATURE:  
/ OTHER INFORMATION: Primer  
US-10-911-318-81

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1281 TGTGATCCCATCACTGTGAC 1300  
Db 21 TCTGCTCCATCACTGTGAC 2

RESULT 356  
US-09-294-121A-97/C  
/ Sequence 97, Application US/09294121A  
/ Patent No. US20020069422A1  
/ GENERAL INFORMATION:  
/ APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
/ APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO  
/ TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
/ TITLE OF INVENTION: ISOLATES  
/ NUMBER OF SEQUENCES: 97  
/ CORRESPONDENCE ADDRESS:  
/ ADDRESSEE: BIERMAN & MUSERLIAN  
/ STREET: 600 THIRD AVENUE  
/ CITY: NEW YORK  
/ STATE: NEW YORK  
/ COUNTRY: USA  
/ ZIP: 10016  
/ COMPUTER READABLE FORM:  
/ MEDIUM TYPE: floppy disk  
/ COMPUTER: IBM PC compatible  
/ OPERATING SYSTEM: PC-DOS/MS-DOS  
/ SOFTWARE: ASCII  
/ CURRENT APPLICATION DATA:  
/ APPLICATION NUMBER: US/09/294,121A  
/ FILING DATE:  
/ CLASSIFICATION:  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: 08/256,568  
/ FILING DATE: 18-JUL-1994  
/ APPLICATION NUMBER: PCT/EP93/03325  
/ FILING DATE: 26-NOV-1993  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: EP/93/402,129.6  
/ FILING DATE: 31-AUG-1993  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: EP/92/403,222.0  
/ FILING DATE: 27-NOV-1992  
/ ATTORNEY/AGENT INFORMATION:  
/ NAME: CHARLES A. MUSERLIAN  
/ REGISTRATION NUMBER: 19,683  
/ REFERENCE/DOCKET NUMBER: 410.004  
/ TELECOMMUNICATION INFORMATION:

/ TELEPHONE: (212) 661-8000  
/ TELEFAX: (212) 661-8002  
/ INFORMATION FOR SEQ ID NO: 97:  
/ SEQUENCE CHARACTERISTICS:  
/ LENGTH: 16 base pairs  
/ TYPE: nucleic acid  
/ STRANDEDNESS: single  
/ TOPOLOGY: linear  
/ MOLECULE TYPE: CDNA  
/ HYPOTHETICAL: NO  
/ ANTI-SENSE: YES  
US-09-294-121A-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCTTCAGGCCCCC 1523  
Db 16 CAGCTTCAGGCCCCC 1

RESULT 357  
US-09-899-082A-97/C  
/ Sequence 97, Application US/09899082A  
/ Patent No. US2002010638A1  
/ GENERAL INFORMATION:  
/ APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
/ APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO  
/ TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
/ TITLE OF INVENTION: ISOLATES  
/ NUMBER OF SEQUENCES: 97  
/ CORRESPONDENCE ADDRESS:  
/ ADDRESSEE: BIERMAN & MUSERLIAN  
/ STREET: 600 THIRD AVENUE  
/ CITY: NEW YORK  
/ STATE: NEW YORK  
/ COUNTRY: USA  
/ ZIP: 10016  
/ COMPUTER READABLE FORM:  
/ MEDIUM TYPE: floppy disk  
/ COMPUTER: IBM PC compatible  
/ OPERATING SYSTEM: PC-DOS/MS-DOS  
/ SOFTWARE: ASCII  
/ CURRENT APPLICATION DATA:  
/ APPLICATION NUMBER: US/09/899,082A  
/ FILING DATE: 06-Jul-2001  
/ CLASSIFICATION: <Unknown>  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: US/09/378,900  
/ FILING DATE: <Unknown>  
/ APPLICATION NUMBER: 08/256,568  
/ FILING DATE: 18-JUL-1994  
/ APPLICATION NUMBER: PCT/EP93/03325  
/ FILING DATE: 26-NOV-1993  
/ APPLICATION NUMBER: EP/93/402,129.6  
/ FILING DATE: 31-AUG-1993  
/ APPLICATION NUMBER: EP/92/403,222.0  
/ FILING DATE: 27-NOV-1992  
/ ATTORNEY/AGENT INFORMATION:  
/ NAME: CHARLES A. MUSERLIAN  
/ REGISTRATION NUMBER: 19,683  
/ REFERENCE/DOCKET NUMBER: 410.004  
/ TELECOMMUNICATION INFORMATION:  
/ TELEPHONE: (212) 661-8000  
/ TELEFAX: (212) 661-8002  
/ INFORMATION FOR SEQ ID NO: 97:  
/ SEQUENCE CHARACTERISTICS:  
/ LENGTH: 16 base pairs  
/ TYPE: nucleic acid  
/ STRANDEDNESS: single  
/ TOPOLOGY: linear  
/ MOLECULE TYPE: CDNA

HYPOTHETICAL: NO  
ANTI-SENSE: YES  
SEQUENCE DESCRIPTION: SEQ ID NO: 97;  
US-09-899-082A-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523  
DB 16 CAGCCTCCAGGCCCC 1

RESULT 358  
US-09-899-302-97/c  
; Sequence 97, Application US/09899302  
; Patent No. US20020168626A1  
; GENERAL INFORMATION:  
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSMYN, HUGO  
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
; TITLE OF INVENTION: ISOLATES  
; NUMBER OF SEQUENCES: 97  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BIERMAN & MUSERLIAN  
; STREET: 600 THIRD AVENUE  
; CITY: NEW YORK  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 10016  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/899,302  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/378,900  
; FILING DATE:  
; APPLICATION NUMBER: 08/256,568  
; FILING DATE: 18-JUL-1994  
; APPLICATION NUMBER: PCT/EP93/03325  
; FILING DATE: 26-NOV-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: EP/93/402,129.6  
; FILING DATE: 31-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: EP/92/403,222.0  
; FILING DATE: 27-NOV-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CHARLES A. MUSERLIAN  
; REGISTRATION NUMBER: 19,683  
; REFERENCE/DOCKET NUMBER: 410,004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 661-8000  
; TELEFAX: (212) 661-8002  
; INFORMATION FOR SEQ ID NO: 97:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 16 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: YES  
US-09-899-302-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1523  
DB 16 CAGCCTCCAGGCCCC 1

RESULT 359  
US-09-899-044-97/c  
; Sequence 97, Application US/09899044  
; Publication No. US20030036053A1  
; GENERAL INFORMATION:  
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSMYN, HUGO  
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
; TITLE OF INVENTION: ISOLATES  
; NUMBER OF SEQUENCES: 97  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BIERMAN & MUSERLIAN  
; STREET: 600 THIRD AVENUE  
; CITY: NEW YORK  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 10016  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/899,044  
; FILING DATE: 06-JUL-2001  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/378,900  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: PCT/EP93/03325  
; FILING DATE: 26-NOV-1993  
; APPLICATION NUMBER: EP/93/402,129.6  
; FILING DATE: 31-AUG-1993  
; APPLICATION NUMBER: EP/92/403,222.0  
; FILING DATE: 27-NOV-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CHARLES A. MUSERLIAN  
; REGISTRATION NUMBER: 19,683  
; REFERENCE/DOCKET NUMBER: 410,004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 661-8000  
; TELEFAX: (212) 661-8002  
; INFORMATION FOR SEQ ID NO: 97:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 16 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: YES  
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:  
US-09-899-044-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1523  
DB 16 CAGCCTCCAGGCCCC 1

RESULT 360  
US-10-822-711-97/c  
; Sequence 97, Application US/10822711

```
; Publication No. US20040191768A1
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEBERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/822,711
; FILING DATE: 13-Apr-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,082A
; FILING DATE: 06-Jul-2001
; APPLICATION NUMBER: US/09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-Jul-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-Nov-1993
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-Aug-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-Nov-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHEICAL: NO
; ANTI-SENSE: YES
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-10-822-711-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCAGGCCCC 1523
DB 16 CAGCCTCAGGCCCC 1

RESULT 361
US-10-160-787-84/c
; Sequence 84, Application US/10160787
; Publication No. US20030225256A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 2 EXPRESSION
; FILE REFERENCE: RTS-0204
; CURRENT APPLICATION NUMBER: US/10/160,787
```

```
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-787-84

Query Match 1.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1583 CATGGGAAGACAGAA 1598
DB 17 CATGGGAAGACAGAA 2

RESULT 362
US-10-160-787-137
; Sequence 137, Application US/10160787
; Publication No. US20030225256A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 2 EXPRESSION
; FILE REFERENCE: RTS-0204
; CURRENT APPLICATION NUMBER: US/10/160,787
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-787-137

Query Match 1.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1583 CATGGGAAGACAGAA 1598
DB 4 CATGGGAAGACAGAA 19

RESULT 363
US-10-646-391A-24
; Sequence 24, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burthard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC-P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
```



US-10-646-391A-24

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 2.8e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATTAATAACTGCT 1634

DB 1 UAATTCACAAACACGUTT 19

RESULT 364

US-10-646-391A-26

Sequence 26, Application US/10646391A  
Publication No. US20040082534A1

GENERAL INFORMATION:

APPLICANT: Jansen, Burkhard

TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels

FILE REFERENCE: UBC-P-035

CURRENT APPLICATION NUMBER: US/10/646,391A

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/319,748

PRIOR FILING DATE: 2002-12-02

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

PRIOR APPLICATION NUMBER: US 60/473,387

PRIOR FILING DATE: 2003-05-20

NUMBER OF SEQ ID NOS: 43

SOFTWARE: PatentIn version 3.2

SEQ ID NO 26

LENGTH: 19

TYPE: DNA

ORGANISM: artificial

FEATURE:

OTHER INFORMATION: RNAi for human clusterin

US-10-646-391A-26

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 2.8e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATTAATAACTGCT 1634

DB 1 UAATTCACAAACACGUTT 19

RESULT 365

US-10-646-391A-27/c

Sequence 27, Application US/10646391A  
Publication No. US20040082534A1

GENERAL INFORMATION:

APPLICANT: Jansen, Burkhard

TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels

FILE REFERENCE: UBC-P-035

CURRENT APPLICATION NUMBER: US/10/646,391A

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/319,748

PRIOR FILING DATE: 2002-12-02

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

PRIOR APPLICATION NUMBER: US 60/473,387

PRIOR FILING DATE: 2003-05-20

NUMBER OF SEQ ID NOS: 43

SOFTWARE: PatentIn version 3.2

SEQ ID NO 27

LENGTH: 19

TYPE: DNA

ORGANISM: artificial

FEATURE:

OTHER INFORMATION: RNAi for human clusterin

US-10-646-391A-27

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 2.8e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1614 ACTAATTCATTAATAACTGCT 1632

DB 19 AATAATTCACAAACACGTT 1

RESULT 366

US-10-646-436-7

Sequence 7, Application US/10646436  
Publication No. US20040096882A1

GENERAL INFORMATION:

APPLICANT: Jansen, Burkhard

APPLICANT: Gleave, Martin

APPLICANT: Signaevsky, Maxim

APPLICANT: Beraldi, Eliana

APPLICANT: Trougakos, Ioannis

APPLICANT: Gonos, Efethachios

TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins

FILE REFERENCE: UBC-P-030

CURRENT APPLICATION NUMBER: US/10/646,436

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

PRIOR APPLICATION NUMBER: US 60/473,387

PRIOR FILING DATE: 2003-05-20

NUMBER OF SEQ ID NOS: 68

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 19

TYPE: DNA

ORGANISM: artificial

FEATURE:

OTHER INFORMATION: RNAi for human clusterin

US-10-646-436-7

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 2.8e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATTAATAACTGCT 1634

DB 1 UAATTCACAAACACGUTT 19

RESULT 367

US-10-646-436-8/c

Sequence 8, Application US/10646436  
Publication No. US20040096882A1

GENERAL INFORMATION:

APPLICANT: Jansen, Burkhard

APPLICANT: Gleave, Martin

APPLICANT: Signaevsky, Maxim

APPLICANT: Beraldi, Eliana

APPLICANT: Trougakos, Ioannis

APPLICANT: Gonos, Efethachios

TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins

FILE REFERENCE: UBC-P-030

CURRENT APPLICATION NUMBER: US/10/646,436

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

```

; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-8

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1614 ACTAATTCATAAATCTGT 1632
Db      19 AATATTCACAACTGT 1

RESULT 368
US-10-667-271-305
; Sequence 305, Application US/10667271
; Publication No. US20040209831A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Beigelman, Leonid
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis C Virus (HCV)
; FILE REFERENCE: 400/129 (MBH02-763B)
; CURRENT APPLICATION NUMBER: US/10/667,271
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT / US03/05043
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT / US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: USSN 60/401,104
; PRIOR FILING DATE: 2002-08-05
; PRIOR APPLICATION NUMBER: USSN 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: USSN 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: USSN 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: USSN 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: USSN 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: USSN 60/409,293
; PRIOR FILING DATE: 2002-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1705
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 305
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-667-271-305

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.8e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAACCAACG 240
Db      19 CTCATAGAAAAACCAACG 240
```

```

Db      1 CUCAAGAAAAACCAACG 19

RESULT 369
US-10-667-271-1001/c
; Sequence 1001, Application US/10667271
; Publication No. US20040209831A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Beigelman, Leonid
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis C Virus (HCV)
; FILE REFERENCE: 400/129 (MBH02-763B)
; CURRENT APPLICATION NUMBER: US/10/667,271
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT / US03/05043
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT / US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: USSN 60/401,104
; PRIOR FILING DATE: 2002-08-05
; PRIOR APPLICATION NUMBER: USSN 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: USSN 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: USSN 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: USSN 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: USSN 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: USSN 60/409,293
; PRIOR FILING DATE: 2002-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1705
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1001
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-667-271-1001

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAACCAACG 240
Db      19 CTCATAGAAAAACCAACG 1

RESULT 370
US-09-866-108-8666
; Sequence 8666, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 8666  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8666

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAGCCAGAGAGAGAA 289  
DB 1 GAGCCAGAGAGAGAA 17

RESULT 371  
US-09-780-533A-170/c  
Sequence 170, Application US/09780533A  
Publication No. US20030060611A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Blatt, Larry  
APPLICANT: MCSwigen, Jim  
APPLICANT: Chowrita, Bharat  
APPLICANT: Haeblerl, Pete  
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
FILE REFERENCE: MBH00, 878-A (400/011)  
CURRENT FILING DATE: US/09/780,533A  
CURRENT FILING DATE: 2001-02-09  
PRIOR APPLICATION NUMBER: US 60/181,797  
PRIOR FILING DATE: 2000-02-11  
NUMBER OF SEQ ID NOS: 6679  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 170  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-780-533A-170

Query Match 0.9%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1619 TTCAATAAACTGCTT 1635  
DB 17 TTCAATAAACTGCTT 1

RESULT 372  
US-09-740-332-1542  
Sequence 1542, Application US/09740332  
Publication No. US20030125270A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
FILE REFERENCE: RPI 400/003  
CURRENT FILING DATE: US/09/740,332  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9704  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1542  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-1542

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 2.4e+02;  
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 766 TCCAGCCCATGTTCCAG 782  
DB 1 TCCAGCCCATGTTCCAG 17

RESULT 373  
US-09-740-332-3013/c  
Sequence 3013, Application US/09740332  
Publication No. US20030125270A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
FILE REFERENCE: RPI 400/003  
CURRENT FILING DATE: US/09/740,332  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9704  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3013  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-3013

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 767 CCAGCCATGTTCCAGC 783  
DB 17 CCAGCCATGTTCCAGC 1

RESULT 374

```
US-09-817-879-1542
; Sequence 1542, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1542
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1542

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      766 TCCACGCCCATGTTCCAG 782
Db      1 UCCACGCCCAUGUCCGG 17

RESULT 375
US-09-817-879-3013/c
; Sequence 3013, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3013
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3013

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      767 CCACGCCCATGTTCCAGC 783
Db      17 CCACGCCCATGTTCCGGC 1

RESULT 376
US-10-669-841-4135
; Sequence 4135, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
```

```
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/04205 (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4135

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      766 TCCACGCCCATGTTCCAG 782
Db      1 UCCACGCCCAUGUCCGG 17

RESULT 377
US-10-669-841-5606/c
; Sequence 5606, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/04205 (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
```

PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055  
PRIOR FILING DATE: 2001-12-05  
PRIOR APPLICATION NUMBER: US 60/358,580  
PRIOR FILING DATE: 2002-02-20  
PRIOR APPLICATION NUMBER: US 60/363,124  
PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5606  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-5606

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 767 CCAGCCATGTTCCAGC 783  
Db 17 CCAGCCATGTTCCGCGC 1

RESULT 378  
US-10-723-361-8666  
Sequence 8666, Application US/10723361  
Publication No. US20040137589A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wenheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105  
CURRENT APPLICATION NUMBER: US/10/723,361  
CURRENT FILING DATE: 2003-11-26  
PRIOR APPLICATION NUMBER: US 09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 8666  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-723-361-8666

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCAGAGAGAA 289  
Db 1 GAAGCCAGAGAGAA 17

RESULT 379  
US-10-828-394-19/c  
Sequence 19, Application US/10828394  
Publication No. US20040220131A1  
GENERAL INFORMATION:  
APPLICANT: Jackson, John  
APPLICANT: Burt, Helen  
APPLICANT: Springate, Christopher  
APPLICANT: Gleave, Martin  
TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
FILE REFERENCE: UBC-P-033  
CURRENT APPLICATION NUMBER: US/10/828,394  
CURRENT FILING DATE: 2004-04-19  
PRIOR APPLICATION NUMBER: US 60/464,159  
PRIOR FILING DATE: 2003-04-18  
NUMBER OF SEQ ID NOS: 23  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 19  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: clusterin targeted siRNA  
US-10-828-394-19

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1616 TAATTCATAAACTGT 1632  
Db 17 TAATTCACAAACTGT 1

RESULT 380  
US-10-828-395-19/c  
Sequence 19, Application US/10828395  
Publication No. US20040224914A1  
GENERAL INFORMATION:  
APPLICANT: Jackson, John  
APPLICANT: Burt, Helen  
APPLICANT: Springate, Christopher  
APPLICANT: Gleave, Martin  
TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
FILE REFERENCE: UBC-P-032  
CURRENT APPLICATION NUMBER: US/10/828,395  
CURRENT FILING DATE: 2004-04-19  
PRIOR APPLICATION NUMBER: US 60/464,159  
PRIOR FILING DATE: 2003-04-18

; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: clusterin targeted siRNA sequence  
US-10-828-395-19

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1616 TAATCAATAAACTGT 1632  
Db 17 TAATTCACAAACTGT 1

RESULT 381  
US-10-758-451-883/C  
; Sequence 883, Application US/10758451  
; Publication No. US20050014711A1  
; GENERAL INFORMATION:  
; APPLICANT: East Carolina University  
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D  
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY (IES)  
; TITLE OF INVENTION: INFLAMMATION  
; FILE REFERENCE: 30775-706.301  
; CURRENT APPLICATION NUMBER: US/10/758,451  
; CURRENT FILING DATE: 2004-01-14  
; PRIOR APPLICATION NUMBER: 09/093,972  
; PRIOR FILING DATE: 1998-06-09  
; NUMBER OF SEQ ID NOS: 996  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 883  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-758-451-883

Query Match 0.9%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1531 CCCAGCCTCTCCCG 1545  
Db 15 CCCAGCCTCTCCCG 1

RESULT 382  
US-09-740-332-3014/C  
; Sequence 3014, Application US/09740332  
; Publication No. US20030125270A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; TITLE OF INVENTION: Hepatitis C Virus Infection  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3014  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate

US-09-740-332-3014

Query Match 0.9%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCCCATGTTCC 780  
Db 15 TCCAGCCCATGTTCC 1

RESULT 383  
US-09-817-879-3014/C  
; Sequence 3014, Application US/09817879  
; Publication No. US20030171311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; TITLE OF INVENTION: Hepatitis C Virus Infection  
; FILE REFERENCE: MBHB00-801-P  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3014  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3014

Query Match 0.9%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCCCATGTTCC 780  
Db 15 TCCAGCCCATGTTCC 1

RESULT 384  
US-10-669-841-5607/C  
; Sequence 5607, Application US/10669841  
; Publication No. US20040127446A1  
; GENERAL INFORMATION:  
; APPLICANT: Sinna Therapeutics, Inc.  
; APPLICANT: Lawrence, Blact  
; APPLICANT: Dennis, Macejak  
; APPLICANT: James, McSwiggen  
; APPLICANT: David, Morrissey  
; APPLICANT: Pamela, Pavco  
; APPLICANT: Patricia, Lee  
; APPLICANT: Kenneth, Draper  
; APPLICANT: Elisabeth, Roberts  
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT  
; TITLE OF INVENTION: VIRUS REPLICATION  
; FILE REFERENCE: 400/042US (MBHB02-249-E)  
; CURRENT APPLICATION NUMBER: US/10/669,841  
; CURRENT FILING DATE: 2003-09-23  
; PRIOR APPLICATION NUMBER: PCT/US02/09187  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: US 60/296,876  
; PRIOR FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/335,059  
; PRIOR FILING DATE: 2001-10-24  
; PRIOR APPLICATION NUMBER: US 60/337,055  
; PRIOR FILING DATE: 2001-12-05  
; PRIOR APPLICATION NUMBER: US 60/358,580  
; PRIOR FILING DATE: 2002-02-20  
; PRIOR APPLICATION NUMBER: US 60/363,124

PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5607  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-5607

Query Match 0.9%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCC 780  
|||  
Db 15 TCCACGCCATGTTCC 1

RESULT 385  
US-10-497-692-11  
Sequence 11, Application US/10497692  
Publication No. US2005004056A1  
GENERAL INFORMATION:  
APPLICANT: Weise, Martin  
APPLICANT: Eulenbery, Karsten  
APPLICANT: Fritsch, Rudiger  
APPLICANT: Hader, Thomas  
APPLICANT: Bronner, Gunter  
APPLICANT: Steuernagel, Arnd  
TITLE OF INVENTION: PTP10D, Tec protein tyrosine kinase and ETRP homologous proteins  
FILE REFERENCE: 2923-632  
CURRENT FILING DATE: 2004-06-04  
PRIOR APPLICATION NUMBER: US/10/497,692  
PRIOR FILING DATE: 2002-12-04  
PRIOR APPLICATION NUMBER: PCT/EP02/13744  
PRIOR FILING DATE: 2002-12-04  
PRIOR APPLICATION NUMBER: EP 01 000 010.5  
PRIOR FILING DATE: 2002-01-02  
PRIOR APPLICATION NUMBER: EP 01 129 138.2  
PRIOR FILING DATE: 2001-12-07  
PRIOR APPLICATION NUMBER: EP 01 128 844.6  
PRIOR FILING DATE: 2001-12-04  
NUMBER OF SEQ ID NOS: 20  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 11  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: mouse PTPRB reverse primer  
US-10-497-692-11

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 3.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 764 CTTCCAGCCATGTTCCA 781  
|||  
|||

Db 1 CTTCCAGCCATGTTCCA 18

RESULT 386  
US-09-866-108-8352/C  
Sequence 8352, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: A60MICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Acomica Sequence Listing Engine  
SEQ ID NO 8352  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTGCTG 1124  
|||  
Db 17 CAGCTCTCTGCTG 2

RESULT 387  
US-09-866-108-8353/C  
Sequence 8353, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang

```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8353

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1109 CACCTCCTCTGCTG 1124
DB      16 CAGCTCTCTTCTG 1

RESULT 388
; US-09-866-108-8665
; Sequence 8665, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8665

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      273 GAAGCCAAAGAGAGA 288
DB      2 GAAGCCAAAGAGAGA 17

RESULT 389
; US-09-866-108-8667
; Sequence 8667, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```



```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO: 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8667

```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      274 AAGCCAGAGAGAGAA 289
DB      1 AAGCCAGAGAGAGAA 16

```

```

RESULT 390
US-09-866-108-10037/C
; Sequence 10037, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWITCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 15752
;
; PRIOR APPLICATION NUMBER: PCT/US01/00662

```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO: 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10037

```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      715 CCGCATGTCGCGAG 730
DB      17 CCGCATGTCGCGAG 2

```

```

RESULT 391
US-09-866-108-10038/C
; Sequence 10038, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWITCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752

```

```
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10038
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10038

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      715 CCGCATGTCGCCAG 730
Db      16 CCGCATGTCACAG 1

RESULT 392
US-09-928-412-7
; Sequence 7, Application US/09928412
; Patent No. US20020123623A1
; GENERAL INFORMATION:
; APPLICANT: KAWAKAKI, Akiyoshi
; APPLICANT: EBINUMA, Hiroyasu
; TITLE OF INVENTION: TRANSCRIPTION FACTOR CONTROLLING PHENTYLPROPANOIC
; FILE REFERENCE: 4859-0027-0
; CURRENT APPLICATION NUMBER: US/09/928,412
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/282,146
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: JP 10-125171
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-03-31
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 7
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-928-412-7

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1104 CTGACACCTCCCTCT 1119
Db      2 CTGACACCTCTCTCT 17

RESULT 393
US-09-780-533A-171/c
; Sequence 171, Application US/09780533A
; Publication No. US2003006011A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowdria, Bharat
; APPLICANT: Haebertl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 171
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-09-780-533A-171

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1619 TTCATTAATAACTGTCT 1634
Db      16 TTCATTAATAACTGTCT 1

RESULT 394
US-09-877-478-1745/c
; Sequence 1745, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1745

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1519 CCCCCAATCCGCCCA 1534
Db      16 CCCCCAATCTCTCCA 1

RESULT 395
US-09-740-332-1543
; Sequence 1543, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals Inc.
; APPLICANT: Hepatitis C Virus Infection
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPT 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; PRIOR FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1543
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1543
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      768 CACGCCATGTTCCAGC 783
Db      1 CACGCCAUGUCCGCGC 16
```

```
RESULT 396
US-09-817-879-1543
; Sequence 1543, Application US/09817879
; Publication No. US2003017111A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
```

```
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1543
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1543
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      768 CACGCCATGTTCCAGC 783
Db      1 CACGCCAUGUCCGCGC 16
```

```
RESULT 397
US-10-298-255-4
; Sequence 4, Application US/10298255
; Publication No. US20030134312A1
```

```
; GENERAL INFORMATION:
; APPLICANT: BURGONE, LEIGH A.
; TITLE OF INVENTION: METHODS AND MATERIALS FOR DETECTING GENETIC MATERIAL
; FILE REFERENCE: 45858-56064
; CURRENT APPLICATION NUMBER: US/10/298,255
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: 60/336,005
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 4
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-298-255-4
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
```

```
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy      1508 CAGCCTCAGGCCCC 1523
Db      1 CAGCCTCAGGAGCCCC 16
```

```
RESULT 398
US-10-238-700-2912/c
; Sequence 2912, Application US/10238700
; Publication No. US20030153521A1
```

```
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
```

```
; FILE REFERENCE: 400/057 (MHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2912
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2912
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      1507 CCAGCTCAGGCCCC 1522
Db      17 CCAGCTCAGGCCCC 2
```

```
RESULT 399
US-10-339-793-366
; Sequence 366, Application US/10339793
; Publication No. US20030180764A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Shang, Jin
```

```
; TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; FILE REFERENCE: 37-000310US
; CURRENT APPLICATION NUMBER: US/10/339,793
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 443
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 366
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-793-366
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      990 ACCAACACCCCTCCC 1005
Db      2 ATCAACAACCCCTCCC 17
```

```
RESULT 400
US-10-342-902-1745/c
; Sequence 1745, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Diaper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MEHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; PRIOR FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1745
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy 1519 CCCCCAATCGGCCCA 1534
Db 16 CCCCCAATCGGCCCA 1
```

```
RESULT 401
US-10-138-674-8431/c
; Sequence 8431, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8431
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8431
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy 1545 GCTCTGATCCTGCAC 1560
Db 17 GCTCTGATCCTGCAC 2
```

RESULT 402

```
US-10-287-949A-8431/c
; Sequence 8431, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8431
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8431
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy 1545 GCTCTGATCCTGCAC 1560
Db 17 GCTCTGATCCTGCAC 2
```

```
RESULT 403
US-10-669-841-1745/c
; Sequence 1745, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Diaper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
```

SEQ ID NO 1745  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Hepatitis B virus  
US-10-669-841-1745

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1;

1519 CCCCCCTCGCCCA 1534  
Db 16 CCCCCACTCTCCCA 1

RESULT 404  
US-10-669-841-4136  
Sequence 4136, Application US/10669841  
Publication No. US20040127446A1

GENERAL INFORMATION:  
APPLICANT: Sirta Therapeutics, Inc.  
APPLICANT: Lawrence, Blat  
APPLICANT: Dennis, Macejak  
APPLICANT: James, McSwigen  
APPLICANT: David, Morrissey  
APPLICANT: Pamela, Favco  
APPLICANT: Patricia, Lee  
APPLICANT: Kenneth, Draper  
APPLICANT: Elisabeth, Roberts  
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION  
FILE REFERENCE: 400/04205 (HBB02-249-E)  
CURRENT FILING DATE: 2003-09-23  
PRIOR APPLICATION NUMBER: PCT/US02/09187  
PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055  
PRIOR FILING DATE: 2001-12-05  
PRIOR APPLICATION NUMBER: US 60/358,580  
PRIOR FILING DATE: 2002-02-20  
PRIOR APPLICATION NUMBER: US 60/363,124  
PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See file wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: Patent in version 3.0  
SEQ ID NO 4136  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-4136

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 75.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 12; Conservative 3; Mismatches 1;

Qy 768 CACGCATGTTCCAGC 783  
Db 1 CACGCCAUGUCCGCC 16

RESULT 405  
US-10-723-361-8352/C  
Sequence 8352, Application US/10723361  
Publication No. US20040137589A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105  
CURRENT FILING DATE: 2003-11-26  
PRIOR APPLICATION NUMBER: US/10/723,361  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263,6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See file wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 8352  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-723-361-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1;

Qy 1109 CACCTCCTCTGCTG 1124  
Db 17 CAGCTCCTCTGCTG 2

RESULT 406  
US-10-723-361-8353/C  
Sequence 8353, Application US/10723361  
Publication No. US20040137589A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105

```

; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8353
```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservativity 0; Mismatches 1; Indels 0; Gaps 0;

QY      1109 CACCTCCTCCTTGCTG 1124
Db      16 CAGCTCCTCCTTGCTG 1
```

```

RESULT 407
US-10-723-361-8665
; Sequence 8665, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8665
```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservativity 0; Mismatches 1; Indels 0; Gaps 0;

QY      273 GAAGCCAAAGAAGA 288
Db      2 GAAGCCAAAGAAGA 17
```

```

RESULT 408
US-10-723-361-8667
; Sequence 8667, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8667
```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservativity 0; Mismatches 1; Indels 0; Gaps 0;

QY      274 AAGCCAAAGAAGA 289
Db      1 AAGCCAAAGAAGA 16
```

```
RESULT 409
US-10-723-361-10037/C
; Sequence 10037, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10037

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      715 CCCGCATCGTCCGACG 730
DB      17 CCCGCATCGTCCACAG 2

RESULT 410
US-10-723-361-10038/C
; Sequence 10038, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
```

```
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10038
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10038

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      715 CCCGCATCGTCCGACG 730
DB      16 CCCGCATCGTCCACAG 1

RESULT 411
US-10-712-633-3472/C
; Sequence 3472, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Galad
; APPLICANT: McSwiggan, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MBBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3472
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
```

US-10-712-633-3472

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTCTGATCTGCAC 1560

Db 17 GCTCTGATCTGCAC 2

RESULT 412

US-10-724-270-1591/c

; Sequence 1591, Application US/10724270  
; Publication No. US20050080031A1  
; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level

; FILE REFERENCE: 400/046-US (MBH02-326-A)

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: PCT/US02/16840

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/318,471

; PRIOR FILING DATE: 2001-09-10

; PRIOR APPLICATION NUMBER: US 60/296,249

; PRIOR FILING DATE: 2001-06-06

; PRIOR APPLICATION NUMBER: US 60/294,140

; PRIOR FILING DATE: 2001-05-29

; PRIOR APPLICATION NUMBER: US 10/238,700

; PRIOR FILING DATE: 2002-09-10

; PRIOR APPLICATION NUMBER: US 10/163,552

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 10/157,580

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2002-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/417,012

; PRIOR FILING DATE: 2003-04-16

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 6810

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO: 1591

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-724-270-1591

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCTCCAGCCCC 1522

Db 17 CCAGCTCCAGCCCC 2

RESULT 413

US-11-016-291-4

; Sequence 4, Application US/11016291  
; Publication No. US20050095641A1  
; GENERAL INFORMATION:

; APPLICANT: BURGONE, LEIGH A.

; TITLE OF INVENTION: METHODS AND MATERIALS FOR DETECTING GENETIC MATERIAL

; FILE REFERENCE: 45858-56064

; CURRENT FILING DATE: 2004-12-17

; PRIOR APPLICATION NUMBER: 60/336,005

; PRIOR FILING DATE: 2001-11-15

; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO: 4  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-11-016-291-4

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGAGCCCC 1523

Db 1 CAGCTCCAGAGCCCC 16

RESULT 414

US-09-263-959-1251/c

; Sequence 1251, Application US/09263959  
; Patent No. US20020150891A1  
; GENERAL INFORMATION:

; APPLICANT: Hood, Leroy E.

; APPLICANT: Koop, Ben F.

; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI

; NUMBER OF SEQUENCES: 1279

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Seed and Berry LLP

; STREET: 6300 Columbia Center, 701 Fifth Avenue

; CITY: Seattle

; STATE: Washington

; COUNTRY: US

; ZIP: 98104-7092

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/263,959

; FILING DATE: 05-MAR-1999

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: McMaisters, David D.

; REGISTRATION NUMBER: 33,963

; REFERENCE/DOCKET NUMBER: 920010.426C2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (206) 622-4900

; TELEFAX: (206) 682-6031

; INFORMATION FOR SEQ ID NO: 1251:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 18 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-09-263-959-1251

Query Match 0.9%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 3.3e+02; 1; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 634 TCACCGGAGAGCCCCA 649

Db 17 TCACCGGAGAGCCCCA 2

RESULT 415

US-10-108-260A-5102

; Sequence 5102, Application US/10108260A  
; Publication No. US20040005560A1



```

; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1el full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5102
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized p
US-10-108-260A-5102

Query Match          0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1094 GTGAGAGTGCTCAAC 1109
DB      1 GTGAGAGTGCTCGAC 16

RESULT 416
US-10-758-451-884/c
; Sequence 884, Application US/10758451
; Publication No. US20050014711A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICION, ALLERGY (IES)
; FILE REFERENCE: 30775-706.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: 09/093,972
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 884
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-884

Query Match          0.9%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1532 CCAGCCTCTCCCG 1545
DB      14 CCAGCCTCTCCCG 1

RESULT 417
US-09-930-423-9
; Sequence 9, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 17
; TYPE: RNA
```

```

; ORGANISM: Homo Sapiens
US-09-930-423-9

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCG 1544
DB      1 CCCAGCCTCTCCCG 14

RESULT 418
US-09-930-423-359
; Sequence 359, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 359
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-359

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCG 1544
DB      3 CCCAGCCTCTCCCG 16

RESULT 419
US-09-930-423-360
; Sequence 360, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-360

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCG 1544
DB      2 CCCAGCCTCTCCCG 15

RESULT 420
US-09-740-332-1541
; Sequence 1541, Application US/09740332
```

```
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1541

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCGCCATGTTTC 779
Db 4 UCCAGCGCCAUUUUC 17

RESULT 421
US-09-745-237A-9
; Sequence 9, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-9

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1531 CCCAGCCTCTCCCC 1544
Db 1 CCCAGCCUCUCCCC 14

RESULT 422
US-09-745-237A-359
; Sequence 359, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 359
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-359

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1531 CCCAGCCTCTCCCC 1544
Db 3 CCCAGCCUCUCCCC 16

RESULT 423
US-09-745-237A-360
; Sequence 360, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-360

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1531 CCCAGCCTCTCCCC 1544
Db 2 CCCAGCCUCUCCCC 15

RESULT 424
US-09-817-879-1541
; Sequence 1541, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1541

Query Match
Best Local Similarity 0.9%; Score 14; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCAGCGCCATGTTTC 779
Db 4 UCCAGCGCCAUUUUC 17
```

```
RESULT 425
US-10-307-005-955/c
; Sequence 955, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO 955
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Eucalyptus camaldulensis
US-10-307-005-955

Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1202 GGTCCACACGGGTGG 1215
      |||||
      14 GGTCCACACGGGTGG 1

RESULT 426
US-10-307-005-956
; Sequence 956, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO 956
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Eucalyptus camaldulensis
US-10-307-005-956
```

```
Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1202 GGTCCACACGGGTGG 1215
      |||||
      4 GGTCCACACGGGTGG 17

RESULT 427
US-10-669-841-4134
; Sequence 4134, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4134
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4134

Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      766 TCCACGCCATGTTTC 779
      :|||||:|:|
      DB      4 UCCACGCCAUGGUC 17

RESULT 428
```

```
US-09-866-108-1895/c
; Sequence 1895, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1895

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      93 GAGAGTGGGAGGTCCT 109
Db      17 GAGAGAGGCCAGGTCCT 1

RESULT 429
US-09-866-108-2643/c
; Sequence 2643, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
```

```
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2643
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2643

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      845 CTTCCAGCACCCGCCAA 861
Db      17 CTGCCAGACCCGCCAA 1

RESULT 430
US-09-866-108-7355
; Sequence 7355, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 7355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7355

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      270 GAGAGGCCGACGAGAA 286
      |||||
Db      1 GAGAGGCCGACGAGAA 17
```

```

RESULT 431
US-09-866-108-7485/c
; Sequence 7485, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7485

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      1530 GCCAGCCTCTCCCGC 1546
      |||||
Db      17 GTCCAGCCTCTCTCCGC 1
```

```

RESULT 432
US-09-866-108-8568
; Sequence 8568, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8568

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      292 AGGATGCCCTTAATGAG 308
Db      1 AGGATGACCTGAATGAG 17

RESULT 433
US-09-866-108-8660
; Sequence 8660, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-09-866-108-8660

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      267 CTGAGAGAGCCCAAGAA 283
Db      1 CTGAGAGAGCCCAAGAA 17

RESULT 434
US-09-866-108-8661
; Sequence 8661, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8661
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8661

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      268 TAGAGAGAGCCCAAGAG 284
Db      1 TGAGAGAGCCCAAGAG 17
```

```
RESULT 435
US-09-866-108-8663
; Sequence 8663, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 8663
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8663

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      270 GAAGAGCCAGAGAGAA 286
DB      1 GAGGAGCCAGAGAGGA 17
```

```
RESULT 436
US-09-866-108-8664
; Sequence 8664, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
```

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 8664
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8664

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      271 AAGAGCCAGAGAGAG 287
DB      1 AGGAGCCAGAGAGAG 17
```

```
RESULT 437
US-09-866-108-9687/C
; Sequence 9687, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9687

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy      93 GGAGGTGGGCGAGTCCT 109
Db      17 GGAGGTGGGCGAGTCCT 1

```

```

RESULT 438
US-09-866-108-9688/c
; Sequence 9688, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9688

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy      92 GGAGGTGGGCGAGTCCT 108
Db      17 GGAGGTGGGCGAGTCCT 1

```

```

RESULT 439
US-09-866-108-9689/c
; Sequence 9689, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30

```



```

; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9689
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9689

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GCGAGAGTGGCGCAGCTC 107
DB 17 GCGAGAGTGGCGCAGCTC 1

RESULT 440
US-09-776-291A-4/c
; Sequence 4, Application US/09776291A
; Patent No. US20020123046A1
; GENERAL INFORMATION:
; APPLICANT: SMITH, Lloyd W.
; APPLICANT: HOOD, Leroy E.
; APPLICANT: HUNKAPILLER, Michael W.
; APPLICANT: HUNKAPILLER, Tim J.
; APPLICANT: CONNELL, Charles R.
; TITLE OF INVENTION: AUTOMATED DNA SEQUENCING TECHNIQUE
; FILE REFERENCE: 243132000106
; CURRENT APPLICATION NUMBER: US/09/776,291A
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 08/484,340
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/361,176
; PRIOR FILING DATE: 1994-12-21
; PRIOR APPLICATION NUMBER: 07/898,019
; PRIOR FILING DATE: 1992-06-12
; PRIOR APPLICATION NUMBER: 07/660,160
; PRIOR FILING DATE: 1991-02-21
; PRIOR APPLICATION NUMBER: 07/106,232
; PRIOR FILING DATE: 1987-10-07
; PRIOR APPLICATION NUMBER: 06/722,742
; PRIOR FILING DATE: 1985-04-11
; PRIOR APPLICATION NUMBER: 06/689,013
; PRIOR FILING DATE: 1985-01-02
; PRIOR APPLICATION NUMBER: 06/570,973
; PRIOR FILING DATE: 1984-01-16
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct
US-09-776-291A-4

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1357 AAGCGCTGCAGGAGATAC 1373
DB 17 ATGCTCTGCAGGAGATAC 1
```

```

RESULT 441
US-09-864-785-115
; Sequence 115, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MEHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 115
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-115

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 988 CCACCACACCCCTCC 1004
DB 1 CCACCACACCCCTCC 17

RESULT 442
US-09-864-785-117
; Sequence 117, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MEHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 117
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-117

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 992 CAACAACCCCTCCAG 1008
DB 1 CAACAACCCCTCCAG 17

RESULT 443
US-09-864-785-213
; Sequence 213, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 213
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-213

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1501 CAGCCCCCAGCCTCCAG 1517
Db      1 CAGACCCCGAGCCUCAG 17

RESULT 444
US-09-864-785-215
; Sequence 215, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 215
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-215

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1505 CCCGAGCCTCCAGGCC 1521
Db      1 CCCGAGCCTCCAGGCC 17

RESULT 445
US-09-864-785-336
; Sequence 336, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
```

```
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-336

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1505 CCCGAGCCTCCAGGCC 1521
Db      1 CCCGAGCCTCCAGGCC 17

RESULT 446
US-09-864-785-1519
; Sequence 1519, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1519
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1519

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1502 AGGCCCCAGCCTCCAG 1518
Db      1 AGACCCCGAGCCUCAG 17

RESULT 447
US-09-864-785-1520
; Sequence 1520, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1520
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-1520

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 3.3e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1506 CCCAGCTCCAGGCCCC 1522  
|||||:|||||  
DB 1 CCCAGCTCCAGGCCCC 17

RESULT 448  
US-09-864-785-2036  
Sequence 2036, Application US/09864785  
Patent No. US20020177568A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Draper, Ken  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
FILE REFERENCE: 400/022 (MBH800-812-D)  
CURRENT APPLICATION NUMBER: US/09/864,785  
NUMBER OF SEQ ID NOS: 3929  
SOFTWARE: Patent in version 3.0  
SEQ ID NO 2036  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-2036

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 3.3e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 989 CACCAACAACCCCTCCC 1005  
|||||:|||||  
DB 1 CACCAACAACCCCTCCC 17

RESULT 449  
US-09-961-077-687/C  
Sequence 687, Application US/09961077  
Publication No. US20030014775A1  
GENERAL INFORMATION:  
APPLICANT: Zwick, Michael G.  
Edington, Brent E.  
McSwiggen, James A.  
Merlo, Patricia Ann Owens  
Guo, Lining  
Skokut, Thomas A.  
Young, Scott A.  
Folkerts, Otto  
Merlo, Donald J.  
TITLE OF INVENTION: COMPOSITION AND METHODS FOR  
MODULATION OF GENE EXPRESSION  
IN PLANTS  
NUMBER OF SEQUENCES: 1263  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Lyon & Lyon  
STREET: 633 West Fifth Street  
Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
Storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/961,077  
FILING DATE: 21-SEP-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/679,645  
FILING DATE: July 12, 1996  
APPLICATION NUMBER: 60/001,135  
FILING DATE: July 13, 1995  
APPLICATION NUMBER: 08/300,726  
FILING DATE: September 2, 1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 219/247  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 687:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 687:  
US-09-961-077-687

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1213 TGGCTTCCCACTTCT 1229  
|||||:|||||  
DB 17 TGGCTGCAACACTTCT 1

RESULT 450  
US-09-780-533A-1053/C  
Sequence 1053, Application US/09780533A  
Publication No. US20030060611A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Blatt, Larry  
APPLICANT: McSwiggen, Jim  
APPLICANT: Chowrita, Bharat  
APPLICANT: Haederil, Pete  
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
FILE REFERENCE: MBH800,878-A (400/011)  
CURRENT APPLICATION NUMBER: US/09/780,533A  
CURRENT FILING DATE: 2001-02-09  
PRIOR APPLICATION NUMBER: US 60/181,797  
PRIOR FILING DATE: 2000-02-11  
NUMBER OF SEQ ID NOS: 6679  
SOFTWARE: Patent in version 3.0  
SEQ ID NO 1053  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-780-533A-1053

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1622 AATAAACTGCTCTTG 1638  
|||||:|||||  
DB 17 AATAAACTGCTCTTG 1

RESULT 451  
US-09-780-533A-1885/C  
; Sequence 1885, Application US/09780533A  
; Publication No. US2003006011A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowitza, Bharat  
; APPLICANT: Haebertli, Peter  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MHB00,878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1885  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-1885

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1621 CAATAAACTGCTTGT 1637  
Db 17 CATTAAACTGCTCTTT 1

RESULT 452  
US-09-093-972C-874/C  
; Sequence 874, Application US/09093972C  
; Publication No. US20030087845A1  
; GENERAL INFORMATION:  
; APPLICANT: Nyce, Jonathan W.  
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
; BRONCHOCONSTRICITION, ALLERGY(IES) & INFLAMMATION  
; NUMBER OF SEQUENCES: 996  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
; STREET: 7 Clarke Drive  
; CITY: Cranbury  
; STATE: New Jersey  
; COUNTRY: USA  
; ZIP: 08512  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/093,972C  
; FILING DATE: 09-Jun-1998  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/472,527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 08/757,024  
; FILING DATE: 26-11-1996  
; APPLICATION NUMBER: US 08/472,527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 09/016,464  
; FILING DATE: 30-January-1998  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Amzel, Viviana  
; REGISTRATION NUMBER: 30,930

REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 609-409-3035  
; TELEFAX: 413-254-9245  
; TELEX: <Unknown>  
; INFORMATION FOR SEQ ID NO: 874:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; SEQUENCE DESCRIPTION: SEQ ID NO: 874:  
US-09-093-972C-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546  
Db 17 GCCCAGCCTGTGCCCG 1

RESULT 453  
US-09-093-972C-944/C  
; Sequence 944, Application US/09093972C  
; Publication No. US20030087845A1  
; GENERAL INFORMATION:  
; APPLICANT: Nyce, Jonathan W.  
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
; BRONCHOCONSTRICITION, ALLERGY(IES) & INFLAMMATION  
; NUMBER OF SEQUENCES: 996  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
; STREET: 7 Clarke Drive  
; CITY: Cranbury  
; STATE: New Jersey  
; COUNTRY: USA  
; ZIP: 08512  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: floppy disk  
; OPERATING SYSTEM: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/093,972C  
; FILING DATE: 09-Jun-1998  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/472,527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 08/757,024  
; FILING DATE: 26-11-1996  
; APPLICATION NUMBER: US 08/472,527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 09/016,464  
; FILING DATE: 30-January-1998  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Amzel, Viviana  
; REGISTRATION NUMBER: 30,930  
; REFERENCE/DOCKET NUMBER: EPI-00672  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 609-409-3035  
; TELEFAX: 413-254-9245  
; TELEX: <Unknown>  
; INFORMATION FOR SEQ ID NO: 944:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

1117 CCTTGTGAGCAGCTG 1133  
|| : ||||| ||| : |

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.

```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3012
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3012

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      769  ACGCCATGTTCCAGCCC 785
Db      17  ACGCCATGTTCCGCTC 1

RESULT 459
US-09-792-818-440/c
; Sequence 440, Application US/09792818
; Publication No. US20030134806a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; TITLE OF INVENTION: (GRD) Gene
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 440
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-440

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1539  CTCCCGCTCTGATCC 1555
Db      17  CTCCCGCTGTGAACC 1

RESULT 460
US-09-745-237A-57/c
; Sequence 57, Application US/09745237A
; Publication No. US20030143708a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 57
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-57

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      643  AGCCCCGAGTACTTAC 659
Db      17  AGCCCCGAGTGCCTTC 1

RESULT 461
US-09-817-879-632
; Sequence 632, Application US/09817879
; Publication No. US20030171311a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-632

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 3.3e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY      1400  TGTGATGTTGCTTTTG 1416
Db      1  TUGUGAUGAUGCUGUG 17

RESULT 462
US-09-817-879-2161
; Sequence 2161, Application US/09817879
; Publication No. US20030171311a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2161

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

QY 689 GAGCCCTCCTCTCT 705  
Db 1 GAUACUCACUUCUUCU 17

## RESULT 463

US-09-817-879-3012/C  
Sequence 3012, Application US/09817879  
Publication No. US20030171311A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to HIV Infection  
FILE REFERENCE: MH800-801-F  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9703  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3012  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3012

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 769 AGCCATGTCACGCC 785  
Db 17 AGCCATGTCACGCCCTC 1

## RESULT 464

US-10-079-625-25  
Sequence 25, Application US/10079625  
Publication No. US20020182676A1  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
TITLE OF INVENTION: THE OB RECEPTOR AND TREATMENT OF BODY WEIGHT DISORDERS,  
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/079,625  
FILING DATE: 2002-FEB-19  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/654,564  
FILING DATE: 28-MAY-1997  
APPLICATION NUMBER: 08/708,123  
FILING DATE: 03-SEP-1996  
APPLICATION NUMBER: 08/638,524  
FILING DATE: 26-APR-1996

APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Melkiohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/019002  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-10-079-625-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17

## RESULT 465

US-10-079-625-27  
Sequence 27, Application US/10079625  
Publication No. US20020182676A1  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
TITLE OF INVENTION: THE OB RECEPTOR AND TREATMENT OF BODY WEIGHT DISORDERS,  
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/079,625  
FILING DATE: 2002-FEB-19  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/654,564  
FILING DATE: 28-MAY-1997  
APPLICATION NUMBER: 08/708,123  
FILING DATE: 03-SEP-1996  
APPLICATION NUMBER: 08/638,524  
FILING DATE: 26-APR-1996

APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Melkielejohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/019002  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-10-079-625-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCGCCCTCAG 676  
Db 1 CACTATTGCCCCCTCAG 17

RESULT 466  
US-10-060-756A-748  
Sequence 748, Application US/10060756A  
Publication No. US20030046717A1  
GENERAL INFORMATION:  
APPLICANT: Zhang, Jian  
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
FILE REFERENCE: PB0177  
CURRENT APPLICATION NUMBER: US/10/060,756A  
CURRENT FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
PRIOR APPLICATION NUMBER: US 60/327,898  
PRIOR FILING DATE: 2001-10-09  
NUMBER OF SEQ ID NOS: 4804  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 748  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-060-756A-748

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 521 CACGACTCCTGCTGGA 537  
Db 1 CACGACTCCTGCTGGA 17

RESULT 467  
US-10-060-756A-749  
Sequence 749, Application US/10060756A  
Publication No. US20030046717A1  
GENERAL INFORMATION:  
APPLICANT: Zhang, Jian  
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
FILE REFERENCE: PB0177  
CURRENT APPLICATION NUMBER: US/10/060,756A  
CURRENT FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
PRIOR APPLICATION NUMBER: US 60/327,898  
PRIOR FILING DATE: 2001-10-09  
NUMBER OF SEQ ID NOS: 4804  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 749  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-060-756A-749

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATGACCTCCTGCTGGA 538  
Db 1 AGCGACTCCTGCTGGA 17

RESULT 468  
US-10-060-756A-1238  
Sequence 1238, Application US/10060756A  
Publication No. US20030046717A1  
GENERAL INFORMATION:  
APPLICANT: Zhang, Jian  
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
FILE REFERENCE: PB0177  
CURRENT APPLICATION NUMBER: US/10/060,756A  
CURRENT FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30



```

1 PRIOR APPLICATION NUMBER: US 09/864,761
2
3 PRIOR FILING DATE: 2001-05-23
4
5 PRIOR APPLICATION NUMBER: US 60/327,898
6
7 PRIOR FILING DATE: 2001-10-09
8
9 NUMBER OF SEQ ID NOS: 4804
10
11 SOFTWARE: Acemica Sequence Listing Engine
12
13 SEQ ID NO 1238
14
15 LENGTH: 17
16
17 TYPE: DNA
18
19 ORGANISM: Homo sapiens
20
21 US-10-060-756A-1238

```

Query Match	0.8%	Score 13.8	DB 1	Length 17
Best Local Similarity	88.2%	Pred No.3.3e+02		
Matches 15	Conservative 0	Mismatches 2	Indels 0	Gaps 0

QY	1273	TCTTTGACTCTGATCCC	1289
Db	1	TCTGTGACTGTGATCCC	17

```

RESULT 469
US-10-156-306-2719/c
; Sequence 2719, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2719
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2719

```

QY	1400	TGTGATGTTGCTTTG	1416
Db	17	TGTGATGTTGATTCTG	1

```

RESULT 470
US-10-156-306-5069
; Sequence 5069, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-gamma and PKR
; FILE REFERENCE: MEMB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5069
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5069

```

Query Match	0.8;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	58.8%;	Pred. No. 3.3e+02;		
Matches 10; Conservative	5;	Mismatches 2;	Indels 0;	Gaps 0;

QY 697 ACTTCTTCTTCCAG 713  
||::||:|:|||||  
Db 1 ACUUCGCGUCCAG 17

```

RESULT 471
US-10-156-306-5948
; Sequence 5948, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwysen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 5948
; LENGTH: 17
;
; TYPE: RNA
;
; ORGANISM: Homo sapiens
US-10-156-306-5948

```

QY	698	CTTCCTCTTCCCAAGT	714
		::  : :     :	
Db	1	CUUCUGCUGUCCCAAGU	17

```

RESULT 472
US-10-430-882-880
/ Sequence 880, Application US/10430882
/ Publication No. US20030203870A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Lawrence Blatt
/ APPLICANT: James McSwiggen
/ APPLICANT: Bharat Chowitra
/ APPLICANT: Peter Haebelii
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C
/ FILE REFERENCE: MBHB0-878-H (400/112)
/ CURRENT APPLICATION NUMBER: US/10/430,882
/ CURRENT FILING DATE: 2003-05-06
/ PRIOR APPLICATION NUMBER: 09/827,395
/ PRIOR FILING DATE: 2001-04-05
/ PRIOR APPLICATION NUMBER: 09/780,533
/ PRIOR FILING DATE: 2001-02-09
/ PRIOR APPLICATION NUMBER: PCT/US01/04273
/ PRIOR FILING DATE: 2001-02-09
/ PRIOR APPLICATION NUMBER: 60/181,797
/ PRIOR FILING DATE: 2000-02-11
/ PRIOR APPLICATION NUMBER: PCT/US02/10512
/ PRIOR FILING DATE: 2002-04-03
/ NUMBER OF SEQ ID NOS: 2617
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 880
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-430-882-880

```

Query Match	0.8%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	70.6%;	Pred. No. 3.3e+02;		
Matches 12; Conservative	3;	Mismatches 2;	Indels 0;	Gaps 0
QY	1117	CCCTGCTGAGACGACTG	1133	
	:	:		



PRIOR APPLICATION NUMBER: 60/197,769  
PRIOR FILING DATE: 2000-04-14  
PRIOR APPLICATION NUMBER: 60/150,713  
PRIOR FILING DATE: 1999-08-31  
NUMBER OF SEQ ID NOS: 5586  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 564  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-712-672-564

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 98.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 101 GCAGGCTCTGGGGGACC 117  
DB 17 GCAGGCCCGAGGGGACC 1

RESULT 478  
US-10-712-672-1193  
Sequence 1193, Application US/10712672  
Publication No. US20040102413A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Chowitra, Bharat  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme  
FILE REFERENCE: MEHB00-882-C (400/019)  
CURRENT FILING DATE: 2003-11-13  
PRIOR APPLICATION NUMBER: US/09/653,225  
PRIOR FILING DATE: 2000-08-31  
PRIOR APPLICATION NUMBER: 60/197,769  
PRIOR FILING DATE: 2000-04-14  
PRIOR APPLICATION NUMBER: 60/150,713  
PRIOR FILING DATE: 1999-08-31  
NUMBER OF SEQ ID NOS: 5586  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1193  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-712-672-1193

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 3.3e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 1321 GGAAGACCTTAATT 1337  
DB 1 GGAAGACCTTAATT 17

RESULT 479  
US-10-669-841-3225  
Sequence 3225, Application US/10669841  
Publication No. US20040127446A1  
GENERAL INFORMATION:  
APPLICANT: Sirna Therapeutics, Inc.  
APPLICANT: Lawrence, Blact  
APPLICANT: Dennis, Macejak  
APPLICANT: James, McSwiggen  
APPLICANT: David, Morrissey  
APPLICANT: Pamela, Pavco  
APPLICANT: Patricia, Lee  
APPLICANT: Kenneth, Draper  
APPLICANT: Elisabeth, Roberts  
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA  
TITLE OF INVENTION: VIRUS REPLICATION

FILE REFERENCE: 400/042US (MEHB02-249-E)  
CURRENT APPLICATION NUMBER: US/10/669,841  
CURRENT FILING DATE: 2003-09-23  
PRIOR APPLICATION NUMBER: PCT/US02/09187  
PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055  
PRIOR FILING DATE: 2001-12-05  
PRIOR APPLICATION NUMBER: US 60/358,580  
PRIOR FILING DATE: 2002-02-20  
PRIOR APPLICATION NUMBER: US 60/363,124  
PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3225  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
NAME/KEY: misc\_feature  
LOCATION: 1  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-3225

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 3.3e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

OY 1400 TGTGATGTCCTTTG 1416  
DB 1 UGUGAUGAUGUCUG 17

RESULT 480  
US-10-669-841-4754  
Sequence 4754, Application US/10669841  
Publication No. US20040127446A1  
GENERAL INFORMATION:  
APPLICANT: Sirna Therapeutics, Inc.  
APPLICANT: Lawrence, Blact  
APPLICANT: Dennis, Macejak  
APPLICANT: James, McSwiggen  
APPLICANT: David, Morrissey  
APPLICANT: Pamela, Pavco  
APPLICANT: Patricia, Lee  
APPLICANT: Kenneth, Draper  
APPLICANT: Elisabeth, Roberts  
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA  
TITLE OF INVENTION: VIRUS REPLICATION  
FILE REFERENCE: 400/042US (MEHB02-249-E)  
CURRENT APPLICATION NUMBER: US/10/669,841  
CURRENT FILING DATE: 2003-09-23  
PRIOR APPLICATION NUMBER: PCT/US02/09187  
PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055

```

; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4754
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      689 GAGGCGTCACTTCTCT 705
Db      1 GAUAGCUCACUCUCUCU 17
```

```

RESULT 481
US-10-669-841-5605/c
; Sequence 5605, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPV
; FILE REFERENCE: 400/042US (MHB02-249-E)
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
```

```

; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5605
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      769 ACGCCATGTTCCAGCCC 785
Db      17 ACGCCATGTTCCGCGCTC 1
```

```

RESULT 482
US-10-723-361-1895/c
; Sequence 1895, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1895
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
```

Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGTCCT 109  
Db 17 GAGAGAGCCGAGTCCT 1

RESULT 483

US-10-723-361-2643/c  
; Sequence 2643, Application US/10723361  
; Publication No. US20040137589A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105

CURRENT FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105

CURRENT FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAGAGGCCAGAGAA 286  
Db 1 GAGAGGCCAGAGAA 17

RESULT 485

US-10-723-361-7485/c

; Sequence 7485, Application US/10723361

; Publication No. US20040137589A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105

CURRENT FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

PRIOR FILING DATE: 2003-11-26

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7485
```

```

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1530 GCCCAGCCTCTCCCGC 1546
Db      17  GTCCAGCCTCTCTCGC 1
```

## RESULT 486

```

; Sequence 8568, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```

; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8568
```

```

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      292 AGATGCGCTTAATGAG 308
Db      1  AGATGACCTGAATGAG 17
```

## RESULT 487

```

; Sequence 8660, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```

; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8660
```

```

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      267 CTGAGAGACCCAGAA 283
Db      1  CTGAGAGAACCAAGAA 17
```

## RESULT 488

```

; Sequence 8661, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```

; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
US-10-723-361-8661
```

```
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; CURRENT FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263,6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 8661
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-8661
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Oy      268 TAGAAGCCAGAGAG 284
Db      1 TGGAGAGCCAGAGAG 17
```

```
RESULT 489
US-10-723-361-8663
;; Sequence 8663, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; CURRENT FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263,6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 8663
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-8663
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Oy      270 GAGAGCCAGAGAG 286
Db      1 GAGAGCCAGAGAG 17
```

```
RESULT 490
US-10-723-361-8664
;; Sequence 8664, Application US/10723361
;; Publication No. US20040137589A1
;; GENERAL INFORMATION:
```

```
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;; FILE REFERENCE: PB0105
;; CURRENT APPLICATION NUMBER: US/10/723,361
;; CURRENT FILING DATE: 2003-11-26
;; PRIOR APPLICATION NUMBER: US 09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263,6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 8664
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-723-361-8664
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Oy      271 AAGAGCCAGAGAG 287
Db      1 AGGAGCCAGAGAG 17
```

```
RESULT 491
US-10-723-361-9687/c
; Sequence 9687, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9687

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 93 GAGAGTGGGCGAGTCT 109
Db 17 GAGAGTGGGCGAGTCT 1

RESULT 492
US-10-723-361-9688/c
; Sequence 9688, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
```

```
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9688

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 92 GAGAGTGGGCGAGTCC 108
Db 17 GAGAGTGGGCGAGTCC 1

RESULT 493
US-10-723-361-9689/c
; Sequence 9689, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```



```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9689
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9689

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      91 GCGAGAGTGGCGCAGTC 107
Db      17 GCGAGAGTGGCGCAGTC 1

RESULT 494
US-10-758-451-944/C
; Sequence 944, Application US/10758451
; Publication No. US20050014711A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY (IES)
; FILE REFERENCE: 30775-706.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: 09/093,972
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 944
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-944

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1530 GCCCAGCCTCTCCCGC 1546
Db      17 GCCCAGCCTCTCCCGC 1

RESULT 495
US-10-890-776A-748
; Sequence 748, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 748
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-748

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      521 CATGACTCCTCTCTGG 537
Db      1 CAGCGACTCCTCTCTGG 17

RESULT 496
US-10-890-776A-749
; Sequence 749, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 749
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-749

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      522 ATGAGCTCCCTCTGGA 538
Db      1 ACGGACTCCTCTCTGGA 17

RESULT 497
US-10-890-776A-1238
; Sequence 1238, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
```

```

; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 1238
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-1238

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1273 TCTTGACTCTGATCCC 1289
Db      1 TCTGTGACTGTGATCCC 17

```

Search completed: September 13, 2005, 10:47:07  
 Job time : 12 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:53:12 ; Search time 0.001 Seconds  
(without alignments)  
824.786 Million cell updates/sec

Title: us-10-828-394-1

Perfect score: 1643  
Sequence: 1 gaattccgcgcgtgaccgag.....taaacgtctgtgagctg 1643

Scoring table: IDENTITY NUC  
Gapop 10.0, Gapext 0.5

Searched: 8 segs, 251 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 500 summaries

Database: retcd:\*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	47	2.9	48	1	H93557
2	40.2	2.4	46	1	T74174
3	39	2.4	39	1	BF339449
4	39	2.4	39	1	BF342092
5	39	2.4	40	1	T71848
6	16	1.0	48	1	H93557
7	12.8	0.8	39	1	BF339449
8	12.8	0.8	39	1	BF342092
9	12.8	0.8	46	1	T74174
10	12.6	0.8	40	1	T71848
11	11.4	0.7	13	1	CM020522
12	11.4	0.7	14	1	CF278327
13	11	0.7	12	1	CN752857
14	9	0.5	12	1	CN752857
15	8.2	0.5	13	1	CM020522
16	8.2	0.5	14	1	CF278327

## ALIGNMENTS

RESULT 1  
H93557 48 bp mRNA linear EST 01-DEC-1995  
LOCUS H93557  
DEFINITION yv1d11.r1 Soares fetal liver spleen INFIS Homo sapiens cDNA clone IMAGE:242709.5' similar to gb:xi14723 CLUSTERIN PRECURSOR (HUMAN); mRNA sequence.  
ACCESSION H93557  
VERSION H93557.1 GI:1099885  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

## REFERENCE

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo. 1 (bases 1 to 48)

## AUTHORS

Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaaskis, E., Waterston, R., Williamson, A., Wohlmann, P. and Wilson, R.

## TITLE

The WashU-Merck EST Project  
JOURNAL  
COMMENT Unpublished (1995)

## CONTACT

Contact: Wilson RK

Washington University School of Medicine  
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu

High quality sequence starts: 1  
High quality sequence stops: 1  
Source: IMAGE Consortium, LNL  
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information.  
Trace considered overall poor quality  
Seq primer: M13RP1  
High quality sequence stop: 1.  
Location/Qualifiers

## FEATURES

## SOURCE

1..48

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="GDB:3791842"

/db\_xref="taxon:9606"

/clone="IMAGE:242709"

/sex="male"

/dev\_stage="20 week-post conception fetus"

/lab\_host="DH10B (ampicillin resistant)"

/clone\_lib="Soares fetal liver spleen INFIS"

/note="Organ: Liver and Spleen. Vector: p773D (Pharmacia) with a modified polylinker; Site\_1: Pac I; Site\_2: Eco RI; 1st strand cDNA was primed with a Pac I - oligo(dT) primer (5' AACGTGAAGAATTAATTAAGATCTTTTCTTTTCTTTT 3'), double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac I and cloned into the Pac I and Eco RI sites of the modified p773 vector. Library went through one round of normalization. Library constructed by Bento Soares and M. Fatima Bernaldo."

Query Match 2.9%; Score 47; DB 1; Length 48;  
Best Local Similarity 97.9%; Pred. No. 0.54; Indels 0; Gaps 0;

Matches 47; Conservative 0; Mismatches 1;

QY 1136 CGAGCAGTTTAAGTGGTGTCCCGGCTGCAACCTCAGCAAGCGCA 1183

DB 1 CGAGCAGTTTAAGTGGTGTCCCGGCTGCAACCTCAGCAAGCGCA 48

## RESULT 2

T74174 46 bp mRNA linear EST 02-MAR-1995

## LOCUS

LOCUS T74174/c

## DEFINITION

yc60b12.bl StrataGene liver (#937224) Homo sapiens cDNA clone IMAGE:55055.3' similar to gb:xi14723 CLUSTERIN PRECURSOR (HUMAN); mRNA sequence.

## ACCESSION

T74174

## VERSION

T74174.1 GI:690849

## KEYWORDS

EST.

## SOURCE

Homo sapiens (human)

## ORGANISM

Homo sapiens

## REFERENCE

1. (bases 1 to 46)

## AUTHORS

Hillier, L., Lennon, G., Becker, M., Bernaldo, M.F., Chiapelli, B., Chisoe, S., Dietrich, N., Dubuque, T., Favello, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Lacey, M., Le, M., Le, N., Marra, M., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Scheinberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Trevaaskis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R.

and Maria, M.  
Generation and analysis of 280,000 human expressed sequence tags  
JOURNAL  
Genome Res. 6 (9), 807-828 (1996)  
MEDLINE  
97044478  
PUBMED  
8889549  
COMMENT  
Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@wustl.wustl.edu  
High quality sequence starts: 1  
High quality sequence stops: 1  
Source: IMAGE Consortium, LNLN  
This clone is available royalty-free through LNLN; contact the  
IMAGE Consortium (info@image.lnl.gov) for further information.  
Trace considered overall poor quality  
Seq primer: -21ml3  
High quality sequence stop: 1.  
Location/Qualifiers

FEATURES  
source  
1. .46  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:502112"  
/db\_xref="taxon:9606"  
/clone="IMAGE:85055"  
/sex="male"  
/dev\_stage="49 years old"  
/lab\_host="SO2 cells (kanamycin resistant)"  
/clone\_id="Stratagene liver (#937224)"  
/note="Organ: liver; Vector: pBluescript SK; Site 1:  
EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer:  
Oligo dt. Hepatectomy from normal male caucasian. Average  
insert size: 1.1 kb; uni-ZAP XR Vector; ~5' adaptor  
sequence: 5' GAATTCGACGACG 3' ~3' adaptor sequence: 5'  
CTGAGTTTCTTTTCTTTT 3'."

Query Match  
Best Local Similarity 91.3%; Pred. No. 1.1;  
Matches 42; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1553 TCCTGCACTTACACCTGCTGCTGCTCAGGAAGAACAGAA 1598  
|||||  
46 TCCTGNAAGCTAAAAACCGACTCTGCTGCTCATGGAAGAACAGAA 1

RESULT 3  
BF339449 39 bp mRNA linear EST 22-NOV-2000  
LOCUS 602039103F1 NCI CGAP\_Brn64 Homo sapiens cDNA clone IMAGE:4186752  
DEFINITION 5', mRNA sequence.  
ACCESSION BF339449  
VERSION BF339449.1 GI:11285904  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 39)  
NIH-MGC http://mgc.nci.nih.gov/.  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: cgabs-r@mail.nih.gov  
Tissue Procurement: David N. Louis, M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LNLN at:  
http://image.lnl.gov  
Plate: LHM9508 row: 5 column: 01  
High quality sequence stop: 38.

FEATURES  
source

Location/Qualifiers  
1. .39  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:4186752"  
/tissue\_type="glioblastoma with EGFR amplification"  
/lab\_host="DH10B (T1 phage-resistant)"  
/clone\_id="NCI CGAP Brn64"  
/note="Organ: brain; Vector: pCMV-SPORT6; Site 1: NotI;  
Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
Average insert size 1.57 kb. Constructed by Life  
Technologies. Note: this is a NCI CGAP Library."

Query Match  
Best Local Similarity 100.0%; Pred. No. 1.2;  
Matches 39; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 416 GTTCTACGACGCGCTGACGAAGTGCTCAGGCTGTGT 454  
|||||  
Db 1 GTTCTACGACGCGCTGACGAAGTGCTCAGGCTGTGT 39

RESULT 4  
BF342092 39 bp mRNA linear EST 22-NOV-2000  
LOCUS 602012848F1 NCI CGAP\_Brn64 Homo sapiens cDNA clone IMAGE:4148962  
DEFINITION 5', mRNA sequence.  
ACCESSION BF342092  
VERSION BF342092.1 GI:11288842  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 39)  
NIH-MGC http://mgc.nci.nih.gov/.  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: cgabs-r@mail.nih.gov  
Tissue Procurement: David N. Louis, M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LNLN at:  
http://image.lnl.gov  
Plate: LHM9409 row: 0 column: 11  
High quality sequence stop: 37.  
Location/Qualifiers

FEATURES  
source

1. .39  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:4148962"  
/tissue\_type="glioblastoma with EGFR amplification"  
/lab\_host="DH10B (T1 phage-resistant)"  
/clone\_id="NCI CGAP Brn64"  
/note="Organ: brain; Vector: pCMV-SPORT6; Site 1: NotI;  
Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
Average insert size 1.57 kb. Constructed by Life  
Technologies. Note: this is a NCI CGAP Library."

Query Match  
Best Local Similarity 100.0%; Pred. No. 1.2;  
Matches 39; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 416 GTTCTACGACGCGCTGACGAAGTGCTCAGGCTGTGT 454  
|||||  
Db 1 GTTCTACGACGCGCTGACGAAGTGCTCAGGCTGTGT 39

RESULT 5  
LOCUS T71848/c  
DEFINITION T71848 40 bp mRNA linear EST 01-MAR-1995  
y64e06.b1 StrataGene liver (#937224) Homo sapiens cDNA clone  
IMAGE:85474 3' similar to gb:U14723 CLUSTERIN PRECURSOR (HUMAN);  
mRNA sequence.

ACCESSION T71848  
VERSION T71848.1 GI:686369  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 40)  
Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiappelli, B.,  
Chisoe, S., Dietrich, N., Dubuque, T., Favello, A., Gish, W.,  
Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N.,  
Mardis, E., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L.,  
Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Tierney, M., J.,  
Trevaekis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R.,  
and Marra, M.

TITLE Generation and analysis of 280,000 human expressed sequence tags  
JOURNAL Genome Res. 6 (9), 807-828 (1996)  
MEDLINE 97044478  
PUBMED 8889549

COMMENT Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu

Insert Size: 26  
High quality sequence starts: 1 High quality sequence stops: 1  
Source: IMAGE Consortium, LNL This clone is available royalty-free  
through LNL; contact the IMAGE Consortium (info@image.llnl.gov)  
for further information. Trace considered overall poor quality  
Seq primer: -21m3  
High quality sequence stop: 1.  
Location/Qualifiers

FEATURES  
source  
1..40  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:502531"  
/db\_xref="taxon:9606"  
/clone="IMAGE:85474"  
/sex="male"  
/dev\_stage="49 years old"  
/lab\_host="SOLR cells (kanamycin resistant)"  
/clone\_lib="Stratagene liver (#937224)"  
/note="Organ: liver; Vector: pBlueScript SK; Site: 1;  
EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer:  
Oligo dT. Hepatectomy from normal male caucasian. Average  
insert size: 1.1 kb; Uni-ZAP XR Vector; ~5' adaptor  
sequence: 5' GAATTCGGCAGCAG 3' ~3' adaptor sequence: 5'  
CTCAGCTTTTCTTTTCTTTT 3'."

Query Match 2.4%; Score 39; DB 1; Length 40;  
Best Local Similarity 97.5%; Pred. No. 1.2;  
Matches 39; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OR 1512 CTCGAGGCCCACTCGCGCCAGCTCCCGCTCGG 1551  
|||||  
DB 40 CTCGAGGCCCACTCGCGCCAGCTCCCGCTCGG 1

RESULT 6  
LOCUS H93557 48 bp mRNA linear EST 01-DEC-1995  
DEFINITION yv14d11.r1 Soares fetal liver spleen INFLS Homo sapiens cDNA clone  
IMAGE:242709 5' similar to gb:U14723 CLUSTERIN PRECURSOR (HUMAN);  
mRNA sequence.

ACCESSION H93557  
VERSION H93557.1 GI:1099885

KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 48)  
Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M.,  
Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M.,  
Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F.,  
Trevaekis, E., Waterston, R., Williamson, A., Wohlmann, P. and  
Wilson, R.

TITLE The WashU-Merck EST Project  
JOURNAL Unpublished (1995)  
COMMENT Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu

High quality sequence starts: 1  
High quality sequence stops: 1  
Source: IMAGE Consortium, LNL  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
Trace considered overall poor quality  
Seq primer: M13RPI  
High quality sequence stop: 1.  
Location/Qualifiers

FEATURES  
source  
1..48  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:3791842"  
/db\_xref="taxon:9606"  
/clone="IMAGE:242709"  
/sex="male"  
/dev\_stage="20 week-post conception fetus"  
/lab\_host="DH10B (ampicillin resistant)"  
/clone\_lib="Soares fetal liver spleen INFLS"  
/note="Organ: Liver and Spleen; Vector: pTZ19 (Pharmacia)  
with a modified polylinker; Site 1: Pac I; Site 2: Eco RI;  
1st strand cDNA was primed with a Pac I - oligo(dT) primer  
[5' AACCTGAGAAATTAATTAAGATCTTTTCTTTTCTTTT 3'],  
double-stranded cDNA was ligated to Eco RI adaptors  
(Pharmacia), digested with Pac I and cloned into the Pac I  
and Eco RI sites of the modified pTZ19 vector. Library  
went through one round of normalization. Library  
constructed by Bento Soares and M. Patricia Bonaldo."

Query Match 1.0%; Score 16; DB 1; Length 48;  
Best Local Similarity 66.7%; Pred. No. 9;  
Matches 22; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OR 627 AGGTTCTTACCCGAGAGCCCGAGATACCTAC 659  
|||||  
DB 36 AGGTTTNCACCGGACACCCAGTAACTGC 4

RESULT 7  
LOCUS BF339449/c 39 bp mRNA linear EST 22-NOV-2000  
DEFINITION 602039103f1 NCI CGAP\_Brn64 Homo sapiens cDNA clone IMAGE:4186752  
5' mRNA sequence.

ACCESSION BF339449  
VERSION BF339449.1 GI:11285904  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 39)  
NIH-MGC http://mgc.nci.nih.gov/  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)

## COMMENT

Contact: Robert Strausberg, Ph.D.  
Email: cgapbs-remail.nih.gov  
Tissue Procurement: David N. Louis, M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:  
http://image.llnl.gov  
Plate: LLM9508 row: f column: 01  
High quality sequence stop: 38.  
Location/Qualifiers

## FEATURES

## source

1..39  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:4186752"  
/tissue\_type="glioblastoma with EGFR amplification"  
/lab\_host="DH10B (T1 phage-resistant)"  
/clone\_lib="NCI CGAP Brn64"  
/note="Organ: brain; Vector: PCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 1.57 kb. Constructed by Life Technologies. Note: this is a NCI CGAP Library."

Query Match  
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 39;  
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 415 AGTTCTACGACGCGTCTGCAGAA 438

Db 25 ACTTCTCAGACGCGTCTGCAGAA 2

RESULT 8  
BF342092/c 39 bp mRNA linear EST 22-NOV-2000  
LOCUS 60201284BF1 NCI CGAP\_Brn64 Homo sapiens cDNA clone IMAGE:4148962  
DEFINITION 5', mRNA sequence.  
ACCESSION BF342092  
VERSION BF342092.1 GI:11288842  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 39)  
NTH-MGC http://mgc.nci.nih.gov/  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: cgapbs-remail.nih.gov  
Tissue Procurement: David N. Louis, M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:  
http://image.llnl.gov  
Plate: LLM9409 row: c column: 11  
High quality sequence stop: 37.  
Location/Qualifiers

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

## FEATURES

## source

1..39  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:4148962"  
/tissue\_type="glioblastoma with EGFR amplification"  
/lab\_host="DH10B (T1 phage-resistant)"  
/clone\_lib="NCI CGAP Brn64"  
/note="Organ: brain; Vector: PCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 1.57 kb. Constructed by Life

Technologies. Note: this is a NCI CGAP Library."

Query Match  
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 39;  
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 415 AGTTCTACGACGCGTCTGCAGAA 438

Db 25 ACTTCTCAGACGCGTCTGCAGAA 2

RESULT 9  
T74174 46 bp mRNA linear EST 02-MAR-1995  
LOCUS YC60b12.g1 Stragene liver (#937224) Homo sapiens cDNA clone  
DEFINITION IMAGE:85055 3' similar to gb:U14723 CLUSTERIN PRECURSOR (HUMAN);  
MRNA sequence.  
T74174  
T74174.1 GI:690849  
EST.  
ACCESSION T74174  
VERSION T74174.1 GI:690849  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 46)  
Chisoe, S., Dietrich, N., Dubaque, T., Favello, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N., Mardis, E., Moore, S., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Trevaskis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R. and Marra, M.  
Generation and analysis of 280,000 human expressed sequence tags  
Genome Res. 6 (9), 807-828 (1996)  
97044478  
MEDLINE 8889549  
JOURNAL  
COMMENT

Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu  
High quality sequence starts: 1  
High quality sequence stops: 1  
Source: IMAGE Consortium, LNL  
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.  
Trace considered overall poor quality  
Seq primer: -21m13  
High quality sequence stop: 1.  
Location/Qualifiers

## FEATURES

## source

1..46  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:502112"  
/db\_xref="taxon:9606"  
/clone="IMAGE:85055"  
/sex="male"  
/dev\_stage="49 years old"  
/lab\_host="SOLR cells (kanamycin resistant)"  
/clone\_lib="Stratagene liver (#937224)"  
/note="Organ: liver; Vector: pBluescript SK; Site 1: EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer: Oligo dt. Hepatectomy from normal male caucasian. Average insert size: 1.1 kb; Uni-ZAP XR Vector; -5' adaptor sequence: 5' GAATTCGACGAG 3' -3' adaptor sequence: 5' CTCGAGTTTCTTTTCTTTT 3'"

Query Match  
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 46;  
Matches 23; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 1573 CTCTGCTGCTCATGGAGAGACGAATTGCTCTGCATGCA 1613

Db 3 CTGTTTCCATGACGACGAGTCCGGTTTAGCGTCA 43

RESULT 10  
T71848 40 bp mRNA linear EST 01-MAR-1995  
LOCUS T71848  
DEFINITION y64e06.g1 Stratagene liver (#937224) Homo sapiens cDNA clone IMAGE:85474 3' similar to gb:U14723 CLUSTERIN PRECURSOR (HUMAN); mRNA sequence.

ACCESSION T71848  
VERSION T71848  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chapelli, B., Chissee, S., Dietrich, N., Dubague, T., Favello, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N., Mardis, E., Moore, B., Morris, W., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Trevaskis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R. and Marra, M.  
TITLE Generation and analysis of 280,000 human expressed sequence tags  
JOURNAL Genome Res. 6 (9), 807-828 (1996)  
MEDLINE 97044478  
PUBMED 8889549  
COMMENT Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu  
Insert Size: 26  
High quality sequence starts: 1 High quality sequence stops: 1  
Source: IMAGE Consortium, LNL This clone is available royalty-free through LNL; contact the IMAGE Consortium (infoimage.lnl.gov) for further information. Trace considered overall poor quality  
Seq primer: -21m13  
High quality sequence stop: 1.  
Location/Qualifiers  
1..40  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:502531"  
/db\_xref="taxon:9606"  
/clone="IMAGE:85474"  
/sex="male"  
/dev\_stage="49 years old"  
/lab\_host="SOLR cells (kanamycin resistant)"  
/clone\_lib="Stratagene liver (#937224)"  
/note="Organ: liver; Vector: pBluescript SK; Site 1: EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer: Oligo dt. Hepatectomy from normal male caucasian. Average insert size: 1.1 kb, Uni-ZAP XR Vector; ~5' adaptor sequence: 5' CTCGAGTTTCTTTTCTTTTCTTTT 3' "

Query Match 0.8%; Score 12.6; DB 1; Length 40;  
Best Local Similarity 58.3%; Pred. No. 11; Indels 0; Gaps 0;  
Matches 21; Conservative 0; Mismatches 15

Qy 84 CTGACCTGGAGAGTGGCAGGCTCTCGGGGACACG 119  
Db 2 CAGAGCGGAGAGGCTGGCGGAGTTTGGGGCCTCG 37

RESULT 11  
LOCUS CM020522  
DEFINITION GC0792 TIGEM gene trap library Mus musculus cDNA clone m4.E4.D08,

ACCESSION CM020522  
VERSION CM020522.1 GI:52789782  
KEYWORDS GSS.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE Cobellis, G., Nicolini, G., Marra, E., Barbaisi, M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Balabio, A. and Cortese, R.  
TITLE Tagging genes with cassette-exchange sites  
JOURNAL Unpublished (2004)  
COMMENT Contact: TIGEM  
107  
TIGEM  
Via P. Castellino, 111, 80131 NAPOLI, ITALY  
Tel: +39081532205  
Fax: +390815790919  
Email: cobellis@tigem.it  
Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM  
Class: Gene Trap.

FEATURES  
source  
1..13  
Location/Qualifiers  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="129 Ola"  
/db\_xref="taxon:10090"  
/clone="m4.E4.D08"  
/sex="male"  
/cell\_type="Embryonic stem cell"  
/cell\_line="E14"  
/clone\_lib="TIGEM gene trap library"  
/note="Vector: pRL1p1"

Query Match 0.7%; Score 11.4; DB 1; Length 13;  
Best Local Similarity 92.3%; Pred. No. 14; Indels 0; Gaps 0;  
Matches 12; Conservative 0; Mismatches 1

Qy 1498 AACGAGGCCCGAG 1510  
Db 13 AACGAGGCCCGAG 1

RESULT 12  
CF278327/c 14 bp mRNA linear EST 14-AUG-2003  
LOCUS 14ETL--04-D06.b1 Rice etiolated leaf plasmid cDNA library (14ETL)  
DEFINITION Oryza sativa (Japonica cultivar-group) cDNA clone 14ETL--04-D06, mRNA sequence.

ACCESSION CF278327  
VERSION CF278327.1 GI:33655713  
KEYWORDS EST.  
SOURCE Oryza sativa (Japonica cultivar-group)  
ORGANISM Oryza sativa (Japonica cultivar-group)  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Euphorbiaceae; Oryzaceae; Oryza.  
REFERENCE Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, U.K., Kim, Y.-K. and Nahm, B.H.  
TITLE Large-scale Sequencing Analysis of Rice ESTs  
JOURNAL Unpublished (2003)  
COMMENT Contact: Nahm B.H.  
Genomics and Genetics Institute, GreenGene Biotech Inc., Division of Bioscience and Bioinformatics, Myongji University  
Yongin, Kyonggi, Korea  
Tel: 82 31 330 6193  
Fax: 82 31 321 6355  
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES  
source

## Location/Qualifiers

1. .14  
/organism="Oryza sativa (japonica cultivar-group)"  
/mol\_type="mRNA"  
/cultivar="Nackdong"  
/db\_xref="taxon:39947"  
/clone="14ETL--04-D06"  
/tissue\_type="leaf"  
/dev\_stage="14 days after germination"  
/lab\_host="E.coli DH10B"  
/clone\_lib="Rice etiolated leaf plasmid cDNA library (14ETL)"  
/note="Vector: pCR4-TOPO, Site 1: EcoRI, mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.7%; Score 11.4; DB 1; Length 14;  
Best Local Similarity 92.3%; Pred. No. 14;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 272 AGAAGCAGAG 284

Db 14 AGAAGCAGAG 2

## RESULT 13

CN752857/c

LOCUS APHL3JD-VII-F11 APHL3JD Acyrthosiphon pisum cDNA clone 12 bp mRNA linear EST 19-MAY-2004

DEFINITION APHL3JDV11F11 5', mRNA sequence.

ACCESSION CN752857

VERSION CN752857.1 GI:47517854

KEYWORDS EST.

SOURCE Acyrthosiphon pisum (pea aphid)

ORGANISM

Acyrthosiphon pisum (pea aphid)  
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;  
Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.

1 (bases 1 to 12)

Hunter,W., Martinez-Torres,D., Rabhe,Y., Sabater-Munoz,B.,  
Stern,D., Tagu,D. and Wincker,P.

REFERENCE An expressed sequence tags database for the pea aphid Acyrthosiphon

AUTHORS pisum

TITLE

JOURNAL

COMMENT Unpublished (2004)  
Contact: D. Tagu  
INRA Rennes  
UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France  
Tel: +33.2.23.48.51.65  
Fax: +33.2.23.48.51.50

Risk of contamination by bacterial sequences from obligatory  
(Buchnera) or facultative endosymbionts.

PCR Primers

FORWARD: GCCGCATTAAGTGGTATAGCA

Plate: VII row: F column: 11.

Location/Qualifiers

FEATURES

source

1. .12  
/organism="Acyrthosiphon pisum"  
/mol\_type="mRNA"  
/cultivar="yr2"  
/db\_xref="taxon:7029"  
/clone="APHL3JDV11F11"  
/tissue\_type="head"  
/dev\_stage="third instar nymph (U3)"  
/lab\_host="TOP10"  
/clone\_lib="APHL3JD"  
/note="Vector: pDNR-LIB, Site 1: SfiI, Site 2: SfiI, B;  
Sample name: APHL3JD ; Plant growth place: INRA-Rennes,  
UMR BIO3P, BP 35327, 35653 Le Rheu cedex, France ; Soil  
conditions: peat ; Sowing date: 18/01/2003 ; Harvesting  
date: 03/02/2003 ; Stress date: no stress ; Description:  
aphids inoculated on one-week old Vicia faba germinations  
under non sterile conditions. ; experimental condition:  
long photoperiod (16-hr light/8-hr dark at 18 c)"

Query Match 0.7%; Score 11; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 14;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 279 AAGAGAGAG 289

Db 11 AAGAGAGAG 1

## RESULT 14

CN752857

LOCUS APHL3JD-VII-F11 APHL3JD Acyrthosiphon pisum cDNA clone 12 bp mRNA linear EST 19-MAY-2004

DEFINITION APHL3JDV11F11 5', mRNA sequence.

ACCESSION CN752857

VERSION CN752857.1 GI:47517854

KEYWORDS EST.

SOURCE

ORGANISM

Acyrthosiphon pisum (pea aphid)  
Acyrthosiphon pisum  
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;  
Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.

1 (bases 1 to 12)

Hunter,W., Martinez-Torres,D., Rabhe,Y., Sabater-Munoz,B.,  
Stern,D., Tagu,D. and Wincker,P.

REFERENCE An expressed sequence tags database for the pea aphid Acyrthosiphon

AUTHORS pisum

TITLE

JOURNAL

COMMENT Unpublished (2004)  
Contact: D. Tagu  
INRA Rennes  
UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France  
Tel: +33.2.23.48.51.65  
Fax: +33.2.23.48.51.50

Risk of contamination by bacterial sequences from obligatory  
(Buchnera) or facultative endosymbionts.

PCR Primers

FORWARD: GCCGCATTAAGTGGTATAGCA

Plate: VII row: F column: 11.

Location/Qualifiers

FEATURES

source

1. .12  
/organism="Acyrthosiphon pisum"  
/mol\_type="mRNA"  
/cultivar="yr2"  
/db\_xref="taxon:7029"  
/clone="APHL3JDV11F11"  
/tissue\_type="head"  
/dev\_stage="third instar nymph (U3)"  
/lab\_host="TOP10"  
/clone\_lib="APHL3JD"  
/note="Vector: pDNR-LIB, Site 1: SfiI, Site 2: SfiI, B;  
Sample name: APHL3JD ; Plant growth place: INRA-Rennes,  
UMR BIO3P, BP 35327, 35653 Le Rheu cedex, France ; Soil  
conditions: peat ; Sowing date: 18/01/2003 ; Harvesting  
date: 03/02/2003 ; Stress date: no stress ; Description:  
aphids inoculated on one-week old Vicia faba germinations  
under non sterile conditions. ; experimental condition:  
long photoperiod (16-hr light/8-hr dark at 18 c)"

Query Match 0.5%; Score 9; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 17;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 698 CTTCTTCTT 706

Db 3 CTTCTTCTT 11

## RESULT 15

CW020522

LOCUS CW020522 13 bp mRNA linear GSS 28-SEP-2004

DEFINITION GCU792 TIGEM gene trap library Mus musculus cDNA clone m4.B4.D08,  
mRNA sequence.



ACCESSION C9020522 GI:52789782  
 VERSION C9020522.1  
 KEYWORDS GSS.  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 13)  
 REFERENCE Cobellis G., Nicolans G., Marra, E., Barbaisi M., Sardiello, M., Di  
 Giorgio, F.P., Iovino, N., Zollo, M., Ballibio, A. and Cortese, R.  
 Tagging genes with cassette-exchange sites  
 Unpublished (2004)  
 TITLE JOURNAL  
 COMMENT Contact: TIGEM  
 107  
 TIGEM  
 via P. Castellino, 111, 80131 NAPOLI, ITALY  
 Tel: +390816132205  
 Fax: +390815790919  
 Email: cobellis@tigem.it  
 Sequence tag generated by 5' RACE of total RNA from gene trap ES  
 cell line. ES cell lines harboring insertion mutation of target  
 gene are available upon request from TIGEM. Annotation information  
 available from TIGEM  
 Class: Gene Trap.  
 Location/Qualifiers  
 1..13  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /strain="129 Ola"  
 /db\_xref="taxon:10090"  
 /clone="tm4.E4.D08"  
 /sex="male"  
 /cell\_type="Embryonic stem cell"  
 /cell\_line="E14"  
 /clone\_lib="TIGEM gene trap library"  
 /note="Vector: pFLIP1"  
 Query Match 0.5%; Score 8.2; DB 1; Length 13;  
 Best Local Similarity 76.9%; Pred. No. 18;  
 Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Oy 443 CTCAGGCTGGTT 455  
 |||||  
 1 CTGGAGCTGTT 13  
 Db  
 RESULT 16  
 CF278327 14 bp mRNA linear EST 14-AUG-2003  
 LOCUS 14ETL--04-D06.b1 Rice etiolated leaf plasmid cDNA library (14ETL)  
 DEFINITION Oryza sativa (japonica cultivar-group) cDNA clone 14ETL--04-D06,  
 mRNA sequence.  
 CF278327  
 ACCESSION CF278327.1 GI:33655713  
 VERSION CF278327  
 KEYWORDS EST.  
 SOURCE Oryza sativa (japonica cultivar-group)  
 ORGANISM Oryza sativa (japonica cultivar-group)  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
 Ehrhartoideae; Oryzaceae; Oryza.  
 1 (bases 1 to 14)  
 REFERENCE Kim, J.S., Jun, K.W., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,  
 Song, S.I., Kim, J.K., Kim, Y.-K. and Nam, B.H.  
 Large-scale Sequencing Analysis of Rice ESTs  
 Unpublished (2003)  
 TITLE JOURNAL  
 COMMENT Contact: Nahm B.H.  
 Genomics and Genetics Institute, Greengene Biotech Inc.; Division  
 of Bioscience and Bioinformatics, Myongji University  
 Yongin, Kyeonggi, Korea  
 Tel: 82 31 330 6193  
 Fax: 82 31 321 6355  
 Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.  
 FEATURES  
 Location/Qualifiers

source  
 1..14  
 /organism="Oryza sativa (japonica cultivar-group)"  
 /mol\_type="mRNA"  
 /cultivar="Nackdong"  
 /db\_xref="taxon:39947"  
 /clone="14ETL--04-D06"  
 /issue="leaf"  
 /dev\_stage="14 days after germination"  
 /lab\_host="E.coli DH10B"  
 /clone\_lib="Rice etiolated leaf plasmid cDNA library  
 (14ETL)"  
 /note="Vector: pCR4-TOPO, Site 1: EcoRI; mRNA was capped  
 with oligoribonucleotides and then used as templates for  
 RT-PCR."  
 Query Match 0.5%; Score 8.2; DB 1; Length 14;  
 Best Local Similarity 76.9%; Pred. No. 18;  
 Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Oy 697 ACTTCTTCTTCC 709  
 |||||  
 1 ACTTCTTCTTCC 13  
 Db  
 Search completed: September 13, 2005, 10:53:12  
 Job time : 0.001 secs

***This Page Blank (uspto)***

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 15:23:21 ; Search time 128 Seconds  
(without alignments)  
268.452 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21  
Sequence: 1 cagcagcagagcttcacat 21

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 1209694

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents NA:  
1: /cgn2\_6/ptodata/1/ina/5A.COMB.seq:\*  
2: /cgn2\_6/ptodata/1/ina/5B.COMB.seq:\*  
3: /cgn2\_6/ptodata/1/ina/6A.COMB.seq:\*  
4: /cgn2\_6/ptodata/1/ina/6B.COMB.seq:\*  
5: /cgn2\_6/ptodata/1/ina/PCCTS.COMB.seq:\*  
6: /cgn2\_6/ptodata/1/ina/backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17.8	84.8	50	US-09-485-632B-15	Sequence 15, Appl
2	16.2	77.1	32	US-09-410-935B-6	Sequence 6, Appl
3	16.2	77.1	32	US-09-784-403A-6	Sequence 6, Appl
4	16	76.2	25	US-09-396-196G-7759	Sequence 7759, Ap
5	15.4	73.3	45	US-07-885-689A-7	Sequence 7, Appl
6	15.2	72.4	22	US-09-823-549-46	Sequence 46, Appl
7	14.8	70.5	31	US-10-007-010-43	Sequence 43, Appl
8	14.8	70.5	31	US-08-467-603-35	Sequence 35, Appl
9	14.8	70.5	31	US-08-466-793-35	Sequence 35, Appl
10	14.8	70.5	31	US-08-491-861A-35	Sequence 35, Appl
11	14.8	70.5	31	US-09-374-671A-35	Sequence 35, Appl
12	14.6	69.5	25	US-09-396-196G-10991	Sequence 10991, A
13	14.6	69.5	25	US-09-396-196G-74836	Sequence 74836, A
14	14.6	69.5	44	US-09-110-959A-11	Sequence 11, Appl
15	14.2	67.6	20	US-09-205-860-3	Sequence 163, App
16	14.2	67.6	20	US-09-657-452A-163	Sequence 57, App
17	14.2	67.6	24	US-09-360-545-57	Sequence 103491,
18	14.2	67.6	25	US-09-396-196G-103491	Sequence 103491,
19	14.2	67.6	30	US-09-130-663-10	Sequence 10, Appl
20	14.2	67.6	30	US-09-432-335-10	Sequence 10, Appl
21	14.2	67.6	30	US-09-254-023B-20	Sequence 20, Appl
22	14.2	67.6	30	US-09-614-023-10	Sequence 10, Appl
23	14.2	67.6	47	US-09-422-978-3015	Sequence 3015, Ap
24	13.8	65.7	18	US-09-256-496-15	Sequence 15, Appl
25	13.8	65.7	25	US-09-396-196G-35606	Sequence 35606, A
26	13.8	65.7	25	US-09-396-196G-44424	Sequence 44424, A
27	13.8	65.7	25	US-09-396-196G-44425	Sequence 44425, A

28	13.8	65.7	25	US-09-396-196G-44426	Sequence 44426, A
29	13.8	65.7	25	US-09-396-196G-44427	Sequence 44427, A
30	13.8	65.7	25	US-09-396-196G-108268	Sequence 108268,
31	13.8	65.7	28	US-08-887-145-35	Sequence 35, Appl
32	13.8	65.7	30	US-09-586-216C-19	Sequence 19, Appl
33	13.8	65.7	37	US-08-467-603-54	Sequence 54, Appl
34	13.8	65.7	37	US-08-466-793-54	Sequence 54, Appl
35	13.8	65.7	37	US-08-491-861A-54	Sequence 54, Appl
36	13.8	65.7	37	US-09-374-671A-54	Sequence 54, Appl
37	13.8	65.7	41	US-09-586-216C-4	Sequence 87, Appl
38	13.6	64.8	20	US-09-517-467B-87	Sequence 4550, Ap
39	13.6	64.8	20	US-09-198-452A-4550	Sequence 6, Appl
40	13.6	64.8	23	US-09-489-085A-6	Sequence 7746, Ap
41	13.6	64.8	25	US-09-396-196G-7746	Sequence 10990, A
42	13.6	64.8	25	US-09-396-196G-10990	Sequence 68315, A
43	13.6	64.8	25	US-09-396-196G-68315	Patent No. 5463174
44	13.6	64.8	27	US-09-396-196G-5463174-1	Patent No. 5463174
45	13.6	64.8	27	US-09-396-196G-5463174-1	Patent No. 5463174

## ALIGNMENTS

RESULT 1  
US-09-485-632B-15/c  
Sequence 15, Application US/09485632B  
Patent No. 6605280  
GENERAL INFORMATION:  
APPLICANT: No. 66052801ck, Daniela  
APPLICANT: Dinarello, Charles  
APPLICANT: Rubinstein, Menachem  
APPLICANT: Kim, Soo Hyun  
TITLE OF INVENTION: Interleukin-18 Binding Proteins, their Preparation and  
TITLE OF INVENTION: Use  
FILE REFERENCE: 20993-001  
CURRENT APPLICATION NUMBER: US/09/485, 632B  
CURRENT FILING DATE: 2000-10-12  
PRIOR APPLICATION NUMBER: 1198/00379  
PRIOR FILING DATE: 1998-08-11  
PRIOR APPLICATION NUMBER: 125463  
PRIOR FILING DATE: 1998-07-22  
PRIOR APPLICATION NUMBER: 122134  
PRIOR FILING DATE: 1997-11-06  
PRIOR APPLICATION NUMBER: 121869  
PRIOR FILING DATE: 1997-09-29  
PRIOR APPLICATION NUMBER: 121639  
PRIOR FILING DATE: 1997-08-27  
PRIOR APPLICATION NUMBER: 121554  
PRIOR FILING DATE: 1997-08-14  
NUMBER OF SEQ ID NOS: 15  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 15  
LENGTH: 50  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Chemically synthesized  
US-09-485-632B-15  
Query Match 84.8%; Score 17.8; DB 4; Length 50;  
Best Local Similarity 90.5%; Pred. No. 80;  
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGCTTCATCAT 21  
DB 42 CAGCAGCAGAGCTTCATCAT 22  
RESULT 2  
US-09-410-935B-6  
Sequence 6, Application US/09410935B  
Patent No. 6504083  
GENERAL INFORMATION:

```
; APPLICANT: Barbour, Eric
; APPLICANT: Eucilaire Meyer, Terry
; APPLICANT: Eid Saad, Mohammed
; TITLE OF INVENTION: No. 6504083e1 Maize Promoters
; FILE REFERENCE: 5718-72
; CURRENT APPLICATION NUMBER: US/09/410,935B
; CURRENT FILING DATE: 1999-10-04
; PRIOR APPLICATION NUMBER: US 60/107,201
; PRIOR FILING DATE: 1998-11-05
; PRIOR APPLICATION NUMBER: US 60/103,294
; PRIOR FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gene specific primer 1 for Gos-2
US-09-410-935B-6
```

```
Query Match          77.1%; Score 16.2; DB 4; Length 32;
Best Local Similarity 85.7%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1 CAGCAGCAGAGTCTTCATCAT 21
        |||||
Db       3 CAGCACCAGAGTCTCTCAGCAT 23
```

```
RESULT 3
US-09-784-403A-6
; Sequence 6, Application US/097844403A
; Patent No. 6670467
; GENERAL INFORMATION:
; APPLICANT: Barbour, Eric
; APPLICANT: Eucilaire Meyer, Terry
; APPLICANT: Eid Saad, Mohammed
; TITLE OF INVENTION: No. 6670467e1 Maize Promoters
; FILE REFERENCE: 35718/208067
; CURRENT APPLICATION NUMBER: US/09/784,403A
; CURRENT FILING DATE: 2001-02-15
; PRIOR APPLICATION NUMBER: US 60/107,201
; PRIOR FILING DATE: 1998-11-05
; PRIOR APPLICATION NUMBER: US 60/103,294
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 09/410,935
; PRIOR FILING DATE: 1999-10-04
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gene specific primer 1 for Gos-2
US-09-784-403A-6
```

```
Query Match          77.1%; Score 16.2; DB 4; Length 32;
Best Local Similarity 85.7%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1 CAGCAGCAGAGTCTTCATCAT 21
        |||||
Db       3 CAGCACCAGAGTCTCTCAGCAT 23
```

```
RESULT 4
US-09-396-196G-7759/c
; Sequence 7759, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
```

```
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affimetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7759
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-7759
```

```
Query Match          76.2%; Score 16; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2 AGCAGCAGAGTCTTCA 17
        |||||
Db       16 AGCAGCAGAGTCTTCA 1
```

```
RESULT 5
US-07-885-689A-7
; Sequence 7, Application US/07885689A
; Patent No. 5366876
; GENERAL INFORMATION:
; APPLICANT: Cho, Joong M.
; APPLICANT: Lee, Tae H.
; APPLICANT: Chung, Hyun H.
; APPLICANT: Lee, Yong B.
; APPLICANT: Lee, Tae G.
; APPLICANT: Park, Young W.
; APPLICANT: Han, Kyu B.
; TITLE OF INVENTION: Method for Production of Bovine Growth
; TITLE OF INVENTION: Hormone Using a Synthetic Gene.
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Birch, Stewart, Kolash & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/885,689A
; FILING DATE: 19-MAY-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30,350
; REFERENCE/DOCKET NUMBER: 377-144P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHEICAL: NO
; FEATURE:
```

NAME/KEY: -  
LOCATION: 1.45  
OTHER INFORMATION: /label= oligonucleotide  
OTHER INFORMATION: /note= "U7 oligonucleotide portion of synthetic  
OTHER INFORMATION: BGH gene, Figure 1."  
US-07-885-689A-7

Query Match 73.3%; Score 15.4; DB 1; Length 45;  
Best Local Similarity 94.1%; Pred. No. 9.2e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4 CAGCAGAGTTCATCA 20  
DB 21 CAGCAGAGTTCACCA 37

RESULT 6  
US-09-823-549-46

Sequence 46, Application US/09823549  
Patent No. 6664442

GENERAL INFORMATION:

APPLICANT: McConlogue, Lisa C

APPLICANT: Games, Kate D.

APPLICANT: Yednock, Theodore A.

APPLICANT: Hua, Tan

APPLICANT: Messersmith, Elizabeth

APPLICANT: Baird, Frederique

TITLE OF INVENTION: SCREENING MARKERS AND METHODS FOR NEURODEGENERATIVE DISORDERS

FILE REFERENCE: 015270-009110US

CURRENT APPLICATION NUMBER: US/09/823,549

CURRENT FILING DATE: 2001-03-30

PRIOR FILING DATE: 2000-03-30

NUMBER OF SEQ ID NOS: 85

SOFTWARE: PatentIn version 3.1

SEQ ID NO 46

LENGTH: 22

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: IL-12 p40, #1 forward primer

US-09-823-549-46

Query Match 72.4%; Score 15.2; DB 4; Length 22;  
Best Local Similarity 85.0%; Pred. No. 1e+03;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 CAGCAGAGTTCATCA 20  
DB 2 CAGCAGAGTTCATCA 21

RESULT 7  
US-10-007-010-43

Sequence 43, Application US/10007010  
Patent No. 6828151

GENERAL INFORMATION:

APPLICANT: Alexander H. Borchers

APPLICANT: Kenneth W. Doble

TITLE OF INVENTION: ANTISENSE MODULATION OF HCK EXPRESSION

FILE REFERENCE: RTS-0345

CURRENT APPLICATION NUMBER: US/10/007,010

CURRENT FILING DATE: 2001-12-04

NUMBER OF SEQ ID NOS: 87

SEQ ID NO 43

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Antisense Oligonucleotide

Best Local Similarity 88.9%; Pred. No. 1.5e+03;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 3 GCACAGAGTTCATCA 20  
DB 1 GCTGCAGAGTTCATCA 18

RESULT 8  
US-08-467-603-35/C

Sequence 35, Application US/08467603  
Patent No. 5843672

GENERAL INFORMATION:

APPLICANT: Morgenstern, Jay P.

APPLICANT: Kanieczny, Andriy

APPLICANT: Bizindakas, Christine B.

APPLICANT: Brauer, Andrew W.

TITLE OF INVENTION: Allergenic Proteins and

TITLE OF INVENTION: Peptides from Dog

TITLE OF INVENTION: Dander and Uses Therefor

NUMBER OF SEQUENCES: 104

CORRESPONDENCE ADDRESS:

ADDRESSEE: LATITE & COCKFIELD

STREET: 60 State Street, suite 510

CITY: Boston

STATE: MA

COUNTRY: USA

ZIP: 02109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: ASCII-text

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/467,603

FILING DATE:

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/156,549

FILING DATE:

APPLICATION NUMBER: 07/999,712

FILING DATE: 31-Dec-92

ATTORNEY/AGENT INFORMATION:

NAME: Mandragoras, Amy E.

REGISTRATION NUMBER: 36,207

REFERENCE/DOCKET NUMBER: IMI-026CP(IRC-048CP)

TELEPHONE: (617) 227-7400

TELEFAX: (617) 227-5941

INFORMATION FOR SEQ ID NO: 35:

SEQUENCE CHARACTERISTICS:

LENGTH: 31 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: CDNA

US-08-467-603-35

Query Match 70.5%; Score 14.8; DB 2; Length 31;  
Best Local Similarity 88.9%; Pred. No. 1.6e+03;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 AGCAGAGGTTTCATC 19  
DB 24 AGCAGAGGTTTCATC 7

RESULT 9  
US-08-466-793-35/C

Sequence 35, Application US/08466793  
Patent No. 5891716

GENERAL INFORMATION:

APPLICANT: Morgenstern, Jay P.

```

1  APPLICANT: Kanieczny, Andrzej
2  APPLICANT: Bizindaukas, Christine B.
3  APPLICANT: Brauer, Andrew W.
4  TITLE OF INVENTION: Allergenic Proteins and
5  TITLE OF INVENTION: Peptides from Dog
6  TITLE OF INVENTION: Dander and Uses Therefor
7  NUMBER OF SEQUENCES: 104
8  CORRESPONDENCE ADDRESS:
9  ADDRESSEE: LAHIVE & COCKFIELD
10 STREET: 60 State Street, suite 510
11 CITY: Boston
12 STATE: MA
13 COUNTRY: USA
14 ZIP: 02109
15
16 COMPUTER READABLE FORM:
17
18 MEDIUM TYPE: Floppy disk
19 COMPUTER: IBM PC compatible
20 OPERATING SYSTEM: PC-DOS/MS-DOS
21 SOFTWARE: ASCII-text
22
23 CURRENT APPLICATION DATA:
24 APPLICATION NUMBER: US/08/466,793
25 FILING DATE: 06-JUN-1995
26 CLASSIFICATION: 435
27
28 PRIOR APPLICATION DATA:
29 APPLICATION NUMBER: US 08/156,549
30 FILING DATE: 22-NOV-1993
31 APPLICATION NUMBER: 07/999,712
32 FILING DATE: 31-Dec-92
33
34 ATTORNEY/AGENT INFORMATION:
35 NAME: Mandragouras, Amy E.
36 REGISTRATION NUMBER: 36,207
37
38 REFERENCE/DOCKET NUMBER: IMI-026CP(IPC-048CP)
39
40 TELECOMMUNICATION INFORMATION:
41 TELEPHONE: (617) 227-7400
42 TELEFAX: (617) 227-5941
43
44 INFORMATION FOR SEQ ID NO: 35:
45 SEQUENCE CHARACTERISTICS:
46 LENGTH: 31 base pairs
47 TYPE: nucleic acid
48 STRANDEDNESS: single
49 TOPOLOGY: linear
50 MOLECULE TYPE: CDNA
51
52 US-08-466-793-35
53
54 Query Match 70.5%; Score 14.8; DB 2; Length 31;
55 Best Local Similarity 88.9%; Pred.No.1.6e+03;
56 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
57
58 OY 2 AGCAGCAGAGTCTTCATC 19
59 |||||
60 Db 24 AGGAGCAGAGTCTTCATC 7
61
62
63 RESULT 10
64 US-08-491-861A-35/c
65 Sequence 35, Application US/08491861A
66 Patent No. 5939283
67
68 GENERAL INFORMATION:
69 APPLICANT: Morgenstern, Jay P.
70 APPLICANT: Kanieczny, Andrzej
71 APPLICANT: Bizindaukas, Christine B.
72 APPLICANT: Brauer, Andrew W.
73 TITLE OF INVENTION: Allergenic Proteins and Peptides from Dog
74 TITLE OF INVENTION: Dander and Uses Therefor
75 NUMBER OF SEQUENCES: 104
76 CORRESPONDENCE ADDRESS:
77 ADDRESSEE: LAHIVE & COCKFIELD, LLP
78 STREET: 28 State Street
79 CITY: Boston
80 STATE: MA
81 COUNTRY: USA
82 ZIP: 02109
83
84 COMPUTER READABLE FORM:
85

```

```

1 MEDIUM TYPE: Floppy disk
2 COMPUTER: IBM PC compatible
3 OPERATING SYSTEM: PC-DOS/MS-DOS
4 SOFTWARE: ASCII-text
5
6 CURRENT APPLICATION DATA:
7 APPLICATION NUMBER: US/08/491,861A
8 FILING DATE: 27-OCT-1995
9 CLASSIFICATION: 435
10
11 PRIOR APPLICATION DATA:
12 APPLICATION NUMBER: 07/999,712
13 FILING DATE: 31-Dec-92
14 ATTORNEY/AGENT INFORMATION:
15 NAME: Mandragouras, Amy E.
16 REGISTRATION NUMBER: 36,207
17 REFERENCE/DOCKET NUMBER: IMI-026CP (IPC-048CP)
18
19 TELECOMMUNICATION INFORMATION:
20 TELEPHONE: (617) 227-7400
21 TELEFAX: (617) 742-4214
22 INFORMATION FOR SEQ ID NO: 35:
23 SEQUENCE CHARACTERISTICS:
24 LENGTH: 31 base pairs
25 TYPE: nucleic acid
26 STRANDEDNESS: single
27 TOPOLOGY: linear
28 MOLECULE TYPE: cDNA
29 US-08-491-861A-35
30
31 Query Match 70.5%; Score 14.8; DB 2; Length 31;
32 Best Local Similarity 88.9%; Pred. No. 1.6e+03;
33 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
34
35 QY 2 AGCAGCAGGCTTCATC 19
36 Db 24 AGGAGCAGGCTTCATC 7
37
38 RESULT 11
39 US-09-374-671A-35/C
40 Sequence 35, Application US/09374671A
41 Patent No. 6489118
42 GENERAL INFORMATION:
43 APPLICANT: Morgenslern, Jay P.
44 konieczny, Andrzej
45 Bizindaukas, Christine B.
46 Brauer, Andrew W.
47 TITLE OF INVENTION: Allergenic Protein and Peptides from Dog
48 Dander and Uses Therefor
49 NUMBER OF SEQUENCES: 109
50 CORRESPONDENCE ADDRESS:
51 ADDRESSEE: Amy E. Mandragouras
52 STREET: 28 State Street
53 CITY: Boston
54 STATE: MA
55 COUNTRY: USA
56 ZIP: 02109
57
58 COMPUTER READABLE FORM:
59 MEDIUM TYPE: Floppy disk
60 COMPUTER: IBM PC compatible
61 OPERATING SYSTEM: PC-DOS/MS-DOS
62 SOFTWARE: ASCII Text
63 CURRENT APPLICATION DATA:
64 APPLICATION NUMBER: US/09/374,671A
65 FILING DATE: 16-Aug-1999
66 PRIOR APPLICATION DATA:
67 APPLICATION NUMBER: US 08/156,549
68 FILING DATE: 1993-NOV-22
69 APPLICATION NUMBER: US 07/999,712
70 FILING DATE: 1992-DEC-31
71 ATTORNEY/AGENT INFORMATION:
72 NAME: DiGiorgio, Jeanne M.
73 REGISTRATION NUMBER: 41,710
74 REFERENCE/DOCKET NUMBER: IMI-026C2CNCRA
75 TELECOMMUNICATION INFORMATION:

```

TELEPHONE: (617) 227-7400  
TELEFAX: (617) 742-4214  
INFORMATION FOR SEQ ID NO: 35:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 31 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
SEQUENCE DESCRIPTION: SEQ ID NO: 35:  
US-09-374-671A-35

Query Match 70.5%; Score 14.6; DB 4; Length 31;  
Best Local Similarity 88.9%; Pred. No. 1.9e+03;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGCTTTCATC 19  
DB 24 AGCAGCAGAGCTTTCATC 7

RESULT 12  
US-09-396-196G-10991  
Sequence 10991, Application US/09396196G  
Patent No. 6821724  
GENERAL INFORMATION:  
APPLICANT: Michael Miltmann  
APPLICANT: David Mack  
APPLICANT: David Lockhart  
TITLE OF INVENTION: Methods of Genetic Analysis  
FILE REFERENCE: 3101.1  
CURRENT APPLICATION NUMBER: US/09/396,196G  
CURRENT FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: 60/100,678  
PRIOR FILING DATE: 1998-09-17  
NUMBER OF SEQ ID NOS: 127806  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 10991  
LENGTH: 25  
TYPE: DNA  
ORGANISM: Mus musculus  
US-09-396-196G-10991

Query Match 69.5%; Score 14.6; DB 4; Length 25;  
Best Local Similarity 81.0%; Pred. No. 1.9e+03;  
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTTTCATC 21  
DB 3 CAGCAGCAGAGCTTTCATC 23

RESULT 13  
US-09-396-196G-74836  
Sequence 74836, Application US/09396196G  
Patent No. 6821724  
GENERAL INFORMATION:  
APPLICANT: Michael Miltmann  
APPLICANT: David Mack  
APPLICANT: David Lockhart  
TITLE OF INVENTION: Methods of Genetic Analysis  
FILE REFERENCE: 3101.1  
CURRENT APPLICATION NUMBER: US/09/396,196G  
CURRENT FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: 60/100,678  
PRIOR FILING DATE: 1998-09-17  
NUMBER OF SEQ ID NOS: 127806  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 74836  
LENGTH: 25  
TYPE: DNA

ORGANISM: mus musculus  
US-09-396-196G-74836

Query Match 69.5%; Score 14.6; DB 4; Length 25;  
Best Local Similarity 81.0%; Pred. No. 1.9e+03;  
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTTTCATC 21  
DB 4 CAGCAGCAGAGCTTTCATC 24

RESULT 14  
US-09-110-959A-11  
Sequence 11, Application US/09110959A  
Patent No. 6268197  
GENERAL INFORMATION:  
APPLICANT: Schuelin, Martin  
APPLICANT: Outtrup, Helle  
APPLICANT: Jorgensen, Per Lina  
APPLICANT: Bjornvad, Made Bakelund  
TITLE OF INVENTION: Alkaline Xyloglucanase  
FILE REFERENCE: 5206.200-US  
CURRENT APPLICATION NUMBER: US/09/110,959A  
CURRENT FILING DATE: 1998-07-07  
PRIOR APPLICATION NUMBER: 0822/97  
PRIOR FILING DATE: 1997-07-07  
PRIOR APPLICATION NUMBER: 1213/97  
PRIOR FILING DATE: 1997-10-24  
PRIOR APPLICATION NUMBER: 60/054,039  
PRIOR FILING DATE: 1997-07-28  
PRIOR APPLICATION NUMBER: 60/063,694  
PRIOR FILING DATE: 1997-10-28  
NUMBER OF SEQ ID NOS: 14  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 11  
LENGTH: 44  
TYPE: DNA  
ORGANISM: Bacillus sp.  
US-09-110-959A-11

Query Match 69.5%; Score 14.6; DB 3; Length 44;  
Best Local Similarity 81.0%; Pred. No. 2.1e+03;  
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTTTCATC 21  
DB 12 CAGCAGCGCGGCTTTCATC 32

RESULT 15  
US-09-205-860-3  
Sequence 3, Application US/09205860  
Patent No. 5981732  
GENERAL INFORMATION:  
APPLICANT: Lex M. Cowseert  
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION  
FILE REFERENCE: RTS-0031  
CURRENT APPLICATION NUMBER: US/09/205,860  
CURRENT FILING DATE: 1998-12-04  
NUMBER OF SEQ ID NOS: 87  
SEQ ID NO 3  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: PCR Primer  
US-09-205-860-3

Query Match 67.6%; Score 14.2; DB 2; Length 20;  
Best Local Similarity 84.2%; Pred. No. 2.8e+03;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Mon Nov 7 09:30:48 2005

us-10-828-394-5.rni

Page 6

Qy	1	CAGCAGCAGAGTCTTCATC	19
Db	2	CAGCAGCAGGATCTTCACC	20

Search completed: September 3, 2005, 16:22:35  
Job time : 131 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 15:24:25 ; Search time 603 Seconds  
(without alignments)  
228.072 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21  
Sequence: 1 cagcagcagcagcttcacatc 21

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 7338684 seqs, 3274456166 residues

Total number of hits satisfying chosen parameters: 8349320

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

Published Applications NA:\*

- 1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq.\*
- 2: /cgn2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq.\*
- 3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq.\*
- 4: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq.\*
- 5: /cgn2\_6/ptodata/1/pubpna/PCTUS\_PUBCOMB.seq.\*
- 6: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq.\*
- 7: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq.\*
- 8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq.\*
- 9: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq.\*
- 10: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq.\*
- 11: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq.\*
- 12: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq.\*
- 13: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 14: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 15: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 16: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 17: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 18: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 19: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 20: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 21: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 22: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq.\*
- 23: /cgn2\_6/ptodata/1/pubpna/US11\_NEW\_PUB.seq.\*
- 24: /cgn2\_6/ptodata/1/pubpna/US11\_NEW\_PUB.seq.\*
- 25: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq.\*
- 26: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	21	100.0	21	9 US-09-944-326-4	Sequence 4, Appli
2	21	100.0	21	10 US-09-967-726A-4	Sequence 4, Appli
3	21	100.0	21	16 US-10-080-794-4	Sequence 4, Appli
4	21	100.0	21	18 US-10-646-391A-4	Sequence 4, Appli
5	21	100.0	21	20 US-10-828-394-5	Sequence 5, Appli
6	21	100.0	21	20 US-10-828-395-5	Sequence 5, Appli
7	21	100.0	23	18 US-10-646-436-66	Sequence 66, Appli

C	8	20	95.2	21	18	US-10-646-391A-28	Sequence 28, Appli
C	9	20	95.2	21	18	US-10-646-436-9	Sequence 28, Appli
C	10	20	95.2	25	21	US-10-956-157-236817	Sequence 236817, Ap
C	11	19	90.5	19	18	US-10-646-391A-42	Sequence 42, Appli
C	12	19	90.5	19	18	US-10-646-391A-43	Sequence 43, Appli
C	13	19	90.5	19	18	US-10-646-436-67	Sequence 67, Appli
C	14	19	90.5	19	18	US-10-646-436-68	Sequence 68, Appli
C	15	19	90.5	21	18	US-10-646-391A-29	Sequence 29, Appli
C	16	19	90.5	21	18	US-10-646-436-10	Sequence 10, Appli
C	17	17.8	84.8	21	10	US-09-967-726A-15	Sequence 15, Appli
C	18	17.8	84.8	21	16	US-10-080-794-15	Sequence 17, Appli
C	19	17.8	84.8	50	11	US-09-790-338A-17	Sequence 15, Appli
C	20	17.8	84.8	50	18	US-10-434-583-15	Sequence 285427, Ap
C	21	17	81.0	25	21	US-10-956-157-285427	Sequence 187913, Sequence 217934, Sequence 174230, Sequence 6, Appli
C	22	16.4	78.1	25	22	US-10-719-956-187913	Sequence 187913, Sequence 217934, Sequence 174230, Sequence 6, Appli
C	23	16.4	78.1	25	21	US-10-719-956-217934	Sequence 187913, Sequence 217934, Sequence 174230, Sequence 6, Appli
C	24	16.2	77.1	25	21	US-10-956-157-174230	Sequence 187913, Sequence 217934, Sequence 174230, Sequence 6, Appli
C	25	16.2	77.1	32	14	US-10-278-355-6	Sequence 6, Appli
C	26	16.2	77.1	32	18	US-10-690-034-6	Sequence 6, Appli
C	27	16	76.2	25	21	US-10-809-189-7759	Sequence 7759, Ap
C	28	15.8	75.2	25	22	US-10-719-956-190997	Sequence 180997, Sequence 180998, Sequence 539340, Sequence 582252, Sequence 589108, Sequence 678358, Sequence 46, Appli
C	29	15.8	75.2	25	22	US-10-719-956-190998	Sequence 180997, Sequence 180998, Sequence 539340, Sequence 582252, Sequence 589108, Sequence 678358, Sequence 46, Appli
C	30	15.4	73.3	25	22	US-10-719-956-539340	Sequence 539340, Sequence 582252, Sequence 589108, Sequence 678358, Sequence 46, Appli
C	31	15.4	73.3	25	22	US-10-719-956-562252	Sequence 539340, Sequence 582252, Sequence 589108, Sequence 678358, Sequence 46, Appli
C	32	15.4	73.3	25	22	US-10-719-956-599108	Sequence 539340, Sequence 582252, Sequence 589108, Sequence 678358, Sequence 46, Appli
C	33	15.4	73.3	25	22	US-10-719-956-678358	Sequence 539340, Sequence 582252, Sequence 589108, Sequence 678358, Sequence 46, Appli
C	34	15.2	72.4	22	9	US-09-823-549-46	Sequence 46, Appli
C	35	15.2	72.4	22	20	US-10-685-992-46	Sequence 46, Appli
C	36	15.2	72.4	25	21	US-10-719-900-79840	Sequence 79840, A
C	37	15.2	72.4	25	21	US-10-719-900-99916	Sequence 99916, A
C	38	15.2	72.4	25	21	US-10-719-900-516755	Sequence 516755, A
C	39	15.2	72.4	25	21	US-10-719-900-859600	Sequence 859600, A
C	40	15.2	72.4	25	22	US-10-719-956-74777	Sequence 74777, A
C	41	15.2	72.4	25	22	US-10-719-956-483005	Sequence 483005, A
C	42	14.8	70.5	20	15	US-10-007-010-43	Sequence 43, Appli
C	43	14.8	70.5	21	9	US-09-944-326-1	Sequence 1, Appli
C	44	14.8	70.5	21	9	US-09-944-326-2	Sequence 2, Appli
C	45	14.8	70.5	21	10	US-09-967-726A-1	Sequence 1, Appli

#### ALIGNMENTS

RESULT 1  
US-09-944-326-4  
Sequence 4, Application US/09944326  
Patent No. US20020128220A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
FILE REFERENCE: UBC.P-020-2  
CURRENT APPLICATION NUMBER: US/09/944,326  
CURRENT FILING DATE: 2001-08-30  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
NUMBER OF SEQ ID NOS: 14  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 4  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-4  
Query Match 100.0%; Score 21; DB 9; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 2

US-09-967-726A-4  
; Sequence 4, Application US/09967726A  
; Publication No. US20030158130A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; APPLICANT: Zellweger, Tobias  
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2  
; FILE REFERENCE: UBC.P-022  
; CURRENT APPLICATION NUMBER: US/09/967,726A  
; CURRENT FILING DATE: 2001-09-28  
; NUMBER OF SEQ ID NOS: 15  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-09-967-726A-4

Query Match 100.0%; Score 21; DB 10; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 3

US-10-080-794-4  
; Sequence 4, Application US/10080794  
; Publication No. US2003016591A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; APPLICANT: Monia, Brett P.  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
; FILE REFERENCE: UBC.P-020-3  
; CURRENT APPLICATION NUMBER: US/10/080,794  
; CURRENT FILING DATE: 2002-02-22  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; PRIOR APPLICATION NUMBER: 09/944,326  
; PRIOR FILING DATE: 2001-08-30  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-4

Query Match 100.0%; Score 21; DB 16; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 4

US-10-646-391A-4  
; Sequence 4, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-646-391A-4

Query Match 100.0%; Score 21; DB 18; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 5

US-10-828-394-5  
; Sequence 5, Application US/10828394  
; Publication No. US20040220131A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
; FILE REFERENCE: UBC.P-033  
; CURRENT APPLICATION NUMBER: US/10/828,394  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-394-5

Query Match 100.0%; Score 21; DB 20; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

```
RESULT 6
US-10-828-395-5
; Sequence 5, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleeve, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-5

Query Match          100.0%; Score 21; DB 20; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  CAGCAGCAGAGTCTTCATCAT 21
Db      1  CAGCAGCAGAGTCTTCATCAT 21

RESULT 7
US-10-646-436-66/c
; Sequence 66, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleeve, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-66

Query Match          100.0%; Score 21; DB 18; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  CAGCAGCAGAGTCTTCATCAT 21
Db      23 CAGCAGCAGAGTCTTCATCAT 3

RESULT 8
```

```
US-10-646-391A-28/c
; Sequence 28, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleeve, Martin
; APPLICANT: Jansen, Burkhard
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-28

Query Match          95.2%; Score 20; DB 18; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2  AGCAGCAGAGTCTTCATCAT 21
Db      20 AGCAGCAGAGTCTTCATCAT 1

RESULT 9
US-10-646-436-9/c
; Sequence 9, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleeve, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-9

Query Match          95.2%; Score 20; DB 18; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2  AGCAGCAGAGTCTTCATCAT 21
```

Db 20 AGCAGCAGAGCTTCATCAT 1

RESULT 10  
US-10-956-157-236817/c  
; Sequence 236817, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; PRIOR APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 236817  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-236817

Query Match 95.2%; Score 20; DB 21; Length 25;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGCTTCATCAT 21  
Db 25 AGCAGCAGAGCTTCATCAT 6

RESULT 11  
US-10-646-391A-42/c  
; Sequence 42, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleeave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 42  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-42

Query Match 90.5%; Score 19; DB 18; Length 19;  
Best Local Similarity 100.0%; Pred. No. 31;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTCATCAT 21  
Db 19 GCAGCAGAGCTTCATCAT 1

RESULT 12  
US-10-646-391A-43

; Sequence 43, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleeave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 43  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-43

Query Match 90.5%; Score 19; DB 18; Length 19;  
Best Local Similarity 73.7%; Pred. No. 31;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTCATCAT 21  
Db 1 GCAGCAGAGCTTCATCAT 19

RESULT 13  
US-10-646-436-67/c  
; Sequence 67, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleeave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; APPLICANT: Gonos, Efethios  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC.P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 67  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-436-67

Query Match 90.5%; Score 19; DB 18; Length 19;  
Best Local Similarity 100.0%; Pred. No. 31;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTCATCAT 21

DB 19 GCAGCAGAGCTTTCATCAT 1

RESULT 14

US-10-646-436-68

; Sequence 68, Application US/10646436

; Publication No. US20040096882A1

; GENERAL INFORMATION:

; APPLICANT: Jansen, Burkhard

; APPLICANT: Gleave, Martin

; APPLICANT: Signaevsky, Maxim

; APPLICANT: Beraldi, Eliana

; APPLICANT: Trougakos, Ioannis

; APPLICANT: Gonos, Efstrathios

; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins

; FILE REFERENCE: UBC.P-030

; CURRENT APPLICATION NUMBER: US/10/646,436

; PRIOR FILING DATE: 2003-08-21

; PRIOR APPLICATION NUMBER: US 60/405,193

; PRIOR FILING DATE: 2002-08-21

; PRIOR APPLICATION NUMBER: US 60/408,152

; PRIOR FILING DATE: 2002-09-03

; PRIOR APPLICATION NUMBER: US 60/473,387

; PRIOR FILING DATE: 2003-05-20

; NUMBER OF SEQ ID NOS: 68

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 68

; LENGTH: 19

; TYPE: RNA

; ORGANISM: artificial

; FEATURE:

; OTHER INFORMATION: RNAi for human clusterin

US-10-646-436-68

Query Match 90.5%; Score 19; DB 18; Length 19;

Best Local Similarity 73.7%; Pred. No. 31;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTTCATCAT 21

DB 1 GCAGCAGAGGUCUCCAUCAU 19

RESULT 15

US-10-646-391A-29

; Sequence 29, Application US/10646391A

; Publication No. US20040082534A1

; GENERAL INFORMATION:

; APPLICANT: Jansen, Burkhard

; APPLICANT: Gleave, Martin

; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels

; FILE REFERENCE: UBC.P-035

; CURRENT APPLICATION NUMBER: US/10/646,391A

; PRIOR FILING DATE: 2003-08-21

; PRIOR APPLICATION NUMBER: US 60/405,193

; PRIOR FILING DATE: 2002-08-21

; PRIOR APPLICATION NUMBER: US 60/319,748

; PRIOR FILING DATE: 2002-12-02

; PRIOR APPLICATION NUMBER: US 60/408,152

; PRIOR FILING DATE: 2002-09-03

; PRIOR APPLICATION NUMBER: US 60/473,387

; PRIOR FILING DATE: 2003-05-20

; NUMBER OF SEQ ID NOS: 43

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 29

; LENGTH: 21

; TYPE: DNA

; ORGANISM: artificial

; FEATURE:

; OTHER INFORMATION: RNAi for human clusterin

US-10-646-391A-29

Query Match 90.5%; Score 19; DB 18; Length 21;

Best Local Similarity 73.7%; Pred. No. 31;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTTCATCAT 21

DB 1 GCAGCAGAGGUCUCCAUCAU 19

Search completed: September 3, 2005, 16:32:54  
Job time : 609 secs

***This Page Blank (uspto)***



REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
AUTHORS 1 Jansen, B., Gleave, M.E., Signaevsky, M., Beraldi, E., Trougakos, I. and Gonos, E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 66 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..23  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 100.0%; Score 21; DB 6; Length 23;  
Best Local Similarity 100.0%; Pred. No. 49;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGCTTTCATCAT 21  
23 CAGCAGCAGAGCTTTCATCAT 3  
Db 23 CAGCAGCAGAGCTTTCATCAT 3  
RESULT 3  
CQ786121/c 21 bp DNA linear PAT 24-MAR-2004  
LOCUS Sequence 9 from Patent WO2004018676.  
CQ786121  
CQ786121.1 GI:45721224  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS 1 Jansen, B., Gleave, M.E., Signaevsky, M., Beraldi, E., Trougakos, I. and Gonos, E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 9 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 95.2%; Score 20; DB 6; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 2 AGCAGCAGAGCTTTCATCAT 21  
20 AGCAGCAGAGCTTTCATCAT 1  
Db 20 AGCAGCAGAGCTTTCATCAT 1  
RESULT 4  
CQ786639/c 21 bp DNA linear PAT 24-MAR-2004  
LOCUS Sequence 28 from Patent WO2004018675.  
CQ786639  
CQ786639.1 GI:45721659  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS 1 Jansen, B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 28 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source 1..21  
location/Qualifiers

/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 95.2%; Score 20; DB 6; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 2 AGCAGCAGAGCTTTCATCAT 21  
20 AGCAGCAGAGCTTTCATCAT 1  
Db 20 AGCAGCAGAGCTTTCATCAT 1  
RESULT 5  
CQ786179/c 19 bp RNA linear PAT 24-MAR-2004  
LOCUS Sequence 67 from Patent WO2004018676.  
CQ786179  
CQ786179.1 GI:45721282  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS 1 Jansen, B., Gleave, M.E., Signaevsky, M., Beraldi, E., Trougakos, I. and Gonos, E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 67 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..19  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 90.5%; Score 19; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 4.5e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3 GCAGCAGAGCTTTCATCAT 21  
19 GCAGCAGAGCTTTCATCAT 1  
Db 19 GCAGCAGAGCTTTCATCAT 1  
RESULT 6  
CQ786180 19 bp RNA linear PAT 24-MAR-2004  
LOCUS Sequence 68 from Patent WO2004018676.  
CQ786180  
CQ786180.1 GI:45721283  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS 1 Jansen, B., Gleave, M.E., Signaevsky, M., Beraldi, E., Trougakos, I. and Gonos, E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 68 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..19  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 90.5%; Score 19; DB 6; Length 19;



Best Local Similarity 100.0%; Pred. No. 4.5e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21  
|||||  
Db 1 GCAGCAGAGTCTTCATCAT 19

## RESULT 7

CQ786653/c 19 bp RNA linear PAT 24-MAR-2004

LOCUS Sequence 42 from Patent WO2004018675.

DEFINITION CQ786653

ACCESSION CQ786653.1 GI:45721673

VERSION CQ786653.1

KEYWORDS

SOURCE

ORGANISM synthetic construct

REFERENCE 1 other sequences; artificial sequences.

AUTHORS Jansen, B.

TITLE Treatment of melanoma by reduction in clusterin levels

JOURNAL Patent: WO 2004018675-A 42 04-MAR-2004;

The University of British Columbia (CA); Gleave, Martin E. (CA)

FEATURES 1..19

source /organism="synthetic construct"

/mol\_type="unassigned RNA"

/db\_xref="taxon:32630"

/note="RNAi for human clusterin"

## ORIGIN

Query Match 90.5%; Score 19; DB 6; Length 19;

Best Local Similarity 100.0%; Pred. No. 4.5e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21  
|||||  
Db 19 GCAGCAGAGTCTTCATCAT 1

## RESULT 8

CQ786654 19 bp RNA linear PAT 24-MAR-2004

LOCUS Sequence 43 from Patent WO2004018675.

DEFINITION CQ786654

ACCESSION CQ786654.1 GI:45721674

VERSION CQ786654.1

KEYWORDS

SOURCE

ORGANISM synthetic construct

REFERENCE 1 other sequences; artificial sequences.

AUTHORS Jansen, B.

TITLE Treatment of melanoma by reduction in clusterin levels

JOURNAL Patent: WO 2004018675-A 43 04-MAR-2004;

The University of British Columbia (CA); Gleave, Martin E. (CA)

FEATURES 1..19

source /organism="synthetic construct"

/mol\_type="unassigned RNA"

/db\_xref="taxon:32630"

/note="RNAi for human clusterin"

## ORIGIN

Query Match 90.5%; Score 19; DB 6; Length 19;

Best Local Similarity 100.0%; Pred. No. 4.5e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21  
|||||  
Db 1 GCAGCAGAGTCTTCATCAT 19

## RESULT 9

CQ786122 21 bp DNA linear PAT 24-MAR-2004

LOCUS Sequence 10 from Patent WO2004018676.

DEFINITION CQ786122

ACCESSION CQ786122.1 GI:45721225

VERSION CQ786122.1

KEYWORDS

SOURCE

ORGANISM synthetic construct

REFERENCE 1 other sequences; artificial sequences.

AUTHORS Jansen, B., Gleave, M.E., Signaevsky, M., Beraldi, E., Trougakos, I. and

Gonos, E.

TITLE Rnai probes targeting cancer-related proteins

JOURNAL Patent: WO 2004018676-A 10 04-MAR-2004;

The University of British Columbia (CA)

FEATURES 1..21

source /organism="synthetic construct"

/mol\_type="unassigned DNA"

/db\_xref="taxon:32630"

/note="RNAi for human clusterin"

## ORIGIN

Query Match 90.5%; Score 19; DB 6; Length 21;

Best Local Similarity 100.0%; Pred. No. 4.5e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21  
|||||  
Db 1 GCAGCAGAGTCTTCATCAT 19

## RESULT 10

CQ786640 21 bp DNA linear PAT 24-MAR-2004

LOCUS Sequence 29 from Patent WO2004018675.

DEFINITION CQ786640

ACCESSION CQ786640.1 GI:45721660

VERSION CQ786640.1

KEYWORDS

SOURCE

ORGANISM synthetic construct

REFERENCE 1 other sequences; artificial sequences.

AUTHORS Jansen, B.

TITLE Treatment of melanoma by reduction in clusterin levels

JOURNAL Patent: WO 2004018675-A 29 04-MAR-2004;

The University of British Columbia (CA); Gleave, Martin E. (CA)

FEATURES 1..21

source /organism="synthetic construct"

/mol\_type="unassigned DNA"

/db\_xref="taxon:32630"

/note="RNAi for human clusterin"

## ORIGIN

Query Match 90.5%; Score 19; DB 6; Length 21;

Best Local Similarity 100.0%; Pred. No. 4.5e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21  
|||||  
Db 1 GCAGCAGAGTCTTCATCAT 19

## RESULT 11

AR374192 50 bp DNA linear PAT 18-DEC-2003

LOCUS Sequence 15 from patent US 6605280.

DEFINITION AR374192

ACCESSION AR374192.1 GI:40076792

VERSION AR374192.1

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

Unclassified.  
1 (bases 1 to 50)  
Novick,D., Dinaarello,C., Rubinstein,M. and Kilm,S.H.  
Interleukin-18 binding proteins, their preparation and use for  
blocking the activity of IL-18  
Patent: US 6605280-A 15 12-AUG-2003;  
Location/Qualifiers  
1..50  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 84.8%; Score 17.8; DB 6; Length 50;  
Best Local Similarity 90.5%; Pred. No. 1.6e+03;  
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 42 CAGCAGCAGAGTCTTCATCAT 22

RESULT 12  
AR274120 AR274120 32 bp DNA linear PAT 10-APR-2003  
LOCUS Sequence 6 from patent US 6504083.  
DEFINITION AR274120  
ACCESSION AR274120  
VERSION AR274120.1 GI:29706097  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 32)  
AUTHORS Barbour,E., Meyer,T.E.C. and Saad,M.E.  
TITLE Maize Gm-2 promoters  
JOURNAL Patent: US 6504083-A 6 07-JAN-2003;  
FEATURES Location/Qualifiers  
1..32  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 77.1%; Score 16.2; DB 6; Length 32;  
Best Local Similarity 85.7%; Pred. No. 9.6e+03;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 3 CAGCAGCAGAGTCTTCATCAT 23

RESULT 13  
AR444937 AR444937 32 bp DNA linear PAT 20-FEB-2004  
LOCUS Sequence 6 from patent US 6670467.  
DEFINITION AR444937  
ACCESSION AR444937  
VERSION AR444937.1 GI:42672814  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 32)  
AUTHORS Barbour,E., Meyer,T.E.C. and Saad,M.E.  
TITLE Maize promoters  
JOURNAL Patent: US 6670467-A 6 30-DEC-2003;  
FEATURES Location/Qualifiers  
1..32  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 77.1%; Score 16.2; DB 6; Length 32;  
Best Local Similarity 85.7%; Pred. No. 9.6e+03;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 3 CAGCAGCAGAGTCTTCATCAT 23

RESULT 14  
A76301 A76301 48 bp DNA linear PAT 19-OCT-1999  
LOCUS Sequence 7 from Patent WO9319173.  
DEFINITION A76301  
ACCESSION A76301  
VERSION A76301.1 GI:6088388  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 48)  
AUTHORS Maegerl,H.  
TITLE DNA CODING FOR APHRODISIN  
JOURNAL Patent: WO 9319173-A 7 30-SEP-1993;  
FORSMANN WOLFF GEORG (DE)  
FEATURES Location/Qualifiers  
1..48  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
1..>48  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAB58600.1"  
/db\_xref="GI:6088389"  
/translation="MWKILILALVFSIAHA"

ORIGIN  
Query Match 77.1%; Score 16.2; DB 6; Length 48;  
Best Local Similarity 85.7%; Pred. No. 9.3e+03;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 21 CAGCAGCAGAGTCTTCATCAT 1

RESULT 15  
E01067 E01067 48 bp DNA linear PAT 29-SEP-1997  
LOCUS DNA sequence coding for human pancreas-2 signal peptide.  
DEFINITION E01067  
ACCESSION E01067  
VERSION E01067.1 GI:2169326  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 48)  
AUTHORS Takiguchi,H., Furukawa,H. and Tani,T.  
TITLE PRODUCTION OF PANCREAS ELASTASE  
JOURNAL Patent: JP 1987000276-A 9 06-JAN-1987;  
SANKYO CO LTD NIPPON SODA CO LTD, NISSAN CHEM IND LTD, TOYO SODA  
MFG CO LTD  
OS homo sapiens (human)  
PN JP 1987000276-A/9  
PD 06-JAN-1987  
PF 25-JUN-1985 JP 1985138494  
PI TAKIGUCHI HIROSHI, FURUKAWA HIDEHIKO, TANI TOKIO PC  
C12N9/66,A61K35/74,A61K37/54,C12N15/00//C07H21/04,(C12N9/66, PC  
C12R1:19),  
PC (C12N15/00,C12R1:19);  
CC strandedness: Double;  
CC topology: linear;  
CC hypothetical: No;  
CC anti-sense: No;  
CC \*source: tissue\_type=pancreas;

FH	Key	Location/Qualifiers
FH	sig_peptide	1..48
FT		/product='human pancreas elastase-2 signal
FT		peptide'.

FEATURES

source  
 1..48  
 /organism='Homo sapiens'  
 /mol\_type='genomic DNA'  
 /db\_xref='taxon:9606'

ORIGIN

Query Match 77.1%; Score 16.2; DB 6; Length 48;  
 Best Local Similarity 85.7%; Pred. No. 9.3e+03;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
 |||||  
 DB 21 CAGCAGCAGAGTCTTCATCAT 1

Search completed: September 3, 2005, 15:29:38  
 Job time : 1864 secs

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 12:59:00 ; Search time 430 Seconds  
(without alignments)  
289.104 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21  
Sequence: 1 cagcagcagcagctctcatcatc 21

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 4167226

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N\_Geneseq\_16Dec04:\*

1: Geneseqn1980s:.\*  
2: Geneseqn1990s:.\*  
3: Geneseqn2000s:.\*  
4: Geneseqn2001as:.\*  
5: Geneseqn2001bs:.\*  
6: Geneseqn2002as:.\*  
7: Geneseqn2002bs:.\*  
8: Geneseqn2003as:.\*  
9: Geneseqn2003bs:.\*  
10: Geneseqn2003cs:.\*  
11: Geneseqn2003ds:.\*  
12: Geneseqn2004as:.\*  
13: Geneseqn2004bs:.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	21	100.0	21	3	AAA94226 Human tes
2	21	100.0	21	10	ACF36398 TRPM-2 an
3	21	100.0	21	11	ADM83069 Human TRP
4	21	100.0	21	12	ADL70406 Antisense
5	21	100.0	23	12	ADL70521 Human glu
6	20	95.2	21	12	ADL70464 RNAi for
7	20	95.2	21	12	ADL70430 RNAi for
8	19	90.5	19	12	ADL70522 RNAi for
9	19	90.5	19	12	ADL70523 RNAi for
10	19	90.5	19	12	ADL70444 RNAi for
11	19	90.5	19	12	ADL70445 RNAi for
12	19	90.5	21	12	ADL70465 RNAi for
13	19	90.5	21	12	ADL70431 RNAi for
14	17.8	84.8	21	10	ACF36409 DNA seque
15	17.8	84.8	21	11	ADM83080 Control T
16	17.8	84.8	50	2	AA24790 Interleuk
17	16.2	77.1	32	3	AAA09140 Gos-2 pro
18	16.2	77.1	50	3	AAA11024 Human mat
19	15.2	72.4	22	4	AA515291 Mouse IL-
20	15.2	72.4	40	3	AA26146 Polynucle

21	15	71.4	22	12	AD129045	Adi29045 Oligonuci	
c	22	15	71.4	33	6	ABQ80863	Abq80863 Hexapetol
23	14.8	70.5	20	10	AA621195	Aad62195 Human hae	
24	14.8	70.5	21	3	AAA94224	Aaa94224 Murine te	
25	14.8	70.5	21	3	AAA94223	Aaa94223 Murine te	
26	14.8	70.5	21	10	ACF36395	ACF36395 TRPM-2 am	
27	14.8	70.5	21	10	ACF36396	ACF36396 DNA seque	
28	14.8	70.5	21	11	ADM83067	Adm83067 Human TRP	
29	14.8	70.5	21	11	ADM83066	Adm83066 Human TRP	
30	14.8	70.5	21	12	ADL70404	Adl70404 Antisense	
c	31	14.8	70.5	27	4	AAH40683	Aah40683 SNP speci
c	32	14.8	70.5	30	2	AAZ12445	Aaz12445 PCR prime
c	33	14.8	70.5	31	2	AAQ69972	Aaq69972 5' sense 1
c	34	14.6	69.5	24	6	ABL61345	AbL61345 Naja naja
c	35	14.6	69.5	33	6	ABK49118	Abk49118 Human tra
c	36	14.6	69.5	34	4	AAH79384	Aah79384 Plasmolem
37	14.6	69.5	44	2	AAK06964	Aak06964 Bacillus	
38	14.4	68.6	30	8	ABZ77331	Abz77331 Nucleotid	
39	14.2	67.6	20	2	AAZ31857	Aaz31857 PCR prime	
40	14.2	67.6	20	6	ABK69555	Abk69555 Rat phosp	
c	41	14.2	67.6	20	12	ADH64379	Adh64379 Human glu
c	42	14.2	67.6	20	12	ADH63983	Adh63983 Human glu
c	43	14.2	67.6	22	3	AA584494	Aac58494 Human PRO
c	44	14.2	67.6	22	3	AAA37208	Aaa37208 Human PRO
c	45	14.2	67.6	22	4	AAF54314	Aaf54314 Primer #4

ALIGNMENTS

#### ALIGNMENTS

RESULT 1  
ID AAA94226 standard; DNA; 21 BP.  
XX  
AC AAA94226;  
XX  
DT 12-JAN-2001 (first entry)  
XX  
DE Human testosterone-repressed prostate message-2 antisense oligo #2.  
XX  
KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
XX  
OS Homo sapiens.  
XX  
XX  
XX WO200049937-A2.  
XX  
XX 31-AUG-2000.  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
XX  
XX 26-FEB-1999; 99US-0121726P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C;  
PI WPI; 2000-533132/48.  
DR  
XX  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
XX  
XX Claim 3; Page 36; 38pp; English.  
PS  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumors, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumor cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective

XX SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 3; Length 21;  
Best Local Similarity 100.0%; Pred. No. 8.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGTCTTCATCAT 21  
DB 1 CAGCAGCAGAGTCTTCATCAT 21  
RESULT 2  
ACF36398  
ID ACF36398 standard; DNA; 21 BP.  
AC ACF36398;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE TRPM-2 antisense oligonucleotide.  
XX  
KM TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
XX  
OS Synthetic.  
XX OS Homo sapiens.  
XX PN WO2003072591-A1.  
XX PD 04-SEP-2003.  
XX PF 20-FEB-2003; 2003WO-US005305.  
XX PR 22-FEB-2002; 2002US-00080794.  
XX PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
XX WPI; 2003-689981/65.  
XX  
PT New modified antisense oligonucleotide, useful particularly for treating  
PT prostate cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Claim 1; Page 25; 44pp; English.  
XX  
XX The invention relates to a compound consisting of an oligonucleotide with  
XX a phosphorothioate backbone throughout in which: (a) sugars on  
XX nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
XX remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
XX positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
XX ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
XX prostate cancer cells to the androgen-independent state, in vivo or in  
XX vitro; (b) to treat prostate cancer (after initially withdrawing  
XX androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
XX cells (prostatic, renal, non-small cell lung, urothelial transitional,  
XX ovarian and some breast cancer cells) that express abnormal levels of  
XX TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
XX increase stability in vivo and activity (both in vivo or in vitro) and  
XX result in a synergistic increase in effect when (I) is used with  
XX chemotherapeutic agents or other antisense oligonucleotides directed  
XX against other antiapoptotic genes. The present sequence represents a  
XX specific example of an anti-apoptotic protein TRPM-2 (testosterone-  
XX repressed prostate message-2) antisense oligonucleotide  
SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 10; Length 21;  
Best Local Similarity 100.0%; Pred. No. 8.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGTCTTCATCAT 21

DB 1 CAGCAGCAGAGTCTTCATCAT 21  
RESULT 3  
ADM83069  
ID ADM83069 standard; DNA; 21 BP.  
XX  
XX ADM83069;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
XX Human TRPM-2 antisense oligonucleotide #4.  
XX  
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
XX Homo sapiens.  
XX OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
XX US2003158130-A1.  
XX  
XX 21-AUG-2003.  
XX  
XX 28-SEP-2001; 2001US-00967726.  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
XX PR 28-SEP-2000; 2000US-0236301P.  
XX PR 10-AUG-2001; 2001US-00913325.  
XX  
XX (GLEA/) GLEAVE M.  
XX (RENN/) RENNIE P S.  
XX (MIYA/) MIYAKE H.  
XX (NELS/) NELSON C.  
XX (ZELL/) ZELLMESER T.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX WPI; 2003-778017/73.  
XX  
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
XX Claim 4; SEQ ID NO 4; 14pp; English.  
XX  
XX The present invention provides a method for treating cancer in which  
XX cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
XX The invention is useful for enhancing the chemo-sensitivity or radiation-  
XX sensitivity of cancer cells for treating cancer such as prostate cancer,  
XX bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
XX (RCC). The invention is also useful in antisense gene therapy. The  
XX present sequence is human testosterone-repressed prostate message-2 (TRPM  
XX -2) antisense oligodeoxyribonucleotide (ODN).  
SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 11; Length 21;  
Best Local Similarity 100.0%; Pred. No. 8.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGTCTTCATCAT 21  
DB 1 CAGCAGCAGAGTCTTCATCAT 21

CC	ADL70406	standard; DNA; 21 BP.
XX	ADL70406;	
AC	ADL70406;	
XX	ADL70406;	
DT	20-MAY-2004	(first entry)
XX	Antisense oligonucleotide to human clusterin.	
DE	Antisense oligonucleotide to human clusterin.	
XX	Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.	
KW	Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.	
XX	Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.	
OS	Homosapiens.	
XX	Synthetic.	
FT	Key	Location/Qualifiers
FT	modified_base	1..21
FT	/*tag= b	
FT	/mod_base= OTHER	
FT	/note= "OTHER= phosphorothioate nucleotides"	
FT	modified_base	1..4
FT	/*tag= a	
FT	/mod_base= OTHER	
FT	/note= "OTHER= 2'-O-methoxyethyl modifications"	
FT	modified_base	18..21
FT	/*tag= c	
FT	/mod_base= OTHER	
FT	/note= "OTHER= 2'-O-methoxyethyl modifications"	
PN	WO2004018675-A1.	
PD	04-MAR-2004.	
XX	04-MAR-2004.	
XX	21-AUG-2003; 2003WO-CA001276.	
PR	21-AUG-2002; 2002US-0405193P.	
PR	03-SEP-2002; 2002US-0408152P.	
PR	02-DEC-2002; 2002US-0319748P.	
PR	20-MAY-2003; 2003US-0472387P.	
XX	(UYBR-) UNIV BRITISH COLUMBIA.	
PA	(UYBR-) UNIV BRITISH COLUMBIA.	
PA	(GLEA/) GLEAVE M E.	
XX	(GLEA/) GLEAVE M E.	
PI	Jansen B;	
DR	WPI; 2004-226651/21.	
XX	WPI; 2004-226651/21.	
XX	WPI; 2004-226651/21.	
PT	Treating melanoma in a mammalian subject comprises administering to the	
PT	subject a therapeutic agent effective to reduce the effective amount of	
PT	clusterin in the melanoma cells.	
XX	clusterin in the melanoma cells.	
PS	Claim 7; SEQ ID NO 4; 32pp; English.	
XX	Claim 7; SEQ ID NO 4; 32pp; English.	
XX	Claim 7; SEQ ID NO 4; 32pp; English.	
CC	The present sequence is that of an antisense oligonucleotide targeted to	
CC	human clusterin ADL70403. The invention relates to the treatment of	
CC	melanoma through reduction in the effective amount of clusterin. The	
CC	therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421	
CC	or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.	
CC	The antisense oligonucleotides are complementary to a region of the	
CC	clusterin mRNA spanning either the translation initiation site or the	
CC	termination site. They may be modified to increase stability in vivo,	
CC	e.g. they may be employed as phosphorothioate derivatives and may have 2'	
CC	-O-(2-methoxyethyl) (MOE) modifications in the 5' and 3' 'wings'. The	
CC	present antisense oligonucleotide is particularly preferred. It is	
CC	targeted to the translation initiation codon and next 6 codons of the	
CC	human clusterin sequence. It has a phosphorothioate backbone throughout	
CC	and MOE wings, the remaining nucleotides being 2'-deoxynucleotides. In an	
CC	example from the invention, this antisense oligonucleotide provided a	
CC	dose-dependent down-regulation of clusterin in human melanoma cells,	
CC	leading to an increase in apoptotic cell death. In one melanoma cell line	
CC	(607B) this alone was sufficient to lead to complete cell death. In	
CC	another melanoma cell line, the surviving cells showed increased	

CC	sensitivity to subsequent treatment with cisplatin. A claimed method for
CC	regulating expression of bcl-xl in a subject or cell line comprises
CC	administering an agent effective to modulate the amount of clusterin
CC	expression. In clusterin-expressing cells, expression of bcl-xl is down-
CC	regulated when the effective amount of clusterin is reduced. Such
CC	inhibition is significant because bcl-xl is known to act as an inhibitor
CC	of apoptosis.
XX	
SQ	Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match	100.0%; Score 21; DB 12; Length 21;
Best Local Similarity	100.0%; Pred. No. 8.2;
Matches	21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy	1 CAGCAGCAGAGCTTTCATCAT 21       1 CAGCAGCAGAGCTTTCATCAT 21
Db	
RESULT 5	
ID	ADL70521/c
XX	ADL70521 standard; cDNA; 23 BP.
AC	ADL70521;
XX	
DT	20-MAY-2004 (first entry)
DE	
XX	Human clusterin target for RNAi.
KM	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KN	ss.
OS	Homo sapiens.
OS	Synthetic.
XX	
RN	WO2004018676-A2.
PD	
PF	21-AUG-2003; 2003WO-CA001277.
XX	
PR	21-AUG-2002; 2002US-0405193P.
PR	03-SEP-2002; 2002US-0408152P.
XX	
PR	20-MAY-2003; 2003US-0472387P.
XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.
PI	
PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI	Gonos ES;
XX	
DR	WPI; 2004-226852/21.
XX	
PT	New RNA molecule less than 49 bases and having a sequence effective to
PT	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
XX	
PS	Example 6; SEQ ID NO 66; 63bp; English.
XX	
CC	The present sequence is a human clusterin cDNA target for a double-
CC	stranded short interfering RNA (siRNA) of the invention ADL70522-
CC	ADL70523. It was used in an example from the invention to demonstrate
CC	clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
CC	known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC	tumor cells following androgen withdrawal, and has also been shown to be
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC	siRNAs of the invention can be used alone or in combination with other
CC	chemotherapy or apoptosis inducing treatments for the treatment of
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment

CC of Alzheimer's disease.  
XX  
SQ Sequence 23 BP; 5 A; 5 C; 7 G; 6 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 12; Length 23;  
Best Local Similarity 100.0%; Pred. No. 8.3;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGCTTCATCAT 21  
23 CAGCAGCAGAGCTTCATCAT 3  
Db 23 CAGCAGCAGAGCTTCATCAT 3  
RESULT 6  
ADL70464/C  
ID ADL70464 standard; RNA; 21 BP.  
XX  
AC ADL70464;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; neurotropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
XX PN WO2004018676-A2.  
XX  
XX PD 04-MAR-2004.  
XX  
XX PF 21-AUG-2003; 2003WO-CA001277.  
XX  
XX PR 21-AUG-2002; 2002US-0405193P.  
XX PR 03-SEP-2002; 2002US-0408152P.  
XX PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP,  
XX PI Gonos ES;  
XX  
XX DR WPI; 2004-226852/21.  
XX  
XX PT New RNA molecule less than 49 bases and having a sequence effective to  
XX PT mediate degradation or block translation of mRNA that is the  
XX PT transcriptional product of a target gene, useful for treating Alzheimer's  
XX PT disease or cancer.  
XX  
XX PS Claim 4; SEQ ID NO 9; 63p; English.  
XX  
XX CC The present sequence is the gene strand of a short interfering RNA  
XX CC (siRNA) targeted to human clusterin. The antisense strand is also  
XX CC provided ADL70465. The siRNA can be used to interfere with the expression  
XX CC of clusterin. Clusterin, also known as testosterone-repressed prostate  
XX CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
XX CC increased amounts by prostate tumour cells following androgen withdrawal,  
XX CC and has also been shown to be critical for neuritic toxicity in mouse  
XX CC models of Alzheimer's disease. siRNAs of the invention can be used alone  
XX CC or in combination with other chemotherapy or apoptosis inducing  
XX CC treatments for the treatment of prostate cancer, sarcomas such as  
XX CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
XX CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
XX CC melanoma, and also for the treatment of Alzheimer's disease.

XX  
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;  
Query Match 95.2%; Score 20; DB 12; Length 21;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 2 AGCAGCAGAGCTTCATCAT 21  
20 AGCAGCAGAGCTTCATCAT 1  
Db 20 AGCAGCAGAGCTTCATCAT 1  
RESULT 7  
ADL70430/C  
ID ADL70430 standard; RNA; 21 BP.  
XX  
AC ADL70430;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytosolic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX PN WO2004018675-A1.  
XX  
XX PD 04-MAR-2004.  
XX  
XX PF 21-AUG-2003; 2003WO-CA001276.  
XX  
XX PR 21-AUG-2002; 2002US-0405193P.  
XX PR 03-SEP-2002; 2002US-0408152P.  
XX PR 02-DEC-2002; 2002US-0319748P.  
XX PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX PA (GLEA/) GLEAVE M E.  
XX  
XX PI Jansen B;  
XX PI  
XX XX  
XX DR WPI; 2004-226851/21.  
XX  
XX PT Treating melanoma in a mammalian subject comprises administering to the  
XX PT subject a therapeutic agent effective to reduce the effective amount of  
XX PT clusterin in the melanoma cells.  
XX  
XX PS Claim 20; SEQ ID NO 28; 32p; English.  
XX  
XX CC The present sequence is that of a short interfering RNA (siRNA) molecule  
XX CC targeted to human clusterin ADL70403. The invention relates to the  
XX CC treatment of melanoma through reduction in the effective amount of  
XX CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
XX CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
XX CC targeted to clusterin. The siRNA molecules direct cleavage of clusterin  
XX CC mRNA. A method for regulating expression of bcl-xl in a subject or cell  
XX CC line comprises administering an agent effective to modulate the amount of  
XX CC clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
XX CC is down-regulated when the effective amount of clusterin is reduced. Such  
XX CC inhibition is significant because bcl-xl is known to act as an inhibitor  
XX CC of apoptosis.  
XX  
XX SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;



Query Match 95.2%; Score 20; DB 12; Length 21;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 AGCAGCAGAGTCTTCATCAT 21  
Db 20 AGCAGCAGAGTCTTCATCAT 1

## RESULT 8

ADL70522/C  
ID ADL70522 standard; RNA; 19 BP.

AC ADL70522;

DT 20-MAY-2004 (first entry)

DE RNAi for human clusterin.

XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;

KM cytosstatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;

XX ss.

OS Homo sapiens.

OS Synthetic.

FT Key Location/Qualifiers  
FT modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"

XX WO2004018676-A2.

XX 04-MAR-2004.

XX 21-AUG-2003; 2003WO-CA001277.

XX 21-AUG-2002; 2002US-0405193P.

XX 03-SEP-2002; 2002US-0408152P.

XX 20-MAY-2003; 2003US-0472387P.

XX (UVR-) UNIV BRITISH COLUMBIA.

XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;  
XX Gonos ES;

XX WPI; 2004-226852/21.

XX New RNA molecule less than 49 bases and having a sequence effective to  
XX mediate degradation or block translation of mRNA that is the  
XX transcriptional product of a target gene, useful for treating Alzheimer's  
XX disease or cancer.

XX Claim 4; SEQ ID NO 67; 63pp; English.

XX The present sequence is the sense strand of a short interfering RNA  
XX (siRNA) targeted to a specific portion ADL70521 of human clusterin CDNA.  
XX The antisense strand is also provided ADL70523. The siRNA can be used to  
XX interfere with the expression of clusterin. Clusterin, also known as  
XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
XX tumour cells following androgen withdrawal, and has also been shown to be  
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.  
XX siRNAs of the invention can be used alone or in combination with other  
XX chemotherapy or apoptosis inducing treatments for the treatment of  
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
XX anaplastic large cell lymphoma and melanoma, and also for the treatment  
XX of Alzheimer's disease. In an example from the invention, the present  
XX siRNA was used to examine the effects of clusterin gene silencing in PC-3  
XX prostate cancer cells. A reduction in clusterin transcript was observed.

SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 100.0%; Pred. No. 64;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21  
Db 19 GCAGCAGAGTCTTCATCAT 1

## RESULT 9

ADL70523  
ID ADL70523 standard; RNA; 19 BP.

AC ADL70523;

DT 20-MAY-2004 (first entry)

DE RNAi for human clusterin.

XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;

KM cytosstatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;

XX ss.

OS Homo sapiens.

OS Synthetic.

FT Key Location/Qualifiers  
FT modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"

XX WO2004018676-A2.

XX 04-MAR-2004.

XX 21-AUG-2003; 2003WO-CA001277.

XX 21-AUG-2002; 2002US-0405193P.

XX 03-SEP-2002; 2002US-0408152P.

XX 20-MAY-2003; 2003US-0472387P.

XX (UVR-) UNIV BRITISH COLUMBIA.

XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;  
XX Gonos ES;

XX WPI; 2004-226852/21.

XX New RNA molecule less than 49 bases and having a sequence effective to  
XX mediate degradation or block translation of mRNA that is the  
XX transcriptional product of a target gene, useful for treating Alzheimer's  
XX disease or cancer.

XX Claim 4; SEQ ID NO 68; 63pp; English.

XX The present sequence is the antisense strand of a short interfering RNA  
XX (siRNA) targeted to a specific portion ADL70521 of human clusterin CDNA.  
XX The sense strand is also provided ADL70522. The siRNA can be used to  
XX interfere with the expression of clusterin. Clusterin, also known as  
XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
XX tumour cells following androgen withdrawal, and has also been shown to be  
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.  
XX siRNAs of the invention can be used alone or in combination with other  
XX chemotherapy or apoptosis inducing treatments for the treatment of  
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
XX anaplastic large cell lymphoma and melanoma, and also for the treatment  
XX of Alzheimer's disease. In an example from the invention, the present  
XX siRNA was used to examine the effects of clusterin gene silencing in PC-3

CC prostate cancer cells. A reduction in clusterin transcript was observed.  
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
XX  
Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 73.7%; Pred. No. 64;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
QY 3 GCACGAGAGTCTTCATCAT 21  
Db 1 GCACGAGAGTCTTCATCAT 19  
RESULT 10  
ADL70444/C  
ID ADL70444 standard; RNA; 19 BP.  
XX  
AC ADL70444;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KM short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN W02004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
XX  
DR WPI; 2004-226851/21.  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
PS Claim 20; SEQ ID NO 42; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xl in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xl is known to act as an inhibitor  
CC of apoptosis.  
SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 100.0%; Pred. No. 64;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3 GCACGAGAGTCTTCATCAT 21  
Db 19 GCACGAGAGTCTTCATCAT 1  
RESULT 11  
ADL70445  
ID ADL70445 standard; RNA; 19 BP.  
XX  
AC ADL70445;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KM short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN W02004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
XX  
DR WPI; 2004-226851/21.  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
PS Claim 20; SEQ ID NO 43; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xl in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xl is known to act as an inhibitor  
CC of apoptosis.  
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
XX  
Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 73.7%; Pred. No. 64;

QY	3	GCAGCAGAGCTCTCATCAT	21
		::: :: :	
		GCAGCAGAGCTCTCATCAT	19
Db			
	RESULT 13		
	ADL70431		
XX	ID	ADL70431 standard; RNA; 21 BP.	
XX	AC	ADL70431;	
XX	DT	20-MAY-2004 (first entry)	
XX	DE	RNAi for human clusterin.	
XX	KW	Human; clusterin; RNAi; melanoma; cytosolic; gene silencing;	
XX	KW	short interfering RNA; siRNA; DNA-RNA hybrid; ss.	
XX	OS	Homo sapiens.	
XX	OS	Synthetic.	
XX	Key	Location/Qualifiers	
XX	FT	modified_base	20..21
XX	FT	/tag= a	
XX	FT	/mod_base= OTHER	
XX	FT	/note= "OTHER= TT"	
XX	XX	WO2004018675-A1.	
XX	PD	04-MAR-2004.	
XX	PF	21-AUG-2003; 2003WO-CA001276.	
XX	PR	21-AUG-2002; 2002US-0405193P.	
XX	PR	03-SEP-2002; 2002US-0408152P.	
XX	PR	02-DEC-2002; 2002US-0319748P.	
XX	PR	20-MAY-2003; 2003US-0472387P.	
XX	PA	(UYBR-) UNIV BRITISH COLUMBIA.	
XX	PA	(GLEA/) GLEAVE M E.	
XX	P1	Jansen B;	
XX	DR	WPI; 2004-226851/21.	
XX	PT	Treating melanoma in a mammalian subject comprises administering to the	
XX	PT	subject a therapeutic agent effective to reduce the effective amount of	
XX	PT	clusterin in the melanoma cells.	
XX	PS	Claim 20; SEQ ID NO 29; 32pp; English.	
XX	CC	The present sequence is that of a short interfering RNA (siRNA) molecule	
XX	CC	targeted to human clusterin ADL70403. The invention relates to the	
XX	CC	treatment of melanoma through reduction in the effective amount of	
XX	CC	clusterin. The therapeutic agent may be an antisense oligonucleotide	
XX	CC	ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445	
XX	CC	targeted to clusterin. The siRNAs molecules direct cleavage of clusterin	
XX	CC	mRNA. A method for regulating expression of bcl-xl in a subject or cell	
XX	CC	line comprises administering an agent effective to modulate the amount of	
XX	CC	clusterin expression. In clusterin-expressing cells, expression of bcl-xl	
XX	CC	is down-regulated when the effective amount of clusterin is reduced. Such	
XX	CC	inhibition is significant because bcl-xl is known to act as an inhibitor	
XX	CC	of apoptosis.	
XX	CC	Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;	
XX	Query Match	90.5%; Score 19; DB 12; Length 21;	
XX	Best Local Similarity	73.7%; Pred. No. 65;	
XX	Matches 14; Conservativity	5; Mismatches 0; Indels 0; Gaps 0	
QY	3	GCAGCAGCTCTCATCAT	21
		::: :: :	
		GCAGCAGCTCTCATCAT	19

Db 1 GCAGCAGAGCUCUACAUCAU 19

RESULT 14  
ACF36409  
ID ACF36409 standard; DNA, 21 BP.  
AC ACF36409;  
XX  
XX 18-DEC-2003 (first entry)  
DT  
XX  
DE DNA sequence of a TRPM-2 mismatch control oligonucleotide.  
XX  
KM TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KM prostate cancer; anti-apoptotic protein; antisense; ss.  
XX  
OS Synthetic.  
XX  
PN WC2003072591-A1.  
XX  
PD 04-SEP-2003.  
XX  
PF 20-FEB-2003; 2003MO-US005305.  
XX  
PR 22-FEB-2002; 2002US-00080794.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
XX  
DR WPI; 2003-689981/65.  
XX  
PT New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Example 13; Page 20; 44pp; English.  
XX  
CC The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (1) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (1)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (1) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents a  
CC mismatch control oligonucleotide, used in antisense assays of anti-  
CC apoptotic protein TRPM-2 (testosterone-repressed prostate message-2)  
XX  
XX Sequence 21 BP; 7 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 84.8%; Score 17.8; DB 10; Length 21;  
Best Local Similarity 90.5%; Pred. No. 2.3e+02;  
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTTTCATCAT 21  
Db 1 CAGCAGCAGAGCTTTCATCAT 21

RESULT 15  
ADM83080  
ID ADM83080 standard; DNA, 21 BP.  
XX  
XX ADM83080;  
XX

DT 03-JUN-2004 (first entry)  
XX  
XX Control TRPM-2 mismatch oligonucleotide.  
DE  
XX  
KM Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KM radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KM lung cancer; renal cell carcinoma; RCC; antisense gene therapy; ss.  
XX  
XX Unidentified.  
XX  
XX US2003158130-A1.  
XX  
XX 21-AUG-2003.  
XX  
XX 28-SEP-2001; 2001US-00967726.  
XX  
XX 25-FEB-2000; 2000MO-US004875.  
XX  
XX 28-SEP-2000; 2000US-0236301P.  
XX  
XX 10-AUG-2001; 2001US-00913325.  
XX  
XX (GLEA/) GLEAVE M.  
XX  
XX (RENN/) RENNIE P S.  
XX  
XX (MIYA/) MIYAKE H.  
XX  
XX (NELS/) NELSON C.  
XX  
XX (ZELL/) ZELLWEGER T.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
XX WPI; 2003-778017/73.  
XX  
XX  
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
XX  
XX Disclosure; SEQ ID NO 15; 14pp; English.  
XX  
XX  
XX The present invention provides a method for treating cancer in which  
XX cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
XX The invention is useful for enhancing the chemo-sensitivity or radiation-  
XX sensitivity of cancer cells for treating cancer such as prostate cancer,  
XX bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
XX (RCC). The invention is also useful in antisense gene therapy. The  
XX present sequence is control testosterone-repressed prostate message-2  
XX (TRPM-2) mismatch oligonucleotide. The oligonucleotide is used in the  
XX exemplification of the invention.

QY 1 CAGCAGCAGAGCTTTCATCAT 21  
Db 1 CAGCAGCAGAGCTTTCATCAT 21

Search completed: September 3, 2005, 14:58:27  
Job time : 435 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 14:58:36 ; Search time 3027 Seconds  
(without alignments)  
264.073 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21

Sequence: 1 cagcagcagcagcttcacat 21

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 159776

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : EST:\*

1: gb\_esc1:\*\n2: gb\_esc2:\*\n3: gb\_esc3:\*\n4: gb\_esc4:\*\n5: gb\_esc5:\*\n6: gb\_esc6:\*\n7: gb\_esc7:\*\n8: gb\_esc8:\*\n9: gb\_esc9:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	14.8	70.5	46	1	AA916352 oh80e11.8
2	14.6	69.5	44	7	W25663 zc64e08.r1
3	14	66.7	50	8	BH861678 BH861678
4	13.6	64.8	42	9	CC794149 SALK_0439
5	13.4	63.8	50	9	CG869035 AB0164.Sa
6	13	61.9	21	8	AZ802584 2M0061105
7	13	61.9	41	8	BH908888 SALK_0510
8	13	61.9	43	1	AA973632 oc48b04.s
9	13	61.9	48	9	AL948370 Arabidops
10	12.8	61.0	50	1	AU107924 AU107924
11	12.8	61.0	50	1	AU107925 AU107925
12	12.8	61.0	50	1	AU107928 AU107928
13	12.8	61.0	50	1	AU107929 AU107929
14	12.6	60.0	39	9	AL760945 Arabidops
15	12.6	60.0	43	1	A1766391 wh1d04.x
16	12.6	60.0	46	6	AA561123 v141c01.r
17	12.6	60.0	46	6	CB213634 OM03914
18	12.6	60.0	47	9	CL212422 G040E010.G
19	12.6	60.0	50	1	AU105963 AU105963
20	12.6	60.0	50	1	AU105967 AU105967
21	12.6	60.0	50	1	AU105968 AU105968
22	12.6	60.0	50	1	AU105972 AU105972
23	12.6	60.0	50	1	AA566984 1038 lob1
24	12.4	59.0	37	8	AZ797149 2M0053009

C 25	12.2	58.1	35	8	AZ332831	AZ332831	1M0061C05
C 26	12.2	58.1	36	9	AJ587667	AJ587667	Aradidops
C 27	12.2	58.1	43	8	AZ610505	AZ610505	IM0435N18
C 28	12.2	58.1	46	1	AA109083	mp37b05.r	AA109083
C 29	12.2	58.1	49	1	AA052336	mb35b02.r	AA052336
C 30	12.2	58.1	49	1	AA864073	vx86f02.r	AA864073
C 31	12.2	58.1	50	1	AU104442	AU104442	AU104442
C 32	12.2	58.1	50	1	CR155807	Reverse 8	CR155807
C 33	12.2	57.1	33	8	AZ305164	IM0037N24	AZ305164
C 34	12.2	57.1	33	8	AZ185999	1M0037N24	AZ185999
C 35	12.2	57.1	34	1	AA16347	mq70g12.r	AA16347
C 36	12.2	57.1	34	4	B1246596	602958318	B1246596
C 37	12.2	57.1	34	9	AG201385	Pan. t991	AG201385
C 38	12.2	57.1	35	9	BX285461	Aradidops	BX285461
C 39	12.2	57.1	40	8	BH910804	SALK_0626	BH910804
C 40	12.2	57.1	40	9	CG774406	1123018G0	CG774406
C 41	12.2	57.1	41	8	BZ586362	3590.1.16	BZ586362
C 42	12.2	57.1	46	6	CA964065	CG10207	CA964065
C 43	12.2	57.1	46	7	H92446	Yc89b09.r1	H92446
C 44	12.2	57.1	46	7	T74174	yc60b12.81	T74174
C 45	12.2	57.1	47	8	AZ772648	1M0583N12	AZ772648

## ALIGNMENTS

RESULT 1  
LOCUS AA916352 46 bp mRNA linear EST 14-APR-1998  
DEFINITION oh80e11.81 NCI\_CGAP\_C08 Homo sapiens CDNA clone IMAGE:1473356 3'  
similiar to TR:Q15347 Q15347 RAGA. [1] ;, mRNA sequence.

AA916352  
ACCESSION AA916352  
VERSION AA916352.1 GI:3055744  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

AUTHORS NCI-CGAP  
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
Tumor Gene Index

JOURNAL Unpublished (1997)  
CONTACT: Robert Strausberg, Ph.D.

COMMENT Email: cgaabs-remail.nih.gov  
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.  
Emmert-Buck, M.D., Ph.D.

CDNA Library Preparation: M. Bento Soares, Ph.D.  
CDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:

www-bio.llnl.gov/dbir/image/image.html

Trace considered overall poor quality  
Seq primer: -40m3 fwd. RT from Amersham  
High quality sequence stop: 1.

Location/Qualifiers  
1. 46

/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:1473356"  
/feature\_type="adenocarcinoma"  
/lab\_host="DH10B"  
/clone\_lib="NCI CGAP C08"

/note="Organ: colon; Vector: pTT73D-Pac (Pharmacia) with a  
modified polylinker; 1st strand cDNA was prepared from  
colon adenocarcinoma, and was then primed with a Not I -  
oligo(dT) primer. Double-stranded cDNA was ligated to Eco  
RI adaptors (Pharmacia), digested with Not I and cloned  
into the Not I and Eco RI sites of the modified pTT73  
vector. Library is normalized. Library was constructed by

## FEATURES

source

ORIGIN Bento Soares and M. Fatima Bonaldo. "

Query Match 70.5%; Score 14.8; DB 1; Length 46;  
 Best Local Similarity 88.9%; Pred. No. 4.2e+04;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCAT 18  
 |||||  
 20 CAGCAGCTTAGTCTTCAT 37

RESULT 2  
 W25663 44 bp mRNA linear EST 25-NOV-1996  
 LOCUS ZC6408.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone  
 DEFINITION IMAGE:327110.5', similar to gb:U5183\_cds1 HEAT SHOCK PROTEIN HSP  
 90-ALPHA (HUMAN);, mRNA sequence.

ACCESSION W25663  
 VERSION W25663  
 KEYWORDS GI:1303517  
 SOURCE EST.  
 ORGANISM Homo sapiens (human)  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 44)  
 Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M.,  
 Holtman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M.,  
 Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F.,  
 Trevasakis, E., Waterston, R., Williamson, A., Woldmann, P. and  
 Wilson, R.  
 The Mashu-Merck EST Project  
 Unpublished (1995)  
 JOURNAL Contact: Wilson RK  
 COMMENT Washington University School of Medicine  
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
 Tel: 314 286 1800  
 Fax: 314 286 1810  
 Email: est@watson.wustl.edu  
 This clone is available royalty-free through LNL; contact the  
 IMAGE Consortium (info@image.llnl.gov) for further information.  
 Trace considered overall poor quality  
 Insrt Length: 596 Std Error: 0.00  
 Seq primer: mob.REGA+ET  
 High quality sequence stop: 1.  
 Location/Qualifiers  
 1. 44  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="GDB:1261312"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:327110"  
 /sex="unknown"  
 /dev\_stage="19 weeks"  
 /lab\_host="DH10B (ampicillin resistant)"  
 /clone\_id="Soares fetal heart NbHH19W"  
 /note="Organ: heart; Vector: pTZ19; Site 1: Not I; Site 2: Eco RI; 1st  
 modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st  
 strand cDNA was primed with a Not I - oligo(dT) primer [5'  
 TGTACCATCTGAAGTGGAGCGCGCCGATCTTTTCTTTTCTTTT 3',  
 double-stranded cDNA was size selected, ligated to Eco RI  
 adapters (Pharmacia), digested with Not I and cloned into  
 the Not I and Eco RI sites of a modified pTZ19 vector  
 (Pharmacia). Library went through one round of  
 normalization to a Cot = 5. Library constructed by  
 M.Fatima Bonaldo. This library was constructed from the  
 same fetus as the fetal lung library, Soares fetal lung  
 NBHL19W."

ORIGIN

Query Match 69.5%; Score 14.6; DB 7; Length 44;  
 Best Local Similarity 81.0%; Pred. No. 5.2e+04;  
 Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCAT 21  
 |||||  
 26 CAGCAGTAGGTCACTTCAT 6

RESULT 3  
 BH861678/c 50 bp DNA linear GSS 05-AUG-2002  
 LOCUS SALK\_087727 Arabidopsis thaliana TDNA insertion lines Arabidopsis  
 thaliana genomic clone SALK\_087727, genomic survey sequence.

ACCESSION BH861678  
 VERSION BH861678  
 KEYWORDS GI:22097004  
 SOURCE GSS.  
 ORGANISM Arabidopsis thaliana (thale cress)  
 Arabidopsis thaliana  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
 1 (bases 1 to 50)  
 Alonso, J.M., Leisse, T.J., Barajas, P., Chen, H., Cheuk, R.,  
 Gadrinab, C., Jeake, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L.,  
 Shinn, P., Zimmerman, J. and Ecker, J.R.  
 A Sequence-Indexed Library of Insertion Mutations in the  
 Arabidopsis Genome  
 Unpublished (2001)  
 JOURNAL Contact: Joseph R. Ecker  
 COMMENT Salk Institute Genomic Analysis Laboratory (SIGNAL)  
 The Salk Institute for Biological Studies (SIGNAL)  
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
 Tel: 858 453 4100 x1752  
 Fax: 858 558 6379  
 Email: eckers@salk.edu  
 This is single pass sequence recovered from the left border of  
 TDNA.  
 Class: TDNA tagged.  
 Location/Qualifiers  
 1. 50  
 /organism="Arabidopsis thaliana"  
 /mol\_type="genomic DNA"  
 /ecotype="Col-0"  
 /db\_xref="taxon:3702"  
 /clone="SALK\_087727"  
 /note="PCR was performed on Arabidopsis thaliana lines  
 each of which contains one or more TDNA insertion  
 elements. The resultant fragment for each line was  
 directly sequenced to determine the genomic sequence at  
 the site of insertion. Details of the protocols used can  
 be found at [http://signal.salk.edu/cdna\\_protocols.html](http://signal.salk.edu/cdna_protocols.html)"

ORIGIN

Query Match 66.7%; Score 14; DB 8; Length 50;  
 Best Local Similarity 100.0%; Pred. No. 9.8e+04;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 CAGCAGAGTCTTC 16  
 |||||  
 41 GCAGCAGAGTCTTC 28

RESULT 4  
 CC794149/c 42 bp DNA linear GSS 01-JUN-2003  
 LOCUS SALK\_043910.30.25.x Arabidopsis thaliana TDNA insertion lines  
 Arabidopsis thaliana genomic clone SALK\_043910.30.25.x, genomic  
 survey sequence.

ACCESSION CC794149  
 VERSION CC794149  
 KEYWORDS GI:32389372  
 SOURCE GSS.  
 ORGANISM Arabidopsis thaliana (thale cress)  
 Arabidopsis thaliana  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

REFERENCE  
AUTHORS

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.

## TITLE

1 (bases 1 to 42)  
Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,  
Gadindb,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,  
Shim,P., Zimmerman,J. and Ecker,J.R.  
A Sequence-indexed library of insertion Mutations in the  
Arabidopsis Genome  
Unpublished (2001)

JOURNAL  
COMMENT

Contact: Joseph R. Ecker  
Salk Institute Genomic Analysis Laboratory (SIGAL)  
The Salk Institute for Biological Studies  
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
Tel: 858 453 4100 x1752  
Fax: 858 558 6379  
Email: ecker@salk.edu  
This is single pass sequence recovered from the left border of  
TDNA.

Class: TDNA tagged.

FEATURES  
source

Location/Qualifiers  
1..42  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/ecotype="Col-0"  
/db\_xref="taxon:3702"  
/clone\_lib="Arabidopsis thaliana TDNA insertion lines"  
/note="PCR was performed on Arabidopsis thaliana lines  
each of which contains one or more TDNA insertion  
elements. The resultant fragment for each line was  
directly sequenced to determine the genomic sequence at  
the site of insertion. Details of the protocols used can  
be found at [http://signal.salk.edu/tdna\\_protocols.html](http://signal.salk.edu/tdna_protocols.html)"

## ORIGIN

Query Match 64.8%; Score 13.6; DB 9; Length 42;  
Best Local Similarity 80.0%; Pred. No. 1.5e+05;  
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 2 AGCAGCAGAGCTTCATCAT 21  
|||  
29 AGAAACCGAGTCATCATCAT 10

RESULT 5  
CG869035/c

LOCUS AB0164 Sanger Institute Gene Trap Library pGT01xr Mus musculus  
DEFINITION CDNA, mRNA sequence.  
ACCESSION CG869035 50 bp mRNA linear GSS 26-NOV-2003  
VERSION CG869035.1 GI:38532715  
KEYWORDS GSS.

SOURCE  
ORGANISM

Mus musculus (house mouse)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
AUTHORS Sanger Institute Gene Trap Resource - SIGTR.  
TITLE <http://www.sanger.ac.uk/Postgenomics/genetrp/>  
JOURNAL Unpublished (2003)  
COMMENT Contact: Sanger Institute Gene Trap Resource - SIGTR  
Wellcome Trust Sanger Institute  
Email: [info.genetrp@sanger.ac.uk](mailto:info.genetrp@sanger.ac.uk)  
Sequence tag generated by 5' RACE of total RNA from gene trap ES  
cell line. ES cell lines harboring insertion mutation of target  
gene are available upon request from Sanger Institute Gene Trap  
Resource. Annotation information available from  
<http://www.sanger.ac.uk/Postgenomics/genetrp/>  
Class: Gene Trap.

FEATURES  
source

Location/Qualifiers  
1..50  
/organism="Mus musculus"  
/mol\_type="mRNA"

## ORIGIN

Query Match 63.8%; Score 13.4; DB 9; Length 50;  
Best Local Similarity 93.3%; Pred. No. 1.8e+05;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 CAGAGCTTCATCAT 21  
|||  
48 CAGAGCTTCATCAT 34

RESULT 6  
AZ802584

LOCUS 21 bp DNA linear GSS 16-FEB-2001  
DEFINITION 2M0061105R Mouse 10kb plasmid UGCM library Mus musculus genomic  
clone UGCM0061105 R, genomic survey sequence.

ACCESSION AZ802584  
VERSION AZ802584.1 GI:12954907  
KEYWORDS GSS.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus

REFERENCE  
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 21)  
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,  
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,  
Rilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von  
Niederhausern,A. and Wright,D. Weiss,R.  
Mouse whole genome scaffolding with paired end reads from 10kb  
Plasmid inserts  
Unpublished (2000)  
Contact: Robert B. Weiss  
University of Utah Genome Center  
University of Utah  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT  
84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: [ddunn@genetics.utah.edu](mailto:ddunn@genetics.utah.edu)  
Insert Length: 10000 Std Error: 0.00  
Plate: 0061 row: 1 column: 05  
Seq primer: CACACAGAAACGCTATGACC  
Class: Plasmid ends  
High quality sequence stop: 21.

FEATURES  
source

Location/Qualifiers  
1..21  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone\_lib="UGCM0061105"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/note="Vector: PMD42nv. Purified genomic DNA from M.  
musculus C57BL/6J (male) was obtained from the Jackson  
Laboratory Mouse DNA Resource  
(<http://www.jax.org/resources/documents/dnares/>). The DNA  
was hydrodynamically sheared by repeated passage through a  
0.005 inch orifice at constant velocity. The sheared DNA  
was blunt end-repaired with T4 DNA polymerase and T4  
polynucleotide kinase. Adaptor oligonucleotides were  
ligated to the blunt ends in high molar excess. The  
adapted DNA was purified and size-selected for a 9.5 to  
10.5 kb range using preparative agarose gel  
electrophoresis. Vector DNA was prepared from a derivative  
of pMD42 (gi14732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

## ORIGIN

Query Match 61.9%; Score 13; DB 8; Length 21;  
Best Local Similarity 76.2%; Pred. No. 2.5e+05;  
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGCTTCATCAT 21  
|||||  
Db 1 CAGCAGCAGCATACACATCAT 21

RESULT 7  
BH908888 41 bp DNA linear GSS 04-SEP-2002  
LOCUS SALK\_051042.25.80.x Arabidopsis thaliana T-DNA insertion lines  
DEFINITION Arabidopsis thaliana genomic clone SALK\_051042.25.80.x, genomic survey sequence.

ACCESSION BH908888  
VERSION BH908888.1 GI:22721821  
KEYWORDS Arabidopsis thaliana (chale cress)  
SOURCE Arabidopsis thaliana

ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 (bases 1 to 41)  
Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Garrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmermann,J. and Ecker,J.R.  
TITLE A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis genome  
JOURNAL Unpublished (2001)  
COMMENT Contact: Joseph R. Ecker  
The Salk Institute Genomic Analysis Laboratory (SIGAL)  
Salk Institute for Biological Studies  
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
Tel: 858 453 4100 X1752  
Fax: 858 558 6379  
Email: ecker@salk.edu  
This is single pass sequence recovered from the left border of T-DNA. This sequence lies within an annotated exon of At5g58140.  
Class: T-DNA tagged.

## FEATURES

## source

1..41  
Location/Qualifiers  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/ecotype="Col-0"  
/db\_xref="taxon:3702"  
/clone\_lib="SALK\_051042.25.80.x"  
/note="Arabidopsis thaliana T-DNA insertion lines"  
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more T-DNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at [http://signal.salk.edu/tDNA\\_protocols.html](http://signal.salk.edu/tDNA_protocols.html)"

## ORIGIN

Query Match 61.9%; Score 13; DB 8; Length 41;  
Best Local Similarity 76.2%; Pred. No. 2.7e+05;  
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGCTTCATCAT 21  
|||||  
Db 19 CAGCAGGGGATCTTACCAT 39

RESULT 8  
AA973632 43 bp mRNA linear EST 17-JUN-1998  
LOCUS 004804.B1 NCI CGAP Ins Homo sapiens cDNA clone IMAGE:156931 3', similar to SW:K0E\_CERAE P33194 POSSIBLE DNA-REPAIR PROTEIN XP-E, mRNA sequence.

ACCESSION AA973632  
VERSION AA973632.1 GI:3148812  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 43)  
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.  
AUTHORS National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index  
TITLE Unpublished (1997)

JOURNAL Contact: Robert Strausberg, Ph.D.  
COMMENT Email: [cgapbs-remail.nih.gov](mailto:cgapbs-remail.nih.gov)  
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emert-Buck, M.D., Ph.D.

cDNA Library Preparation: M. Bento Soares, Ph.D.  
cDNA Library Arrayed by: Greg Lennon, Ph.D.  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/ILMIL at: [www-bio.lnl.gov/bbrp/image/image.html](http://www-bio.lnl.gov/bbrp/image/image.html)

Trace considered overall poor quality  
Insert Length: 703 Std Error: 0.00  
Seq primer: -40ml3 fwd. ET from Amersham  
High quality sequence stop: 1.

## FEATURES

## source

1..43  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone\_lib="IMAGE:156931"  
/tisue\_type="carcinoid"  
/lab\_host="DH10B"  
/clone\_lib="NCI-CGAP Ins"  
/note="Organ: Lung; Vector: pVT30-Pac (Pharmacia) with a modified polylinker; 1st strand cDNA was prepared from neuroendocrine lung carcinoid, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pVT3 vector. Library is normalized. Library was constructed by Bento Soares and M. Fatima Bonaldo."

## ORIGIN

Query Match 61.9%; Score 13; DB 1; Length 43;  
Best Local Similarity 76.2%; Pred. No. 2.8e+05;  
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGCTTCATCAT 21  
|||||  
Db 1 CAGCATGAGTCTTCACCAT 21

## RESULT 9

## AL948370/c

LOCUS AL948370 48 bp DNA linear GSS 02-APR-2004  
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-311H09-015792, genomic survey sequence.

ACCESSION AL948370  
VERSION AL948370.1 GI:24404992  
KEYWORDS GSS.

SOURCE Arabidopsis thaliana (chale cress)  
ORGANISM Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;



rosoid; eucroide II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE  
AUTHORS  
TITLE

1 Li,Y., Rosso,M.G., Strizhov,N., Viehoever,P. and Weisshaar,B.  
GABI-Kat SimpleSearch: a flanking sequence tag (FST) database for  
the identification of T-DNA insertion mutants in Arabidopsis  
thaliana  
Bioinformatics 19 (11), 1441-1442 (2003)

JOURNAL  
MEDLINE  
PUBMED  
REFERENCE  
AUTHORS

2 Rosso,M.G., Li,Y., Strizhov,N., Reiss,B., Dekker,K. and  
Weisshaar,B.  
An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for  
flanking sequence tag-based reverse genetics  
Plant Mol. Biol. 53 (1-2), 247-259 (2003)

JOURNAL  
MEDLINE  
PUBMED  
REFERENCE  
AUTHORS

3 Strizhov,N., Li,Y., Rosso,M.G., Viehoever,P., Dekker,K.A. and  
Weisshaar,B.  
High-throughput generation of sequence indexes from T-DNA  
mutagenized Arabidopsis thaliana lines  
Biotechniques 35 (6), 1164-1168 (2003)

JOURNAL  
PUBMED  
REFERENCE  
AUTHORS  
TITLE

4 (bases 1 to 48)  
Strizhov,N., Rosso,M.G., Li,Y. and Weisshaar,B.  
Direct Submission  
Submitted (31-MAR-2004) Weisshaar B., Max-Planck-Institut fuer  
Zuechtungsforchung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany  
This sequence has been recovered from the left border of the T-DNA.  
It indicates an insertion close to or within gene Atcys1110.  
Details on the protocols used for generation of the sequence are  
described in References 1-3. The sequences are generated at the MPI  
for Plant Breeding Research in the context of the GABI-Kat project.  
GABI-Kat is part of the German Plant Genomics program designated  
'GABRI'. Information on line availability can be found at:  
<http://www.mpiz-koeln.mpg.de/GABI-Kat/>.

FEATURES  
source

1..48  
Location/Qualifiers  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/strain="Columbia 0"  
/db\_xref="taxon:3702"  
/clone="GK-311H09-015792"  
/ecotype="Col-0"  
/note="(PCR was performed on DNA from Arabidopsis thaliana  
plants (TI) which were transformed with the T-DNA from  
vector PAC161 (GenBank accession number: AJ537514). The  
lines contain one or more T-DNA insertions. The DNA  
fragment(s) resulting from the PCR were directly sequenced  
to determine the genomic sequence flanking the insertion.  
T-DNA derived sequences were removed."

ORIGIN

Query Match 61.9%; Score 13; DB 9; Length 48;  
Best Local Similarity 76.2%; Pred.No. 2.8e+05;  
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

CY 1 CAGCGACGAGCTTCATCAT 21  
||| ||| |||  
Db 37 CAGCGACGAGAGATTTCAT 17

RESULT 10  
AUT07924  
LOCUS AUT07924 50 bp mRNA linear EST 28-JAN-2004  
DEFINITION Sugano Homo sapiens cDNA library Homo sapiens CDNA clone  
HRC02185, mRNA sequence.  
ACCESSION AUT07924  
VERSION AUT07924.1 GI:13557446  
KEYWORDS EST.  
SOURCE Homo sapiens (human)

ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1 (bases 1 to 50)									
TITLE	Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.									
JOURNAL	Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites									
MEDLINE	EMBO Rep. 2 (5), 388-393 (2001)									
PUBMED	21270072									
COMMENT	Contact: Yutaka Suzuki Department of Virology Institute of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan Email: yusuzuki@ms.u-tokyo.ac.jp Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).									
FEATURES	Location/Qualifiers									
source	1..50 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="HRC02185" /clone_idb="Sugano Homo sapiens cDNA library"									
ORIGIN										
Query Match	61.0%; Score 12.8; DB 1; Length 50;									
Best Local Similarity	87.5%; Pred. No. 3.5e+05;									
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
QY	2 AGCAGCAGAGTCTTCA 17       27 AGCAGCAGAGTCCGCA 42									
RESULT 11										
AUI07925	50 bp mRNA linear EST 28-JAN-2004									
LOCUS	AUI07925 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone									
DEFINITION	Hs106916, mRNA sequence.									
ACCESSION	AUI07925									
VERSION	AUI07925.1 GI:13557447									
KEYWORDS	EST.									
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1 (bases 1 to 50)									
TITLE	Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.									
JOURNAL	Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites									
MEDLINE	EMBO Rep. 2 (5), 388-393 (2001)									
PUBMED	21270072									
COMMENT	Contact: Yutaka Suzuki Department of Virology Institute of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan Email: yusuzuki@ms.u-tokyo.ac.jp Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).									
FEATURES	Location/Qualifiers									
source	1..50 /organism="Homo sapiens" /mol_type="mRNA"									

/db\_xref="taxon:9606"  
/clone="HS106916"  
/clone\_lib="Sugano Homo sapiens cDNA library"

ORIGIN

Query Match 61.0%; Score 12.8; DB 1; Length 50;  
Best Local Similarity 87.5%; Pred. No. 3.5e+05;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 AGCAGCAGAGTCTTCA 17  
Db 27 AGCAGCAGAGTCCGCA 42

RESULT 12  
LOCUS AU107928 50 bp mRNA linear EST 28-JAN-2004  
DEFINITION AU107928 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
ACCESSION AU107928  
VERSION AU107928.1 GI:13557450  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE  
AUTHORS Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Isegai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.  
TITLE Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites  
JOURNAL EMO Rep. 2 (5), 388-393 (2001)  
MEDLINE 21270072  
PUBMED 11375929  
COMMENT Contact: Yutaka Suzuki  
Department of Virology  
Institute of Medical Science, University of Tokyo  
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
Email: yusuzuki@ims.u-tokyo.ac.jp  
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).  
Location/Qualifiers  
1..50  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="ZRV62348"  
/clone\_lib="Sugano Homo sapiens cDNA library"

ORIGIN

Query Match 61.0%; Score 12.8; DB 1; Length 50;  
Best Local Similarity 87.5%; Pred. No. 3.5e+05;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 AGCAGCAGAGTCTTCA 17  
Db 27 AGCAGCAGAGTCCGCA 42

RESULT 13  
LOCUS AU107929 50 bp mRNA linear EST 28-JAN-2004  
DEFINITION AU107929 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
ACCESSION AU107929  
VERSION AU107929.1 GI:13557451  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE  
AUTHORS Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Isegai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.  
TITLE Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites  
JOURNAL EMO Rep. 2 (5), 388-393 (2001)  
MEDLINE 21270072  
PUBMED 11375929  
COMMENT Contact: Yutaka Suzuki  
Department of Virology  
Institute of Medical Science, University of Tokyo  
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
Email: yusuzuki@ims.u-tokyo.ac.jp  
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).  
Location/Qualifiers  
1..50  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="ZRV62348"  
/clone\_lib="Sugano Homo sapiens cDNA library"

ORIGIN

Query Match 61.0%; Score 12.8; DB 1; Length 50;  
Best Local Similarity 87.5%; Pred. No. 3.5e+05;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 AGCAGCAGAGTCTTCA 17  
Db 27 AGCAGCAGAGTCCGCA 42

RESULT 14  
LOCUS AU107945/c 39 bp DNA linear GSS 01-APR-2004  
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-204B10-014508, genomic survey sequence.  
ACCESSION AU107945  
VERSION AU107945.1 GI:21501350  
KEYWORDS GSS.  
SOURCE Arabidopsis thaliana (chale cress)  
ORGANISM Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE  
AUTHORS Li,Y., Rosso,M.G., Strizhov,N., Viehoever,P. and Weisshaar,B.  
TITLE GABI-Kat Simplesearch: a flanking sequence tag (FST) database for the identification of T-DNA insertion mutants in Arabidopsis thaliana  
Bioinformatics 19 (11), 1441-1442 (2003)  
JOURNAL 22755829  
MEDLINE 22755829  
PUBMED 12874060  
REFERENCE  
AUTHORS Rosso,M.G., Li,Y., Strizhov,N., Reiss,B., Dekker,K. and Weisshaar,B.  
TITLE An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for flanking sequence tag-based reverse genetics  
Plant Mol. Biol. 53 (1-2), 247-259 (2003)  
JOURNAL 23117147  
MEDLINE 23117147  
PUBMED 14756321  
REFERENCE  
AUTHORS Strizhov,N., Li,Y., Rosso,M.G., Viehoever,P., Dekker,K.A. and Weisshaar,B.  
TITLE High-throughput generation of sequence indexes from T-DNA mutagenized Arabidopsis thaliana lines  
Biotechniques 35 (6), 1164-1168 (2003)  
JOURNAL 14682050  
PUBMED

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
1 (bases 1 to 50)  
Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Isegai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.  
TITLE Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites  
JOURNAL EMO Rep. 2 (5), 388-393 (2001)  
MEDLINE 21270072  
PUBMED 11375929  
COMMENT Contact: Yutaka Suzuki  
Department of Virology  
Institute of Medical Science, University of Tokyo  
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
Email: yusuzuki@ims.u-tokyo.ac.jp  
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).  
Location/Qualifiers  
1..50  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="ZRV62402"  
/clone\_lib="Sugano Homo sapiens cDNA library"

ORIGIN

Query Match 61.0%; Score 12.8; DB 1; Length 50;  
Best Local Similarity 87.5%; Pred. No. 3.5e+05;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 AGCAGCAGAGTCTTCA 17  
Db 29 AGCAGCAGAGTCCGCA 44

RESULT 14  
LOCUS AU107945/c 39 bp DNA linear GSS 01-APR-2004  
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-204B10-014508, genomic survey sequence.  
ACCESSION AU107945  
VERSION AU107945.1 GI:21501350  
KEYWORDS GSS.  
SOURCE Arabidopsis thaliana (chale cress)  
ORGANISM Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE  
AUTHORS Li,Y., Rosso,M.G., Strizhov,N., Viehoever,P. and Weisshaar,B.  
TITLE GABI-Kat Simplesearch: a flanking sequence tag (FST) database for the identification of T-DNA insertion mutants in Arabidopsis thaliana  
Bioinformatics 19 (11), 1441-1442 (2003)  
JOURNAL 22755829  
MEDLINE 22755829  
PUBMED 12874060  
REFERENCE  
AUTHORS Rosso,M.G., Li,Y., Strizhov,N., Reiss,B., Dekker,K. and Weisshaar,B.  
TITLE An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for flanking sequence tag-based reverse genetics  
Plant Mol. Biol. 53 (1-2), 247-259 (2003)  
JOURNAL 23117147  
MEDLINE 23117147  
PUBMED 14756321  
REFERENCE  
AUTHORS Strizhov,N., Li,Y., Rosso,M.G., Viehoever,P., Dekker,K.A. and Weisshaar,B.  
TITLE High-throughput generation of sequence indexes from T-DNA mutagenized Arabidopsis thaliana lines  
Biotechniques 35 (6), 1164-1168 (2003)  
JOURNAL 14682050  
PUBMED

REFERENCE	4 (bases 1 to 39)
AUTHORS	Strizhnov,N., Rosso,M.G., Li,Y. and Weishaar,B
TITLE	Direct Submission
JOURNAL	Submitted (31-MAR-2004) Weishaar B., Max-Planck Zuchungsforschung, Carl-von-Linne-Weg 10, Koeln
COMMENT	This sequence has been recovered from the left end of a 39 bp fragment. The right end of the fragment is missing. The sequence is identical to the one deposited in GenBank under accession number

**ORIGIN**

Query Match	60.0%	Score 12.6;	DB 9;	Length 39;
Best Local Similarity	78.9%;	Pred. No. 4.2e+05;		
Matches 15;	Conservative 0;	Mismatches 4;	Indels 0;	Gaps 0;

RESULT	LOCUS	DEFINITION
15 A1766391/c	A1766391	43 bp mRNA linear EST 20-DEC-1999 wh1d04.x1 NCI_CGAP Kid1 Homo sapiens cDNA clone IMAGE:2385223 3'

Trace considered overall poor quality  
Insert Length: 641 Std Error: 0.00  
Seq primer: -40UP from Gibco  
High quality sequence stop: 1.

FEATURES	Location/Qualifiers
source	1. .43

## ORIGIN

Query Match	60.0%	Score 12.6;	DB 1;	Length 43;
Best Local Similarity	78.9%;	Pred. No. 4.2e+05;		
Matches 15;	Conservative 0;	Mismatches 4;	Indels 0;	Gaps 0;

Search completed: September 3, 2005, 16:20:16  
Job time : 3031 secs

**This Page Blank (uspto)**